userSet	dbSet	collection	pValueLog	oddsRatio	support	rnkPV	rnkOR	rnkSup	maxRnk	meanRnk	b	c	d	description	cellType	tissue	antibody	treatment	dataSource	filename	size
1	3283	PPARG	5.61753715710516	13.6022777564373	24	1	80	1324	1324	468	2	180	205	PPARG Simpson Golabi Behmel Syndrome adipocytes PPARG	Simpson Golabi Behmel Syndrome adipocytes	NULL	PPARG	NULL	GTRD	EXP000907_Simpson-Golabi-Behmel-Syndrome-adipocytes_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	5143
1	3290	PPARG	3.6883658455038	3.65423237056309	32	2	96	825	825	308	10	172	197	PPARG subcutaneous white adipose tissue PPARG	subcutaneous white adipose tissue	NULL	PPARG		GTRD	EXP034425_subcutaneous-white-adipose-tissue_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	9105
1	3284	PPARG	3.45226672947399	2.10661765612103	82	3	182	13	182	66	50	122	157	PPARG hMADS-3 (adipose-derived stem cells) PPARG	hMADS-3 (adipose-derived stem cells)	NULL	PPARG	differentiaiton inductors	GTRD	EXP033780_hMADS-3--adipose-derived-stem-cells-_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	60933
1	3291	PPARG	3.04974795504182	3.25568082158781	29	4	102	1013	1013	373	10	175	197	PPARG subcutaneous white adipose tissue PPARG	subcutaneous white adipose tissue	NULL	PPARG		GTRD	EXP034426_subcutaneous-white-adipose-tissue_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	6490
1	3285	PPARG	2.89746782250176	1.97592099022798	75	5	281	28	281	105	47	129	160	PPARG hMADS-3 (adipose-derived stem cells) PPARG	hMADS-3 (adipose-derived stem cells)	NULL	PPARG	differentiaiton inductors	GTRD	EXP033781_hMADS-3--adipose-derived-stem-cells-_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	63954
1	3297	PPARG	2.78488958286292	2.36069162909335	43	6	165	429	429	200	21	161	186	PPARG hASC (preadipocytes) PPARG	hASC (preadipocytes)	NULL	PPARG		GEO	GSE21366_pparg_asc_MACS_PPARG_MA0066.1.damo.pwm.bed	16549
1	348	CEBPA	2.77732683490231	Inf	9	7	1	2564	2564	857	0	195	207	CEBPA SGBS (Simpson Golabi Behmel syndrome type 1 adipocytes) CEBPA	SGBS (Simpson Golabi Behmel syndrome type 1 adipocytes)	NULL	CEBPA		GEO	GSE41629_cebpa_sgbs_MACS_CEBPA_MA0102.4.damo.pwm.bed	8140
1	337	CEBPA	2.65946489852919	2.79497429548365	30	8	133	937	937	359	12	174	195	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 100 nM 1,25(OH)2D3 for 2 hrs	GTRD	EXP053362_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	42883
1	336	CEBPA	2.47280949159416	2.68660714175898	29	9	137	1013	1013	386	12	175	195	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 100 nM 1,25(OH)2D3 for 2 hrs	GTRD	EXP053362_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	42489
1	310	CEBPA	2.29682311403975	2.15629279349271	40	10	178	502	502	230	21	164	186	CEBPA mesenchymal stem cells-derived adipocytes CEBPA	mesenchymal stem cells-derived adipocytes	NULL	CEBPA	NULL	GTRD	EXP000565_mesenchymal-stem-cells-derived-adipocytes_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	24225
1	309	CEBPA	2.25580462895444	2.11137028162776	41	11	181	476	476	223	22	163	185	CEBPA mesenchymal stem cells-derived adipocytes CEBPA	mesenchymal stem cells-derived adipocytes	NULL	CEBPA	NULL	GTRD	EXP000565_mesenchymal-stem-cells-derived-adipocytes_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	24151
1	251	ATF3	2.11589803905187	2.17052578555925	35	12	177	691	691	293	18	169	189	ATF3 liver ATF3	liver	BTO:0000759	ATF3		ENCODE	ENCSR480LIS_liver_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	24651
1	345	CEBPA	2.05246144526302	2.21671556240956	32	13	176	825	825	338	16	172	191	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 100 nM 1,25(OH)2D3 for 24 hrs	GTRD	EXP053366_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	51032
1	331	CEBPA	1.92192871522171	1.85837633782792	46	14	302	349	349	222	28	158	179	CEBPA MOLM-13(acute monocytic leukemia(AML), Homo sapiens) CEBPA	MOLM-13(acute monocytic leukemia(AML), Homo sapiens)	BTO:0004175	CEBPA		GTRD	EXP053322_MOLM-13-acute-monocytic-leukemia-AML---Homo-sapiens-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	79312
1	333	CEBPA	1.84713752140628	1.72216500344996	57	15	337	174	337	175	38	147	169	CEBPA U937 (adult acute monocytic leukemia) CEBPA	U937 (adult acute monocytic leukemia)	BTO:0001412	CEBPA		GTRD	EXP053324_U937--adult-acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	103731
1	2006	GATA3	1.84157288821553	Inf	6	16	1	2948	2948	988	0	198	207	GATA3 CD4 GATA3	CD4	NA	GATA3	TH2	GEO	GSE72266_gata3_cd4-th2_MACS_GATA3_MA0037.3.damo.pwm.bed	4444
1	3715	SRF	1.84157288821553	Inf	6	16	1	2948	2948	988	0	198	207	SRF HEL (Erythro Leukemia) SRF	HEL (Erythro Leukemia)	NULL	SRF	Treatment: Treated with 10ng/ml Dox for 24 hours Source: HEL-iMKL1 cells	GTRD	EXP053074_HEL--Erythro-Leukemia-_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	2934
1	3292	PPARG	1.81220084528225	2.02290012358609	33	18	278	778	778	358	18	171	189	PPARG subcutaneous white adipose tissue PPARG	subcutaneous white adipose tissue	NULL	PPARG		GTRD	EXP034433_subcutaneous-white-adipose-tissue_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	12068
1	1989	GATA3	1.77379482278816	5.26510679879406	10	19	84	2442	2442	848	2	194	205	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3	E2	GEO	GSE29073_gata3_mcf7-e2_MACS_GATA3_MA0037.3.damo.pwm.bed	17757
1	3438	RFX1	1.77322817331966	3.19793226802957	15	20	103	1993	1993	705	5	189	202	RFX1 MCF7 (Invasive ductal breast carcinoma) RFX1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RFX1	NA	GTRD	EXP039737_MCF7--Invasive-ductal-breast-carcinoma-_RFX1_MACS_RFX1_MA0509.2.damo.pwm.bed	11335
1	1978	GATA3	1.75592655964076	8.37486975127373	8	21	81	2697	2697	933	1	196	206	GATA3 T47D (invasive ductal carcinoma) GATA3	T47D (invasive ductal carcinoma)	BTO:0001248	GATA3	Passsage: <10	GTRD	EXP049896_T47D--invasive-ductal-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	13101
1	338	CEBPA	1.74346125521168	2.05465208078049	30	22	212	937	937	390	16	174	191	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 0.1 % EtOH for 8 hrs	GTRD	EXP053363_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	40326
1	339	CEBPA	1.74346125521168	2.05465208078049	30	22	212	937	937	390	16	174	191	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 0.1 % EtOH for 8 hrs	GTRD	EXP053363_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	41763
1	3289	PPARG	1.73261049340515	1.82845614589949	41	24	305	476	476	268	25	163	182	PPARG subcutaneous white adipose tissue PPARG	subcutaneous white adipose tissue	NULL	PPARG		GTRD	EXP034424_subcutaneous-white-adipose-tissue_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	13671
1	1287	ESR1	1.72908044206869	2.37647052800038	22	25	164	1459	1459	549	10	182	197	ESR1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) ESR1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	ESR1	Tam-Resist	GTRD	EXP038790_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	36346
1	3800	TCF4	1.6995232948606	1.60299924016577	69	26	376	47	376	150	50	135	157	TCF4 TMD8 (diffuse large B-cell lymphoma) TCF4	TMD8 (diffuse large B-cell lymphoma)	NULL	TCF4	Treatment: 60ng/ml  Tetracyclin for 24 hrs; Genotype: inducible TCF4 expression;	GTRD	EXP058278_TMD8--diffuse-large-B-cell-lymphoma-_TCF4_MACS_TCF4_MA0830.2.damo.pwm.bed	229894
1	340	CEBPA	1.66788871679347	1.95032095313982	32	27	284	825	825	379	18	172	189	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 100 nM 1,25(OH)2D3 for 8 hrs	GTRD	EXP053364_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	48052
1	341	CEBPA	1.63452271162131	1.90651316114644	33	28	289	778	778	365	19	171	188	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 100 nM 1,25(OH)2D3 for 8 hrs	GTRD	EXP053364_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	48915
1	2123	HNF4A	1.62516656108769	1.65199643881828	54	29	360	225	360	205	37	150	170	HNF4A liver HNF4A	liver	BTO:0000759	HNF4A		Array Express	ERP002306_hnf4a_liver_MACS_HNF4A_MA0114.4.damo.pwm.bed	43415
1	3293	PPARG	1.60409489824113	1.69739057913624	47	30	352	333	352	238	31	157	176	PPARG subcutaneous white adipose tissue PPARG	subcutaneous white adipose tissue	NULL	PPARG		GTRD	EXP034435_subcutaneous-white-adipose-tissue_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	14391
1	3088	NR3C1	1.59982338255453	1.57515407442748	67	31	381	68	381	160	49	137	158	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	1 h with 100 nM Dexamethasone (Myers)	ENCODE	ENCSR000BJR_A549_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	44340
1	3005	NFE2L2	1.57338200626749	2.96946679160695	14	32	130	2073	2073	745	5	190	202	NFE2L2 A375 (malignant melanoma) NFE2L2	A375 (malignant melanoma)	BTO:0002806	NFE2L2	A771726	GEO	GSE57431_NFE2L2_a375-a771726_MACS_NFE2L2_MA0150.2.damo.pwm.bed	3322
1	369	CEBPB	1.54843145635937	1.79935917827269	36	33	318	645	645	332	22	168	185	CEBPB monocyte-derived macrophages CEBPB	monocyte-derived macrophages	NULL	CEBPB	IFN-gamma	GTRD	EXP038588_monocyte-derived-macrophages_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	38296
1	120	AR	1.53189993104804	Inf	5	34	1	3053	3053	1030	0	199	207	AR primary prostate cancer AR	primary prostate cancer	NULL	AR	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053242_primary-prostate-cancer_AR_MACS_AR_MA0007.3.damo.pwm.bed	1324
1	4039	TP63	1.51650484557685	2.40232118272295	18	35	163	1785	1785	661	8	186	199	TP63 MCF10A (breast epithelial cells) TP63	MCF10A (breast epithelial cells)	BTO:0001939	TP63	Treatment: DMSO for 6 hrs;	GTRD	EXP057961_MCF10A--breast-epithelial-cells-_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	26768
1	3545	RXRA	1.50328900916502	1.66770517795352	45	36	356	383	383	258	30	159	177	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP045021_liver_RXRA_MACS_RXRA_MA0159.1.damo.pwm.bed	40103
1	3713	SRF	1.49086866696037	7.29191889888432	7	37	82	2812	2812	977	1	197	206	SRF HEL (Erythro Leukemia) SRF	HEL (Erythro Leukemia)	NULL	SRF	Treatment: No treatment, no TPA  Source: HEL-iMKL1 cells	GTRD	EXP053072_HEL--Erythro-Leukemia-_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	3350
1	3714	SRF	1.49086866696037	7.29191889888432	7	37	82	2812	2812	977	1	197	206	SRF HEL (Erythro Leukemia) SRF	HEL (Erythro Leukemia)	NULL	SRF	Treatment: Treated with 10ng/ml Dox for 24 hours Source: HEL-iMKL1 cells	GTRD	EXP053073_HEL--Erythro-Leukemia-_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	5115
1	389	CEBPB	1.48397640678071	2.65274075219484	15	39	138	1993	1993	723	6	189	201	CEBPB THP-1 (acute monocytic leukemia) CEBPB	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPB	Treatment: untreated, IAV NS1(EP mRNA)	GTRD	EXP047815_THP-1--acute-monocytic-leukemia-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	18251
1	1224	ESR1	1.47749656904458	3.16365590660805	12	40	104	2233	2233	792	4	192	203	ESR1 endometrioid adenocarcinoma ESR1	endometrioid adenocarcinoma	NULL	ESR1	tumor B	GTRD	EXP036415_endometrioid-adenocarcinoma_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	4921
1	344	CEBPA	1.47101430051041	1.80179297946054	33	41	308	778	778	376	20	171	187	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 100 nM 1,25(OH)2D3 for 24 hrs	GTRD	EXP053366_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	52197
1	3418	REST	1.45575325628091	1.89620160377332	28	42	292	1068	1068	467	16	176	191	REST liver REST	liver	BTO:0000759	REST		GTRD	EXP039422_liver_REST_MACS_REST_MA0138.2.damo.pwm.bed	13352
1	384	CEBPB	1.38537082368796	3.49560176766756	10	43	100	2442	2442	862	3	194	204	CEBPB OCI-AML3 CEBPB	OCI-AML3	BTO:0004620	CEBPB	Control No Treatment	GTRD	EXP040655_OCI-AML3_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	8826
1	3439	RFX1	1.38537082368796	3.49560176766756	10	43	100	2442	2442	862	3	194	204	RFX1 MCF7 (Invasive ductal breast carcinoma) RFX1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RFX1	NA	GTRD	EXP039775_MCF7--Invasive-ductal-breast-carcinoma-_RFX1_MACS_RFX1_MA0509.2.damo.pwm.bed	10102
1	2610	JUND	1.38470991867944	1.92233836231586	25	45	287	1262	1262	531	14	179	193	JUND liver JUND	liver	BTO:0000759	JUND		GTRD	EXP039345_liver_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	17620
1	3205	OTX2	1.38470991867944	1.92233836231586	25	45	287	1262	1262	531	14	179	193	OTX2 D341 Med (medulloblastoma) OTX2	D341 Med (medulloblastoma)	NULL	OTX2	CRISPR.OTX2.2	GTRD	EXP038204_D341-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	44120
1	1898	GATA1	1.38088389344944	2.7433671048521	13	47	136	2153	2153	779	5	191	202	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	NULL	GTRD	EXP000523_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	13610
1	1252	ESR1	1.34837973934839	2.25703833708668	17	48	175	1846	1846	690	8	187	199	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	320min E2	GTRD	EXP038342_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	30630
1	347	CEBPA	1.32078607906409	1.55185940992339	49	49	395	299	395	248	35	155	172	CEBPA Kasumi-1 (acute myeloblastic leukemia) CEBPA	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	CEBPA		GTRD	EXP058118_Kasumi-1--acute-myeloblastic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	64358
1	335	CEBPA	1.32028825400115	1.81832947664287	27	50	307	1135	1135	497	16	177	191	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 0.1 % EtOH for 2 hrs	GTRD	EXP053361_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	43181
1	1834	FOXA2	1.31589391485095	1.96110140100492	22	51	282	1459	1459	597	12	182	195	FOXA2 definitive endoderm(dEN, ES derived) FOXA2	definitive endoderm(dEN, ES derived)	NULL	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL	GTRD	EXP049292_definitive-endoderm-dEN--ES-derived-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	44513
1	2614	JUND	1.31589391485095	1.96110140100492	22	51	282	1459	1459	597	12	182	195	JUND liver JUND	liver	BTO:0000759	JUND		GTRD	EXP039345_liver_JUND_MACS_JUND_MA1144.1.damo.pwm.bed	15576
1	332	CEBPA	1.30928430919579	1.54055825023683	50	53	405	275	405	244	36	154	171	CEBPA U937 (adult acute monocytic leukemia) CEBPA	U937 (adult acute monocytic leukemia)	BTO:0001412	CEBPA		GTRD	EXP053324_U937--adult-acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	96696
1	1899	GATA1	1.303734136004	2.46324931108914	14	54	155	2073	2073	761	6	190	201	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	NULL	GTRD	EXP000523_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	14159
1	1192	ESR1	1.295525872425	2.12524163262948	18	55	179	1785	1785	673	9	186	198	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	vehicle	GTRD	EXP030929_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	20054
1	1160	ESR1	1.27823074360217	2.88551536782835	11	56	131	2332	2332	840	4	193	203	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		Array Express	ERP000209_esr1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	15953
1	1980	GATA3	1.27823074360217	2.88551536782835	11	56	131	2332	2332	840	4	193	203	GATA3 T47D (invasive ductal carcinoma) GATA3	T47D (invasive ductal carcinoma)	BTO:0001248	GATA3	Passsage: <10 Genotype: wt/R330fs mutant with CRISPR	GTRD	EXP049898_T47D--invasive-ductal-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	13449
1	3294	PPARG	1.2498213298177	2.01983690647066	19	58	279	1697	1697	678	10	185	197	PPARG subcutaneous white adipose tissue PPARG	subcutaneous white adipose tissue	NULL	PPARG		GTRD	EXP034436_subcutaneous-white-adipose-tissue_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	5421
1	3239	PKNOX1	1.24048596098468	2.26323116715553	15	59	173	1993	1993	742	7	189	200	PKNOX1 HeLa (cervical adenocarcinoma) PKNOX1	HeLa (cervical adenocarcinoma)	BTO:0000567	PKNOX1	NA	GTRD	EXP047569_HeLa--cervical-adenocarcinoma-_PKNOX1_MACS_PKNOX1_MA0782.2.damo.pwm.bed	5710
1	3355	RELA	1.24048596098468	2.26323116715553	15	59	173	1993	1993	742	7	189	200	RELA MCF7 (Invasive ductal breast carcinoma) RELA	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RELA	TNFa for 45m	GTRD	EXP036987_MCF7--Invasive-ductal-breast-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	11030
1	1659	FOXA1	1.23542246844819	1.47026077031181	58	61	480	154	480	232	44	146	163	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	10 nm DHT	GTRD	EXP033301_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	187434
1	249	ATF3	1.2233355174868	Inf	4	62	1	3182	3182	1080	0	200	207	ATF3 K562 (myelogenous leukemia) ATF3	K562 (myelogenous leukemia)	NULL	ATF3		ENCODE	ENCSR000DOG_K562_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	548
1	2046	GFI1	1.2233355174868	Inf	4	62	1	3182	3182	1080	0	200	207	GFI1 AML (monocytes and acute myeloid leukemia) GFI1	AML (monocytes and acute myeloid leukemia)	NULL	GFI1	Treatment: LSD1 inhibitor OG86	GTRD	EXP049355_AML--monocytes-and-acute-myeloid-leukemia-_GFI1_MACS_GFI1_MA0038.2.damo.pwm.bed	1542
1	314	CEBPA	1.21736989217236	1.78519312983335	25	64	319	1262	1262	548	15	179	192	CEBPA U937 (adult acute monocytic leukemia) CEBPA	U937 (adult acute monocytic leukemia)	BTO:0001412	CEBPA	dmso	GTRD	EXP000947_U937--adult-acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	43146
1	601	CTCF	1.21736989217236	1.78519312983335	25	64	319	1262	1262	548	15	179	192	CTCF CD4+ T-cells CTCF	CD4+ T-cells	NULL	CTCF		GTRD	EXP030880_CD4--T-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	22927
1	1950	GATA2	1.21736989217236	1.78519312983335	25	64	319	1262	1262	548	15	179	192	GATA2 LNCaP (prostate carcinoma) GATA2	LNCaP (prostate carcinoma)	BTO:0001321	GATA2		GEO	GSE52725_gata2_lncap_MACS_GATA2_MA0036.3.damo.pwm.bed	59875
1	2612	JUND	1.21736989217236	1.78519312983335	25	64	319	1262	1262	548	15	179	192	JUND liver JUND	liver	BTO:0000759	JUND		GTRD	EXP039345_liver_JUND_MACS_JUND_MA1141.1.damo.pwm.bed	18585
1	3305	PRDM1	1.20986839367296	1.93368631149848	20	68	285	1606	1606	653	11	184	196	PRDM1 HEK293 (embryonic kidney) PRDM1	HEK293 (embryonic kidney)	NULL	PRDM1		GTRD	EXP039715_HEK293--embryonic-kidney-_PRDM1_MACS_PRDM1_MA0508.3.damo.pwm.bed	15602
1	3871	TFAP2A	1.20986839367296	1.93368631149848	20	68	285	1606	1606	653	11	184	196	TFAP2A MCF7 (Invasive ductal breast carcinoma) TFAP2A	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2A		GEO	GSE60270_tfap2a_mcf7_MACS_TFAP2A_MA0872.1.damo.pwm.bed	9161
1	342	CEBPA	1.20130025378369	1.64582929714502	32	70	367	825	825	421	21	172	186	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 0.1 % EtOH for 24 hrs	GTRD	EXP053365_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	50732
1	2749	MEIS1	1.19639026122022	2.51960239956809	12	71	154	2233	2233	819	5	192	202	MEIS1 SEM (childhood B acute lymphoblastic leukemia) MEIS1	SEM (childhood B acute lymphoblastic leukemia)	NULL	MEIS1	NA	GEO	GSE38339_meis1_sem_MACS_MEIS1_MA0498.2.damo.pwm.bed	11850
1	1500	FLI1	1.18756335279517	2.11328490095638	16	72	180	1909	1909	720	8	188	199	FLI1 A-673 clone Asp114 (Ewing sarcoma) FLI1	A-673 clone Asp114 (Ewing sarcoma)	NULL	FLI1	Passage: 15-19	GTRD	EXP049959_A-673-clone-Asp114--Ewing-sarcoma-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	12717
1	3441	RFX1	1.17627904257442	3.13043248714826	9	73	105	2564	2564	914	3	195	204	RFX1 K562 (myelogenous leukemia) RFX1	K562 (myelogenous leukemia)	NULL	RFX1	NA	GTRD	EXP039819_K562--myelogenous-leukemia-_RFX1_MACS_RFX1_MA0509.2.damo.pwm.bed	10739
1	794	CTCF	1.17461963468391	1.8619548356126	21	74	294	1535	1535	634	12	183	195	CTCF KMS-11 (Plasma cell myeloma) CTCF	KMS-11 (Plasma cell myeloma)	BTO:0003932	CTCF		GTRD	EXP040254_KMS-11--Plasma-cell-myeloma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29708
1	2137	HNF4A	1.17252016758936	1.52803002153917	42	75	449	454	454	326	30	162	177	HNF4A liver HNF4A	liver	BTO:0000759	HNF4A		GTRD	EXP039987_liver_HNF4A_MACS_HNF4A_MA1494.1.damo.pwm.bed	47525
1	334	CEBPA	1.16629573611572	1.70267261857945	27	76	351	1135	1135	521	17	177	190	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 0.1 % EtOH for 2 hrs	GTRD	EXP053361_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	41403
1	312	CEBPA	1.16529990391919	1.59815849025787	34	77	378	729	729	395	23	170	184	CEBPA U937 (adult acute monocytic leukemia) CEBPA	U937 (adult acute monocytic leukemia)	BTO:0001412	CEBPA	bio	GTRD	EXP000946_U937--adult-acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	63716
1	2022	GATA4	1.14327308943261	1.80131674836028	22	78	309	1459	1459	615	13	182	194	GATA4 BJ (fibroblasts) GATA4	BJ (fibroblasts)	NULL	GATA4	Genotype: V5-untarged	GTRD	EXP049304_BJ--fibroblasts-_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	104447
1	4135	YY1	1.14254815539994	1.99669033122539	17	79	280	1846	1846	735	9	187	198	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1		GTRD	EXP038605_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	4795
1	1949	GATA2	1.08991488368461	1.70445150264162	24	80	350	1324	1324	585	15	180	192	GATA2 LNCaP (prostate carcinoma) GATA2	LNCaP (prostate carcinoma)	BTO:0001321	GATA2		GEO	GSE38391_gata2_lncap_MACS_GATA2_MA0036.3.damo.pwm.bed	57820
1	2150	HNF4G	1.08766805848833	2.61020502816831	10	81	139	2442	2442	887	4	194	203	HNF4G liver HNF4G	liver	BTO:0000759	HNF4G		GTRD	EXP039746_liver_HNF4G_MACS_HNF4G_MA0484.2.damo.pwm.bed	10104
1	3718	SRF	1.07859290889225	2.10157962357466	14	82	183	2073	2073	779	7	190	200	SRF HEL (Erythro Leukemia) SRF	HEL (Erythro Leukemia)	NULL	SRF	Treatment: Treated with 10ng/ml Dox & 15nM TPA for 24 horus Genotype: mkl overexpressed	GTRD	EXP053077_HEL--Erythro-Leukemia-_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	9304
1	1172	ESR1	1.07608289424725	3.63219099637879	7	83	97	2812	2812	997	2	197	205	ESR1 ZR-75-1 (invasive ductal carcinoma) ESR1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	ESR1		Array Express	ERP000783_esr1_zr751_MACS_ESR1_MA0112.3.damo.pwm.bed	25666
1	1999	GATA3	1.07608289424725	3.63219099637879	7	83	97	2812	2812	997	2	197	205	GATA3 BE2C GATA3	BE2C	NULL	GATA3		GEO	GSE65664_gata3_be2c_MACS_GATA3_MA0037.3.damo.pwm.bed	20942
1	2004	GATA3	1.07608289424725	3.63219099637879	7	83	97	2812	2812	997	2	197	205	GATA3 thymocytes GATA3	thymocytes	NULL	GATA3		GEO	GSE71751_gata3_thymocyte_MACS_GATA3_MA0037.3.damo.pwm.bed	7129
1	343	CEBPA	1.07109388349983	1.562767992187	32	86	383	825	825	431	22	172	185	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 0.1 % EtOH for 24 hrs	GTRD	EXP053365_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	52528
1	2136	HNF4A	1.07109388349983	1.562767992187	32	86	383	825	825	431	22	172	185	HNF4A liver HNF4A	liver	BTO:0000759	HNF4A		GTRD	EXP039987_liver_HNF4A_MACS_HNF4A_MA0114.4.damo.pwm.bed	36215
1	3870	TFAP2A	1.06990245487493	1.82731152786545	19	88	306	1697	1697	697	11	185	196	TFAP2A MCF7 (Invasive ductal breast carcinoma) TFAP2A	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2A		GEO	GSE60270_tfap2a_mcf7_MACS_TFAP2A_MA0810.1.damo.pwm.bed	8794
1	3888	TFAP2C	1.0613724590481	1.35867820913726	75	89	602	28	602	240	62	129	145	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p33; Treatment: 5 days in 5iLAF;	GTRD	EXP047537_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	71372
1	3890	TFAP2C	1.05872314772365	1.35611433656068	76	90	603	26	603	240	63	128	144	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p33; Treatment: 5 days in 5iLAF;	GTRD	EXP047537_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	73524
1	841	CTCF	1.02711022966847	1.59985408753588	27	91	377	1135	1135	534	18	177	189	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: dexamethasone 6hr	GTRD	EXP047812_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36132
1	2134	HNF4A	1.02479780327808	1.42947854341646	46	92	519	349	519	320	35	158	172	HNF4A liver HNF4A	liver	BTO:0000759	HNF4A		GTRD	EXP039657_liver_HNF4A_MACS_HNF4A_MA0114.4.damo.pwm.bed	52373
1	1212	ESR1	1.02066129234288	2.29812220331469	11	93	169	2332	2332	865	5	193	202	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2 treatment	GTRD	EXP036168_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	18212
1	1374	ESR1	1.02066129234288	2.29812220331469	11	93	169	2332	2332	865	5	193	202	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: vehicle (0.01% EtOH) for 30 mins Genotype: wildtype-ER	GTRD	EXP053341_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	15436
1	1964	GATA3	1.02066129234288	2.29812220331469	11	93	169	2332	2332	865	5	193	202	GATA3 MDA-MB-231 (breast adenocarcinoma) GATA3	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	GATA3		GTRD	EXP035434_MDA-MB-231--breast-adenocarcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	17713
1	1977	GATA3	1.02066129234288	2.29812220331469	11	93	169	2332	2332	865	5	193	202	GATA3 BE2C GATA3	BE2C	NULL	GATA3	Treatment: untreated	GTRD	EXP049487_BE2C_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	22831
1	961	CTCF	1.0171509383507	1.36565198247456	63	97	568	103	568	256	51	141	156	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm2610_MACS_CTCF_MA0139.1.damo.pwm.bed	66631
1	308	CEBPA	1.01367998839394	1.71025199235988	21	98	340	1535	1535	658	13	183	194	CEBPA U937 (adult acute monocytic leukemia) CEBPA	U937 (adult acute monocytic leukemia)	BTO:0001412	CEBPA		Array Express	ERP008568_cebpa_u937_MACS_CEBPA_MA0102.4.damo.pwm.bed	26296
1	370	CEBPB	1.01367998839394	1.71025199235988	21	98	340	1535	1535	658	13	183	194	CEBPB monocyte-derived macrophages CEBPB	monocyte-derived macrophages	NULL	CEBPB	none	GTRD	EXP038589_monocyte-derived-macrophages_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	23918
1	250	ATF3	1.00962873717937	1.57241806028785	28	100	382	1068	1068	517	19	176	188	ATF3 liver ATF3	liver	BTO:0000759	ATF3		ENCODE	ENCSR205FOW_liver_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	15186
1	2750	MEIS2	1.00535111165111	1.47563098780825	37	101	476	607	607	395	27	167	180	MEIS2 K562 (myelogenous leukemia) MEIS2	K562 (myelogenous leukemia)	NULL	MEIS2	NA	ENCODE	ENCSR851BNE_K562_MEIS2_MACS_MEIS2_MA0774.1.damo.pwm.bed	41488
1	4144	YY1	0.997185177442206	1.86952304951257	16	102	293	1909	1909	768	9	188	198	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1		GTRD	EXP038614_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	4138
1	3223	PBX2	0.995349430036488	1.34404204378169	69	103	613	47	613	254	57	135	150	PBX2 PBX2	NA	NA	PBX2	NA	NA	ENCSR979UVS_K562_PBX2_MACS_PBX2_MA1113.2.damo.pwm.bed	110496
1	665	CTCF	0.990048247145561	1.66433845707938	22	104	359	1459	1459	641	14	182	193	CTCF HCT-116 (colon carcinoma) CTCF	HCT-116 (colon carcinoma)	BTO:0001109	CTCF		GTRD	EXP038269_HCT-116--colon-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27713
1	1983	GATA3	0.981761983811246	5.15832154979442	5	105	85	3053	3053	1080	1	199	206	GATA3 T47D (invasive ductal carcinoma) GATA3	T47D (invasive ductal carcinoma)	BTO:0001248	GATA3	Passsage: <10	GTRD	EXP049905_T47D--invasive-ductal-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	4076
1	2727	MEF2B	0.981761983811246	5.15832154979442	5	105	85	3053	3053	1080	1	199	206	MEF2B SU-DHL-10 (diffuse large B-cell lymphoma) MEF2B	SU-DHL-10 (diffuse large B-cell lymphoma)	NULL	MEF2B	Genotype: wiltype MEF2B	GTRD	EXP048299_SU-DHL-10--diffuse-large-B-cell-lymphoma-_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	9686
1	3565	SMAD3	0.981761983811246	5.15832154979442	5	105	85	3053	3053	1080	1	199	206	SMAD3 HMLE-Twist-ER (breast cancer) SMAD3	HMLE-Twist-ER (breast cancer)	NULL	SMAD3	Treatment: no CellType: Immortalized human mammary epithelial cells	GTRD	EXP047889_HMLE-Twist-ER--breast-cancer-_SMAD3_MACS_SMAD3_MA1622.1.damo.pwm.bed	2374
1	4029	TP63	0.981761983811246	5.15832154979442	5	105	85	3053	3053	1080	1	199	206	TP63 neonatal keratinocytes TP63	neonatal keratinocytes	NULL	TP63		GTRD	EXP031101_neonatal-keratinocytes_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	6993
1	320	CEBPA	0.978668270885392	1.52551142118185	30	109	450	937	937	499	21	174	186	CEBPA MV-4-11 (Childhood acute monocytic leukemia) CEBPA	MV-4-11 (Childhood acute monocytic leukemia)	BTO:0004479	CEBPA		GTRD	EXP037965_MV4-11--childhood-acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	39886
1	856	CTCF	0.978668270885392	1.52551142118185	30	109	450	937	937	499	21	174	186	CTCF HeLa S3 (cervical adenocarcinoma) CTCF	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	CTCF	treatment: no block with TSA CellPopulation:unsynchronized	GTRD	EXP048091_HeLa-S3--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45753
1	3286	PPARG	0.978668270885392	1.52551142118185	30	109	450	937	937	499	21	174	186	PPARG subcutaneous white adipose tissue PPARG	subcutaneous white adipose tissue	NULL	PPARG		GTRD	EXP034422_subcutaneous-white-adipose-tissue_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	9670
1	1318	ESR1	0.97668662125003	2.76907346604493	8	112	134	2697	2697	981	3	196	204	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 500 nM AZD201 2 hr; Passage: p19;	GTRD	EXP047701_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	16665
1	2731	MEF2B	0.97668662125003	2.76907346604493	8	112	134	2697	2697	981	3	196	204	MEF2B HEK293-A MEF2B	HEK293-A	NULL	MEF2B	Genotype: wildtype MEF2B-V5;	GTRD	EXP055127_HEK293-A_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	6120
1	319	CEBPA	0.974990936060468	1.43773648252761	40	114	500	502	502	372	30	164	177	CEBPA MV-4-11 (Childhood acute monocytic leukemia) CEBPA	MV-4-11 (Childhood acute monocytic leukemia)	BTO:0004479	CEBPA		GTRD	EXP037965_MV4-11--childhood-acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	46332
1	1247	ESR1	0.968791132157444	1.62459441756108	23	115	373	1391	1391	626	15	181	192	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	10min E2	GTRD	EXP038337_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	40458
1	4134	YY1	0.967934729844855	2.09008919728278	12	116	184	2233	2233	844	6	192	201	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1		GTRD	EXP038604_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	2589
1	4145	YY1	0.967934729844855	2.09008919728278	12	116	184	2233	2233	844	6	192	201	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1		GTRD	EXP038615_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	2073
1	2710	MAX	0.961517144035801	1.36112267384985	56	118	573	192	573	294	45	148	162	MAX MKL-1 (Merkel cell carcinoma) MAX	MKL-1 (Merkel cell carcinoma)	NULL	MAX	Treatment: no treatment Markel Cell: positive	GTRD	EXP048813_MKL-1--Merkel-cell-carcinoma-_MAX_MACS_MAX_MA0059.1.damo.pwm.bed	53512
1	955	CTCF	0.957566007726482	1.41660612470439	42	119	528	454	528	367	32	162	175	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm19193_MACS_CTCF_MA0139.1.damo.pwm.bed	46307
1	4051	TP63	0.940211155325588	1.47009745666979	33	120	481	778	778	460	24	171	183	TP63 keratinocytes TP63	keratinocytes	NULL	TP63	D2	GEO	GSE59824_tp63_keratinocyte-d2_MACS_TP63_MA0525.2.damo.pwm.bed	44767
1	1230	ESR1	0.937188602583326	1.72206898303262	18	121	338	1785	1785	748	11	186	196	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	TNFa for 45m	GTRD	EXP036983_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	22345
1	3869	TFAP2A	0.937188602583326	1.72206898303262	18	121	338	1785	1785	748	11	186	196	TFAP2A MCF7 (Invasive ductal breast carcinoma) TFAP2A	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2A		GEO	GSE60270_tfap2a_mcf7_MACS_TFAP2A_MA0003.4.damo.pwm.bed	8755
1	993	CTCFL	0.936168624083789	1.33458786875773	62	123	621	118	621	287	51	142	156	CTCFL OVCAR8 (high grade ovarian serous adenocarcinoma) CTCFL	OVCAR8 (high grade ovarian serous adenocarcinoma)	BTO:0003054	CTCFL	NA	GEO	GSE70764_ctcfl_ovcar8_MACS_CTCFL_MA1102.2.damo.pwm.bed	27711
1	346	CEBPA	0.934859614220345	1.3897057544472	45	124	551	383	551	353	35	159	172	CEBPA Kasumi-1 (acute myeloblastic leukemia) CEBPA	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	CEBPA		GTRD	EXP058118_Kasumi-1--acute-myeloblastic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	63304
1	945	CTCF	0.934859614220345	1.3897057544472	45	124	551	383	551	353	35	159	172	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm10847_MACS_CTCF_MA0139.1.damo.pwm.bed	42527
1	3916	TFAP2C	0.932624020485571	1.33088996490559	63	126	630	103	630	286	52	141	155	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	E2	GEO	GSE23852_tfap2c_mcf7-e2_MACS_TFAP2C_MA0814.2.damo.pwm.bed	39682
1	313	CEBPA	0.932088122625864	1.55926372701808	25	127	388	1262	1262	592	17	179	190	CEBPA U937 (adult acute monocytic leukemia) CEBPA	U937 (adult acute monocytic leukemia)	BTO:0001412	CEBPA	dmso	GTRD	EXP000947_U937--adult-acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	41983
1	481	CTCF	0.932088122625864	1.55926372701808	25	127	388	1262	1262	592	17	179	190	CTCF lung CTCF	lung	BTO:0000763	CTCF		ENCODE	ENCSR000DMH_lung_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	24478
1	915	CTCF	0.918729312124877	1.44044413069156	35	129	499	691	691	440	26	169	181	CTCF GM18526 (B – cells Lymphoblastoid Cell Lines) CTCF	GM18526 (B – cells Lymphoblastoid Cell Lines)	NULL	CTCF		GTRD	EXP054525_GM18526--B-–-cells-Lymphoblastoid-Cell-Lines-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42615
1	188	AR	0.915871411817411	Inf	3	130	1	3316	3316	1150	0	201	207	AR prostate AR	prostate	NULL	AR		GEO	GSE65478_AR_prostate-res_MACS_AR_MA0007.3.damo.pwm.bed	2708
1	608	CTCF	0.915871411817411	Inf	3	130	1	3316	3316	1150	0	201	207	CTCF CD34+ hematopoietic stem cells-derived proerythroblasts CTCF	CD34+ hematopoietic stem cells-derived proerythroblasts	NULL	CTCF	2-trimester fetal liver	GTRD	EXP031445_CD34--hematopoietic-stem-cells-derived-proerythroblasts_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	2336
1	1699	FOXA1	0.915871411817411	Inf	3	130	1	3316	3316	1150	0	201	207	FOXA1 A1A3(breast cancer cells) FOXA1	A1A3(breast cancer cells)	NULL	FOXA1	Treatment: 1hr Dex, Doxycycline 72 hr CellLine: A1A3 from T47D cell line Genotype: Brg1 knockdown	GTRD	EXP048407_A1A3-breast-cancer-cells-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	5294
1	1849	FOXJ2	0.915871411817411	Inf	3	130	1	3316	3316	1150	0	201	207	FOXJ2 K562 (myelogenous leukemia) FOXJ2	K562 (myelogenous leukemia)	NULL	FOXJ2	NA	ENCODE	ENCSR847LBF_K562_FOXJ2_MACS_FOXJ2_MA0614.1.damo.pwm.bed	1009
1	1923	GATA1	0.915871411817411	Inf	3	130	1	3316	3316	1150	0	201	207	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	MYO1D Hub KO	GTRD	EXP040811_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	5256
1	1984	GATA3	0.915871411817411	Inf	3	130	1	3316	3316	1150	0	201	207	GATA3 T47D (invasive ductal carcinoma) GATA3	T47D (invasive ductal carcinoma)	BTO:0001248	GATA3	Passsage: <10 Genotype: wt/R330fs mutant with CRISPR	GTRD	EXP049906_T47D--invasive-ductal-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	2260
1	1990	GATA3	0.915871411817411	Inf	3	130	1	3316	3316	1150	0	201	207	GATA3 Jurkat (T-cells) GATA3	Jurkat (T-cells)	BTO:0000661	GATA3		GEO	GSE29180_gata3_jurkat_MACS_GATA3_MA0037.3.damo.pwm.bed	4035
1	3059	NR2F1	0.915871411817411	Inf	3	130	1	3316	3316	1150	0	201	207	NR2F1 H9-derived neural crest cells NR2F1	H9-derived neural crest cells	NULL	NR2F1	NA	GTRD	EXP030994_H9-derived-neural-crest-cells_NR2F1_MACS_NR2F1_MA0017.2.damo.pwm.bed	3183
1	3298	PPARG	0.915871411817411	Inf	3	130	1	3316	3316	1150	0	201	207	PPARG THP-1 (acute monocytic leukemia) PPARG	THP-1 (acute monocytic leukemia)	BTO:0001370	PPARG	DIFF	GEO	GSE25426_pparg_thp1-diff_MACS_PPARG_MA0066.1.damo.pwm.bed	565
1	3321	RARG	0.915871411817411	Inf	3	130	1	3316	3316	1150	0	201	207	RARG RWPE1 (prostate epithelial cells) RARG	RWPE1 (prostate epithelial cells)	BTO:0003709	RARG	Treatment: 10 uM CD437 for 2 hr Gender: male Source: non-malignant prostate cell line infected with BAC-RARG-EGFP	GTRD	EXP048636_RWPE1--prostate-epithelial-cells-_RARG_MACS_RARG_MA1553.1.damo.pwm.bed	809
1	3562	SMAD2	0.915871411817411	Inf	3	130	1	3316	3316	1150	0	201	207	SMAD2 endoderm SMAD2	endoderm	NA	SMAD2	NA	GEO	GSE29422_smad2_endoderm_MACS_SMAD2_MA0513.1.damo.pwm.bed	5064
1	3799	TCF4	0.915559184249971	1.36736358860319	48	141	561	317	561	340	38	156	169	TCF4 SU-DHL-2 (anaplastic large cell lymphoma) TCF4	SU-DHL-2 (anaplastic large cell lymphoma)	NULL	TCF4	Treatment: 60 ng/ml Tetracyclin for 24 hrs; Genotype: inducible TCF4 expression;	GTRD	EXP058276_SU-DHL-2--anaplastic-large-cell-lymphoma-_TCF4_MACS_TCF4_MA0830.2.damo.pwm.bed	216932
1	387	CEBPB	0.912681555260464	1.66684697936965	19	142	357	1697	1697	732	12	185	195	CEBPB THP-1 (acute monocytic leukemia) CEBPB	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPB	Treatment: untreated, eGFP(EP mRNA)	GTRD	EXP047813_THP-1--acute-monocytic-leukemia-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	24461
1	1250	ESR1	0.912681555260464	1.66684697936965	19	142	357	1697	1697	732	12	185	195	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	80min E2	GTRD	EXP038340_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	37461
1	361	CEBPB	0.912263199498502	1.30952118033451	70	144	667	42	667	284	59	134	148	CEBPB IMR90 (lung fibroblasts) CEBPB	IMR90 (lung fibroblasts)	NULL	CEBPB		ENCODE	ENCSR000EFM_IMR-90_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	167175
1	2056	GLIS3	0.909772071584459	1.36075040536887	49	145	574	299	574	339	39	155	168	GLIS3 H9 GLIS3	H9	NULL	GLIS3	Genotype: inducible Glis3 expression Treatment: with Doxycycline , 12 hrs Source: G3- human embryonic stem cells	GTRD	EXP052996_H9_GLIS3_MACS_GLIS3_MA0737.1.damo.pwm.bed	37175
1	1182	ESR1	0.906822855453393	2.33768619226357	9	146	166	2564	2564	959	4	195	203	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Estrogen	GTRD	EXP000559_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	8205
1	3700	SREBF1	0.906822855453393	2.33768619226357	9	146	166	2564	2564	959	4	195	203	SREBF1 MCF7 (Invasive ductal breast carcinoma) SREBF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	SREBF1		ENCODE	ENCSR197DJH_MCF-7_SREBF1_MACS_SREBF1_MA0595.1.damo.pwm.bed	4411
1	3709	SRF	0.906822855453393	2.33768619226357	9	146	166	2564	2564	959	4	195	203	SRF HCT-116 (colon carcinoma) SRF	HCT-116 (colon carcinoma)	BTO:0001109	SRF		ENCODE	ENCSR000BSC_HCT116_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	4979
1	3196	OTX2	0.901511273982468	1.50784755876398	27	149	462	1135	1135	582	19	177	188	OTX2 HUES64 (embryonic stem cells) OTX2	HUES64 (embryonic stem cells)	NULL	OTX2		GTRD	EXP036799_HUES64--embryonic-stem-cells-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	20866
1	491	CTCF	0.899893606531549	1.41517048221879	37	150	534	607	607	430	28	167	179	CTCF spleen CTCF	spleen	BTO:0001281	CTCF		ENCODE	ENCSR000DNI_spleen_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30745
1	3889	TFAP2C	0.896868428916867	1.29270842855334	78	151	689	21	689	287	67	126	140	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p33; Treatment: 5 days in 5iLAF;	GTRD	EXP047537_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	73500
1	573	CTCF	0.894087608498339	1.34300548860715	52	152	614	244	614	337	42	152	165	CTCF HeLa S3 (cervical adenocarcinoma) CTCF	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	CTCF	NULL	GTRD	EXP000597_HeLa-S3--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	80090
1	1938	GATA2	0.889787655546867	1.83022965202018	14	153	303	2073	2073	843	8	190	199	GATA2 CD34+ hematopoietic stem cells GATA2	CD34+ hematopoietic stem cells	NULL	GATA2		GTRD	EXP031975_CD34--hematopoietic-stem-cells_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	15505
1	1955	GATA2	0.889787655546867	1.83022965202018	14	153	303	2073	2073	843	8	190	199	GATA2 LNCaP (prostate carcinoma) GATA2	LNCaP (prostate carcinoma)	BTO:0001321	GATA2	FBS	GEO	GSE69043_gata2_lncap-fbs_MACS_GATA2_MA0036.3.damo.pwm.bed	27170
1	327	CEBPA	0.888061958371865	1.48605486116108	28	155	470	1068	1068	564	20	176	187	CEBPA Kasumi-1 (acute myeloblastic leukemia) CEBPA	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	CEBPA	Treatment: estradiol; Genotype: inducible version of CEBPA (C/EBPalpha-ER);	GTRD	EXP047677_Kasumi-1--acute-myeloblastic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	31193
1	865	CTCF	0.888061958371865	1.48605486116108	28	155	470	1068	1068	564	20	176	187	CTCF ID00014 (lymphoblastoid cell, DiGeorge syndrome) CTCF	ID00014 (lymphoblastoid cell, DiGeorge syndrome)	NULL	CTCF	Genotype: 22q11 deletion Cell type: lymphoblastoid cell Age: 34	GTRD	EXP048875_ID00014--lymphoblastoid-cell--DiGeorge-syndrome-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39999
1	891	CTCF	0.876537037639107	1.32340688580701	56	157	632	192	632	327	46	148	161	CTCF TTC-1240 (Rhabdoid tumor of the kidney) CTCF	TTC-1240 (Rhabdoid tumor of the kidney)	NULL	CTCF	Treatment: lentivirally infected with empty vector control	GTRD	EXP053111_TTC-1240--Rhabdoid-tumor-of-the-kidney-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	69124
1	3509	RXRA	0.87565201135733	1.46637620458518	29	158	484	1013	1013	552	21	175	186	RXRA HepG2 (hepatoblastoma) RXRA	HepG2 (hepatoblastoma)	BTO:0000599	RXRA		ENCODE	ENCSR000BHU_HepG2_RXRA_MACS_RXRA_MA0512.2.damo.pwm.bed	19422
1	4069	USF1	0.87565201135733	1.46637620458518	29	158	484	1013	1013	552	21	175	186	USF1 HepG2 (hepatoblastoma) USF1	HepG2 (hepatoblastoma)	BTO:0000599	USF1		ENCODE	ENCSR000BGM_HepG2_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	21469
1	817	CTCF	0.871605929619939	1.58020148700188	21	160	379	1535	1535	691	14	183	193	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: IFNb treated 6hr, IAV NS1(EP mRNA)	GTRD	EXP047762_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	26399
1	3206	OTX2	0.871605929619939	1.58020148700188	21	160	379	1535	1535	691	14	183	193	OTX2 D341 Med (medulloblastoma) OTX2	D341 Med (medulloblastoma)	NULL	OTX2	CRISPR.OTX2.4	GTRD	EXP038205_D341-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	43257
1	2644	KLF5	0.868986635998176	1.31503351915147	58	162	657	154	657	324	48	146	159	KLF5 HEK293T (embryonic kidney) KLF5	HEK293T (embryonic kidney)	BTO:0002181	KLF5	Treatment: Over-expressing KLF5 WT	GTRD	EXP049096_HEK293T--embryonic-kidney-_KLF5_MACS_KLF5_MA0599.1.damo.pwm.bed	20113
1	468	CTCF	0.864167792837803	1.44852401287431	30	163	494	937	937	531	22	174	185	CTCF GM13977 (female B-cells) CTCF	GM13977 (female B-cells)	NULL	CTCF		ENCODE	ENCSR000DLB_GM13977_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34287
1	1114	EOMES	0.862042543006699	3.09827439620751	6	164	106	2948	2948	1070	2	198	205	EOMES HUES64 (embryonic stem cells) EOMES	HUES64 (embryonic stem cells)	NULL	EOMES	NA	GTRD	EXP036786_HUES64--embryonic-stem-cells-_EOMES_MACS_EOMES_MA0800.1.damo.pwm.bed	12216
1	1214	ESR1	0.862042543006699	3.09827439620751	6	164	106	2948	2948	1070	2	198	205	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2 treatment	GTRD	EXP036170_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	15658
1	1987	GATA3	0.862042543006699	3.09827439620751	6	164	106	2948	2948	1070	2	198	205	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3	Treatment: with Estrogen;	GTRD	EXP058227_MCF7--Invasive-ductal-breast-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	10636
1	2215	IRF4	0.862042543006699	3.09827439620751	6	164	106	2948	2948	1070	2	198	205	IRF4 OCI-LY3 (diffuse large B-cell lymphoma) IRF4	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	IRF4		GEO	GSE56857_irf4_ocily3_MACS_IRF4_MA1419.1.damo.pwm.bed	6603
1	946	CTCF	0.858979605075591	1.30395629227151	61	168	674	127	674	323	51	143	156	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm12878_MACS_CTCF_MA0139.1.damo.pwm.bed	64122
1	254	ATF3	0.854579634265826	2.07886454345064	10	169	186	2442	2442	932	5	194	202	ATF3 K562 (myelogenous leukemia) ATF3	K562 (myelogenous leukemia)	NULL	ATF3		GTRD	EXP039361_K562--myelogenous-leukemia-_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	20308
1	847	CTCF	0.854579634265826	2.07886454345064	10	169	186	2442	2442	932	5	194	202	CTCF WA09 (embryonic stem cells) CTCF	WA09 (embryonic stem cells)	NULL	CTCF	Treatment: under heat shock conditions	GTRD	EXP047907_WA09--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	12526
1	1112	EOMES	0.854579634265826	2.07886454345064	10	169	186	2442	2442	932	5	194	202	EOMES HUES64 (embryonic stem cells) EOMES	HUES64 (embryonic stem cells)	NULL	EOMES	NA	GTRD	EXP036702_HUES64--embryonic-stem-cells-_EOMES_MACS_EOMES_MA0800.1.damo.pwm.bed	6888
1	1235	ESR1	0.854579634265826	2.07886454345064	10	169	186	2442	2442	932	5	194	202	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	BYL719	GTRD	EXP037592_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	8846
1	1260	ESR1	0.854579634265826	2.07886454345064	10	169	186	2442	2442	932	5	194	202	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP038373_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	15427
1	1588	FOSL2	0.854579634265826	2.07886454345064	10	169	186	2442	2442	932	5	194	202	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP039650_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	9111
1	1589	FOSL2	0.854579634265826	2.07886454345064	10	169	186	2442	2442	932	5	194	202	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP039650_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	9257
1	1590	FOSL2	0.854579634265826	2.07886454345064	10	169	186	2442	2442	932	5	194	202	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP039650_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	9369
1	1591	FOSL2	0.854579634265826	2.07886454345064	10	169	186	2442	2442	932	5	194	202	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP039650_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	9369
1	3427	REST	0.854579634265826	2.07886454345064	10	169	186	2442	2442	932	5	194	202	REST CRC107 (colorectal cancer metastatic stem cells) REST	CRC107 (colorectal cancer metastatic stem cells)	NULL	REST	Source: organoid dissociation;	GTRD	EXP058085_CRC107--colorectal-cancer-metastatic-stem-cells-_REST_MACS_REST_MA0138.2.damo.pwm.bed	6528
1	628	CTCF	0.854211572773071	1.54560694043251	22	179	396	1459	1459	678	15	182	192	CTCF HUES64 (embryonic stem cells) CTCF	HUES64 (embryonic stem cells)	NULL	CTCF		GTRD	EXP036698_HUES64--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	32556
1	788	CTCF	0.85351212005666	1.43226072904667	31	180	516	881	881	526	23	173	184	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP040193_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	44167
1	916	CTCF	0.85351212005666	1.43226072904667	31	180	516	881	881	526	23	173	184	CTCF GM19099 (female B-cells Lymphoblastoid Cell Lines) CTCF	GM19099 (female B-cells Lymphoblastoid Cell Lines)	NULL	CTCF		GTRD	EXP054529_GM19099--female-B-cells-Lymphoblastoid-Cell-Lines-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41850
1	1703	FOXA1	0.85351212005666	1.43226072904667	31	180	516	881	881	526	23	173	184	FOXA1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) FOXA1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	FOXA1	Treatment: 45 min ethanol	GTRD	EXP048439_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	46104
1	950	CTCF	0.850374325702179	1.29441117706224	64	183	682	95	682	320	54	140	153	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm18486_MACS_CTCF_MA0139.1.damo.pwm.bed	57283
1	951	CTCF	0.849330281062114	1.35042731934821	44	184	608	408	608	400	35	160	172	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm18505_MACS_CTCF_MA0139.1.damo.pwm.bed	44479
1	474	CTCF	0.843601359920675	1.41738839647633	32	185	526	825	825	512	24	172	183	CTCF HeLa S3 (cervical adenocarcinoma) CTCF	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	CTCF		ENCODE	ENCSR000DLO_HeLa-S3_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49889
1	914	CTCF	0.843601359920675	1.41738839647633	32	185	526	825	825	512	24	172	183	CTCF GM18505 (female B-cells Lymphoblastoid Cell Lines) CTCF	GM18505 (female B-cells Lymphoblastoid Cell Lines)	NULL	CTCF		GTRD	EXP054523_GM18505--female-B-cells-Lymphoblastoid-Cell-Lines-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39311
1	623	CTCF	0.838501542310169	1.51537770858008	23	187	453	1391	1391	677	16	181	191	CTCF BEAS-2B (bronchial epithelium) CTCF	BEAS-2B (bronchial epithelium)	NULL	CTCF		GTRD	EXP033453_BEAS-2B--bronchial-epithelium-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	19835
1	816	CTCF	0.838501542310169	1.51537770858008	23	187	453	1391	1391	677	16	181	191	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: IFNb treated 6hr, eGFP(EP mRNA)	GTRD	EXP047761_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27682
1	2023	GATA4	0.838501542310169	1.51537770858008	23	187	453	1391	1391	677	16	181	191	GATA4 BJ (fibroblasts) GATA4	BJ (fibroblasts)	NULL	GATA4	Genotype: Clonal FOXA2 doxycycline inducible cells	GTRD	EXP049376_BJ--fibroblasts-_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	116368
1	2772	MXI1	0.834363121767295	1.40374074030416	33	190	543	778	778	504	25	171	182	MXI1 K562 (myelogenous leukemia) MXI1	K562 (myelogenous leukemia)	NULL	MXI1	NA	ENCODE	ENCSR000EGZ_K562_MXI1_MACS_MXI1_MA1108.2.damo.pwm.bed	7695
1	964	CTCF	0.834284035441124	1.67449998986939	16	191	355	1909	1909	818	10	188	197	CTCF GP5d (colon adenocarcinoma) CTCF	GP5d (colon adenocarcinoma)	NULL	CTCF	SIRAD21	GEO	GSE51234_ctcf_gp5d-sirad21_MACS_CTCF_MA0139.1.damo.pwm.bed	23882
1	403	CEBPB	0.819150961244448	1.31365407974577	50	192	662	275	662	376	41	154	166	CEBPB hMSC CEBPB	hMSC	NA	CEBPB	DMI_HI	GEO	GSE68864_cebpb_hmsc-dmi-hi_MACS_CEBPB_MA0466.2.damo.pwm.bed	64807
1	1858	FOXP1	0.813810842115787	1.90638048706501	11	193	290	2332	2332	938	6	193	201	FOXP1 SU-DHL-6 (diffuse large B-cell lymphoma) FOXP1	SU-DHL-6 (diffuse large B-cell lymphoma)	NULL	FOXP1	NA	Array Express	ERP010999_foxp1_sudhl6_MACS_FOXP1_MA0481.3.damo.pwm.bed	13126
1	4153	YY1	0.813810842115787	1.90638048706501	11	193	290	2332	2332	938	6	193	201	YY1 WA01 (H1, human embryonic stem cells) YY1	WA01 (H1, human embryonic stem cells)	NULL	YY1		GEO	GSE39096_yy1_esc-h1_MACS_YY1_MA0095.2.damo.pwm.bed	5935
1	381	CEBPB	0.812079508356501	1.61793982121899	17	195	375	1846	1846	805	11	187	196	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP040177_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	17090
1	633	CTCF	0.811238772723014	1.46510807192988	25	196	486	1262	1262	648	18	179	189	CTCF OCI-LY7 (diffuse large B-cell lymphoma) CTCF	OCI-LY7 (diffuse large B-cell lymphoma)	NULL	CTCF		GTRD	EXP036841_OCI-LY7--diffuse-large-B-cell-lymphoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	43733
1	2729	MEF2B	0.811238772723014	1.46510807192988	25	196	486	1262	1262	648	18	179	189	MEF2B SU-DHL-10 (diffuse large B-cell lymphoma) MEF2B	SU-DHL-10 (diffuse large B-cell lymphoma)	NULL	MEF2B	Genotype: MEF2B- D83V mutant	GTRD	EXP048301_SU-DHL-10--diffuse-large-B-cell-lymphoma-_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	16222
1	404	CEBPB	0.800248875836843	1.29113130163684	55	198	690	211	690	366	46	149	161	CEBPB hMSC CEBPB	hMSC	NA	CEBPB	DMI_LOW	GEO	GSE68864_cebpb_hmsc-dmi-low_MACS_CEBPB_MA0466.2.damo.pwm.bed	68585
1	390	CEBPB	0.799335531868373	1.4439965962118	26	199	495	1204	1204	633	19	178	188	CEBPB THP-1 (acute monocytic leukemia) CEBPB	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPB	Treatment: Pam3csk4 treated 4hr, IAV NS1(EP mRNA)	GTRD	EXP047816_THP-1--acute-monocytic-leukemia-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	40757
1	3141	NR3C1	0.796307518588407	1.34960551564463	38	200	612	576	612	463	30	166	177	NR3C1 HASM2 (Human airway smooth muscle 2) NR3C1	HASM2 (Human airway smooth muscle 2)	NULL	NR3C1	Treatment: dexamethasone for 4 hr Genotype: Ad-GFP transduction	GTRD	EXP049656_HASM2--Human-airway-smooth-muscle-2-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	42684
1	367	CEBPB	0.791001047273904	1.28018040894124	58	201	711	154	711	355	49	146	158	CEBPB SUM159PT (Triple negative breast cancer) CEBPB	SUM159PT (Triple negative breast cancer)	NULL	CEBPB	100nM trametinib, 300nM JQ1	GTRD	EXP037882_SUM159PT--pleiomorphic-breast-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	98230
1	867	CTCF	0.78839920334305	1.4250318067069	27	202	520	1135	1135	619	20	177	187	CTCF ID00014 (lymphoblastoid cell, DiGeorge syndrome) CTCF	ID00014 (lymphoblastoid cell, DiGeorge syndrome)	NULL	CTCF	Genotype: 22q11 deletion Cell type: lymphoblastoid cell Age: 11	GTRD	EXP048877_ID00014--lymphoblastoid-cell--DiGeorge-syndrome-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38854
1	3287	PPARG	0.78839920334305	1.4250318067069	27	202	520	1135	1135	619	20	177	187	PPARG subcutaneous white adipose tissue PPARG	subcutaneous white adipose tissue	NULL	PPARG		GTRD	EXP034422_subcutaneous-white-adipose-tissue_PPARG_MACS_PPARG_MA0066.1.damo.pwm.bed	8823
1	3443	RFX3	0.78839920334305	1.4250318067069	27	202	520	1135	1135	619	20	177	187	RFX3 HepG2 (hepatoblastoma) RFX3	HepG2 (hepatoblastoma)	BTO:0000599	RFX3	NA	GTRD	EXP039359_HepG2--hepatoblastoma-_RFX3_MACS_RFX3_MA0798.2.damo.pwm.bed	11404
1	1113	EOMES	0.788014307049169	2.41132917633671	7	205	156	2812	2812	1060	3	197	204	EOMES HUES64 (embryonic stem cells) EOMES	HUES64 (embryonic stem cells)	NULL	EOMES	NA	GTRD	EXP036785_HUES64--embryonic-stem-cells-_EOMES_MACS_EOMES_MA0800.1.damo.pwm.bed	19498
1	1281	ESR1	0.788014307049169	2.41132917633671	7	205	156	2812	2812	1060	3	197	204	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GTRD	EXP038769_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12074
1	1780	FOXA1	0.788014307049169	2.41132917633671	7	205	156	2812	2812	1060	3	197	204	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	DHT24H	GEO	GSE58428_foxa1_lncap-dht24h_MACS_FOXA1_MA0148.4.damo.pwm.bed	11460
1	1893	GATA1	0.788014307049169	2.41132917633671	7	205	156	2812	2812	1060	3	197	204	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1		ENCODE	ENCSR000EWM_K562_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	7904
1	1948	GATA2	0.788014307049169	2.41132917633671	7	205	156	2812	2812	1060	3	197	204	GATA2 TF-1 (erythroleukemia) GATA2	TF-1 (erythroleukemia)	BTO:0004760	GATA2	Genotype: wildtype; Treatment: DOX for 6 days;	GTRD	EXP055346_TF-1--erythroleukemia-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	36006
1	2477	JUNB	0.788014307049169	2.41132917633671	7	205	156	2812	2812	1060	3	197	204	JUNB K562 (myelogenous leukemia) JUNB	K562 (myelogenous leukemia)	NULL	JUNB		ENCODE	ENCSR795IYP_K562_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	4064
1	3701	SREBF1	0.788014307049169	2.41132917633671	7	205	156	2812	2812	1060	3	197	204	SREBF1 MCF7 (Invasive ductal breast carcinoma) SREBF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	SREBF1		ENCODE	ENCSR197DJH_MCF-7_SREBF1_MACS_SREBF1_MA0829.2.damo.pwm.bed	3673
1	954	CTCF	0.784094142412399	1.3328975532025	40	212	627	502	627	447	32	164	175	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm19099_MACS_CTCF_MA0139.1.damo.pwm.bed	40225
1	3020	NFIL3	0.784094142412399	1.3328975532025	40	212	627	502	627	447	32	164	175	NFIL3 HepG2 (hepatoblastoma) NFIL3	HepG2 (hepatoblastoma)	BTO:0000599	NFIL3	NA	GTRD	EXP040167_HepG2--hepatoblastoma-_NFIL3_MACS_NFIL3_MA0025.2.damo.pwm.bed	41501
1	399	CEBPB	0.780984988411791	1.78322780707903	12	214	323	2233	2233	923	7	192	200	CEBPB monocyte CEBPB	monocyte	NA	CEBPB	MACROPHAGE	GEO	GSE31621_cebpb_monocyte-macro_MACS_CEBPB_MA0466.2.damo.pwm.bed	14991
1	1316	ESR1	0.780984988411791	1.78322780707903	12	214	323	2233	2233	923	7	192	200	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: vehicle(DMSO 2 hr); Passage: p19;	GTRD	EXP047699_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	20433
1	2131	HNF4A	0.780984988411791	1.78322780707903	12	214	323	2233	2233	923	7	192	200	HNF4A HUES64 (embryonic stem cells) HNF4A	HUES64 (embryonic stem cells)	NULL	HNF4A		GTRD	EXP036715_HUES64--embryonic-stem-cells-_HNF4A_MACS_HNF4A_MA1494.1.damo.pwm.bed	4716
1	4132	YY1	0.780984988411791	1.78322780707903	12	214	323	2233	2233	923	7	192	200	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1		GTRD	EXP038602_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	3135
1	4142	YY1	0.780984988411791	1.78322780707903	12	214	323	2233	2233	923	7	192	200	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1		GTRD	EXP038612_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	2972
1	376	CEBPB	0.778318467152872	1.40790768012584	28	219	542	1068	1068	610	21	176	186	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP039834_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	23959
1	1829	FOXA2	0.775432920279394	1.53104718834055	19	220	420	1697	1697	779	13	185	194	FOXA2 liver FOXA2	liver	BTO:0000759	FOXA2		GTRD	EXP039847_liver_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	25199
1	388	CEBPB	0.768998945430887	1.39237383761441	29	221	545	1013	1013	593	22	175	185	CEBPB THP-1 (acute monocytic leukemia) CEBPB	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPB	Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA)	GTRD	EXP047814_THP-1--acute-monocytic-leukemia-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	41566
1	3310	RARA	0.768998945430887	1.39237383761441	29	221	545	1013	1013	593	22	175	185	RARA HepG2 (hepatoblastoma) RARA	HepG2 (hepatoblastoma)	BTO:0000599	RARA		GTRD	EXP039479_HepG2--hepatoblastoma-_RARA_MACS_RARA_MA0730.1.damo.pwm.bed	33293
1	368	CEBPB	0.763510763464255	1.30539231534499	44	223	670	408	670	434	36	160	171	CEBPB MV-4-11 (Childhood acute monocytic leukemia) CEBPB	MV-4-11 (Childhood acute monocytic leukemia)	BTO:0004479	CEBPB		GTRD	EXP037966_MV4-11--childhood-acute-monocytic-leukemia-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	56973
1	328	CEBPA	0.760360060791979	1.37822345010756	30	224	558	937	937	573	23	174	184	CEBPA Kasumi-1 (acute myeloblastic leukemia) CEBPA	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	CEBPA	Treatment: estradiol; Genotype: inducible version of CEBPA (C/EBPalpha-ER);	GTRD	EXP047677_Kasumi-1--acute-myeloblastic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	33345
1	1	AR	0.760120620019618	1.49696996978531	20	225	463	1606	1606	765	14	184	193	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR		Array Express	ERP001226_AR_lncap_MACS_AR_MA0007.3.damo.pwm.bed	31151
1	373	CEBPB	0.760120620019618	1.49696996978531	20	225	463	1606	1606	765	14	184	193	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039561_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	18054
1	3309	RARA	0.75480649607257	1.29398117465596	46	227	685	349	685	420	38	158	169	RARA HepG2 (hepatoblastoma) RARA	HepG2 (hepatoblastoma)	BTO:0000599	RARA		GTRD	EXP039479_HepG2--hepatoblastoma-_RARA_MACS_RARA_MA0729.1.damo.pwm.bed	50529
1	1130	ERG	0.753912935603007	1.69091184535114	13	228	353	2153	2153	911	8	191	199	ERG HAEC (human aortic endothelial cells) ERG	HAEC (human aortic endothelial cells)	NULL	ERG	control, 4h	GTRD	EXP038045_HAEC--human-aortic-endothelial-cells-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	5549
1	1931	GATA2	0.753912935603007	1.69091184535114	13	228	353	2153	2153	911	8	191	199	GATA2 K562 (myelogenous leukemia) GATA2	K562 (myelogenous leukemia)	NULL	GATA2		ENCODE	ENCSR000EWG_K562_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	19220
1	685	CTCF	0.752332574462751	1.36528416701104	31	230	569	881	881	560	24	173	183	CTCF esophagus squamous epithelium CTCF	esophagus squamous epithelium	NULL	CTCF		GTRD	EXP039438_esophagus-squamous-epithelium_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29178
1	815	CTCF	0.752332574462751	1.36528416701104	31	230	569	881	881	560	24	173	183	CTCF CD34+ hematopoietic stem cells CTCF	CD34+ hematopoietic stem cells	NULL	CTCF		GTRD	EXP040768_CD34--hematopoietic-stem-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35044
1	864	CTCF	0.752332574462751	1.36528416701104	31	230	569	881	881	560	24	173	183	CTCF PANC1 (pancreatic ductal adenocarcinoma) CTCF	PANC1 (pancreatic ductal adenocarcinoma)	NULL	CTCF		GTRD	EXP048791_PANC1--pancreatic-ductal-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42756
1	365	CEBPB	0.750792950264596	1.28875777530013	47	233	701	333	701	422	39	157	168	CEBPB SUM159PT (Triple negative breast cancer) CEBPB	SUM159PT (Triple negative breast cancer)	NULL	CEBPB	100nM trametinib	GTRD	EXP037880_SUM159PT--pleiomorphic-breast-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	78320
1	3734	STAT3	0.746392983572038	1.46747437225823	21	234	482	1535	1535	750	15	183	192	STAT3 MDA-MB-157 (triple negative breast carcinoma) STAT3	MDA-MB-157 (triple negative breast carcinoma)	NULL	STAT3	ethanol	GTRD	EXP037700_MDA-MB-157--breast-carcinoma-_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	18608
1	4040	TP63	0.746392983572038	1.46747437225823	21	234	482	1535	1535	750	15	183	192	TP63 MCF10A (breast epithelial cells) TP63	MCF10A (breast epithelial cells)	BTO:0001939	TP63	Treatment: 5 uM Nutlin3A for 6 hrs;	GTRD	EXP057962_MCF10A--breast-epithelial-cells-_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	35495
1	351	CEBPB	0.744856637581365	1.35341122176361	32	236	606	825	825	556	25	172	182	CEBPB K562 (myelogenous leukemia) CEBPB	K562 (myelogenous leukemia)	NULL	CEBPB		ENCODE	ENCSR000BRQ_K562_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	38939
1	928	CTCF	0.744856637581365	1.35341122176361	32	236	606	825	825	556	25	172	182	CTCF MDA-MB-157 (triple negative breast carcinoma) CTCF	MDA-MB-157 (triple negative breast carcinoma)	NULL	CTCF	Treatment: untreated;	GTRD	EXP058203_MDA-MB-157--triple-negative-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41339
1	359	CEBPB	0.743375965045135	1.27916039556526	49	238	712	299	712	416	41	155	166	CEBPB HepG2 (hepatoblastoma) CEBPB	HepG2 (hepatoblastoma)	BTO:0000599	CEBPB		ENCODE	ENCSR000EEE_HepG2_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	122200
1	139	AR	0.741262969116338	4.1072900023366	4	239	89	3182	3182	1170	1	200	206	AR LNCaP C4-2B (prostate carcinoma) AR	LNCaP C4-2B (prostate carcinoma)	BTO:0004959	AR	DHT	GEO	GSE40050_AR_c42b-dht_MACS_AR_MA0007.3.damo.pwm.bed	2350
1	1233	ESR1	0.741262969116338	4.1072900023366	4	239	89	3182	3182	1170	1	200	206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2, DEX	GTRD	EXP037446_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	7711
1	1243	ESR1	0.741262969116338	4.1072900023366	4	239	89	3182	3182	1170	1	200	206	ESR1 breast tumor xenograft ESR1	breast tumor xenograft	NULL	ESR1	estrogen	GTRD	EXP038284_breast-tumor-xenograft_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	4681
1	1921	GATA1	0.741262969116338	4.1072900023366	4	239	89	3182	3182	1170	1	200	206	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	MYO1D Non-hub KO	GTRD	EXP040809_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	7411
1	1988	GATA3	0.741262969116338	4.1072900023366	4	239	89	3182	3182	1170	1	200	206	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3	DMSO	GEO	GSE29073_gata3_mcf7-dmso_MACS_GATA3_MA0037.3.damo.pwm.bed	9092
1	2231	JUN	0.741262969116338	4.1072900023366	4	239	89	3182	3182	1170	1	200	206	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN		ENCODE	ENCSR176EXN_MCF-7_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	2304
1	3712	SRF	0.741262969116338	4.1072900023366	4	239	89	3182	3182	1170	1	200	206	SRF HEL (Erythro Leukemia) SRF	HEL (Erythro Leukemia)	NULL	SRF	Treatment: No treatment, no TPA  Source: HEL-iMKL1 cells	GTRD	EXP053071_HEL--Erythro-Leukemia-_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	3239
1	804	CTCF	0.737880234352151	1.34248212825514	33	246	615	778	778	546	26	171	181	CTCF SH-SY5Y (neuroblastoma) CTCF	SH-SY5Y (neuroblastoma)	BTO:0000793	CTCF		GTRD	EXP040383_SH-SY5Y--neuroblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45030
1	2850	MYC	0.736911689147888	2.06786875246524	8	247	196	2697	2697	1050	4	196	203	MYC HUES64 (embryonic stem cells) MYC	HUES64 (embryonic stem cells)	NULL	MYC		GTRD	EXP036779_HUES64--embryonic-stem-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	1153
1	3251	POU5F1	0.736911689147888	2.06786875246524	8	247	196	2697	2697	1050	4	196	203	POU5F1 HUES64 (embryonic stem cells) POU5F1	HUES64 (embryonic stem cells)	NULL	POU5F1		GTRD	EXP032064_HUES64--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	12065
1	3440	RFX1	0.736911689147888	2.06786875246524	8	247	196	2697	2697	1050	4	196	203	RFX1 K562 (myelogenous leukemia) RFX1	K562 (myelogenous leukemia)	NULL	RFX1	NA	GTRD	EXP039804_K562--myelogenous-leukemia-_RFX1_MACS_RFX1_MA0509.2.damo.pwm.bed	11385
1	3462	RUNX1	0.736911689147888	2.06786875246524	8	247	196	2697	2697	1050	4	196	203	RUNX1 CD4+ CD25- T-cells RUNX1	CD4+ CD25- T-cells	NULL	RUNX1		GTRD	EXP032571_CD4--CD25--T-cells_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	2054
1	3591	SOX17	0.736911689147888	2.06786875246524	8	247	196	2697	2697	1050	4	196	203	SOX17 HUES64 (embryonic stem cells) SOX17	HUES64 (embryonic stem cells)	NULL	SOX17	NA	GTRD	EXP036748_HUES64--embryonic-stem-cells-_SOX17_MACS_SOX17_MA0078.1.damo.pwm.bed	10689
1	3719	SRF	0.736911689147888	2.06786875246524	8	247	196	2697	2697	1050	4	196	203	SRF HEL (Erythro Leukemia) SRF	HEL (Erythro Leukemia)	NULL	SRF	Treatment: Treated with 10ng/ml Dox & 15nM TPA for 24 horus Genotype: mkl overexpressed	GTRD	EXP053078_HEL--Erythro-Leukemia-_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	5675
1	4054	TP63	0.736911689147888	2.06786875246524	8	247	196	2697	2697	1050	4	196	203	TP63 HaCaT (keratinocytes) TP63	HaCaT (keratinocytes)	BTO:0000552	TP63	caRAS_TGFB	GEO	GSE60814_tp63_hacat-caras-tgfb_MACS_TP63_MA0525.2.damo.pwm.bed	11712
1	1488	FLI1	0.734014195433776	1.44170212069652	22	254	498	1459	1459	737	16	182	191	FLI1 megakaryocytes FLI1	megakaryocytes	NULL	FLI1	NULL	GTRD	EXP000354_megakaryocytes_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	7348
1	850	CTCF	0.731357927586707	1.33239255569763	34	255	629	729	729	538	27	170	180	CTCF HeLa (cervical adenocarcinoma) CTCF	HeLa (cervical adenocarcinoma)	BTO:0000567	CTCF	Plasmids: pGK-dCas9-SunTag (Addgene #100943) + pEF1a-NLS-scFvGCN4-DNMT3A (Addgene #100941) + pEf1a-SHB_1-gRNA-GFP	GTRD	EXP048002_HeLa--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	44708
1	3073	NR2F2	0.731158292497021	1.61915660727667	14	256	374	2073	2073	901	9	190	198	NR2F2 HepG2 (hepatoblastoma) NR2F2	HepG2 (hepatoblastoma)	BTO:0000599	NR2F2		ENCODE	ENCSR000BVM_HepG2_NR2F2_MACS_NR2F2_MA1111.1.damo.pwm.bed	14856
1	2708	MAX	0.7252498398716	1.32305308736526	35	257	633	691	691	527	28	169	179	MAX liver MAX	liver	BTO:0000759	MAX		GTRD	EXP039825_liver_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	12946
1	1392	ESR1	0.722794166492401	1.41899686725841	23	258	523	1391	1391	724	17	181	190	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GEO	GSE41561_esr1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	42520
1	1880	GABPA	0.722794166492401	1.41899686725841	23	258	523	1391	1391	724	17	181	190	GABPA liver GABPA	liver	BTO:0000759	GABPA		GTRD	EXP039904_liver_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	5654
1	2611	JUND	0.722794166492401	1.41899686725841	23	258	523	1391	1391	724	17	181	190	JUND liver JUND	liver	BTO:0000759	JUND		GTRD	EXP039345_liver_JUND_MACS_JUND_MA0492.1.damo.pwm.bed	19074
1	307	CEBPA	0.714139756328386	1.30632645657927	37	261	668	607	668	512	30	167	177	CEBPA liver CEBPA	liver	BTO:0000759	CEBPA		Array Express	ERP002306_cebpa_liver_MACS_CEBPA_MA0102.4.damo.pwm.bed	29334
1	1833	FOXA2	0.714139756328386	1.30632645657927	37	261	668	607	668	512	30	167	177	FOXA2 KerCT (keratenocytes) FOXA2	KerCT (keratenocytes)	NULL	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL	GTRD	EXP049290_KerCT--keratenocytes-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	82979
1	798	CTCF	0.712577830499853	1.39884810816429	24	263	544	1324	1324	710	18	180	189	CTCF H929 (plasma cell myeloma) CTCF	H929 (plasma cell myeloma)	BTO:0002416	CTCF		GTRD	EXP040275_H929--plasma-cell-myeloma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39497
1	1126	ERG	0.711735826155437	1.56179588273359	15	264	385	1993	1993	881	10	189	197	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG		GTRD	EXP037055_VCaP--prostate-carcinoma-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	5383
1	1259	ESR1	0.711735826155437	1.56179588273359	15	264	385	1993	1993	881	10	189	197	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Doxycycline + E2	GTRD	EXP038371_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	29876
1	3300	PRDM1	0.711735826155437	1.56179588273359	15	264	385	1993	1993	881	10	189	197	PRDM1 HEK293 (embryonic kidney) PRDM1	HEK293 (embryonic kidney)	NULL	PRDM1		GTRD	EXP035871_HEK293--embryonic-kidney-_PRDM1_MACS_PRDM1_MA0508.3.damo.pwm.bed	14703
1	949	CTCF	0.71013918350778	1.23644174525159	62	267	784	118	784	390	54	142	153	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm12892_MACS_CTCF_MA0139.1.damo.pwm.bed	63003
1	695	CTCF	0.709079007454515	1.29881434894796	38	268	679	576	679	508	31	166	176	CTCF Peyer's patch CTCF	Peyer's patch	NULL	CTCF		GTRD	EXP039475_Peyer-s-patch_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38959
1	960	CTCF	0.705223527808556	1.22996627386265	65	269	799	89	799	386	57	139	150	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm2588_MACS_CTCF_MA0139.1.damo.pwm.bed	65600
1	1820	FOXA2	0.703237336717767	1.38085280904781	25	270	557	1262	1262	696	19	179	188	FOXA2 liver FOXA2	liver	BTO:0000759	FOXA2	CARN1618	Array Express	ERP008682_foxa2_liver-carn1618_MACS_FOXA2_MA0047.3.damo.pwm.bed	31178
1	3919	TFAP2C	0.701092926179697	1.22438831239592	68	271	810	56	810	379	60	136	147	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	ETOH	GEO	GSE23852_tfap2c_mcf7-etoh_MACS_TFAP2C_MA0814.2.damo.pwm.bed	45573
1	146	AR	0.699171256481558	1.8618420916092	9	272	295	2564	2564	1040	5	195	202	AR DU145 (prostate carcinoma) AR	DU145 (prostate carcinoma)	BTO:0001332	AR	ARQ6540X	GEO	GSE47987_AR_du145-arq6540x_MACS_AR_MA0007.3.damo.pwm.bed	17439
1	1177	ESR1	0.699171256481558	1.8618420916092	9	272	295	2564	2564	1040	5	195	202	ESR1 ESR1	NA	NA	ESR1	NA	Array Express	ERP003828_esr1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	24033
1	1226	ESR1	0.699171256481558	1.8618420916092	9	272	295	2564	2564	1040	5	195	202	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2+ICI	GTRD	EXP036976_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	9899
1	1936	GATA2	0.699171256481558	1.8618420916092	9	272	295	2564	2564	1040	5	195	202	GATA2 K562 (myelogenous leukemia) GATA2	K562 (myelogenous leukemia)	NULL	GATA2	bio	GTRD	EXP000941_K562--myelogenous-leukemia-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	21473
1	2000	GATA3	0.699171256481558	1.8618420916092	9	272	295	2564	2564	1040	5	195	202	GATA3 Kelly (neuroblastoma) GATA3	Kelly (neuroblastoma)	NULL	GATA3		GEO	GSE65664_gata3_kelly_MACS_GATA3_MA0037.3.damo.pwm.bed	23550
1	3233	PHOX2B	0.699171256481558	1.8618420916092	9	272	295	2564	2564	1040	5	195	202	PHOX2B BE2C PHOX2B	BE2C	NULL	PHOX2B	Treatment: untreated	GTRD	EXP049479_BE2C_PHOX2B_MACS_PHOX2B_MA0681.2.damo.pwm.bed	48348
1	3353	RELA	0.699171256481558	1.8618420916092	9	272	295	2564	2564	1040	5	195	202	RELA MCF7 (Invasive ductal breast carcinoma) RELA	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RELA	IL1b+ICI	GTRD	EXP036979_MCF7--Invasive-ductal-breast-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	8982
1	3904	TFAP2C	0.696674122735365	1.21815666145641	72	279	842	36	842	386	64	132	143	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p52; Genotype: TFAP2C -/-; Treatment: transduced construct that allows doxycycline inducible expression of TFAP2C;	GTRD	EXP047543_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	35290
1	48	AR	0.694945205105994	1.51490538414608	16	280	456	1909	1909	882	11	188	196	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	siOCT1	GTRD	EXP036096_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	30214
1	640	CTCF	0.694945205105994	1.51490538414608	16	280	456	1909	1909	882	11	188	196	CTCF PC9 (lung adenocarcinoma) CTCF	PC9 (lung adenocarcinoma)	NULL	CTCF		GTRD	EXP036850_PC9--lung-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29589
1	814	CTCF	0.694945205105994	1.51490538414608	16	280	456	1909	1909	882	11	188	196	CTCF HCT-116-RAD21-mAC CTCF	HCT-116-RAD21-mAC	NULL	CTCF	500uM auxin (360 min)	GTRD	EXP040680_HCT-116-RAD21-mAC_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	22257
1	1315	ESR1	0.694945205105994	1.51490538414608	16	280	456	1909	1909	882	11	188	196	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: tamoxifen 1μM for 1hr;	GTRD	EXP047664_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	23085
1	1666	FOXA1	0.694945205105994	1.51490538414608	16	280	456	1909	1909	882	11	188	196	FOXA1 HUES64 (embryonic stem cells) FOXA1	HUES64 (embryonic stem cells)	NULL	FOXA1		GTRD	EXP036704_HUES64--embryonic-stem-cells-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	28531
1	4049	TP63	0.694945205105994	1.51490538414608	16	280	456	1909	1909	882	11	188	196	TP63 keratinocytes TP63	keratinocytes	NULL	TP63		GEO	GSE56674_tp63_keratinocyte_MACS_TP63_MA0525.2.damo.pwm.bed	26690
1	2309	JUN	0.694666258751305	1.36468854143192	26	286	572	1204	1204	687	20	178	187	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039416_A549--lung-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	18784
1	509	CTCF	0.687801582856359	1.26789258109545	43	287	744	429	744	487	36	161	171	CTCF GM12869 (female B-cells) CTCF	GM12869 (female B-cells)	NULL	CTCF		ENCODE	ENCSR000DRJ_GM12869_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48219
1	452	CTCF	0.680841278381749	1.2579782822174	45	288	747	383	747	473	38	159	169	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000AUV_B_cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40097
1	660	CTCF	0.680273770650533	1.47586872768764	17	289	472	1846	1846	869	12	187	195	CTCF E23 retina CTCF	E23 retina	NULL	CTCF		GTRD	EXP037802_E23-retina_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	20748
1	937	CTCF	0.680273770650533	1.47586872768764	17	289	472	1846	1846	869	12	187	195	CTCF BL41(Burkitt lymphoma) CTCF	BL41(Burkitt lymphoma)	NULL	CTCF		GEO	GSE31485_ctcf_bl41_MACS_CTCF_MA0139.1.damo.pwm.bed	25986
1	2613	JUND	0.680273770650533	1.47586872768764	17	289	472	1846	1846	869	12	187	195	JUND liver JUND	liver	BTO:0000759	JUND		GTRD	EXP039345_liver_JUND_MACS_JUND_MA1142.1.damo.pwm.bed	12884
1	3137	NR3C1	0.680273770650533	1.47586872768764	17	289	472	1846	1846	869	12	187	195	NR3C1 Ishikawa (endometrial adenocarcinoma) NR3C1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	NR3C1	Treatment: 100 nM Dexamethasone for 1 hour	GTRD	EXP048234_Ishikawa--endometrial-adenocarcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	10171
1	505	CTCF	0.679488633825599	1.33685651462303	28	293	620	1068	1068	660	22	176	185	CTCF GM12865 (female B-cells) CTCF	GM12865 (female B-cells)	NULL	CTCF		ENCODE	ENCSR000DRE_GM12865_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	33736
1	807	CTCF	0.672741993684747	1.32479879790771	29	294	631	1013	1013	646	23	175	184	CTCF CD34+ stem cells-derived erythroblasts CTCF	CD34+ stem cells-derived erythroblasts	NULL	CTCF	Fetal	GTRD	EXP040425_CD34--stem-cells-derived-erythroblasts_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39787
1	2706	MAX	0.671727554145439	1.24510647911723	48	295	775	317	775	462	41	156	166	MAX liver MAX	liver	BTO:0000759	MAX		GTRD	EXP039669_liver_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	16160
1	1119	ERG	0.669987757089773	1.72453575883454	10	296	328	2442	2442	1020	6	194	201	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	siERG	GTRD	EXP000726_VCaP--prostate-carcinoma-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	3130
1	1530	FOS	0.669987757089773	1.72453575883454	10	296	328	2442	2442	1020	6	194	201	FOS MCF7 (Invasive ductal breast carcinoma) FOS	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOS	E2	GTRD	EXP000619_MCF7--Invasive-ductal-breast-carcinoma-_FOS_MACS_FOS_MA0099.3.damo.pwm.bed	8690
1	1531	FOS	0.669987757089773	1.72453575883454	10	296	328	2442	2442	1020	6	194	201	FOS MCF7 (Invasive ductal breast carcinoma) FOS	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOS	E2	GTRD	EXP000619_MCF7--Invasive-ductal-breast-carcinoma-_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	9079
1	1532	FOS	0.669987757089773	1.72453575883454	10	296	328	2442	2442	1020	6	194	201	FOS MCF7 (Invasive ductal breast carcinoma) FOS	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOS	E2	GTRD	EXP000619_MCF7--Invasive-ductal-breast-carcinoma-_FOS_MACS_FOS_MA1134.1.damo.pwm.bed	8615
1	1533	FOS	0.669987757089773	1.72453575883454	10	296	328	2442	2442	1020	6	194	201	FOS MCF7 (Invasive ductal breast carcinoma) FOS	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOS	E2	GTRD	EXP000619_MCF7--Invasive-ductal-breast-carcinoma-_FOS_MACS_FOS_MA1141.1.damo.pwm.bed	8340
1	1667	FOXA1	0.669987757089773	1.72453575883454	10	296	328	2442	2442	1020	6	194	201	FOXA1 HUES64 (embryonic stem cells) FOXA1	HUES64 (embryonic stem cells)	NULL	FOXA1		GTRD	EXP036787_HUES64--embryonic-stem-cells-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	18406
1	2045	GFI1	0.669987757089773	1.72453575883454	10	296	328	2442	2442	1020	6	194	201	GFI1 AML (monocytes and acute myeloid leukemia) GFI1	AML (monocytes and acute myeloid leukemia)	NULL	GFI1	Treatment: DMSo vehicle	GTRD	EXP049354_AML--monocytes-and-acute-myeloid-leukemia-_GFI1_MACS_GFI1_MA0038.2.damo.pwm.bed	4911
1	3948	THAP11	0.669987757089773	1.72453575883454	10	296	328	2442	2442	1020	6	194	201	THAP11 HUES64 (embryonic stem cells) THAP11	HUES64 (embryonic stem cells)	NULL	THAP11	NA	GTRD	EXP036774_HUES64--embryonic-stem-cells-_THAP11_MACS_THAP11_MA1573.1.damo.pwm.bed	1517
1	4041	TP63	0.669987757089773	1.72453575883454	10	296	328	2442	2442	1020	6	194	201	TP63 MCF10A (breast epithelial cells) TP63	MCF10A (breast epithelial cells)	BTO:0001939	TP63	Treatment: DMSO for 6 hrs;	GTRD	EXP057966_MCF10A--breast-epithelial-cells-_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	13671
1	1254	ESR1	0.667336883318186	1.44287445700475	18	305	496	1785	1785	862	13	186	194	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	1280min E2	GTRD	EXP038344_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	20695
1	1934	GATA2	0.667336883318186	1.44287445700475	18	305	496	1785	1785	862	13	186	194	GATA2 K562 (myelogenous leukemia) GATA2	K562 (myelogenous leukemia)	NULL	GATA2	NULL	GTRD	EXP000524_K562--myelogenous-leukemia-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	24373
1	510	CTCF	0.666480000452534	1.31377414457863	30	307	658	937	937	634	24	174	183	CTCF GM12870 (male B-cells) CTCF	GM12870 (male B-cells)	NULL	CTCF		ENCODE	ENCSR000DRK_GM12870_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38893
1	743	CTCF	0.666480000452534	1.31377414457863	30	307	658	937	937	634	24	174	183	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039808_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42477
1	808	CTCF	0.666480000452534	1.31377414457863	30	307	658	937	937	634	24	174	183	CTCF CD34+ stem cells-derived erythroblasts CTCF	CD34+ stem cells-derived erythroblasts	NULL	CTCF	Adult	GTRD	EXP040426_CD34--stem-cells-derived-erythroblasts_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48367
1	887	CTCF	0.666419008017962	1.23764677316905	50	310	783	275	783	456	43	154	164	CTCF EOL-1 (Acute myeloid leukemia) CTCF	EOL-1 (Acute myeloid leukemia)	BTO:0002405	CTCF	Treatment: untreated	GTRD	EXP053093_EOL-1--Acute-myeloid-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	76394
1	2135	HNF4A	0.66164736966485	1.2309490791706	52	311	791	244	791	449	45	152	162	HNF4A liver HNF4A	liver	BTO:0000759	HNF4A		GTRD	EXP039657_liver_HNF4A_MACS_HNF4A_MA1494.1.damo.pwm.bed	61931
1	143	AR	0.660654906341638	1.30365908274146	31	312	675	881	881	623	25	173	182	AR AR	NA	NA	AR	NA	GEO	GSE45201_AR_mdamb453-dht_MACS_AR_MA0007.3.damo.pwm.bed	21220
1	638	CTCF	0.660654906341638	1.30365908274146	31	312	675	881	881	623	25	173	182	CTCF DOHH2 (diffuse large B-cell lymphoma) CTCF	DOHH2 (diffuse large B-cell lymphoma)	NULL	CTCF		GTRD	EXP036846_DOHH2--diffuse-large-B-cell-lymphoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41661
1	803	CTCF	0.660654906341638	1.30365908274146	31	312	675	881	881	623	25	173	182	CTCF OCI-LY1 (diffuse large B-cell lymphoma) CTCF	OCI-LY1 (diffuse large B-cell lymphoma)	NULL	CTCF		GTRD	EXP040321_OCI-LY1--diffuse-large-B-cell-lymphoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	50544
1	2988	NEUROG2	0.660654906341638	1.30365908274146	31	312	675	881	881	623	25	173	182	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	2 DPT	GTRD	EXP037157_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	25285
1	1095	ELF4	0.660371088940051	2.56986713176094	5	316	140	3053	3053	1170	2	199	205	ELF4 HEK293T (embryonic kidney) ELF4	HEK293T (embryonic kidney)	BTO:0002181	ELF4	NA	GTRD	EXP039387_HEK293T--embryonic-kidney-_ELF4_MACS_ELF4_MA0641.1.damo.pwm.bed	1386
1	1197	ESR1	0.660371088940051	2.56986713176094	5	316	140	3053	3053	1170	2	199	205	ESR1 LTED (breast cancer) ESR1	LTED (breast cancer)	NULL	ESR1	none	GTRD	EXP033909_LTED--breast-cancer-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	3518
1	1985	GATA3	0.660371088940051	2.56986713176094	5	316	140	3053	3053	1170	2	199	205	GATA3 T47D (invasive ductal carcinoma) GATA3	T47D (invasive ductal carcinoma)	BTO:0001248	GATA3	Passsage: <10 Genotype: wt/R330fs mutant with CRISPR	GTRD	EXP049907_T47D--invasive-ductal-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	6385
1	2152	HNF4G	0.660371088940051	2.56986713176094	5	316	140	3053	3053	1170	2	199	205	HNF4G LNCaP (prostate carcinoma) HNF4G	LNCaP (prostate carcinoma)	BTO:0001321	HNF4G	Treatment: Cells were harvested in log phase growth Genotype: HNF4G overexpression	GTRD	EXP048991_LNCaP--prostate-carcinoma-_HNF4G_MACS_HNF4G_MA0484.2.damo.pwm.bed	4215
1	2461	JUN	0.660371088940051	2.56986713176094	5	316	140	3053	3053	1170	2	199	205	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: RUNX1/ETO knockdown;	GTRD	EXP058212_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	1963
1	2464	JUN	0.660371088940051	2.56986713176094	5	316	140	3053	3053	1170	2	199	205	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: RUNX1/ETO knockdown;	GTRD	EXP058212_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	1855
1	2465	JUN	0.660371088940051	2.56986713176094	5	316	140	3053	3053	1170	2	199	205	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: RUNX1/ETO knockdown;	GTRD	EXP058212_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	1840
1	2466	JUN	0.660371088940051	2.56986713176094	5	316	140	3053	3053	1170	2	199	205	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: RUNX1/ETO knockdown;	GTRD	EXP058212_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	1822
1	2468	JUN	0.660371088940051	2.56986713176094	5	316	140	3053	3053	1170	2	199	205	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: RUNX1/ETO knockdown;	GTRD	EXP058212_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	1821
1	3704	SRF	0.660371088940051	2.56986713176094	5	316	140	3053	3053	1170	2	199	205	SRF GM12878 (female B-cells lymphoblastoid cell line) SRF	GM12878 (female B-cells lymphoblastoid cell line)	NULL	SRF		ENCODE	ENCSR000BGE_GM12878_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	2174
1	3705	SRF	0.660371088940051	2.56986713176094	5	316	140	3053	3053	1170	2	199	205	SRF WA01 (H1, human embryonic stem cells) SRF	WA01 (H1, human embryonic stem cells)	NULL	SRF		ENCODE	ENCSR000BIV_H1-hESC_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	3162
1	4138	YY1	0.660371088940051	2.56986713176094	5	316	140	3053	3053	1170	2	199	205	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1	YY1-mutated (p.Lys179*)	GTRD	EXP038608_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	1045
1	4149	YY1	0.660371088940051	2.56986713176094	5	316	140	3053	3053	1170	2	199	205	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1	YY1-mutated (p.Leu366Pro)	GTRD	EXP038619_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	1004
1	4151	YY1	0.660371088940051	2.56986713176094	5	316	140	3053	3053	1170	2	199	205	YY1 Jurkat (T-cells) YY1	Jurkat (T-cells)	BTO:0000661	YY1		GTRD	EXP049911_Jurkat--T-cells-_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	856
1	374	CEBPB	0.655839836754516	1.41462860591925	19	330	535	1697	1697	854	14	185	193	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB		GTRD	EXP039590_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	19721
1	866	CTCF	0.655839836754516	1.41462860591925	19	330	535	1697	1697	854	14	185	193	CTCF ID00015 (lymphoblastoid cell) CTCF	ID00015 (lymphoblastoid cell)	NULL	CTCF	Genotype: wildtype Cell type: lymphoblastoid cell	GTRD	EXP048876_ID00015--lymphoblastoid-cell-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	26561
1	1664	FOXA1	0.655839836754516	1.41462860591925	19	330	535	1697	1697	854	14	185	193	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	DHT 10 nM	GTRD	EXP036101_VCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	26826
1	599	CTCF	0.65522526344267	1.29434914397716	32	333	683	825	825	614	26	172	181	CTCF normal epidermal keratinocytes CTCF	normal epidermal keratinocytes	NULL	CTCF		GTRD	EXP030405_normal-epidermal-keratinocytes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	47278
1	898	CTCF	0.65522526344267	1.29434914397716	32	333	683	825	825	614	26	172	181	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF	Treatment: None;	GTRD	EXP054035_K562--myelogenous-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	55566
1	958	CTCF	0.650048127445488	1.21456760504216	58	335	847	154	847	445	51	146	156	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm19240_MACS_CTCF_MA0139.1.damo.pwm.bed	61208
1	1715	FOXA1	0.650048127445488	1.21456760504216	58	335	847	154	847	445	51	146	156	FOXA1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) FOXA1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	FOXA1	Treatment: 45 min 10^-8 E2	GTRD	EXP048457_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	100585
1	947	CTCF	0.648457491557687	1.21228993779135	59	337	856	143	856	445	52	145	155	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm12890_MACS_CTCF_MA0139.1.damo.pwm.bed	62500
1	1251	ESR1	0.646654235023555	1.62650464737003	11	338	368	2332	2332	1010	7	193	200	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	160min E2	GTRD	EXP038341_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	20868
1	1302	ESR1	0.646654235023555	1.62650464737003	11	338	368	2332	2332	1010	7	193	200	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	100nm E2 (45 min)	GTRD	EXP040951_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	17965
1	4060	TP63	0.646654235023555	1.62650464737003	11	338	368	2332	2332	1010	7	193	200	TP63 MCF10A (breast epithelial cells) TP63	MCF10A (breast epithelial cells)	BTO:0001939	TP63	DCIS	GEO	GSE72009_tp63_mcf10dcis_MACS_TP63_MA0525.2.damo.pwm.bed	12720
1	4131	YY1	0.646654235023555	1.62650464737003	11	338	368	2332	2332	1010	7	193	200	YY1 HeLa (cervical adenocarcinoma) YY1	HeLa (cervical adenocarcinoma)	BTO:0000567	YY1		GTRD	EXP036996_HeLa--cervical-adenocarcinoma-_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	2764
1	4136	YY1	0.646654235023555	1.62650464737003	11	338	368	2332	2332	1010	7	193	200	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1		GTRD	EXP038606_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	2418
1	861	CTCF	0.645552709768397	1.39018222395144	20	343	547	1606	1606	832	15	184	192	CTCF MDM(monocyte derived macrophages) CTCF	MDM(monocyte derived macrophages)	NULL	CTCF	Treatment: mock infected, time post infection 24 hr	GTRD	EXP048655_MDM-monocyte-derived-macrophages-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	22628
1	1837	FOXA2	0.645552709768397	1.39018222395144	20	343	547	1606	1606	832	15	184	192	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL Genotype: FOXA2 mimo	GTRD	EXP049299_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	117553
1	3106	NR3C1	0.645552709768397	1.39018222395144	20	343	547	1606	1606	832	15	184	192	NR3C1 MCF7 (Invasive ductal breast carcinoma) NR3C1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NR3C1	E2, DEX	GTRD	EXP037450_MCF7--Invasive-ductal-breast-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	29455
1	3226	PBX3	0.645552709768397	1.39018222395144	20	343	547	1606	1606	832	15	184	192	PBX3 A549 (lung carcinoma) PBX3	A549 (lung carcinoma)	BTO:0000018	PBX3	NA	ENCODE	ENCSR000BTN_A549_PBX3_MACS_PBX3_MA1114.1.damo.pwm.bed	7138
1	893	CTCF	0.645412127725953	1.27780142269698	34	347	713	729	729	596	28	170	179	CTCF HNEK (epidermal keratinocytes) CTCF	HNEK (epidermal keratinocytes)	NULL	CTCF	Treatment: None;	GTRD	EXP054030_HNEK--epidermal-keratinocytes-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48232
1	957	CTCF	0.644191723179691	1.20610145078127	62	348	866	118	866	444	55	142	152	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm19239_MACS_CTCF_MA0139.1.damo.pwm.bed	66075
1	962	CTCF	0.642927501361532	1.20423599418194	63	349	877	103	877	443	56	141	151	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm2630_MACS_CTCF_MA0139.1.damo.pwm.bed	66301
1	501	CTCF	0.640969004414045	1.27042164233157	35	350	732	691	732	591	29	169	178	CTCF Caco-2 (colon adenocarcinoma) CTCF	Caco-2 (colon adenocarcinoma)	BTO:0000195	CTCF		ENCODE	ENCSR000DQN_Caco-2_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41356
1	2979	NEUROG2	0.640969004414045	1.27042164233157	35	350	732	691	732	591	29	169	178	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	0.5 DPT	GTRD	EXP037152_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	27188
1	163	AR	0.639567735505362	1.19916872663782	66	352	883	78	883	438	59	138	148	AR LHSAR (prostate epithelial cells) AR	LHSAR (prostate epithelial cells)	NULL	AR	LACZ	GEO	GSE56288_AR_lhsar-lacz_MACS_AR_MA0007.3.damo.pwm.bed	118921
1	3920	TFAP2C	0.63858379110305	1.1976431003793	67	353	885	68	885	435	60	137	147	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	ETOH	GEO	GSE23852_tfap2c_mcf7-etoh_MACS_TFAP2C_MA0815.1.damo.pwm.bed	44638
1	484	CTCF	0.63680084398832	1.26355904258253	36	354	745	645	745	581	30	168	177	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		ENCODE	ENCSR000DMR_MCF-7_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	63664
1	553	CTCF	0.632885726079236	1.25716402130706	37	355	748	607	748	570	31	167	176	CTCF KARPAS-422 (diffuse large B-cell lymphoma) CTCF	KARPAS-422 (diffuse large B-cell lymphoma)	BTO:0004981	CTCF		ENCODE	ENCSR113REG_Karpas-422_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	52837
1	330	CEBPA	0.627915094127113	1.35000836769818	22	356	609	1459	1459	808	17	182	190	CEBPA Kasumi-1 (acute myeloblastic leukemia) CEBPA	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	CEBPA	Treatment: ethanol; Genotype: inducible version of CEBPA (C/EBPalpha-ER);	GTRD	EXP047678_Kasumi-1--acute-myeloblastic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	47021
1	643	CTCF	0.627915094127113	1.35000836769818	22	356	609	1459	1459	808	17	182	190	CTCF hepatocytes CTCF	hepatocytes	NULL	CTCF		GTRD	EXP036855_hepatocytes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30461
1	1793	FOXA1	0.627915094127113	1.35000836769818	22	356	609	1459	1459	808	17	182	190	FOXA1 PDAC FOXA1	PDAC	NA	FOXA1	KOKLF5	GEO	GSE64557_foxa1_pdac-koklf5_MACS_FOXA1_MA0148.4.damo.pwm.bed	30749
1	1184	ESR1	0.62751805824866	1.55302418277536	12	359	390	2233	2233	994	8	192	199	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP000882_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	15997
1	1272	ESR1	0.62751805824866	1.55302418277536	12	359	390	2233	2233	994	8	192	199	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP038385_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	19528
1	2126	HNF4A	0.62751805824866	1.55302418277536	12	359	390	2233	2233	994	8	192	199	HNF4A HepG2 (hepatoblastoma) HNF4A	HepG2 (hepatoblastoma)	BTO:0000599	HNF4A	NULL	GTRD	EXP000307_HepG2--hepatoblastoma-_HNF4A_MACS_HNF4A_MA0114.4.damo.pwm.bed	12759
1	3945	THAP11	0.62751805824866	1.55302418277536	12	359	390	2233	2233	994	8	192	199	THAP11 HUES64 (embryonic stem cells) THAP11	HUES64 (embryonic stem cells)	NULL	THAP11	NA	GTRD	EXP036770_HUES64--embryonic-stem-cells-_THAP11_MACS_THAP11_MA1573.1.damo.pwm.bed	2156
1	4159	ZNF143	0.62751805824866	1.55302418277536	12	359	390	2233	2233	994	8	192	199	ZNF143 CUTLL1 (T-cell lymphoblastic lymphoma 1) ZNF143	CUTLL1 (T-cell lymphoblastic lymphoma 1)	NULL	ZNF143		GEO	GSE29600_znf143_cutll_MACS_ZNF143_MA0088.2.damo.pwm.bed	5324
1	2986	NEUROG2	0.625738567937418	1.24560841353484	39	364	773	547	773	561	33	165	174	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	2 DPT	GTRD	EXP037156_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	35358
1	3492	RUNX1	0.625738567937418	1.24560841353484	39	364	773	547	773	561	33	165	174	RUNX1 ME-1 (acute myeloid leukemia ) RUNX1	ME-1 (acute myeloid leukemia )	NULL	RUNX1		GEO	GSE46044_runx1_me1_MACS_RUNX1_MA0002.2.damo.pwm.bed	18632
1	315	CEBPA	0.622473409681758	1.24037607529727	40	366	776	502	776	548	34	164	173	CEBPA HepG2 (hepatoblastoma) CEBPA	HepG2 (hepatoblastoma)	BTO:0000599	CEBPA	none	GTRD	EXP030935_HepG2--hepatoblastoma-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	55309
1	569	CTCF	0.622473409681758	1.24037607529727	40	366	776	502	776	548	34	164	173	CTCF pancreatic islets CTCF	pancreatic islets	NULL	CTCF		Array Express	ERP004003_ctcf_islet_MACS_CTCF_MA0139.1.damo.pwm.bed	48736
1	2129	HNF4A	0.622473409681758	1.24037607529727	40	366	776	502	776	548	34	164	173	HNF4A HepG2 (hepatoblastoma) HNF4A	HepG2 (hepatoblastoma)	BTO:0000599	HNF4A	none	GTRD	EXP030930_HepG2--hepatoblastoma-_HNF4A_MACS_HNF4A_MA1494.1.damo.pwm.bed	40673
1	487	CTCF	0.620299028212617	1.33331326771329	23	369	622	1391	1391	794	18	181	189	CTCF medulloblastoma CTCF	medulloblastoma	NULL	CTCF		ENCODE	ENCSR000DMY_medulloblastoma_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37314
1	965	CTCF	0.620299028212617	1.33331326771329	23	369	622	1391	1391	794	18	181	189	CTCF GP5d (colon adenocarcinoma) CTCF	GP5d (colon adenocarcinoma)	NULL	CTCF		GEO	GSE51234_ctcf_gp5d_MACS_CTCF_MA0139.1.damo.pwm.bed	45854
1	1450	ETS1	0.620299028212617	1.33331326771329	23	369	622	1391	1391	794	18	181	189	ETS1 GM12878 (female B-cells lymphoblastoid cell line) ETS1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ETS1		ENCODE	ENCSR000BKA_GM12878_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	6666
1	3552	RXRB	0.619394560700911	1.23546639583523	41	372	787	476	787	545	35	163	172	RXRB HepG2 (hepatoblastoma) RXRB	HepG2 (hepatoblastoma)	BTO:0000599	RXRB	NA	GTRD	EXP039365_HepG2--hepatoblastoma-_RXRB_MACS_RXRB_MA0855.1.damo.pwm.bed	42074
1	909	CTCF	0.613746181958069	1.22651205444064	43	373	804	429	804	535	37	161	170	CTCF RO01746 (CD14+ monocytes) CTCF	RO01746 (CD14+ monocytes)	NULL	CTCF	Treatment: None;	GTRD	EXP054064_RO01746--CD14--monocytes-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39399
1	952	CTCF	0.613746181958069	1.22651205444064	43	373	804	429	804	535	37	161	170	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm18526_MACS_CTCF_MA0139.1.damo.pwm.bed	45767
1	1453	ETS1	0.613347086517147	1.31840405361948	24	375	634	1324	1324	778	19	180	188	ETS1 CD4+ CD25+ CD45RA+ T-cells ETS1	CD4+ CD25+ CD45RA+ T-cells	NULL	ETS1		GTRD	EXP032565_CD4--CD25--CD45RA--T-cells_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	8541
1	218	ARNT	0.612054738935246	2.05709489206338	6	376	203	2948	2948	1180	3	198	204	ARNT HEK293T (embryonic kidney) ARNT	HEK293T (embryonic kidney)	BTO:0002181	ARNT		GTRD	EXP039727_HEK293T--embryonic-kidney-_ARNT_MACS_ARNT_MA0006.1.damo.pwm.bed	1238
1	704	CTCF	0.612054738935246	2.05709489206338	6	376	203	2948	2948	1180	3	198	204	CTCF transverse colon CTCF	transverse colon	NULL	CTCF		GTRD	EXP039548_transverse-colon_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	5586
1	1379	ESR1	0.612054738935246	2.05709489206338	6	376	203	2948	2948	1180	3	198	204	ESR1 MCF7L-P(immortalized breast epithelial cell line) ESR1	MCF7L-P(immortalized breast epithelial cell line)	NULL	ESR1	Treatment: treated with E2 for 24 hrs;	GTRD	EXP057865_MCF7L-P-immortalized-breast-epithelial-cell-line-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	6601
1	1501	FLI1	0.612054738935246	2.05709489206338	6	376	203	2948	2948	1180	3	198	204	FLI1 A-673 clone Asp114 (Ewing sarcoma) FLI1	A-673 clone Asp114 (Ewing sarcoma)	NULL	FLI1	Passage: 15-19	GTRD	EXP049960_A-673-clone-Asp114--Ewing-sarcoma-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	12288
1	1665	FOXA1	0.612054738935246	2.05709489206338	6	376	203	2948	2948	1180	3	198	204	FOXA1 HUES64 (embryonic stem cells) FOXA1	HUES64 (embryonic stem cells)	NULL	FOXA1		GTRD	EXP036703_HUES64--embryonic-stem-cells-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	9252
1	3592	SOX17	0.612054738935246	2.05709489206338	6	376	203	2948	2948	1180	3	198	204	SOX17 HUES64 (embryonic stem cells) SOX17	HUES64 (embryonic stem cells)	NULL	SOX17	NA	GTRD	EXP036750_HUES64--embryonic-stem-cells-_SOX17_MACS_SOX17_MA0078.1.damo.pwm.bed	14803
1	3980	TP53	0.612054738935246	2.05709489206338	6	376	203	2948	2948	1180	3	198	204	TP53 PHA-simulated human T-lynphocytes TP53	PHA-simulated human T-lynphocytes	NULL	TP53	Treatment: 0.3 ug/ml Doxorubicin for 24 hrs Source: healthy volunteer #90	GTRD	EXP048270_PHA-simulated-human-T-lynphocytes_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	4034
1	3983	TP53	0.612054738935246	2.05709489206338	6	376	203	2948	2948	1180	3	198	204	TP53 PHA-simulated human T-lynphocytes TP53	PHA-simulated human T-lynphocytes	NULL	TP53	Treatment: 10 uM Nutlin-3 for 24 hrs Source: healthy volunteer #104	GTRD	EXP048274_PHA-simulated-human-T-lynphocytes_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	2996
1	4139	YY1	0.612054738935246	2.05709489206338	6	376	203	2948	2948	1180	3	198	204	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1	YY1 hemizygous deletion	GTRD	EXP038609_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	1033
1	722	CTCF	0.611507836056611	1.49591310750993	13	385	465	2153	2153	1000	9	191	198	CTCF stomach CTCF	stomach	BTO:0001307	CTCF		GTRD	EXP039678_stomach_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	16025
1	1175	ESR1	0.611507836056611	1.49591310750993	13	385	465	2153	2153	1000	9	191	198	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	GLYC	Array Express	ERP002305_esr1_mcf7-glyc_MACS_ESR1_MA0112.3.damo.pwm.bed	20733
1	1241	ESR1	0.611507836056611	1.49591310750993	13	385	465	2153	2153	1000	9	191	198	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	White Medium + E2	GTRD	EXP037779_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	23102
1	2780	MYBL2	0.611507836056611	1.49591310750993	13	385	465	2153	2153	1000	9	191	198	MYBL2 HepG2 (hepatoblastoma) MYBL2	HepG2 (hepatoblastoma)	BTO:0000599	MYBL2	NA	ENCODE	ENCSR000BRO_HepG2_MYBL2_MACS_MYBL2_MA0777.1.damo.pwm.bed	9893
1	3428	REST	0.611507836056611	1.49591310750993	13	385	465	2153	2153	1000	9	191	198	REST CRC107 (colorectal cancer metastatic stem cells) REST	CRC107 (colorectal cancer metastatic stem cells)	NULL	REST	Source: organoid integrity;	GTRD	EXP058086_CRC107--colorectal-cancer-metastatic-stem-cells-_REST_MACS_REST_MA0138.2.damo.pwm.bed	11191
1	395	CEBPB	0.61115474079413	1.22242271129281	44	390	830	408	830	543	38	160	169	CEBPB JB6 (Human anaplastic large cell lymphoma) CEBPB	JB6 (Human anaplastic large cell lymphoma)	BTO:0004831	CEBPB	Treatment: DMSO for 3 hrs	GTRD	EXP053279_JB6--Human-anaplastic-large-cell-lymphoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	112514
1	3549	RXRA	0.61115474079413	1.22242271129281	44	390	830	408	830	543	38	160	169	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP045021_liver_RXRA_MACS_RXRA_MA1148.1.damo.pwm.bed	44058
1	70	AR	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: CaP cells were infected with EZH2 knockdown lentivirus and maintained for 2-3 days before fixation, ethanol, shTRIM24 Genotype: wildtype Source: prostate cancer cells	GTRD	EXP048075_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	2798
1	140	AR	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	AR AR	NA	NA	AR	NA	GEO	GSE40050_AR_lncap-dht_MACS_AR_MA0007.3.damo.pwm.bed	1373
1	150	AR	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	AR AR	NA	NA	AR	NA	GEO	GSE48308_AR_lncap-dht100nm_MACS_AR_MA0007.3.damo.pwm.bed	262
1	180	AR	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	R1881_SHCTR	GEO	GSE61268_AR_lncap-r1881-shctr_MACS_AR_MA0007.3.damo.pwm.bed	1085
1	185	AR	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR		GEO	GSE62492_AR_lncap_MACS_AR_MA0007.3.damo.pwm.bed	648
1	262	ATF4	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	ATF4 hMSC ATF4	hMSC	NA	ATF4		GEO	GSE68864_atf4_hmsc_MACS_ATF4_MA0833.2.damo.pwm.bed	539
1	1279	ESR1	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	ESR1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) ESR1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	ESR1	vehicle	GTRD	EXP038761_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	4048
1	1411	ESR1	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	TNF	GEO	GSE59530_esr1_mcf7-tnf_MACS_ESR1_MA0112.3.damo.pwm.bed	441
1	1443	ESRRA	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	ESRRA GM12878 (female B-cells lymphoblastoid cell line) ESRRA	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ESRRA		ENCODE	ENCSR000DYQ_GM12878_ESRRA_MACS_ESRRA_MA0592.3.damo.pwm.bed	788
1	1696	FOXA1	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	FOXA1 A1A3(breast cancer cells) FOXA1	A1A3(breast cancer cells)	NULL	FOXA1	Treatment: 1hr EtOH, PBS 72 hr CellLine: A1A3 from T47D cell line	GTRD	EXP048401_A1A3-breast-cancer-cells-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	4867
1	1698	FOXA1	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	FOXA1 A1A3(breast cancer cells) FOXA1	A1A3(breast cancer cells)	NULL	FOXA1	Treatment: 1hr EtOH, Doxycycline 72 hr CellLine: A1A3 from T47D cell line Genotype: Brg1 knockdown	GTRD	EXP048405_A1A3-breast-cancer-cells-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	4671
1	1991	GATA3	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	GATA3 CCRF-CEM (T acute lymphoblastic leukemia) GATA3	CCRF-CEM (T acute lymphoblastic leukemia)	BTO:0000736	GATA3		GEO	GSE33850_gata3_ccrfcem_MACS_GATA3_MA0037.3.damo.pwm.bed	497
1	2144	HNF4A	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	HNF4A LoVo (colorectal adenocarcinoma) HNF4A	LoVo (colorectal adenocarcinoma)	BTO:0000666	HNF4A	PHASEM	GEO	GSE51290_hnf4a_lovo-phaseM_MACS_HNF4A_MA0114.4.damo.pwm.bed	1262
1	2217	ISL1	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	ISL1 Kelly (neuroblastoma) ISL1	Kelly (neuroblastoma)	NULL	ISL1	Treatment: untreated	GTRD	EXP049485_Kelly--neuroblastoma-_ISL1_MACS_ISL1_MA1608.1.damo.pwm.bed	8286
1	3089	NR3C1	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	NR3C1 HepG2 (hepatoblastoma) NR3C1	HepG2 (hepatoblastoma)	BTO:0000599	NR3C1	low-glucose DMEM with 0.5% BSA supplemented with 1uM forskolin and 1mM pyruvate for 6h. (Snyder)	ENCODE	ENCSR000EEV_HepG2_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	154
1	3261	POU5F1	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	POU5F1 WA09 (embryonic stem cells) POU5F1	WA09 (embryonic stem cells)	NULL	POU5F1	Treatment: under normal conditions	GTRD	EXP047914_WA09--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	10568
1	3262	POU5F1	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	POU5F1 WA09 (embryonic stem cells) POU5F1	WA09 (embryonic stem cells)	NULL	POU5F1	Treatment: under normal conditions	GTRD	EXP047914_WA09--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	9222
1	3316	RARG	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	RARG RWPE1 (prostate epithelial cells) RARG	RWPE1 (prostate epithelial cells)	BTO:0003709	RARG	Treatment: 10 uM DMSO for 2 hr Gender: male Source: non-malignant prostate cell line infected with BAC-RARG-EGFP	GTRD	EXP048631_RWPE1--prostate-epithelial-cells-_RARG_MACS_RARG_MA1553.1.damo.pwm.bed	1173
1	3594	SOX2	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	SOX2 HUES64 (embryonic stem cells) SOX2	HUES64 (embryonic stem cells)	NULL	SOX2		GTRD	EXP032066_HUES64--embryonic-stem-cells-_SOX2_MACS_SOX2_MA0143.4.damo.pwm.bed	4329
1	3616	SOX2	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	SOX2 glioma SOX2	glioma	NA	SOX2	stem	GEO	GSE67282_sox2_gsc_MACS_SOX2_MA0143.4.damo.pwm.bed	3094
1	3767	TAL1	0.609499473256693	Inf	2	392	1	3462	3462	1280	0	202	207	TAL1 CCRF-CEM (T acute lymphoblastic leukemia) TAL1	CCRF-CEM (T acute lymphoblastic leukemia)	BTO:0000736	TAL1	NA	GEO	GSE33850_tal1_ccrfcem_MACS_TAL1_MA0091.1.damo.pwm.bed	2262
1	511	CTCF	0.606977872379358	1.30501335008268	25	413	671	1262	1262	782	20	179	187	CTCF GM12872 (male B-cells) CTCF	GM12872 (male B-cells)	NULL	CTCF		ENCODE	ENCSR000DRN_GM12872_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35699
1	1702	FOXA1	0.606977872379358	1.30501335008268	25	413	671	1262	1262	782	20	179	187	FOXA1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) FOXA1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	FOXA1	Treatment: 45 min 10^-7 4OHT	GTRD	EXP048438_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	45395
1	2976	NEUROG2	0.606977872379358	1.30501335008268	25	413	671	1262	1262	782	20	179	187	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	2 DPT	GTRD	EXP037151_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	26640
1	362	CEBPB	0.606389898968159	1.21492480616375	46	416	846	349	846	537	40	158	167	CEBPB K562 (myelogenous leukemia) CEBPB	K562 (myelogenous leukemia)	NULL	CEBPB		ENCODE	ENCSR000EHE_K562_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	64969
1	433	CTCF	0.601123170077413	1.29292471277391	26	417	686	1204	1204	769	21	178	186	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		ENCODE	ENCSR000AHD_MCF-7_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	53329
1	679	CTCF	0.601123170077413	1.29292471277391	26	417	686	1204	1204	769	21	178	186	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039388_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37673
1	1266	ESR1	0.601123170077413	1.29292471277391	26	417	686	1204	1204	769	21	178	186	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Doxycycline	GTRD	EXP038379_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	42927
1	386	CEBPB	0.597895783580793	1.45026219379538	14	420	488	2073	2073	994	10	190	197	CEBPB HL-60 (acute myeloid leukemia) CEBPB	HL-60 (acute myeloid leukemia)	BTO:0000738	CEBPB		GTRD	EXP040801_HL-60--acute-myeloid-leukemia-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	11047
1	860	CTCF	0.597895783580793	1.45026219379538	14	420	488	2073	2073	994	10	190	197	CTCF HCT-116 (colon carcinoma) CTCF	HCT-116 (colon carcinoma)	BTO:0001109	CTCF		GTRD	EXP048607_HCT-116--colon-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	18673
1	1640	FOXA1	0.597895783580793	1.45026219379538	14	420	488	2073	2073	994	10	190	197	FOXA1 ZR-75-1 (invasive ductal carcinoma) FOXA1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	FOXA1	E2_TAM	Array Express	ERP000380_foxa1_zr751-e2-tam_MACS_FOXA1_MA0148.4.damo.pwm.bed	50437
1	1655	FOXA1	0.597895783580793	1.45026219379538	14	420	488	2073	2073	994	10	190	197	FOXA1 CyT49-derived endodermal cells FOXA1	CyT49-derived endodermal cells	NULL	FOXA1	none	GTRD	EXP033207_CyT49-derived-endodermal-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	24003
1	1906	GATA1	0.597895783580793	1.45026219379538	14	420	488	2073	2073	994	10	190	197	GATA1 CD36+ erythroid cells GATA1	CD36+ erythroid cells	NULL	GATA1	BRG1 KD shLuc control	GTRD	EXP000914_CD36--erythroid-cells_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	22864
1	2784	MYC	0.597895783580793	1.45026219379538	14	420	488	2073	2073	994	10	190	197	MYC HeLa S3 (cervical adenocarcinoma) MYC	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	MYC		ENCODE	ENCSR000DLN_HeLa-S3_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	3176
1	768	CTCF	0.595725347471928	1.28196105483154	27	426	702	1135	1135	754	22	177	185	CTCF uterus CTCF	uterus	BTO:0001424	CTCF		GTRD	EXP040058_uterus_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	23646
1	917	CTCF	0.595725347471928	1.28196105483154	27	426	702	1135	1135	754	22	177	185	CTCF GM19193 (female B-cells Lymphoblastoid Cell Lines) CTCF	GM19193 (female B-cells Lymphoblastoid Cell Lines)	NULL	CTCF		GTRD	EXP054531_GM19193--female-B-cells-Lymphoblastoid-Cell-Lines-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40090
1	598	CTCF	0.590735354781363	1.27197609219885	28	428	729	1068	1068	742	23	176	184	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF		GTRD	EXP030404_K562--myelogenous-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46962
1	4052	TP63	0.590735354781363	1.27197609219885	28	428	729	1068	1068	742	23	176	184	TP63 keratinocytes TP63	keratinocytes	NULL	TP63	D4	GEO	GSE59824_tp63_keratinocyte-d4_MACS_TP63_MA0525.2.damo.pwm.bed	41698
1	4053	TP63	0.590735354781363	1.27197609219885	28	428	729	1068	1068	742	23	176	184	TP63 keratinocytes TP63	keratinocytes	NULL	TP63	D7	GEO	GSE59824_tp63_keratinocyte-d7_MACS_TP63_MA0525.2.damo.pwm.bed	39977
1	1815	FOXA2	0.590455210543469	1.18973971968015	55	431	904	211	904	515	49	149	158	FOXA2 HepG2 (hepatoblastoma) FOXA2	HepG2 (hepatoblastoma)	BTO:0000599	FOXA2		ENCODE	ENCSR000BNI_HepG2_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	87150
1	568	CTCF	0.586168661088816	1.41294713273912	15	432	538	1993	1993	988	11	189	196	CTCF GM12878 (female B-cells lymphoblastoid cell line) CTCF	GM12878 (female B-cells lymphoblastoid cell line)	NULL	CTCF		Array Express	ERP002246_ctcf_gm12878_MACS_CTCF_MA0139.1.damo.pwm.bed	23352
1	1789	FOXA1	0.586168661088816	1.41294713273912	15	432	538	1993	1993	988	11	189	196	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1		GEO	GSE60270_foxa1_mcf7_MACS_FOXA1_MA0148.4.damo.pwm.bed	19430
1	1828	FOXA2	0.586168661088816	1.41294713273912	15	432	538	1993	1993	988	11	189	196	FOXA2 HUES64 (embryonic stem cells) FOXA2	HUES64 (embryonic stem cells)	NULL	FOXA2		GTRD	EXP036788_HUES64--embryonic-stem-cells-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	27540
1	4037	TP63	0.586168661088816	1.41294713273912	15	432	538	1993	1993	988	11	189	196	TP63 human keratinocytes TP63	human keratinocytes	NULL	TP63	Treatment: Day 0 of epidermal differentiation Genotype: wildtype Source: background cell line WA 09	GTRD	EXP053351_human-keratinocytes_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	35404
1	3950	THRB	0.586111164822628	1.26284792741198	29	436	746	1013	1013	732	24	175	183	THRB HepG2 (hepatoblastoma) THRB	HepG2 (hepatoblastoma)	BTO:0000599	THRB	NA	GTRD	EXP039315_HepG2--hepatoblastoma-_THRB_MACS_THRB_MA1574.1.damo.pwm.bed	15992
1	1658	FOXA1	0.584565772529822	1.18007514158269	60	437	921	137	921	498	54	144	153	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	vehicle, control	GTRD	EXP033300_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	209675
1	770	CTCF	0.581816544466099	1.25447417312709	30	438	752	937	937	709	25	174	182	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP040063_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38230
1	773	CTCF	0.581816544466099	1.25447417312709	30	438	752	937	937	709	25	174	182	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP040072_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42215
1	1420	ESR1	0.581816544466099	1.25447417312709	30	438	752	937	937	709	25	174	182	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	R5020	GEO	GSE68355_ESR1_mcf7-r5020_MACS_ESR1_MA0112.3.damo.pwm.bed	44488
1	1704	FOXA1	0.581816544466099	1.25447417312709	30	438	752	937	937	709	25	174	182	FOXA1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) FOXA1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	FOXA1	Treatment: 45 min ethanol	GTRD	EXP048440_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	50876
1	2034	GATA6	0.581816544466099	1.25447417312709	30	438	752	937	937	709	25	174	182	GATA6 definitive endoderm from HUES8 GATA6	definitive endoderm from HUES8	NULL	GATA6	Genotype: SOX17-GFP knockout; Treatment: JNKi;	GTRD	EXP057915_definitive-endoderm-from-HUES8_GATA6_MACS_GATA6_MA1104.2.damo.pwm.bed	76992
1	3915	TFAP2C	0.580266537571675	1.17256868742923	65	443	936	89	936	489	59	139	148	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	E2	GEO	GSE23852_tfap2c_mcf7-e2_MACS_TFAP2C_MA0524.2.damo.pwm.bed	40376
1	3917	TFAP2C	0.579572593671229	1.17128379054134	66	444	938	78	938	487	60	138	147	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	E2	GEO	GSE23852_tfap2c_mcf7-e2_MACS_TFAP2C_MA0815.1.damo.pwm.bed	41093
1	3918	TFAP2C	0.579572593671229	1.17128379054134	66	444	938	78	938	487	60	138	147	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	ETOH	GEO	GSE23852_tfap2c_mcf7-etoh_MACS_TFAP2C_MA0524.2.damo.pwm.bed	44966
1	1133	ERG	0.579399482091834	1.80075732674323	7	446	310	2812	2812	1190	4	197	203	ERG HUVEC-C (HUVEC, umbilical vein endothelial cells) ERG	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ERG	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048202_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	3857
1	1164	ESR1	0.579399482091834	1.80075732674323	7	446	310	2812	2812	1190	4	197	203	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SHFOXA1_E2	Array Express	ERP000380_esr1_mcf7-shfoxa1-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	14212
1	1358	ESR1	0.579399482091834	1.80075732674323	7	446	310	2812	2812	1190	4	197	203	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 15 mins of 10nM Estradiol and then 10nM Estradiol + 10 nM Dexamethasone for 60 mins Genotype: ER+/PR+	GTRD	EXP049941_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	22831
1	1414	ESR1	0.579399482091834	1.80075732674323	7	446	310	2812	2812	1190	4	197	203	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SHCTR_E2	GEO	GSE60270_esr1_mcf7-shctr-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	13136
1	1463	ETS1	0.579399482091834	1.80075732674323	7	446	310	2812	2812	1190	4	197	203	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1		GTRD	EXP038278_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	2734
1	3150	NR3C1	0.579399482091834	1.80075732674323	7	446	310	2812	2812	1190	4	197	203	NR3C1 HeLa-B2 NR3C1	HeLa-B2	NA	NR3C1	TA_TNFA	GEO	GSE24518_nr3c1_helab2-ta-tnfa_MACS_NR3C1_MA0113.3.damo.pwm.bed	5431
1	3809	TCF7L2	0.579399482091834	1.80075732674323	7	446	310	2812	2812	1190	4	197	203	TCF7L2 HEK293 (embryonic kidney) TCF7L2	HEK293 (embryonic kidney)	NULL	TCF7L2		ENCODE	ENCSR000EUY_HEK293_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	6815
1	4055	TP63	0.579399482091834	1.80075732674323	7	446	310	2812	2812	1190	4	197	203	TP63 HaCaT (keratinocytes) TP63	HaCaT (keratinocytes)	BTO:0000552	TP63	dnRAS_TGFB	GEO	GSE60814_tp63_hacat-dnras-tgfb_MACS_TP63_MA0525.2.damo.pwm.bed	7195
1	350	CEBPB	0.577820077571855	1.24676820087935	31	454	768	881	881	701	26	173	181	CEBPB HepG2 (hepatoblastoma) CEBPB	HepG2 (hepatoblastoma)	BTO:0000599	CEBPB		ENCODE	ENCSR000BQI_HepG2_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	29379
1	488	CTCF	0.577820077571855	1.24676820087935	31	454	768	881	881	701	26	173	181	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF		ENCODE	ENCSR000DNA_A549_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	43187
1	512	CTCF	0.577820077571855	1.24676820087935	31	454	768	881	881	701	26	173	181	CTCF GM12873 (female B-cells) CTCF	GM12873 (female B-cells)	NULL	CTCF		ENCODE	ENCSR000DRP_GM12873_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42772
1	4124	YY1	0.577790778512108	1.16780848309205	69	457	942	47	942	482	63	135	144	YY1 HCT-116 (colon carcinoma) YY1	HCT-116 (colon carcinoma)	BTO:0001109	YY1		ENCODE	ENCSR000BNX_HCT116_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	31954
1	237	ASCL1	0.575953232301089	1.38188490750591	16	458	553	1909	1909	973	12	188	195	ASCL1 NCI-H82 (small cell lung carcinoma) ASCL1	NCI-H82 (small cell lung carcinoma)	BTO:0003026	ASCL1		GEO	GSE69394_ascl1_h82_MACS_ASCL1_MA1100.2.damo.pwm.bed	22415
1	463	CTCF	0.575953232301089	1.38188490750591	16	458	553	1909	1909	973	12	188	195	CTCF GM10248 (male B-cells) CTCF	GM10248 (male B-cells)	NULL	CTCF		ENCODE	ENCSR000DKP_GM10248_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	17330
1	3192	ONECUT2	0.575953232301089	1.38188490750591	16	458	553	1909	1909	973	12	188	195	ONECUT2 LNCaP (prostate carcinoma) ONECUT2	LNCaP (prostate carcinoma)	BTO:0001321	ONECUT2	Treatment: hypoxia(0.2% O2);	GTRD	EXP057824_LNCaP--prostate-carcinoma-_ONECUT2_MACS_ONECUT2_MA0756.1.damo.pwm.bed	103981
1	3946	THAP11	0.575953232301089	1.38188490750591	16	458	553	1909	1909	973	12	188	195	THAP11 HUES64 (embryonic stem cells) THAP11	HUES64 (embryonic stem cells)	NULL	THAP11	NA	GTRD	EXP036772_HUES64--embryonic-stem-cells-_THAP11_MACS_THAP11_MA1573.1.damo.pwm.bed	3160
1	2846	MYC	0.574094380975269	1.23965622337366	32	462	779	825	825	689	27	172	180	MYC HUES64 (embryonic stem cells) MYC	HUES64 (embryonic stem cells)	NULL	MYC		GTRD	EXP036777_HUES64--embryonic-stem-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	7128
1	311	CEBPA	0.570615470175158	1.23307500194344	33	463	788	778	788	676	28	171	179	CEBPA U937 (adult acute monocytic leukemia) CEBPA	U937 (adult acute monocytic leukemia)	BTO:0001412	CEBPA	bio	GTRD	EXP000946_U937--adult-acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	61348
1	644	CTCF	0.570615470175158	1.23307500194344	33	463	788	778	788	676	28	171	179	CTCF hepatocytes CTCF	hepatocytes	NULL	CTCF		GTRD	EXP036856_hepatocytes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38484
1	2978	NEUROG2	0.570615470175158	1.23307500194344	33	463	788	778	788	676	28	171	179	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	0.5 DPT	GTRD	EXP037152_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	26855
1	478	CTCF	0.566971008837952	1.35563334498151	17	466	604	1846	1846	972	13	187	194	CTCF kidney CTCF	kidney	BTO:0000671	CTCF		ENCODE	ENCSR000DMC_kidney_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	24703
1	1314	ESR1	0.566971008837952	1.35563334498151	17	466	604	1846	1846	972	13	187	194	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: 17beta estradiol 10nM for 1hr;	GTRD	EXP047663_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	24013
1	360	CEBPB	0.564316051026686	1.22129406983775	35	468	832	691	832	664	30	169	177	CEBPB HepG2 (hepatoblastoma) CEBPB	HepG2 (hepatoblastoma)	BTO:0000599	CEBPB	low-glucose DMEM with 0.5% BSA supplemented with 1uM forskolin and 1mM pyruvate for 6h. (Snyder)	ENCODE	ENCSR000EEX_HepG2_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	29037
1	398	CEBPB	0.564316051026686	1.22129406983775	35	468	832	691	832	664	30	169	177	CEBPB SU-DHL-1 (Anaplastic large cell lymphoma) CEBPB	SU-DHL-1 (Anaplastic large cell lymphoma)	BTO:0005058	CEBPB	Treatment: 300 nM Crizotinib for 3 hrs	GTRD	EXP053284_SU-DHL-1--Anaplastic-large-cell-lymphoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	110571
1	316	CEBPA	0.561460356593547	1.21600599663395	36	470	843	645	843	653	31	168	176	CEBPA HepG2 (hepatoblastoma) CEBPA	HepG2 (hepatoblastoma)	BTO:0000599	CEBPA	none	GTRD	EXP030935_HepG2--hepatoblastoma-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	53520
1	930	CTCF	0.561460356593547	1.21600599663395	36	470	843	645	843	653	31	168	176	CTCF HT1080 (fibrosarcoma) CTCF	HT1080 (fibrosarcoma)	NULL	CTCF	Treatment: 3 uM final concentration of CBL0137 for 6hrs;	GTRD	EXP058382_HT1080--fibrosarcoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46769
1	3142	NR3C1	0.561460356593547	1.21600599663395	36	470	843	645	843	653	31	168	176	NR3C1 HASM2 (Human airway smooth muscle 2) NR3C1	HASM2 (Human airway smooth muscle 2)	NULL	NR3C1	Treatment: dexamethasone for 4 hr Genotype: Ad-GFP transduction	GTRD	EXP049657_HASM2--Human-airway-smooth-muscle-2-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	43217
1	3238	PKNOX1	0.559009614816558	1.33316227096531	18	473	625	1785	1785	961	14	186	193	PKNOX1 MCF7 (Invasive ductal breast carcinoma) PKNOX1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	PKNOX1	NA	GTRD	EXP040011_MCF7--Invasive-ductal-breast-carcinoma-_PKNOX1_MACS_PKNOX1_MA0782.2.damo.pwm.bed	15582
1	3420	REST	0.559009614816558	1.33316227096531	18	473	625	1785	1785	961	14	186	193	REST HEK293 (embryonic kidney) REST	HEK293 (embryonic kidney)	NULL	REST		GTRD	EXP039673_HEK293--embryonic-kidney-_REST_MACS_REST_MA0138.2.damo.pwm.bed	9695
1	2161	HOXB13	0.558780432972158	1.21106982816602	37	475	863	607	863	648	32	167	175	HOXB13 VCaP (prostate carcinoma) HOXB13	VCaP (prostate carcinoma)	BTO:0003215	HOXB13	siERG	GTRD	EXP038438_VCaP--prostate-carcinoma-_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	69679
1	588	CTCF	0.556263124198895	1.20645395349527	38	476	864	576	864	639	33	166	174	CTCF FB8470 (fibroblasts) CTCF	FB8470 (fibroblasts)	NULL	CTCF	NULL	GTRD	EXP001023_FB8470--fibroblasts-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45900
1	699	CTCF	0.556263124198895	1.20645395349527	38	476	864	576	864	639	33	166	174	CTCF gastroesophageal sphincter CTCF	gastroesophageal sphincter	NULL	CTCF		GTRD	EXP039525_gastroesophageal-sphincter_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	28813
1	655	CTCF	0.555626771253275	1.6469918244521	8	478	361	2697	2697	1180	5	196	202	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	control; 100 nM 17-beta-estradiol for 0h	GTRD	EXP037646_MCF7--Invasive-ductal-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	13190
1	1859	FOXP1	0.555626771253275	1.6469918244521	8	478	361	2697	2697	1180	5	196	202	FOXP1 U2932 (diffuse large B-cell lymphoma) FOXP1	U2932 (diffuse large B-cell lymphoma)	NULL	FOXP1	NA	Array Express	ERP010999_foxp1_u2932_MACS_FOXP1_MA0481.3.damo.pwm.bed	6774
1	1892	GATA1	0.555626771253275	1.6469918244521	8	478	361	2697	2697	1180	5	196	202	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1		ENCODE	ENCSR000EFT_K562_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	14403
1	2958	MYOD1	0.555626771253275	1.6469918244521	8	478	361	2697	2697	1180	5	196	202	MYOD1 dermal fibroblasts MYOD1	dermal fibroblasts	BTO:0004419	MYOD1	NA	GTRD	EXP038296_dermal-fibroblasts_MYOD1_MACS_MYOD1_MA0499.2.damo.pwm.bed	3957
1	4137	YY1	0.555626771253275	1.6469918244521	8	478	361	2697	2697	1180	5	196	202	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1	YY1-mutated (p.Asp380Tyr)	GTRD	EXP038607_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	2034
1	4162	ZNF143	0.555626771253275	1.6469918244521	8	478	361	2697	2697	1180	5	196	202	ZNF143 HPB-ALL (T acute lymphoblastic leukemia) ZNF143	HPB-ALL (T acute lymphoblastic leukemia)	BTO:0001952	ZNF143		GEO	GSE39263_znf143_hpball_MACS_ZNF143_MA0088.2.damo.pwm.bed	1435
1	2987	NEUROG2	0.553896638935066	1.20213048900239	39	484	878	547	878	636	34	165	173	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	2 DPT	GTRD	EXP037156_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	34688
1	1873	GABPA	0.551904024710053	1.31371619405758	19	485	661	1697	1697	948	15	185	192	GABPA HL-60 (acute myeloid leukemia) GABPA	HL-60 (acute myeloid leukemia)	BTO:0000738	GABPA		ENCODE	ENCSR000BTK_HL-60_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	7472
1	795	CTCF	0.551670376873735	1.19807474623342	40	486	884	502	884	624	35	164	172	CTCF foreskin keratinocyte CTCF	foreskin keratinocyte	NULL	CTCF	1mM calcium (CHEBI:86158) for 2 day	GTRD	EXP040256_foreskin-keratinocyte_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46661
1	527	CTCF	0.545523897839982	1.29672847788453	20	487	680	1606	1606	924	16	184	191	CTCF HL-60 (acute myeloid leukemia) CTCF	HL-60 (acute myeloid leukemia)	BTO:0000738	CTCF		ENCODE	ENCSR000DUP_HL-60_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31926
1	3400	REST	0.545523897839982	1.29672847788453	20	487	680	1606	1606	924	16	184	191	REST PFSK1 (primitive neuroectodermal tumor) REST	PFSK1 (primitive neuroectodermal tumor)	NULL	REST		ENCODE	ENCSR000BOX_PFSK-1_REST_MACS_REST_MA0138.2.damo.pwm.bed	13730
1	903	CTCF	0.539764804596462	1.28176580241756	21	489	704	1535	1535	909	17	183	190	CTCF NA-A (astrocytes) CTCF	NA-A (astrocytes)	NULL	CTCF	Treatment: None;	GTRD	EXP054040_NA-A--astrocytes-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37670
1	1542	FOS	0.539764804596462	1.28176580241756	21	489	704	1535	1535	909	17	183	190	FOS MCF7 (Invasive ductal breast carcinoma) FOS	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOS		GTRD	EXP040137_MCF7--Invasive-ductal-breast-carcinoma-_FOS_MACS_FOS_MA0099.3.damo.pwm.bed	42631
1	1754	FOXA1	0.539764804596462	1.28176580241756	21	489	704	1535	1535	909	17	183	190	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	E2	GEO	GSE23852_foxa1_mcf7-e2_MACS_FOXA1_MA0148.4.damo.pwm.bed	60110
1	605	CTCF	0.537929945399363	1.17306453373096	48	492	929	317	929	579	43	156	164	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	oestrogen	GTRD	EXP030932_MCF7--Invasive-ductal-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	81857
1	64	AR	0.537436906194571	1.54452220444476	9	493	397	2564	2564	1150	6	195	201	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	dihydrotestosterone (DHT)	GTRD	EXP038192_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	4218
1	86	AR	0.537436906194571	1.54452220444476	9	493	397	2564	2564	1150	6	195	201	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: 10 nM DHT for 4 hrs	GTRD	EXP049276_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	32515
1	243	ATF3	0.537436906194571	1.54452220444476	9	493	397	2564	2564	1150	6	195	201	ATF3 GM12878 (female B-cells lymphoblastoid cell line) ATF3	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ATF3		ENCODE	ENCSR000BJY_GM12878_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	2516
1	719	CTCF	0.537436906194571	1.54452220444476	9	493	397	2564	2564	1150	6	195	201	CTCF suprapubic skin CTCF	suprapubic skin	NULL	CTCF		GTRD	EXP039663_suprapubic-skin_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	6317
1	1162	ESR1	0.537436906194571	1.54452220444476	9	493	397	2564	2564	1150	6	195	201	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	Array Express	ERP000380_esr1_mcf7-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	14114
1	1979	GATA3	0.537436906194571	1.54452220444476	9	493	397	2564	2564	1150	6	195	201	GATA3 T47D (invasive ductal carcinoma) GATA3	T47D (invasive ductal carcinoma)	BTO:0001248	GATA3	Passsage: <10	GTRD	EXP049897_T47D--invasive-ductal-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	16786
1	3102	NR3C1	0.537436906194571	1.54452220444476	9	493	397	2564	2564	1150	6	195	201	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	etoh	GTRD	EXP036230_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	11080
1	3136	NR3C1	0.537436906194571	1.54452220444476	9	493	397	2564	2564	1150	6	195	201	NR3C1 Ishikawa (endometrial adenocarcinoma) NR3C1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	NR3C1	Treatment: 100 nM Dexamethasone and 10 nM Estradiol for 1 hour	GTRD	EXP048232_Ishikawa--endometrial-adenocarcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	10499
1	2707	MAX	0.535398611314194	1.16838486006556	50	501	940	275	940	572	45	154	162	MAX liver MAX	liver	BTO:0000759	MAX		GTRD	EXP039669_liver_MAX_MACS_MAX_MA0059.1.damo.pwm.bed	16902
1	434	CTCF	0.534542009594464	1.26849113631862	22	502	737	1459	1459	899	18	182	189	CTCF GM12878 (female B-cells lymphoblastoid cell line) CTCF	GM12878 (female B-cells lymphoblastoid cell line)	NULL	CTCF		ENCODE	ENCSR000AKB_GM12878_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30236
1	566	CTCF	0.534542009594464	1.26849113631862	22	502	737	1459	1459	899	18	182	189	CTCF ZR-75-1 (invasive ductal carcinoma) CTCF	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	CTCF		Array Express	ERP000783_ctcf_zr751_MACS_CTCF_MA0139.1.damo.pwm.bed	38750
1	753	CTCF	0.534542009594464	1.26849113631862	22	502	737	1459	1459	899	18	182	189	CTCF 22RV1 (prostate carcinoma) CTCF	22RV1 (prostate carcinoma)	BTO:0002999	CTCF	10 nM 17β-hydroxy-5α-androstan-3-one (CHEBI:16330) for 4 hour	GTRD	EXP039943_22RV1--prostate-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34792
1	872	CTCF	0.534542009594464	1.26849113631862	22	502	737	1459	1459	899	18	182	189	CTCF GM17942 (lymphoblastoid cell) CTCF	GM17942 (lymphoblastoid cell)	NULL	CTCF	Genotype: 22q11 deletion Cell type: lymphoblastoid cell Age: 6	GTRD	EXP051028_GM17942--lymphoblastoid-cell-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34738
1	1381	ESR1	0.534542009594464	1.26849113631862	22	502	737	1459	1459	899	18	182	189	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: with Estrogen;	GTRD	EXP058225_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	35934
1	1808	FOXA1	0.534542009594464	1.26849113631862	22	502	737	1459	1459	899	18	182	189	FOXA1 ZR-75-1 (invasive ductal carcinoma) FOXA1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	FOXA1	E2	GEO	GSE72249_foxa1_zr751-e2_MACS_FOXA1_MA0148.4.damo.pwm.bed	63618
1	3417	REST	0.534542009594464	1.26849113631862	22	502	737	1459	1459	899	18	182	189	REST liver REST	liver	BTO:0000759	REST		GTRD	EXP039414_liver_REST_MACS_REST_MA0138.2.damo.pwm.bed	12400
1	620	CTCF	0.533154808117365	1.16417927156532	52	509	955	244	955	569	47	152	160	CTCF erythroid progenitors CTCF	erythroid progenitors	BTO:0002731	CTCF	none	GTRD	EXP033119_erythroid-progenitors_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	73102
1	888	CTCF	0.530269658692523	1.15864164520659	55	510	966	211	966	562	50	149	157	CTCF MOLM-13(acute monocytic leukemia(AML), Homo sapiens) CTCF	MOLM-13(acute monocytic leukemia(AML), Homo sapiens)	BTO:0004175	CTCF	Treatment: treated with 1:10.000 DMSO for 48hr	GTRD	EXP053099_MOLM-13-acute-monocytic-leukemia-AML---Homo-sapiens-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	77437
1	1818	FOXA2	0.530269658692523	1.15864164520659	55	510	966	211	966	562	50	149	157	FOXA2 pancreatic islets FOXA2	pancreatic islets	NULL	FOXA2		Array Express	ERP004003_foxa2_islet_MACS_FOXA2_MA0047.3.damo.pwm.bed	146564
1	2948	MYCN	0.530269658692523	1.15864164520659	55	510	966	211	966	562	50	149	157	MYCN Kelly (neuroblastoma) MYCN	Kelly (neuroblastoma)	NULL	MYCN	Treatment: untreated	GTRD	EXP049488_Kelly--neuroblastoma-_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	26612
1	495	CTCF	0.529785977819535	1.25663840105397	23	513	749	1391	1391	884	19	181	188	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DPP_fibroblast_of_pedal_digit_skin_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30004
1	733	CTCF	0.529785977819535	1.25663840105397	23	513	749	1391	1391	884	19	181	188	CTCF MM1.S (plasma cell myeloma) CTCF	MM1.S (plasma cell myeloma)	BTO:0003933	CTCF		GTRD	EXP039740_MM1.S--plasma-cell-myeloma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31577
1	1971	GATA3	0.529785977819535	1.25663840105397	23	513	749	1391	1391	884	19	181	188	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3		GTRD	EXP039573_MCF7--Invasive-ductal-breast-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	36204
1	400	CEBPB	0.52942465794157	1.15697861030144	56	516	974	192	974	561	51	148	156	CEBPB LS180 (colon cancer) CEBPB	LS180 (colon cancer)	NULL	CEBPB	125	GEO	GSE31939_cebpb_ls180-125_MACS_CEBPB_MA0466.2.damo.pwm.bed	116278
1	948	CTCF	0.52863385354737	1.1553988413072	57	517	975	174	975	555	52	147	155	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm12891_MACS_CTCF_MA0139.1.damo.pwm.bed	66327
1	1148	ERG	0.52863385354737	1.1553988413072	57	517	975	174	975	555	52	147	155	ERG TSU-1621-MT (adult acute myeloid leukemia) ERG	TSU-1621-MT (adult acute myeloid leukemia)	NULL	ERG		GEO	GSE60477_erg_tsu1621mt_MACS_ERG_MA0474.2.damo.pwm.bed	31788
1	1057	EGR1	0.527895016522576	1.15389801479932	58	519	981	154	981	551	53	146	154	EGR1 GM12878 (female B-cells lymphoblastoid cell line) EGR1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	EGR1		ENCODE	ENCSR000BMQ_GM12878_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	18885
1	2951	MYCN	0.527206075923379	1.15247213811545	59	520	988	143	988	550	54	145	153	MYCN BE2C MYCN	BE2C	NULL	MYCN		GEO	GSE80151_mycn_be2c_MACS_MYCN_MA0104.4.damo.pwm.bed	28694
1	2709	MAX	0.525970315432072	1.14983074233427	61	521	992	127	992	547	56	143	151	MAX MKL-1 (Merkel cell carcinoma) MAX	MKL-1 (Merkel cell carcinoma)	NULL	MAX	Treatment: no treatment Markel Cell: positive	GTRD	EXP048813_MKL-1--Merkel-cell-carcinoma-_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	57096
1	592	CTCF	0.525439068080442	1.24599473501435	24	522	771	1324	1324	872	20	180	187	CTCF GM12878 (female B-cells lymphoblastoid cell line) CTCF	GM12878 (female B-cells lymphoblastoid cell line)	NULL	CTCF		GTRD	EXP030398_GM12878--female-B-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	33576
1	3069	NR2F1	0.525439068080442	1.24599473501435	24	522	771	1324	1324	872	20	180	187	NR2F1 GM12878 (female B-cells lymphoblastoid cell line) NR2F1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	NR2F1	NA	GTRD	EXP040024_GM12878--female-B-cells-_NR2F1_MACS_NR2F1_MA1537.1.damo.pwm.bed	16135
1	1269	ESR1	0.523012677876765	1.47136923436328	10	524	477	2442	2442	1150	7	194	200	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	Doxycycline	GTRD	EXP038382_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	17182
1	1956	GATA2	0.523012677876765	1.47136923436328	10	524	477	2442	2442	1150	7	194	200	GATA2 TF-1 (erythroleukemia) GATA2	TF-1 (erythroleukemia)	BTO:0004760	GATA2		GEO	GSE73207_gata2_tf1_MACS_GATA2_MA0036.3.damo.pwm.bed	50857
1	1963	GATA3	0.523012677876765	1.47136923436328	10	524	477	2442	2442	1150	7	194	200	GATA3 Th2-cells GATA3	Th2-cells	BTO:0001679	GATA3		GTRD	EXP031084_Th2-cells_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	13453
1	3901	TFAP2C	0.522973058931538	1.14248357301464	68	527	1028	56	1028	537	63	136	144	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p52; Genotype: TFAP2C -/-; Treatment: transduced construct that allows doxycycline inducible expression of TFAP2C;	GTRD	EXP047542_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	35163
1	3903	TFAP2C	0.522696269807102	1.14164265075583	69	528	1029	47	1029	535	64	135	143	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p52; Genotype: TFAP2C -/-; Treatment: transduced construct that allows doxycycline inducible expression of TFAP2C;	GTRD	EXP047543_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	34397
1	584	CTCF	0.521453061110922	1.23638782452699	25	529	785	1262	1262	859	21	179	186	CTCF CD36+ erythroid cells CTCF	CD36+ erythroid cells	NULL	CTCF	BRG1 KD shLuc control	GTRD	EXP000909_CD36--erythroid-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34810
1	693	CTCF	0.521453061110922	1.23638782452699	25	529	785	1262	1262	859	21	179	186	CTCF transverse colon CTCF	transverse colon	NULL	CTCF		GTRD	EXP039472_transverse-colon_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27619
1	715	CTCF	0.517787285001178	1.22767668970738	26	531	800	1204	1204	845	22	178	185	CTCF esophagus squamous epithelium CTCF	esophagus squamous epithelium	NULL	CTCF		GTRD	EXP039620_esophagus-squamous-epithelium_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27971
1	1246	ESR1	0.517787285001178	1.22767668970738	26	531	800	1204	1204	845	22	178	185	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	5min E2	GTRD	EXP038336_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	48348
1	1360	ESR1	0.517787285001178	1.22767668970738	26	531	800	1204	1204	845	22	178	185	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: Vehicle for4 hrs Genotype: ER+/PR+	GTRD	EXP049945_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	23242
1	2699	MAX	0.517787285001178	1.22767668970738	26	531	800	1204	1204	845	22	178	185	MAX NB4 (acute promyelocytic leukemia ) MAX	NB4 (acute promyelocytic leukemia )	NULL	MAX		ENCODE	ENCSR000EHS_NB4_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	10368
1	615	CTCF	0.514407175074398	1.21974487376946	27	535	834	1135	1135	835	23	177	184	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF		GTRD	EXP032763_K562--myelogenous-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	47995
1	684	CTCF	0.514407175074398	1.21974487376946	27	535	834	1135	1135	835	23	177	184	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF		GTRD	EXP039434_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39320
1	767	CTCF	0.514407175074398	1.21974487376946	27	535	834	1135	1135	835	23	177	184	CTCF esophagus muscularis mucosa CTCF	esophagus muscularis mucosa	NULL	CTCF		GTRD	EXP040054_esophagus-muscularis-mucosa_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	23266
1	979	CTCF	0.514407175074398	1.21974487376946	27	535	834	1135	1135	835	23	177	184	CTCF Delta47 (plasma cell myeloma) CTCF	Delta47 (plasma cell myeloma)	NULL	CTCF		GEO	GSE70764_ctcf_delta47_MACS_CTCF_MA0139.1.damo.pwm.bed	29088
1	1750	FOXA1	0.514407175074398	1.21974487376946	27	535	834	1135	1135	835	23	177	184	FOXA1 ZR-75-1 (invasive ductal carcinoma) FOXA1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	FOXA1	Treatment: hormone-deprived cells treated with vehicle;	GTRD	EXP058105_ZR-75-1--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	62226
1	1807	FOXA1	0.514407175074398	1.21974487376946	27	535	834	1135	1135	835	23	177	184	FOXA1 ZR-75-1 (invasive ductal carcinoma) FOXA1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	FOXA1	DEX	GEO	GSE72249_foxa1_zr751-dex_MACS_FOXA1_MA0148.4.damo.pwm.bed	72458
1	2038	GATA6	0.514407175074398	1.21974487376946	27	535	834	1135	1135	835	23	177	184	GATA6 definitive endoderm from HUES8 GATA6	definitive endoderm from HUES8	NULL	GATA6	Genotype: SOX17-GFP knockout;	GTRD	EXP057932_definitive-endoderm-from-HUES8_GATA6_MACS_GATA6_MA1104.2.damo.pwm.bed	73409
1	4027	TP63	0.514407175074398	1.21974487376946	27	535	834	1135	1135	835	23	177	184	TP63 keratinocytes TP63	keratinocytes	NULL	TP63	NULL	GTRD	EXP000292_keratinocytes_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	43062
1	24	AR	0.514116200144858	3.06708284717465	3	543	110	3316	3316	1320	1	201	206	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	BICALUTAMIDE	GTRD	EXP032853_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	5030
1	93	AR	0.514116200144858	3.06708284717465	3	543	110	3316	3316	1320	1	201	206	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: vehicle (charcoal stripped) for 6 hrs  TF: full-length AR (AR-FL)	GTRD	EXP049390_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	2795
1	109	AR	0.514116200144858	3.06708284717465	3	543	110	3316	3316	1320	1	201	206	AR LNCaP95 AR	LNCaP95	NULL	AR	Treatment: 10 nM ETOH for 4 hrs Genotype: parental (none transfection)	GTRD	EXP052952_LNCaP95_AR_MACS_AR_MA0007.3.damo.pwm.bed	7515
1	114	AR	0.514116200144858	3.06708284717465	3	543	110	3316	3316	1320	1	201	206	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment:  transfected twice with with 5nM of siControl every 24 hours, 100nM of ETOH for 2 hrs, 100nM of ETOH for 2 hrs	GTRD	EXP052983_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	2651
1	1165	ESR1	0.514116200144858	3.06708284717465	3	543	110	3316	3316	1320	1	201	206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	TAM	Array Express	ERP000380_esr1_mcf7-tam_MACS_ESR1_MA0112.3.damo.pwm.bed	5899
1	1189	ESR1	0.514116200144858	3.06708284717465	3	543	110	3316	3316	1320	1	201	206	ESR1 H3396 (breast carcinoma) ESR1	H3396 (breast carcinoma)	NULL	ESR1	E2	GTRD	EXP001013_H3396--breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	5305
1	1213	ESR1	0.514116200144858	3.06708284717465	3	543	110	3316	3316	1320	1	201	206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Vehicle treatment	GTRD	EXP036169_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	9086
1	1244	ESR1	0.514116200144858	3.06708284717465	3	543	110	3316	3316	1320	1	201	206	ESR1 breast tumor xenograft ESR1	breast tumor xenograft	NULL	ESR1	estrogen plus progesterone	GTRD	EXP038286_breast-tumor-xenograft_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	4210
1	1321	ESR1	0.514116200144858	3.06708284717465	3	543	110	3316	3316	1320	1	201	206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 500 nM AZD201 2 hr; Passage: p20;	GTRD	EXP047704_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	11644
1	1391	ESR1	0.514116200144858	3.06708284717465	3	543	110	3316	3316	1320	1	201	206	ESR1 breast ESR1	breast	NA	ESR1	tumor_GOODOUTCOME	GEO	GSE40867_esr1_breast-cancer-goodOutcome_MACS_ESR1_MA0112.3.damo.pwm.bed	2193
1	1823	FOXA2	0.514116200144858	3.06708284717465	3	543	110	3316	3316	1320	1	201	206	FOXA2 endometrioid adenocarcinoma FOXA2	endometrioid adenocarcinoma	NULL	FOXA2	tumor A	GTRD	EXP036409_endometrioid-adenocarcinoma_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	1480
1	1920	GATA1	0.514116200144858	3.06708284717465	3	543	110	3316	3316	1320	1	201	206	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	MYO1D Non-hub KO	GTRD	EXP040809_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	6940
1	2027	GATA4	0.514116200144858	3.06708284717465	3	543	110	3316	3316	1320	1	201	206	GATA4 YCC3 (gastric adenocarcinoma) GATA4	YCC3 (gastric adenocarcinoma)	NULL	GATA4		GEO	GSE51705_gata4_ycc3_MACS_GATA4_MA0482.2.damo.pwm.bed	5733
1	2190	HSF1	0.514116200144858	3.06708284717465	3	543	110	3316	3316	1320	1	201	206	HSF1 ZR-75-1 (invasive ductal carcinoma) HSF1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	HSF1		GEO	GSE38901_hsf1_zr751_MACS_HSF1_MA0486.2.damo.pwm.bed	795
1	2668	MAF	0.514116200144858	3.06708284717465	3	543	110	3316	3316	1320	1	201	206	MAF Th17-cells MAF	Th17-cells	BTO:0005655	MAF	CellType:pool of expanded Th17 clones; Tissue: primary Th17-IL-10+ lymphocytes; ActivationState: resting;Day:0;	GTRD	EXP047560_Th17-cells_MAF_MACS_MAF_MA1520.1.damo.pwm.bed	997
1	2724	MEF2A	0.514116200144858	3.06708284717465	3	543	110	3316	3316	1320	1	201	206	MEF2A K562 (myelogenous leukemia) MEF2A	K562 (myelogenous leukemia)	NULL	MEF2A	NA	ENCODE	ENCSR000BNV_K562_MEF2A_MACS_MEF2A_MA0052.4.damo.pwm.bed	3534
1	3060	NR2F1	0.514116200144858	3.06708284717465	3	543	110	3316	3316	1320	1	201	206	NR2F1 H9-derived neural crest cells NR2F1	H9-derived neural crest cells	NULL	NR2F1	NA	GTRD	EXP030994_H9-derived-neural-crest-cells_NR2F1_MACS_NR2F1_MA1537.1.damo.pwm.bed	4108
1	3609	SOX2	0.514116200144858	3.06708284717465	3	543	110	3316	3316	1320	1	201	206	SOX2 hESC-1 (Embryonic stem cells) SOX2	hESC-1 (Embryonic stem cells)	NULL	SOX2		GEO	GSE18292_sox2_esc_MACS_SOX2_MA0143.4.damo.pwm.bed	12842
1	4044	TP63	0.514116200144858	3.06708284717465	3	543	110	3316	3316	1320	1	201	206	TP63 HCC95 (squamous cell lung carcinoma) TP63	HCC95 (squamous cell lung carcinoma)	NULL	TP63		GEO	GSE46837_tp63_hcc95_MACS_TP63_MA0525.2.damo.pwm.bed	2893
1	4148	YY1	0.514116200144858	3.06708284717465	3	543	110	3316	3316	1320	1	201	206	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1	YY1 hemizygous deletion	GTRD	EXP038618_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	752
1	827	CTCF	0.511283154400752	1.2124953348467	28	563	855	1068	1068	829	24	176	183	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 4hr, IAV NS1(EP mRNA), siWAPL(siRNA)	GTRD	EXP047783_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40823
1	778	CTCF	0.51126321263925	1.41654182020972	11	564	529	2332	2332	1140	8	193	199	CTCF omental fat pad CTCF	omental fat pad	NULL	CTCF		GTRD	EXP040090_omental-fat-pad_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	10433
1	1407	ESR1	0.51126321263925	1.41654182020972	11	564	529	2332	2332	1140	8	193	199	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2_TNF	GEO	GSE59530_esr1_mcf7-e2-tnf_MACS_ESR1_MA0112.3.damo.pwm.bed	18407
1	1731	FOXA1	0.51126321263925	1.41654182020972	11	564	529	2332	2332	1140	8	193	199	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	Passsage: <10 Genotype: wt/R330fs mutant with CRISPR	GTRD	EXP049902_T47D--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	16562
1	2222	JUN	0.51126321263925	1.41654182020972	11	564	529	2332	2332	1140	8	193	199	JUN HepG2 (hepatoblastoma) JUN	HepG2 (hepatoblastoma)	BTO:0000599	JUN		ENCODE	ENCSR000EEK_HepG2_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	20853
1	4141	YY1	0.51126321263925	1.41654182020972	11	564	529	2332	2332	1140	8	193	199	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1		GTRD	EXP038611_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	2571
1	912	CTCF	0.508389754133128	1.20584656366256	29	569	867	1013	1013	816	25	175	182	CTCF GM10847 (female B-cells Lymphoblastoid Cell Lines) CTCF	GM10847 (female B-cells Lymphoblastoid Cell Lines)	NULL	CTCF		GTRD	EXP054511_GM10847--female-B-cells-Lymphoblastoid-Cell-Lines-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38343
1	3195	OTX2	0.508389754133128	1.20584656366256	29	569	867	1013	1013	816	25	175	182	OTX2 HUES64 (embryonic stem cells) OTX2	HUES64 (embryonic stem cells)	NULL	OTX2		GTRD	EXP036726_HUES64--embryonic-stem-cells-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	34253
1	574	CTCF	0.505704915422108	1.1997295970427	30	571	879	937	937	796	26	174	181	CTCF HUVEC-C (HUVEC, umbilical vein endothelial cells) CTCF	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	CTCF	NULL	GTRD	EXP000598_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48775
1	901	CTCF	0.505704915422108	1.1997295970427	30	571	879	937	937	796	26	174	181	CTCF GM12878 (female B-cells lymphoblastoid cell line) CTCF	GM12878 (female B-cells lymphoblastoid cell line)	NULL	CTCF	Treatment: None;	GTRD	EXP054038_GM12878--female-B-cells-lymphoblastoid-cell-line-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	43477
1	1751	FOXA1	0.505704915422108	1.1997295970427	30	571	879	937	937	796	26	174	181	FOXA1 ZR-75-1 (invasive ductal carcinoma) FOXA1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	FOXA1	Treatment: hormone-deprived cells treated with 10 nM estrogen for 45 mins;	GTRD	EXP058106_ZR-75-1--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	82035
1	3742	STAT3	0.505704915422108	1.1997295970427	30	571	879	937	937	796	26	174	181	STAT3 JB6 (Human anaplastic large cell lymphoma) STAT3	JB6 (Human anaplastic large cell lymphoma)	BTO:0004831	STAT3	Treatment: DMSO for 3 hrs	GTRD	EXP053277_JB6--Human-anaplastic-large-cell-lymphoma-_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	17784
1	828	CTCF	0.503209430363402	1.19408569503403	31	575	890	881	890	782	27	173	180	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 7hr+Flavopiridol 3hr, IAV NS1(EP mRNA), siWAPL(siRNA)	GTRD	EXP047784_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37205
1	2037	GATA6	0.503209430363402	1.19408569503403	31	575	890	881	890	782	27	173	180	GATA6 definitive endoderm from HUES8 GATA6	definitive endoderm from HUES8	NULL	GATA6	Genotype: SOX17-GFP knockout;	GTRD	EXP057930_definitive-endoderm-from-HUES8_GATA6_MACS_GATA6_MA1104.2.damo.pwm.bed	98417
1	3103	NR3C1	0.503209430363402	1.19408569503403	31	575	890	881	890	782	27	173	180	NR3C1 BEAS-2B (bronchial epithelium) NR3C1	BEAS-2B (bronchial epithelium)	NULL	NR3C1	dexamethasone	GTRD	EXP036257_BEAS-2B--bronchial-epithelium-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	27789
1	673	CTCF	0.501490411149332	1.37393313203877	12	578	559	2233	2233	1120	9	192	198	CTCF spleen CTCF	spleen	BTO:0001281	CTCF		GTRD	EXP039321_spleen_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	16199
1	2127	HNF4A	0.501490411149332	1.37393313203877	12	578	559	2233	2233	1120	9	192	198	HNF4A HepG2 (hepatoblastoma) HNF4A	HepG2 (hepatoblastoma)	BTO:0000599	HNF4A	NULL	GTRD	EXP000307_HepG2--hepatoblastoma-_HNF4A_MACS_HNF4A_MA1494.1.damo.pwm.bed	13234
1	2128	HNF4A	0.500886490507157	1.1888645157432	32	580	905	825	905	770	28	172	179	HNF4A HepG2 (hepatoblastoma) HNF4A	HepG2 (hepatoblastoma)	BTO:0000599	HNF4A	none	GTRD	EXP030930_HepG2--hepatoblastoma-_HNF4A_MACS_HNF4A_MA0114.4.damo.pwm.bed	37426
1	2765	MNT	0.500886490507157	1.1888645157432	32	580	905	825	905	770	28	172	179	MNT HepG2 (hepatoblastoma) MNT	HepG2 (hepatoblastoma)	BTO:0000599	MNT	NA	GTRD	EXP039947_HepG2--hepatoblastoma-_MNT_MACS_MNT_MA0825.1.damo.pwm.bed	7914
1	3899	TFAP2C	0.500886490507157	1.1888645157432	32	580	905	825	905	770	28	172	179	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p28; CellType: Prime UCLA1 hESSCs;	GTRD	EXP047540_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	13121
1	382	CEBPB	0.496700871227315	1.17952255211106	34	583	922	729	922	745	30	170	177	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP040190_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	36053
1	3553	SCRT1	0.494813582331607	1.17533142825324	35	584	923	691	923	733	31	169	176	SCRT1 HEK293 (embryonic kidney) SCRT1	HEK293 (embryonic kidney)	NULL	SCRT1	NA	GTRD	EXP035930_HEK293--embryonic-kidney-_SCRT1_MACS_SCRT1_MA0743.2.damo.pwm.bed	91668
1	171	AR	0.493224876689432	1.33987874083055	13	585	616	2153	2153	1120	10	191	197	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	DHT24H_SHRUNX1	GEO	GSE58428_AR_vcap-dht24h-shrunx1_MACS_AR_MA0007.3.damo.pwm.bed	28873
1	742	CTCF	0.493224876689432	1.33987874083055	13	585	616	2153	2153	1120	10	191	197	CTCF vagina CTCF	vagina	BTO:0000243	CTCF		GTRD	EXP039806_vagina_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	13945
1	1052	EBF1	0.493224876689432	1.33987874083055	13	585	616	2153	2153	1120	10	191	197	EBF1 hASC (preadipocytes) EBF1	hASC (preadipocytes)	NULL	EBF1	NA	GEO	GSE54889_ebf1_asc_MACS_EBF1_MA0154.4.damo.pwm.bed	9666
1	1996	GATA3	0.493224876689432	1.33987874083055	13	585	616	2153	2153	1120	10	191	197	GATA3 T47D (invasive ductal carcinoma) GATA3	T47D (invasive ductal carcinoma)	BTO:0001248	GATA3		GEO	GSE51274_gata3_t47d_MACS_GATA3_MA0037.3.damo.pwm.bed	27000
1	397	CEBPB	0.493049164496901	1.17142065529394	36	589	937	645	937	724	32	168	175	CEBPB SU-DHL-1 (Anaplastic large cell lymphoma) CEBPB	SU-DHL-1 (Anaplastic large cell lymphoma)	BTO:0005058	CEBPB	Treatment: DMSO for 3 hrs	GTRD	EXP053283_SU-DHL-1--Anaplastic-large-cell-lymphoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	100244
1	502	CTCF	0.491398432475492	1.16776507108667	37	590	943	607	943	713	33	167	174	CTCF GM06990 (female B-cells) CTCF	GM06990 (female B-cells)	NULL	CTCF		ENCODE	ENCSR000DQW_GM06990_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	44667
1	3225	PBX3	0.488405952313024	1.16113323389311	39	591	965	547	965	701	35	165	172	PBX3 GM12878 (female B-cells lymphoblastoid cell line) PBX3	GM12878 (female B-cells lymphoblastoid cell line)	NULL	PBX3	NA	ENCODE	ENCSR000BGR_GM12878_PBX3_MACS_PBX3_MA1114.1.damo.pwm.bed	29964
1	292	BHLHE40	0.48613828931961	1.31204656086187	14	592	663	2073	2073	1110	11	190	196	BHLHE40 A549 (lung carcinoma) BHLHE40	A549 (lung carcinoma)	BTO:0000018	BHLHE40	NA	ENCODE	ENCSR000DYJ_A549_BHLHE40_MACS_BHLHE40_MA0464.2.damo.pwm.bed	2498
1	326	CEBPA	0.48613828931961	1.31204656086187	14	592	663	2073	2073	1110	11	190	196	CEBPA SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) CEBPA	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	CEBPA	Treatment: ethanol; Genotype: inducible version of CEBPA (C/EBPalpha-ER);	GTRD	EXP047670_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	7785
1	944	CTCF	0.48613828931961	1.31204656086187	14	592	663	2073	2073	1110	11	190	196	CTCF lymphocyte CTCF	lymphocyte	NA	CTCF	blood	GEO	GSE46832_ctcf_lymphocyte-blood_MACS_CTCF_MA0139.1.damo.pwm.bed	15293
1	2221	JUN	0.48613828931961	1.31204656086187	14	592	663	2073	2073	1110	11	190	196	JUN HeLa S3 (cervical adenocarcinoma) JUN	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	JUN		ENCODE	ENCSR000EDG_HeLa-S3_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	19799
1	406	CEBPB	0.483473792642037	1.15010744137521	43	596	989	429	989	671	39	161	168	CEBPB hFOB 1.19 (fetal osteoblast) CEBPB	hFOB 1.19 (fetal osteoblast)	BTO:0005224	CEBPB	DIFF	GEO	GSE82295_cebpb_hfob-diff_MACS_CEBPB_MA0466.2.damo.pwm.bed	63028
1	616	CTCF	0.483473792642037	1.15010744137521	43	596	989	429	989	671	39	161	168	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF	5-aza-2’-deoxycytidine (decitabine; Sigma, A3656) dissolved in DMSO to 10mM. Drug was administered at 1uM daily for 3 days. Control K562 cells were mock treated with DMSO.	GTRD	EXP032764_K562--myelogenous-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	62574
1	1874	GABPA	0.483473792642037	1.15010744137521	43	596	989	429	989	671	39	161	168	GABPA MCF7 (Invasive ductal breast carcinoma) GABPA	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GABPA		ENCODE	ENCSR000BUK_MCF-7_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	13111
1	1778	FOXA1	0.482428803459917	1.14773739312721	44	599	999	408	999	669	40	160	167	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	SHPIAS1_R1881	GEO	GSE56086_foxa1_vcap-shpias1-r1881_MACS_FOXA1_MA0148.4.damo.pwm.bed	150822
1	364	CEBPB	0.480534226680265	1.14338582479022	46	600	1024	349	1024	658	42	158	165	CEBPB SUM159PT (Triple negative breast cancer) CEBPB	SUM159PT (Triple negative breast cancer)	NULL	CEBPB	DMSO	GTRD	EXP037879_SUM159PT--pleiomorphic-breast-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	71597
1	575	CTCF	0.480534226680265	1.14338582479022	46	600	1024	349	1024	658	42	158	165	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF	NULL	GTRD	EXP000599_K562--myelogenous-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	73652
1	929	CTCF	0.480534226680265	1.14338582479022	46	600	1024	349	1024	658	42	158	165	CTCF HT1080 (fibrosarcoma) CTCF	HT1080 (fibrosarcoma)	NULL	CTCF	Treatment: none;	GTRD	EXP058381_HT1080--fibrosarcoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	72872
1	931	CTCF	0.480534226680265	1.14338582479022	46	600	1024	349	1024	658	42	158	165	CTCF HT1080 (fibrosarcoma) CTCF	HT1080 (fibrosarcoma)	NULL	CTCF	Treatment: none;	GTRD	EXP058383_HT1080--fibrosarcoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	81070
1	1099	ELK1	0.479993482374317	1.28888176965165	15	604	691	1993	1993	1100	12	189	195	ELK1 HeLa S3 (cervical adenocarcinoma) ELK1	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	ELK1		ENCODE	ENCSR000ECI_HeLa-S3_ELK1_MACS_ELK1_MA0028.2.damo.pwm.bed	3506
1	1135	ERG	0.479993482374317	1.28888176965165	15	604	691	1993	1993	1100	12	189	195	ERG HUVEC-C (HUVEC, umbilical vein endothelial cells) ERG	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ERG	Treatment: agent VEGF, timepoint 12 Passage: P3-6	GTRD	EXP048204_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	8121
1	1273	ESR1	0.479993482374317	1.28888176965165	15	604	691	1993	1993	1100	12	189	195	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	none	GTRD	EXP038386_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	22462
1	1327	ESR1	0.479993482374317	1.28888176965165	15	604	691	1993	1993	1100	12	189	195	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 500 nM AZD201 2 hr; Passage: p22;	GTRD	EXP047710_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	24135
1	1682	FOXA1	0.479993482374317	1.28888176965165	15	604	691	1993	1993	1100	12	189	195	FOXA1 ZR-75-1 (invasive ductal carcinoma) FOXA1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	FOXA1		GTRD	EXP038764_ZR-75-1--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	59360
1	1693	FOXA1	0.479993482374317	1.28888176965165	15	604	691	1993	1993	1100	12	189	195	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1		GTRD	EXP040141_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	37981
1	1800	FOXA1	0.479993482374317	1.28888176965165	15	604	691	1993	1993	1100	12	189	195	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	SHGATA2_R1881	GEO	GSE69043_foxa1_lncap-shgata2-r1881_MACS_FOXA1_MA0148.4.damo.pwm.bed	36554
1	1929	GATA2	0.479993482374317	1.28888176965165	15	604	691	1993	1993	1100	12	189	195	GATA2 K562 (myelogenous leukemia) GATA2	K562 (myelogenous leukemia)	NULL	GATA2		ENCODE	ENCSR000DKA_K562_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	26344
1	2154	HNF4G	0.479993482374317	1.28888176965165	15	604	691	1993	1993	1100	12	189	195	HNF4G 22RV1 (prostate carcinoma) HNF4G	22RV1 (prostate carcinoma)	BTO:0002999	HNF4G	Treatment: Cells were harvested in log phase growth Genotype: knockdown HNF4G	GTRD	EXP048997_22RV1--prostate-carcinoma-_HNF4G_MACS_HNF4G_MA0484.2.damo.pwm.bed	13939
1	3053	NR2C2	0.479993482374317	1.28888176965165	15	604	691	1993	1993	1100	12	189	195	NR2C2 HepG2 (hepatoblastoma) NR2C2	HepG2 (hepatoblastoma)	BTO:0000599	NR2C2	NULL	GTRD	EXP000578_HepG2--hepatoblastoma-_NR2C2_MACS_NR2C2_MA0504.1.damo.pwm.bed	5299
1	3086	NR3C1	0.476783098733921	1.13440120448575	51	614	1042	261	1042	639	47	153	160	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	1 h with 50 nM Dexamethasone (Myers)	ENCODE	ENCSR000BHF_A549_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	51277
1	401	CEBPB	0.474624825013833	1.12876090596959	55	615	1061	211	1061	629	51	149	156	CEBPB LS180 (colon cancer) CEBPB	LS180 (colon cancer)	NULL	CEBPB		GEO	GSE31939_cebpb_ls180_MACS_CEBPB_MA0466.2.damo.pwm.bed	92692
1	255	ATF3	0.474614473562507	1.26930789470238	16	616	734	1909	1909	1090	13	188	194	ATF3 K562 (myelogenous leukemia) ATF3	K562 (myelogenous leukemia)	NULL	ATF3		GTRD	EXP040300_K562--myelogenous-leukemia-_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	40651
1	1932	GATA2	0.474614473562507	1.26930789470238	16	616	734	1909	1909	1090	13	188	194	GATA2 SH-SY5Y (neuroblastoma) GATA2	SH-SY5Y (neuroblastoma)	BTO:0000793	GATA2		ENCODE	ENCSR000EYB_SH-SY5Y_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	44579
1	2732	MEF2B	0.474614473562507	1.26930789470238	16	616	734	1909	1909	1090	13	188	194	MEF2B HEK293-A MEF2B	HEK293-A	NULL	MEF2B	Genotype: wildtype MEF2B-V5;	GTRD	EXP055128_HEK293-A_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	16216
1	1490	FLI1	0.474185380048658	1.12752698972868	56	619	1062	192	1062	624	52	148	155	FLI1 Kasumi-1 (acute myeloblastic leukemia) FLI1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	FLI1		GTRD	EXP037191_Kasumi-1--acute-myeloblastic-leukemia-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	34336
1	219	ARNT	0.473987549614752	2.04653630731589	4	620	214	3182	3182	1340	2	200	205	ARNT HEK293T (embryonic kidney) ARNT	HEK293T (embryonic kidney)	BTO:0002181	ARNT		GTRD	EXP039727_HEK293T--embryonic-kidney-_ARNT_MACS_ARNT_MA0259.1.damo.pwm.bed	959
1	707	CTCF	0.473987549614752	2.04653630731589	4	620	214	3182	3182	1340	2	200	205	CTCF lower leg skin CTCF	lower leg skin	NULL	CTCF		GTRD	EXP039574_lower-leg-skin_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	877
1	1232	ESR1	0.473987549614752	2.04653630731589	4	620	214	3182	3182	1340	2	200	205	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP037445_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	7316
1	1348	ESR1	0.473987549614752	2.04653630731589	4	620	214	3182	3182	1340	2	200	205	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: E2 (estrogen) for 45 min  Genotype: TET2 knockout Passage: 6-10	GTRD	EXP048688_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	6157
1	1496	FLI1	0.473987549614752	2.04653630731589	4	620	214	3182	3182	1340	2	200	205	FLI1 HUVEC-C (HUVEC, umbilical vein endothelial cells) FLI1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FLI1	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048205_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	2489
1	1513	FLI1	0.473987549614752	2.04653630731589	4	620	214	3182	3182	1340	2	200	205	FLI1 SK-N-MC (Askin tumor) FLI1	SK-N-MC (Askin tumor)	BTO:0002914	FLI1		GEO	GSE61944_fli1_skmnc_MACS_FLI1_MA0475.2.damo.pwm.bed	2647
1	1630	FOXA1	0.473987549614752	2.04653630731589	4	620	214	3182	3182	1340	2	200	205	FOXA1 Ishikawa (endometrial adenocarcinoma) FOXA1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	FOXA1	1 h with 0.02% Dimethyl sufloxide (DMSO) (Myers)	ENCODE	ENCSR000BKW_Ishikawa_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	4846
1	1675	FOXA1	0.473987549614752	2.04653630731589	4	620	214	3182	3182	1340	2	200	205	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	100 nM 17-beta-estradiol for 3h	GTRD	EXP037654_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	6237
1	2048	GFI1B	0.473987549614752	2.04653630731589	4	620	214	3182	3182	1340	2	200	205	GFI1B SET2 (Adult acute megakaryoblastic leukemia, Homo Sapiens) GFI1B	SET2 (Adult acute megakaryoblastic leukemia, Homo Sapiens)	NULL	GFI1B	Treatment: DMSO; Genotype: wildtype;	GTRD	EXP058347_SET2--Adult-acute-megakaryoblastic-leukemia--Homo-Sapiens-_GFI1B_MACS_GFI1B_MA0483.1.damo.pwm.bed	3543
1	2197	IRF1	0.473987549614752	2.04653630731589	4	620	214	3182	3182	1340	2	200	205	IRF1 K562 (myelogenous leukemia) IRF1	K562 (myelogenous leukemia)	NULL	IRF1	Interferon gamma treatment - 30 minutes (Snyder)	ENCODE	ENCSR000EGK_K562_IRF1_MACS_IRF1_MA0050.2.damo.pwm.bed	1346
1	2463	JUN	0.473987549614752	2.04653630731589	4	620	214	3182	3182	1340	2	200	205	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: RUNX1/ETO knockdown;	GTRD	EXP058212_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	1998
1	2883	MYC	0.473987549614752	2.04653630731589	4	620	214	3182	3182	1340	2	200	205	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 1;	GTRD	EXP047487_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	805
1	2884	MYC	0.473987549614752	2.04653630731589	4	620	214	3182	3182	1340	2	200	205	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 1;	GTRD	EXP047487_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	888
1	3802	TCF7	0.473987549614752	2.04653630731589	4	620	214	3182	3182	1340	2	200	205	TCF7 K562 (myelogenous leukemia) TCF7	K562 (myelogenous leukemia)	NULL	TCF7		ENCODE	ENCSR863KUB_K562_TCF7_MACS_TCF7_MA0769.2.damo.pwm.bed	3359
1	4045	TP63	0.473987549614752	2.04653630731589	4	620	214	3182	3182	1340	2	200	205	TP63 KYSE70 (esophageal squamous carcinoma) TP63	KYSE70 (esophageal squamous carcinoma)	NULL	TP63		GEO	GSE46837_tp63_kyse70_MACS_TP63_MA0525.2.damo.pwm.bed	2712
1	956	CTCF	0.473782725828977	1.12635621061951	57	635	1064	174	1064	624	53	147	154	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm19238_MACS_CTCF_MA0139.1.damo.pwm.bed	63960
1	3902	TFAP2C	0.471510641649907	1.11752675769892	67	636	1088	68	1088	597	63	137	144	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p52; Genotype: TFAP2C -/-; Treatment: transduced construct that allows doxycycline inducible expression of TFAP2C;	GTRD	EXP047542_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	35300
1	1078	ELF1	0.471437527365607	1.11688492689052	68	637	1093	56	1093	595	64	136	143	ELF1 HepG2 (hepatoblastoma) ELF1	HepG2 (hepatoblastoma)	BTO:0000599	ELF1		ENCODE	ENCSR000BMZ_HepG2_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	29760
1	3900	TFAP2C	0.471437527365607	1.11688492689052	68	637	1093	56	1093	595	64	136	143	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p52; Genotype: TFAP2C -/-; Treatment: transduced construct that allows doxycycline inducible expression of TFAP2C;	GTRD	EXP047542_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	36939
1	3905	TFAP2C	0.471437527365607	1.11688492689052	68	637	1093	56	1093	595	64	136	143	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p52; Genotype: TFAP2C -/-; Treatment: transduced construct that allows doxycycline inducible expression of TFAP2C;	GTRD	EXP047543_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	33143
1	659	CTCF	0.46986768087639	1.25255599381908	17	640	763	1846	1846	1080	14	187	193	CTCF E18 retina CTCF	E18 retina	NULL	CTCF		GTRD	EXP037801_E18-retina_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	19936
1	691	CTCF	0.46986768087639	1.25255599381908	17	640	763	1846	1846	1080	14	187	193	CTCF LNCaP (prostate carcinoma) CTCF	LNCaP (prostate carcinoma)	BTO:0001321	CTCF	10 nM 17β-hydroxy-5α-androstan-3-one (CHEBI:16330) for 4 hour	GTRD	EXP039468_LNCaP--prostate-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31277
1	812	CTCF	0.46986768087639	1.25255599381908	17	640	763	1846	1846	1080	14	187	193	CTCF HeLa Kyoto (cervical adenocarcinoma) CTCF	HeLa Kyoto (cervical adenocarcinoma)	NULL	CTCF	Wapl/Pds5A/B depletion	GTRD	EXP040506_HeLa-Kyoto--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	43723
1	1735	FOXA1	0.46986768087639	1.25255599381908	17	640	763	1846	1846	1080	14	187	193	FOXA1 LNCaP95 FOXA1	LNCaP95	NULL	FOXA1	Treatment: 10 nM ETOH for 4 hrs Genotype: shARv7 transfection	GTRD	EXP052941_LNCaP95_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	35823
1	2787	MYC	0.46986768087639	1.25255599381908	17	640	763	1846	1846	1080	14	187	193	MYC MCF7 (Invasive ductal breast carcinoma) MYC	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	MYC	45 min with 100 nM Estradiol (Crawford)	ENCODE	ENCSR000DMP_MCF-7_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	4260
1	378	CEBPB	0.46564971345562	1.23806215681267	18	645	780	1785	1785	1070	15	186	192	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039935_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	19276
1	843	CTCF	0.46564971345562	1.23806215681267	18	645	780	1785	1785	1070	15	186	192	CTCF MDM(monocyte derived macrophages) CTCF	MDM(monocyte derived macrophages)	NULL	CTCF	Treatment: H5N1 IAV infected 6hr	GTRD	EXP047826_MDM-monocyte-derived-macrophages-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29557
1	4002	TP53	0.46564971345562	1.23806215681267	18	645	780	1785	1785	1070	15	186	192	TP53 SaOS2 (osteosarcoma) TP53	SaOS2 (osteosarcoma)	BTO:0000971	TP53		GEO	GSE15780_tp53_saos_MACS_TP53_MA0106.3.damo.pwm.bed	20246
1	43	AR	0.461879186106322	1.22540344040855	19	648	806	1697	1697	1050	16	185	191	AR LNCaP C4-2 (prostate carcinoma) AR	LNCaP C4-2 (prostate carcinoma)	BTO:0005672	AR	10 nmol/l of mibolerone	GTRD	EXP034502_LNCaP-C4-2--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	52310
1	842	CTCF	0.461879186106322	1.22540344040855	19	648	806	1697	1697	1050	16	185	191	CTCF MDM(monocyte derived macrophages) CTCF	MDM(monocyte derived macrophages)	NULL	CTCF	Treatment: mock infected 6hr	GTRD	EXP047825_MDM-monocyte-derived-macrophages-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30753
1	845	CTCF	0.461879186106322	1.22540344040855	19	648	806	1697	1697	1050	16	185	191	CTCF MDM(monocyte derived macrophages) CTCF	MDM(monocyte derived macrophages)	NULL	CTCF	Treatment: IFNb treated 6hr	GTRD	EXP047828_MDM-monocyte-derived-macrophages-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	28851
1	4129	YY1	0.461879186106322	1.22540344040855	19	648	806	1697	1697	1050	16	185	191	YY1 K562 (myelogenous leukemia) YY1	K562 (myelogenous leukemia)	NULL	YY1		ENCODE	ENCSR000EWF_K562_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	6122
1	571	CTCF	0.458491082449297	1.21425641221537	20	652	849	1606	1606	1040	17	184	190	CTCF HL-60 (acute myeloid leukemia) CTCF	HL-60 (acute myeloid leukemia)	BTO:0000738	CTCF		Array Express	ERP008568_ctcf_hl60_MACS_CTCF_MA0139.1.damo.pwm.bed	28129
1	604	CTCF	0.458491082449297	1.21425641221537	20	652	849	1606	1606	1040	17	184	190	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	oestrogen, CTCF siRNA	GTRD	EXP030931_MCF7--Invasive-ductal-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36803
1	664	CTCF	0.458491082449297	1.21425641221537	20	652	849	1606	1606	1040	17	184	190	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF	+DOX 3 days, mutant CTCF	GTRD	EXP038268_K562--myelogenous-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	24725
1	1154	ESR1	0.458491082449297	1.21425641221537	20	652	849	1606	1606	1040	17	184	190	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	1 h with 100 nM Genistein (Myers)	ENCODE	ENCSR000BJS_T47D_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	27112
1	1248	ESR1	0.458491082449297	1.21425641221537	20	652	849	1606	1606	1040	17	184	190	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	20min E2	GTRD	EXP038338_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	43395
1	1903	GATA1	0.458491082449297	1.21425641221537	20	652	849	1606	1606	1040	17	184	190	GATA1 primary erythroblasts GATA1	primary erythroblasts	NULL	GATA1	NULL	GTRD	EXP000701_primary-erythroblasts_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	25824
1	329	CEBPA	0.455432781315375	1.20436951206289	21	658	869	1535	1535	1020	18	183	189	CEBPA Kasumi-1 (acute myeloblastic leukemia) CEBPA	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	CEBPA	Treatment: ethanol; Genotype: inducible version of CEBPA (C/EBPalpha-ER);	GTRD	EXP047678_Kasumi-1--acute-myeloblastic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	45915
1	595	CTCF	0.455432781315375	1.20436951206289	21	658	869	1535	1535	1020	18	183	189	CTCF mammary epithelial cells CTCF	mammary epithelial cells	NULL	CTCF		GTRD	EXP030401_mammary-epithelial-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36660
1	734	CTCF	0.455432781315375	1.20436951206289	21	658	869	1535	1535	1020	18	183	189	CTCF ovary CTCF	ovary	BTO:0000975	CTCF		GTRD	EXP039745_ovary_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	17703
1	1543	FOS	0.455432781315375	1.20436951206289	21	658	869	1535	1535	1020	18	183	189	FOS MCF7 (Invasive ductal breast carcinoma) FOS	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOS		GTRD	EXP040137_MCF7--Invasive-ductal-breast-carcinoma-_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	43869
1	1544	FOS	0.455432781315375	1.20436951206289	21	658	869	1535	1535	1020	18	183	189	FOS MCF7 (Invasive ductal breast carcinoma) FOS	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOS		GTRD	EXP040137_MCF7--Invasive-ductal-breast-carcinoma-_FOS_MACS_FOS_MA1134.1.damo.pwm.bed	42967
1	1545	FOS	0.455432781315375	1.20436951206289	21	658	869	1535	1535	1020	18	183	189	FOS MCF7 (Invasive ductal breast carcinoma) FOS	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOS		GTRD	EXP040137_MCF7--Invasive-ductal-breast-carcinoma-_FOS_MACS_FOS_MA1141.1.damo.pwm.bed	42986
1	3237	PKNOX1	0.455432781315375	1.20436951206289	21	658	869	1535	1535	1020	18	183	189	PKNOX1 HEK293T (embryonic kidney) PKNOX1	HEK293T (embryonic kidney)	BTO:0002181	PKNOX1	NA	GTRD	EXP039342_HEK293T--embryonic-kidney-_PKNOX1_MACS_PKNOX1_MA0782.2.damo.pwm.bed	28993
1	4155	YY2	0.455432781315375	1.20436951206289	21	658	869	1535	1535	1020	18	183	189	YY2 HeLa (cervical adenocarcinoma) YY2	HeLa (cervical adenocarcinoma)	BTO:0000567	YY2	NA	GTRD	EXP048879_HeLa--cervical-adenocarcinoma-_YY2_MACS_YY2_MA0748.2.damo.pwm.bed	5606
1	454	CTCF	0.452661197324253	1.19554414051781	22	666	888	1459	1459	1000	19	182	188	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BHW_A549_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	33961
1	3880	TFAP2C	0.452661197324253	1.19554414051781	22	666	888	1459	1459	1000	19	182	188	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions;	GTRD	EXP047534_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	9543
1	119	AR	0.451094585353707	1.70634724327708	5	668	342	3053	3053	1350	3	199	204	AR primary prostate cancer AR	primary prostate cancer	NULL	AR	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053233_primary-prostate-cancer_AR_MACS_AR_MA0007.3.damo.pwm.bed	4520
1	149	AR	0.451094585353707	1.70634724327708	5	668	342	3053	3053	1350	3	199	204	AR DU145 (prostate carcinoma) AR	DU145 (prostate carcinoma)	BTO:0001332	AR		GEO	GSE47987_AR_du145_MACS_AR_MA0007.3.damo.pwm.bed	11076
1	217	ARNT	0.451094585353707	1.70634724327708	5	668	342	3053	3053	1350	3	199	204	ARNT HEK293T (embryonic kidney) ARNT	HEK293T (embryonic kidney)	BTO:0002181	ARNT		GTRD	EXP039727_HEK293T--embryonic-kidney-_ARNT_MACS_ARNT_MA0004.1.damo.pwm.bed	909
1	1205	ESR1	0.451094585353707	1.70634724327708	5	668	342	3053	3053	1350	3	199	204	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1		GTRD	EXP035621_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	9594
1	1300	ESR1	0.451094585353707	1.70634724327708	5	668	342	3053	3053	1350	3	199	204	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2 for 3h	GTRD	EXP040895_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	9309
1	1766	FOXA1	0.451094585353707	1.70634724327708	5	668	342	3053	3053	1350	3	199	204	FOXA1 LNCaP C4-2B (prostate carcinoma) FOXA1	LNCaP C4-2B (prostate carcinoma)	BTO:0004959	FOXA1		GEO	GSE40050_foxa1_c42b_MACS_FOXA1_MA0148.4.damo.pwm.bed	10874
1	2462	JUN	0.451094585353707	1.70634724327708	5	668	342	3053	3053	1350	3	199	204	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: RUNX1/ETO knockdown;	GTRD	EXP058212_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	1912
1	2467	JUN	0.451094585353707	1.70634724327708	5	668	342	3053	3053	1350	3	199	204	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: RUNX1/ETO knockdown;	GTRD	EXP058212_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	1775
1	472	CTCF	0.450140685263324	1.18762142031656	23	676	908	1391	1391	992	20	181	187	CTCF GM20000 (B-cells) CTCF	GM20000 (B-cells)	NULL	CTCF		ENCODE	ENCSR000DLG_GM20000_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	25439
1	713	CTCF	0.450140685263324	1.18762142031656	23	676	908	1391	1391	992	20	181	187	CTCF Peyer's patch CTCF	Peyer's patch	NULL	CTCF		GTRD	EXP039612_Peyer-s-patch_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	19138
1	857	CTCF	0.450140685263324	1.18762142031656	23	676	908	1391	1391	992	20	181	187	CTCF HeLa S3 (cervical adenocarcinoma) CTCF	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	CTCF	treatment: no block with TSA CellPopulation:unsynchronized	GTRD	EXP048092_HeLa-S3--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	33861
1	1894	GATA1	0.450140685263324	1.18762142031656	23	676	908	1391	1391	992	20	181	187	GATA1 erythroblasts GATA1	erythroblasts	NULL	GATA1		ENCODE	ENCSR000EXP_erythroblast_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	28149
1	634	CTCF	0.447841478933908	1.18047273989829	24	680	919	1324	1324	974	21	180	186	CTCF OCI-LY7 (diffuse large B-cell lymphoma) CTCF	OCI-LY7 (diffuse large B-cell lymphoma)	NULL	CTCF		GTRD	EXP036842_OCI-LY7--diffuse-large-B-cell-lymphoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41743
1	869	CTCF	0.447841478933908	1.18047273989829	24	680	919	1324	1324	974	21	180	186	CTCF MIA PaCa-2 (pancreatic ductal adenocarcinoma) CTCF	MIA PaCa-2 (pancreatic ductal adenocarcinoma)	NULL	CTCF	Treatment: none	GTRD	EXP049078_MIA-PaCa-2--pancreatic-ductal-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	32801
1	504	CTCF	0.44573851093336	1.17399287574128	25	682	924	1262	1262	956	22	179	185	CTCF GM12864 (male B-cells) CTCF	GM12864 (male B-cells)	NULL	CTCF		ENCODE	ENCSR000DRB_GM12864_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36934
1	772	CTCF	0.44573851093336	1.17399287574128	25	682	924	1262	1262	956	22	179	185	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP040071_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36454
1	786	CTCF	0.44573851093336	1.17399287574128	25	682	924	1262	1262	956	22	179	185	CTCF gastroesophageal sphincter CTCF	gastroesophageal sphincter	NULL	CTCF		GTRD	EXP040169_gastroesophageal-sphincter_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30274
1	2910	MYC	0.44573851093336	1.17399287574128	25	682	924	1262	1262	956	22	179	185	MYC MYC	NA	NA	MYC	NA	GEO	GSE30726_myc_ra1_MACS_MYC_MA0147.3.damo.pwm.bed	4724
1	2977	NEUROG2	0.44573851093336	1.17399287574128	25	682	924	1262	1262	956	22	179	185	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	2 DPT	GTRD	EXP037151_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	25527
1	678	CTCF	0.443810508483186	1.16809490871376	26	687	941	1204	1204	944	23	178	184	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP039386_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38755
1	585	CTCF	0.442039292320935	1.16270641122758	27	688	960	1135	1135	928	24	177	183	CTCF CD36+ erythroid cells CTCF	CD36+ erythroid cells	NULL	CTCF	BRG1 RNAi KD	GTRD	EXP000910_CD36--erythroid-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31602
1	741	CTCF	0.442039292320935	1.16270641122758	27	688	960	1135	1135	928	24	177	183	CTCF pancreas CTCF	pancreas	BTO:0000988	CTCF		GTRD	EXP039805_pancreas_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	33645
1	823	CTCF	0.442039292320935	1.16270641122758	27	688	960	1135	1135	928	24	177	183	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA), siNIPBL(siRNA)	GTRD	EXP047779_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36084
1	3615	SOX2	0.442039292320935	1.16270641122758	27	688	960	1135	1135	928	24	177	183	SOX2 hiPSC SOX2	hiPSC	NULL	SOX2		GEO	GSE56567_sox2_ipsc_MACS_SOX2_MA0143.4.damo.pwm.bed	44530
1	3786	TCF12	0.442039292320935	1.16270641122758	27	688	960	1135	1135	928	24	177	183	TCF12 Kasumi-1 (acute myeloblastic leukemia) TCF12	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	TCF12	NA	GEO	GSE43834_tcf12_kasumi1_MACS_TCF12_MA0521.1.damo.pwm.bed	12148
1	611	CTCF	0.440409227024741	1.15776654939893	28	693	969	1068	1068	910	25	176	182	CTCF HCT-116 (colon carcinoma) CTCF	HCT-116 (colon carcinoma)	BTO:0001109	CTCF	DNMT1KO	GTRD	EXP032759_HCT-116--colon-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39216
1	654	CTCF	0.440409227024741	1.15776654939893	28	693	969	1068	1068	910	25	176	182	CTCF epidermal keratinocytes CTCF	epidermal keratinocytes	NULL	CTCF	day6 of differentiation	GTRD	EXP037598_epidermal-keratinocytes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40305
1	2989	NEUROG2	0.440409227024741	1.15776654939893	28	693	969	1068	1068	910	25	176	182	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	2 DPT	GTRD	EXP037157_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	23944
1	3227	PDX1	0.440409227024741	1.15776654939893	28	693	969	1068	1068	910	25	176	182	PDX1 pancreatic islets PDX1	pancreatic islets	NULL	PDX1		Array Express	ERP001456_pdx1_islet_MACS_PDX1_MA0132.2.damo.pwm.bed	47872
1	3589	SOX13	0.440409227024741	1.15776654939893	28	693	969	1068	1068	910	25	176	182	SOX13 HepG2 (hepatoblastoma) SOX13	HepG2 (hepatoblastoma)	BTO:0000599	SOX13	NA	GTRD	EXP040100_HepG2--hepatoblastoma-_SOX13_MACS_SOX13_MA1120.1.damo.pwm.bed	45807
1	499	CTCF	0.438906785687047	1.15322385388782	29	698	982	1013	1013	898	26	175	181	CTCF BE2C CTCF	BE2C	NULL	CTCF		ENCODE	ENCSR000DQD_BE2C_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48616
1	637	CTCF	0.438906785687047	1.15322385388782	29	698	982	1013	1013	898	26	175	181	CTCF DOHH2 (diffuse large B-cell lymphoma) CTCF	DOHH2 (diffuse large B-cell lymphoma)	NULL	CTCF		GTRD	EXP036845_DOHH2--diffuse-large-B-cell-lymphoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46511
1	658	CTCF	0.438906785687047	1.15322385388782	29	698	982	1013	1013	898	26	175	181	CTCF E16 retina CTCF	E16 retina	NULL	CTCF		GTRD	EXP037800_E16-retina_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29622
1	683	CTCF	0.438906785687047	1.15322385388782	29	698	982	1013	1013	898	26	175	181	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP039407_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	43168
1	821	CTCF	0.438906785687047	1.15322385388782	29	698	982	1013	1013	898	26	175	181	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 4hr, IAV NS1(EP mRNA), siCtrl(siRNA)	GTRD	EXP047777_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39467
1	1171	ESR1	0.438906785687047	1.15322385388782	29	698	982	1013	1013	898	26	175	181	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		Array Express	ERP000783_esr1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	67491
1	635	CTCF	0.437520201931067	1.1490344860693	30	704	993	937	993	878	27	174	180	CTCF IPSC-derived bipolar neuron CTCF	IPSC-derived bipolar neuron	NULL	CTCF		GTRD	EXP036843_IPSC-derived-bipolar-neuron_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49668
1	793	CTCF	0.437520201931067	1.1490344860693	30	704	993	937	993	878	27	174	180	CTCF human cardiac myocytes CTCF	human cardiac myocytes	NULL	CTCF		GTRD	EXP040253_human-cardiac-myocytes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40422
1	824	CTCF	0.437520201931067	1.1490344860693	30	704	993	937	993	878	27	174	180	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 4hr, IAV NS1(EP mRNA), siNIPBL(siRNA)	GTRD	EXP047780_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37519
1	1193	ESR1	0.437520201931067	1.1490344860693	30	704	993	937	993	878	27	174	180	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GTRD	EXP032284_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	54857
1	2847	MYC	0.437520201931067	1.1490344860693	30	704	993	937	993	878	27	174	180	MYC HUES64 (embryonic stem cells) MYC	HUES64 (embryonic stem cells)	NULL	MYC		GTRD	EXP036777_HUES64--embryonic-stem-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	7009
1	4050	TP63	0.437520201931067	1.1490344860693	30	704	993	937	993	878	27	174	180	TP63 keratinocytes TP63	keratinocytes	NULL	TP63	D0	GEO	GSE59824_tp63_keratinocyte-d0_MACS_TP63_MA0525.2.damo.pwm.bed	42276
1	697	CTCF	0.436239189350267	1.14516087571332	31	710	1019	881	1019	870	28	173	179	CTCF RWPE2 CTCF	RWPE2	NULL	CTCF		GTRD	EXP039498_RWPE2_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45527
1	851	CTCF	0.436239189350267	1.14516087571332	31	710	1019	881	1019	870	28	173	179	CTCF HeLa (cervical adenocarcinoma) CTCF	HeLa (cervical adenocarcinoma)	BTO:0000567	CTCF	Plasmids: GK-dCas9-SunTag (Addgene #100943) + pEF1a-NLS-scFvGCN4-DNMT3A (Addgene #100941) + pEf1a-MIR152_3-gRNA-GFP	GTRD	EXP048003_HeLa--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45853
1	853	CTCF	0.436239189350267	1.14516087571332	31	710	1019	881	1019	870	28	173	179	CTCF HeLa (cervical adenocarcinoma) CTCF	HeLa (cervical adenocarcinoma)	BTO:0000567	CTCF	Plasmids: pGK-dCas9-SunTag (Addgene #100943) + pEF1a-NLS-scFvGCN4-DNMT3A (Addgene #100941) + pEf1a-MIR152-gRNA-GFP	GTRD	EXP048005_HeLa--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	43259
1	2439	JUN	0.436239189350267	1.14516087571332	31	710	1019	881	1019	870	28	173	179	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057919_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	30792
1	3898	TFAP2C	0.436239189350267	1.14516087571332	31	710	1019	881	1019	870	28	173	179	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p28; CellType: Prime UCLA1 hESSCs;	GTRD	EXP047540_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	12691
1	276	BACH2	0.436051296030743	1.5362776925243	6	715	406	2948	2948	1360	4	198	203	BACH2 DOHH2 (diffuse large B-cell lymphoma) BACH2	DOHH2 (diffuse large B-cell lymphoma)	NULL	BACH2		GEO	GSE69558_bach2_dohh2_MACS_BACH2_MA1101.2.damo.pwm.bed	4297
1	1157	ESR1	0.436051296030743	1.5362776925243	6	715	406	2948	2948	1360	4	198	203	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	1 h with 0.02% Dimethyl sufloxide (DMSO) (Myers)	ENCODE	ENCSR000BLL_T47D_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	2757
1	1207	ESR1	0.436051296030743	1.5362776925243	6	715	406	2948	2948	1360	4	198	203	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1		GTRD	EXP035789_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	7588
1	1255	ESR1	0.436051296030743	1.5362776925243	6	715	406	2948	2948	1360	4	198	203	ESR1 endometrioid adenocarcinoma ESR1	endometrioid adenocarcinoma	NULL	ESR1	Tamoxifen-associated	GTRD	EXP038345_endometrioid-adenocarcinoma_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	11177
1	1376	ESR1	0.436051296030743	1.5362776925243	6	715	406	2948	2948	1360	4	198	203	ESR1 MCF7L-P(immortalized breast epithelial cell line) ESR1	MCF7L-P(immortalized breast epithelial cell line)	NULL	ESR1	Treatment: treated with E2 for 1 hr;	GTRD	EXP057859_MCF7L-P-immortalized-breast-epithelial-cell-line-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12230
1	1648	FOXA1	0.436051296030743	1.5362776925243	6	715	406	2948	2948	1360	4	198	203	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	E2	GTRD	EXP000617_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	12259
1	1827	FOXA2	0.436051296030743	1.5362776925243	6	715	406	2948	2948	1360	4	198	203	FOXA2 HUES64 (embryonic stem cells) FOXA2	HUES64 (embryonic stem cells)	NULL	FOXA2		GTRD	EXP036706_HUES64--embryonic-stem-cells-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	6521
1	2735	MEF2B	0.436051296030743	1.5362776925243	6	715	406	2948	2948	1360	4	198	203	MEF2B HEK293-A MEF2B	HEK293-A	NULL	MEF2B	Genotype: D83V-MEF2B-V5;	GTRD	EXP055131_HEK293-A_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	4026
1	3047	NR2C1	0.436051296030743	1.5362776925243	6	715	406	2948	2948	1360	4	198	203	NR2C1 K562 (myelogenous leukemia) NR2C1	K562 (myelogenous leukemia)	NULL	NR2C1	NA	GTRD	EXP039725_K562--myelogenous-leukemia-_NR2C1_MACS_NR2C1_MA1535.1.damo.pwm.bed	2878
1	3117	NR3C1	0.436051296030743	1.5362776925243	6	715	406	2948	2948	1360	4	198	203	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP040168_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	3810
1	3216	PAX5	0.436051296030743	1.5362776925243	6	715	406	2948	2948	1360	4	198	203	PAX5 Raji (Burkitt lymphoma) PAX5	Raji (Burkitt lymphoma)	BTO:0001154	PAX5	none	GTRD	EXP031938_Raji--Burkitt-lymphoma-_PAX5_MACS_PAX5_MA0014.3.damo.pwm.bed	7144
1	3250	POU5F1	0.436051296030743	1.5362776925243	6	715	406	2948	2948	1360	4	198	203	POU5F1 HUES64 (embryonic stem cells) POU5F1	HUES64 (embryonic stem cells)	NULL	POU5F1		GTRD	EXP032064_HUES64--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	15254
1	3253	POU5F1	0.436051296030743	1.5362776925243	6	715	406	2948	2948	1360	4	198	203	POU5F1 HUES64 (embryonic stem cells) POU5F1	HUES64 (embryonic stem cells)	NULL	POU5F1		GTRD	EXP036730_HUES64--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	6069
1	4147	YY1	0.436051296030743	1.5362776925243	6	715	406	2948	2948	1360	4	198	203	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1	YY1-mutated (p.Lys179*)	GTRD	EXP038617_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	1029
1	645	CTCF	0.435054713504597	1.14157064050598	32	729	1030	825	1030	861	29	172	178	CTCF hepatocytes CTCF	hepatocytes	NULL	CTCF		GTRD	EXP036857_hepatocytes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41646
1	507	CTCF	0.433958805257517	1.13823572165453	33	730	1034	778	1034	847	30	171	177	CTCF GM12867 (female B-cells) CTCF	GM12867 (female B-cells)	NULL	CTCF		ENCODE	ENCSR000DRH_GM12867_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40953
1	3402	REST	0.433958805257517	1.13823572165453	33	730	1034	778	1034	847	30	171	177	REST GM12878 (female B-cells lymphoblastoid cell line) REST	GM12878 (female B-cells lymphoblastoid cell line)	NULL	REST		ENCODE	ENCSR000BQS_GM12878_REST_MACS_REST_MA0138.2.damo.pwm.bed	13304
1	355	CEBPB	0.432944406906081	1.13513168678686	34	732	1036	729	1036	832	31	170	176	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB		ENCODE	ENCSR000BUB_A549_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	41194
1	555	CTCF	0.432944406906081	1.13513168678686	34	732	1036	729	1036	832	31	170	176	CTCF Loucy (adult T acute lymphoblastic leukemia) CTCF	Loucy (adult T acute lymphoblastic leukemia)	NULL	CTCF		ENCODE	ENCSR464DKE_Loucy_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	61498
1	3850	TFAP2A	0.432944406906081	1.13513168678686	34	732	1036	729	1036	832	31	170	176	TFAP2A MCF7 (Invasive ductal breast carcinoma) TFAP2A	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2A		GTRD	EXP032577_MCF7--Invasive-ductal-breast-carcinoma-_TFAP2A_MACS_TFAP2A_MA0003.4.damo.pwm.bed	37642
1	84	AR	0.432005244528426	1.1322371635529	35	735	1052	691	1052	826	32	169	175	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: case	GTRD	EXP049252_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	29541
1	524	CTCF	0.432005244528426	1.1322371635529	35	735	1052	691	1052	826	32	169	175	CTCF HepG2 (hepatoblastoma) CTCF	HepG2 (hepatoblastoma)	BTO:0000599	CTCF		ENCODE	ENCSR000DUG_HepG2_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	52602
1	646	CTCF	0.432005244528426	1.1322371635529	35	735	1052	691	1052	826	32	169	175	CTCF neutrophils CTCF	neutrophils	NULL	CTCF		GTRD	EXP036862_neutrophils_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	19923
1	306	CEBPA	0.43113572144563	1.12953337620555	36	738	1059	645	1059	814	33	168	174	CEBPA HepG2 (hepatoblastoma) CEBPA	HepG2 (hepatoblastoma)	BTO:0000599	CEBPA		Array Express	ERP000209_cebpa_hepg2_MACS_CEBPA_MA0102.4.damo.pwm.bed	37742
1	1965	GATA3	0.43113572144563	1.12953337620555	36	738	1059	645	1059	814	33	168	174	GATA3 MDA-MB-231 (breast adenocarcinoma) GATA3	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	GATA3		GTRD	EXP035435_MDA-MB-231--breast-adenocarcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	103007
1	356	CEBPB	0.430330828805228	1.12700376396132	37	740	1063	607	1063	803	34	167	173	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB		ENCODE	ENCSR000DYI_A549_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	90011
1	806	CTCF	0.429586070138306	1.12463366478608	38	741	1068	576	1068	795	35	166	172	CTCF NB69 (neuroblastoma) CTCF	NB69 (neuroblastoma)	BTO:0005426	CTCF		GTRD	EXP040385_NB69--neuroblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	62006
1	831	CTCF	0.429586070138306	1.12463366478608	38	741	1068	576	1068	795	35	166	172	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Pam3csk4 treated (025m)	GTRD	EXP047798_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	57379
1	2120	HNF4A	0.429586070138306	1.12463366478608	38	741	1068	576	1068	795	35	166	172	HNF4A HepG2 (hepatoblastoma) HNF4A	HepG2 (hepatoblastoma)	BTO:0000599	HNF4A		ENCODE	ENCSR000BLF_HepG2_HNF4A_MACS_HNF4A_MA0114.4.damo.pwm.bed	49223
1	3933	TFAP2C	0.428386741529882	1.08860365990482	86	744	1159	7	1159	637	83	118	124	TFAP2C A375 (malignant melanoma) TFAP2C	A375 (malignant melanoma)	BTO:0002806	TFAP2C	DMSO	GEO	GSE41234_tfap2c_a375-dmso_MACS_TFAP2C_MA0815.1.damo.pwm.bed	66171
1	561	CTCF	0.428261156425791	1.12032131293126	40	745	1084	502	1084	777	37	164	170	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	TAM	Array Express	ERP000380_ctcf_mcf7-tam_MACS_CTCF_MA0139.1.damo.pwm.bed	46305
1	2776	MYB	0.428261156425791	1.12032131293126	40	745	1084	502	1084	777	37	164	170	MYB AML (monocytes and acute myeloid leukemia) MYB	AML (monocytes and acute myeloid leukemia)	NULL	MYB	Treatment: LSD1 inhibitor OG86	GTRD	EXP049357_AML--monocytes-and-acute-myeloid-leukemia-_MYB_MACS_MYB_MA0100.3.damo.pwm.bed	24880
1	437	CTCF	0.427674040401341	1.11835706414739	41	747	1086	476	1086	770	38	163	169	CTCF keratinocytes CTCF	keratinocytes	NULL	CTCF		ENCODE	ENCSR000ALJ_keratinocyte_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	51999
1	838	CTCF	0.427674040401341	1.11835706414739	41	747	1086	476	1086	770	38	163	169	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 360min + Flavopiridol 240min	GTRD	EXP047805_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	55919
1	982	CTCF	0.427133049700216	1.11650799300728	42	749	1096	454	1096	766	39	162	168	CTCF OVCAR8 (high grade ovarian serous adenocarcinoma) CTCF	OVCAR8 (high grade ovarian serous adenocarcinoma)	BTO:0003054	CTCF		GEO	GSE70764_ctcf_ovcar8_MACS_CTCF_MA0139.1.damo.pwm.bed	61455
1	321	CEBPA	0.425379289617687	1.1101077631477	46	750	1110	349	1110	736	43	158	164	CEBPA HepG2 (hepatoblastoma) CEBPA	HepG2 (hepatoblastoma)	BTO:0000599	CEBPA		GTRD	EXP040183_HepG2--hepatoblastoma-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	59957
1	552	CTCF	0.425379289617687	1.1101077631477	46	750	1110	349	1110	736	43	158	164	CTCF DOHH2 (diffuse large B-cell lymphoma) CTCF	DOHH2 (diffuse large B-cell lymphoma)	NULL	CTCF		ENCODE	ENCSR084RDK_DOHH2_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	56288
1	193	AR	0.425318805932982	1.43427251746485	7	752	501	2812	2812	1360	5	197	202	AR MDA-MB-453 (breast adenocarcinoma) AR	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	AR	R1881_SICTR	GEO	GSE70161_AR_mdamb453-r1881-sictr_MACS_AR_MA0007.3.damo.pwm.bed	21354
1	777	CTCF	0.425318805932982	1.43427251746485	7	752	501	2812	2812	1360	5	197	202	CTCF omental fat pad CTCF	omental fat pad	NULL	CTCF		GTRD	EXP040089_omental-fat-pad_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	4809
1	1109	ELK4	0.425318805932982	1.43427251746485	7	752	501	2812	2812	1360	5	197	202	ELK4 HEK293 (embryonic kidney) ELK4	HEK293 (embryonic kidney)	NULL	ELK4	NULL	GTRD	EXP000103_HEK293--embryonic-kidney-_ELK4_MACS_ELK4_MA0076.2.damo.pwm.bed	1186
1	1190	ESR1	0.425318805932982	1.43427251746485	7	752	501	2812	2812	1360	5	197	202	ESR1 H3396 (breast carcinoma) ESR1	H3396 (breast carcinoma)	NULL	ESR1	E2	GTRD	EXP001016_H3396--breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	18111
1	1196	ESR1	0.425318805932982	1.43427251746485	7	752	501	2812	2812	1360	5	197	202	ESR1 LTED (breast cancer) ESR1	LTED (breast cancer)	NULL	ESR1	none	GTRD	EXP033908_LTED--breast-cancer-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	14962
1	1320	ESR1	0.425318805932982	1.43427251746485	7	752	501	2812	2812	1360	5	197	202	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 500nM RAD001 2hr; Passage: p20;	GTRD	EXP047703_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	18219
1	1656	FOXA1	0.425318805932982	1.43427251746485	7	752	501	2812	2812	1360	5	197	202	FOXA1 CyT49-derived endodermal cells FOXA1	CyT49-derived endodermal cells	NULL	FOXA1	none	GTRD	EXP033208_CyT49-derived-endodermal-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	17166
1	1765	FOXA1	0.425318805932982	1.43427251746485	7	752	501	2812	2812	1360	5	197	202	FOXA1 LNCaP C4-2B (prostate carcinoma) FOXA1	LNCaP C4-2B (prostate carcinoma)	BTO:0004959	FOXA1	DHT	GEO	GSE40050_foxa1_c42b-dht_MACS_FOXA1_MA0148.4.damo.pwm.bed	17925
1	1855	FOXO1	0.425318805932982	1.43427251746485	7	752	501	2812	2812	1360	5	197	202	FOXO1 B-cells FOXO1	B-cells	NULL	FOXO1	GERMINAL_CENTER	GEO	GSE68349_foxo1_gcb_MACS_FOXO1_MA0480.1.damo.pwm.bed	5068
1	2931	MYC	0.425318805932982	1.43427251746485	7	752	501	2812	2812	1360	5	197	202	MYC breast MYC	breast	NA	MYC	primary	GEO	GSE66252_myc_primary-breast_MACS_MYC_MA0147.3.damo.pwm.bed	1343
1	2932	MYC	0.425318805932982	1.43427251746485	7	752	501	2812	2812	1360	5	197	202	MYC IMEC MYC	IMEC	NA	MYC		GEO	GSE70001_myc_imec_MACS_MYC_MA0147.3.damo.pwm.bed	1498
1	3793	TCF3	0.425318805932982	1.43427251746485	7	752	501	2812	2812	1360	5	197	202	TCF3 TCF3	NA	NA	TCF3	NA	GEO	GSE72828_tcf3_ra1_MACS_TCF3_MA0522.3.damo.pwm.bed	4794
1	4059	TP63	0.425318805932982	1.43427251746485	7	752	501	2812	2812	1360	5	197	202	TP63 keratinocytes TP63	keratinocytes	NULL	TP63	epidermal_KDPAF	GEO	GSE67382_tp63_epidermal-keratinocyte-kdpaf_MACS_TP63_MA0525.2.damo.pwm.bed	13674
1	4133	YY1	0.425318805932982	1.43427251746485	7	752	501	2812	2812	1360	5	197	202	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1		GTRD	EXP038603_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	1844
1	4146	YY1	0.425318805932982	1.43427251746485	7	752	501	2812	2812	1360	5	197	202	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1	YY1-mutated (p.Asp380Tyr)	GTRD	EXP038616_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	1459
1	1813	FOXA1	0.424718653548966	1.10741582390348	48	767	1112	317	1112	732	45	156	162	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	DMSO	GEO	GSE83860_foxa1_lncap-dmso_MACS_FOXA1_MA0148.4.damo.pwm.bed	177567
1	1633	FOXA1	0.424183470034965	1.10500771046747	50	768	1119	275	1119	721	47	154	160	FOXA1 HepG2 (hepatoblastoma) FOXA1	HepG2 (hepatoblastoma)	BTO:0000599	FOXA1		ENCODE	ENCSR000BMO_HepG2_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	73152
1	2211	IRF4	0.423959309307998	1.10389965911946	51	769	1123	261	1123	718	48	153	159	IRF4 MM1.S (plasma cell myeloma) IRF4	MM1.S (plasma cell myeloma)	BTO:0003933	IRF4		GEO	GSE49224_irf4_mm1s_MACS_IRF4_MA1419.1.damo.pwm.bed	50917
1	938	CTCF	0.423591742453904	1.09207232111158	68	770	1149	56	1149	658	65	136	142	CTCF BCBL-1 (B-cell lymphoma) CTCF	BCBL-1 (B-cell lymphoma)	BTO:0002727	CTCF		GEO	GSE38411_ctcf_bcbl1_MACS_CTCF_MA0139.1.damo.pwm.bed	67252
1	959	CTCF	0.423591742453904	1.09207232111158	68	770	1149	56	1149	658	65	136	142	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm2255_MACS_CTCF_MA0139.1.damo.pwm.bed	66228
1	4113	WT1	0.423118875564789	1.09443918271517	63	772	1143	103	1143	673	60	141	147	WT1 K562 (myelogenous leukemia) WT1	K562 (myelogenous leukemia)	NULL	WT1	NA	GTRD	EXP037398_K562--myelogenous-leukemia-_WT1_MACS_WT1_MA1627.1.damo.pwm.bed	117299
1	2720	MAX	0.423094264700619	1.09763274428974	58	773	1132	154	1132	686	55	146	152	MAX NCI-H2171 (small cell lung carcinoma) MAX	NCI-H2171 (small cell lung carcinoma)	NULL	MAX		GEO	GSE41105_max_ncih2171_MACS_MAX_MA0058.3.damo.pwm.bed	61822
1	2836	MYC	0.423060197959543	1.09691920066582	59	774	1136	143	1136	684	56	145	151	MYC HCT-116 (colon carcinoma) MYC	HCT-116 (colon carcinoma)	BTO:0001109	MYC		GTRD	EXP036148_HCT-116--colon-carcinoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	13706
1	3625	SP1	0.423060197959543	1.09691920066582	59	774	1136	143	1136	684	56	145	151	SP1 A549 (lung carcinoma) SP1	A549 (lung carcinoma)	BTO:0000018	SP1	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BPE_A549_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	27083
1	2689	MAX	0.423051730651496	1.09560763906073	61	776	1138	127	1138	680	58	143	149	MAX WA01 (H1, human embryonic stem cells) MAX	WA01 (H1, human embryonic stem cells)	NULL	MAX		ENCODE	ENCSR000BSJ_H1-hESC_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	48378
1	762	CTCF	0.417238824151651	1.36630575031224	8	777	562	2697	2697	1350	6	196	201	CTCF suprapubic skin CTCF	suprapubic skin	NULL	CTCF		GTRD	EXP040026_suprapubic-skin_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	6679
1	1454	ETS1	0.417238824151651	1.36630575031224	8	777	562	2697	2697	1350	6	196	201	ETS1 CD4+ CD25+ CD45RA+ T-cells ETS1	CD4+ CD25+ CD45RA+ T-cells	NULL	ETS1		GTRD	EXP032566_CD4--CD25--CD45RA--T-cells_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	3129
1	1689	FOXA1	0.417238824151651	1.36630575031224	8	777	562	2697	2697	1350	6	196	201	FOXA1 liver FOXA1	liver	BTO:0000759	FOXA1		GTRD	EXP039777_liver_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	13900
1	3260	POU5F1	0.417238824151651	1.36630575031224	8	777	562	2697	2697	1350	6	196	201	POU5F1 bipolar neuron POU5F1	bipolar neuron	NULL	POU5F1	0.5 μg/mL doxycycline hyclate (CHEBI:34730) for 4 day	GTRD	EXP039660_bipolar-neuron_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	4457
1	3555	SCRT2	0.417238824151651	1.36630575031224	8	777	562	2697	2697	1350	6	196	201	SCRT2 HEK293 (embryonic kidney) SCRT2	HEK293 (embryonic kidney)	NULL	SCRT2	NA	GTRD	EXP040055_HEK293--embryonic-kidney-_SCRT2_MACS_SCRT2_MA0744.2.damo.pwm.bed	19475
1	4143	YY1	0.417238824151651	1.36630575031224	8	777	562	2697	2697	1350	6	196	201	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1		GTRD	EXP038613_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	2017
1	80	AR	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: Cells were harvested in log phase growth Genotype: wildtype	GTRD	EXP048992_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	6850
1	194	AR	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	AR MDA-MB-453 (breast adenocarcinoma) AR	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	AR	R1881_SIPIAS1	GEO	GSE70161_AR_mdamb453-r1881-sipias1_MACS_AR_MA0007.3.damo.pwm.bed	27179
1	258	ATF4	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	ATF4 HAP1 (chronic myelogenous leukemia) ATF4	HAP1 (chronic myelogenous leukemia)	NULL	ATF4	2 mM histidinol, 24 hours	GTRD	EXP035034_HAP1--chronic-myelogenous-leukemia-_ATF4_MACS_ATF4_MA0833.2.damo.pwm.bed	22710
1	265	ATF7	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	ATF7 HepG2 (hepatoblastoma) ATF7	HepG2 (hepatoblastoma)	BTO:0000599	ATF7	NA	GTRD	EXP040022_HepG2--hepatoblastoma-_ATF7_MACS_ATF7_MA0834.1.damo.pwm.bed	30110
1	1270	ESR1	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	Doxycycline + E2	GTRD	EXP038383_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	15711
1	1608	FOSL2	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039800_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	7389
1	1609	FOSL2	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039800_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	7385
1	1610	FOSL2	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039800_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	7303
1	1611	FOSL2	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039800_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	7471
1	2169	HOXB13	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	HOXB13 LNCaP95 HOXB13	LNCaP95	NULL	HOXB13	Treatment: 10 nM ETOH for 4 hrs Genotype: shGFP transfection	GTRD	EXP052943_LNCaP95_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	16713
1	2493	JUNB	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039341_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	13575
1	2494	JUNB	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039341_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	14029
1	2495	JUNB	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039341_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	14257
1	2496	JUNB	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039341_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	14370
1	2497	JUNB	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039341_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	13466
1	2498	JUNB	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039341_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	13418
1	3037	NKX2-5	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	NKX2-5 BGO3 (embryonic stem cells) NKX2-5	BGO3 (embryonic stem cells)	NULL	NKX2-5	Treatment: no	GTRD	EXP049256_BGO3--embryonic-stem-cells-_NKX2-5_MACS_NKX2-5_MA0063.2.damo.pwm.bed	9892
1	3232	PHOX2B	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	PHOX2B CLB-Ga (neuroblastoma) PHOX2B	CLB-Ga (neuroblastoma)	NULL	PHOX2B	none	GTRD	EXP039004_CLB-Ga--neuroblastoma-_PHOX2B_MACS_PHOX2B_MA0681.2.damo.pwm.bed	43820
1	3588	SOX13	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	SOX13 HepG2 (hepatoblastoma) SOX13	HepG2 (hepatoblastoma)	BTO:0000599	SOX13	NA	ENCODE	ENCSR445ACU_HepG2_SOX13_MACS_SOX13_MA1120.1.damo.pwm.bed	11547
1	3947	THAP11	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	THAP11 HUES64 (embryonic stem cells) THAP11	HUES64 (embryonic stem cells)	NULL	THAP11	NA	GTRD	EXP036773_HUES64--embryonic-stem-cells-_THAP11_MACS_THAP11_MA1573.1.damo.pwm.bed	2021
1	4057	TP63	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	TP63 HaCaT (keratinocytes) TP63	HaCaT (keratinocytes)	BTO:0000552	TP63	LacZ_TGFB	GEO	GSE60814_tp63_hacat-lacz-tgfb_MACS_TP63_MA0525.2.damo.pwm.bed	12030
1	4160	ZNF143	0.410921440330189	1.31779248325541	9	783	635	2564	2564	1330	7	195	200	ZNF143 HeLa (cervical adenocarcinoma) ZNF143	HeLa (cervical adenocarcinoma)	BTO:0000567	ZNF143		GEO	GSE31417_znf143_hela_MACS_ZNF143_MA0088.2.damo.pwm.bed	1274
1	1423	ESR1	0.405842300451133	1.2814393589554	10	805	707	2442	2442	1320	8	194	199	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	R5020	GEO	GSE68355_ESR1_t47d-r5020_MACS_ESR1_MA0112.3.damo.pwm.bed	15334
1	1826	FOXA2	0.405842300451133	1.2814393589554	10	805	707	2442	2442	1320	8	194	199	FOXA2 HUES64 (embryonic stem cells) FOXA2	HUES64 (embryonic stem cells)	NULL	FOXA2		GTRD	EXP036705_HUES64--embryonic-stem-cells-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	22449
1	2759	MITF	0.405842300451133	1.2814393589554	10	805	707	2442	2442	1320	8	194	199	MITF 501Mel (melanoma) MITF	501Mel (melanoma)	BTO:0002956	MITF		GEO	GSE61965_mitf_501mel_MACS_MITF_MA0620.3.damo.pwm.bed	24233
1	3094	NR3C1	0.405842300451133	1.2814393589554	10	805	707	2442	2442	1320	8	194	199	NR3C1 LNCaP (prostate carcinoma) NR3C1	LNCaP (prostate carcinoma)	BTO:0001321	NR3C1	100 nM Dex	GTRD	EXP030502_LNCaP--prostate-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	24559
1	1502	FLI1	0.401670505240772	1.25319411179071	11	809	757	2332	2332	1300	9	193	198	FLI1 A-673 clone Asp114 (Ewing sarcoma) FLI1	A-673 clone Asp114 (Ewing sarcoma)	NULL	FLI1	Passage: 15-19	GTRD	EXP049961_A-673-clone-Asp114--Ewing-sarcoma-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	13458
1	1890	GABPA	0.401670505240772	1.25319411179071	11	809	757	2332	2332	1300	9	193	198	GABPA DU145 (prostate carcinoma) GABPA	DU145 (prostate carcinoma)	BTO:0001332	GABPA		GEO	GSE59021_gabpa_du145_MACS_GABPA_MA0062.3.damo.pwm.bed	2381
1	2591	JUND	0.401670505240772	1.25319411179071	11	809	757	2332	2332	1300	9	193	198	JUND MCF7 (Invasive ductal breast carcinoma) JUND	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUND		ENCODE	ENCSR000BSU_MCF-7_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	9818
1	2606	JUND	0.401670505240772	1.25319411179071	11	809	757	2332	2332	1300	9	193	198	JUND Calu-3 (lung adenocarcinoma) JUND	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUND		GTRD	EXP037684_Calu-3--lung-adenocarcinoma-_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	7269
1	2607	JUND	0.401670505240772	1.25319411179071	11	809	757	2332	2332	1300	9	193	198	JUND Calu-3 (lung adenocarcinoma) JUND	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUND		GTRD	EXP037684_Calu-3--lung-adenocarcinoma-_JUND_MACS_JUND_MA1141.1.damo.pwm.bed	7302
1	3501	RUNX1	0.401670505240772	1.25319411179071	11	809	757	2332	2332	1300	9	193	198	RUNX1 CD34+ cells RUNX1	CD34+ cells	NULL	RUNX1	ADULT	GEO	GSE70660_runx1_cd34-adult_MACS_RUNX1_MA0002.2.damo.pwm.bed	8322
1	324	CEBPA	0.398185959845026	1.23062518700181	12	815	792	2233	2233	1280	10	192	197	CEBPA SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) CEBPA	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	CEBPA	Treatment: estradiol; Genotype: inducible version of CEBPA (C/EBPalpha-ER);	GTRD	EXP047669_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	8978
1	854	CTCF	0.398185959845026	1.23062518700181	12	815	792	2233	2233	1280	10	192	197	CTCF HeLa S3 (cervical adenocarcinoma) CTCF	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	CTCF	treatment: no block with TSA CellPopulation:synchronized	GTRD	EXP048089_HeLa-S3--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	14324
1	1156	ESR1	0.398185959845026	1.23062518700181	12	815	792	2233	2233	1280	10	192	197	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	1 h with 10 nM Estradiol (Myers)	ENCODE	ENCSR000BKN_T47D_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	25282
1	1283	ESR1	0.398185959845026	1.23062518700181	12	815	792	2233	2233	1280	10	192	197	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	siFOXA1	GTRD	EXP038771_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	29996
1	1355	ESR1	0.398185959845026	1.23062518700181	12	815	792	2233	2233	1280	10	192	197	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	Passsage: <10 Genotype: wt/R330fs mutant with CRISPR	GTRD	EXP049895_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12798
1	1748	FOXA1	0.398185959845026	1.23062518700181	12	815	792	2233	2233	1280	10	192	197	FOXA1 ZR-75-1 (invasive ductal carcinoma) FOXA1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	FOXA1	Treatment: hormone-deprived cells treated with 10 nM estrogen for 45 mins;	GTRD	EXP058103_ZR-75-1--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	36354
1	3771	TBX21	0.398185959845026	1.23062518700181	12	815	792	2233	2233	1280	10	192	197	TBX21 Th1-cells TBX21	Th1-cells	BTO:0001678	TBX21		GTRD	EXP031082_Th1-cells_TBX21_MACS_TBX21_MA0690.1.damo.pwm.bed	13777
1	183	AR	0.395236043074409	1.21218512982605	13	822	857	2153	2153	1280	11	191	196	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	SHCTR_DHT	GEO	GSE62492_AR_lncap-shctr-dht_MACS_AR_MA0007.3.damo.pwm.bed	36882
1	240	ATF2	0.395236043074409	1.21218512982605	13	822	857	2153	2153	1280	11	191	196	ATF2 HepG2 (hepatoblastoma) ATF2	HepG2 (hepatoblastoma)	BTO:0000599	ATF2	NA	GTRD	EXP039835_HepG2--hepatoblastoma-_ATF2_MACS_ATF2_MA1632.1.damo.pwm.bed	60525
1	813	CTCF	0.395236043074409	1.21218512982605	13	822	857	2153	2153	1280	11	191	196	CTCF HCT-116-RAD21-mAC CTCF	HCT-116-RAD21-mAC	NULL	CTCF	N/A	GTRD	EXP040679_HCT-116-RAD21-mAC_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	18959
1	1907	GATA1	0.395236043074409	1.21218512982605	13	822	857	2153	2153	1280	11	191	196	GATA1 CD36+ erythroid cells GATA1	CD36+ erythroid cells	NULL	GATA1	BRG1 KD shLuc control	GTRD	EXP000914_CD36--erythroid-cells_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	23405
1	2016	GATA4	0.395236043074409	1.21218512982605	13	822	857	2153	2153	1280	11	191	196	GATA4 iPSC-derived cardiomyocytes GATA4	iPSC-derived cardiomyocytes	NULL	GATA4		GTRD	EXP037716_iPSC-derived-cardiomyocytes_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	10796
1	3798	TCF4	0.395236043074409	1.21218512982605	13	822	857	2153	2153	1280	11	191	196	TCF4 Kasumi-1 (acute myeloblastic leukemia) TCF4	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	TCF4	Genotype: overexpress E2-2 Source: Myeloblast Cell type:  leukemic cell line with an 8;21 chromosome translocation Passage: 4-5	GTRD	EXP053214_Kasumi-1--acute-myeloblastic-leukemia-_TCF4_MACS_TCF4_MA0830.2.damo.pwm.bed	11826
1	12	AR	0.392711280879658	1.19684224857653	14	828	886	2073	2073	1260	12	190	195	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	R1881	GTRD	EXP000731_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	37939
1	863	CTCF	0.392711280879658	1.19684224857653	14	828	886	2073	2073	1260	12	190	195	CTCF MDM(monocyte derived macrophages) CTCF	MDM(monocyte derived macrophages)	NULL	CTCF	Treatment: ZIKV-bystander, time post infection 24 hr  ViralStrain: ZIKV-FSS13025	GTRD	EXP048657_MDM-monocyte-derived-macrophages-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	19092
1	567	CTCF	0.390530916326457	1.18388226469103	15	830	912	1993	1993	1240	13	189	194	CTCF 81-3 CTCF	81-3	NA	CTCF		Array Express	ERP002246_ctcf_813_MACS_CTCF_MA0139.1.damo.pwm.bed	29631
1	603	CTCF	0.390530916326457	1.18388226469103	15	830	912	1993	1993	1240	13	189	194	CTCF Jurkat (T-cells) CTCF	Jurkat (T-cells)	BTO:0000661	CTCF		GTRD	EXP030882_Jurkat--T-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	18929
1	871	CTCF	0.390530916326457	1.18388226469103	15	830	912	1993	1993	1240	13	189	194	CTCF HUES64 (embryonic stem cells) CTCF	HUES64 (embryonic stem cells)	NULL	CTCF	Genotype: CTCF knockout	GTRD	EXP049757_HUES64--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35186
1	973	CTCF	0.390530916326457	1.18388226469103	15	830	912	1993	1993	1240	13	189	194	CTCF Jurkat (T-cells) CTCF	Jurkat (T-cells)	BTO:0000661	CTCF		GEO	GSE68976_ctcf_jurkat_MACS_CTCF_MA0139.1.damo.pwm.bed	31435
1	1005	E2F1	0.390530916326457	1.18388226469103	15	830	912	1993	1993	1240	13	189	194	E2F1 HeLa S3 (cervical adenocarcinoma) E2F1	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	E2F1		ENCODE	ENCSR000EVJ_HeLa-S3_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	3015
1	2220	JUN	0.390530916326457	1.18388226469103	15	830	912	1993	1993	1240	13	189	194	JUN HeLa S3 (cervical adenocarcinoma) JUN	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	JUN		ENCODE	ENCSR000EDG_HeLa-S3_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	22278
1	3746	STAT3	0.390530916326457	1.18388226469103	15	830	912	1993	1993	1240	13	189	194	STAT3 OCI-LY3 (diffuse large B-cell lymphoma) STAT3	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	STAT3		GEO	GSE50723_stat3_ocily3_MACS_STAT3_MA0144.2.damo.pwm.bed	4627
1	372	CEBPB	0.388633953547562	1.17279496253655	16	837	930	1909	1909	1230	14	188	193	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039499_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	18104
1	855	CTCF	0.388633953547562	1.17279496253655	16	837	930	1909	1909	1230	14	188	193	CTCF HeLa S3 (cervical adenocarcinoma) CTCF	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	CTCF	treatment: no block with TSA CellPopulation:synchronized	GTRD	EXP048090_HeLa-S3--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	23677
1	1738	FOXA1	0.388633953547562	1.17279496253655	16	837	930	1909	1909	1230	14	188	193	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053227_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	56740
1	2638	KLF4	0.388633953547562	1.17279496253655	16	837	930	1909	1909	1230	14	188	193	KLF4 hiPSC KLF4	hiPSC	NULL	KLF4		GEO	GSE56567_klf4_ipsc_MACS_KLF4_MA0039.4.damo.pwm.bed	6113
1	3054	NR2C2	0.388633953547562	1.17279496253655	16	837	930	1909	1909	1230	14	188	193	NR2C2 HepG2 (hepatoblastoma) NR2C2	HepG2 (hepatoblastoma)	BTO:0000599	NR2C2	NULL	GTRD	EXP000578_HepG2--hepatoblastoma-_NR2C2_MACS_NR2C2_MA1536.1.damo.pwm.bed	5363
1	3189	ONECUT1	0.388633953547562	1.17279496253655	16	837	930	1909	1909	1230	14	188	193	ONECUT1 liver ONECUT1	liver	BTO:0000759	ONECUT1	NA	Array Express	ERP002306_onecut1_liver_MACS_ONECUT1_MA0679.2.damo.pwm.bed	30084
1	3070	NR2F1	0.386973384247428	1.16320617537398	17	843	956	1846	1846	1220	15	187	192	NR2F1 GM12878 (female B-cells lymphoblastoid cell line) NR2F1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	NR2F1	NA	GTRD	EXP040024_GM12878--female-B-cells-_NR2F1_MACS_NR2F1_MA1538.1.damo.pwm.bed	13490
1	3076	NR2F2	0.386973384247428	1.16320617537398	17	843	956	1846	1846	1220	15	187	192	NR2F2 liver NR2F2	liver	BTO:0000759	NR2F2		GTRD	EXP040003_liver_NR2F2_MACS_NR2F2_MA1111.1.damo.pwm.bed	16133
1	3121	NR3C1	0.386973384247428	1.16320617537398	17	843	956	1846	1846	1220	15	187	192	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 15 minute	GTRD	EXP040273_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	28099
1	4034	TP63	0.386973384247428	1.16320617537398	17	843	956	1846	1846	1220	15	187	192	TP63 JHU-029 (laryngeal squamous cell carcinoma) TP63	JHU-029 (laryngeal squamous cell carcinoma)	BTO:0003888	TP63		GTRD	EXP037974_JHU-029--laryngeal-squamous-cell-carcinoma-_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	15762
1	3931	TFAP2C	0.38593879205895	1.06701031535691	86	847	1232	7	1232	695	84	118	123	TFAP2C A375 (malignant melanoma) TFAP2C	A375 (malignant melanoma)	BTO:0002806	TFAP2C	DMSO	GEO	GSE41234_tfap2c_a375-dmso_MACS_TFAP2C_MA0524.2.damo.pwm.bed	65829
1	558	CTCF	0.385512343805136	1.15483527439931	18	848	977	1785	1785	1200	16	186	191	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	E2_SHCTCF	Array Express	ERP000209_ctcf_mcf7-e2-shctcf_MACS_CTCF_MA0139.1.damo.pwm.bed	32561
1	1117	ERF	0.385512343805136	1.15483527439931	18	848	977	1785	1785	1200	16	186	191	ERF VCaP (prostate carcinoma) ERF	VCaP (prostate carcinoma)	BTO:0003215	ERF	NA	GTRD	EXP038639_VCaP--prostate-carcinoma-_ERF_MACS_ERF_MA0760.1.damo.pwm.bed	10409
1	1129	ERG	0.385512343805136	1.15483527439931	18	848	977	1785	1785	1200	16	186	191	ERG HAEC (human aortic endothelial cells) ERG	HAEC (human aortic endothelial cells)	NULL	ERG	TNFa, 4h	GTRD	EXP038041_HAEC--human-aortic-endothelial-cells-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	7127
1	3163	NR4A1	0.385512343805136	1.15483527439931	18	848	977	1785	1785	1200	16	186	191	NR4A1 Kasumi-1 (acute myeloblastic leukemia) NR4A1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	NR4A1	NA	GEO	GSE79491_nr4a1_kasumi1_MACS_NR4A1_MA1112.2.damo.pwm.bed	15572
1	453	CTCF	0.384221479965387	1.14746766038153	19	852	1012	1697	1697	1190	17	185	190	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	1 h with 100 nM Dexamethasone (Myers)	ENCODE	ENCSR000BHV_A549_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	32812
1	666	CTCF	0.384221479965387	1.14746766038153	19	852	1012	1697	1697	1190	17	185	190	CTCF MCF10A (breast epithelial cells) CTCF	MCF10A (breast epithelial cells)	BTO:0001939	CTCF		GTRD	EXP038623_MCF10A--breast-epithelial-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42899
1	710	CTCF	0.384221479965387	1.14746766038153	19	852	1012	1697	1697	1190	17	185	190	CTCF spleen CTCF	spleen	BTO:0001281	CTCF		GTRD	EXP039581_spleen_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	24151
1	810	CTCF	0.384221479965387	1.14746766038153	19	852	1012	1697	1697	1190	17	185	190	CTCF HeLa Kyoto (cervical adenocarcinoma) CTCF	HeLa Kyoto (cervical adenocarcinoma)	NULL	CTCF	Wapl-depletion	GTRD	EXP040504_HeLa-Kyoto--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	47767
1	873	CTCF	0.384221479965387	1.14746766038153	19	852	1012	1697	1697	1190	17	185	190	CTCF GM12878 (female B-cells lymphoblastoid cell line) CTCF	GM12878 (female B-cells lymphoblastoid cell line)	NULL	CTCF	Genotype: wildtype Cell type: lymphoblastoid cell Age: no	GTRD	EXP051029_GM12878--female-B-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31343
1	1877	GABPA	0.384221479965387	1.14746766038153	19	852	1012	1697	1697	1190	17	185	190	GABPA GM12878 (female B-cells lymphoblastoid cell line) GABPA	GM12878 (female B-cells lymphoblastoid cell line)	NULL	GABPA		ENCODE	ENCSR331HPA_GM12878_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	9338
1	3275	POU5F1	0.384221479965387	1.14746766038153	19	852	1012	1697	1697	1190	17	185	190	POU5F1 HUES8 (Embryonic stem cell, blastocyst stage) POU5F1	HUES8 (Embryonic stem cell, blastocyst stage)	NULL	POU5F1	Genotype: SOX17-GFP knockout;	GTRD	EXP057925_HUES8--Embryonic-stem-cell--blastocyst-stage-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	33539
1	470	CTCF	0.383441457276625	1.06681464747239	80	859	1233	19	1233	704	78	124	129	CTCF GM19239 (male B-cells lymphoblastoid cell line) CTCF	GM19239 (male B-cells lymphoblastoid cell line)	NULL	CTCF		ENCODE	ENCSR000DLE_GM19239_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	100872
1	154	AR	0.3830771074944	1.14093642399007	20	860	1031	1606	1606	1170	18	184	189	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	SHCTR	GEO	GSE52725_AR_lncap-shctr_MACS_AR_MA0007.3.damo.pwm.bed	51338
1	1323	ESR1	0.3830771074944	1.14093642399007	20	860	1031	1606	1606	1170	18	184	189	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 500nM RAD001 2hr; Passage: p21;	GTRD	EXP047706_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	28169
1	1902	GATA1	0.3830771074944	1.14093642399007	20	860	1031	1606	1606	1170	18	184	189	GATA1 primary erythroblasts GATA1	primary erythroblasts	NULL	GATA1	NULL	GTRD	EXP000701_primary-erythroblasts_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	25151
1	650	CTCF	0.382059886234519	1.13510979712412	21	863	1039	1535	1535	1150	19	183	188	CTCF COLO-829 (melanoma) CTCF	COLO-829 (melanoma)	NULL	CTCF		GTRD	EXP037459_COLO-829--melanoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	33045
1	766	CTCF	0.382059886234519	1.13510979712412	21	863	1039	1535	1535	1150	19	183	188	CTCF thyroid gland CTCF	thyroid gland	NULL	CTCF		GTRD	EXP040050_thyroid-gland_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	22949
1	2076	HAND2	0.382059886234519	1.13510979712412	21	863	1039	1535	1535	1150	19	183	188	HAND2 BE2C HAND2	BE2C	NULL	HAND2	Treatment: untreated	GTRD	EXP049480_BE2C_HAND2_MACS_HAND2_MA1638.1.damo.pwm.bed	39403
1	630	CTCF	0.381153856107523	1.12988236854227	22	866	1055	1459	1459	1130	20	182	187	CTCF HUES64 (embryonic stem cells) CTCF	HUES64 (embryonic stem cells)	NULL	CTCF		GTRD	EXP036700_HUES64--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41282
1	1755	FOXA1	0.381153856107523	1.12988236854227	22	866	1055	1459	1459	1130	20	182	187	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	ETOH	GEO	GSE23852_foxa1_mcf7-etoh_MACS_FOXA1_MA0148.4.damo.pwm.bed	50862
1	3033	NFYB	0.381153856107523	1.12988236854227	22	866	1055	1459	1459	1130	20	182	187	NFYB K562 (myelogenous leukemia) NFYB	K562 (myelogenous leukemia)	NULL	NFYB	NA	GEO	GSE26439_nfyb_k562_MACS_NFYB_MA0502.2.damo.pwm.bed	8302
1	3879	TFAP2C	0.381153856107523	1.12988236854227	22	866	1055	1459	1459	1130	20	182	187	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions;	GTRD	EXP047534_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	9989
1	383	CEBPB	0.380345720754018	1.12516880911712	23	870	1065	1391	1391	1110	21	181	186	CEBPB monocyte-derived macrophages CEBPB	monocyte-derived macrophages	NULL	CEBPB		GTRD	EXP040652_monocyte-derived-macrophages_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	30539
1	1249	ESR1	0.380345720754018	1.12516880911712	23	870	1065	1391	1391	1110	21	181	186	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	40min E2	GTRD	EXP038339_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	48248
1	1809	FOXA1	0.380345720754018	1.12516880911712	23	870	1065	1391	1391	1110	21	181	186	FOXA1 ZR-75-1 (invasive ductal carcinoma) FOXA1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	FOXA1		GEO	GSE72249_foxa1_zr751_MACS_FOXA1_MA0148.4.damo.pwm.bed	75734
1	538	CTCF	0.37962430766881	1.12089930825502	24	873	1079	1324	1324	1090	22	180	185	CTCF NB4 (acute promyelocytic leukemia ) CTCF	NB4 (acute promyelocytic leukemia )	NULL	CTCF		ENCODE	ENCSR000DWN_NB4_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42878
1	1194	ESR1	0.37962430766881	1.12089930825502	24	873	1079	1324	1324	1090	22	180	185	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GTRD	EXP032285_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	48845
1	1210	ESR1	0.37962430766881	1.12089930825502	24	873	1079	1324	1324	1090	22	180	185	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	100nM E2, 120min	GTRD	EXP035984_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	45848
1	3530	RXRA	0.37962430766881	1.12089930825502	24	873	1079	1324	1324	1090	22	180	185	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA WT	GTRD	EXP040815_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA0115.1.damo.pwm.bed	10246
1	4120	YY1	0.37962430766881	1.12089930825502	24	873	1079	1324	1324	1090	22	180	185	YY1 GM12892 (female B-cells lymphoblastoid cell line) YY1	GM12892 (female B-cells lymphoblastoid cell line)	NULL	YY1		ENCODE	ENCSR000BLT_GM12892_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	13411
1	717	CTCF	0.378980155772654	1.11701620072869	25	878	1089	1262	1262	1080	23	179	184	CTCF breast epithelial cells CTCF	breast epithelial cells	NULL	CTCF		GTRD	EXP039639_breast-epithelial-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27143
1	1701	FOXA1	0.378980155772654	1.11701620072869	25	878	1089	1262	1262	1080	23	179	184	FOXA1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) FOXA1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	FOXA1	Treatment: 45 min 10^-7 4OHT	GTRD	EXP048437_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	44391
1	2308	JUN	0.378980155772654	1.11701620072869	25	878	1089	1262	1262	1080	23	179	184	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039416_A549--lung-carcinoma-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	17007
1	4028	TP63	0.378980155772654	1.11701620072869	25	878	1089	1262	1262	1080	23	179	184	TP63 keratinocytes TP63	keratinocytes	NULL	TP63	NULL	GTRD	EXP000293_keratinocytes_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	35453
1	963	CTCF	0.378718105623869	1.06842439082599	66	882	1228	78	1228	729	64	138	143	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_snyder_MACS_CTCF_MA0139.1.damo.pwm.bed	79374
1	1678	FOXA1	0.378405196424196	1.11347143674323	26	883	1097	1204	1204	1060	24	178	183	FOXA1 22RV1 (prostate carcinoma) FOXA1	22RV1 (prostate carcinoma)	BTO:0002999	FOXA1		GTRD	EXP038434_22RV1--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	41798
1	631	CTCF	0.377892503910026	1.11022465914639	27	884	1106	1135	1135	1040	25	177	182	CTCF HUES64 (embryonic stem cells) CTCF	HUES64 (embryonic stem cells)	NULL	CTCF		GTRD	EXP036701_HUES64--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41491
1	736	CTCF	0.377892503910026	1.11022465914639	27	884	1106	1135	1135	1040	25	177	182	CTCF 22RV1 (prostate carcinoma) CTCF	22RV1 (prostate carcinoma)	BTO:0002999	CTCF		GTRD	EXP039762_22RV1--prostate-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37949
1	746	CTCF	0.377892503910026	1.11022465914639	27	884	1106	1135	1135	1040	25	177	182	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039845_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41750
1	1341	ESR1	0.377892503910026	1.11022465914639	27	884	1106	1135	1135	1040	25	177	182	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP048587_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	14604
1	520	CTCF	0.377436098259453	1.10724172433256	28	888	1113	1068	1113	1020	26	176	181	CTCF HCT-116 (colon carcinoma) CTCF	HCT-116 (colon carcinoma)	BTO:0001109	CTCF		ENCODE	ENCSR000DTO_HCT116_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45066
1	1635	FOXA1	0.377436098259453	1.10724172433256	28	888	1113	1068	1113	1020	26	176	181	FOXA1 A549 (lung carcinoma) FOXA1	A549 (lung carcinoma)	BTO:0000018	FOXA1	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BRD_A549_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	35292
1	2429	JUN	0.377436098259453	1.10724172433256	28	888	1113	1068	1113	1020	26	176	181	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057912_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	38816
1	3374	RELA	0.377436098259453	1.10724172433256	28	888	1113	1068	1113	1020	26	176	181	RELA HUVEC-C (HUVEC, umbilical vein endothelial cells) RELA	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	RELA	TNF_30M	GEO	GSE34500_rela_huvec-tnf-30m_MACS_RELA_MA0107.1.damo.pwm.bed	16788
1	830	CTCF	0.377030787929547	1.10449355181633	29	892	1120	1013	1120	1010	27	175	180	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 20min	GTRD	EXP047797_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49408
1	2149	HNF4G	0.377030787929547	1.10449355181633	29	892	1120	1013	1120	1010	27	175	180	HNF4G HepG2 (hepatoblastoma) HNF4G	HepG2 (hepatoblastoma)	BTO:0000599	HNF4G		ENCODE	ENCSR000BNJ_HepG2_HNF4G_MACS_HNF4G_MA0484.2.damo.pwm.bed	28815
1	3739	STAT3	0.377030787929547	1.10449355181633	29	892	1120	1013	1120	1010	27	175	180	STAT3 MCF10A-ER-Src STAT3	MCF10A-ER-Src	NULL	STAT3	Genotype: transformed	GTRD	EXP048576_MCF10A-ER-Src_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	31673
1	2837	MYC	0.376965894029819	1.0705853491254	59	895	1220	143	1220	753	57	145	150	MYC HCT-116 (colon carcinoma) MYC	HCT-116 (colon carcinoma)	BTO:0001109	MYC		GTRD	EXP036148_HCT-116--colon-carcinoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	13153
1	1080	ELF1	0.376752363331187	1.07098800470193	58	896	1218	154	1218	756	56	146	151	ELF1 MCF7 (Invasive ductal breast carcinoma) ELF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ELF1		ENCODE	ENCSR000BSS_MCF-7_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	23176
1	1632	FOXA1	0.376752363331187	1.07098800470193	58	896	1218	154	1218	756	56	146	151	FOXA1 HepG2 (hepatoblastoma) FOXA1	HepG2 (hepatoblastoma)	BTO:0000599	FOXA1		ENCODE	ENCSR000BLE_HepG2_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	92811
1	818	CTCF	0.376672043199329	1.10195522031389	30	898	1124	937	1124	986	28	174	179	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: untreated, eGFP(EP mRNA), siCtrl(siRNA)	GTRD	EXP047774_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41424
1	465	CTCF	0.376355893453304	1.09960525083428	31	899	1125	881	1125	968	29	173	178	CTCF GM12878 (female B-cells lymphoblastoid cell line) CTCF	GM12878 (female B-cells lymphoblastoid cell line)	NULL	CTCF		ENCODE	ENCSR000DKV_GM12878_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45729
1	522	CTCF	0.376355893453304	1.09960525083428	31	899	1125	881	1125	968	29	173	178	CTCF HEK293 (embryonic kidney) CTCF	HEK293 (embryonic kidney)	NULL	CTCF		ENCODE	ENCSR000DTW_HEK293_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54149
1	748	CTCF	0.376355893453304	1.09960525083428	31	899	1125	881	1125	968	29	173	178	CTCF pancreas CTCF	pancreas	BTO:0000988	CTCF		GTRD	EXP039864_pancreas_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38583
1	837	CTCF	0.376355893453304	1.09960525083428	31	899	1125	881	1125	968	29	173	178	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 180min + Flavopiridol 60min	GTRD	EXP047804_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49240
1	2719	MAX	0.376355038656887	1.07187420502434	56	903	1216	192	1216	770	54	148	153	MAX NCI-H128 (small cell lung carcinoma) MAX	NCI-H128 (small cell lung carcinoma)	BTO:0003025	MAX		GEO	GSE41105_max_h128_MACS_MAX_MA0058.3.damo.pwm.bed	20272
1	2911	MYC	0.376355038656887	1.07187420502434	56	903	1216	192	1216	770	54	148	153	MYC MM1.S (plasma cell myeloma) MYC	MM1.S (plasma cell myeloma)	BTO:0003933	MYC	DMSO	GEO	GSE36354_myc_mm1s-dmso_MACS_MYC_MA0147.3.damo.pwm.bed	18528
1	913	CTCF	0.376078843220913	1.09742503314782	32	905	1133	825	1133	954	30	172	177	CTCF GM18486 (Lymphoblastoid Cell Lines) CTCF	GM18486 (Lymphoblastoid Cell Lines)	NULL	CTCF		GTRD	EXP054521_GM18486--Lymphoblastoid-Cell-Lines-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38745
1	986	CTCF	0.376078843220913	1.09742503314782	32	905	1133	825	1133	954	30	172	177	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	NORMOXIA	GEO	GSE78113_ctcf_mcf7-normoxia_MACS_CTCF_MA0139.1.damo.pwm.bed	43891
1	3204	OTX2	0.376078843220913	1.09742503314782	32	905	1133	825	1133	954	30	172	177	OTX2 D341 Med (medulloblastoma) OTX2	D341 Med (medulloblastoma)	NULL	OTX2	CRISPR.GFP2	GTRD	EXP038203_D341-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	66447
1	263	ATF7	0.375837803068044	1.0953983632584	33	908	1139	778	1139	942	31	171	176	ATF7 GM12878 (female B-cells lymphoblastoid cell line) ATF7	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ATF7	NA	GTRD	EXP039442_GM12878--female-B-cells-_ATF7_MACS_ATF7_MA0834.1.damo.pwm.bed	32534
1	613	CTCF	0.375837803068044	1.0953983632584	33	908	1139	778	1139	942	31	171	176	CTCF HCT-116 (colon carcinoma) CTCF	HCT-116 (colon carcinoma)	BTO:0001109	CTCF	No special treatment	GTRD	EXP032761_HCT-116--colon-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54018
1	819	CTCF	0.375837803068044	1.0953983632584	33	908	1139	778	1139	942	31	171	176	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA), siCtrl(siRNA)	GTRD	EXP047775_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42871
1	2766	MNT	0.375837803068044	1.0953983632584	33	908	1139	778	1139	942	31	171	176	MNT HepG2 (hepatoblastoma) MNT	HepG2 (hepatoblastoma)	BTO:0000599	MNT	NA	GTRD	EXP040038_HepG2--hepatoblastoma-_MNT_MACS_MNT_MA0825.1.damo.pwm.bed	32142
1	3398	REST	0.375837659620454	1.07342571806391	53	912	1210	236	1210	786	51	151	156	REST K562 (myelogenous leukemia) REST	K562 (myelogenous leukemia)	NULL	REST		ENCODE	ENCSR000BMW_K562_REST_MACS_REST_MA0138.2.damo.pwm.bed	28812
1	1723	FOXA1	0.375630032343306	1.09351106759908	34	913	1147	729	1147	930	32	170	175	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	Treatment: Cells were harvested in log phase growth Genotype: HNF4G overexpression	GTRD	EXP048989_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	104307
1	4121	YY1	0.375630032343306	1.09351106759908	34	913	1147	729	1147	930	32	170	175	YY1 K562 (myelogenous leukemia) YY1	K562 (myelogenous leukemia)	NULL	YY1		ENCODE	ENCSR000BMH_K562_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	26993
1	1140	ERG	0.375549089947126	1.0746264490654	51	915	1209	261	1209	795	49	153	158	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	DHAT_18H	GEO	GSE28950_erg_vcap-dhat-18h_MACS_ERG_MA0474.2.damo.pwm.bed	30241
1	3852	TFAP2A	0.375453091457246	1.09175069555662	35	916	1151	691	1151	919	33	169	174	TFAP2A MCF7 (Invasive ductal breast carcinoma) TFAP2A	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2A		GTRD	EXP032577_MCF7--Invasive-ductal-breast-carcinoma-_TFAP2A_MACS_TFAP2A_MA0872.1.damo.pwm.bed	39514
1	391	CEBPB	0.375422910957897	1.07528224534916	50	917	1208	275	1208	800	48	154	159	CEBPB HEE (human epididymis epithelial cells) CEBPB	HEE (human epididymis epithelial cells)	NULL	CEBPB	Treatment: without treatment of R1881 (methyltrienolone)	GTRD	EXP048165_HEE--human-epididymis-epithelial-cells-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	82129
1	702	CTCF	0.375304801880964	1.09010479940207	36	918	1152	645	1152	905	34	168	173	CTCF neutrophils CTCF	neutrophils	NULL	CTCF		GTRD	EXP039544_neutrophils_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	21336
1	1966	GATA3	0.375304801880964	1.09010479940207	36	918	1152	645	1152	905	34	168	173	GATA3 MDA-MB-231 (breast adenocarcinoma) GATA3	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	GATA3		GTRD	EXP035436_MDA-MB-231--breast-adenocarcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	70531
1	1055	EBF3	0.375209135495457	1.07671555291199	48	920	1197	317	1197	811	46	156	161	EBF3 SK-N-SH (neuroblastoma) EBF3	SK-N-SH (neuroblastoma)	BTO:0001620	EBF3	NA	GTRD	EXP038092_SK-N-SH--neuroblastoma-_EBF3_MACS_EBF3_MA1637.1.damo.pwm.bed	43729
1	396	CEBPB	0.375183212436492	1.08856512445994	37	921	1160	607	1160	896	35	167	172	CEBPB JB6 (Human anaplastic large cell lymphoma) CEBPB	JB6 (Human anaplastic large cell lymphoma)	BTO:0004831	CEBPB	Treatment: 300 nM Crizotinib for 3 hrs	GTRD	EXP053280_JB6--Human-anaplastic-large-cell-lymphoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	103437
1	1644	FOXA1	0.375183212436492	1.08856512445994	37	921	1160	607	1160	896	35	167	172	FOXA1 liver FOXA1	liver	BTO:0000759	FOXA1		Array Express	ERP002306_foxa1_liver_MACS_FOXA1_MA0148.4.damo.pwm.bed	37943
1	1142	ERG	0.375086570746857	1.08712315549546	38	923	1162	576	1162	887	36	166	171	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG		GEO	GSE28950_erg_vcap_MACS_ERG_MA0474.2.damo.pwm.bed	16434
1	2058	GRHL2	0.375050480281128	1.07832799491873	46	924	1187	349	1187	820	44	158	163	GRHL2 MCF7 (Invasive ductal breast carcinoma) GRHL2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GRHL2	No treatment	GTRD	EXP037435_MCF7--Invasive-ductal-breast-carcinoma-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	59389
1	832	CTCF	0.375013298941979	1.08577118460151	39	925	1163	547	1163	878	37	165	170	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 30min	GTRD	EXP047799_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54662
1	670	CTCF	0.374961972893995	1.08450232041148	40	926	1170	502	1170	866	38	164	169	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		GTRD	EXP038773_MCF7--Invasive-ductal-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	56808
1	953	CTCF	0.374961972893995	1.08450232041148	40	926	1170	502	1170	866	38	164	169	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm18951_MACS_CTCF_MA0139.1.damo.pwm.bed	43977
1	1216	ESR1	0.374961972893995	1.08450232041148	40	926	1170	502	1170	866	38	164	169	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	10 nM Estradiol	GTRD	EXP036366_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	19410
1	2626	KLF1	0.374961972893995	1.08450232041148	40	926	1170	502	1170	866	38	164	169	KLF1 HEK293 (embryonic kidney) KLF1	HEK293 (embryonic kidney)	NULL	KLF1	NA	GTRD	EXP039484_HEK293--embryonic-kidney-_KLF1_MACS_KLF1_MA0493.1.damo.pwm.bed	18389
1	3527	RXRA	0.374961972893995	1.08450232041148	40	926	1170	502	1170	866	38	164	169	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP040231_liver_RXRA_MACS_RXRA_MA1147.1.damo.pwm.bed	38162
1	990	CTCFL	0.37495209258424	1.08014324648757	44	931	1185	408	1185	841	42	160	165	CTCFL Delta47 (plasma cell myeloma) CTCFL	Delta47 (plasma cell myeloma)	NULL	CTCFL	NA	GEO	GSE70764_ctcfl_delta47_MACS_CTCFL_MA1102.2.damo.pwm.bed	13249
1	3460	RUNX1	0.37495209258424	1.08014324648757	44	931	1185	408	1185	841	42	160	165	RUNX1 CD34+ hematopoietic stem cells RUNX1	CD34+ hematopoietic stem cells	NULL	RUNX1		GTRD	EXP031976_CD34--hematopoietic-stem-cells_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	25141
1	1634	FOXA1	0.374931304394756	1.08331038356175	41	933	1175	476	1175	861	39	163	168	FOXA1 A549 (lung carcinoma) FOXA1	A549 (lung carcinoma)	BTO:0000018	FOXA1	1 h with 100 nM Dexamethasone (Myers)	ENCODE	ENCSR000BPX_A549_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	52980
1	1752	FOXA1	0.374931304394756	1.08331038356175	41	933	1175	476	1175	861	39	163	168	FOXA1 22RV1 (prostate carcinoma) FOXA1	22RV1 (prostate carcinoma)	BTO:0002999	FOXA1	Treatment: DHT10 nM for 24 hrs;	GTRD	EXP058393_22RV1--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	166482
1	3949	THAP11	0.37492737673485	1.08113561434725	43	935	1184	429	1184	849	41	161	166	THAP11 HepG2 (hepatoblastoma) THAP11	HepG2 (hepatoblastoma)	BTO:0000599	THAP11	NA	GTRD	EXP039449_HepG2--hepatoblastoma-_THAP11_MACS_THAP11_MA1573.1.damo.pwm.bed	32459
1	3923	TFAP2C	0.350957273414839	1.04763885395509	95	936	1303	2	1303	747	94	109	113	TFAP2C BT-474 (breast invasive ductal carcinoma) TFAP2C	BT-474 (breast invasive ductal carcinoma)	BTO:0001932	TFAP2C		GEO	GSE36351_tfap2c_bt474_MACS_TFAP2C_MA0815.1.damo.pwm.bed	92008
1	1480	ETV5	0.338840584940322	1.04468375342249	69	937	1313	47	1313	766	68	135	139	ETV5 HepG2 (hepatoblastoma) ETV5	HepG2 (hepatoblastoma)	BTO:0000599	ETV5	NA	GTRD	EXP044865_HepG2--hepatoblastoma-_ETV5_MACS_ETV5_MA0765.2.damo.pwm.bed	47542
1	1790	FOXA1	0.333384884073096	1.04560931827773	56	938	1312	192	1312	814	55	148	152	FOXA1 LNCaP-abl (Prostate carcinoma) FOXA1	LNCaP-abl (Prostate carcinoma)	NULL	FOXA1	SHCREB1	GEO	GSE63034_foxa1_lncap-abl-shcreb1_MACS_FOXA1_MA0148.4.damo.pwm.bed	156193
1	2712	MAX	0.332973205647188	1.04576996098071	55	939	1311	211	1311	820	54	149	153	MAX MKL-1 (Merkel cell carcinoma) MAX	MKL-1 (Merkel cell carcinoma)	NULL	MAX	Treatment: no treatment Markel Cell: positive	GTRD	EXP048815_MKL-1--Merkel-cell-carcinoma-_MAX_MACS_MAX_MA0059.1.damo.pwm.bed	45558
1	907	CTCF	0.332562203857669	1.04594596446492	54	940	1309	225	1309	825	53	150	154	CTCF DND41 (acute lymphoblastic leukemia) CTCF	DND41 (acute lymphoblastic leukemia)	NULL	CTCF	Treatment: None;	GTRD	EXP054054_DND41--acute-lymphoblastic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	72222
1	3240	PLAG1	0.332562203857669	1.04594596446492	54	940	1309	225	1309	825	53	150	154	PLAG1 K562 (myelogenous leukemia) PLAG1	K562 (myelogenous leukemia)	NULL	PLAG1	Treatment: no	GTRD	EXP048311_K562--myelogenous-leukemia-_PLAG1_MACS_PLAG1_MA0163.1.damo.pwm.bed	26684
1	1147	ERG	0.33215178100844	1.04613802660638	53	942	1308	236	1308	829	52	151	155	ERG TSU-1621-MT (adult acute myeloid leukemia) ERG	TSU-1621-MT (adult acute myeloid leukemia)	NULL	ERG	ATRA	GEO	GSE60477_erg_tsu1621mt-atra_MACS_ERG_MA0474.2.damo.pwm.bed	70044
1	920	CTCF	0.331741837604918	1.04634690507924	52	943	1306	244	1306	831	51	152	156	CTCF MCF7L-P(immortalized breast epithelial cell line) CTCF	MCF7L-P(immortalized breast epithelial cell line)	NULL	CTCF	Treatment: untreated;	GTRD	EXP057858_MCF7L-P-immortalized-breast-epithelial-cell-line-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	102321
1	1350	ESR1	0.331741837604918	1.04634690507924	52	943	1306	244	1306	831	51	152	156	ESR1 MDA-MB-231 (breast adenocarcinoma) ESR1	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	ESR1	Treatment: E2, 100 nM, 45 min Genotype: ER-alfa wildtype	GTRD	EXP049531_MDA-MB-231--breast-adenocarcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	38641
1	358	CEBPB	0.330922980836141	1.04681847629426	50	945	1304	275	1304	841	49	154	158	CEBPB HeLa S3 (cervical adenocarcinoma) CEBPB	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	CEBPB		ENCODE	ENCSR000EDA_HeLa-S3_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	94544
1	980	CTCF	0.330922980836141	1.04681847629426	50	945	1304	275	1304	841	49	154	158	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF		GEO	GSE70764_ctcf_k562_MACS_CTCF_MA0139.1.damo.pwm.bed	58776
1	890	CTCF	0.329695675089691	1.04767504340659	47	947	1302	333	1302	861	46	157	161	CTCF Jurkat (T-cells) CTCF	Jurkat (T-cells)	BTO:0000661	CTCF	Treatment: untreated	GTRD	EXP053106_Jurkat--T-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	69416
1	921	CTCF	0.329286388501584	1.04800491194373	46	948	1299	349	1299	865	45	158	162	CTCF MCF7L-P(immortalized breast epithelial cell line) CTCF	MCF7L-P(immortalized breast epithelial cell line)	NULL	CTCF	Treatment: treated with E2 for 1 hr;	GTRD	EXP057860_MCF7L-P-immortalized-breast-epithelial-cell-line-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	55950
1	1508	FLI1	0.329286388501584	1.04800491194373	46	948	1299	349	1299	865	45	158	162	FLI1 UAE FLI1	UAE	NA	FLI1		GEO	GSE23730_fli1_uae_MACS_FLI1_MA0475.2.damo.pwm.bed	20528
1	2585	JUND	0.329286388501584	1.04800491194373	46	948	1299	349	1299	865	45	158	162	JUND HepG2 (hepatoblastoma) JUND	HepG2 (hepatoblastoma)	BTO:0000599	JUND		ENCODE	ENCSR000BGK_HepG2_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	30124
1	448	CTCF	0.328876813870184	1.0483591683583	45	951	1297	383	1297	877	44	159	163	CTCF DND41 (acute lymphoblastic leukemia) CTCF	DND41 (acute lymphoblastic leukemia)	NULL	CTCF		ENCODE	ENCSR000AQU_DND-41_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	56279
1	556	CTCF	0.328876813870184	1.0483591683583	45	951	1297	383	1297	877	44	159	163	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR822CEA_neural_cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41722
1	534	CTCF	0.328056302361136	1.04914707970276	43	953	1296	429	1296	893	42	161	165	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DVP_endothelial_cell_of_umbilical_vein_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48130
1	409	CEBPG	0.327645104589085	1.04958424389357	42	954	1293	454	1293	900	41	162	166	CEBPG HepG2 (hepatoblastoma) CEBPG	HepG2 (hepatoblastoma)	BTO:0000599	CEBPG	NA	GTRD	EXP039427_HepG2--hepatoblastoma-_CEBPG_MACS_CEBPG_MA0838.1.damo.pwm.bed	52750
1	1178	ESR1	0.327645104589085	1.04958424389357	42	954	1293	454	1293	900	41	162	166	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	LY2	Array Express	ERP003844_esr1_ly2_MACS_ESR1_MA0112.3.damo.pwm.bed	57056
1	1871	GABPA	0.327645104589085	1.04958424389357	42	954	1293	454	1293	900	41	162	166	GABPA A549 (lung carcinoma) GABPA	A549 (lung carcinoma)	BTO:0000018	GABPA	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BPY_A549_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	13968
1	709	CTCF	0.327233096013141	1.05005285337698	41	957	1292	476	1292	908	40	163	167	CTCF prostate gland CTCF	prostate gland	BTO:0001129	CTCF		GTRD	EXP039579_prostate-gland_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34113
1	517	CTCF	0.32682013207343	1.05055514735853	40	958	1291	502	1291	917	39	164	168	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DTF_cardiac_fibroblast_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48643
1	1141	ERG	0.326406061498846	1.05109360525228	39	959	1288	547	1288	931	38	165	169	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	DHAT_2H	GEO	GSE28950_erg_vcap-dhat-2h_MACS_ERG_MA0474.2.damo.pwm.bed	20614
1	1291	ESR1	0.326406061498846	1.05109360525228	39	959	1288	547	1288	931	38	165	169	ESR1 breast tumour metastasis ESR1	breast tumour metastasis	NULL	ESR1	Metastasis	GTRD	EXP038796_breast-tumour-metastasis_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	42475
1	3295	PPARG	0.326406061498846	1.05109360525228	39	959	1288	547	1288	931	38	165	169	PPARG HepG2 (hepatoblastoma) PPARG	HepG2 (hepatoblastoma)	BTO:0000599	PPARG		GTRD	EXP039615_HepG2--hepatoblastoma-_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	35923
1	539	CTCF	0.325990725610245	1.05167097900582	38	962	1287	576	1287	942	37	166	170	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DWQ_foreskin_fibroblast_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42052
1	508	CTCF	0.32557395754209	1.05229033081829	37	963	1285	607	1285	952	36	167	171	CTCF GM12868 (female B-cells) CTCF	GM12868 (female B-cells)	NULL	CTCF		ENCODE	ENCSR000DRI_GM12868_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	44018
1	3140	NR3C1	0.32557395754209	1.05229033081829	37	963	1285	607	1285	952	36	167	171	NR3C1 HASM2 (Human airway smooth muscle 2) NR3C1	HASM2 (Human airway smooth muscle 2)	NULL	NR3C1	Treatment: dexamethasone for 4 hr	GTRD	EXP049655_HASM2--Human-airway-smooth-muscle-2-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	44714
1	1136	ERG	0.325155581370098	1.05295507732996	36	965	1282	645	1282	964	35	168	172	ERG RWPE1 (prostate epithelial cells) ERG	RWPE1 (prostate epithelial cells)	BTO:0003709	ERG	Infection: retrovirus expressing FLAG-ERG Treatment: nearly confluent 150 mm dishes were treated with 1% formaldehyde, and harvested in Farnham lysis buffer and a crude nuclear pellet collected after centrifugation	GTRD	EXP048484_RWPE1--prostate-epithelial-cells-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	23936
1	1460	ETS1	0.325155581370098	1.05295507732996	36	965	1282	645	1282	964	35	168	172	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1	VEGF stimulation for 1hour	GTRD	EXP038275_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	14192
1	4117	YY1	0.325155581370098	1.05295507732996	36	965	1282	645	1282	964	35	168	172	YY1 WA01 (H1, human embryonic stem cells) YY1	WA01 (H1, human embryonic stem cells)	NULL	YY1		ENCODE	ENCSR000BKD_H1-hESC_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	24716
1	477	CTCF	0.324735411130148	1.05366904161569	35	968	1280	691	1280	980	34	169	173	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF		ENCODE	ENCSR000DMA_K562_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	57087
1	2160	HOXB13	0.324735411130148	1.05366904161569	35	968	1280	691	1280	980	34	169	173	HOXB13 VCaP (prostate carcinoma) HOXB13	VCaP (prostate carcinoma)	BTO:0003215	HOXB13	siCtl	GTRD	EXP038437_VCaP--prostate-carcinoma-_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	61301
1	550	CTCF	0.3243132497109	1.0544365146373	34	970	1277	729	1277	992	33	170	174	CTCF SK-N-SH (neuroblastoma) CTCF	SK-N-SH (neuroblastoma)	BTO:0001620	CTCF		ENCODE	ENCSR000EIC_SK-N-SH_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46740
1	632	CTCF	0.3243132497109	1.0544365146373	34	970	1277	729	1277	992	33	170	174	CTCF HUES64 (embryonic stem cells) CTCF	HUES64 (embryonic stem cells)	NULL	CTCF		GTRD	EXP036784_HUES64--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	56925
1	801	CTCF	0.3243132497109	1.0544365146373	34	970	1277	729	1277	992	33	170	174	CTCF PC3(bone mets prostate adenocarcinoma) CTCF	PC3(bone mets prostate adenocarcinoma)	NULL	CTCF		GTRD	EXP040291_PC3-bone-mets-prostate-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	57582
1	607	CTCF	0.323888887599187	1.05526232822434	33	973	1275	778	1275	1010	32	171	175	CTCF HepG2 (hepatoblastoma) CTCF	HepG2 (hepatoblastoma)	BTO:0000599	CTCF	none	GTRD	EXP030934_HepG2--hepatoblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	51256
1	981	CTCF	0.323888887599187	1.05526232822434	33	973	1275	778	1275	1010	32	171	175	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		GEO	GSE70764_ctcf_mcf7_MACS_CTCF_MA0139.1.damo.pwm.bed	51481
1	3104	NR3C1	0.323462101453043	1.05615194218606	32	975	1274	825	1274	1020	31	172	176	NR3C1 BEAS-2B (bronchial epithelium) NR3C1	BEAS-2B (bronchial epithelium)	NULL	NR3C1	dexamethasone + TNF	GTRD	EXP036258_BEAS-2B--bronchial-epithelium-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	26852
1	1150	ERG	0.323032652472011	1.05711154885205	31	976	1271	881	1271	1040	30	173	177	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	SH1_DHT	GEO	GSE79128_erg_vcap-sh1-dht_MACS_ERG_MA0474.2.damo.pwm.bed	14781
1	3198	OTX2	0.323032652472011	1.05711154885205	31	976	1271	881	1271	1040	30	173	177	OTX2 HUES64 (embryonic stem cells) OTX2	HUES64 (embryonic stem cells)	NULL	OTX2		GTRD	EXP036801_HUES64--embryonic-stem-cells-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	19474
1	3230	PDX1	0.323032652472011	1.05711154885205	31	976	1271	881	1271	1040	30	173	177	PDX1 iPS (derived pancreatic precursor cells) PDX1	iPS (derived pancreatic precursor cells)	NULL	PDX1		GTRD	EXP047965_iPS--derived-pancreatic-precursor-cells-_PDX1_MACS_PDX1_MA0132.2.damo.pwm.bed	34092
1	565	CTCF	0.322600284527918	1.05814819924875	30	979	1265	937	1265	1060	29	174	178	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	TAM	Array Express	ERP000783_ctcf_mcf7-tam_MACS_CTCF_MA0139.1.damo.pwm.bed	41342
1	825	CTCF	0.322600284527918	1.05814819924875	30	979	1265	937	1265	1060	29	174	178	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 7hr+Flavopiridol 3hr, IAV NS1(EP mRNA), siNIPBL(siRNA)	GTRD	EXP047781_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40366
1	1889	GABPA	0.322600284527918	1.05814819924875	30	979	1265	937	1265	1060	29	174	178	GABPA VCaP (prostate carcinoma) GABPA	VCaP (prostate carcinoma)	BTO:0003215	GABPA		GEO	GSE49091_gabpa_vcap_MACS_GABPA_MA0062.3.damo.pwm.bed	32492
1	3000	NFE2L2	0.322600284527918	1.05814819924875	30	979	1265	937	1265	1060	29	174	178	NFE2L2 IMR90 (lung fibroblasts) NFE2L2	IMR90 (lung fibroblasts)	NULL	NFE2L2		GTRD	EXP039771_IMR90--lung-fibroblasts-_NFE2L2_MACS_NFE2L2_MA0150.2.damo.pwm.bed	29082
1	3710	SRF	0.322600284527918	1.05814819924875	30	979	1265	937	1265	1060	29	174	178	SRF Ishikawa (endometrial adenocarcinoma) SRF	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	SRF		ENCODE	ENCSR000BTD_Ishikawa_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	13088
1	4064	TWIST1	0.322600284527918	1.05814819924875	30	979	1265	937	1265	1060	29	174	178	TWIST1 BE2C TWIST1	BE2C	NULL	TWIST1		GEO	GSE80151_twist1_be2c_MACS_TWIST1_MA1123.2.damo.pwm.bed	33187
1	450	CTCF	0.322164722011134	1.05926995632067	29	985	1259	1013	1259	1090	28	175	179	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	1 h with 100 nM Dexamethasone (Myers)	ENCODE	ENCSR000AUE_A549_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	50435
1	537	CTCF	0.322164722011134	1.05926995632067	29	985	1259	1013	1259	1090	28	175	179	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		ENCODE	ENCSR000DWH_MCF-7_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	55196
1	641	CTCF	0.322164722011134	1.05926995632067	29	985	1259	1013	1259	1090	28	175	179	CTCF MM1.S (plasma cell myeloma) CTCF	MM1.S (plasma cell myeloma)	BTO:0003933	CTCF		GTRD	EXP036853_MM1.S--plasma-cell-myeloma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38961
1	852	CTCF	0.322164722011134	1.05926995632067	29	985	1259	1013	1259	1090	28	175	179	CTCF HeLa (cervical adenocarcinoma) CTCF	HeLa (cervical adenocarcinoma)	BTO:0000567	CTCF	Plasmids: pGK-dCas9-SunTag (Addgene #100943) + pEF1a-NLS-scFvGCN4-DNMT3A (Addgene #100941) + pEf1a-CCDC85C_3-gRNA-GFP	GTRD	EXP048004_HeLa--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46456
1	4081	USF2	0.322164722011134	1.05926995632067	29	985	1259	1013	1259	1090	28	175	179	USF2 HeLa S3 (cervical adenocarcinoma) USF2	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	USF2		ENCODE	ENCSR000ECW_HeLa-S3_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	19106
1	4087	USF2	0.322164722011134	1.05926995632067	29	985	1259	1013	1259	1090	28	175	179	USF2 HepG2 (hepatoblastoma) USF2	HepG2 (hepatoblastoma)	BTO:0000599	USF2		GTRD	EXP038547_HepG2--hepatoblastoma-_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	23582
1	371	CEBPB	0.321725667337079	1.06048608220853	28	991	1255	1068	1255	1100	27	176	180	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039491_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	28660
1	554	CTCF	0.321725667337079	1.06048608220853	28	991	1255	1068	1255	1100	27	176	180	CTCF SU-DHL-6 (diffuse large B-cell lymphoma) CTCF	SU-DHL-6 (diffuse large B-cell lymphoma)	NULL	CTCF		ENCODE	ENCSR125DKL_SUDHL6_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38826
1	858	CTCF	0.321725667337079	1.06048608220853	28	991	1255	1068	1255	1100	27	176	180	CTCF LUHMES (lund human mesencephalic cells) CTCF	LUHMES (lund human mesencephalic cells)	NULL	CTCF	Sex: female Passages: 3-10 Stage: neural progenitor cells, undifferentiated Treatment: Prior to differentiation, cells were seeded at 3.5 x 10^6 per T75 flask containing complete growth medium and incubated at 37 °C for 24 hr	GTRD	EXP048229_LUHMES--lund-human-mesencephalic-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40427
1	919	CTCF	0.321725667337079	1.06048608220853	28	991	1255	1068	1255	1100	27	176	180	CTCF HAP1 (chronic myelogenous leukemia) CTCF	HAP1 (chronic myelogenous leukemia)	NULL	CTCF	Genotype: Wapl and SCC4 knockout;	GTRD	EXP055798_HAP1--chronic-myelogenous-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42615
1	619	CTCF	0.321282798044631	1.06180726875374	27	995	1250	1135	1250	1130	26	177	181	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF	none	GTRD	EXP033055_K562--myelogenous-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49563
1	636	CTCF	0.321282798044631	1.06180726875374	27	995	1250	1135	1250	1130	26	177	181	CTCF IPSC-derived bipolar neuron CTCF	IPSC-derived bipolar neuron	NULL	CTCF		GTRD	EXP036844_IPSC-derived-bipolar-neuron_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46772
1	749	CTCF	0.321282798044631	1.06180726875374	27	995	1250	1135	1250	1130	26	177	181	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039866_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39186
1	791	CTCF	0.321282798044631	1.06180726875374	27	995	1250	1135	1250	1130	26	177	181	CTCF foreskin keratinocyte CTCF	foreskin keratinocyte	NULL	CTCF	1mM calcium (CHEBI:86158) for 5 day	GTRD	EXP040244_foreskin-keratinocyte_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41490
1	2437	JUN	0.321282798044631	1.06180726875374	27	995	1250	1135	1250	1130	26	177	181	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057919_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	28594
1	161	AR	0.320835763401274	1.06324592333351	26	1000	1244	1204	1244	1150	25	178	182	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR		GEO	GSE56086_AR_vcap_MACS_AR_MA0007.3.damo.pwm.bed	88405
1	826	CTCF	0.320835763401274	1.06324592333351	26	1000	1244	1204	1244	1150	25	178	182	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA), siWAPL(siRNA)	GTRD	EXP047782_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37402
1	922	CTCF	0.320835763401274	1.06324592333351	26	1000	1244	1204	1244	1150	25	178	182	CTCF MCF7L-P(immortalized breast epithelial cell line) CTCF	MCF7L-P(immortalized breast epithelial cell line)	NULL	CTCF	Treatment: treated with E2 for 4 hrs;	GTRD	EXP057862_MCF7L-P-immortalized-breast-epithelial-cell-line-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36084
1	2024	GATA4	0.320835763401274	1.06324592333351	26	1000	1244	1204	1244	1150	25	178	182	GATA4 BJ (fibroblasts) GATA4	BJ (fibroblasts)	NULL	GATA4	Genotype: Clonal FOXA2 doxycycline inducible cells, FOXA2 and GATA4 coexpressing	GTRD	EXP049377_BJ--fibroblasts-_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	53558
1	3191	ONECUT2	0.320835763401274	1.06324592333351	26	1000	1244	1204	1244	1150	25	178	182	ONECUT2 LNCaP (prostate carcinoma) ONECUT2	LNCaP (prostate carcinoma)	BTO:0001321	ONECUT2	Treatment: normoxia;	GTRD	EXP057823_LNCaP--prostate-carcinoma-_ONECUT2_MACS_ONECUT2_MA0756.1.damo.pwm.bed	240258
1	3426	REST	0.320835763401274	1.06324592333351	26	1000	1244	1204	1244	1150	25	178	182	REST Jurkat (T-cells) REST	Jurkat (T-cells)	BTO:0000661	REST		GTRD	EXP054615_Jurkat--T-cells-_REST_MACS_REST_MA0138.2.damo.pwm.bed	24996
1	761	CTCF	0.320384180408066	1.0647473269129	25	1006	1238	1262	1262	1170	24	179	183	CTCF pancreas CTCF	pancreas	BTO:0000988	CTCF		GTRD	EXP040012_pancreas_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30150
1	765	CTCF	0.320384180408066	1.0647473269129	25	1006	1238	1262	1262	1170	24	179	183	CTCF Peyer's patch CTCF	Peyer's patch	NULL	CTCF		GTRD	EXP040031_Peyer-s-patch_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34238
1	918	CTCF	0.320384180408066	1.0647473269129	25	1006	1238	1262	1262	1170	24	179	183	CTCF HAP1 (chronic myelogenous leukemia) CTCF	HAP1 (chronic myelogenous leukemia)	NULL	CTCF	Genotype: wildtype;	GTRD	EXP055795_HAP1--chronic-myelogenous-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39480
1	1108	ELK4	0.320384180408066	1.0647473269129	25	1006	1238	1262	1262	1170	24	179	183	ELK4 HeLa S3 (cervical adenocarcinoma) ELK4	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	ELK4		ENCODE	ENCSR000EVI_HeLa-S3_ELK4_MACS_ELK4_MA0076.2.damo.pwm.bed	6307
1	3433	REST	0.320384180408066	1.0647473269129	25	1006	1238	1262	1262	1170	24	179	183	REST CD4 REST	CD4	NA	REST		GEO	GSE49570_rest_cd4t_MACS_REST_MA0138.2.damo.pwm.bed	7540
1	3897	TFAP2C	0.320384180408066	1.0647473269129	25	1006	1238	1262	1262	1170	24	179	183	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p28; CellType: Prime UCLA1 hESSCs;	GTRD	EXP047540_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	11244
1	422	CREB1	0.31992762906906	1.06646665791033	24	1012	1234	1324	1324	1190	23	180	184	CREB1 MCF7 (Invasive ductal breast carcinoma) CREB1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CREB1		GTRD	EXP039962_MCF7--Invasive-ductal-breast-carcinoma-_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	35189
1	536	CTCF	0.31992762906906	1.06646665791033	24	1012	1234	1324	1324	1190	23	180	184	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF		ENCODE	ENCSR000DWE_K562_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38895
1	1660	FOXA1	0.31992762906906	1.06646665791033	24	1012	1234	1324	1324	1190	23	180	184	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1		GTRD	EXP035474_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	81709
1	2431	JUN	0.31992762906906	1.06646665791033	24	1012	1234	1324	1324	1190	23	180	184	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057912_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	33132
1	1286	ESR1	0.319465646752278	1.06835501870276	23	1016	1229	1391	1391	1210	22	181	185	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Cocktail_90	GTRD	EXP038789_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	42050
1	1705	FOXA1	0.319465646752278	1.06835501870276	23	1016	1229	1391	1391	1210	22	181	185	FOXA1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) FOXA1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	FOXA1	Treatment: 45 min ethanol	GTRD	EXP048441_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	38637
1	2109	HLF	0.319465646752278	1.06835501870276	23	1016	1229	1391	1391	1210	22	181	185	HLF HepG2 (hepatoblastoma) HLF	HepG2 (hepatoblastoma)	BTO:0000599	HLF	NA	GTRD	EXP039776_HepG2--hepatoblastoma-_HLF_MACS_HLF_MA0043.3.damo.pwm.bed	35579
1	354	CEBPB	0.318997721419216	1.07043634045151	22	1019	1221	1459	1459	1230	21	182	186	CEBPB Ishikawa (endometrial adenocarcinoma) CEBPB	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	CEBPB		ENCODE	ENCSR000BTT_Ishikawa_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	24753
1	357	CEBPB	0.318997721419216	1.07043634045151	22	1019	1221	1459	1459	1230	21	182	186	CEBPB WA01 (H1, human embryonic stem cells) CEBPB	WA01 (H1, human embryonic stem cells)	NULL	CEBPB		ENCODE	ENCSR000EBV_H1-hESC_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	27375
1	445	CTCF	0.318997721419216	1.07043634045151	22	1019	1221	1459	1459	1230	21	182	186	CTCF astrocytes CTCF	astrocytes	NULL	CTCF		ENCODE	ENCSR000AOO_astrocyte_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36329
1	783	CTCF	0.318997721419216	1.07043634045151	22	1019	1221	1459	1459	1230	21	182	186	CTCF gastrocnemius medialis CTCF	gastrocnemius medialis	NULL	CTCF		GTRD	EXP040134_gastrocnemius-medialis_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	24694
1	1497	FLI1	0.318997721419216	1.07043634045151	22	1019	1221	1459	1459	1230	21	182	186	FLI1 HUVEC-C (HUVEC, umbilical vein endothelial cells) FLI1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FLI1	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048206_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	13219
1	2700	MAX	0.318997721419216	1.07043634045151	22	1019	1221	1459	1459	1230	21	182	186	MAX WA01 (H1, human embryonic stem cells) MAX	WA01 (H1, human embryonic stem cells)	NULL	MAX		ENCODE	ENCSR000EUP_H1-hESC_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	15082
1	2921	MYC	0.318997721419216	1.07043634045151	22	1019	1221	1459	1459	1230	21	182	186	MYC HeLa (cervical adenocarcinoma) MYC	HeLa (cervical adenocarcinoma)	BTO:0000567	MYC		GEO	GSE44672_myc_hela_MACS_MYC_MA0147.3.damo.pwm.bed	8042
1	464	CTCF	0.318523283432338	1.0727393461577	21	1026	1211	1535	1535	1260	20	183	187	CTCF GM10266 (male B-cells) CTCF	GM10266 (male B-cells)	NULL	CTCF		ENCODE	ENCSR000DKR_GM10266_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	24911
1	681	CTCF	0.318523283432338	1.0727393461577	21	1026	1211	1535	1535	1260	20	183	187	CTCF adrenal gland CTCF	adrenal gland	BTO:0000047	CTCF		GTRD	EXP039402_adrenal-gland_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31219
1	711	CTCF	0.318523283432338	1.0727393461577	21	1026	1211	1535	1535	1260	20	183	187	CTCF pancreas CTCF	pancreas	BTO:0000988	CTCF		GTRD	EXP039586_pancreas_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	32347
1	730	CTCF	0.318523283432338	1.0727393461577	21	1026	1211	1535	1535	1260	20	183	187	CTCF PANC1 (pancreatic ductal adenocarcinoma) CTCF	PANC1 (pancreatic ductal adenocarcinoma)	NULL	CTCF		GTRD	EXP039705_PANC1--pancreatic-ductal-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35937
1	1499	FLI1	0.318523283432338	1.0727393461577	21	1026	1211	1535	1535	1260	20	183	187	FLI1 HUVEC-C (HUVEC, umbilical vein endothelial cells) FLI1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FLI1	Treatment: agent VEGF, timepoint 12 Passage: P3-6	GTRD	EXP048208_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	13603
1	617	CTCF	0.318041695557564	1.07529881164483	20	1031	1198	1606	1606	1280	19	184	188	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF		GTRD	EXP032934_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29314
1	686	CTCF	0.318041695557564	1.07529881164483	20	1031	1198	1606	1606	1280	19	184	188	CTCF esophagus squamous epithelium CTCF	esophagus squamous epithelium	NULL	CTCF		GTRD	EXP039453_esophagus-squamous-epithelium_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	24899
1	757	CTCF	0.318041695557564	1.07529881164483	20	1031	1198	1606	1606	1280	19	184	188	CTCF spleen CTCF	spleen	BTO:0001281	CTCF		GTRD	EXP039980_spleen_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	28165
1	787	CTCF	0.318041695557564	1.07529881164483	20	1031	1198	1606	1606	1280	19	184	188	CTCF transverse colon CTCF	transverse colon	NULL	CTCF		GTRD	EXP040192_transverse-colon_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	23005
1	868	CTCF	0.318041695557564	1.07529881164483	20	1031	1198	1606	1606	1280	19	184	188	CTCF IMR-5 (Neuroblastoma) CTCF	IMR-5 (Neuroblastoma)	NULL	CTCF		GTRD	EXP048888_IMR-5--Neuroblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27853
1	894	CTCF	0.318041695557564	1.07529881164483	20	1031	1198	1606	1606	1280	19	184	188	CTCF HepG2 (hepatoblastoma) CTCF	HepG2 (hepatoblastoma)	BTO:0000599	CTCF	Treatment: None;	GTRD	EXP054031_HepG2--hepatoblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	43983
1	2035	GATA6	0.318041695557564	1.07529881164483	20	1031	1198	1606	1606	1280	19	184	188	GATA6 definitive endoderm from HUES8 GATA6	definitive endoderm from HUES8	NULL	GATA6	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057920_definitive-endoderm-from-HUES8_GATA6_MACS_GATA6_MA1104.2.damo.pwm.bed	38824
1	2121	HNF4A	0.318041695557564	1.07529881164483	20	1031	1198	1606	1606	1280	19	184	188	HNF4A HepG2 (hepatoblastoma) HNF4A	HepG2 (hepatoblastoma)	BTO:0000599	HNF4A	low-glucose DMEM with 0.5% BSA supplemented with 1uM forskolin and 1mM pyruvate for 6h. (Snyder)	ENCODE	ENCSR000EEU_HepG2_HNF4A_MACS_HNF4A_MA0114.4.damo.pwm.bed	16323
1	3032	NFYB	0.318041695557564	1.07529881164483	20	1031	1198	1606	1606	1280	19	184	188	NFYB K562 (myelogenous leukemia) NFYB	K562 (myelogenous leukemia)	NULL	NFYB	NA	ENCODE	ENCSR000EGQ_K562_NFYB_MACS_NFYB_MA0502.2.damo.pwm.bed	11601
1	3744	STAT3	0.318041695557564	1.07529881164483	20	1031	1198	1606	1606	1280	19	184	188	STAT3 SU-DHL-1 (Anaplastic large cell lymphoma) STAT3	SU-DHL-1 (Anaplastic large cell lymphoma)	BTO:0005058	STAT3	Treatment: DMSO for 3 hrs	GTRD	EXP053281_SU-DHL-1--Anaplastic-large-cell-lymphoma-_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	13426
1	246	ATF3	0.317552240650882	1.07815724690086	19	1041	1188	1697	1697	1310	18	185	189	ATF3 K562 (myelogenous leukemia) ATF3	K562 (myelogenous leukemia)	NULL	ATF3		ENCODE	ENCSR000BNU_K562_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	11145
1	476	CTCF	0.317552240650882	1.07815724690086	19	1041	1188	1697	1697	1310	18	185	189	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DLW_endothelial_cell_of_umbilical_vein_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39265
1	480	CTCF	0.317552240650882	1.07815724690086	19	1041	1188	1697	1697	1310	18	185	189	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DMF_LNCaP_clone_FGC_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35290
1	723	CTCF	0.317552240650882	1.07815724690086	19	1041	1188	1697	1697	1310	18	185	189	CTCF PC9 (lung adenocarcinoma) CTCF	PC9 (lung adenocarcinoma)	NULL	CTCF		GTRD	EXP039683_PC9--lung-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38535
1	747	CTCF	0.317552240650882	1.07815724690086	19	1041	1188	1697	1697	1310	18	185	189	CTCF thyroid gland CTCF	thyroid gland	NULL	CTCF		GTRD	EXP039861_thyroid-gland_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30049
1	1782	FOXA1	0.317552240650882	1.07815724690086	19	1041	1188	1697	1697	1310	18	185	189	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	DHT24H	GEO	GSE58428_foxa1_vcap-dht24h_MACS_FOXA1_MA0148.4.damo.pwm.bed	47458
1	1847	FOXA2	0.317552240650882	1.07815724690086	19	1041	1188	1697	1697	1310	18	185	189	FOXA2 Caco-2 (colon adenocarcinoma) FOXA2	Caco-2 (colon adenocarcinoma)	BTO:0000195	FOXA2		GEO	GSE66218_foxa2_caco2_MACS_FOXA2_MA0047.3.damo.pwm.bed	35643
1	2898	MYC	0.317552240650882	1.07815724690086	19	1041	1188	1697	1697	1310	18	185	189	MYC CUTLL1 (T-cell lymphoblastic lymphoma 1) MYC	CUTLL1 (T-cell lymphoblastic lymphoma 1)	NULL	MYC	Treatment: no	GTRD	EXP049351_CUTLL1--T-cell-lymphoblastic-lymphoma-1-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	4601
1	3243	POU2F2	0.317552240650882	1.07815724690086	19	1041	1188	1697	1697	1310	18	185	189	POU2F2 GM12891 (male B- cells lymphoblastoid cell line) POU2F2	GM12891 (male B- cells lymphoblastoid cell line)	NULL	POU2F2		ENCODE	ENCSR000BII_GM12891_POU2F2_MACS_POU2F2_MA0507.1.damo.pwm.bed	8838
1	755	CTCF	0.317054106338223	1.08136717087447	18	1050	1177	1785	1785	1340	17	186	190	CTCF gastrocnemius medialis CTCF	gastrocnemius medialis	NULL	CTCF		GTRD	EXP039954_gastrocnemius-medialis_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	17791
1	784	CTCF	0.317054106338223	1.08136717087447	18	1050	1177	1785	1785	1340	17	186	190	CTCF LNCaP C4-2B (prostate carcinoma) CTCF	LNCaP C4-2B (prostate carcinoma)	BTO:0004959	CTCF		GTRD	EXP040145_LNCaP-C4-2B--prostate-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37006
1	975	CTCF	0.317054106338223	1.08136717087447	18	1050	1177	1785	1785	1340	17	186	190	CTCF hESC-1 (Embryonic stem cells) CTCF	hESC-1 (Embryonic stem cells)	NULL	CTCF	PRIMED	GEO	GSE69646_ctcf_esc-primed_MACS_CTCF_MA0139.1.damo.pwm.bed	26931
1	1514	FOS	0.317054106338223	1.08136717087447	18	1050	1177	1785	1785	1340	17	186	190	FOS K562 (myelogenous leukemia) FOS	K562 (myelogenous leukemia)	NULL	FOS		ENCODE	ENCSR000DKB_K562_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	17072
1	2897	MYC	0.317054106338223	1.08136717087447	18	1050	1177	1785	1785	1340	17	186	190	MYC CUTLL1 (T-cell lymphoblastic lymphoma 1) MYC	CUTLL1 (T-cell lymphoblastic lymphoma 1)	NULL	MYC	Treatment: no	GTRD	EXP049351_CUTLL1--T-cell-lymphoblastic-lymphoma-1-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	4282
1	3711	SRF	0.317054106338223	1.08136717087447	18	1050	1177	1785	1785	1340	17	186	190	SRF MCF7 (Invasive ductal breast carcinoma) SRF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	SRF		ENCODE	ENCSR000BVA_MCF-7_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	7099
1	3876	TFAP2C	0.317054106338223	1.08136717087447	18	1050	1177	1785	1785	1340	17	186	190	TFAP2C WA09 (embryonic stem cells) TFAP2C	WA09 (embryonic stem cells)	NULL	TFAP2C	BMP4 for 3 day	GTRD	EXP040713_WA09--embryonic-stem-cells-_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	20734
1	564	CTCF	0.316546365740598	1.0849942393682	17	1057	1164	1846	1846	1360	16	187	191	CTCF MCF10A (breast epithelial cells) CTCF	MCF10A (breast epithelial cells)	BTO:0001939	CTCF		Array Express	ERP000783_ctcf_mcf10a_MACS_CTCF_MA0139.1.damo.pwm.bed	30466
1	1430	ESR1	0.316546365740598	1.0849942393682	17	1057	1164	1846	1846	1360	16	187	191	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GEO	GSE71276_esr1_mcf7-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	16082
1	1663	FOXA1	0.316546365740598	1.0849942393682	17	1057	1164	1846	1846	1360	16	187	191	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	none	GTRD	EXP036100_VCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	25742
1	1940	GATA2	0.316546365740598	1.0849942393682	17	1057	1164	1846	1846	1360	16	187	191	GATA2 SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) GATA2	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	GATA2		GTRD	EXP037840_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	23536
1	3068	NR2F1	0.316546365740598	1.0849942393682	17	1057	1164	1846	1846	1360	16	187	191	NR2F1 GM12878 (female B-cells lymphoblastoid cell line) NR2F1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	NR2F1	NA	GTRD	EXP040024_GM12878--female-B-cells-_NR2F1_MACS_NR2F1_MA0017.2.damo.pwm.bed	15052
1	3877	TFAP2C	0.316546365740598	1.0849942393682	17	1057	1164	1846	1846	1360	16	187	191	TFAP2C WA09 (embryonic stem cells) TFAP2C	WA09 (embryonic stem cells)	NULL	TFAP2C	BMP4 for 3 day	GTRD	EXP040713_WA09--embryonic-stem-cells-_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	20838
1	461	CTCF	0.316027952922197	1.08912162414514	16	1063	1154	1909	1909	1380	15	188	192	CTCF HCT-116 (colon carcinoma) CTCF	HCT-116 (colon carcinoma)	BTO:0001109	CTCF		ENCODE	ENCSR000BSE_HCT116_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37233
1	809	CTCF	0.316027952922197	1.08912162414514	16	1063	1154	1909	1909	1380	15	188	192	CTCF HeLa Kyoto (cervical adenocarcinoma) CTCF	HeLa Kyoto (cervical adenocarcinoma)	NULL	CTCF	Wild type	GTRD	EXP040503_HeLa-Kyoto--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39051
1	811	CTCF	0.316027952922197	1.08912162414514	16	1063	1154	1909	1909	1380	15	188	192	CTCF HeLa Kyoto (cervical adenocarcinoma) CTCF	HeLa Kyoto (cervical adenocarcinoma)	NULL	CTCF	Pds5SA/B depletion	GTRD	EXP040505_HeLa-Kyoto--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	44523
1	1749	FOXA1	0.316027952922197	1.08912162414514	16	1063	1154	1909	1909	1380	15	188	192	FOXA1 ZR-75-1 (invasive ductal carcinoma) FOXA1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	FOXA1	Treatment: hormone-deprived cells treated with vehicle;	GTRD	EXP058104_ZR-75-1--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	38746
1	1867	GABPA	0.316027952922197	1.08912162414514	16	1063	1154	1909	1909	1380	15	188	192	GABPA GABPA	NA	NA	GABPA	NA	NA	ENCSR000BGC_GM12878_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	3715
1	625	CTCF	0.315497631183526	1.09385626885601	15	1068	1144	1993	1993	1400	14	189	193	CTCF embryonic stem cells CTCF	embryonic stem cells	NULL	CTCF		GTRD	EXP035701_embryonic-stem-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29273
1	781	CTCF	0.315497631183526	1.09385626885601	15	1068	1144	1993	1993	1400	14	189	193	CTCF stomach CTCF	stomach	BTO:0001307	CTCF		GTRD	EXP040118_stomach_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	21775
1	1986	GATA3	0.315497631183526	1.09385626885601	15	1068	1144	1993	1993	1400	14	189	193	GATA3 Jurkat (T-cells) GATA3	Jurkat (T-cells)	BTO:0000661	GATA3		GTRD	EXP053327_Jurkat--T-cells-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	20834
1	3922	TFAP2C	0.315005369480281	1.02772050157644	96	1071	1314	1	1314	795	96	108	111	TFAP2C BT-474 (breast invasive ductal carcinoma) TFAP2C	BT-474 (breast invasive ductal carcinoma)	BTO:0001932	TFAP2C		GEO	GSE36351_tfap2c_bt474_MACS_TFAP2C_MA0814.2.damo.pwm.bed	97552
1	125	AR	0.314953951478107	1.09933803236426	14	1072	1129	2073	2073	1420	13	190	194	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	DHAT_2H	GEO	GSE28950_AR_vcap-dhat-2h_MACS_AR_MA0007.3.damo.pwm.bed	45864
1	692	CTCF	0.314953951478107	1.09933803236426	14	1072	1129	2073	2073	1420	13	190	194	CTCF spleen CTCF	spleen	BTO:0001281	CTCF		GTRD	EXP039469_spleen_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	15524
1	3119	NR3C1	0.314953951478107	1.09933803236426	14	1072	1129	2073	2073	1420	13	190	194	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 10 minute	GTRD	EXP040223_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	24200
1	3921	TFAP2C	0.314499935052996	1.02746602811682	95	1075	1315	2	1315	797	95	109	112	TFAP2C BT-474 (breast invasive ductal carcinoma) TFAP2C	BT-474 (breast invasive ductal carcinoma)	BTO:0001932	TFAP2C		GEO	GSE36351_tfap2c_bt474_MACS_TFAP2C_MA0524.2.damo.pwm.bed	92132
1	184	AR	0.314395196918457	1.10574939585982	13	1076	1117	2153	2153	1450	12	191	195	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	SHFOXP1_DHT	GEO	GSE62492_AR_lncap-shfoxp1-dht_MACS_AR_MA0007.3.damo.pwm.bed	34532
1	4048	TP63	0.314395196918457	1.10574939585982	13	1076	1117	2153	2153	1450	12	191	195	TP63 keratinocytes TP63	keratinocytes	NULL	TP63	CISP	GEO	GSE56674_tp63_keratinocyte-cisp_MACS_TP63_MA0525.2.damo.pwm.bed	26510
1	1101	ELK1	0.313819307235459	1.11334430732094	12	1078	1098	2233	2233	1470	11	192	196	ELK1 K562 (myelogenous leukemia) ELK1	K562 (myelogenous leukemia)	NULL	ELK1		ENCODE	ENCSR338QAC_K562_ELK1_MACS_ELK1_MA0028.2.damo.pwm.bed	3535
1	1173	ESR1	0.313819307235459	1.11334430732094	12	1078	1098	2233	2233	1470	11	192	196	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	Array Express	ERP000901_esr1_mcf7-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	29112
1	1303	ESR1	0.313819307235459	1.11334430732094	12	1078	1098	2233	2233	1470	11	192	196	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	100nm E2 (90 min)	GTRD	EXP040952_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	20150
1	1720	FOXA1	0.313819307235459	1.11334430732094	12	1078	1098	2233	2233	1470	11	192	196	FOXA1 22RV1 (prostate carcinoma) FOXA1	22RV1 (prostate carcinoma)	BTO:0002999	FOXA1	Treatment: ethanol	GTRD	EXP048914_22RV1--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	21482
1	1740	FOXA1	0.313819307235459	1.11334430732094	12	1078	1098	2233	2233	1470	11	192	196	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053231_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	19565
1	1741	FOXA1	0.313819307235459	1.11334430732094	12	1078	1098	2233	2233	1470	11	192	196	FOXA1 primary prostate cancer FOXA1	primary prostate cancer	NULL	FOXA1	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053235_primary-prostate-cancer_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	18091
1	2012	GATA4	0.313819307235459	1.11334430732094	12	1078	1098	2233	2233	1470	11	192	196	GATA4 HUES64 (embryonic stem cells) GATA4	HUES64 (embryonic stem cells)	NULL	GATA4	shGATA4	GTRD	EXP036791_HUES64--embryonic-stem-cells-_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	50386
1	3450	RFX5	0.313819307235459	1.11334430732094	12	1078	1098	2233	2233	1470	11	192	196	RFX5 MCF7 (Invasive ductal breast carcinoma) RFX5	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RFX5	NA	ENCODE	ENCSR924TVL_MCF-7_RFX5_MACS_RFX5_MA0510.2.damo.pwm.bed	6720
1	57	AR	0.313223773581158	1.12248102781588	11	1086	1071	2332	2332	1500	10	193	197	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	R1881	GTRD	EXP037066_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	49037
1	1284	ESR1	0.313223773581158	1.12248102781588	11	1086	1071	2332	2332	1500	10	193	197	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GTRD	EXP038775_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	16322
1	1297	ESR1	0.313223773581158	1.12248102781588	11	1086	1071	2332	2332	1500	10	193	197	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	5 nM E2 for 30 min	GTRD	EXP040892_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	20218
1	1325	ESR1	0.313223773581158	1.12248102781588	11	1086	1071	2332	2332	1500	10	193	197	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: vehicle(DMSO 2 hr); Passage: p22;	GTRD	EXP047708_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	22985
1	1695	FOXA1	0.313223773581158	1.12248102781588	11	1086	1071	2332	2332	1500	10	193	197	FOXA1 breast tumor FOXA1	breast tumor	NULL	FOXA1	Male	GTRD	EXP040666_breast-tumor_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	15158
1	1885	GABPA	0.313223773581158	1.12248102781588	11	1086	1071	2332	2332	1500	10	193	197	GABPA HeLa (cervical adenocarcinoma) GABPA	HeLa (cervical adenocarcinoma)	BTO:0000567	GABPA		GEO	GSE31417_gabpa_hela_MACS_GABPA_MA0062.3.damo.pwm.bed	2460
1	3122	NR3C1	0.313223773581158	1.12248102781588	11	1086	1071	2332	2332	1500	10	193	197	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 5 minute	GTRD	EXP040277_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	17961
1	3761	T	0.313223773581158	1.12248102781588	11	1086	1071	2332	2332	1500	10	193	197	T H9 T	H9	NULL	T	ENDODERM	GEO	GSE60606_t_hes-endoderm_MACS_T_MA0009.2.damo.pwm.bed	14361
1	460	CTCF	0.312605488106442	1.13367303760172	10	1094	1043	2442	2442	1530	9	194	198	CTCF Ishikawa (endometrial adenocarcinoma) CTCF	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	CTCF	1 h with 0.02% Dimethyl sufloxide (DMSO) (Myers)	ENCODE	ENCSR000BQE_Ishikawa_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	19255
1	714	CTCF	0.312605488106442	1.13367303760172	10	1094	1043	2442	2442	1530	9	194	198	CTCF sigmoid colon CTCF	sigmoid colon	BTO:0000645	CTCF		GTRD	EXP039618_sigmoid-colon_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	15835
1	1319	ESR1	0.312605488106442	1.13367303760172	10	1094	1043	2442	2442	1530	9	194	198	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: vehicle(DMSO 2 hr); Passage: p20;	GTRD	EXP047702_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	16489
1	1498	FLI1	0.312605488106442	1.13367303760172	10	1094	1043	2442	2442	1530	9	194	198	FLI1 HUVEC-C (HUVEC, umbilical vein endothelial cells) FLI1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FLI1	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048207_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	6327
1	2158	HOXB13	0.312605488106442	1.13367303760172	10	1094	1043	2442	2442	1530	9	194	198	HOXB13 LNCaP (prostate carcinoma) HOXB13	LNCaP (prostate carcinoma)	BTO:0001321	HOXB13		GTRD	EXP038431_LNCaP--prostate-carcinoma-_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	24401
1	2401	JUN	0.312605488106442	1.13367303760172	10	1094	1043	2442	2442	1530	9	194	198	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048211_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	7635
1	2608	JUND	0.312605488106442	1.13367303760172	10	1094	1043	2442	2442	1530	9	194	198	JUND Calu-3 (lung adenocarcinoma) JUND	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUND		GTRD	EXP037684_Calu-3--lung-adenocarcinoma-_JUND_MACS_JUND_MA1142.1.damo.pwm.bed	7355
1	2609	JUND	0.312605488106442	1.13367303760172	10	1094	1043	2442	2442	1530	9	194	198	JUND Calu-3 (lung adenocarcinoma) JUND	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUND		GTRD	EXP037684_Calu-3--lung-adenocarcinoma-_JUND_MACS_JUND_MA1144.1.damo.pwm.bed	7378
1	3252	POU5F1	0.312605488106442	1.13367303760172	10	1094	1043	2442	2442	1530	9	194	198	POU5F1 HUES64 (embryonic stem cells) POU5F1	HUES64 (embryonic stem cells)	NULL	POU5F1		GTRD	EXP036730_HUES64--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	8638
1	756	CTCF	0.311960522076731	1.14769053424616	9	1103	1000	2564	2564	1560	8	195	199	CTCF sigmoid colon CTCF	sigmoid colon	BTO:0000645	CTCF		GTRD	EXP039971_sigmoid-colon_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	10219
1	1144	ERG	0.311960522076731	1.14769053424616	9	1103	1000	2564	2564	1560	8	195	199	ERG RWPE1 (prostate epithelial cells) ERG	RWPE1 (prostate epithelial cells)	BTO:0003709	ERG		GEO	GSE37752_erg_rwpe1_MACS_ERG_MA0474.2.damo.pwm.bed	5763
1	1271	ESR1	0.311960522076731	1.14769053424616	9	1103	1000	2564	2564	1560	8	195	199	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	none	GTRD	EXP038384_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12869
1	1804	FOXA1	0.311960522076731	1.14769053424616	9	1103	1000	2564	2564	1560	8	195	199	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	DEX	GEO	GSE72249_foxa1_t47d-dex_MACS_FOXA1_MA0148.4.damo.pwm.bed	18760
1	1968	GATA3	0.311960522076731	1.14769053424616	9	1103	1000	2564	2564	1560	8	195	199	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3	E2	GTRD	EXP037456_MCF7--Invasive-ductal-breast-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	22785
1	2223	JUN	0.311960522076731	1.14769053424616	9	1103	1000	2564	2564	1560	8	195	199	JUN HepG2 (hepatoblastoma) JUN	HepG2 (hepatoblastoma)	BTO:0000599	JUN		ENCODE	ENCSR000EEK_HepG2_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	20528
1	2499	JUNB	0.311960522076731	1.14769053424616	9	1103	1000	2564	2564	1560	8	195	199	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039341_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	14093
1	2529	JUNB	0.311960522076731	1.14769053424616	9	1103	1000	2564	2564	1560	8	195	199	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039831_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	9893
1	3412	REST	0.311960522076731	1.14769053424616	9	1103	1000	2564	2564	1560	8	195	199	REST acute promyelocytic leukemia blasts REST	acute promyelocytic leukemia blasts	BTO:0004585	REST		GTRD	EXP031799_acute-promyelocytic-leukemia-blasts_REST_MACS_REST_MA0138.2.damo.pwm.bed	8131
1	3448	RFX5	0.311960522076731	1.14769053424616	9	1103	1000	2564	2564	1560	8	195	199	RFX5 SK-N-SH (neuroblastoma) RFX5	SK-N-SH (neuroblastoma)	BTO:0001620	RFX5	NA	ENCODE	ENCSR000EHY_SK-N-SH_RFX5_MACS_RFX5_MA0510.2.damo.pwm.bed	4369
1	3568	SMAD3	0.311960522076731	1.14769053424616	9	1103	1000	2564	2564	1560	8	195	199	SMAD3 HMLE-Twist-ER (breast cancer) SMAD3	HMLE-Twist-ER (breast cancer)	NULL	SMAD3	CellType: immortalized human mammary epithelial cells Treatment:TGF--beta	GTRD	EXP047899_HMLE-Twist-ER--breast-cancer-_SMAD3_MACS_SMAD3_MA1622.1.damo.pwm.bed	14968
1	4018	TP53	0.311960522076731	1.14769053424616	9	1103	1000	2564	2564	1560	8	195	199	TP53 keratinocytes TP53	keratinocytes	NULL	TP53	CISP	GEO	GSE56674_tp53_keratinocyte-cisp_MACS_TP53_MA0106.3.damo.pwm.bed	12610
1	127	AR	0.311283786197041	1.16574377794766	8	1115	944	2697	2697	1590	7	196	200	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	1F5_SIFOXA1	GEO	GSE30623_ar_lncap1f5-sifoxa1_MACS_AR_MA0007.3.damo.pwm.bed	22086
1	189	AR	0.311283786197041	1.16574377794766	8	1115	944	2697	2697	1590	7	196	200	AR prostate AR	prostate	NULL	AR		GEO	GSE65478_AR_prostate_MACS_AR_MA0007.3.damo.pwm.bed	12596
1	862	CTCF	0.311283786197041	1.16574377794766	8	1115	944	2697	2697	1590	7	196	200	CTCF MDM(monocyte derived macrophages) CTCF	MDM(monocyte derived macrophages)	NULL	CTCF	Treatment: ZIKV-bystander, time post infection 24 hr  ViralStrain: ZIKV-FSS13025	GTRD	EXP048656_MDM-monocyte-derived-macrophages-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	10574
1	1367	ESR1	0.311283786197041	1.16574377794766	8	1115	944	2697	2697	1590	7	196	200	ESR1 primary breast cancer ESR1	primary breast cancer	NULL	ESR1	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053237_primary-breast-cancer_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	3800
1	1575	FOSL2	0.311283786197041	1.16574377794766	8	1115	944	2697	2697	1590	7	196	200	FOSL2 MCF7 (Invasive ductal breast carcinoma) FOSL2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOSL2		ENCODE	ENCSR546KCN_MCF-7_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	10597
1	1896	GATA1	0.311283786197041	1.16574377794766	8	1115	944	2697	2697	1590	7	196	200	GATA1 megakaryocytes GATA1	megakaryocytes	NULL	GATA1	NULL	GTRD	EXP000351_megakaryocytes_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	8784
1	1897	GATA1	0.311283786197041	1.16574377794766	8	1115	944	2697	2697	1590	7	196	200	GATA1 megakaryocytes GATA1	megakaryocytes	NULL	GATA1	NULL	GTRD	EXP000351_megakaryocytes_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	9298
1	2746	MEIS1	0.311283786197041	1.16574377794766	8	1115	944	2697	2697	1590	7	196	200	MEIS1 CHRF28811 MEIS1	CHRF28811	NA	MEIS1	NA	Array Express	ERR063469_meis1_chrf28811_MACS_MEIS1_MA0498.2.damo.pwm.bed	19457
1	3035	NKX2-5	0.311283786197041	1.16574377794766	8	1115	944	2697	2697	1590	7	196	200	NKX2-5 embryonic stem cells NKX2-5	embryonic stem cells	NULL	NKX2-5	Treatment: no	GTRD	EXP049255_embryonic-stem-cells_NKX2-5_MACS_NKX2-5_MA0063.2.damo.pwm.bed	10460
1	3446	RFX5	0.311283786197041	1.16574377794766	8	1115	944	2697	2697	1590	7	196	200	RFX5 IMR90 (lung fibroblasts) RFX5	IMR90 (lung fibroblasts)	NULL	RFX5	NA	ENCODE	ENCSR000EFD_IMR-90_RFX5_MACS_RFX5_MA0510.2.damo.pwm.bed	3624
1	3788	TCF3	0.311283786197041	1.16574377794766	8	1115	944	2697	2697	1590	7	196	200	TCF3 Kasumi-1 (acute myeloblastic leukemia) TCF3	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	TCF3	Genotype: overexpress E2A Source: Myeloblast Cell type:  leukemic cell line with an 8;21 chromosome translocation Passage: 4-5	GTRD	EXP053212_Kasumi-1--acute-myeloblastic-leukemia-_TCF3_MACS_TCF3_MA0091.1.damo.pwm.bed	5348
1	67	AR	0.310568486613879	1.18984975706087	7	1126	893	2812	2812	1610	6	197	201	AR breast tumor AR	breast tumor	NULL	AR	Female	GTRD	EXP040660_breast-tumor_AR_MACS_AR_MA0007.3.damo.pwm.bed	6126
1	182	AR	0.310568486613879	1.18984975706087	7	1126	893	2812	2812	1610	6	197	201	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	R1881	GEO	GSE62492_AR_lncap-r1881_MACS_AR_MA0007.3.damo.pwm.bed	17613
1	977	CTCF	0.310568486613879	1.18984975706087	7	1126	893	2812	2812	1610	6	197	201	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF		GEO	GSE69962_ctcf_thp1_MACS_CTCF_MA0139.1.damo.pwm.bed	4977
1	1106	ELK1	0.310568486613879	1.18984975706087	7	1126	893	2812	2812	1610	6	197	201	ELK1 IMR90 (lung fibroblasts) ELK1	IMR90 (lung fibroblasts)	NULL	ELK1		GTRD	EXP039606_IMR90--lung-fibroblasts-_ELK1_MACS_ELK1_MA0028.2.damo.pwm.bed	1685
1	1258	ESR1	0.310568486613879	1.18984975706087	7	1126	893	2812	2812	1610	6	197	201	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Doxycycline	GTRD	EXP038370_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	16403
1	1435	ESR1	0.310568486613879	1.18984975706087	7	1126	893	2812	2812	1610	6	197	201	ESR1 ZR-75-1 (invasive ductal carcinoma) ESR1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	ESR1	E2	GEO	GSE72249_esr1_zr751-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	22135
1	1772	FOXA1	0.310568486613879	1.18984975706087	7	1126	893	2812	2812	1610	6	197	201	FOXA1 DU145 (prostate carcinoma) FOXA1	DU145 (prostate carcinoma)	BTO:0001332	FOXA1	FOXA1_HIGH	GEO	GSE47987_foxa1_du145-foxa1-high_MACS_FOXA1_MA0148.4.damo.pwm.bed	39567
1	2015	GATA4	0.310568486613879	1.18984975706087	7	1126	893	2812	2812	1610	6	197	201	GATA4 iPSC-derived cardiomyocytes GATA4	iPSC-derived cardiomyocytes	NULL	GATA4		GTRD	EXP037714_iPSC-derived-cardiomyocytes_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	12073
1	2851	MYC	0.310568486613879	1.18984975706087	7	1126	893	2812	2812	1610	6	197	201	MYC HUES64 (embryonic stem cells) MYC	HUES64 (embryonic stem cells)	NULL	MYC		GTRD	EXP036779_HUES64--embryonic-stem-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	1171
1	3279	POU5F1	0.310568486613879	1.18984975706087	7	1126	893	2812	2812	1610	6	197	201	POU5F1 hiPSC POU5F1	hiPSC	NULL	POU5F1		GEO	GSE56567_pou5f1_ipsc_MACS_POU5F1_MA1115.1.damo.pwm.bed	16342
1	3997	TP53	0.310568486613879	1.18984975706087	7	1126	893	2812	2812	1610	6	197	201	TP53 IMR90 (lung fibroblasts) TP53	IMR90 (lung fibroblasts)	NULL	TP53	Treatment: nutlin3a (5uM final) for 6hrs; Passage: 30-35;	GTRD	EXP054820_IMR90--lung-fibroblasts-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	4223
1	467	CTCF	0.310484931765823	1.02558693614874	87	1137	1316	6	1316	820	87	117	120	CTCF GM12892 (female B-cells lymphoblastoid cell line) CTCF	GM12892 (female B-cells lymphoblastoid cell line)	NULL	CTCF		ENCODE	ENCSR000DKY_GM12892_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	120943
1	75	AR	0.309805203425514	1.22363878497588	6	1138	811	2948	2948	1630	5	198	202	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: non-target siNT+R1881	GTRD	EXP048920_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	16191
1	264	ATF7	0.309805203425514	1.22363878497588	6	1138	811	2948	2948	1630	5	198	202	ATF7 MCF7 (Invasive ductal breast carcinoma) ATF7	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ATF7	NA	GTRD	EXP039990_MCF7--Invasive-ductal-breast-carcinoma-_ATF7_MACS_ATF7_MA0834.1.damo.pwm.bed	16845
1	291	BHLHE40	0.309805203425514	1.22363878497588	6	1138	811	2948	2948	1630	5	198	202	BHLHE40 HepG2 (hepatoblastoma) BHLHE40	HepG2 (hepatoblastoma)	BTO:0000599	BHLHE40	NA	ENCODE	ENCSR000BID_HepG2_BHLHE40_MACS_BHLHE40_MA0464.2.damo.pwm.bed	3107
1	1289	ESR1	0.309805203425514	1.22363878497588	6	1138	811	2948	2948	1630	5	198	202	ESR1 ZR-75-1 (invasive ductal carcinoma) ESR1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	ESR1	Tam-Responsive	GTRD	EXP038793_ZR-75-1--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	22743
1	1306	ESR1	0.309805203425514	1.22363878497588	6	1138	811	2948	2948	1630	5	198	202	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	100nm E2 (90 min)	GTRD	EXP040955_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	11485
1	1734	FOXA1	0.309805203425514	1.22363878497588	6	1138	811	2948	2948	1630	5	198	202	FOXA1 LNCaP95 FOXA1	LNCaP95	NULL	FOXA1	Treatment: 10 nM ETOH for 4 hrs Genotype: shGFP transfection	GTRD	EXP052940_LNCaP95_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	17604
1	1993	GATA3	0.309805203425514	1.22363878497588	6	1138	811	2948	2948	1630	5	198	202	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3	E2	GEO	GSE40129_gata3_mcf7-e2_MACS_GATA3_MA0037.3.damo.pwm.bed	23777
1	2145	HNF4A	0.309805203425514	1.22363878497588	6	1138	811	2948	2948	1630	5	198	202	HNF4A LoVo (colorectal adenocarcinoma) HNF4A	LoVo (colorectal adenocarcinoma)	BTO:0000666	HNF4A	PHASES	GEO	GSE51290_hnf4a_lovo-phaseS_MACS_HNF4A_MA0114.4.damo.pwm.bed	5483
1	2266	JUN	0.309805203425514	1.22363878497588	6	1138	811	2948	2948	1630	5	198	202	JUN Calu-3 (lung adenocarcinoma) JUN	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUN		GTRD	EXP037683_Calu-3--lung-adenocarcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	5443
1	3093	NR3C1	0.309805203425514	1.22363878497588	6	1138	811	2948	2948	1630	5	198	202	NR3C1 LNCaP (prostate carcinoma) NR3C1	LNCaP (prostate carcinoma)	BTO:0001321	NR3C1	100 nM DEX	GTRD	EXP030498_LNCaP--prostate-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	17237
1	3109	NR3C1	0.309805203425514	1.22363878497588	6	1138	811	2948	2948	1630	5	198	202	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039313_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	4718
1	3111	NR3C1	0.309805203425514	1.22363878497588	6	1138	811	2948	2948	1630	5	198	202	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP039685_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	4624
1	3113	NR3C1	0.309805203425514	1.22363878497588	6	1138	811	2948	2948	1630	5	198	202	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039722_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	3113
1	3315	RARA	0.309805203425514	1.22363878497588	6	1138	811	2948	2948	1630	5	198	202	RARA U937 (adult acute monocytic leukemia) RARA	U937 (adult acute monocytic leukemia)	BTO:0001412	RARA	Treatment: 3 mg/mL ATRA for 3 days	GTRD	EXP049794_U937--adult-acute-monocytic-leukemia-_RARA_MACS_RARA_MA1149.1.damo.pwm.bed	4468
1	3422	REST	0.309805203425514	1.22363878497588	6	1138	811	2948	2948	1630	5	198	202	REST GM23338 REST	GM23338	NULL	REST		GTRD	EXP045141_GM23338_REST_MACS_REST_MA0138.2.damo.pwm.bed	8092
1	3789	TCF3	0.309805203425514	1.22363878497588	6	1138	811	2948	2948	1630	5	198	202	TCF3 Kasumi-1 (acute myeloblastic leukemia) TCF3	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	TCF3	Genotype: overexpress E2A Source: Myeloblast Cell type:  leukemic cell line with an 8;21 chromosome translocation Passage: 4-5	GTRD	EXP053212_Kasumi-1--acute-myeloblastic-leukemia-_TCF3_MACS_TCF3_MA0522.3.damo.pwm.bed	4845
1	4150	YY1	0.309805203425514	1.22363878497588	6	1138	811	2948	2948	1630	5	198	202	YY1 HEK293 (embryonic kidney) YY1	HEK293 (embryonic kidney)	NULL	YY1		GTRD	EXP040324_HEK293--embryonic-kidney-_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	969
1	4154	YY2	0.309805203425514	1.22363878497588	6	1138	811	2948	2948	1630	5	198	202	YY2 HEK293 (embryonic kidney) YY2	HEK293 (embryonic kidney)	NULL	YY2	NA	GTRD	EXP039558_HEK293--embryonic-kidney-_YY2_MACS_YY2_MA0748.2.damo.pwm.bed	1384
1	4161	ZNF143	0.309805203425514	1.22363878497588	6	1138	811	2948	2948	1630	5	198	202	ZNF143 HEK293T (embryonic kidney) ZNF143	HEK293T (embryonic kidney)	BTO:0002181	ZNF143		GEO	GSE39263_znf143_hek293t_MACS_ZNF143_MA0088.2.damo.pwm.bed	1903
1	11	AR	0.308980213658286	1.27437078233023	5	1157	714	3053	3053	1640	4	199	203	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	ethanol	GTRD	EXP000730_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	5727
1	38	AR	0.308980213658286	1.27437078233023	5	1157	714	3053	3053	1640	4	199	203	AR ovarian granulosa cells AR	ovarian granulosa cells	NULL	AR		GTRD	EXP033702_ovarian-granulosa-cells_AR_MACS_AR_MA0007.3.damo.pwm.bed	9053
1	363	CEBPB	0.308980213658286	1.27437078233023	5	1157	714	3053	3053	1640	4	199	203	CEBPB GM12878 (female B-cells lymphoblastoid cell line) CEBPB	GM12878 (female B-cells lymphoblastoid cell line)	NULL	CEBPB		ENCODE	ENCSR681NOM_GM12878_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	2717
1	1083	ELF1	0.308980213658286	1.27437078233023	5	1157	714	3053	3053	1640	4	199	203	ELF1 MCF7 (Invasive ductal breast carcinoma) ELF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ELF1		ENCODE	ENCSR475SOC_MCF-7_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	1331
1	1309	ESR1	0.308980213658286	1.27437078233023	5	1157	714	3053	3053	1640	4	199	203	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	100nm E2 (90 min)	GTRD	EXP040958_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	8439
1	1410	ESR1	0.308980213658286	1.27437078233023	5	1157	714	3053	3053	1640	4	199	203	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SHFOXA1_E2_TNF	GEO	GSE59530_esr1_mcf7-shfoxa1-e2-tnf_MACS_ESR1_MA0112.3.damo.pwm.bed	9552
1	1649	FOXA1	0.308980213658286	1.27437078233023	5	1157	714	3053	3053	1640	4	199	203	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	NULL	GTRD	EXP000618_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	8401
1	1676	FOXA1	0.308980213658286	1.27437078233023	5	1157	714	3053	3053	1640	4	199	203	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1		GTRD	EXP038333_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	17608
1	1830	FOXA2	0.308980213658286	1.27437078233023	5	1157	714	3053	3053	1640	4	199	203	FOXA2 liver FOXA2	liver	BTO:0000759	FOXA2		GTRD	EXP039928_liver_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	12337
1	2170	HOXB13	0.308980213658286	1.27437078233023	5	1157	714	3053	3053	1640	4	199	203	HOXB13 LNCaP95 HOXB13	LNCaP95	NULL	HOXB13	Treatment: 10 nM ETOH for 4 hrs Genotype: shARv7 transfection	GTRD	EXP052944_LNCaP95_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	12629
1	3050	NR2C2	0.308980213658286	1.27437078233023	5	1157	714	3053	3053	1640	4	199	203	NR2C2 HepG2 (hepatoblastoma) NR2C2	HepG2 (hepatoblastoma)	BTO:0000599	NR2C2		ENCODE	ENCSR000EVS_HepG2_NR2C2_MACS_NR2C2_MA0504.1.damo.pwm.bed	1714
1	3312	RARA	0.308980213658286	1.27437078233023	5	1157	714	3053	3053	1640	4	199	203	RARA U937 (adult acute monocytic leukemia) RARA	U937 (adult acute monocytic leukemia)	BTO:0001412	RARA	Treatment: 3 mg/mL ATRA for 3 days	GTRD	EXP049794_U937--adult-acute-monocytic-leukemia-_RARA_MACS_RARA_MA0159.1.damo.pwm.bed	3951
1	3357	RELA	0.308980213658286	1.27437078233023	5	1157	714	3053	3053	1640	4	199	203	RELA HuH7 (hepatocellular carcinoma) RELA	HuH7 (hepatocellular carcinoma)	BTO:0001950	RELA	10ng/ml IL-1alpha for 1 h	GTRD	EXP037989_HuH7--hepatocellular-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	2103
1	3727	STAT1	0.308980213658286	1.27437078233023	5	1157	714	3053	3053	1640	4	199	203	STAT1 AGS (gastric adenocarcinoma) STAT1	AGS (gastric adenocarcinoma)	BTO:0001007	STAT1		GTRD	EXP048898_AGS--gastric-adenocarcinoma-_STAT1_MACS_STAT1_MA0517.1.damo.pwm.bed	1527
1	4140	YY1	0.308980213658286	1.27437078233023	5	1157	714	3053	3053	1640	4	199	203	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1	YY1-mutated (p.Leu366Pro)	GTRD	EXP038610_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	1188
1	19	AR	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	1000 nM CPA	GTRD	EXP030505_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	3346
1	131	AR	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	R1881_10C30	GEO	GSE32892_AR_vcap-r1881-10c30_MACS_AR_MA0007.3.damo.pwm.bed	10411
1	203	AR	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	R1881	GEO	GSE79128_AR_vcap-r1881_MACS_AR_MA0007.3.damo.pwm.bed	9419
1	299	CDX2	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	CDX2 LS174T (colon adenocarcinoma) CDX2	LS174T (colon adenocarcinoma)	BTO:0001553	CDX2		GTRD	EXP038476_LS174T--colon-adenocarcinoma-_CDX2_MACS_CDX2_MA0465.2.damo.pwm.bed	7149
1	379	CEBPB	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP039961_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	5210
1	402	CEBPB	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	CEBPB CEBPB	NA	NA	CEBPB	NA	GEO	GSE66192_cebpb_cd14-oxldl_MACS_CEBPB_MA0466.2.damo.pwm.bed	3427
1	1027	E2F1	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	E2F1 hTERT-RPE1 E2F1	hTERT-RPE1	BTO:0004790	E2F1		GTRD	EXP055165_hTERT-RPE1_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	798
1	1431	ESR1	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GEO	GSE72249_esr1_mcf7-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	14015
1	1650	FOXA1	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	E2	GTRD	EXP000623_T47D--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	9600
1	1882	GABPA	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	GABPA THP-1 (acute monocytic leukemia) GABPA	THP-1 (acute monocytic leukemia)	BTO:0001370	GABPA	Treatment: 100 nM ethanol for 24 hrs	GTRD	EXP049795_THP-1--acute-monocytic-leukemia-_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	1795
1	1908	GATA1	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	bio	GTRD	EXP000939_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	21913
1	1909	GATA1	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	bio	GTRD	EXP000939_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	22135
1	1912	GATA1	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	GATA1 CD34+ hematopoietic stem cells-derived proerythroblasts GATA1	CD34+ hematopoietic stem cells-derived proerythroblasts	NULL	GATA1	2-trimester fetal liver	GTRD	EXP031447_CD34--hematopoietic-stem-cells-derived-proerythroblasts_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	4475
1	1913	GATA1	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	GATA1 CD34+ hematopoietic stem cells-derived proerythroblasts GATA1	CD34+ hematopoietic stem cells-derived proerythroblasts	NULL	GATA1	2-trimester fetal liver	GTRD	EXP031447_CD34--hematopoietic-stem-cells-derived-proerythroblasts_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	4838
1	1933	GATA2	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	GATA2 megakaryocytes GATA2	megakaryocytes	NULL	GATA2	NULL	GTRD	EXP000352_megakaryocytes_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	3278
1	1997	GATA3	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3	E2	GEO	GSE60270_gata3_mcf7-e2_MACS_GATA3_MA0037.3.damo.pwm.bed	12027
1	2189	HSF1	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	HSF1 SK-BR-3 (breast adenocarcinoma) HSF1	SK-BR-3 (breast adenocarcinoma)	BTO:0002419	HSF1		GEO	GSE38901_hsf1_skbr3_MACS_HSF1_MA0486.2.damo.pwm.bed	2547
1	2228	JUN	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN	30 m of Interferon alpha (Snyder)	ENCODE	ENCSR000EGH_K562_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	3867
1	2647	KLF5	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	KLF5 HCC95 (squamous cell lung carcinoma) KLF5	HCC95 (squamous cell lung carcinoma)	NULL	KLF5	Treatment: Over-expressing KLF5 WT	GTRD	EXP049099_HCC95--squamous-cell-lung-carcinoma-_KLF5_MACS_KLF5_MA0599.1.damo.pwm.bed	1270
1	2834	MYC	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	MYC HCT-116 (colon carcinoma) MYC	HCT-116 (colon carcinoma)	BTO:0001109	MYC		GTRD	EXP036146_HCT-116--colon-carcinoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	704
1	2835	MYC	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	MYC HCT-116 (colon carcinoma) MYC	HCT-116 (colon carcinoma)	BTO:0001109	MYC		GTRD	EXP036146_HCT-116--colon-carcinoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	681
1	2996	NFE2L2	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	NFE2L2 HepG2 (hepatoblastoma) NFE2L2	HepG2 (hepatoblastoma)	BTO:0000599	NFE2L2		ENCODE	ENCSR488EES_HepG2_NFE2L2_MACS_NFE2L2_MA0150.2.damo.pwm.bed	10584
1	3036	NKX2-5	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	NKX2-5 embryonic stem cells NKX2-5	embryonic stem cells	NULL	NKX2-5	Treatment: no	GTRD	EXP049255_embryonic-stem-cells_NKX2-5_MACS_NKX2-5_MA0503.1.damo.pwm.bed	8329
1	3380	RELA	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	RELA MCF7 (Invasive ductal breast carcinoma) RELA	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RELA	TNF	GEO	GSE59530_rela_mcf7-tnf_MACS_RELA_MA0107.1.damo.pwm.bed	844
1	3393	REST	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	REST SK-N-SH (neuroblastoma) REST	SK-N-SH (neuroblastoma)	BTO:0001620	REST		ENCODE	ENCSR000BJJ_SK-N-SH_REST_MACS_REST_MA0138.2.damo.pwm.bed	5092
1	3563	SMAD2	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	SMAD2 hESC-1 (Embryonic stem cells) SMAD2	hESC-1 (Embryonic stem cells)	NULL	SMAD2	NA	GEO	GSE29422_smad2_esc_MACS_SMAD2_MA0513.1.damo.pwm.bed	1571
1	3595	SOX2	0.308072134088984	1.35898330664607	4	1172	575	3182	3182	1640	3	200	204	SOX2 HUES64 (embryonic stem cells) SOX2	HUES64 (embryonic stem cells)	NULL	SOX2		GTRD	EXP036751_HUES64--embryonic-stem-cells-_SOX2_MACS_SOX2_MA0142.1.damo.pwm.bed	6027
1	5	AR	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	AR stimulated	GTRD	EXP000407_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	10563
1	13	AR	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	ethanol	GTRD	EXP000732_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	1354
1	111	AR	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	AR LNCaP95 AR	LNCaP95	NULL	AR	Treatment: 10 nM ETOH for 4 hrs Genotype: parental (none transfection)	GTRD	EXP052954_LNCaP95_AR_MACS_AR_MA0007.3.damo.pwm.bed	7983
1	159	AR	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	AR AR	NA	NA	AR	NA	GEO	GSE55062_AR_vcap_MACS_AR_MA0007.3.damo.pwm.bed	8080
1	192	AR	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	SHFOXA1_RPMIFBS	GEO	GSE69043_AR_lncap-shfoxa1-rpmifbs_MACS_AR_MA0007.3.damo.pwm.bed	2514
1	700	CTCF	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	CTCF stomach CTCF	stomach	BTO:0001307	CTCF		GTRD	EXP039534_stomach_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	1594
1	995	CUX1	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	CUX1 K562 (myelogenous leukemia) CUX1	K562 (myelogenous leukemia)	NULL	CUX1	NA	ENCODE	ENCSR000EFO_K562_CUX1_MACS_CUX1_MA0754.1.damo.pwm.bed	3142
1	1299	ESR1	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	ICI for 3h	GTRD	EXP040894_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	5952
1	1313	ESR1	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: ethanol 1hr;	GTRD	EXP047662_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	6903
1	1346	ESR1	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: E2 (estrogen) for 45 min  Genotype: wildtype TET2 Passage: 6-10	GTRD	EXP048686_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	7663
1	1375	ESR1	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	ESR1 MCF7L-P(immortalized breast epithelial cell line) ESR1	MCF7L-P(immortalized breast epithelial cell line)	NULL	ESR1	Treatment: untreated;	GTRD	EXP057857_MCF7L-P-immortalized-breast-epithelial-cell-line-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	6875
1	1377	ESR1	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	ESR1 MCF7L-P(immortalized breast epithelial cell line) ESR1	MCF7L-P(immortalized breast epithelial cell line)	NULL	ESR1	Treatment: treated with E2 for 4 hrs;	GTRD	EXP057861_MCF7L-P-immortalized-breast-epithelial-cell-line-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	4050
1	1378	ESR1	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	ESR1 MCF7L-P(immortalized breast epithelial cell line) ESR1	MCF7L-P(immortalized breast epithelial cell line)	NULL	ESR1	Treatment: treated with E2 for 16 hrs;	GTRD	EXP057863_MCF7L-P-immortalized-breast-epithelial-cell-line-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	7751
1	1652	FOXA1	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	regular medium	GTRD	EXP000721_VCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	15841
1	1945	GATA2	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	GATA2 HUVEC-C (HUVEC, umbilical vein endothelial cells) GATA2	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	GATA2	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048218_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	6477
1	2104	HIF1A	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	HIF1A RCC 7860 (Renal cell carcinoma) HIF1A	RCC 7860 (Renal cell carcinoma)	BTO:0003781	HIF1A		GEO	GSE34871_hif1a_786o_MACS_HIF1A_MA1106.1.damo.pwm.bed	1945
1	3045	NR2C1	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	NR2C1 K562 (myelogenous leukemia) NR2C1	K562 (myelogenous leukemia)	NULL	NR2C1	NA	GTRD	EXP039366_K562--myelogenous-leukemia-_NR2C1_MACS_NR2C1_MA1535.1.damo.pwm.bed	4650
1	3056	NR2C2	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	NR2C2 VA13 (transformed lung fibroblasts) NR2C2	VA13 (transformed lung fibroblasts)	NULL	NR2C2		GEO	GSE46237_nr2c2_wi38va13_MACS_NR2C2_MA0504.1.damo.pwm.bed	1134
1	3061	NR2F1	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	NR2F1 H9-derived neural crest cells NR2F1	H9-derived neural crest cells	NULL	NR2F1	NA	GTRD	EXP030994_H9-derived-neural-crest-cells_NR2F1_MACS_NR2F1_MA1538.1.damo.pwm.bed	4292
1	3301	PRDM1	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	PRDM1 HUES64 (embryonic stem cells) PRDM1	HUES64 (embryonic stem cells)	NULL	PRDM1		GTRD	EXP036693_HUES64--embryonic-stem-cells-_PRDM1_MACS_PRDM1_MA0508.3.damo.pwm.bed	3638
1	3391	REST	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	REST GM12878 (female B-cells lymphoblastoid cell line) REST	GM12878 (female B-cells lymphoblastoid cell line)	NULL	REST		ENCODE	ENCSR000BGF_GM12878_REST_MACS_REST_MA0138.2.damo.pwm.bed	5824
1	3618	SOX2	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	SOX2 hiPSC SOX2	hiPSC	NULL	SOX2	KDP53_INHI	GEO	GSE67282_sox2_ipsc-kdp53-inhi_MACS_SOX2_MA0143.4.damo.pwm.bed	5053
1	3743	STAT3	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	STAT3 JB6 (Human anaplastic large cell lymphoma) STAT3	JB6 (Human anaplastic large cell lymphoma)	BTO:0004831	STAT3	Treatment: 300 nM Crizotinib for 3 hrs	GTRD	EXP053278_JB6--Human-anaplastic-large-cell-lymphoma-_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	601
1	3781	TCF12	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	TCF12 GM12878 (female B-cells lymphoblastoid cell line) TCF12	GM12878 (female B-cells lymphoblastoid cell line)	NULL	TCF12	NA	GTRD	EXP039314_GM12878--female-B-cells-_TCF12_MACS_TCF12_MA0521.1.damo.pwm.bed	3302
1	3782	TCF12	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	TCF12 GM12878 (female B-cells lymphoblastoid cell line) TCF12	GM12878 (female B-cells lymphoblastoid cell line)	NULL	TCF12	NA	GTRD	EXP039314_GM12878--female-B-cells-_TCF12_MACS_TCF12_MA1648.1.damo.pwm.bed	3332
1	3981	TP53	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	TP53 PHA-simulated human T-lynphocytes TP53	PHA-simulated human T-lynphocytes	NULL	TP53	Treatment: 10 uM Nutlin-3 for 24 hrs Source: healthy volunteer #90	GTRD	EXP048271_PHA-simulated-human-T-lynphocytes_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	3055
1	4066	TWIST1	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	TWIST1 SHEP-21N TWIST1	SHEP-21N	NA	TWIST1	DOX_24H	GEO	GSE80151_twist1_shep21-dox-24h_MACS_TWIST1_MA1123.2.damo.pwm.bed	2273
1	4100	VDR	0.307044240782383	1.52827912350267	3	1199	421	3316	3316	1650	2	201	205	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	EtOH for 24h	GTRD	EXP037994_THP-1--acute-monocytic-leukemia-_VDR_MACS_VDR_MA0693.2.damo.pwm.bed	3874
1	8	AR	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	NT	GTRD	EXP000723_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	1441
1	15	AR	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	AR metastatic prostate cancer tissue AR	metastatic prostate cancer tissue	NULL	AR	NULL	GTRD	EXP000738_metastatic-prostate-cancer-tissue_AR_MACS_AR_MA0007.3.damo.pwm.bed	5951
1	29	AR	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	BICALUTAMIDE	GTRD	EXP032864_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	3028
1	60	AR	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	NOV induced	GTRD	EXP037263_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	2249
1	69	AR	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: CaP cells were infected with EZH2 knockdown lentivirus and maintained for 2-3 days before fixation ,  ethanol,  knockout control Genotype: wildtype Source: prostate cancer cells	GTRD	EXP048074_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	3986
1	83	AR	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: exclude	GTRD	EXP049187_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	6307
1	85	AR	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: Ethanol for 4 hrs	GTRD	EXP049275_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	4164
1	126	AR	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR		GEO	GSE28950_AR_vcap_MACS_AR_MA0007.3.damo.pwm.bed	3623
1	137	AR	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	SHFOXA1_R1881_HD	GEO	GSE37345_AR_lncap-shfoxa1-r1881-hd_MACS_AR_MA0007.3.damo.pwm.bed	603
1	191	AR	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	SHFOXA1_PHFRPMIFCS	GEO	GSE69043_AR_lncap-shfoxa1-phfrpmifcs_MACS_AR_MA0007.3.damo.pwm.bed	778
1	289	BCL6B	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	BCL6B HEK293 (embryonic kidney) BCL6B	HEK293 (embryonic kidney)	NULL	BCL6B	NA	GTRD	EXP040074_HEK293--embryonic-kidney-_BCL6B_MACS_BCL6B_MA0731.1.damo.pwm.bed	1777
1	1002	DUX4	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	DUX4 LHCN-M2 (myoblasts) DUX4	LHCN-M2 (myoblasts)	BTO:0005046	DUX4	250 ng/ml doxycycline 6hrs	GTRD	EXP036164_LHCN-M2--myoblasts-_DUX4_MACS_DUX4_MA0468.1.damo.pwm.bed	9681
1	1049	E2F8	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	E2F8 MCF7 (Invasive ductal breast carcinoma) E2F8	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	E2F8	NA	GTRD	EXP040284_MCF7--Invasive-ductal-breast-carcinoma-_E2F8_MACS_E2F8_MA0865.1.damo.pwm.bed	386
1	1097	ELF4	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	ELF4 ELF4	NA	NA	ELF4	NA	GEO	GSE53357_elf4_t3m1_MACS_ELF4_MA0641.1.damo.pwm.bed	187
1	1170	ESR1	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	ESR1 ZR-75-1 (invasive ductal carcinoma) ESR1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	ESR1	E2_TAM	Array Express	ERP000380_esr1_zr751-e2-tam_MACS_ESR1_MA0112.3.damo.pwm.bed	6017
1	1239	ESR1	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	ESR1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) ESR1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	ESR1	White Medium	GTRD	EXP037776_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	7077
1	1278	ESR1	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GTRD	EXP038760_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	2949
1	1357	ESR1	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 10 nM Dexamethasone for 60 mins Genotype: ER+/PR+	GTRD	EXP049940_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	8382
1	1417	ESR1	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SHGATA3_E2	GEO	GSE60270_esr1_mcf7-shgata3-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	2489
1	1433	ESR1	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	E2	GEO	GSE72249_esr1_t47d-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	5326
1	1546	FOS	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	FOS THP-1 (acute monocytic leukemia) FOS	THP-1 (acute monocytic leukemia)	BTO:0001370	FOS	Treatment: untreated, eGFP(EP mRNA)	GTRD	EXP047823_THP-1--acute-monocytic-leukemia-_FOS_MACS_FOS_MA0099.3.damo.pwm.bed	1488
1	1547	FOS	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	FOS THP-1 (acute monocytic leukemia) FOS	THP-1 (acute monocytic leukemia)	BTO:0001370	FOS	Treatment: untreated, eGFP(EP mRNA)	GTRD	EXP047823_THP-1--acute-monocytic-leukemia-_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	1379
1	1548	FOS	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	FOS THP-1 (acute monocytic leukemia) FOS	THP-1 (acute monocytic leukemia)	BTO:0001370	FOS	Treatment: untreated, eGFP(EP mRNA)	GTRD	EXP047823_THP-1--acute-monocytic-leukemia-_FOS_MACS_FOS_MA1134.1.damo.pwm.bed	1395
1	1549	FOS	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	FOS THP-1 (acute monocytic leukemia) FOS	THP-1 (acute monocytic leukemia)	BTO:0001370	FOS	Treatment: untreated, eGFP(EP mRNA)	GTRD	EXP047823_THP-1--acute-monocytic-leukemia-_FOS_MACS_FOS_MA1141.1.damo.pwm.bed	1415
1	1654	FOXA1	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	FOXA1 CyT49-derived endodermal cells FOXA1	CyT49-derived endodermal cells	NULL	FOXA1	none	GTRD	EXP033206_CyT49-derived-endodermal-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	10034
1	1947	GATA2	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	GATA2 HUVEC-C (HUVEC, umbilical vein endothelial cells) GATA2	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	GATA2	Treatment: agent VEGF, timepoint 12 Passage: P3-6	GTRD	EXP048220_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	4900
1	1982	GATA3	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	GATA3 T47D (invasive ductal carcinoma) GATA3	T47D (invasive ductal carcinoma)	BTO:0001248	GATA3	Passsage: <10	GTRD	EXP049904_T47D--invasive-ductal-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	4722
1	2003	GATA3	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	GATA3 Jurkat (T-cells) GATA3	Jurkat (T-cells)	BTO:0000661	GATA3		GEO	GSE68976_gata3_jurkat_MACS_GATA3_MA0037.3.damo.pwm.bed	6813
1	2052	GFI1B	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	GFI1B CD34+ cells GFI1B	CD34+ cells	NULL	GFI1B		GEO	GSE52924_gfi1b_cd34_MACS_GFI1B_MA0483.1.damo.pwm.bed	2688
1	2142	HNF4A	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	HNF4A GP5d (colon adenocarcinoma) HNF4A	GP5d (colon adenocarcinoma)	NULL	HNF4A	SIRAD21	GEO	GSE51234_hnf4a_gp5d-sirad21_MACS_HNF4A_MA0114.4.damo.pwm.bed	1441
1	2175	HSF1	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	HSF1 MCF7 (Invasive ductal breast carcinoma) HSF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	HSF1		ENCODE	ENCSR062HDL_MCF-7_HSF1_MACS_HSF1_MA0486.2.damo.pwm.bed	319
1	2178	HSF1	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	HSF1 WA09 (embryonic stem cells) HSF1	WA09 (embryonic stem cells)	NULL	HSF1	Treatment: under heat shock conditions	GTRD	EXP047923_WA09--embryonic-stem-cells-_HSF1_MACS_HSF1_MA0486.2.damo.pwm.bed	1974
1	2180	HSF1	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	HSF1 BPLER (mammary epithelial cells) HSF1	BPLER (mammary epithelial cells)	NULL	HSF1		GEO	GSE38901_hsf1_bpler_MACS_HSF1_MA0486.2.damo.pwm.bed	939
1	2187	HSF1	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	HSF1 MCF7 (Invasive ductal breast carcinoma) HSF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	HSF1		GEO	GSE38901_hsf1_mcf7_MACS_HSF1_MA0486.2.damo.pwm.bed	821
1	2474	JUN	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	JUN BT-549 (breast invasive ductal carcinoma) JUN	BT-549 (breast invasive ductal carcinoma)	BTO:0002548	JUN		GEO	GSE71976_jun_bt549_MACS_JUN_MA0488.1.damo.pwm.bed	3138
1	2475	JUN	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	JUN BT-549 (breast invasive ductal carcinoma) JUN	BT-549 (breast invasive ductal carcinoma)	BTO:0002548	JUN		GEO	GSE71976_jun_bt549_MACS_JUN_MA0489.1.damo.pwm.bed	3024
1	2624	JUND	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	JUND hFOB 1.19 (fetal osteoblast) JUND	hFOB 1.19 (fetal osteoblast)	BTO:0005224	JUND	DIFF	GEO	GSE82295_jund_hfob-diff_MACS_JUND_MA0492.1.damo.pwm.bed	711
1	3074	NR2F2	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	NR2F2 H9-derived neural crest cells NR2F2	H9-derived neural crest cells	NULL	NR2F2		GTRD	EXP030995_H9-derived-neural-crest-cells_NR2F2_MACS_NR2F2_MA1111.1.damo.pwm.bed	2893
1	3126	NR3C1	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	NR3C1 MCF10A (breast epithelial cells) NR3C1	MCF10A (breast epithelial cells)	BTO:0001939	NR3C1	Treatment: untreated;	GTRD	EXP047624_MCF10A--breast-epithelial-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	4063
1	3133	NR3C1	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	NR3C1 MCF10A (breast epithelial cells) NR3C1	MCF10A (breast epithelial cells)	BTO:0001939	NR3C1	Treatment: EGF + DEX 20 min;	GTRD	EXP047631_MCF10A--breast-epithelial-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	3299
1	3147	NR3C1	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	NR3C1 monocytes of peripheral blood NR3C1	monocytes of peripheral blood	NULL	NR3C1	Treatment: treated with 1 micromolar (1uM) TA for 4 hours; Source: Adult Human Peripheral Blood; Donor:Buffycoat 12;	GTRD	EXP057900_monocytes-of-peripheral-blood_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	1019
1	3264	POU5F1	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	POU5F1 WA09 (embryonic stem cells) POU5F1	WA09 (embryonic stem cells)	NULL	POU5F1	Treatment: under heat shock conditions	GTRD	EXP047915_WA09--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	7316
1	3269	POU5F1	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	POU5F1 MRC-5 (fetal lung fibroblasts) POU5F1	MRC-5 (fetal lung fibroblasts)	BTO:0001590	POU5F1	Treatment: Oct4, Sox2, Klf4 and Myc addition for 5 days Passage: 8	GTRD	EXP048951_MRC-5--fetal-lung-fibroblasts-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	11369
1	3270	POU5F1	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	POU5F1 MRC-5 (fetal lung fibroblasts) POU5F1	MRC-5 (fetal lung fibroblasts)	BTO:0001590	POU5F1	Treatment: Oct4, Sox2, Klf4 and Myc addition for 5 days Passage: 8	GTRD	EXP048951_MRC-5--fetal-lung-fibroblasts-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	10333
1	3320	RARG	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	RARG RWPE1 (prostate epithelial cells) RARG	RWPE1 (prostate epithelial cells)	BTO:0003709	RARG	Treatment: 10 uM DMSO for 2 hr Gender: male Source: non-malignant prostate cell line infected with BAC-RARG-EGFP	GTRD	EXP048635_RWPE1--prostate-epithelial-cells-_RARG_MACS_RARG_MA1553.1.damo.pwm.bed	1522
1	3593	SOX2	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	SOX2 HUES64 (embryonic stem cells) SOX2	HUES64 (embryonic stem cells)	NULL	SOX2		GTRD	EXP032066_HUES64--embryonic-stem-cells-_SOX2_MACS_SOX2_MA0142.1.damo.pwm.bed	4670
1	3614	SOX2	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	SOX2 RENVM SOX2	RENVM	NA	SOX2	SHSOX2	GEO	GSE49404_sox2_renvm-shsox2_MACS_SOX2_MA0143.4.damo.pwm.bed	1985
1	3838	TEAD4	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	TEAD4 HCT-116 (colon carcinoma) TEAD4	HCT-116 (colon carcinoma)	BTO:0001109	TEAD4		ENCODE	ENCSR000BVJ_HCT116_TEAD4_MACS_TEAD4_MA0809.2.damo.pwm.bed	4173
1	4128	YY1	0.305822946051765	2.03618660689609	2	1227	229	3462	3462	1640	1	202	206	YY1 GM12878 (female B-cells lymphoblastoid cell line) YY1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	YY1		ENCODE	ENCSR000EUM_GM12878_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	650
1	9	AR	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	siERG	GTRD	EXP000725_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	2233
1	68	AR	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	AR MCF-7 C4-12 (invasive breast ductal carcinoma) AR	MCF-7 C4-12 (invasive breast ductal carcinoma)	NULL	AR	Female	GTRD	EXP040661_MCF-7-C4-12--invasive-breast-ductal-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	1516
1	157	AR	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	AR PC3(bone mets prostate adenocarcinoma) AR	PC3(bone mets prostate adenocarcinoma)	NULL	AR		GEO	GSE54110_AR_pc3_MACS_AR_MA0007.3.damo.pwm.bed	1553
1	177	AR	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	ETOH_SHCTR	GEO	GSE61268_AR_lncap-etoh-shctr_MACS_AR_MA0007.3.damo.pwm.bed	325
1	211	AR	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	DMSO	GEO	GSE83860_AR_lncap-dmso_MACS_AR_MA0007.3.damo.pwm.bed	663
1	994	CUX1	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	CUX1 GM12878 (female B-cells lymphoblastoid cell line) CUX1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	CUX1	NA	ENCODE	ENCSR000DYR_GM12878_CUX1_MACS_CUX1_MA0754.1.damo.pwm.bed	184
1	1048	E2F7	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	E2F7 K562 (myelogenous leukemia) E2F7	K562 (myelogenous leukemia)	NULL	E2F7	NA	GTRD	EXP039849_K562--myelogenous-leukemia-_E2F7_MACS_E2F7_MA0758.1.damo.pwm.bed	337
1	1075	EHF	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	EHF Calu-3 (lung adenocarcinoma) EHF	Calu-3 (lung adenocarcinoma)	BTO:0002750	EHF		GEO	GSE63398_ehf_calu3_MACS_EHF_MA0598.3.damo.pwm.bed	78
1	1167	ESR1	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	TAMR_TAM	Array Express	ERP000380_esr1_mcf7tamr-tam_MACS_ESR1_MA0112.3.damo.pwm.bed	1838
1	1168	ESR1	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	TAMR	Array Express	ERP000380_esr1_mcf7tamr_MACS_ESR1_MA0112.3.damo.pwm.bed	1682
1	1221	ESR1	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	ESR1 endometrioid adenocarcinoma ESR1	endometrioid adenocarcinoma	NULL	ESR1	tumor A	GTRD	EXP036408_endometrioid-adenocarcinoma_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	1706
1	1343	ESR1	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	CellSubtype: stable ESR1-PCDH11X fusion expressing model Treatment: Hormone-deprived media using RPMI1640 without phenol red and 10% charcoal-stripped FBS) for 5-7 days	GTRD	EXP048599_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	2300
1	1347	ESR1	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: DMSO for 45 min  Genotype: TET2 knockout Passage: 6-10	GTRD	EXP048687_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	1026
1	1412	ESR1	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GEO	GSE59530_esr1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	765
1	1895	GATA1	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	GATA1 erythroblasts GATA1	erythroblasts	NULL	GATA1		ENCODE	ENCSR000EXR_erythroblast_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	633
1	1922	GATA1	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	MYO1D Hub KO	GTRD	EXP040811_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	4753
1	1961	GATA3	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3		ENCODE	ENCSR000EWV_MCF-7_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	3208
1	1975	GATA3	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	GATA3 A1A3(breast cancer cells) GATA3	A1A3(breast cancer cells)	NULL	GATA3	Treatment: 1hr EtOH, PBS 72 hr CellLine: A1A3 from T47D cell line	GTRD	EXP048402_A1A3-breast-cancer-cells-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	4616
1	1998	GATA3	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3		GEO	GSE60270_gata3_mcf7_MACS_GATA3_MA0037.3.damo.pwm.bed	343
1	2001	GATA3	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	GATA3 NGP (neuroblastoma) GATA3	NGP (neuroblastoma)	NULL	GATA3		GEO	GSE65664_gata3_ngp_MACS_GATA3_MA0037.3.damo.pwm.bed	5086
1	2029	GATA6	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	GATA6 HUES64 (embryonic stem cells) GATA6	HUES64 (embryonic stem cells)	NULL	GATA6		GTRD	EXP036710_HUES64--embryonic-stem-cells-_GATA6_MACS_GATA6_MA1104.2.damo.pwm.bed	6531
1	2095	HIF1A	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	HIF1A HKC8 (kidney proximal tubule cell line) HIF1A	HKC8 (kidney proximal tubule cell line)	NULL	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 48 hours	GTRD	EXP048746_HKC8--kidney-proximal-tubule-cell-line-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	126
1	2649	KLF5	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	KLF5 AGS (gastric adenocarcinoma) KLF5	AGS (gastric adenocarcinoma)	BTO:0001007	KLF5		GEO	GSE51705_klf5_ags_MACS_KLF5_MA0599.1.damo.pwm.bed	498
1	2778	MYB	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	MYB MV-4-11 (Childhood acute monocytic leukemia) MYB	MV-4-11 (Childhood acute monocytic leukemia)	BTO:0004479	MYB	Treatment: TG3 control peptide	GTRD	EXP049402_MV4-11--childhood-acute-monocytic-leukemia-_MYB_MACS_MYB_MA0100.3.damo.pwm.bed	268
1	2925	MYC	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	MYC LS174T (colon adenocarcinoma) MYC	LS174T (colon adenocarcinoma)	BTO:0001553	MYC	DMSO	GEO	GSE59223_myc_ls174t-dmso_MACS_MYC_MA0147.3.damo.pwm.bed	387
1	3042	NR1H3	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	NR1H3 SGBS (Simpson Golabi Behmel syndrome type 1 adipocytes) NR1H3	SGBS (Simpson Golabi Behmel syndrome type 1 adipocytes)	NULL	NR1H3	NA	GEO	GSE41629_nr1h3_sgbs_MACS_NR1H3_MA0494.1.damo.pwm.bed	543
1	3241	POU2F1	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	POU2F1 LNCaP (prostate carcinoma) POU2F1	LNCaP (prostate carcinoma)	BTO:0001321	POU2F1	none	GTRD	EXP036097_LNCaP--prostate-carcinoma-_POU2F1_MACS_POU2F1_MA0785.1.damo.pwm.bed	946
1	3244	POU2F2	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	POU2F2 BJAB (Burkitt lymphoma) POU2F2	BJAB (Burkitt lymphoma)	BTO:0001931	POU2F2	BIRA_T223A	GEO	GSE79480_pou2f2_bjab-birA-t223a_MACS_POU2F2_MA0507.1.damo.pwm.bed	577
1	3245	POU2F2	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	POU2F2 BJAB (Burkitt lymphoma) POU2F2	BJAB (Burkitt lymphoma)	BTO:0001931	POU2F2	BIRA	GEO	GSE79480_pou2f2_bjab-birA_MACS_POU2F2_MA0507.1.damo.pwm.bed	462
1	3263	POU5F1	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	POU5F1 WA09 (embryonic stem cells) POU5F1	WA09 (embryonic stem cells)	NULL	POU5F1	Treatment: under heat shock conditions	GTRD	EXP047915_WA09--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	7724
1	3317	RARG	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	RARG RWPE1 (prostate epithelial cells) RARG	RWPE1 (prostate epithelial cells)	BTO:0003709	RARG	Treatment: 10 uM CD437 for 2 hr Gender: male Source: non-malignant prostate cell line infected with BAC-RARG-EGFP	GTRD	EXP048632_RWPE1--prostate-epithelial-cells-_RARG_MACS_RARG_MA0859.1.damo.pwm.bed	1102
1	3429	REST	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	REST CRC121 (colorectal cancer metastatic stem cells) REST	CRC121 (colorectal cancer metastatic stem cells)	NULL	REST	Source: organoid dissociation;	GTRD	EXP058087_CRC121--colorectal-cancer-metastatic-stem-cells-_REST_MACS_REST_MA0138.2.damo.pwm.bed	1784
1	3488	RUNX1	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	RUNX1 CCRF-CEM (T acute lymphoblastic leukemia) RUNX1	CCRF-CEM (T acute lymphoblastic leukemia)	BTO:0000736	RUNX1		GEO	GSE33850_runx1_ccrfcem_MACS_RUNX1_MA0002.2.damo.pwm.bed	280
1	3717	SRF	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	SRF HEL (Erythro Leukemia) SRF	HEL (Erythro Leukemia)	NULL	SRF	Treatment: Treated with 15nM TPA for 24 hours Source: HEL-iMKL1 cells	GTRD	EXP053076_HEL--Erythro-Leukemia-_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	1657
1	3821	TCF7L2	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	TCF7L2 MDA-MB-453 (breast adenocarcinoma) TCF7L2	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	TCF7L2	DHT	GEO	GSE45201_tcf7l2_mdamb453-dht_MACS_TCF7L2_MA0523.1.damo.pwm.bed	81
1	3891	TFAP2C	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p28; CellType: Prime UCLA1 hESSCs;	GTRD	EXP047538_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	84
1	3892	TFAP2C	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p28; CellType: Prime UCLA1 hESSCs;	GTRD	EXP047538_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	139
1	3893	TFAP2C	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p28; CellType: Prime UCLA1 hESSCs;	GTRD	EXP047538_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	205
1	3991	TP53	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	TP53 NCI-H460 (Large cell lung carcinoma) TP53	NCI-H460 (Large cell lung carcinoma)	BTO:0002207	TP53	Treatment: 4GY for 2hrs;	GTRD	EXP051020_NCI-H460--Large-cell-lung-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	1719
1	4038	TP63	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	TP63 tongue TP63	tongue	BTO:0001385	TP63	Source: Head and neck squamous cell carcinoma;	GTRD	EXP057764_tongue_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	994
1	4043	TP63	0.304211654450171	Inf	1	1276	1	3655	3655	1640	0	203	207	TP63 EP156T (primary prostate cells) TP63	EP156T (primary prostate cells)	NULL	TP63		GEO	GSE43111_tp63_ep156t_MACS_TP63_MA0525.2.damo.pwm.bed	4469
1	1076	ELF1	0.301323259380909	1.02217368886962	69	1317	1317	47	1317	894	69	135	138	ELF1 GM12878 (female B-cells lymphoblastoid cell line) ELF1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ELF1		ENCODE	ENCSR000BMB_GM12878_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	36841
1	297	BHLHE40	0.299728359742471	1.02169142752562	66	1318	1318	78	1318	905	66	138	141	BHLHE40 IMR90 (lung fibroblasts) BHLHE40	IMR90 (lung fibroblasts)	NULL	BHLHE40	NA	GTRD	EXP039939_IMR90--lung-fibroblasts-_BHLHE40_MACS_BHLHE40_MA0464.2.damo.pwm.bed	37168
1	2687	MAX	0.299728359742471	1.02169142752562	66	1318	1318	78	1318	905	66	138	141	MAX K562 (myelogenous leukemia) MAX	K562 (myelogenous leukemia)	NULL	MAX		ENCODE	ENCSR000BLP_K562_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	73610
1	3213	PAX5	0.298646601030499	1.02138140828024	64	1320	1320	95	1320	912	64	140	143	PAX5 GM12878 (female B-cells lymphoblastoid cell line) PAX5	GM12878 (female B-cells lymphoblastoid cell line)	NULL	PAX5		ENCODE	ENCSR000BHD_GM12878_PAX5_MACS_PAX5_MA0014.3.damo.pwm.bed	41397
1	3630	SP1	0.298099441669895	1.02122969841603	63	1321	1321	103	1321	915	63	141	144	SP1 HCT-116 (colon carcinoma) SP1	HCT-116 (colon carcinoma)	BTO:0001109	SP1		GTRD	EXP036142_HCT-116--colon-carcinoma-_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	13810
1	4074	USF1	0.297547746415157	1.02108012639102	62	1322	1322	118	1322	921	62	142	145	USF1 SK-N-SH (neuroblastoma) USF1	SK-N-SH (neuroblastoma)	BTO:0001620	USF1	6 μM all-trans-retinoic acid (CHEBI:15367) for 48 hour	ENCODE	ENCSR000BMF_SK-N-SH_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	45840
1	2697	MAX	0.296991239011449	1.02093264733205	61	1323	1323	127	1323	924	61	143	146	MAX HepG2 (hepatoblastoma) MAX	HepG2 (hepatoblastoma)	BTO:0000599	MAX		ENCODE	ENCSR000EDS_HepG2_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	22343
1	544	CTCF	0.296429630644335	1.02078721761304	60	1324	1324	137	1324	928	60	144	147	CTCF SK-N-SH (neuroblastoma) CTCF	SK-N-SH (neuroblastoma)	BTO:0001620	CTCF	6 μM all-trans-retinoic acid (CHEBI:15367) for 48 hour	ENCODE	ENCSR000DXQ_SK-N-SH_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	58517
1	626	CTCF	0.29412591310333	1.02022516090372	56	1325	1325	192	1325	947	56	148	151	CTCF HEK293 (embryonic kidney) CTCF	HEK293 (embryonic kidney)	NULL	CTCF		GTRD	EXP035951_HEK293--embryonic-kidney-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	52324
1	1344	ESR1	0.29412591310333	1.02022516090372	56	1325	1325	192	1325	947	56	148	151	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GTRD	EXP048609_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	99509
1	393	CEBPB	0.292328140775847	1.01982316931515	53	1327	1327	236	1327	963	53	151	154	CEBPB HEE (human epididymis epithelial cells) CEBPB	HEE (human epididymis epithelial cells)	NULL	CEBPB	Treatment: without treatment of R1881 (methyltrienolone)	GTRD	EXP048167_HEE--human-epididymis-epithelial-cells-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	82167
1	1680	FOXA1	0.292328140775847	1.01982316931515	53	1327	1327	236	1327	963	53	151	154	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	siERG	GTRD	EXP038436_VCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	151036
1	2872	MYC	0.291713444312251	1.0196927000121	52	1329	1329	244	1329	967	52	152	155	MYC NCI-H2171 (small cell lung carcinoma) MYC	NCI-H2171 (small cell lung carcinoma)	NULL	MYC	Treatment: Treatment withKL-1 or KL-2 inhibitors was administrated only once; Genotype: mutation by amplification of MYC;	GTRD	EXP047290_NCI-H2171--small-cell-lung-carcinoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	56690
1	3831	TEAD3	0.291713444312251	1.0196927000121	52	1329	1329	244	1329	967	52	152	155	TEAD3 HepG2 (hepatoblastoma) TEAD3	HepG2 (hepatoblastoma)	BTO:0000599	TEAD3	NA	GTRD	EXP040048_HepG2--hepatoblastoma-_TEAD3_MACS_TEAD3_MA0808.1.damo.pwm.bed	59658
1	3546	RXRA	0.291090282941081	1.01956393698205	51	1331	1331	261	1331	974	51	153	156	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP045021_liver_RXRA_MACS_RXRA_MA0512.2.damo.pwm.bed	50608
1	543	CTCF	0.290458168694941	1.01943684696969	50	1332	1332	275	1332	980	50	154	157	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DXI_bronchial_epithelial_cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	55364
1	1812	FOXA1	0.289816583017427	1.01931139757836	49	1333	1333	299	1333	988	49	155	158	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	DHT	GEO	GSE83860_foxa1_lncap-dht_MACS_FOXA1_MA0148.4.damo.pwm.bed	185046
1	908	CTCF	0.289164973950701	1.01918755724247	48	1334	1334	317	1334	995	48	156	159	CTCF CD20+ CTCF	CD20+	NULL	CTCF	Treatment: None;	GTRD	EXP054057_CD20-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	47818
1	366	CEBPB	0.288502753008213	1.01906529520101	47	1335	1335	333	1335	1000	47	157	160	CEBPB SUM159PT (Triple negative breast cancer) CEBPB	SUM159PT (Triple negative breast cancer)	NULL	CEBPB	300nM JQ1	GTRD	EXP037881_SUM159PT--pleiomorphic-breast-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	84027
1	3526	RXRA	0.287143917586382	1.01882538682854	45	1336	1336	383	1336	1020	45	159	162	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP040231_liver_RXRA_MACS_RXRA_MA1146.1.damo.pwm.bed	43203
1	775	CTCF	0.286445910023667	1.01870768277407	44	1337	1337	408	1337	1030	44	160	163	CTCF GM23338 CTCF	GM23338	NULL	CTCF		GTRD	EXP040082_GM23338_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	96946
1	1079	ELF1	0.286445910023667	1.01870768277407	44	1337	1337	408	1337	1030	44	160	163	ELF1 A549 (lung carcinoma) ELF1	A549 (lung carcinoma)	BTO:0000018	ELF1	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BPT_A549_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	12470
1	2775	MYB	0.286445910023667	1.01870768277407	44	1337	1337	408	1337	1030	44	160	163	MYB AML (monocytes and acute myeloid leukemia) MYB	AML (monocytes and acute myeloid leukemia)	NULL	MYB	Treatment: DMSo vehicle	GTRD	EXP049356_AML--monocytes-and-acute-myeloid-leukemia-_MYB_MACS_MYB_MA0100.3.damo.pwm.bed	35638
1	532	CTCF	0.284268048617785	1.01836323967719	41	1340	1340	476	1340	1050	41	163	166	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DVH_kidney_epithelial_cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54942
1	577	CTCF	0.284268048617785	1.01836323967719	41	1340	1340	476	1340	1050	41	163	166	CTCF lymphoblastoid cells CTCF	lymphoblastoid cells	NULL	CTCF	NULL	GTRD	EXP000776_lymphoblastoid-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	57566
1	923	CTCF	0.284268048617785	1.01836323967719	41	1340	1340	476	1340	1050	41	163	166	CTCF MCF7L-P(immortalized breast epithelial cell line) CTCF	MCF7L-P(immortalized breast epithelial cell line)	NULL	CTCF	Treatment: treated with E2 for 16 hrs;	GTRD	EXP057864_MCF7L-P-immortalized-breast-epithelial-cell-line-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	53000
1	1832	FOXA2	0.284268048617785	1.01836323967719	41	1340	1340	476	1340	1050	41	163	166	FOXA2 KerCT (keratenocytes) FOXA2	KerCT (keratenocytes)	NULL	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL	GTRD	EXP049289_KerCT--keratenocytes-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	112221
1	449	CTCF	0.281944747648143	1.01803125158747	38	1344	1344	576	1344	1090	38	166	169	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000ATN_CD14-positive_monocyte_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35404
1	2926	MYC	0.2811328675076	1.01792324060341	37	1345	1345	607	1345	1100	37	167	170	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	SHCTR	GEO	GSE60223_myc_p493-shctr_MACS_MYC_MA0147.3.damo.pwm.bed	13725
1	4075	USF1	0.2811328675076	1.01792324060341	37	1345	1345	607	1345	1100	37	167	170	USF1 A549 (lung carcinoma) USF1	A549 (lung carcinoma)	BTO:0000018	USF1	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BPV_A549_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	13288
1	542	CTCF	0.280300106460271	1.01781651599799	36	1347	1347	645	1347	1110	36	168	171	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DXD_epithelial_cell_of_proximal_tubule_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54704
1	2823	MYC	0.280300106460271	1.01781651599799	36	1347	1347	645	1347	1110	36	168	171	MYC Raji (Burkitt lymphoma) MYC	Raji (Burkitt lymphoma)	BTO:0001154	MYC	100 nM of JQ1	GTRD	EXP035850_Raji--Burkitt-lymphoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	10412
1	3081	NR2F6	0.280300106460271	1.01781651599799	36	1347	1347	645	1347	1110	36	168	171	NR2F6 HepG2 (hepatoblastoma) NR2F6	HepG2 (hepatoblastoma)	BTO:0000599	NR2F6	NA	GTRD	EXP039812_HepG2--hepatoblastoma-_NR2F6_MACS_NR2F6_MA0677.1.damo.pwm.bed	37608
1	716	CTCF	0.279444990326977	1.01771105492594	35	1350	1350	691	1350	1130	35	169	172	CTCF hepatocytes CTCF	hepatocytes	NULL	CTCF		GTRD	EXP039638_hepatocytes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45693
1	3012	NFIC	0.279444990326977	1.01771105492594	35	1350	1350	691	1350	1130	35	169	172	NFIC Ishikawa (endometrial adenocarcinoma) NFIC	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	NFIC	NA	ENCODE	ENCSR000BUT_Ishikawa_NFIC_MACS_NFIC_MA0161.2.damo.pwm.bed	35059
1	3193	OSR2	0.279444990326977	1.01771105492594	35	1350	1350	691	1350	1130	35	169	172	OSR2 HEK293 (embryonic kidney) OSR2	HEK293 (embryonic kidney)	NULL	OSR2	NA	GTRD	EXP035913_HEK293--embryonic-kidney-_OSR2_MACS_OSR2_MA1646.1.damo.pwm.bed	24856
1	1457	ETS1	0.278565903977645	1.01760683507979	34	1353	1353	729	1353	1140	34	170	173	ETS1 CD4+ CD25- T-cells ETS1	CD4+ CD25- T-cells	NULL	ETS1		GTRD	EXP032569_CD4--CD25--T-cells_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	11658
1	492	CTCF	0.277661072936731	1.01750383467412	33	1354	1354	778	1354	1160	33	171	174	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF		ENCODE	ENCSR000DPF_A549_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54615
1	514	CTCF	0.277661072936731	1.01750383467412	33	1354	1354	778	1354	1160	33	171	174	CTCF GM12875 (female B-cells) CTCF	GM12875 (female B-cells)	NULL	CTCF		ENCODE	ENCSR000DRU_GM12875_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40047
1	545	CTCF	0.277661072936731	1.01750383467412	33	1354	1354	778	1354	1160	33	171	174	CTCF WERI-Rb-1 (retinoblastoma) CTCF	WERI-Rb-1 (retinoblastoma)	BTO:0001178	CTCF		ENCODE	ENCSR000DXW_WERI-Rb-1_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	56123
1	1768	FOXA1	0.277661072936731	1.01750383467412	33	1354	1354	778	1354	1160	33	171	174	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	SIGATA	GEO	GSE40129_foxa1_mcf7-sigata_MACS_FOXA1_MA0148.4.damo.pwm.bed	105907
1	3207	OTX2	0.277661072936731	1.01750383467412	33	1354	1354	778	1354	1160	33	171	174	OTX2 D283 Med (medulloblastoma) OTX2	D283 Med (medulloblastoma)	NULL	OTX2	shGFP	GTRD	EXP038209_D283-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	113190
1	456	CTCF	0.2767285419572	1.01740203243037	32	1359	1359	825	1359	1180	32	172	175	CTCF SK-N-SH (neuroblastoma) CTCF	SK-N-SH (neuroblastoma)	BTO:0001620	CTCF	6 μM all-trans-retinoic acid (CHEBI:15367) for 48 hour	ENCODE	ENCSR000BLX_SK-N-SH_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	47999
1	589	CTCF	0.2767285419572	1.01740203243037	32	1359	1359	825	1359	1180	32	172	175	CTCF FB0167P (progeria fibroblasts) CTCF	FB0167P (progeria fibroblasts)	NULL	CTCF	NULL	GTRD	EXP001025_FB0167P--progeria-fibroblasts-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40258
1	680	CTCF	0.2767285419572	1.01740203243037	32	1359	1359	825	1359	1180	32	172	175	CTCF adrenal gland CTCF	adrenal gland	BTO:0000047	CTCF		GTRD	EXP039398_adrenal-gland_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35331
1	1831	FOXA2	0.2767285419572	1.01740203243037	32	1359	1359	825	1359	1180	32	172	175	FOXA2 HepG2 (hepatoblastoma) FOXA2	HepG2 (hepatoblastoma)	BTO:0000599	FOXA2		GTRD	EXP039957_HepG2--hepatoblastoma-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	64510
1	792	CTCF	0.275766149951175	1.01730140756217	31	1363	1363	881	1363	1200	31	173	176	CTCF SK-N-SH (neuroblastoma) CTCF	SK-N-SH (neuroblastoma)	BTO:0001620	CTCF		GTRD	EXP040246_SK-N-SH--neuroblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48218
1	1409	ESR1	0.275766149951175	1.01730140756217	31	1363	1363	881	1363	1200	31	173	176	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SHCTR_E2_TNF	GEO	GSE59530_esr1_mcf7-shctr-e2-tnf_MACS_ESR1_MA0112.3.damo.pwm.bed	30131
1	2598	JUND	0.275766149951175	1.01730140756217	31	1363	1363	881	1363	1200	31	173	176	JUND HepG2 (hepatoblastoma) JUND	HepG2 (hepatoblastoma)	BTO:0000599	JUND		ENCODE	ENCSR000EEI_HepG2_JUND_MACS_JUND_MA0492.1.damo.pwm.bed	79618
1	586	CTCF	0.274771500517762	1.01720193976124	30	1366	1366	937	1366	1220	30	174	177	CTCF HepG2 (hepatoblastoma) CTCF	HepG2 (hepatoblastoma)	BTO:0000599	CTCF	NULL	GTRD	EXP000992_HepG2--hepatoblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	57315
1	835	CTCF	0.274771500517762	1.01720193976124	30	1366	1366	937	1366	1220	30	174	177	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 120min	GTRD	EXP047802_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48052
1	911	CTCF	0.274771500517762	1.01720193976124	30	1366	1366	937	1366	1220	30	174	177	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	Treatment: 1 h with 100 nM Dexamethasone;	GTRD	EXP054084_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54719
1	1761	FOXA1	0.274771500517762	1.01720193976124	30	1366	1366	937	1366	1220	30	174	177	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	SHFOXA1_R1881	GEO	GSE37345_foxa1_lncap-shfoxa1-r1881_MACS_FOXA1_MA0148.4.damo.pwm.bed	74518
1	744	CTCF	0.273741927119318	1.01710360918368	29	1370	1370	1013	1370	1250	29	175	178	CTCF upper lobe of left lung CTCF	upper lobe of left lung	NULL	CTCF		GTRD	EXP039832_upper-lobe-of-left-lung_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	32256
1	820	CTCF	0.273741927119318	1.01710360918368	29	1370	1370	1013	1370	1250	29	175	178	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 0hr, IAV NS1(EP mRNA), siCtrl(siRNA)	GTRD	EXP047776_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41322
1	3929	TFAP2C	0.273656841144195	1.00385752702581	81	1372	1715	16	1715	1030	82	123	125	TFAP2C SK-BR-3 (breast adenocarcinoma) TFAP2C	SK-BR-3 (breast adenocarcinoma)	BTO:0002419	TFAP2C		GEO	GSE36351_tfap2c_skbr3_MACS_TFAP2C_MA0814.2.damo.pwm.bed	91147
1	435	CTCF	0.272674451712608	1.01700639643678	28	1373	1372	1068	1373	1270	28	176	179	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF		ENCODE	ENCSR000AKO_K562_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48698
1	874	CTCF	0.272674451712608	1.01700639643678	28	1373	1372	1068	1373	1270	28	176	179	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: no stress  Source: T47D whole cell	GTRD	EXP053041_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	47893
1	3792	TCF3	0.272674451712608	1.01700639643678	28	1373	1372	1068	1373	1270	28	176	179	TCF3 TCF3	NA	NA	TCF3	NA	GEO	GSE59538_TCF3_icn12_MACS_TCF3_MA0522.3.damo.pwm.bed	33348
1	3972	TP53	0.272674451712608	1.01700639643678	28	1373	1372	1068	1373	1270	28	176	179	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	Nutlin	GTRD	EXP037749_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	29663
1	600	CTCF	0.271565735322328	1.01691028256629	27	1377	1376	1135	1377	1300	27	177	180	CTCF normal lung fibroblasts CTCF	normal lung fibroblasts	NULL	CTCF		GTRD	EXP030406_normal-lung-fibroblasts_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37174
1	1706	FOXA1	0.271565735322328	1.01691028256629	27	1377	1376	1135	1377	1300	27	177	180	FOXA1 MCF7 WS8 cells FOXA1	MCF7 WS8 cells	NULL	FOXA1	Treatment: 45 min 10^-7 4OHT	GTRD	EXP048445_MCF7-WS8-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	45932
1	3430	REST	0.271565735322328	1.01691028256629	27	1377	1376	1135	1377	1300	27	177	180	REST CRC121 (colorectal cancer metastatic stem cells) REST	CRC121 (colorectal cancer metastatic stem cells)	NULL	REST	Source: organoid integrity;	GTRD	EXP058088_CRC121--colorectal-cancer-metastatic-stem-cells-_REST_MACS_REST_MA0138.2.damo.pwm.bed	11778
1	3532	RXRA	0.271565735322328	1.01691028256629	27	1377	1376	1135	1377	1300	27	177	180	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA WT	GTRD	EXP040815_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA1146.1.damo.pwm.bed	11588
1	4156	ZFX	0.271565735322328	1.01691028256629	27	1377	1376	1135	1377	1300	27	177	180	ZFX NOMO-1 (acute monocytic leukemia) ZFX	NOMO-1 (acute monocytic leukemia)	NULL	ZFX	NA	GEO	GSE43147_zfx_nomo1_MACS_ZFX_MA0146.2.damo.pwm.bed	6072
1	991	CTCFL	0.271492697186472	1.0027190808035	77	1382	1716	24	1716	1040	78	127	129	CTCFL K562 (myelogenous leukemia) CTCFL	K562 (myelogenous leukemia)	NULL	CTCFL	NA	GEO	GSE70764_ctcfl_k562_MACS_CTCFL_MA1102.2.damo.pwm.bed	30120
1	1493	FLI1	0.270412018624893	1.01681524904407	26	1383	1381	1204	1383	1320	26	178	181	FLI1 A-673 clone Asp114 (Ewing sarcoma) FLI1	A-673 clone Asp114 (Ewing sarcoma)	NULL	FLI1		GTRD	EXP047961_A-673-clone-Asp114--Ewing-sarcoma-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	24618
1	2036	GATA6	0.270412018624893	1.01681524904407	26	1383	1381	1204	1383	1320	26	178	181	GATA6 definitive endoderm from HUES8 GATA6	definitive endoderm from HUES8	NULL	GATA6	Genotype: SOX17-GFP knockout; Treatment: JNKi;	GTRD	EXP057922_definitive-endoderm-from-HUES8_GATA6_MACS_GATA6_MA1104.2.damo.pwm.bed	55840
1	2434	JUN	0.270412018624893	1.01681524904407	26	1383	1381	1204	1383	1320	26	178	181	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057912_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	34315
1	547	CTCF	0.269209050053664	1.01672127775622	25	1386	1384	1262	1386	1340	25	179	182	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF		ENCODE	ENCSR000DYD_A549_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40976
1	674	CTCF	0.269209050053664	1.01672127775622	25	1386	1384	1262	1386	1340	25	179	182	CTCF lower leg skin CTCF	lower leg skin	NULL	CTCF		GTRD	EXP039328_lower-leg-skin_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	15213
1	1339	ESR1	0.269209050053664	1.01672127775622	25	1386	1384	1262	1386	1340	25	179	182	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Tamoxifen	GTRD	EXP048585_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12291
1	3582	SNAI2	0.269209050053664	1.01672127775622	25	1386	1384	1262	1386	1340	25	179	182	SNAI2 keratinocytes SNAI2	keratinocytes	NULL	SNAI2	LacZ	GEO	GSE55421_snai2_keratinocytes-lacz_MACS_SNAI2_MA0745.2.damo.pwm.bed	22486
1	751	CTCF	0.267951998190407	1.01662835099151	24	1390	1388	1324	1390	1370	24	180	183	CTCF liver CTCF	liver	BTO:0000759	CTCF		GTRD	EXP039898_liver_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35118
1	822	CTCF	0.267951998190407	1.01662835099151	24	1390	1388	1324	1390	1370	24	180	183	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 7hr+Flavopiridol 3hr, IAV NS1(EP mRNA), siCtrl(siRNA)	GTRD	EXP047778_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34452
1	1914	GATA1	0.267951998190407	1.01662835099151	24	1390	1388	1324	1390	1370	24	180	183	GATA1 CD34+ hematopoietic stem cells-derived proerythroblasts GATA1	CD34+ hematopoietic stem cells-derived proerythroblasts	NULL	GATA1	adult bone marrow	GTRD	EXP031448_CD34--hematopoietic-stem-cells-derived-proerythroblasts_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	19672
1	2684	MAFK	0.267951998190407	1.01662835099151	24	1390	1388	1324	1390	1370	24	180	183	MAFK A549 (lung carcinoma) MAFK	A549 (lung carcinoma)	BTO:0000018	MAFK	NA	ENCODE	ENCSR541WQI_A549_MAFK_MACS_MAFK_MA0496.3.damo.pwm.bed	78790
1	529	CTCF	0.266635344196572	1.01653645143031	23	1394	1392	1391	1394	1390	23	181	184	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DUU_fibroblast_of_mammary_gland_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37332
1	745	CTCF	0.266635344196572	1.01653645143031	23	1394	1392	1391	1394	1390	23	181	184	CTCF LNCaP (prostate carcinoma) CTCF	LNCaP (prostate carcinoma)	BTO:0001321	CTCF		GTRD	EXP039840_LNCaP--prostate-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37017
1	1387	ESR1	0.266635344196572	1.01653645143031	23	1394	1392	1391	1394	1390	23	181	184	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SICTR_E2	GEO	GSE40129_esr1_mcf7-sictr-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	45216
1	1725	FOXA1	0.266635344196572	1.01653645143031	23	1394	1392	1391	1394	1390	23	181	184	FOXA1 22RV1 (prostate carcinoma) FOXA1	22RV1 (prostate carcinoma)	BTO:0002999	FOXA1	Treatment: Cells were harvested in log phase growth Genotype: knockdown HNF4G	GTRD	EXP048995_22RV1--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	43382
1	1915	GATA1	0.266635344196572	1.01653645143031	23	1394	1392	1391	1394	1390	23	181	184	GATA1 CD34+ hematopoietic stem cells-derived proerythroblasts GATA1	CD34+ hematopoietic stem cells-derived proerythroblasts	NULL	GATA1	adult bone marrow	GTRD	EXP031448_CD34--hematopoietic-stem-cells-derived-proerythroblasts_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	19906
1	3934	TFAP4	0.266302901226104	1	68	1399	1717	56	1717	1060	69	136	138	TFAP4 SNU175 (adenocarcinoma) TFAP4	SNU175 (adenocarcinoma)	NULL	TFAP4	NA	GTRD	EXP037552_SNU175--adenocarcinoma-_TFAP4_MACS_TFAP4_MA0691.1.damo.pwm.bed	50260
1	380	CEBPB	0.265252748652007	1.01644556213382	22	1400	1397	1459	1459	1420	22	182	185	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP040158_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	24104
1	447	CTCF	0.265252748652007	1.01644556213382	22	1400	1397	1459	1459	1420	22	182	185	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000APM_fibroblast_of_dermis_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36167
1	698	CTCF	0.265252748652007	1.01644556213382	22	1400	1397	1459	1459	1420	22	182	185	CTCF VCaP (prostate carcinoma) CTCF	VCaP (prostate carcinoma)	BTO:0003215	CTCF		GTRD	EXP039523_VCaP--prostate-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39202
1	721	CTCF	0.265252748652007	1.01644556213382	22	1400	1397	1459	1459	1420	22	182	185	CTCF transverse colon CTCF	transverse colon	NULL	CTCF		GTRD	EXP039677_transverse-colon_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29863
1	899	CTCF	0.265252748652007	1.01644556213382	22	1400	1397	1459	1459	1420	22	182	185	CTCF HMEC (human mammary epithelial cells) CTCF	HMEC (human mammary epithelial cells)	NULL	CTCF	Treatment: None;	GTRD	EXP054036_HMEC--human-mammary-epithelial-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	44084
1	1521	FOS	0.265252748652007	1.01644556213382	22	1400	1397	1459	1459	1420	22	182	185	FOS K562 (myelogenous leukemia) FOS	K562 (myelogenous leukemia)	NULL	FOS	NULL	GTRD	EXP000310_K562--myelogenous-leukemia-_FOS_MACS_FOS_MA0099.3.damo.pwm.bed	18319
1	2323	JUN	0.265252748652007	1.01644556213382	22	1400	1397	1459	1459	1420	22	182	185	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039869_A549--lung-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	12958
1	3065	NR2F1	0.265252748652007	1.01644556213382	22	1400	1397	1459	1459	1420	22	182	185	NR2F1 HepG2 (hepatoblastoma) NR2F1	HepG2 (hepatoblastoma)	BTO:0000599	NR2F1	NA	GTRD	EXP039919_HepG2--hepatoblastoma-_NR2F1_MACS_NR2F1_MA0017.2.damo.pwm.bed	20012
1	3529	RXRA	0.265252748652007	1.01644556213382	22	1400	1397	1459	1459	1420	22	182	185	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA WT	GTRD	EXP040815_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA0065.2.damo.pwm.bed	10567
1	3881	TFAP2C	0.265252748652007	1.01644556213382	22	1400	1397	1459	1459	1420	22	182	185	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions;	GTRD	EXP047534_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	9803
1	485	CTCF	0.263796885245471	1.01635566653362	21	1410	1407	1535	1535	1450	21	183	186	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	45 min with 100 nM Estradiol (Crawford)	ENCODE	ENCSR000DMS_MCF-7_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	47846
1	1019	E2F1	0.263796885245471	1.01635566653362	21	1410	1407	1535	1535	1450	21	183	186	E2F1 Raji (Burkitt lymphoma) E2F1	Raji (Burkitt lymphoma)	BTO:0001154	E2F1		GTRD	EXP035849_Raji--Burkitt-lymphoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	3952
1	3154	NR3C1	0.263796885245471	1.01635566653362	21	1410	1407	1535	1535	1450	21	183	186	NR3C1 U2OS (osteosarcoma) NR3C1	U2OS (osteosarcoma)	BTO:0001938	NR3C1	SHHIC5	GEO	GSE65847_nr3c1_u2os-shhic5_MACS_NR3C1_MA0113.3.damo.pwm.bed	50363
1	439	CTCF	0.262259231056209	1.01626674842163	20	1413	1410	1606	1606	1480	20	184	187	CTCF HepG2 (hepatoblastoma) CTCF	HepG2 (hepatoblastoma)	BTO:0000599	CTCF		ENCODE	ENCSR000AMA_HepG2_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46833
1	927	CTCF	0.262259231056209	1.01626674842163	20	1413	1410	1606	1606	1480	20	184	187	CTCF HEK293T (embryonic kidney) CTCF	HEK293T (embryonic kidney)	BTO:0002181	CTCF		GTRD	EXP058188_HEK293T--embryonic-kidney-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40898
1	1504	FLI1	0.262259231056209	1.01626674842163	20	1413	1410	1606	1606	1480	20	184	187	FLI1 HUVEC-C (HUVEC, umbilical vein endothelial cells) FLI1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FLI1		GTRD	EXP053002_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	15043
1	1713	FOXA1	0.262259231056209	1.01626674842163	20	1413	1410	1606	1606	1480	20	184	187	FOXA1 MCF7 WS8 cells FOXA1	MCF7 WS8 cells	NULL	FOXA1	Treatment: 45 min ethanol	GTRD	EXP048452_MCF7-WS8-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	32606
1	1744	FOXA1	0.262259231056209	1.01626674842163	20	1413	1410	1606	1606	1480	20	184	187	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	Treatment: hormone-deprived cells treated with vehicle;	GTRD	EXP058099_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	52782
1	2074	GRHL2	0.262259231056209	1.01626674842163	20	1413	1410	1606	1606	1480	20	184	187	GRHL2 PEO1 (ovarian cystadenocarcinoma) GRHL2	PEO1 (ovarian cystadenocarcinoma)	NULL	GRHL2		GEO	GSE71018_grhl2_peo1_MACS_GRHL2_MA1105.2.damo.pwm.bed	16801
1	663	CTCF	0.260629799305241	1.01617879194038	19	1419	1416	1697	1697	1510	19	185	188	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF		GTRD	EXP038267_K562--myelogenous-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	26460
1	1981	GATA3	0.260629799305241	1.01617879194038	19	1419	1416	1697	1697	1510	19	185	188	GATA3 T47D (invasive ductal carcinoma) GATA3	T47D (invasive ductal carcinoma)	BTO:0001248	GATA3	Passsage: <10 Genotype: wt/R330fs mutant with CRISPR	GTRD	EXP049899_T47D--invasive-ductal-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	36388
1	2043	GATA6	0.260629799305241	1.01617879194038	19	1419	1416	1697	1697	1510	19	185	188	GATA6 YCC3 (gastric adenocarcinoma) GATA6	YCC3 (gastric adenocarcinoma)	NULL	GATA6		GEO	GSE51705_gata6_ycc3_MACS_GATA6_MA1104.2.damo.pwm.bed	25884
1	3197	OTX2	0.260629799305241	1.01617879194038	19	1419	1416	1697	1697	1510	19	185	188	OTX2 HUES64 (embryonic stem cells) OTX2	HUES64 (embryonic stem cells)	NULL	OTX2		GTRD	EXP036800_HUES64--embryonic-stem-cells-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	23736
1	3506	RUNX2	0.260503765970686	0.996903978777009	59	1423	1718	143	1718	1090	60	145	147	RUNX2 MCF7 (Invasive ductal breast carcinoma) RUNX2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RUNX2	Full Medium + Doxycycline	GTRD	EXP037781_MCF7--Invasive-ductal-breast-carcinoma-_RUNX2_MACS_RUNX2_MA0511.2.damo.pwm.bed	43261
1	2054	GLIS1	0.259105800306886	0.996138713515149	57	1424	1719	174	1719	1110	58	147	149	GLIS1 HEK293 (embryonic kidney) GLIS1	HEK293 (embryonic kidney)	NULL	GLIS1	NA	GTRD	EXP039340_HEK293--embryonic-kidney-_GLIS1_MACS_GLIS1_MA0735.1.damo.pwm.bed	35774
1	844	CTCF	0.258896794856675	1.01609178157355	18	1425	1420	1785	1785	1540	18	186	189	CTCF MDM(monocyte derived macrophages) CTCF	MDM(monocyte derived macrophages)	NULL	CTCF	Treatment: H5N1-dNS1 IAV infected 6hr	GTRD	EXP047827_MDM-monocyte-derived-macrophages-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30621
1	1326	ESR1	0.258896794856675	1.01609178157355	18	1425	1420	1785	1785	1540	18	186	189	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 500nM RAD001 2hr; Passage: p22;	GTRD	EXP047709_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	26762
1	1709	FOXA1	0.258896794856675	1.01609178157355	18	1425	1420	1785	1785	1540	18	186	189	FOXA1 MCF7 WS8 cells FOXA1	MCF7 WS8 cells	NULL	FOXA1	Treatment: 45 min 10^-8 E2	GTRD	EXP048448_MCF7-WS8-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	31428
1	2133	HNF4A	0.258896794856675	1.01609178157355	18	1425	1420	1785	1785	1540	18	186	189	HNF4A HUES64 (embryonic stem cells) HNF4A	HUES64 (embryonic stem cells)	NULL	HNF4A		GTRD	EXP036796_HUES64--embryonic-stem-cells-_HNF4A_MACS_HNF4A_MA1494.1.damo.pwm.bed	18146
1	3031	NFYB	0.258896794856675	1.01609178157355	18	1425	1420	1785	1785	1540	18	186	189	NFYB HeLa S3 (cervical adenocarcinoma) NFYB	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	NFYB	NA	ENCODE	ENCSR000DNR_HeLa-S3_NFYB_MACS_NFYB_MA0502.2.damo.pwm.bed	6481
1	3235	PKNOX1	0.258896794856675	1.01609178157355	18	1425	1420	1785	1785	1540	18	186	189	PKNOX1 K562 (myelogenous leukemia) PKNOX1	K562 (myelogenous leukemia)	NULL	PKNOX1	NA	ENCODE	ENCSR115SMW_K562_PKNOX1_MACS_PKNOX1_MA0782.2.damo.pwm.bed	27587
1	3634	SP1	0.257659972180349	0.995337081738122	55	1431	1720	211	1720	1120	56	149	151	SP1 HUES64 (embryonic stem cells) SP1	HUES64 (embryonic stem cells)	NULL	SP1		GTRD	EXP036810_HUES64--embryonic-stem-cells-_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	12324
1	3935	TFAP4	0.257659972180349	0.995337081738122	55	1431	1720	211	1720	1120	56	149	151	TFAP4 SNU175 (adenocarcinoma) TFAP4	SNU175 (adenocarcinoma)	NULL	TFAP4	NA	GTRD	EXP037552_SNU175--adenocarcinoma-_TFAP4_MACS_TFAP4_MA1570.1.damo.pwm.bed	44386
1	1265	ESR1	0.257046164488285	1.01600570213687	17	1433	1426	1846	1846	1570	17	187	190	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP038378_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	33120
1	1267	ESR1	0.257046164488285	1.01600570213687	17	1433	1426	1846	1846	1570	17	187	190	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Doxycycline + E2	GTRD	EXP038380_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	39448
1	1475	ETV1	0.257046164488285	1.01600570213687	17	1433	1426	1846	1846	1570	17	187	190	ETV1 A375 (malignant melanoma) ETV1	A375 (malignant melanoma)	BTO:0002806	ETV1	Treatment: cells were harvested in log phase growth	GTRD	EXP048911_A375--malignant-melanoma-_ETV1_MACS_ETV1_MA0761.2.damo.pwm.bed	7705
1	2172	HOXB13	0.257046164488285	1.01600570213687	17	1433	1426	1846	1846	1570	17	187	190	HOXB13 LNCaP (prostate carcinoma) HOXB13	LNCaP (prostate carcinoma)	BTO:0001321	HOXB13		GEO	GSE56288_hoxb13_lncap_MACS_HOXB13_MA0901.2.damo.pwm.bed	49240
1	3580	SNAI2	0.257046164488285	1.01600570213687	17	1433	1426	1846	1846	1570	17	187	190	SNAI2 HUES64 (embryonic stem cells) SNAI2	HUES64 (embryonic stem cells)	NULL	SNAI2		GTRD	EXP036746_HUES64--embryonic-stem-cells-_SNAI2_MACS_SNAI2_MA0745.2.damo.pwm.bed	5748
1	3878	TFAP2C	0.257046164488285	1.01600570213687	17	1433	1426	1846	1846	1570	17	187	190	TFAP2C WA09 (embryonic stem cells) TFAP2C	WA09 (embryonic stem cells)	NULL	TFAP2C	BMP4 for 3 day	GTRD	EXP040713_WA09--embryonic-stem-cells-_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	21103
1	3943	TFE3	0.256917703886421	0.994921155595445	54	1439	1722	225	1722	1130	55	150	152	TFE3 HepG2 (hepatoblastoma) TFE3	HepG2 (hepatoblastoma)	BTO:0000599	TFE3	NA	GTRD	EXP040043_HepG2--hepatoblastoma-_TFE3_MACS_TFE3_MA0831.2.damo.pwm.bed	28555
1	94	AR	0.255061001524133	1.01592053876926	16	1440	1432	1909	1909	1590	16	188	191	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: 10 nM DHT for 6 hrs TF: full-length AR (AR-FL)	GTRD	EXP049391_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	40383
1	764	CTCF	0.255061001524133	1.01592053876926	16	1440	1432	1909	1909	1590	16	188	191	CTCF right atrium auricular region CTCF	right atrium auricular region	NULL	CTCF		GTRD	EXP040028_right-atrium-auricular-region_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	18372
1	2433	JUN	0.255061001524133	1.01592053876926	16	1440	1432	1909	1909	1590	16	188	191	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057912_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	22379
1	2973	NEUROG2	0.255061001524133	1.01592053876926	16	1440	1432	1909	1909	1590	16	188	191	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	1 DPT	GTRD	EXP037149_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	21813
1	3281	POU5F1	0.255061001524133	1.01592053876926	16	1440	1432	1909	1909	1590	16	188	191	POU5F1 hESC-1 (Embryonic stem cells) POU5F1	hESC-1 (Embryonic stem cells)	NULL	POU5F1	PRIMED	GEO	GSE69646_pou5f1_esc-primed_MACS_POU5F1_MA1115.1.damo.pwm.bed	17960
1	3741	STAT3	0.255061001524133	1.01592053876926	16	1440	1432	1909	1909	1590	16	188	191	STAT3 AGS (gastric adenocarcinoma) STAT3	AGS (gastric adenocarcinoma)	BTO:0001007	STAT3		GTRD	EXP048899_AGS--gastric-adenocarcinoma-_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	5908
1	2812	MYC	0.253804652187479	0.993140680513669	50	1446	1723	275	1723	1150	51	154	156	MYC K562 (myelogenous leukemia) MYC	K562 (myelogenous leukemia)	NULL	MYC	NULL	GTRD	EXP000994_K562--myelogenous-leukemia-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	16161
1	1478	ETV1	0.252986782183531	0.992662407955799	49	1447	1724	299	1724	1160	50	155	157	ETV1 LNCaP (prostate carcinoma) ETV1	LNCaP (prostate carcinoma)	BTO:0001321	ETV1		GEO	GSE47120_etv1_lncap_MACS_ETV1_MA0761.2.damo.pwm.bed	20714
1	1290	ESR1	0.252920745329136	1.01583627692433	15	1448	1438	1993	1993	1630	15	189	192	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Tam-Responsive	GTRD	EXP038794_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	41609
1	1336	ESR1	0.252920745329136	1.01583627692433	15	1448	1438	1993	1993	1630	15	189	192	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Rad1901	GTRD	EXP048582_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12118
1	1573	FOSL2	0.252920745329136	1.01583627692433	15	1448	1438	1993	1993	1630	15	189	192	FOSL2 MCF7 (Invasive ductal breast carcinoma) FOSL2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOSL2		ENCODE	ENCSR000BUI_MCF-7_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	24619
1	2132	HNF4A	0.252920745329136	1.01583627692433	15	1448	1438	1993	1993	1630	15	189	192	HNF4A HUES64 (embryonic stem cells) HNF4A	HUES64 (embryonic stem cells)	NULL	HNF4A		GTRD	EXP036796_HUES64--embryonic-stem-cells-_HNF4A_MACS_HNF4A_MA0114.4.damo.pwm.bed	15473
1	3067	NR2F1	0.252920745329136	1.01583627692433	15	1448	1438	1993	1993	1630	15	189	192	NR2F1 HepG2 (hepatoblastoma) NR2F1	HepG2 (hepatoblastoma)	BTO:0000599	NR2F1	NA	GTRD	EXP039919_HepG2--hepatoblastoma-_NR2F1_MACS_NR2F1_MA1538.1.damo.pwm.bed	15204
1	4085	USF2	0.252920745329136	1.01583627692433	15	1448	1438	1993	1993	1630	15	189	192	USF2 A549 (lung carcinoma) USF2	A549 (lung carcinoma)	BTO:0000018	USF2		ENCODE	ENCSR563FBT_A549_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	8159
1	242	ATF2	0.250600086129908	1.015752902362	14	1454	1444	2073	2073	1660	14	190	193	ATF2 K562 (myelogenous leukemia) ATF2	K562 (myelogenous leukemia)	NULL	ATF2	NA	GTRD	EXP039995_K562--myelogenous-leukemia-_ATF2_MACS_ATF2_MA1632.1.damo.pwm.bed	43248
1	261	ATF4	0.250600086129908	1.015752902362	14	1454	1444	2073	2073	1660	14	190	193	ATF4 K562 (myelogenous leukemia) ATF4	K562 (myelogenous leukemia)	NULL	ATF4		GTRD	EXP040245_K562--myelogenous-leukemia-_ATF4_MACS_ATF4_MA0833.2.damo.pwm.bed	35842
1	323	CEBPA	0.250600086129908	1.015752902362	14	1454	1444	2073	2073	1660	14	190	193	CEBPA SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) CEBPA	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	CEBPA	Treatment: estradiol; Genotype: inducible version of CEBPA (C/EBPalpha-ER);	GTRD	EXP047669_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	10812
1	1118	ERG	0.250600086129908	1.015752902362	14	1454	1444	2073	2073	1660	14	190	193	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	NT	GTRD	EXP000724_VCaP--prostate-carcinoma-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	6799
1	1261	ESR1	0.250600086129908	1.015752902362	14	1454	1444	2073	2073	1660	14	190	193	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Doxycycline	GTRD	EXP038374_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	30537
1	1322	ESR1	0.250600086129908	1.015752902362	14	1454	1444	2073	2073	1660	14	190	193	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: vehicle(DMSO 2 hr); Passage: p21;	GTRD	EXP047705_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	24114
1	1784	FOXA1	0.250600086129908	1.015752902362	14	1454	1444	2073	2073	1660	14	190	193	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	E2_TNF	GEO	GSE59530_foxa1_mcf7-e2-tnf_MACS_FOXA1_MA0148.4.damo.pwm.bed	28399
1	2328	JUN	0.250600086129908	1.015752902362	14	1454	1444	2073	2073	1660	14	190	193	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 10 minute	GTRD	EXP040248_A549--lung-carcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	17962
1	2365	JUN	0.250600086129908	1.015752902362	14	1454	1444	2073	2073	1660	14	190	193	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: 17beta estradiol 10nM for 1hr;	GTRD	EXP047660_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	16234
1	1477	ETV1	0.250424787237059	0.991133006509294	46	1463	1725	349	1725	1180	47	158	160	ETV1 GIST ETV1	GIST	NA	ETV1		GEO	GSE22441_etv1_gist_MACS_ETV1_MA0761.2.damo.pwm.bed	18622
1	392	CEBPB	0.249531446699377	0.990587955623325	45	1464	1726	383	1726	1190	46	159	161	CEBPB HEE (human epididymis epithelial cells) CEBPB	HEE (human epididymis epithelial cells)	NULL	CEBPB	Treatment: treatment of 1 nM R1881 (methyltrienolone) for 12 -16 hr	GTRD	EXP048166_HEE--human-epididymis-epithelial-cells-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	86302
1	503	CTCF	0.248067437113846	1.01567040114059	13	1465	1453	2153	2153	1690	13	191	194	CTCF GM12801 (male B-cells) CTCF	GM12801 (male B-cells)	NULL	CTCF		ENCODE	ENCSR000DQY_GM12801_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	21229
1	754	CTCF	0.248067437113846	1.01567040114059	13	1465	1453	2153	2153	1690	13	191	194	CTCF breast epithelial cells CTCF	breast epithelial cells	NULL	CTCF		GTRD	EXP039952_breast-epithelial-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	15441
1	936	CTCF	0.248067437113846	1.01567040114059	13	1465	1453	2153	2153	1690	13	191	194	CTCF BJAB (Burkitt lymphoma) CTCF	BJAB (Burkitt lymphoma)	BTO:0001931	CTCF		GEO	GSE31485_ctcf_bjab_MACS_CTCF_MA0139.1.damo.pwm.bed	23098
1	1774	FOXA1	0.248067437113846	1.01567040114059	13	1465	1453	2153	2153	1690	13	191	194	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1		GEO	GSE52725_foxa1_lncap_MACS_FOXA1_MA0148.4.damo.pwm.bed	40719
1	2125	HNF4A	0.248067437113846	1.01567040114059	13	1465	1453	2153	2153	1690	13	191	194	HNF4A HepG2 (hepatoblastoma) HNF4A	HepG2 (hepatoblastoma)	BTO:0000599	HNF4A	NULL	GTRD	EXP000306_HepG2--hepatoblastoma-_HNF4A_MACS_HNF4A_MA1494.1.damo.pwm.bed	17270
1	2375	JUN	0.248067437113846	1.01567040114059	13	1465	1453	2153	2153	1690	13	191	194	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: tamoxifen 1μM for 1hr;	GTRD	EXP047661_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	15997
1	2506	JUNB	0.248067437113846	1.01567040114059	13	1465	1453	2153	2153	1690	13	191	194	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039540_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	18139
1	3105	NR3C1	0.248067437113846	1.01567040114059	13	1465	1453	2153	2153	1690	13	191	194	NR3C1 MCF7 (Invasive ductal breast carcinoma) NR3C1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NR3C1	ICI, DEX	GTRD	EXP037448_MCF7--Invasive-ductal-breast-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	28242
1	3669	SPI1	0.248067437113846	1.01567040114059	13	1465	1453	2153	2153	1690	13	191	194	SPI1 GM12878 (female B-cells lymphoblastoid cell line) SPI1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	SPI1	Characteristic: robotic ChIP-seq;	GTRD	EXP054624_GM12878--female-B-cells-lymphoblastoid-cell-line-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	39336
1	4091	USF2	0.248067437113846	1.01567040114059	13	1465	1453	2153	2153	1690	13	191	194	USF2 K562 (myelogenous leukemia) USF2	K562 (myelogenous leukemia)	NULL	USF2	Treatment: no	GTRD	EXP048312_K562--myelogenous-leukemia-_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	4553
1	799	CTCF	0.24767922377516	0.989437235745409	43	1475	1727	429	1727	1210	44	161	163	CTCF foreskin keratinocyte CTCF	foreskin keratinocyte	NULL	CTCF		GTRD	EXP040282_foreskin-keratinocyte_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	60376
1	882	CTCF	0.24767922377516	0.989437235745409	43	1475	1727	429	1727	1210	44	161	163	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: triploide, no stress  Source: T47D whole cell	GTRD	EXP053049_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34971
1	1458	ETS1	0.24767922377516	0.989437235745409	43	1475	1727	429	1727	1210	44	161	163	ETS1 RCC 7860 (Renal cell carcinoma) ETS1	RCC 7860 (Renal cell carcinoma)	BTO:0003781	ETS1		GTRD	EXP037740_786-O--renal-carcinoma-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	18438
1	2715	MAX	0.246717877800318	0.988828573535333	42	1478	1730	454	1730	1220	43	162	164	MAX P493-6 (B-cell lymphoma) MAX	P493-6 (B-cell lymphoma)	BTO:0003291	MAX	CMYC_1H	GEO	GSE36354_max_p493-cmyc-1h_MACS_MAX_MA0058.3.damo.pwm.bed	16594
1	4165	ZNF263	0.246266529873731	0.986237556723115	88	1479	1737	5	1737	1070	90	116	117	ZNF263 HEK293 (embryonic kidney) ZNF263	HEK293 (embryonic kidney)	NULL	ZNF263	NA	ENCODE	ENCSR000EVD_HEK293_ZNF263_MACS_ZNF263_MA0528.2.damo.pwm.bed	95450
1	1149	ERG	0.245731240506993	0.988195480361089	41	1480	1731	476	1731	1230	42	163	165	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	DHT	GEO	GSE79128_erg_vcap-dht_MACS_ERG_MA0474.2.damo.pwm.bed	15614
1	1364	ESR1	0.245282755040335	1.01558875960897	12	1481	1463	2233	2233	1730	12	192	195	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 10 nM Estradiol for 45 mins Genotype: ER+/PR+	GTRD	EXP049950_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	7185
1	1422	ESR1	0.245282755040335	1.01558875960897	12	1481	1463	2233	2233	1730	12	192	195	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	PROG	GEO	GSE68355_ESR1_t47d-prog_MACS_ESR1_MA0112.3.damo.pwm.bed	18511
1	1737	FOXA1	0.245282755040335	1.01558875960897	12	1481	1463	2233	2233	1730	12	192	195	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	Treatment: FA (control)	GTRD	EXP053226_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	31696
1	2663	LHX9	0.245282755040335	1.01558875960897	12	1481	1463	2233	2233	1730	12	192	195	LHX9 HCT-116 (colon carcinoma) LHX9	HCT-116 (colon carcinoma)	BTO:0001109	LHX9	Genotype:Expressing LHX9-V5 open reading frame and shKRAS Tissue: colon	GTRD	EXP053274_HCT-116--colon-carcinoma-_LHX9_MACS_LHX9_MA0701.2.damo.pwm.bed	14265
1	3120	NR3C1	0.245282755040335	1.01558875960897	12	1481	1463	2233	2233	1730	12	192	195	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 25 minute	GTRD	EXP040271_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	22096
1	3816	TCF7L2	0.245282755040335	1.01558875960897	12	1481	1463	2233	2233	1730	12	192	195	TCF7L2 HUES64 (embryonic stem cells) TCF7L2	HUES64 (embryonic stem cells)	NULL	TCF7L2		GTRD	EXP036765_HUES64--embryonic-stem-cells-_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	8539
1	724	CTCF	0.244717826212823	0.987536082870707	40	1487	1732	502	1732	1240	41	164	166	CTCF bipolar neuron CTCF	bipolar neuron	NULL	CTCF	0.5 μg/mL doxycycline hyclate (CHEBI:34730) for 4 day	GTRD	EXP039689_bipolar-neuron_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	58024
1	900	CTCF	0.244717826212823	0.987536082870707	40	1487	1732	502	1732	1240	41	164	166	CTCF NHDF-Ad (adult dermal fibroblasts) CTCF	NHDF-Ad (adult dermal fibroblasts)	NULL	CTCF	Treatment: None;	GTRD	EXP054037_NHDF-Ad--adult-dermal-fibroblasts-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54702
1	3075	NR2F2	0.244717826212823	0.987536082870707	40	1487	1732	502	1732	1240	41	164	166	NR2F2 liver NR2F2	liver	BTO:0000759	NR2F2		GTRD	EXP039783_liver_NR2F2_MACS_NR2F2_MA1111.1.damo.pwm.bed	31337
1	3236	PKNOX1	0.244717826212823	0.987536082870707	40	1487	1732	502	1732	1240	41	164	166	PKNOX1 GM12878 (female B-cells lymphoblastoid cell line) PKNOX1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	PKNOX1	NA	GTRD	EXP039329_GM12878--female-B-cells-_PKNOX1_MACS_PKNOX1_MA0782.2.damo.pwm.bed	32796
1	1645	FOXA1	0.243676027825681	0.986848322464932	39	1491	1736	547	1736	1260	40	165	167	FOXA1 FOXA1	NA	NA	FOXA1	NA	Array Express	ERP003828_foxa1_lncap_MACS_FOXA1_MA0148.4.damo.pwm.bed	132324
1	3930	TFAP2C	0.243671276833006	0.984574686725631	83	1492	1746	11	1746	1080	85	121	122	TFAP2C SK-BR-3 (breast adenocarcinoma) TFAP2C	SK-BR-3 (breast adenocarcinoma)	BTO:0002419	TFAP2C		GEO	GSE36351_tfap2c_skbr3_MACS_TFAP2C_MA0815.1.damo.pwm.bed	92490
1	3932	TFAP2C	0.243133442545775	0.984226843755232	82	1493	1747	13	1747	1080	84	122	123	TFAP2C A375 (malignant melanoma) TFAP2C	A375 (malignant melanoma)	BTO:0002806	TFAP2C	DMSO	GEO	GSE41234_tfap2c_a375-dmso_MACS_TFAP2C_MA0814.2.damo.pwm.bed	64172
1	490	CTCF	0.242604103487868	0.986129931478038	38	1494	1738	576	1738	1270	39	166	168	CTCF pancreas CTCF	pancreas	BTO:0000988	CTCF		ENCODE	ENCSR000DND_pancreas_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42176
1	1228	ESR1	0.242604103487868	0.986129931478038	38	1494	1738	576	1738	1270	39	166	168	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2 for 45m	GTRD	EXP036981_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	53037
1	30	AR	0.242194351686653	1.01550796439903	11	1496	1469	2332	2332	1770	11	193	196	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Vehicle	GTRD	EXP032866_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	28284
1	233	ASCL1	0.242194351686653	1.01550796439903	11	1496	1469	2332	2332	1770	11	193	196	ASCL1 SCLC ASCL1	SCLC	NA	ASCL1	ASCLP_NE	GEO	GSE61197_ascl1_sclc-asclp-ne_MACS_ASCL1_MA1100.2.damo.pwm.bed	9966
1	259	ATF4	0.242194351686653	1.01550796439903	11	1496	1469	2332	2332	1770	11	193	196	ATF4 HAP1 (chronic myelogenous leukemia) ATF4	HAP1 (chronic myelogenous leukemia)	NULL	ATF4	2 mM histidinol, 24 hours	GTRD	EXP035035_HAP1--chronic-myelogenous-leukemia-_ATF4_MACS_ATF4_MA0833.2.damo.pwm.bed	36758
1	668	CTCF	0.242194351686653	1.01550796439903	11	1496	1469	2332	2332	1770	11	193	196	CTCF MCF10CA1a (breast metastatic epithelial cells) CTCF	MCF10CA1a (breast metastatic epithelial cells)	NULL	CTCF		GTRD	EXP038625_MCF10CA1a--breast-metastatic-epithelial-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31583
1	870	CTCF	0.242194351686653	1.01550796439903	11	1496	1469	2332	2332	1770	11	193	196	CTCF HUES64 (embryonic stem cells) CTCF	HUES64 (embryonic stem cells)	NULL	CTCF	Genotype: wildtype	GTRD	EXP049756_HUES64--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29994
1	1616	FOSL2	0.242194351686653	1.01550796439903	11	1496	1469	2332	2332	1770	11	193	196	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2		GTRD	EXP040159_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	11846
1	1617	FOSL2	0.242194351686653	1.01550796439903	11	1496	1469	2332	2332	1770	11	193	196	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2		GTRD	EXP040159_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	12162
1	1618	FOSL2	0.242194351686653	1.01550796439903	11	1496	1469	2332	2332	1770	11	193	196	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2		GTRD	EXP040159_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	12298
1	1619	FOSL2	0.242194351686653	1.01550796439903	11	1496	1469	2332	2332	1770	11	193	196	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2		GTRD	EXP040159_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	12590
1	1756	FOXA1	0.242194351686653	1.01550796439903	11	1496	1469	2332	2332	1770	11	193	196	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	DHT	GEO	GSE28264_foxa1_lncap-dht_MACS_FOXA1_MA0148.4.damo.pwm.bed	46187
1	1952	GATA2	0.242194351686653	1.01550796439903	11	1496	1469	2332	2332	1770	11	193	196	GATA2 CD34+ cells GATA2	CD34+ cells	NULL	GATA2	ACY957	GEO	GSE60792_gata2_cd34-acy957_MACS_GATA2_MA0036.3.damo.pwm.bed	23910
1	2141	HNF4A	0.242194351686653	1.01550796439903	11	1496	1469	2332	2332	1770	11	193	196	HNF4A Caco-2 (colon adenocarcinoma) HNF4A	Caco-2 (colon adenocarcinoma)	BTO:0000195	HNF4A	PROLIF	GEO	GSE23436_hnf4a_caco2-prolif_MACS_HNF4A_MA0114.4.damo.pwm.bed	12193
1	2377	JUN	0.242194351686653	1.01550796439903	11	1496	1469	2332	2332	1770	11	193	196	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: tamoxifen 1μM for 1hr;	GTRD	EXP047661_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	15951
1	2930	MYC	0.242194351686653	1.01550796439903	11	1496	1469	2332	2332	1770	11	193	196	MYC HFF (foreskin fibroblast) MYC	HFF (foreskin fibroblast)	NULL	MYC	OHT	GEO	GSE65544_myc_hff-oht_MACS_MYC_MA0147.3.damo.pwm.bed	4199
1	549	CTCF	0.241500161373604	0.985378405599529	37	1510	1740	607	1740	1290	38	167	169	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF		ENCODE	ENCSR000EGM_K562_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	51514
1	989	CTCFL	0.241500161373604	0.985378405599529	37	1510	1740	607	1740	1290	38	167	169	CTCFL K562 (myelogenous leukemia) CTCFL	K562 (myelogenous leukemia)	NULL	CTCFL	NA	ENCODE	ENCSR000BNK_K562_CTCFL_MACS_CTCFL_MA1102.2.damo.pwm.bed	21216
1	1673	FOXA1	0.241500161373604	0.985378405599529	37	1510	1740	607	1740	1290	38	167	169	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	BYL719	GTRD	EXP037593_T47D--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	75821
1	669	CTCF	0.240362142328717	0.98459097182533	36	1513	1743	645	1743	1300	37	168	170	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		GTRD	EXP038767_MCF7--Invasive-ductal-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49563
1	3072	NR2F2	0.240362142328717	0.98459097182533	36	1513	1743	645	1743	1300	37	168	170	NR2F2 MCF7 (Invasive ductal breast carcinoma) NR2F2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NR2F2		ENCODE	ENCSR000BUY_MCF-7_NR2F2_MACS_NR2F2_MA1111.1.damo.pwm.bed	44802
1	3143	NR3C1	0.240362142328717	0.98459097182533	36	1513	1743	645	1743	1300	37	168	170	NR3C1 HASM2 (Human airway smooth muscle 2) NR3C1	HASM2 (Human airway smooth muscle 2)	NULL	NR3C1	Treatment: dexamethasone for 4 hr Genotype: Ad-KLF15 transduction	GTRD	EXP049658_HASM2--Human-airway-smooth-muscle-2-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	47058
1	471	CTCF	0.239757716963671	0.982010457064887	76	1516	1756	26	1756	1100	78	128	129	CTCF GM19240 (B cells Lymphoblastoid Cell Lines) CTCF	GM19240 (B cells Lymphoblastoid Cell Lines)	NULL	CTCF		ENCODE	ENCSR000DLF_GM19240_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	84690
1	353	CEBPB	0.239187799979151	0.983764551068948	35	1517	1748	691	1748	1320	36	169	171	CEBPB MCF7 (Invasive ductal breast carcinoma) CEBPB	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CEBPB		ENCODE	ENCSR000BSR_MCF-7_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	57975
1	513	CTCF	0.239187799979151	0.983764551068948	35	1517	1748	691	1748	1320	36	169	171	CTCF GM12874 (male B-cells) CTCF	GM12874 (male B-cells)	NULL	CTCF		ENCODE	ENCSR000DRR_GM12874_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42119
1	1452	ETS1	0.239187799979151	0.983764551068948	35	1517	1748	691	1748	1320	36	169	171	ETS1 Jurkat E6.1 (T-cells) ETS1	Jurkat E6.1 (T-cells)	BTO:0001948	ETS1	NULL	GTRD	EXP000299_Jurkat-E6.1--T-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	16072
1	198	AR	0.238734089970556	1.01542800241845	10	1520	1483	2442	2442	1820	10	194	197	AR AR	NA	NA	AR	NA	GEO	GSE71704_AR_c42_MACS_AR_MA0007.3.damo.pwm.bed	11087
1	1022	E2F1	0.238734089970556	1.01542800241845	10	1520	1483	2442	2442	1820	10	194	197	E2F1 K562 (myelogenous leukemia) E2F1	K562 (myelogenous leukemia)	NULL	E2F1		GTRD	EXP039542_K562--myelogenous-leukemia-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	2705
1	1066	EGR1	0.238734089970556	1.01542800241845	10	1520	1483	2442	2442	1820	10	194	197	EGR1 liver EGR1	liver	BTO:0000759	EGR1		GTRD	EXP045317_liver_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	6083
1	1274	ESR1	0.238734089970556	1.01542800241845	10	1520	1483	2442	2442	1820	10	194	197	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP038387_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	21980
1	1657	FOXA1	0.238734089970556	1.01542800241845	10	1520	1483	2442	2442	1820	10	194	197	FOXA1 CyT49-derived endodermal cells FOXA1	CyT49-derived endodermal cells	NULL	FOXA1	none	GTRD	EXP033209_CyT49-derived-endodermal-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	24766
1	1806	FOXA1	0.238734089970556	1.01542800241845	10	1520	1483	2442	2442	1820	10	194	197	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1		GEO	GSE72249_foxa1_t47d_MACS_FOXA1_MA0148.4.damo.pwm.bed	24079
1	2396	JUN	0.238734089970556	1.01542800241845	10	1520	1483	2442	2442	1820	10	194	197	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048211_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	8636
1	2397	JUN	0.238734089970556	1.01542800241845	10	1520	1483	2442	2442	1820	10	194	197	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048211_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	8235
1	2398	JUN	0.238734089970556	1.01542800241845	10	1520	1483	2442	2442	1820	10	194	197	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048211_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	8158
1	2402	JUN	0.238734089970556	1.01542800241845	10	1520	1483	2442	2442	1820	10	194	197	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048211_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	7746
1	2403	JUN	0.238734089970556	1.01542800241845	10	1520	1483	2442	2442	1820	10	194	197	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048211_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	8558
1	2623	JUND	0.238734089970556	1.01542800241845	10	1520	1483	2442	2442	1820	10	194	197	JUND HT29 (colon adenocarcinoma) JUND	HT29 (colon adenocarcinoma)	BTO:0000182	JUND	DSMO	GEO	GSE77039_jund_ht29-dsmo_MACS_JUND_MA0491.2.damo.pwm.bed	11616
1	2929	MYC	0.238734089970556	1.01542800241845	10	1520	1483	2442	2442	1820	10	194	197	MYC HFF (foreskin fibroblast) MYC	HFF (foreskin fibroblast)	NULL	MYC	OHT_SHBPTF	GEO	GSE65544_myc_hff-oht-shbptf_MACS_MYC_MA0147.3.damo.pwm.bed	3617
1	3375	RELA	0.238734089970556	1.01542800241845	10	1520	1483	2442	2442	1820	10	194	197	RELA HUVEC-C (HUVEC, umbilical vein endothelial cells) RELA	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	RELA	TNF	GEO	GSE43070_rela_huvec-tnf_MACS_RELA_MA0107.1.damo.pwm.bed	6568
1	3773	TBX5	0.238734089970556	1.01542800241845	10	1520	1483	2442	2442	1820	10	194	197	TBX5 iPSC-derived cardiomyocytes TBX5	iPSC-derived cardiomyocytes	NULL	TBX5		GTRD	EXP037715_iPSC-derived-cardiomyocytes_TBX5_MACS_TBX5_MA0807.1.damo.pwm.bed	10142
1	322	CEBPA	0.237974677858058	0.982895714364348	34	1535	1751	729	1751	1340	35	170	172	CEBPA HepG2 (hepatoblastoma) CEBPA	HepG2 (hepatoblastoma)	BTO:0000599	CEBPA		GTRD	EXP040183_HepG2--hepatoblastoma-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	47349
1	455	CTCF	0.237974677858058	0.982895714364348	34	1535	1751	729	1751	1340	35	170	172	CTCF HepG2 (hepatoblastoma) CTCF	HepG2 (hepatoblastoma)	BTO:0000599	CTCF		ENCODE	ENCSR000BIE_HepG2_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	56292
1	967	CTCF	0.237974677858058	0.982895714364348	34	1535	1751	729	1751	1340	35	170	172	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF	MESEN_STEM	GEO	GSE52457_ctcf_h1-mesen-stem_MACS_CTCF_MA0139.1.damo.pwm.bed	43159
1	1891	GABPA	0.237974677858058	0.982895714364348	34	1535	1751	729	1751	1340	35	170	172	GABPA HepG2 (hepatoblastoma) GABPA	HepG2 (hepatoblastoma)	BTO:0000599	GABPA		GEO	GSE72082_GABPA_hepg2_MACS_GABPA_MA0062.3.damo.pwm.bed	13578
1	2822	MYC	0.237974677858058	0.982895714364348	34	1535	1751	729	1751	1340	35	170	172	MYC Raji (Burkitt lymphoma) MYC	Raji (Burkitt lymphoma)	BTO:0001154	MYC	100 nM of JQ1	GTRD	EXP035850_Raji--Burkitt-lymphoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	9509
1	3311	RARA	0.236720083005992	0.981980631340876	33	1540	1757	778	1757	1360	34	171	173	RARA HepG2 (hepatoblastoma) RARA	HepG2 (hepatoblastoma)	BTO:0000599	RARA		GTRD	EXP039479_HepG2--hepatoblastoma-_RARA_MACS_RARA_MA1149.1.damo.pwm.bed	41628
1	32	AR	0.235421055379758	0.981015009330616	32	1541	1758	825	1758	1370	33	172	174	AR HEK293 (embryonic kidney) AR	HEK293 (embryonic kidney)	NULL	AR	10 nM R1881	GTRD	EXP032871_HEK293--embryonic-kidney-_AR_MACS_AR_MA0007.3.damo.pwm.bed	85213
1	525	CTCF	0.235421055379758	0.981015009330616	32	1541	1758	825	1758	1370	33	172	174	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DUH_foreskin_fibroblast_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42484
1	696	CTCF	0.235421055379758	0.981015009330616	32	1541	1758	825	1758	1370	33	172	174	CTCF epithelial cell of prostate CTCF	epithelial cell of prostate	NULL	CTCF		GTRD	EXP039487_epithelial-cell-of-prostate_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	44953
1	839	CTCF	0.235421055379758	0.981015009330616	32	1541	1758	825	1758	1370	33	172	174	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment:  Flavopiridol 240min	GTRD	EXP047806_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54699
1	3851	TFAP2A	0.235421055379758	0.981015009330616	32	1541	1758	825	1758	1370	33	172	174	TFAP2A MCF7 (Invasive ductal breast carcinoma) TFAP2A	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2A		GTRD	EXP032577_MCF7--Invasive-ductal-breast-carcinoma-_TFAP2A_MACS_TFAP2A_MA0810.1.damo.pwm.bed	36549
1	37	AR	0.234809893757327	1.01534886084355	9	1546	1498	2564	2564	1870	9	195	198	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	10 nmol/l of mibolerone	GTRD	EXP033419_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	37783
1	207	AR	0.234809893757327	1.01534886084355	9	1546	1498	2564	2564	1870	9	195	198	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	SH2_R1881	GEO	GSE79128_AR_vcap-sh2-r1881_MACS_AR_MA0007.3.damo.pwm.bed	25393
1	1288	ESR1	0.234809893757327	1.01534886084355	9	1546	1498	2564	2564	1870	9	195	198	ESR1 BT-474 (breast invasive ductal carcinoma) ESR1	BT-474 (breast invasive ductal carcinoma)	BTO:0001932	ESR1	Tam-Resist	GTRD	EXP038791_BT-474--breast-invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	19237
1	1353	ESR1	0.234809893757327	1.01534886084355	9	1546	1498	2564	2564	1870	9	195	198	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	Passsage: <10	GTRD	EXP049893_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	10420
1	1604	FOSL2	0.234809893757327	1.01534886084355	9	1546	1498	2564	2564	1870	9	195	198	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039757_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	10801
1	1605	FOSL2	0.234809893757327	1.01534886084355	9	1546	1498	2564	2564	1870	9	195	198	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039757_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	11047
1	1606	FOSL2	0.234809893757327	1.01534886084355	9	1546	1498	2564	2564	1870	9	195	198	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039757_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	10994
1	1607	FOSL2	0.234809893757327	1.01534886084355	9	1546	1498	2564	2564	1870	9	195	198	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039757_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	10955
1	1935	GATA2	0.234809893757327	1.01534886084355	9	1546	1498	2564	2564	1870	9	195	198	GATA2 HUVEC-C (HUVEC, umbilical vein endothelial cells) GATA2	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	GATA2	NULL	GTRD	EXP000673_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	20017
1	2130	HNF4A	0.234809893757327	1.01534886084355	9	1546	1498	2564	2564	1870	9	195	198	HNF4A HUES64 (embryonic stem cells) HNF4A	HUES64 (embryonic stem cells)	NULL	HNF4A		GTRD	EXP036715_HUES64--embryonic-stem-cells-_HNF4A_MACS_HNF4A_MA0114.4.damo.pwm.bed	4110
1	3046	NR2C1	0.234809893757327	1.01534886084355	9	1546	1498	2564	2564	1870	9	195	198	NR2C1 GM12878 (female B-cells lymphoblastoid cell line) NR2C1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	NR2C1	NA	GTRD	EXP039607_GM12878--female-B-cells-_NR2C1_MACS_NR2C1_MA1535.1.damo.pwm.bed	3085
1	3416	REST	0.234809893757327	1.01534886084355	9	1546	1498	2564	2564	1870	9	195	198	REST A549 (lung carcinoma) REST	A549 (lung carcinoma)	BTO:0000018	REST		GTRD	EXP036865_A549--lung-carcinoma-_REST_MACS_REST_MA0138.2.damo.pwm.bed	5807
1	3777	TBX5	0.234809893757327	1.01534886084355	9	1546	1498	2564	2564	1870	9	195	198	TBX5 iPSC-derived cardiomyocytes TBX5	iPSC-derived cardiomyocytes	NULL	TBX5	G296S mutant	GTRD	EXP037725_iPSC-derived-cardiomyocytes_TBX5_MACS_TBX5_MA0807.1.damo.pwm.bed	10937
1	4163	ZNF143	0.234124971126983	0.978149151012716	67	1559	1768	68	1768	1130	69	137	138	ZNF143 MCF7 (Invasive ductal breast carcinoma) ZNF143	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ZNF143	E2	GEO	GSE76454_znf143_mcf7-e2_MACS_ZNF143_MA0088.2.damo.pwm.bed	40933
1	3296	PPARG	0.234074332256312	0.979994021058569	31	1560	1763	881	1763	1400	32	173	175	PPARG HepG2 (hepatoblastoma) PPARG	HepG2 (hepatoblastoma)	BTO:0000599	PPARG		GTRD	EXP039615_HepG2--hepatoblastoma-_PPARG_MACS_PPARG_MA0066.1.damo.pwm.bed	33202
1	829	CTCF	0.232676306629596	0.97891221833711	30	1561	1764	937	1764	1420	31	174	176	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: untreated	GTRD	EXP047796_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	51409
1	859	CTCF	0.232676306629596	0.97891221833711	30	1561	1764	937	1764	1420	31	174	176	CTCF LUHMES (lund human mesencephalic cells) CTCF	LUHMES (lund human mesencephalic cells)	NULL	CTCF	Sex: female Passages: 3-10 Stage: dopaminergic neurons, differentiated Treatment: For induction of differentiation, culture medium was changed to freshly prepare DMEM:F12 with 2 mM L-glutamine, 1X N-2, 1 mM cAMP (Carbosynth, Cat # ND07996), 1 mg/mL tetracycline (Sigma, Cat # T7660), and 2 ng/mL glial cell line-derived neurotrophic factor (GDNF) (Sigma, Cat # G1777)	GTRD	EXP048230_LUHMES--lund-human-mesencephalic-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39746
1	983	CTCF	0.232676306629596	0.97891221833711	30	1561	1764	937	1764	1420	31	174	176	CTCF SK-N-SH (neuroblastoma) CTCF	SK-N-SH (neuroblastoma)	BTO:0001620	CTCF		GEO	GSE76815_ctcf_sknsh_MACS_CTCF_MA0139.1.damo.pwm.bed	37228
1	1868	GABPA	0.232676306629596	0.97891221833711	30	1561	1764	937	1764	1420	31	174	176	GABPA HeLa S3 (cervical adenocarcinoma) GABPA	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	GABPA		ENCODE	ENCSR000BHS_HeLa-S3_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	8010
1	459	CTCF	0.231222978358495	0.977763428498372	29	1565	1769	1013	1769	1450	30	175	177	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF		ENCODE	ENCSR000BPJ_K562_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	47386
1	2593	JUND	0.231222978358495	0.977763428498372	29	1565	1769	1013	1769	1450	30	175	177	JUND K562 (myelogenous leukemia) JUND	K562 (myelogenous leukemia)	NULL	JUND		ENCODE	ENCSR000DJX_K562_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	32681
1	133	AR	0.23029358386458	1.01527052711247	8	1567	1511	2697	2697	1920	8	196	199	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	R1881_1C30	GEO	GSE32892_AR_vcap-r1881-1c30_MACS_AR_MA0007.3.damo.pwm.bed	20833
1	220	ARNT	0.23029358386458	1.01527052711247	8	1567	1511	2697	2697	1920	8	196	199	ARNT GM12878 (female B-cells lymphoblastoid cell line) ARNT	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ARNT		GTRD	EXP040302_GM12878--female-B-cells-_ARNT_MACS_ARNT_MA0004.1.damo.pwm.bed	3902
1	221	ARNT	0.23029358386458	1.01527052711247	8	1567	1511	2697	2697	1920	8	196	199	ARNT GM12878 (female B-cells lymphoblastoid cell line) ARNT	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ARNT		GTRD	EXP040302_GM12878--female-B-cells-_ARNT_MACS_ARNT_MA0006.1.damo.pwm.bed	3751
1	976	CTCF	0.23029358386458	1.01527052711247	8	1567	1511	2697	2697	1920	8	196	199	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	2D3	GEO	GSE69962_ctcf_thp1-2d3_MACS_CTCF_MA0139.1.damo.pwm.bed	7179
1	1268	ESR1	0.23029358386458	1.01527052711247	8	1567	1511	2697	2697	1920	8	196	199	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	E2	GTRD	EXP038381_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	14884
1	2020	GATA4	0.23029358386458	1.01527052711247	8	1567	1511	2697	2697	1920	8	196	199	GATA4 iPSC-derived cardiomyocytes GATA4	iPSC-derived cardiomyocytes	NULL	GATA4	G296S mutant	GTRD	EXP037724_iPSC-derived-cardiomyocytes_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	11181
1	2057	GRHL2	0.23029358386458	1.01527052711247	8	1567	1511	2697	2697	1920	8	196	199	GRHL2 LNCaP (prostate carcinoma) GRHL2	LNCaP (prostate carcinoma)	BTO:0001321	GRHL2		GTRD	EXP037342_LNCaP--prostate-carcinoma-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	10213
1	2216	ISL1	0.23029358386458	1.01527052711247	8	1567	1511	2697	2697	1920	8	196	199	ISL1 BE2C ISL1	BE2C	NULL	ISL1	Treatment: untreated	GTRD	EXP049483_BE2C_ISL1_MACS_ISL1_MA1608.1.damo.pwm.bed	33509
1	2528	JUNB	0.23029358386458	1.01527052711247	8	1567	1511	2697	2697	1920	8	196	199	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039831_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	9282
1	2530	JUNB	0.23029358386458	1.01527052711247	8	1567	1511	2697	2697	1920	8	196	199	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039831_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	9136
1	2532	JUNB	0.23029358386458	1.01527052711247	8	1567	1511	2697	2697	1920	8	196	199	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039831_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	9407
1	2533	JUNB	0.23029358386458	1.01527052711247	8	1567	1511	2697	2697	1920	8	196	199	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039831_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	9448
1	2534	JUNB	0.23029358386458	1.01527052711247	8	1567	1511	2697	2697	1920	8	196	199	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039831_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	8947
1	2669	MAF	0.23029358386458	1.01527052711247	8	1567	1511	2697	2697	1920	8	196	199	MAF Th17-cells MAF	Th17-cells	BTO:0005655	MAF	CellType:pool of expanded Th17 clones; Tissue: primary Th17-IL-10+ lymphocytes; ActivationState: recently activeted;Day:5;	GTRD	EXP047561_Th17-cells_MAF_MACS_MAF_MA0501.1.damo.pwm.bed	6191
1	2676	MAFF	0.23029358386458	1.01527052711247	8	1567	1511	2697	2697	1920	8	196	199	MAFF MAFF	NA	NA	MAFF	NA	NA	ENCSR237YZZ_GM12878_MAFF_MACS_MAFF_MA0495.3.damo.pwm.bed	4387
1	2967	NEUROG2	0.23029358386458	1.01527052711247	8	1567	1511	2697	2697	1920	8	196	199	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	0.5 DPT	GTRD	EXP037146_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	14372
1	3038	NKX2-5	0.23029358386458	1.01527052711247	8	1567	1511	2697	2697	1920	8	196	199	NKX2-5 BGO3 (embryonic stem cells) NKX2-5	BGO3 (embryonic stem cells)	NULL	NKX2-5	Treatment: no	GTRD	EXP049256_BGO3--embryonic-stem-cells-_NKX2-5_MACS_NKX2-5_MA0503.1.damo.pwm.bed	9492
1	3454	RUNX1	0.23029358386458	1.01527052711247	8	1567	1511	2697	2697	1920	8	196	199	RUNX1 CMK (acute megakaryoblastic leukemia) RUNX1	CMK (acute megakaryoblastic leukemia)	BTO:0000978	RUNX1		GTRD	EXP000583_CMK--acute-megakaryoblastic-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	11920
1	4083	USF2	0.23029358386458	1.01527052711247	8	1567	1511	2697	2697	1920	8	196	199	USF2 K562 (myelogenous leukemia) USF2	K562 (myelogenous leukemia)	NULL	USF2		ENCODE	ENCSR000EHG_K562_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	3176
1	1120	ERG	0.229889029322602	0.975077872043156	61	1586	1779	127	1779	1160	63	143	144	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	regular medium	GTRD	EXP000734_VCaP--prostate-carcinoma-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	41638
1	410	CEBPG	0.229709896517152	0.976540629397103	28	1587	1771	1068	1771	1480	29	176	178	CEBPG HepG2 (hepatoblastoma) CEBPG	HepG2 (hepatoblastoma)	BTO:0000599	CEBPG	NA	GTRD	EXP039427_HepG2--hepatoblastoma-_CEBPG_MACS_CEBPG_MA1636.1.damo.pwm.bed	35091
1	590	CTCF	0.229709896517152	0.976540629397103	28	1587	1771	1068	1771	1480	29	176	178	CTCF D54 (H54, Human glioblastoma) CTCF	D54 (H54, Human glioblastoma)	NULL	CTCF	NULL	GTRD	EXP001027_D54--glioblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	50994
1	796	CTCF	0.229709896517152	0.976540629397103	28	1587	1771	1068	1771	1480	29	176	178	CTCF A673 (Ewing sarcoma) CTCF	A673 (Ewing sarcoma)	BTO:0003768	CTCF		GTRD	EXP040257_A673--Ewing-sarcoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48974
1	1732	FOXA1	0.229709896517152	0.976540629397103	28	1587	1771	1068	1771	1480	29	176	178	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	Passsage: <10 Genotype: wt/R330fs mutant with CRISPR	GTRD	EXP049903_T47D--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	50363
1	3586	SNAI2	0.229709896517152	0.976540629397103	28	1587	1771	1068	1771	1480	29	176	178	SNAI2 keratinocytes SNAI2	keratinocytes	NULL	SNAI2	SNAI2	GEO	GSE55421_snai2_keratinocytes-snai2_MACS_SNAI2_MA0745.2.damo.pwm.bed	12093
1	677	CTCF	0.228132091002674	0.975235797625589	27	1592	1776	1135	1776	1500	28	177	179	CTCF esophagus muscularis mucosa CTCF	esophagus muscularis mucosa	NULL	CTCF		GTRD	EXP039379_esophagus-muscularis-mucosa_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27434
1	985	CTCF	0.228132091002674	0.975235797625589	27	1592	1776	1135	1776	1500	28	177	179	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	HYPOXIA	GEO	GSE78113_ctcf_mcf7-hypoxia_MACS_CTCF_MA0139.1.damo.pwm.bed	42817
1	1523	FOS	0.228132091002674	0.975235797625589	27	1592	1776	1135	1776	1500	28	177	179	FOS K562 (myelogenous leukemia) FOS	K562 (myelogenous leukemia)	NULL	FOS	NULL	GTRD	EXP000310_K562--myelogenous-leukemia-_FOS_MACS_FOS_MA1134.1.damo.pwm.bed	21500
1	572	CTCF	0.22759257084799	0.97334386002134	58	1595	1783	154	1783	1180	60	146	147	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF	NULL	GTRD	EXP000596_WA01--H1--human-embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	78373
1	526	CTCF	0.226483990939864	0.973839722994364	26	1596	1780	1204	1780	1530	27	178	180	CTCF HFF-Myc (fetal fibroblasts) CTCF	HFF-Myc (fetal fibroblasts)	NULL	CTCF		ENCODE	ENCSR000DUM_HFF-Myc_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37549
1	689	CTCF	0.226483990939864	0.973839722994364	26	1596	1780	1204	1780	1530	27	178	180	CTCF breast epithelial cells CTCF	breast epithelial cells	NULL	CTCF		GTRD	EXP039457_breast-epithelial-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27302
1	3510	RXRA	0.226483990939864	0.973839722994364	26	1596	1780	1204	1780	1530	27	178	180	RXRA GM12878 (female B-cells lymphoblastoid cell line) RXRA	GM12878 (female B-cells lymphoblastoid cell line)	NULL	RXRA		ENCODE	ENCSR000BJD_GM12878_RXRA_MACS_RXRA_MA0512.2.damo.pwm.bed	7983
1	1814	FOXA1	0.225985607590578	0.972099531377206	56	1599	1787	192	1787	1190	58	148	149	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	TNFA	GEO	GSE83860_foxa1_lncap-tnfa_MACS_FOXA1_MA0148.4.damo.pwm.bed	221475
1	2912	MYC	0.225985607590578	0.972099531377206	56	1599	1787	192	1787	1190	58	148	149	MYC NCI-H2171 (small cell lung carcinoma) MYC	NCI-H2171 (small cell lung carcinoma)	NULL	MYC		GEO	GSE36354_myc_ncih2171_MACS_MYC_MA0147.3.damo.pwm.bed	50449
1	2871	MYC	0.22515743660262	0.971447941542346	55	1601	1789	211	1789	1200	57	149	150	MYC NCI-H2171 (small cell lung carcinoma) MYC	NCI-H2171 (small cell lung carcinoma)	NULL	MYC	Treatment: Treatment withKL-1 or KL-2 inhibitors was administrated only once; Genotype: mutation by amplification of MYC;	GTRD	EXP047290_NCI-H2171--small-cell-lung-carcinoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	58030
1	25	AR	0.225000128933104	1.01519298891852	7	1602	1530	2812	2812	1980	7	197	200	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Vehicle	GTRD	EXP032854_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	21369
1	1805	FOXA1	0.225000128933104	1.01519298891852	7	1602	1530	2812	2812	1980	7	197	200	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	E2	GEO	GSE72249_foxa1_t47d-e2_MACS_FOXA1_MA0148.4.damo.pwm.bed	17954
1	2019	GATA4	0.225000128933104	1.01519298891852	7	1602	1530	2812	2812	1980	7	197	200	GATA4 iPSC-derived cardiomyocytes GATA4	iPSC-derived cardiomyocytes	NULL	GATA4	G296S mutant	GTRD	EXP037722_iPSC-derived-cardiomyocytes_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	6893
1	2232	JUN	0.225000128933104	1.01519298891852	7	1602	1530	2812	2812	1980	7	197	200	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN		ENCODE	ENCSR996DUT_A549_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	2282
1	3019	NFIL3	0.225000128933104	1.01519298891852	7	1602	1530	2812	2812	1980	7	197	200	NFIL3 HepG2 (hepatoblastoma) NFIL3	HepG2 (hepatoblastoma)	BTO:0000599	NFIL3	NA	GTRD	EXP038522_HepG2--hepatoblastoma-_NFIL3_MACS_NFIL3_MA0025.2.damo.pwm.bed	7900
1	3567	SMAD3	0.225000128933104	1.01519298891852	7	1602	1530	2812	2812	1980	7	197	200	SMAD3 HMLE-Twist-ER (breast cancer) SMAD3	HMLE-Twist-ER (breast cancer)	NULL	SMAD3	CellType: immortalized human mammary epithelial cells Treatment:TGF--beta	GTRD	EXP047899_HMLE-Twist-ER--breast-cancer-_SMAD3_MACS_SMAD3_MA0513.1.damo.pwm.bed	13957
1	3776	TBX5	0.225000128933104	1.01519298891852	7	1602	1530	2812	2812	1980	7	197	200	TBX5 iPSC-derived cardiomyocytes TBX5	iPSC-derived cardiomyocytes	NULL	TBX5	G296S mutant	GTRD	EXP037723_iPSC-derived-cardiomyocytes_TBX5_MACS_TBX5_MA0807.1.damo.pwm.bed	17357
1	3987	TP53	0.225000128933104	1.01519298891852	7	1602	1530	2812	2812	1980	7	197	200	TP53 IMR90 (lung fibroblasts) TP53	IMR90 (lung fibroblasts)	NULL	TP53	Treatment: etoposide (100uM, 6hrs) Source: IMR90 fetal lung fibroblasts Passage: #30-35	GTRD	EXP048593_IMR90--lung-fibroblasts-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	4613
1	4046	TP63	0.225000128933104	1.01519298891852	7	1602	1530	2812	2812	1980	7	197	200	TP63 TT (hereditary thyroid gland medullary carcinoma) TP63	TT (hereditary thyroid gland medullary carcinoma)	BTO:0003074	TP63		GEO	GSE46837_tp63_tt_MACS_TP63_MA0525.2.damo.pwm.bed	6066
1	4063	TP73	0.225000128933104	1.01519298891852	7	1602	1530	2812	2812	1980	7	197	200	TP73 TP73	NA	NA	TP73	NA	GEO	GSE15780_tp73_saos-rep2_MACS_TP73_MA0861.1.damo.pwm.bed	13096
1	705	CTCF	0.224759326746213	0.972341780194777	25	1612	1784	1262	1784	1550	26	179	181	CTCF upper lobe of left lung CTCF	upper lobe of left lung	NULL	CTCF		GTRD	EXP039550_upper-lobe-of-left-lung_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30524
1	752	CTCF	0.224759326746213	0.972341780194777	25	1612	1784	1262	1784	1550	26	179	181	CTCF prostate gland CTCF	prostate gland	BTO:0001129	CTCF		GTRD	EXP039929_prostate-gland_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30599
1	802	CTCF	0.224759326746213	0.972341780194777	25	1612	1784	1262	1784	1550	26	179	181	CTCF smooth muscle cell CTCF	smooth muscle cell	BTO:0004576	CTCF		GTRD	EXP040298_smooth-muscle-cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38771
1	170	AR	0.2229510118247	0.970729645652196	24	1615	1790	1324	1790	1580	25	180	182	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	DHT24H_SHFOXP1	GEO	GSE58428_AR_vcap-dht24h-shfoxp1_MACS_AR_MA0007.3.damo.pwm.bed	43327
1	682	CTCF	0.2229510118247	0.970729645652196	24	1615	1790	1324	1790	1580	25	180	182	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039406_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37344
1	940	CTCF	0.2229510118247	0.970729645652196	24	1615	1790	1324	1790	1580	25	180	182	CTCF IMR90 (lung fibroblasts) CTCF	IMR90 (lung fibroblasts)	NULL	CTCF		GEO	GSE43070_ctcf_imr90_MACS_CTCF_MA0139.1.damo.pwm.bed	33060
1	1792	FOXA1	0.2229510118247	0.970729645652196	24	1615	1790	1324	1790	1580	25	180	182	FOXA1 LNCaP-abl (Prostate carcinoma) FOXA1	LNCaP-abl (Prostate carcinoma)	NULL	FOXA1		GEO	GSE63034_foxa1_lncap-abl_MACS_FOXA1_MA0148.4.damo.pwm.bed	67466
1	2310	JUN	0.2229510118247	0.970729645652196	24	1615	1790	1324	1790	1580	25	180	182	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039416_A549--lung-carcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	17069
1	3139	NR3C1	0.2229510118247	0.970729645652196	24	1615	1790	1324	1790	1580	25	180	182	NR3C1 HASM2 (Human airway smooth muscle 2) NR3C1	HASM2 (Human airway smooth muscle 2)	NULL	NR3C1	Treatment: dexamethasone for 4 hr	GTRD	EXP049654_HASM2--Human-airway-smooth-muscle-2-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	39106
1	3445	RFX5	0.2229510118247	0.970729645652196	24	1615	1790	1324	1790	1580	25	180	182	RFX5 HepG2 (hepatoblastoma) RFX5	HepG2 (hepatoblastoma)	BTO:0000599	RFX5	NA	ENCODE	ENCSR000EEA_HepG2_RFX5_MACS_RFX5_MA0510.2.damo.pwm.bed	9504
1	910	CTCF	0.222565580407751	0.9693618342871	52	1622	1797	244	1797	1220	54	152	153	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	Treatment: 1 h with 0.02% Ethanol;	GTRD	EXP054083_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	81438
1	720	CTCF	0.221050998653853	0.96898894358092	23	1623	1798	1391	1798	1600	24	181	183	CTCF thoracic aorta CTCF	thoracic aorta	NULL	CTCF		GTRD	EXP039667_thoracic-aorta_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29819
1	1400	ESR1	0.221050998653853	0.96898894358092	23	1623	1798	1391	1798	1600	24	181	183	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	LY2_ETOH	GEO	GSE54592_esr1_ly2-etoh_MACS_ESR1_MA0112.3.damo.pwm.bed	29123
1	3034	NFYC	0.221050998653853	0.96898894358092	23	1623	1798	1391	1798	1600	24	181	183	NFYC HepG2 (hepatoblastoma) NFYC	HepG2 (hepatoblastoma)	BTO:0000599	NFYC	NA	GTRD	EXP039903_HepG2--hepatoblastoma-_NFYC_MACS_NFYC_MA1644.1.damo.pwm.bed	10909
1	2757	MITF	0.22074018024756	0.967848561287265	50	1626	1802	275	1802	1230	52	154	155	MITF melanocytes MITF	melanocytes	NULL	MITF	CTR	GEO	GSE50681_mitf_melanocyte-ctr_MACS_MITF_MA0620.3.damo.pwm.bed	24347
1	1769	FOXA1	0.219795550280393	0.967050705629348	49	1627	1807	299	1807	1240	51	155	156	FOXA1 MDA-MB-453 (breast adenocarcinoma) FOXA1	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	FOXA1	DHT	GEO	GSE45201_foxa1_mdamb453-dht_MACS_FOXA1_MA0148.4.damo.pwm.bed	61439
1	2811	MYC	0.219795550280393	0.967050705629348	49	1627	1807	299	1807	1240	51	155	156	MYC K562 (myelogenous leukemia) MYC	K562 (myelogenous leukemia)	NULL	MYC	NULL	GTRD	EXP000994_K562--myelogenous-leukemia-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	15406
1	2654	KLF9	0.219730424160478	0.968482695850267	92	1629	1801	4	1801	1140	95	112	112	KLF9 GBM1A KLF9	GBM1A	NA	KLF9	NA	GEO	GSE62211_klf9_gbm1a_MACS_KLF9_MA1107.2.damo.pwm.bed	63426
1	739	CTCF	0.219050102425236	0.96710279968975	22	1630	1803	1459	1803	1630	23	182	184	CTCF right lobe of liver CTCF	right lobe of liver	NULL	CTCF		GTRD	EXP039782_right-lobe-of-liver_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31020
1	840	CTCF	0.219050102425236	0.96710279968975	22	1630	1803	1459	1803	1630	23	182	184	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: untreated	GTRD	EXP047811_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30718
1	1332	ESR1	0.219050102425236	0.96710279968975	22	1630	1803	1459	1803	1630	23	182	184	ESR1 Ishikawa (endometrial adenocarcinoma) ESR1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	ESR1	Treatment: 10 nM Estradiol for 1 hour	GTRD	EXP048233_Ishikawa--endometrial-adenocarcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	23628
1	2140	HNF4A	0.219050102425236	0.96710279968975	22	1630	1803	1459	1803	1630	23	182	184	HNF4A Caco-2 (colon adenocarcinoma) HNF4A	Caco-2 (colon adenocarcinoma)	BTO:0000195	HNF4A	DIFF	GEO	GSE23436_hnf4a_caco2-diff_MACS_HNF4A_MA0114.4.damo.pwm.bed	37015
1	1223	ESR1	0.218828306839296	0.9662231140954	48	1634	1809	317	1809	1250	50	156	157	ESR1 endometrioid adenocarcinoma ESR1	endometrioid adenocarcinoma	NULL	ESR1	tumor E	GTRD	EXP036413_endometrioid-adenocarcinoma_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	32917
1	130	AR	0.218650041985767	1.01511623420373	6	1635	1540	2948	2948	2040	6	198	201	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	R1881_10C26	GEO	GSE32892_AR_vcap-r1881-10c26_MACS_AR_MA0007.3.damo.pwm.bed	16533
1	1123	ERG	0.218650041985767	1.01511623420373	6	1635	1540	2948	2948	2040	6	198	201	ERG CD34+ hematopoietic stem cells ERG	CD34+ hematopoietic stem cells	NULL	ERG		GTRD	EXP031971_CD34--hematopoietic-stem-cells_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	6968
1	1180	ESR1	0.218650041985767	1.01511623420373	6	1635	1540	2948	2948	2040	6	198	201	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	hormone starved for 3 days, treated with 10 nM β-estradiol for 45 minutes	GTRD	EXP000178_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	10444
1	1245	ESR1	0.218650041985767	1.01511623420373	6	1635	1540	2948	2948	2040	6	198	201	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	NoTreat	GTRD	EXP038335_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	13663
1	1317	ESR1	0.218650041985767	1.01511623420373	6	1635	1540	2948	2948	2040	6	198	201	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 500nM RAD001 2hr; Passage: p19;	GTRD	EXP047700_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	13154
1	1448	ESRRA	0.218650041985767	1.01511623420373	6	1635	1540	2948	2948	2040	6	198	201	ESRRA BT-474 (breast invasive ductal carcinoma) ESRRA	BT-474 (breast invasive ductal carcinoma)	BTO:0001932	ESRRA	EGF	GEO	GSE81651_esrra_bt474-egf_MACS_ESRRA_MA0592.3.damo.pwm.bed	10551
1	1511	FLI1	0.218650041985767	1.01511623420373	6	1635	1540	2948	2948	2040	6	198	201	FLI1 SK-N-MC (Askin tumor) FLI1	SK-N-MC (Askin tumor)	BTO:0002914	FLI1	SHGFP_48H	GEO	GSE61944_fli1_skmnc-shgfp-48h_MACS_FLI1_MA0475.2.damo.pwm.bed	4122
1	2159	HOXB13	0.218650041985767	1.01511623420373	6	1635	1540	2948	2948	2040	6	198	201	HOXB13 22RV1 (prostate carcinoma) HOXB13	22RV1 (prostate carcinoma)	BTO:0002999	HOXB13		GTRD	EXP038433_22RV1--prostate-carcinoma-_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	9153
1	2264	JUN	0.218650041985767	1.01511623420373	6	1635	1540	2948	2948	2040	6	198	201	JUN Calu-3 (lung adenocarcinoma) JUN	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUN		GTRD	EXP037683_Calu-3--lung-adenocarcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	5419
1	2265	JUN	0.218650041985767	1.01511623420373	6	1635	1540	2948	2948	2040	6	198	201	JUN Calu-3 (lung adenocarcinoma) JUN	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUN		GTRD	EXP037683_Calu-3--lung-adenocarcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	5596
1	2726	MEF2B	0.218650041985767	1.01511623420373	6	1635	1540	2948	2948	2040	6	198	201	MEF2B germinal center B-cells MEF2B	germinal center B-cells	NULL	MEF2B	Treatment: tonsil	GTRD	EXP048298_germinal-center-B-cells_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	13279
1	3115	NR3C1	0.218650041985767	1.01511623420373	6	1635	1540	2948	2948	2040	6	198	201	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039790_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	11362
1	3765	TAL1	0.218650041985767	1.01511623420373	6	1635	1540	2948	2948	2040	6	198	201	TAL1 CHRF28811 TAL1	CHRF28811	NA	TAL1	NA	Array Express	ERP008568_tal1_chrf28811_MACS_TAL1_MA0091.1.damo.pwm.bed	17028
1	3774	TBX5	0.218650041985767	1.01511623420373	6	1635	1540	2948	2948	2040	6	198	201	TBX5 iPSC-derived cardiomyocytes TBX5	iPSC-derived cardiomyocytes	NULL	TBX5		GTRD	EXP037717_iPSC-derived-cardiomyocytes_TBX5_MACS_TBX5_MA0807.1.damo.pwm.bed	9843
1	4106	VDR	0.218650041985767	1.01511623420373	6	1635	1540	2948	2948	2040	6	198	201	VDR LS180 (colon cancer) VDR	LS180 (colon cancer)	NULL	VDR	125	GEO	GSE31939_vdr_ls180-125_MACS_VDR_MA0693.2.damo.pwm.bed	3074
1	3523	RXRA	0.217837372258548	0.965363923035054	47	1650	1810	333	1810	1260	49	157	158	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP040231_liver_RXRA_MACS_RXRA_MA0159.1.damo.pwm.bed	43444
1	3548	RXRA	0.217837372258548	0.965363923035054	47	1650	1810	333	1810	1260	49	157	158	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP045021_liver_RXRA_MACS_RXRA_MA1147.1.damo.pwm.bed	48270
1	672	CTCF	0.216937783164668	0.965051273149185	21	1652	1812	1535	1812	1670	22	183	185	CTCF sigmoid colon CTCF	sigmoid colon	BTO:0000645	CTCF		GTRD	EXP039310_sigmoid-colon_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	23041
1	1208	ESR1	0.216937783164668	0.965051273149185	21	1652	1812	1535	1812	1670	22	183	185	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	sgRNA_enh588	GTRD	EXP035790_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	40909
1	1646	FOXA1	0.216937783164668	0.965051273149185	21	1652	1812	1535	1812	1670	22	183	185	FOXA1 FOXA1	NA	NA	FOXA1	NA	Array Express	ERP003828_foxa1_mcf7_MACS_FOXA1_MA0148.4.damo.pwm.bed	66695
1	1700	FOXA1	0.216937783164668	0.965051273149185	21	1652	1812	1535	1812	1670	22	183	185	FOXA1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) FOXA1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	FOXA1	Treatment: 45 min 10^-7 4OHT	GTRD	EXP048436_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	42154
1	886	CTCF	0.216821595877194	0.964471114560989	46	1656	1816	349	1816	1270	48	158	159	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	110 mM NaCl	GTRD	EXP053053_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	32606
1	924	CTCF	0.215779747460541	0.963542500102143	45	1657	1818	383	1818	1290	47	159	160	CTCF MCF7L-P(immortalized breast epithelial cell line) CTCF	MCF7L-P(immortalized breast epithelial cell line)	NULL	CTCF	Treatment: treated with E2 for 24 hrs;	GTRD	EXP057866_MCF7L-P-immortalized-breast-epithelial-cell-line-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	60686
1	1088	ELF1	0.214710509878698	0.962575701812675	44	1658	1821	408	1821	1300	46	160	161	ELF1 MCF7 (Invasive ductal breast carcinoma) ELF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ELF1		GTRD	EXP040154_MCF7--Invasive-ductal-breast-carcinoma-_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	13690
1	3914	TFAP2C	0.214710509878698	0.962575701812675	44	1658	1821	408	1821	1300	46	160	161	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C		GEO	GSE21234_tfap2c_mcf7_MACS_TFAP2C_MA0815.1.damo.pwm.bed	71805
1	2072	GRHL2	0.214701874209532	0.962810626233859	20	1660	1819	1606	1819	1700	21	184	186	GRHL2 OVCA429 (ovarian cystadenocarcinoma) GRHL2	OVCA429 (ovarian cystadenocarcinoma)	BTO:0002564	GRHL2		GEO	GSE71018_grhl2_ovca429_MACS_GRHL2_MA1105.2.damo.pwm.bed	25102
1	2615	JUND	0.214701874209532	0.962810626233859	20	1660	1819	1606	1819	1700	21	184	186	JUND liver JUND	liver	BTO:0000759	JUND		GTRD	EXP040078_liver_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	13272
1	483	CTCF	0.213595831271204	0.963925046204033	80	1662	1817	19	1817	1170	83	124	124	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		ENCODE	ENCSR000DMO_MCF-7_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	93848
1	3808	TCF7L2	0.212484114264306	0.960516966698779	42	1663	1824	454	1824	1310	44	162	163	TCF7L2 HCT-116 (colon carcinoma) TCF7L2	HCT-116 (colon carcinoma)	BTO:0001109	TCF7L2		ENCODE	ENCSR000EUV_HCT116_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	30724
1	4	AR	0.212328240617274	0.96035237481696	19	1664	1825	1697	1825	1730	20	185	187	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR		Array Express	ERP003503_AR_lncap_MACS_AR_MA0007.3.damo.pwm.bed	27405
1	407	CEBPD	0.212328240617274	0.96035237481696	19	1664	1825	1697	1825	1730	20	185	187	CEBPD HAEC (human aortic endothelial cells) CEBPD	HAEC (human aortic endothelial cells)	NULL	CEBPD	IL1b, 4h	GTRD	EXP038037_HAEC--human-aortic-endothelial-cells-_CEBPD_MACS_CEBPD_MA0836.2.damo.pwm.bed	22798
1	726	CTCF	0.212328240617274	0.96035237481696	19	1664	1825	1697	1825	1730	20	185	187	CTCF transverse colon CTCF	transverse colon	NULL	CTCF		GTRD	EXP039696_transverse-colon_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27484
1	1456	ETS1	0.212328240617274	0.96035237481696	19	1664	1825	1697	1825	1730	20	185	187	ETS1 CD4+ CD25- T-cells ETS1	CD4+ CD25- T-cells	NULL	ETS1		GTRD	EXP032568_CD4--CD25--T-cells_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	8216
1	3938	TFAP4	0.212328240617274	0.96035237481696	19	1664	1825	1697	1825	1730	20	185	187	TFAP4 LNCaP (prostate carcinoma) TFAP4	LNCaP (prostate carcinoma)	BTO:0001321	TFAP4	NA	GEO	GSE28857_tfap4_lncap_MACS_TFAP4_MA0691.1.damo.pwm.bed	12499
1	895	CTCF	0.211323809048926	0.959419123359527	41	1669	1831	476	1831	1330	43	163	164	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF	Treatment: None;	GTRD	EXP054032_WA01--H1--human-embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	79602
1	3884	TFAP2C	0.211323809048926	0.959419123359527	41	1669	1831	476	1831	1330	43	163	164	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions;	GTRD	EXP047535_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	30636
1	1200	ESR1	0.210795800583088	1.01504025115259	5	1671	1555	3053	3053	2090	5	199	202	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	cells transfected with siNCAPG, and 1hr with 100nM E2, double crosslinked	GTRD	EXP034120_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	11536
1	1308	ESR1	0.210795800583088	1.01504025115259	5	1671	1555	3053	3053	2090	5	199	202	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	100nm E2 (45 min)	GTRD	EXP040957_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	14952
1	1739	FOXA1	0.210795800583088	1.01504025115259	5	1671	1555	3053	3053	2090	5	199	202	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	Treatment: FA (control)	GTRD	EXP053230_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	12622
1	1928	GATA2	0.210795800583088	1.01504025115259	5	1671	1555	3053	3053	2090	5	199	202	GATA2 K562 (myelogenous leukemia) GATA2	K562 (myelogenous leukemia)	NULL	GATA2		ENCODE	ENCSR000BKM_K562_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	16843
1	1960	GATA3	0.210795800583088	1.01504025115259	5	1671	1555	3053	3053	2090	5	199	202	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3		ENCODE	ENCSR000EWS_MCF-7_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	10588
1	2358	JUN	0.210795800583088	1.01504025115259	5	1671	1555	3053	3053	2090	5	199	202	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: ethanol 1hr;	GTRD	EXP047659_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	6422
1	2360	JUN	0.210795800583088	1.01504025115259	5	1671	1555	3053	3053	2090	5	199	202	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: ethanol 1hr;	GTRD	EXP047659_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	6787
1	2363	JUN	0.210795800583088	1.01504025115259	5	1671	1555	3053	3053	2090	5	199	202	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: ethanol 1hr;	GTRD	EXP047659_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	7029
1	2635	KLF4	0.210795800583088	1.01504025115259	5	1671	1555	3053	3053	2090	5	199	202	KLF4 WA09 (embryonic stem cells) KLF4	WA09 (embryonic stem cells)	NULL	KLF4	Treatment: under heat shock conditions	GTRD	EXP047913_WA09--embryonic-stem-cells-_KLF4_MACS_KLF4_MA0039.4.damo.pwm.bed	1387
1	3110	NR3C1	0.210795800583088	1.01504025115259	5	1671	1555	3053	3053	2090	5	199	202	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039608_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	3230
1	3112	NR3C1	0.210795800583088	1.01504025115259	5	1671	1555	3053	3053	2090	5	199	202	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039702_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	3294
1	3221	PAX6	0.210795800583088	1.01504025115259	5	1671	1555	3053	3053	2090	5	199	202	PAX6 EndoC-betaH2 (immortalized pancreatic beta cells) PAX6	EndoC-betaH2 (immortalized pancreatic beta cells)	NULL	PAX6	NA	GTRD	EXP037896_EndoC-betaH2--immortalized-pancreatic-beta-cells-_PAX6_MACS_PAX6_MA0069.1.damo.pwm.bed	5528
1	942	CTCF	0.210665531001241	0.961612022205824	75	1683	1823	28	1823	1180	78	129	129	CTCF MM1.S (plasma cell myeloma) CTCF	MM1.S (plasma cell myeloma)	BTO:0003933	CTCF		GEO	GSE43743_ctcf_mm1s_MACS_CTCF_MA0139.1.damo.pwm.bed	54246
1	563	CTCF	0.210129798581998	0.958271224701129	40	1684	1835	502	1835	1340	42	164	165	CTCF hepatocytes CTCF	hepatocytes	NULL	CTCF		Array Express	ERP000395_ctcf_hepatocytes_MACS_CTCF_MA0139.1.damo.pwm.bed	50690
1	2066	GRHL2	0.210129798581998	0.958271224701129	40	1684	1835	502	1835	1340	42	164	165	GRHL2 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) GRHL2	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	GRHL2	Treatment: 45 min ethanol	GTRD	EXP048443_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	40526
1	2342	JUN	0.210129798581998	0.958271224701129	40	1684	1835	502	1835	1340	42	164	165	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN		GTRD	EXP040265_A549--lung-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	18456
1	4076	USF1	0.210129798581998	0.958271224701129	40	1684	1835	502	1835	1340	42	164	165	USF1 Ishikawa (endometrial adenocarcinoma) USF1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	USF1		ENCODE	ENCSR000BSX_Ishikawa_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	25706
1	2617	JUND	0.209800344965673	0.95764203896464	18	1688	1839	1785	1839	1770	19	186	188	JUND liver JUND	liver	BTO:0000759	JUND		GTRD	EXP040078_liver_JUND_MACS_JUND_MA1141.1.damo.pwm.bed	12672
1	2792	MYC	0.209800344965673	0.95764203896464	18	1688	1839	1785	1839	1770	19	186	188	MYC WA01 (H1, human embryonic stem cells) MYC	WA01 (H1, human embryonic stem cells)	NULL	MYC		ENCODE	ENCSR000EBY_H1-hESC_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	6029
1	3028	NFYA	0.209800344965673	0.95764203896464	18	1688	1839	1785	1839	1770	19	186	188	NFYA HeLa S3 (cervical adenocarcinoma) NFYA	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	NFYA	NA	ENCODE	ENCSR000DNS_HeLa-S3_NFYA_MACS_NFYA_MA0060.3.damo.pwm.bed	4589
1	2627	KLF11	0.2087827033109	0.960076133473385	72	1691	1830	36	1830	1190	75	132	132	KLF11 hMADS-3 (adipose-derived stem cells) KLF11	hMADS-3 (adipose-derived stem cells)	NULL	KLF11	differentiaiton inductors	GTRD	EXP033778_hMADS-3--adipose-derived-stem-cells-_KLF11_MACS_KLF11_MA1512.1.damo.pwm.bed	21004
1	394	CEBPB	0.207632926165766	0.955810070771258	38	1692	1843	576	1843	1370	40	166	167	CEBPB HEE (human epididymis epithelial cells) CEBPB	HEE (human epididymis epithelial cells)	NULL	CEBPB	Treatment: treatment of 1 nM R1881 (methyltrienolone) for 12 -16 hr	GTRD	EXP048168_HEE--human-epididymis-epithelial-cells-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	50853
1	579	CTCF	0.207470551942498	0.958982056308397	70	1693	1833	42	1833	1190	73	134	134	CTCF lymphoblastoid cells CTCF	lymphoblastoid cells	NULL	CTCF	NULL	GTRD	EXP000778_lymphoblastoid-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	85518
1	2937	MYC	0.207470551942498	0.958982056308397	70	1693	1833	42	1833	1190	73	134	134	MYC CD34+ cells MYC	CD34+ cells	NULL	MYC		GEO	GSE85488_myc_cd34_MACS_MYC_MA0147.3.damo.pwm.bed	41778
1	629	CTCF	0.207098689166946	0.954637476984094	17	1695	1846	1846	1846	1800	18	187	189	CTCF HUES64 (embryonic stem cells) CTCF	HUES64 (embryonic stem cells)	NULL	CTCF		GTRD	EXP036699_HUES64--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36719
1	1206	ESR1	0.207098689166946	0.954637476984094	17	1695	1846	1846	1846	1800	18	187	189	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GTRD	EXP035788_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	35876
1	1520	FOS	0.207098689166946	0.954637476984094	17	1695	1846	1846	1846	1800	18	187	189	FOS K562 (myelogenous leukemia) FOS	K562 (myelogenous leukemia)	NULL	FOS		ENCODE	ENCSR000FAI_K562_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	11360
1	2428	JUN	0.207098689166946	0.954637476984094	17	1695	1846	1846	1846	1800	18	187	189	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057912_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	26333
1	902	CTCF	0.206325796132928	0.954488248787574	37	1699	1850	607	1850	1390	39	167	168	CTCF HSMM (skeletal muscle myoblasts) CTCF	HSMM (skeletal muscle myoblasts)	NULL	CTCF	Treatment: None;	GTRD	EXP054039_HSMM--skeletal-muscle-myoblasts-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	58345
1	2675	MAFF	0.206325796132928	0.954488248787574	37	1699	1850	607	1850	1390	39	167	168	MAFF HeLa S3 (cervical adenocarcinoma) MAFF	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	MAFF	NA	ENCODE	ENCSR140DSL_HeLa-S3_MAFF_MACS_MAFF_MA0495.3.damo.pwm.bed	48859
1	4164	ZNF143	0.205409983272379	0.957223684727545	67	1701	1842	68	1842	1200	70	137	137	ZNF143 MCF7 (Invasive ductal breast carcinoma) ZNF143	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ZNF143		GEO	GSE76454_znf143_mcf7_MACS_ZNF143_MA0088.2.damo.pwm.bed	48028
1	1466	ETS1	0.204976389331827	0.953099135725061	36	1702	1852	645	1852	1400	38	168	169	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048198_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	14280
1	3670	SPI1	0.204976389331827	0.953099135725061	36	1702	1852	645	1852	1400	38	168	169	SPI1 ME-1 (acute myeloid leukemia ) SPI1	ME-1 (acute myeloid leukemia )	NULL	SPI1		GEO	GSE46044_spi1_me1_MACS_SPI1_MA0080.5.damo.pwm.bed	13585
1	4071	USF1	0.204976389331827	0.953099135725061	36	1702	1852	645	1852	1400	38	168	169	USF1 WA01 (H1, human embryonic stem cells) USF1	WA01 (H1, human embryonic stem cells)	NULL	USF1		ENCODE	ENCSR000BIU_H1-hESC_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	49138
1	47	AR	0.204200087919989	0.95128663138023	16	1705	1857	1909	1909	1820	17	188	190	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	siControl	GTRD	EXP036095_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	33563
1	624	CTCF	0.204200087919989	0.95128663138023	16	1705	1857	1909	1909	1820	17	188	190	CTCF BEAS-2B (bronchial epithelium) CTCF	BEAS-2B (bronchial epithelium)	NULL	CTCF	NiCl2	GTRD	EXP033454_BEAS-2B--bronchial-epithelium-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	24175
1	935	CTCF	0.204200087919989	0.95128663138023	16	1705	1857	1909	1909	1820	17	188	190	CTCF pancreatic islets CTCF	pancreatic islets	NULL	CTCF		GEO	GSE23784_ctcf_islet_MACS_CTCF_MA0139.1.damo.pwm.bed	26632
1	1995	GATA3	0.204200087919989	0.95128663138023	16	1705	1857	1909	1909	1820	17	188	190	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3		GEO	GSE51274_gata3_mcf7_MACS_GATA3_MA0037.3.damo.pwm.bed	38880
1	2432	JUN	0.204200087919989	0.95128663138023	16	1705	1857	1909	1909	1820	17	188	190	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057912_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	22637
1	2723	MEF2A	0.204200087919989	0.95128663138023	16	1705	1857	1909	1909	1820	17	188	190	MEF2A GM12878 (female B-cells lymphoblastoid cell line) MEF2A	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MEF2A	NA	ENCODE	ENCSR000BKB_GM12878_MEF2A_MACS_MEF2A_MA0052.4.damo.pwm.bed	24947
1	2972	NEUROG2	0.204200087919989	0.95128663138023	16	1705	1857	1909	1909	1820	17	188	190	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	1 DPT	GTRD	EXP037149_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	22910
1	3401	REST	0.203582087658711	0.951637232068022	35	1712	1856	691	1856	1420	37	169	170	REST PANC1 (pancreatic ductal adenocarcinoma) REST	PANC1 (pancreatic ductal adenocarcinoma)	NULL	REST		ENCODE	ENCSR000BPK_Panc1_REST_MACS_REST_MA0138.2.damo.pwm.bed	13496
1	587	CTCF	0.203229127885511	0.955307801190831	64	1713	1844	95	1844	1220	67	140	140	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	NULL	GTRD	EXP001021_MCF7--Invasive-ductal-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	82047
1	889	CTCF	0.203229127885511	0.955307801190831	64	1713	1844	95	1844	1220	67	140	140	CTCF SYO-1(Biphasic synovial sarcoma) CTCF	SYO-1(Biphasic synovial sarcoma)	NULL	CTCF	Treatment: lentivirally infected with shControl	GTRD	EXP053102_SYO-1-Biphasic-synovial-sarcoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	79791
1	652	CTCF	0.202140038291513	0.95009642811161	34	1715	1866	729	1866	1440	36	170	171	CTCF epidermal keratinocytes CTCF	epidermal keratinocytes	NULL	CTCF	undifferentiated	GTRD	EXP037596_epidermal-keratinocytes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	51004
1	774	CTCF	0.202140038291513	0.95009642811161	34	1715	1866	729	1866	1440	36	170	171	CTCF heart left ventricle CTCF	heart left ventricle	NULL	CTCF		GTRD	EXP040077_heart-left-ventricle_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34125
1	834	CTCF	0.202140038291513	0.95009642811161	34	1715	1866	729	1866	1440	36	170	171	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 60min	GTRD	EXP047801_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	52712
1	1747	FOXA1	0.202140038291513	0.95009642811161	34	1715	1866	729	1866	1440	36	170	171	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	Treatment: hormone-deprived cells treated with 10 nM estrogen for 45 mins;	GTRD	EXP058102_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	100880
1	1917	GATA1	0.202140038291513	0.95009642811161	34	1715	1866	729	1866	1440	36	170	171	GATA1 CD34+ bone marrow cell-derived erythroid progenitors GATA1	CD34+ bone marrow cell-derived erythroid progenitors	NULL	GATA1		GTRD	EXP038306_CD34--bone-marrow-cell-derived-erythroid-progenitors_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	75764
1	1082	ELF1	0.201076709944794	0.947524429394341	15	1720	1876	1993	1993	1860	16	189	191	ELF1 HCT-116 (colon carcinoma) ELF1	HCT-116 (colon carcinoma)	BTO:0001109	ELF1		ENCODE	ENCSR000BVH_HCT116_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	3975
1	2225	JUN	0.201076709944794	0.947524429394341	15	1720	1876	1993	1993	1860	16	189	191	JUN JUN	NA	NA	JUN	NA	NA	ENCSR000EFA_endothelial_cell_of_umbilical_vein_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	29452
1	2374	JUN	0.201076709944794	0.947524429394341	15	1720	1876	1993	1993	1860	16	189	191	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: tamoxifen 1μM for 1hr;	GTRD	EXP047661_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	18791
1	2795	MYC	0.201076709944794	0.947524429394341	15	1720	1876	1993	1993	1860	16	189	191	MYC NB4 (acute promyelocytic leukemia ) MYC	NB4 (acute promyelocytic leukemia )	NULL	MYC		ENCODE	ENCSR000EHR_NB4_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	5911
1	90	AR	0.200662633772741	1.01496502818602	4	1724	1567	3182	3182	2160	4	200	203	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: 10 nM DHT for 4 hrs Genotype: Bag-1L knockout and Bag-1L wildtype	GTRD	EXP049282_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	16653
1	226	ARNT	0.200662633772741	1.01496502818602	4	1724	1567	3182	3182	2160	4	200	203	ARNT ARNT	NA	NA	ARNT	NA	GEO	GSE67237_arnt_786o-hif2a_MACS_ARNT_MA0004.1.damo.pwm.bed	5112
1	1442	ESR2	0.200662633772741	1.01496502818602	4	1724	1567	3182	3182	2160	4	200	203	ESR2 MCF7 (Invasive ductal breast carcinoma) ESR2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR2	C412_E2	GEO	GSE48096_esr2_mcf7c412-e2_MACS_ESR2_MA0258.2.damo.pwm.bed	1581
1	1821	FOXA2	0.200662633772741	1.01496502818602	4	1724	1567	3182	3182	2160	4	200	203	FOXA2 pancreas FOXA2	pancreas	BTO:0000988	FOXA2	CARN1618	Array Express	ERP008682_foxa2_pancreas-carn1618_MACS_FOXA2_MA0047.3.damo.pwm.bed	4840
1	1925	GATA1	0.200662633772741	1.01496502818602	4	1724	1567	3182	3182	2160	4	200	203	GATA1 CD34+ cells GATA1	CD34+ cells	NULL	GATA1	ERYTH_BMP	GEO	GSE29194_gata1_CD34-eryth-bmp_MACS_GATA1_MA0035.4.damo.pwm.bed	17205
1	2182	HSF1	0.200662633772741	1.01496502818602	4	1724	1567	3182	3182	2160	4	200	203	HSF1 BT-20 (breast invasive ductal carcinoma) HSF1	BT-20 (breast invasive ductal carcinoma)	BTO:0001466	HSF1		GEO	GSE38901_hsf1_bt20_MACS_HSF1_MA0486.2.damo.pwm.bed	2325
1	2186	HSF1	0.200662633772741	1.01496502818602	4	1724	1567	3182	3182	2160	4	200	203	HSF1 MCF10A (breast epithelial cells) HSF1	MCF10A (breast epithelial cells)	BTO:0001939	HSF1	HEAT	GEO	GSE38901_hsf1_mcf10a-heat_MACS_HSF1_MA0486.2.damo.pwm.bed	3514
1	2742	MEF2C	0.200662633772741	1.01496502818602	4	1724	1567	3182	3182	2160	4	200	203	MEF2C GM12878 (female B-cells lymphoblastoid cell line) MEF2C	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MEF2C		ENCODE	ENCSR000BNG_GM12878_MEF2C_MACS_MEF2C_MA0497.1.damo.pwm.bed	7953
1	2781	MYBL2	0.200662633772741	1.01496502818602	4	1724	1567	3182	3182	2160	4	200	203	MYBL2 HeLa (cervical adenocarcinoma) MYBL2	HeLa (cervical adenocarcinoma)	BTO:0000567	MYBL2	NA	GTRD	EXP030954_HeLa--cervical-adenocarcinoma-_MYBL2_MACS_MYBL2_MA0777.1.damo.pwm.bed	1778
1	3314	RARA	0.200662633772741	1.01496502818602	4	1724	1567	3182	3182	2160	4	200	203	RARA U937 (adult acute monocytic leukemia) RARA	U937 (adult acute monocytic leukemia)	BTO:0001412	RARA	Treatment: 3 mg/mL ATRA for 3 days	GTRD	EXP049794_U937--adult-acute-monocytic-leukemia-_RARA_MACS_RARA_MA0730.1.damo.pwm.bed	3161
1	3437	RFX1	0.200662633772741	1.01496502818602	4	1724	1567	3182	3182	2160	4	200	203	RFX1 HepG2 (hepatoblastoma) RFX1	HepG2 (hepatoblastoma)	BTO:0000599	RFX1	NA	ENCODE	ENCSR928API_HepG2_RFX1_MACS_RFX1_MA0509.2.damo.pwm.bed	3047
1	3564	SMAD3	0.200662633772741	1.01496502818602	4	1724	1567	3182	3182	2160	4	200	203	SMAD3 HMLE-Twist-ER (breast cancer) SMAD3	HMLE-Twist-ER (breast cancer)	NULL	SMAD3	Treatment: no CellType: Immortalized human mammary epithelial cells	GTRD	EXP047889_HMLE-Twist-ER--breast-cancer-_SMAD3_MACS_SMAD3_MA0795.1.damo.pwm.bed	2749
1	3807	TCF7L1	0.200662633772741	1.01496502818602	4	1724	1567	3182	3182	2160	4	200	203	TCF7L1 HCT-116 (colon carcinoma) TCF7L1	HCT-116 (colon carcinoma)	BTO:0001109	TCF7L1	NA	GTRD	EXP036153_HCT-116--colon-carcinoma-_TCF7L1_MACS_TCF7L1_MA1421.1.damo.pwm.bed	3794
1	3989	TP53	0.200662633772741	1.01496502818602	4	1724	1567	3182	3182	2160	4	200	203	TP53 UO31 TP53	UO31	BTO:0004234	TP53	Treatment: 4GY for 2hrs;	GTRD	EXP051015_UO31_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	3050
1	4097	VDR	0.200662633772741	1.01496502818602	4	1724	1567	3182	3182	2160	4	200	203	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	100 nM 1,25(OH)2D3 for 2h	GTRD	EXP037993_THP-1--acute-monocytic-leukemia-_VDR_MACS_VDR_MA0074.1.damo.pwm.bed	3641
1	932	CTCF	0.200647125608571	0.948469916744504	33	1739	1873	778	1873	1460	35	171	172	CTCF HT1080 (fibrosarcoma) CTCF	HT1080 (fibrosarcoma)	NULL	CTCF	Treatment: 3 uM final concentration of CBL0137 for 6hrs;	GTRD	EXP058384_HT1080--fibrosarcoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45723
1	3370	RELA	0.200647125608571	0.948469916744504	33	1739	1873	778	1873	1460	35	171	172	RELA GM12878 (female B-cells lymphoblastoid cell line) RELA	GM12878 (female B-cells lymphoblastoid cell line)	NULL	RELA		GTRD	EXP054685_GM12878--female-B-cells-lymphoblastoid-cell-line-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	31878
1	295	BHLHE40	0.200112881159496	0.952469369449055	60	1741	1855	137	1855	1240	63	144	144	BHLHE40 BHLHE40	NA	NA	BHLHE40	NA	NA	ENCSR517QHU_GM12878_BHLHE40_MACS_BHLHE40_MA0464.2.damo.pwm.bed	27839
1	1916	GATA1	0.199099938863628	0.946750090839127	32	1742	1881	825	1881	1480	34	172	173	GATA1 CD34+ bone marrow cell-derived erythroid progenitors GATA1	CD34+ bone marrow cell-derived erythroid progenitors	NULL	GATA1		GTRD	EXP038306_CD34--bone-marrow-cell-derived-erythroid-progenitors_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	72354
1	2927	MYC	0.199099938863628	0.946750090839127	32	1742	1881	825	1881	1480	34	172	173	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	SHTERC	GEO	GSE60223_myc_p493-shterc_MACS_MYC_MA0147.3.damo.pwm.bed	11477
1	486	CTCF	0.19845587283281	0.950910515997721	58	1744	1864	154	1864	1250	61	146	146	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		ENCODE	ENCSR000DMV_MCF-7_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	73190
1	1811	FOXA1	0.19845587283281	0.950910515997721	58	1744	1864	154	1864	1250	61	146	146	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	DHT_TNFA	GEO	GSE83860_foxa1_lncap-dht-tnfa_MACS_FOXA1_MA0148.4.damo.pwm.bed	226031
1	479	CTCF	0.197694793329471	0.943268443545227	14	1746	1889	2073	2073	1900	15	190	192	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DME_LNCaP_clone_FGC_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31196
1	1102	ELK1	0.197694793329471	0.943268443545227	14	1746	1889	2073	2073	1900	15	190	192	ELK1 MCF7 (Invasive ductal breast carcinoma) ELK1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ELK1		ENCODE	ENCSR382WLL_MCF-7_ELK1_MACS_ELK1_MA0028.2.damo.pwm.bed	3996
1	1730	FOXA1	0.197694793329471	0.943268443545227	14	1746	1889	2073	2073	1900	15	190	192	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	Passsage: <10	GTRD	EXP049901_T47D--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	25735
1	2934	MYC	0.197694793329471	0.943268443545227	14	1746	1889	2073	2073	1900	15	190	192	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	SHMYC	GEO	GSE77356_myc_u2os-shmyc_MACS_MYC_MA0147.3.damo.pwm.bed	3935
1	3635	SP1	0.197600536413232	0.950092106072381	57	1750	1871	174	1871	1260	60	147	147	SP1 A375 (malignant melanoma) SP1	A375 (malignant melanoma)	BTO:0002806	SP1	DMSO	GTRD	EXP036992_A375--malignant-melanoma-_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	10372
1	1507	FLI1	0.197494734834252	0.944928421983934	31	1751	1885	881	1885	1510	33	173	174	FLI1 UAE FLI1	UAE	NA	FLI1	ZINC	GEO	GSE23730_fli1_uae-zinc_MACS_FLI1_MA0475.2.damo.pwm.bed	18411
1	1767	FOXA1	0.197494734834252	0.944928421983934	31	1751	1885	881	1885	1510	33	173	174	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	SICTR	GEO	GSE40129_foxa1_mcf7-sictr_MACS_FOXA1_MA0148.4.damo.pwm.bed	77862
1	2693	MAX	0.196726418557916	0.949245944945	56	1753	1872	192	1872	1270	59	148	148	MAX MCF7 (Invasive ductal breast carcinoma) MAX	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	MAX		ENCODE	ENCSR000BUL_MCF-7_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	27761
1	2711	MAX	0.195832802213638	0.948370596840695	55	1754	1875	211	1875	1280	58	149	149	MAX MKL-1 (Merkel cell carcinoma) MAX	MKL-1 (Merkel cell carcinoma)	NULL	MAX	Treatment: no treatment Markel Cell: positive	GTRD	EXP048815_MKL-1--Merkel-cell-carcinoma-_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	47125
1	897	CTCF	0.195827394488773	0.942995316475975	30	1755	1893	937	1893	1530	32	174	175	CTCF HUVEC-C (HUVEC, umbilical vein endothelial cells) CTCF	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	CTCF	Treatment: None;	GTRD	EXP054034_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45374
1	1465	ETS1	0.195827394488773	0.942995316475975	30	1755	1893	937	1893	1530	32	174	175	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048197_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	12978
1	1817	FOXA2	0.195827394488773	0.942995316475975	30	1755	1893	937	1893	1530	32	174	175	FOXA2 FOXA2	NA	NA	FOXA2	NA	Array Express	ERP003828_foxa2_mdamb231_MACS_FOXA2_MA0047.3.damo.pwm.bed	55973
1	4114	WT1	0.195827394488773	0.942995316475975	30	1755	1893	937	1893	1530	32	174	175	WT1 HEK293 (embryonic kidney) WT1	HEK293 (embryonic kidney)	NULL	WT1	NA	GTRD	EXP039730_HEK293--embryonic-kidney-_WT1_MACS_WT1_MA1627.1.damo.pwm.bed	11951
1	3627	SP1	0.194918929359646	0.947464525206589	54	1759	1880	225	1880	1290	57	150	150	SP1 HEK293T (embryonic kidney) SP1	HEK293T (embryonic kidney)	BTO:0002181	SP1		Array Express	ERP007114_sp1_hek293t_MACS_SP1_MA0079.4.damo.pwm.bed	11369
1	557	CTCF	0.194093372500531	0.940939943438427	29	1760	1898	1013	1898	1560	31	175	176	CTCF HepG2 (hepatoblastoma) CTCF	HepG2 (hepatoblastoma)	BTO:0000599	CTCF		Array Express	ERP000209_ctcf_hepg2_MACS_CTCF_MA0139.1.damo.pwm.bed	45224
1	593	CTCF	0.194093372500531	0.940939943438427	29	1760	1898	1013	1898	1560	31	175	176	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF		GTRD	EXP030399_WA01--H1--human-embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	60874
1	1864	FOXP1	0.194093372500531	0.940939943438427	29	1760	1898	1013	1898	1560	31	175	176	FOXP1 HepG2 (hepatoblastoma) FOXP1	HepG2 (hepatoblastoma)	BTO:0000599	FOXP1	NA	GTRD	EXP045046_HepG2--hepatoblastoma-_FOXP1_MACS_FOXP1_MA0481.3.damo.pwm.bed	37646
1	3203	OTX2	0.194093372500531	0.940939943438427	29	1760	1898	1013	1898	1560	31	175	176	OTX2 D341 Med (medulloblastoma) OTX2	D341 Med (medulloblastoma)	NULL	OTX2	CRISPR.GFP1	GTRD	EXP038202_D341-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	65967
1	1045	E2F6	0.19401289461747	0.938412692103724	13	1764	1910	2153	2153	1940	14	191	193	E2F6 HeLa S3 (cervical adenocarcinoma) E2F6	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	E2F6		ENCODE	ENCSR000EVK_HeLa-S3_E2F6_MACS_E2F6_MA0471.2.damo.pwm.bed	2946
1	1694	FOXA1	0.19401289461747	0.938412692103724	13	1764	1910	2153	2153	1940	14	191	193	FOXA1 breast tumor FOXA1	breast tumor	NULL	FOXA1	Female	GTRD	EXP040664_breast-tumor_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	13725
1	1736	FOXA1	0.19401289461747	0.938412692103724	13	1764	1910	2153	2153	1940	14	191	193	FOXA1 LNCaP95 FOXA1	LNCaP95	NULL	FOXA1	Treatment: 10 nM ETOH for 4 hrs Genotype: shARfl transfection	GTRD	EXP052942_LNCaP95_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	26148
1	2064	GRHL2	0.19401289461747	0.938412692103724	13	1764	1910	2153	2153	1940	14	191	193	GRHL2 MCF7 (Invasive ductal breast carcinoma) GRHL2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GRHL2	100nm E2 (45 min)	GTRD	EXP040967_MCF7--Invasive-ductal-breast-carcinoma-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	20068
1	2333	JUN	0.19401289461747	0.938412692103724	13	1764	1910	2153	2153	1940	14	191	193	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 10 minute	GTRD	EXP040248_A549--lung-carcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	18233
1	2364	JUN	0.19401289461747	0.938412692103724	13	1764	1910	2153	2153	1940	14	191	193	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: 17beta estradiol 10nM for 1hr;	GTRD	EXP047660_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	15955
1	1887	GABPA	0.193983997978594	0.946526083712187	53	1770	1883	236	1883	1300	56	151	151	GABPA VCaP (prostate carcinoma) GABPA	VCaP (prostate carcinoma)	BTO:0003215	GABPA	ETOH	GEO	GSE49091_gabpa_vcap-etoh_MACS_GABPA_MA0062.3.damo.pwm.bed	35901
1	436	CTCF	0.192287638164492	0.9388110637147	28	1771	1905	1068	1905	1580	30	176	177	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000ALA_endothelial_cell_of_umbilical_vein_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38209
1	906	CTCF	0.192287638164492	0.9388110637147	28	1771	1905	1068	1905	1580	30	176	177	CTCF HeLa S3 (cervical adenocarcinoma) CTCF	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	CTCF	Treatment: None;	GTRD	EXP054043_HeLa-S3--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54354
1	1441	ESR2	0.192287638164492	0.9388110637147	28	1771	1905	1068	1905	1580	30	176	177	ESR2 MDA-MB-231ERb(triple negative breast cancer) ESR2	MDA-MB-231ERb(triple negative breast cancer)	NULL	ESR2	Treatment: 10 nM LY500307 for 3 hr Passage: 20-25	GTRD	EXP048150_MDA-MB-231ERb-triple-negative-breast-cancer-_ESR2_MACS_ESR2_MA0258.2.damo.pwm.bed	13382
1	1451	ETS1	0.192287638164492	0.9388110637147	28	1771	1905	1068	1905	1580	30	176	177	ETS1 ETS1	NA	NA	ETS1	NA	NA	ENCSR534VHI_induced_pluripotent_stem_cell_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	8882
1	2597	JUND	0.192287638164492	0.9388110637147	28	1771	1905	1068	1905	1580	30	176	177	JUND HepG2 (hepatoblastoma) JUND	HepG2 (hepatoblastoma)	BTO:0000599	JUND		ENCODE	ENCSR000EEI_HepG2_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	75441
1	3176	NRF1	0.192047511401179	0.944605931090314	51	1776	1887	261	1887	1310	54	153	153	NRF1 K562 (myelogenous leukemia) NRF1	K562 (myelogenous leukemia)	NULL	NRF1		ENCODE	ENCSR998AJK_K562_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	13918
1	1092	ELF3	0.191044100780188	0.943559247731239	50	1777	1888	275	1888	1310	53	154	154	ELF3 HepG2 (hepatoblastoma) ELF3	HepG2 (hepatoblastoma)	BTO:0000599	ELF3		GTRD	EXP040160_HepG2--hepatoblastoma-_ELF3_MACS_ELF3_MA0640.2.damo.pwm.bed	37428
1	551	CTCF	0.19040460592257	0.936472640302474	27	1778	1918	1135	1918	1610	29	177	178	CTCF OCI-LY7 (diffuse large B-cell lymphoma) CTCF	OCI-LY7 (diffuse large B-cell lymphoma)	NULL	CTCF		ENCODE	ENCSR027HML_OCI-LY7_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49918
1	1121	ERG	0.19040460592257	0.936472640302474	27	1778	1918	1135	1918	1610	29	177	178	ERG prostate cancer ERG	prostate cancer	NULL	ERG	NULL	GTRD	EXP000736_prostate-cancer_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	10208
1	1459	ETS1	0.19040460592257	0.936472640302474	27	1778	1918	1135	1918	1610	29	177	178	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1		GTRD	EXP038274_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	12009
1	2069	GRHL2	0.19040460592257	0.936472640302474	27	1778	1918	1135	1918	1610	29	177	178	GRHL2 MCF7 WS8 cells GRHL2	MCF7 WS8 cells	NULL	GRHL2	Treatment: 45 min ethanol	GTRD	EXP048455_MCF7-WS8-cells_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	27719
1	4073	USF1	0.19040460592257	0.936472640302474	27	1778	1918	1135	1918	1610	29	177	178	USF1 K562 (myelogenous leukemia) USF1	K562 (myelogenous leukemia)	NULL	USF1		ENCODE	ENCSR000BKT_K562_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	31535
1	99	AR	0.189979456173387	0.93287961299056	12	1783	1933	2233	2233	1980	13	192	194	AR LTAD (long term androgen deprivation) AR	LTAD (long term androgen deprivation)	NULL	AR	Treatment: 24h DHT 10 nM siControl treated	GTRD	EXP049451_LTAD--long-term-androgen-deprivation-_AR_MACS_AR_MA0007.3.damo.pwm.bed	41997
1	570	CTCF	0.189979456173387	0.93287961299056	12	1783	1933	2233	2233	1980	13	192	194	CTCF CHRF28811 CTCF	CHRF28811	NA	CTCF		Array Express	ERP008568_ctcf_chrf28811_MACS_CTCF_MA0139.1.damo.pwm.bed	21169
1	1280	ESR1	0.189979456173387	0.93287961299056	12	1783	1933	2233	2233	1980	13	192	194	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP038768_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	19301
1	2124	HNF4A	0.189979456173387	0.93287961299056	12	1783	1933	2233	2233	1980	13	192	194	HNF4A HepG2 (hepatoblastoma) HNF4A	HepG2 (hepatoblastoma)	BTO:0000599	HNF4A	NULL	GTRD	EXP000306_HepG2--hepatoblastoma-_HNF4A_MACS_HNF4A_MA0114.4.damo.pwm.bed	15842
1	3078	NR2F2	0.189979456173387	0.93287961299056	12	1783	1933	2233	2233	1980	13	192	194	NR2F2 uterus NR2F2	uterus	BTO:0001424	NR2F2	STROMA_ENDOMETRIUM	GEO	GSE52008_nr2f2_stroma-endometrium_MACS_NR2F2_MA1111.1.damo.pwm.bed	16401
1	3352	RELA	0.189979456173387	0.93287961299056	12	1783	1933	2233	2233	1980	13	192	194	RELA SW480 (colon adenocarcinoma) RELA	SW480 (colon adenocarcinoma)	BTO:0000038	RELA	TNF-alpha 16 h	GTRD	EXP036903_SW480--colon-adenocarcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	14544
1	3928	TFAP2C	0.189301982987666	0.946290230139949	83	1789	1884	11	1884	1230	87	121	120	TFAP2C SK-BR-3 (breast adenocarcinoma) TFAP2C	SK-BR-3 (breast adenocarcinoma)	BTO:0002419	TFAP2C		GEO	GSE36351_tfap2c_skbr3_MACS_TFAP2C_MA0524.2.damo.pwm.bed	94946
1	2653	KLF9	0.188961867875548	0.941342701164594	48	1790	1897	317	1897	1330	51	156	156	KLF9 HEK293 (embryonic kidney) KLF9	HEK293 (embryonic kidney)	NULL	KLF9	NA	GTRD	EXP039681_HEK293--embryonic-kidney-_KLF9_MACS_KLF9_MA1107.2.damo.pwm.bed	11770
1	653	CTCF	0.188438053256484	0.933969747001147	26	1791	1926	1204	1926	1640	28	178	179	CTCF epidermal keratinocytes CTCF	epidermal keratinocytes	NULL	CTCF	day3 of differentiation	GTRD	EXP037597_epidermal-keratinocytes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36232
1	1229	ESR1	0.188438053256484	0.933969747001147	26	1791	1926	1204	1926	1640	28	178	179	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	IL1b for 45m	GTRD	EXP036982_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	23633
1	1524	FOS	0.188438053256484	0.933969747001147	26	1791	1926	1204	1926	1640	28	178	179	FOS K562 (myelogenous leukemia) FOS	K562 (myelogenous leukemia)	NULL	FOS	NULL	GTRD	EXP000310_K562--myelogenous-leukemia-_FOS_MACS_FOS_MA1141.1.damo.pwm.bed	21100
1	3415	REST	0.188438053256484	0.933969747001147	26	1791	1926	1204	1926	1640	28	178	179	REST A549 (lung carcinoma) REST	A549 (lung carcinoma)	BTO:0000018	REST		GTRD	EXP036864_A549--lung-carcinoma-_REST_MACS_REST_MA0138.2.damo.pwm.bed	8073
1	1145	ERG	0.187880819199027	0.940167909434187	47	1795	1902	333	1902	1340	50	157	157	ERG ME-1 (acute myeloid leukemia ) ERG	ME-1 (acute myeloid leukemia )	NULL	ERG		GEO	GSE46044_erg_me1_MACS_ERG_MA0474.2.damo.pwm.bed	34772
1	2640	KLF5	0.186771543329571	0.938945151044176	46	1796	1903	349	1903	1350	49	158	158	KLF5 BICR31 (Tongue squamous cell carcinoma cell) KLF5	BICR31 (Tongue squamous cell carcinoma cell)	NULL	KLF5	Treatment: untreated Tumor: Head and neck squamous cell carcinomas	GTRD	EXP049087_BICR31-Tongue-squamous-cell-carcinoma-cell-_KLF5_MACS_KLF5_MA0599.1.damo.pwm.bed	22483
1	3547	RXRA	0.186771543329571	0.938945151044176	46	1796	1903	349	1903	1350	49	158	158	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP045021_liver_RXRA_MACS_RXRA_MA1146.1.damo.pwm.bed	47674
1	101	AR	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	AR R1-AD1 (prostate cancer) AR	R1-AD1 (prostate cancer)	NULL	AR	Treatment: 0.1% DMSO + 1 nM ethanol for 4 hrs	GTRD	EXP049662_R1-AD1--prostate-cancer-_AR_MACS_AR_MA0007.3.damo.pwm.bed	3709
1	155	AR	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	SHGATA2	GEO	GSE52725_AR_lncap-shgata2_MACS_AR_MA0007.3.damo.pwm.bed	6072
1	190	AR	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	RPMIFBS	GEO	GSE69043_AR_lncap-rpmifbs_MACS_AR_MA0007.3.damo.pwm.bed	4426
1	283	BATF3	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	BATF3 KK1 (Adult T acute lymphoblastic leukemia) BATF3	KK1 (Adult T acute lymphoblastic leukemia)	NULL	BATF3	Treatment: BirA enzyme were transduced with N-terminally tagged BATF3 (pRCMV/TO-flag-BIOTIN-BATF3-puro)	GTRD	EXP049476_KK1--Adult-T-acute-lymphoblastic-leukemia-_BATF3_MACS_BATF3_MA0835.2.damo.pwm.bed	10506
1	1004	DUX4	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	DUX4 HEK293 (embryonic kidney) DUX4	HEK293 (embryonic kidney)	NULL	DUX4		GEO	GSE75791_dux4_hek293_MACS_DUX4_MA0468.1.damo.pwm.bed	8376
1	1103	ELK1	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	ELK1 A549 (lung carcinoma) ELK1	A549 (lung carcinoma)	BTO:0000018	ELK1		ENCODE	ENCSR623KNM_A549_ELK1_MACS_ELK1_MA0028.2.damo.pwm.bed	351
1	1312	ESR1	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	100nm E2 (90 min)	GTRD	EXP040961_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12629
1	1512	FLI1	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	FLI1 SK-N-MC (Askin tumor) FLI1	SK-N-MC (Askin tumor)	BTO:0002914	FLI1	SHGFP_96H	GEO	GSE61944_fli1_skmnc-shgfp-96h_MACS_FLI1_MA0475.2.damo.pwm.bed	3773
1	1691	FOXA1	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	FOXA1 liver FOXA1	liver	BTO:0000759	FOXA1		GTRD	EXP039865_liver_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	7027
1	1924	GATA1	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	GATA1 CD34+ cells GATA1	CD34+ cells	NULL	GATA1	ERYTH_BIO	GEO	GSE29194_gata1_CD34-eryth-bio_MACS_GATA1_MA0035.4.damo.pwm.bed	15915
1	1944	GATA2	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	GATA2 HUVEC-C (HUVEC, umbilical vein endothelial cells) GATA2	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	GATA2	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048217_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	6980
1	2014	GATA4	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	GATA4 iPSC-derived cardiomyocytes GATA4	iPSC-derived cardiomyocytes	NULL	GATA4		GTRD	EXP037712_iPSC-derived-cardiomyocytes_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	7746
1	2017	GATA4	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	GATA4 iPSC-derived cardiomyocytes GATA4	iPSC-derived cardiomyocytes	NULL	GATA4		GTRD	EXP037718_iPSC-derived-cardiomyocytes_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	7862
1	2181	HSF1	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	HSF1 breast HSF1	breast	NA	HSF1	tumor	GEO	GSE38901_hsf1_breast-tumor_MACS_HSF1_MA0486.2.damo.pwm.bed	2186
1	2185	HSF1	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	HSF1 HME1 HSF1	HME1	NA	HSF1	HEAT	GEO	GSE38901_hsf1_hme1-heat_MACS_HSF1_MA0486.2.damo.pwm.bed	2679
1	2205	IRF2	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	IRF2 CD34+ cells IRF2	CD34+ cells	NULL	IRF2	ADULT	GEO	GSE70660_irf2_cd34-adult_MACS_IRF2_MA0051.1.damo.pwm.bed	2818
1	2473	JUN	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	JUN BT-549 (breast invasive ductal carcinoma) JUN	BT-549 (breast invasive ductal carcinoma)	BTO:0002548	JUN	TNF	GEO	GSE71976_jun_bt549-tnf_MACS_JUN_MA0489.1.damo.pwm.bed	3168
1	2661	LHX2	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	LHX2 retina LHX2	retina	BTO:0001175	LHX2	pigment	GEO	GSE60024_lhx2_retinal-pigment_MACS_LHX2_MA0700.2.damo.pwm.bed	16574
1	2745	MEF2D	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	MEF2D K562 (myelogenous leukemia) MEF2D	K562 (myelogenous leukemia)	NULL	MEF2D	NA	GTRD	EXP039833_K562--myelogenous-leukemia-_MEF2D_MACS_MEF2D_MA0773.1.damo.pwm.bed	4753
1	3096	NR3C1	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	NR3C1 embryonic kidney NR3C1	embryonic kidney	NULL	NR3C1	dexamethasone	GTRD	EXP032209_embryonic-kidney_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	3085
1	3124	NR3C1	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	NR3C1 MCF-7 C4-12 (invasive breast ductal carcinoma) NR3C1	MCF-7 C4-12 (invasive breast ductal carcinoma)	NULL	NR3C1	Female	GTRD	EXP040662_MCF-7-C4-12--invasive-breast-ductal-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	7915
1	3152	NR3C1	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	NR3C1 LNCaP (prostate carcinoma) NR3C1	LNCaP (prostate carcinoma)	BTO:0001321	NR3C1	1F5_SIFOXA1	GEO	GSE30623_nr3c1_lncap-1f5-sifoxa1_MACS_NR3C1_MA0113.3.damo.pwm.bed	14366
1	3231	PDX1	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	PDX1 hESC-1 (Embryonic stem cells) PDX1	hESC-1 (Embryonic stem cells)	NULL	PDX1		GEO	GSE58685_pdx1_esc_MACS_PDX1_MA0132.2.damo.pwm.bed	9220
1	3273	POU5F1	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	POU5F1 iPSC (induced pluripotent stem cells) POU5F1	iPSC (induced pluripotent stem cells)	NULL	POU5F1	Treatment: iPS protocol 3s2 Passage: 20	GTRD	EXP048953_iPSC--induced-pluripotent-stem-cells-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	8701
1	3413	REST	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	REST WA01 (H1, human embryonic stem cells) REST	WA01 (H1, human embryonic stem cells)	NULL	REST		GTRD	EXP036860_WA01--H1--human-embryonic-stem-cells-_REST_MACS_REST_MA0138.2.damo.pwm.bed	4810
1	3579	SMAD4	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	SMAD4 hESC-1 (Embryonic stem cells) SMAD4	hESC-1 (Embryonic stem cells)	NULL	SMAD4	NA	GEO	GSE29422_smad4_esc_MACS_SMAD4_MA1153.1.damo.pwm.bed	1528
1	3698	SREBF1	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	SREBF1 HepG2 (hepatoblastoma) SREBF1	HepG2 (hepatoblastoma)	BTO:0000599	SREBF1	DMEM with 0.5% BSA supplemented with 100 nM insulin and 10 uM 22-hydroxycholesterol for 6 h. (Snyder)	ENCODE	ENCSR000EEO_HepG2_SREBF1_MACS_SREBF1_MA0829.2.damo.pwm.bed	718
1	3760	STAT6	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	STAT6 monocyte-derived macrophages STAT6	monocyte-derived macrophages	NULL	STAT6	IL-4	GTRD	EXP036840_monocyte-derived-macrophages_STAT6_MACS_STAT6_MA0520.1.damo.pwm.bed	3624
1	3836	TEAD4	0.186752768352704	1.01489055395544	3	1798	1582	3316	3316	2230	3	201	204	TEAD4 MCF7 (Invasive ductal breast carcinoma) TEAD4	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TEAD4		ENCODE	ENCSR000BUO_MCF-7_TEAD4_MACS_TEAD4_MA0809.2.damo.pwm.bed	6589
1	642	CTCF	0.186381023128242	0.93128405831589	25	1827	1940	1262	1940	1680	27	179	180	CTCF MM1.S (plasma cell myeloma) CTCF	MM1.S (plasma cell myeloma)	BTO:0003933	CTCF		GTRD	EXP036854_MM1.S--plasma-cell-myeloma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37929
1	2430	JUN	0.186381023128242	0.93128405831589	25	1827	1940	1262	1940	1680	27	179	180	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057912_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	33939
1	3208	OTX2	0.186381023128242	0.93128405831589	25	1827	1940	1262	1940	1680	27	179	180	OTX2 D283 Med (medulloblastoma) OTX2	D283 Med (medulloblastoma)	NULL	OTX2	shOTX2.1393	GTRD	EXP038210_D283-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	85490
1	1116	ERF	0.185529352045289	0.926362330709565	11	1830	1960	2332	2332	2040	12	193	195	ERF VCaP (prostate carcinoma) ERF	VCaP (prostate carcinoma)	BTO:0003215	ERF	NA	GTRD	EXP038638_VCaP--prostate-carcinoma-_ERF_MACS_ERF_MA0760.1.damo.pwm.bed	5056
1	1930	GATA2	0.185529352045289	0.926362330709565	11	1830	1960	2332	2332	2040	12	193	195	GATA2 GATA2	NA	NA	GATA2	NA	NA	ENCSR000EVW_endothelial_cell_of_umbilical_vein_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	22412
1	3288	PPARG	0.185529352045289	0.926362330709565	11	1830	1960	2332	2332	2040	12	193	195	PPARG subcutaneous white adipose tissue PPARG	subcutaneous white adipose tissue	NULL	PPARG		GTRD	EXP034423_subcutaneous-white-adipose-tissue_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	3917
1	4013	TP53	0.185529352045289	0.926362330709565	11	1830	1960	2332	2332	2040	12	193	195	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	NUT	GEO	GSE46641_tp53_u2os-nut_MACS_TP53_MA0106.3.damo.pwm.bed	12520
1	405	CEBPB	0.184225707393869	0.928394429874472	24	1834	1951	1324	1951	1700	26	180	181	CEBPB hMSC CEBPB	hMSC	NA	CEBPB		GEO	GSE68864_cebpb_hmsc_MACS_CEBPB_MA0466.2.damo.pwm.bed	26163
1	443	CTCF	0.184225707393869	0.928394429874472	24	1834	1951	1324	1951	1700	26	180	181	CTCF myotube CTCF	myotube	BTO:0001760	CTCF		ENCODE	ENCSR000ANS_myotube_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46072
1	597	CTCF	0.184225707393869	0.928394429874472	24	1834	1951	1324	1951	1700	26	180	181	CTCF HUVEC-C (HUVEC, umbilical vein endothelial cells) CTCF	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	CTCF		GTRD	EXP030403_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37816
1	1262	ESR1	0.184225707393869	0.928394429874472	24	1834	1951	1324	1951	1700	26	180	181	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Doxycycline	GTRD	EXP038375_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	58051
1	1835	FOXA2	0.184225707393869	0.928394429874472	24	1834	1951	1324	1951	1700	26	180	181	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL Genotype: cTermCDT1	GTRD	EXP049294_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	73106
1	2648	KLF5	0.184225707393869	0.928394429874472	24	1834	1951	1324	1951	1700	26	180	181	KLF5 HCC95 (squamous cell lung carcinoma) KLF5	HCC95 (squamous cell lung carcinoma)	NULL	KLF5	Treatment: Over-expressing KLF5 WT	GTRD	EXP049100_HCC95--squamous-cell-lung-carcinoma-_KLF5_MACS_KLF5_MA0599.1.damo.pwm.bed	7498
1	2794	MYC	0.18326085307569	0.934957784594986	43	1840	1923	429	1923	1400	46	161	161	MYC K562 (myelogenous leukemia) MYC	K562 (myelogenous leukemia)	NULL	MYC	Interferon gamma treatment - 30 minutes (Snyder)	ENCODE	ENCSR000EGS_K562_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	16280
1	66	AR	0.182024692201582	0.933510477218945	42	1841	1931	454	1931	1410	45	162	162	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR		GTRD	EXP038636_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	25963
1	521	CTCF	0.181963306623696	0.925276334544061	23	1842	1964	1391	1964	1730	25	181	182	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DTR_epithelial_cell_of_esophagus_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36760
1	925	CTCF	0.181963306623696	0.925276334544061	23	1842	1964	1391	1964	1730	25	181	182	CTCF MCF7L-TamR(immortalized breast epithelial, tamoxifen resistant cell line) C	MCF7L-TamR(immortalized breast epithelial, tamoxifen resistant cell line)	NULL	CTCF		GTRD	EXP057868_MCF7L-TamR-immortalized-breast-epithelial--tamoxifen-resistant-cell-line-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36036
1	1373	ESR1	0.181963306623696	0.925276334544061	23	1842	1964	1391	1964	1730	25	181	182	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 10 nM 17-beta-estradiol for 30 mins Genotype: wildtype ER	GTRD	EXP053340_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	53628
1	3489	RUNX1	0.181963306623696	0.925276334544061	23	1842	1964	1391	1964	1730	25	181	182	RUNX1 RUNX1	NA	NA	RUNX1	NA	GEO	GSE42075_runx1_sem_MACS_RUNX1_MA0002.2.damo.pwm.bed	33164
1	115	AR	0.1805788597465	0.918669860103388	10	1846	1982	2442	2442	2090	11	194	196	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment:  transfected twice with with 5nM of siLINC00844 every 24 hours, 100nM of DHT for 2 hrs Genotype: transfected with siLINC00844	GTRD	EXP052984_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	26952
1	1209	ESR1	0.1805788597465	0.918669860103388	10	1846	1982	2442	2442	2090	11	194	196	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	sgRNA_enh588	GTRD	EXP035791_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	9491
1	1550	FOS	0.1805788597465	0.918669860103388	10	1846	1982	2442	2442	2090	11	194	196	FOS THP-1 (acute monocytic leukemia) FOS	THP-1 (acute monocytic leukemia)	BTO:0001370	FOS	Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA)	GTRD	EXP047824_THP-1--acute-monocytic-leukemia-_FOS_MACS_FOS_MA0099.3.damo.pwm.bed	8181
1	1552	FOS	0.1805788597465	0.918669860103388	10	1846	1982	2442	2442	2090	11	194	196	FOS THP-1 (acute monocytic leukemia) FOS	THP-1 (acute monocytic leukemia)	BTO:0001370	FOS	Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA)	GTRD	EXP047824_THP-1--acute-monocytic-leukemia-_FOS_MACS_FOS_MA1134.1.damo.pwm.bed	7915
1	1600	FOSL2	0.1805788597465	0.918669860103388	10	1846	1982	2442	2442	2090	11	194	196	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039732_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	8681
1	1601	FOSL2	0.1805788597465	0.918669860103388	10	1846	1982	2442	2442	2090	11	194	196	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039732_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	9095
1	1602	FOSL2	0.1805788597465	0.918669860103388	10	1846	1982	2442	2442	2090	11	194	196	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039732_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	9041
1	1603	FOSL2	0.1805788597465	0.918669860103388	10	1846	1982	2442	2442	2090	11	194	196	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039732_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	9039
1	2009	GATA4	0.1805788597465	0.918669860103388	10	1846	1982	2442	2442	2090	11	194	196	GATA4 HUES64 (embryonic stem cells) GATA4	HUES64 (embryonic stem cells)	NULL	GATA4		GTRD	EXP036708_HUES64--embryonic-stem-cells-_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	30923
1	2073	GRHL2	0.1805788597465	0.918669860103388	10	1846	1982	2442	2442	2090	11	194	196	GRHL2 OVCAR3 (high grade ovarian serous adenocarcinoma) GRHL2	OVCAR3 (high grade ovarian serous adenocarcinoma)	BTO:0000812	GRHL2		GEO	GSE71018_grhl2_ovcar3_MACS_GRHL2_MA1105.2.damo.pwm.bed	10555
1	2378	JUN	0.1805788597465	0.918669860103388	10	1846	1982	2442	2442	2090	11	194	196	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: tamoxifen 1μM for 1hr;	GTRD	EXP047661_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	16135
1	2399	JUN	0.1805788597465	0.918669860103388	10	1846	1982	2442	2442	2090	11	194	196	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048211_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	8547
1	2400	JUN	0.1805788597465	0.918669860103388	10	1846	1982	2442	2442	2090	11	194	196	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048211_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	8273
1	3138	NR3C1	0.1805788597465	0.918669860103388	10	1846	1982	2442	2442	2090	11	194	196	NR3C1 A1-2 (breast cancer cells) NR3C1	A1-2 (breast cancer cells)	NULL	NR3C1	Treatment: 1hr Dex	GTRD	EXP048394_A1-2--breast-cancer-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	28085
1	469	CTCF	0.180113229577393	0.937664433864716	68	1860	1916	56	1916	1280	72	136	135	CTCF GM19238 (female B-cells lymphoblastoid cell lines) CTCF	GM19238 (female B-cells lymphoblastoid cell lines)	NULL	CTCF		ENCODE	ENCSR000DLD_GM19238_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	73749
1	1047	E2F6	0.180113229577393	0.937664433864716	68	1860	1916	56	1916	1280	72	136	135	E2F6 K562 (myelogenous leukemia) E2F6	K562 (myelogenous leukemia)	NULL	E2F6	NULL	GTRD	EXP000107_K562--myelogenous-leukemia-_E2F6_MACS_E2F6_MA0471.2.damo.pwm.bed	33037
1	610	CTCF	0.179583860445407	0.921901157571145	22	1862	1973	1459	1973	1760	24	182	183	CTCF LNCaP (prostate carcinoma) CTCF	LNCaP (prostate carcinoma)	BTO:0001321	CTCF		GTRD	EXP031556_LNCaP--prostate-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38157
1	1330	ESR1	0.179583860445407	0.921901157571145	22	1862	1973	1459	1973	1760	24	182	183	ESR1 MDA-MB-134 (invasive lobular breast carcinoma) ESR1	MDA-MB-134 (invasive lobular breast carcinoma)	NULL	ESR1	Treatment: a cocktail of 10 µM forskolin plus 100 µM 3-isobutyl-1-methylxanthine (FI) for 1hr Passage: between 10 and12 CellType: Epithelial ERalpha positive breast cancer cell line	GTRD	EXP048179_MDA-MB-134--invasive-lobular-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	29685
1	1662	FOXA1	0.179583860445407	0.921901157571145	22	1862	1973	1459	1973	1760	24	182	183	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	shTET1	GTRD	EXP035558_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	51828
1	2770	MXI1	0.179443363359669	0.930413841278365	40	1865	1943	502	1943	1440	43	164	164	MXI1 HepG2 (hepatoblastoma) MXI1	HepG2 (hepatoblastoma)	BTO:0000599	MXI1	NA	ENCODE	ENCSR000EDU_HepG2_MXI1_MACS_MXI1_MA1108.2.damo.pwm.bed	12228
1	2652	KLF9	0.178094381019716	0.928754890014295	39	1866	1947	547	1947	1450	42	165	165	KLF9 MCF7 (Invasive ductal breast carcinoma) KLF9	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	KLF9	NA	ENCODE	ENCSR125ZYC_MCF-7_KLF9_MACS_KLF9_MA1107.2.damo.pwm.bed	10799
1	3082	NR2F6	0.178094381019716	0.928754890014295	39	1866	1947	547	1947	1450	42	165	165	NR2F6 HepG2 (hepatoblastoma) NR2F6	HepG2 (hepatoblastoma)	BTO:0000599	NR2F6	NA	GTRD	EXP039812_HepG2--hepatoblastoma-_NR2F6_MACS_NR2F6_MA0728.1.damo.pwm.bed	41750
1	3524	RXRA	0.178094381019716	0.928754890014295	39	1866	1947	547	1947	1450	42	165	165	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP040231_liver_RXRA_MACS_RXRA_MA0494.1.damo.pwm.bed	39747
1	3525	RXRA	0.178094381019716	0.928754890014295	39	1866	1947	547	1947	1450	42	165	165	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP040231_liver_RXRA_MACS_RXRA_MA0512.2.damo.pwm.bed	40196
1	578	CTCF	0.177156550090543	0.93462241298028	64	1870	1924	95	1924	1300	68	140	139	CTCF lymphoblastoid cells CTCF	lymphoblastoid cells	NULL	CTCF	NULL	GTRD	EXP000777_lymphoblastoid-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	69154
1	1926	GATA1	0.177156550090543	0.93462241298028	64	1870	1924	95	1924	1300	68	140	139	GATA1 CD34+ cells GATA1	CD34+ cells	NULL	GATA1		GEO	GSE52924_gata1_cd34_MACS_GATA1_MA0035.4.damo.pwm.bed	167676
1	377	CEBPB	0.177076040760254	0.918235307840223	21	1872	1996	1535	1996	1800	23	183	184	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039871_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	22591
1	421	CREB1	0.177076040760254	0.918235307840223	21	1872	1996	1535	1996	1800	23	183	184	CREB1 MCF7 (Invasive ductal breast carcinoma) CREB1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CREB1		GTRD	EXP039430_MCF7--Invasive-ductal-breast-carcinoma-_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	31589
1	657	CTCF	0.177076040760254	0.918235307840223	21	1872	1996	1535	1996	1800	23	183	184	CTCF E14 retina CTCF	E14 retina	NULL	CTCF		GTRD	EXP037799_E14-retina_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	26425
1	1710	FOXA1	0.177076040760254	0.918235307840223	21	1872	1996	1535	1996	1800	23	183	184	FOXA1 MCF7 WS8 cells FOXA1	MCF7 WS8 cells	NULL	FOXA1	Treatment: 45 min 10^-8 E2	GTRD	EXP048449_MCF7-WS8-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	41804
1	2345	JUN	0.177076040760254	0.918235307840223	21	1872	1996	1535	1996	1800	23	183	184	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 20 minute	GTRD	EXP040320_A549--lung-carcinoma-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	20429
1	3087	NR3C1	0.177076040760254	0.918235307840223	21	1872	1996	1535	1996	1800	23	183	184	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	1 h with 5 nM Dexamethasone (Myers)	ENCODE	ENCSR000BHG_A549_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	25540
1	4130	YY1	0.177076040760254	0.918235307840223	21	1872	1996	1535	1996	1800	23	183	184	YY1 NT2-D1 (embryonic carcinoma) YY1	NT2-D1 (embryonic carcinoma)	BTO:0000946	YY1		ENCODE	ENCSR000EXG_NT2_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	8132
1	848	CTCF	0.176703732043048	0.927014985597901	38	1879	1958	576	1958	1470	41	166	166	CTCF WA09 (embryonic stem cells) CTCF	WA09 (embryonic stem cells)	NULL	CTCF	Treatment: under normal conditions	GTRD	EXP047929_WA09--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	72780
1	2863	MYC	0.176703732043048	0.927014985597901	38	1879	1958	576	1958	1470	41	166	166	MYC HCT-116 (colon carcinoma) MYC	HCT-116 (colon carcinoma)	BTO:0001109	MYC	na	GTRD	EXP037785_HCT-116--colon-carcinoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	9626
1	581	CTCF	0.176377715409052	0.933799469465492	63	1881	1930	103	1930	1300	67	141	140	CTCF lymphoblastoid cells CTCF	lymphoblastoid cells	NULL	CTCF	NULL	GTRD	EXP000780_lymphoblastoid-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	66982
1	2698	MAX	0.175582046083403	0.932949376821981	62	1882	1932	118	1932	1310	66	142	141	MAX K562 (myelogenous leukemia) MAX	K562 (myelogenous leukemia)	NULL	MAX		ENCODE	ENCSR000EFV_K562_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	42500
1	535	CTCF	0.175269119098595	0.925188054903124	37	1883	1968	607	1968	1490	40	167	167	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DVQ_fibroblast_of_villous_mesenchyme_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46685
1	2982	NEUROG2	0.175269119098595	0.925188054903124	37	1883	1968	607	1968	1490	40	167	167	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	1 DPT	GTRD	EXP037154_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	34191
1	169	AR	0.175018126988902	0.909449353607601	9	1885	2033	2564	2564	2160	10	195	197	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	DHT24H_SHFOXA1	GEO	GSE58428_AR_vcap-dht24h-shfoxa1_MACS_AR_MA0007.3.damo.pwm.bed	30949
1	877	CTCF	0.175018126988902	0.909449353607601	9	1885	2033	2564	2564	2160	10	195	197	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: no stress  Source: T47D whole cell	GTRD	EXP053044_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31916
1	1203	ESR1	0.175018126988902	0.909449353607601	9	1885	2033	2564	2564	2160	10	195	197	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP034901_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	10873
1	1771	FOXA1	0.175018126988902	0.909449353607601	9	1885	2033	2564	2564	2160	10	195	197	FOXA1 DU145 (prostate carcinoma) FOXA1	DU145 (prostate carcinoma)	BTO:0001332	FOXA1	FOXA1_ARQ6540X	GEO	GSE47987_foxa1_du145-foxa1-arq6540x_MACS_FOXA1_MA0148.4.damo.pwm.bed	50677
1	2138	HNF4A	0.175018126988902	0.909449353607601	9	1885	2033	2564	2564	2160	10	195	197	HNF4A hiPSC HNF4A	hiPSC	NULL	HNF4A	Developmental stage: day 8;	GTRD	EXP057766_hiPSC_HNF4A_MACS_HNF4A_MA0114.4.damo.pwm.bed	6433
1	2550	JUNB	0.175018126988902	0.909449353607601	9	1885	2033	2564	2564	2160	10	195	197	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP040036_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	12431
1	2551	JUNB	0.175018126988902	0.909449353607601	9	1885	2033	2564	2564	2160	10	195	197	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP040036_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	11882
1	2553	JUNB	0.175018126988902	0.909449353607601	9	1885	2033	2564	2564	2160	10	195	197	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP040036_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	11993
1	2554	JUNB	0.175018126988902	0.909449353607601	9	1885	2033	2564	2564	2160	10	195	197	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP040036_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	12490
1	2555	JUNB	0.175018126988902	0.909449353607601	9	1885	2033	2564	2564	2160	10	195	197	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP040036_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	11986
1	2569	JUNB	0.175018126988902	0.909449353607601	9	1885	2033	2564	2564	2160	10	195	197	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP040136_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	10013
1	3118	NR3C1	0.175018126988902	0.909449353607601	9	1885	2033	2564	2564	2160	10	195	197	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 20 minute	GTRD	EXP040221_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	21901
1	3732	STAT3	0.175018126988902	0.909449353607601	9	1885	2033	2564	2564	2160	10	195	197	STAT3 HeLa S3 (cervical adenocarcinoma) STAT3	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	STAT3		ENCODE	ENCSR000EDC_HeLa-S3_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	8628
1	2949	MYCN	0.174769014289745	0.932070928653011	61	1898	1939	127	1939	1320	65	143	142	MYCN SH-EP-NMYCER MYCN	SH-EP-NMYCER	NULL	MYCN	Treatment: 200 nM 4-OHT continuously for 3 hrs;	GTRD	EXP058025_SH-EP-NMYCER_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	24014
1	718	CTCF	0.17442689779034	0.914239086747396	20	1899	2013	1606	2013	1840	22	184	185	CTCF thyroid gland CTCF	thyroid gland	NULL	CTCF		GTRD	EXP039645_thyroid-gland_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29296
1	779	CTCF	0.17442689779034	0.914239086747396	20	1899	2013	1606	2013	1840	22	184	185	CTCF RWPE1 (prostate epithelial cells) CTCF	RWPE1 (prostate epithelial cells)	BTO:0003709	CTCF		GTRD	EXP040101_RWPE1--prostate-epithelial-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	25505
1	1359	ESR1	0.17442689779034	0.914239086747396	20	1899	2013	1606	2013	1840	22	184	185	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 10nM Estradiol + 10 nM Aldosterone for 45 mins Genotype: ER+/PR+	GTRD	EXP049943_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	6551
1	2077	HAND2	0.17442689779034	0.914239086747396	20	1899	2013	1606	2013	1840	22	184	185	HAND2 Kelly (neuroblastoma) HAND2	Kelly (neuroblastoma)	NULL	HAND2	Treatment: untreated	GTRD	EXP049486_Kelly--neuroblastoma-_HAND2_MACS_HAND2_MA1638.1.damo.pwm.bed	28262
1	2414	JUN	0.17442689779034	0.914239086747396	20	1899	2013	1606	2013	1840	22	184	185	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: non-transformed	GTRD	EXP048571_MCF10A-ER-Src_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	38020
1	3030	NFYB	0.17442689779034	0.914239086747396	20	1899	2013	1606	2013	1840	22	184	185	NFYB GM12878 (female B-cells lymphoblastoid cell line) NFYB	GM12878 (female B-cells lymphoblastoid cell line)	NULL	NFYB	NA	ENCODE	ENCSR000DNM_GM12878_NFYB_MACS_NFYB_MA0502.2.damo.pwm.bed	7167
1	451	CTCF	0.173788059128919	0.92326740180163	36	1905	1970	645	1970	1510	39	168	168	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000AUF_A549_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	60800
1	614	CTCF	0.173788059128919	0.92326740180163	36	1905	1970	645	1970	1510	39	168	168	CTCF HCT-116 (colon carcinoma) CTCF	HCT-116 (colon carcinoma)	BTO:0001109	CTCF	DNMT1KO, DNMT3BKO	GTRD	EXP032762_HCT-116--colon-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	60838
1	1014	E2F1	0.17308861380452	0.930223750412107	59	1907	1944	143	1944	1330	63	145	144	E2F1 LNCaP (prostate carcinoma) E2F1	LNCaP (prostate carcinoma)	BTO:0001321	E2F1	BICALUTAMIDE	GTRD	EXP032860_LNCaP--prostate-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	14525
1	1878	GABPA	0.172257863478931	0.921245625180132	35	1908	1976	691	1976	1520	38	169	169	GABPA CD34+CD133+ hematopoietic progenitors GABPA	CD34+CD133+ hematopoietic progenitors	NULL	GABPA	NULL	GTRD	EXP000224_CD34-CD133--hematopoietic-progenitors_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	9848
1	2055	GLIS2	0.172257863478931	0.921245625180132	35	1908	1976	691	1976	1520	38	169	169	GLIS2 HEK293 (embryonic kidney) GLIS2	HEK293 (embryonic kidney)	NULL	GLIS2	NA	GTRD	EXP040045_HEK293--embryonic-kidney-_GLIS2_MACS_GLIS2_MA0736.1.damo.pwm.bed	14280
1	482	CTCF	0.172220045959388	0.929252199085649	58	1910	1945	154	1945	1340	62	146	145	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		ENCODE	ENCSR000DML_MCF-7_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	69084
1	2879	MYC	0.172220045959388	0.929252199085649	58	1910	1945	154	1945	1340	62	146	145	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shSCR;	GTRD	EXP047485_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	20193
1	546	CTCF	0.17162154563598	0.909865233901481	19	1912	2027	1697	2027	1880	21	185	186	CTCF WI-38 (lung fibroblasts) CTCF	WI-38 (lung fibroblasts)	BTO:0000458	CTCF		ENCODE	ENCSR000DYB_WI38_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	26092
1	934	CTCF	0.17162154563598	0.909865233901481	19	1912	2027	1697	2027	1880	21	185	186	CTCF hASC (preadipocytes) CTCF	hASC (preadipocytes)	NULL	CTCF		GEO	GSE21366_ctcf_asc_MACS_CTCF_MA0139.1.damo.pwm.bed	34585
1	1671	FOXA1	0.17162154563598	0.909865233901481	19	1912	2027	1697	2027	1880	21	185	186	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	Nonspecific siRNA	GTRD	EXP037434_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	43842
1	3194	OSR2	0.17162154563598	0.909865233901481	19	1912	2027	1697	2027	1880	21	185	186	OSR2 HEK293 (embryonic kidney) OSR2	HEK293 (embryonic kidney)	NULL	OSR2	NA	GTRD	EXP039901_HEK293--embryonic-kidney-_OSR2_MACS_OSR2_MA1646.1.damo.pwm.bed	13045
1	3234	PHOX2B	0.17162154563598	0.909865233901481	19	1912	2027	1697	2027	1880	21	185	186	PHOX2B Kelly (neuroblastoma) PHOX2B	Kelly (neuroblastoma)	NULL	PHOX2B	Treatment: untreated	GTRD	EXP049489_Kelly--neuroblastoma-_PHOX2B_MACS_PHOX2B_MA0681.2.damo.pwm.bed	116523
1	3738	STAT3	0.17162154563598	0.909865233901481	19	1912	2027	1697	2027	1880	21	185	186	STAT3 MCF10A-ER-Src STAT3	MCF10A-ER-Src	NULL	STAT3	Genotype: non-transformed	GTRD	EXP048575_MCF10A-ER-Src_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	17279
1	1094	ELF3	0.17133171345968	0.92824663580691	57	1918	1957	174	1957	1350	61	147	146	ELF3 PDAC ELF3	PDAC	NA	ELF3	SHCTR	GEO	GSE64557_elf3_pdac-shctr_MACS_ELF3_MA0640.2.damo.pwm.bed	53811
1	523	CTCF	0.17067561534807	0.919114523662912	34	1919	1979	729	1979	1540	37	170	170	CTCF HeLa S3 (cervical adenocarcinoma) CTCF	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	CTCF		ENCODE	ENCSR000DUB_HeLa-S3_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	50574
1	974	CTCF	0.17067561534807	0.919114523662912	34	1919	1979	729	1979	1540	37	170	170	CTCF hESC-1 (Embryonic stem cells) CTCF	hESC-1 (Embryonic stem cells)	NULL	CTCF	NAIVE	GEO	GSE69646_ctcf_esc-naive_MACS_CTCF_MA0139.1.damo.pwm.bed	48958
1	1021	E2F1	0.17067561534807	0.919114523662912	34	1919	1979	729	1979	1540	37	170	170	E2F1 MM1.S (plasma cell myeloma) E2F1	MM1.S (plasma cell myeloma)	BTO:0003933	E2F1	none	GTRD	EXP037393_MM1.S--plasma-cell-myeloma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	7019
1	2821	MYC	0.169038144128255	0.916864984454604	33	1922	2006	778	2006	1570	36	171	171	MYC Raji (Burkitt lymphoma) MYC	Raji (Burkitt lymphoma)	BTO:0001154	MYC		GTRD	EXP035848_Raji--Burkitt-lymphoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	7271
1	3001	NFE2L2	0.169038144128255	0.916864984454604	33	1922	2006	778	2006	1570	36	171	171	NFE2L2 HeLa S3 (cervical adenocarcinoma) NFE2L2	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	NFE2L2		GTRD	EXP039984_HeLa-S3--cervical-adenocarcinoma-_NFE2L2_MACS_NFE2L2_MA0150.2.damo.pwm.bed	18623
1	241	ATF2	0.168699499162742	0.898194488075208	8	1924	2093	2697	2697	2240	9	196	198	ATF2 HEK293 (embryonic kidney) ATF2	HEK293 (embryonic kidney)	NULL	ATF2	NA	GTRD	EXP039894_HEK293--embryonic-kidney-_ATF2_MACS_ATF2_MA1632.1.damo.pwm.bed	16137
1	245	ATF3	0.168699499162742	0.898194488075208	8	1924	2093	2697	2697	2240	9	196	198	ATF3 HepG2 (hepatoblastoma) ATF3	HepG2 (hepatoblastoma)	BTO:0000599	ATF3		ENCODE	ENCSR000BKE_HepG2_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	2220
1	602	CTCF	0.168699499162742	0.898194488075208	8	1924	2093	2697	2697	2240	9	196	198	CTCF HeLa (cervical adenocarcinoma) CTCF	HeLa (cervical adenocarcinoma)	BTO:0000567	CTCF		GTRD	EXP030881_HeLa--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	16368
1	879	CTCF	0.168699499162742	0.898194488075208	8	1924	2093	2697	2697	2240	9	196	198	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: 110 mM NaCl for 30 min  Source: T47D whole cell	GTRD	EXP053046_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	21116
1	1408	ESR1	0.168699499162742	0.898194488075208	8	1924	2093	2697	2697	2240	9	196	198	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GEO	GSE59530_esr1_mcf7-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	21572
1	2531	JUNB	0.168699499162742	0.898194488075208	8	1924	2093	2697	2697	2240	9	196	198	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039831_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	9638
1	2966	NEUROG2	0.168699499162742	0.898194488075208	8	1924	2093	2697	2697	2240	9	196	198	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	0.5 DPT	GTRD	EXP037146_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	15009
1	3190	ONECUT1	0.168699499162742	0.898194488075208	8	1924	2093	2697	2697	2240	9	196	198	ONECUT1 H9 ONECUT1	H9	NULL	ONECUT1	NA	Array Express	ERP004206_onecut1_esc-h9_MACS_ONECUT1_MA0679.2.damo.pwm.bed	44659
1	3725	STAT1	0.168699499162742	0.898194488075208	8	1924	2093	2697	2697	2240	9	196	198	STAT1 HeLa S3 (cervical adenocarcinoma) STAT1	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	STAT1	IFN gamma	GTRD	EXP000489_HeLa-S3--cervical-adenocarcinoma-_STAT1_MACS_STAT1_MA0517.1.damo.pwm.bed	11729
1	1810	FOXA1	0.168642769472888	0.905059109092392	18	1933	2061	1785	2061	1930	20	186	187	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1		GEO	GSE80808_foxa1_mcf7_MACS_FOXA1_MA0148.4.damo.pwm.bed	34605
1	2209	IRF3	0.168642769472888	0.905059109092392	18	1933	2061	1785	2061	1930	20	186	187	IRF3 SK-N-SH (neuroblastoma) IRF3	SK-N-SH (neuroblastoma)	BTO:0001620	IRF3	NA	GTRD	EXP040104_SK-N-SH--neuroblastoma-_IRF3_MACS_IRF3_MA1418.1.damo.pwm.bed	5069
1	2616	JUND	0.168642769472888	0.905059109092392	18	1933	2061	1785	2061	1930	20	186	187	JUND liver JUND	liver	BTO:0000759	JUND		GTRD	EXP040078_liver_JUND_MACS_JUND_MA0492.1.damo.pwm.bed	11969
1	3397	REST	0.168642769472888	0.905059109092392	18	1933	2061	1785	2061	1930	20	186	187	REST HeLa S3 (cervical adenocarcinoma) REST	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	REST		ENCODE	ENCSR000BMN_HeLa-S3_REST_MACS_REST_MA0138.2.damo.pwm.bed	16329
1	4072	USF1	0.168642769472888	0.905059109092392	18	1933	2061	1785	2061	1930	20	186	187	USF1 A549 (lung carcinoma) USF1	A549 (lung carcinoma)	BTO:0000018	USF1	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BJB_A549_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	9280
1	758	CTCF	0.167341996105241	0.914486853127512	32	1938	2008	825	2008	1590	35	172	172	CTCF gastroesophageal sphincter CTCF	gastroesophageal sphincter	NULL	CTCF		GTRD	EXP039983_gastroesophageal-sphincter_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	32429
1	2984	NEUROG2	0.167341996105241	0.914486853127512	32	1938	2008	825	2008	1590	35	172	172	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	1 DPT	GTRD	EXP037155_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	28932
1	580	CTCF	0.166568309666844	0.922646467357725	52	1940	1972	244	1972	1390	56	152	151	CTCF lymphoblastoid cells CTCF	lymphoblastoid cells	NULL	CTCF	NULL	GTRD	EXP000779_lymphoblastoid-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	58835
1	20	AR	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	1000 nM RU486	GTRD	EXP030506_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	920
1	36	AR	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	ethanol	GTRD	EXP033418_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	10948
1	61	AR	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	dihydrotestosterone  (DHT)	GTRD	EXP038188_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	2494
1	176	AR	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	AR LNCaP C4-2B (prostate carcinoma) AR	LNCaP C4-2B (prostate carcinoma)	BTO:0004959	AR	R1881_SHCTR	GEO	GSE61268_AR_c42b-r1881-shctr_MACS_AR_MA0007.3.damo.pwm.bed	3114
1	178	AR	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	HOTAIR	GEO	GSE61268_AR_lncap-hotair_MACS_AR_MA0007.3.damo.pwm.bed	3497
1	199	AR	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	AR LNCaP C4-2B (prostate carcinoma) AR	LNCaP C4-2B (prostate carcinoma)	BTO:0004959	AR		GEO	GSE72714_AR_c42b_MACS_AR_MA0007.3.damo.pwm.bed	2716
1	385	CEBPB	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	CEBPB OCI-AML3 CEBPB	OCI-AML3	BTO:0004620	CEBPB	JQ1, 500 nM for 24 h	GTRD	EXP040656_OCI-AML3_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	4029
1	1143	ERG	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	ERG RWPE1 (prostate epithelial cells) ERG	RWPE1 (prostate epithelial cells)	BTO:0003709	ERG	FLAG	GEO	GSE29808_erg_rwpe1-flag_MACS_ERG_MA0474.2.damo.pwm.bed	464
1	1186	ESR1	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	ETOH (ethanol)	GTRD	EXP000884_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	3683
1	1363	ESR1	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 10 nM E2 + 10 nM R5020 for45 mins Genotype: ER+/PR+	GTRD	EXP049948_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	4653
1	1385	ESR1	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	ESR1 H3396 (breast carcinoma) ESR1	H3396 (breast carcinoma)	NULL	ESR1	E2	GEO	GSE32349_esr1_h3396-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	2486
1	1447	ESRRA	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	ESRRA BT-474 (breast invasive ductal carcinoma) ESRRA	BT-474 (breast invasive ductal carcinoma)	BTO:0001932	ESRRA		GEO	GSE75876_esrra_bt474_MACS_ESRRA_MA0592.3.damo.pwm.bed	2379
1	1620	FOSL2	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP040181_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	3585
1	1621	FOSL2	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP040181_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	3665
1	1622	FOSL2	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP040181_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	3683
1	1623	FOSL2	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP040181_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	3627
1	1674	FOXA1	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	control; 100 nM 17-beta-estradiol for 0h	GTRD	EXP037652_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	3552
1	1863	FOXP1	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	FOXP1 HepG2 (hepatoblastoma) FOXP1	HepG2 (hepatoblastoma)	BTO:0000599	FOXP1	NA	GTRD	EXP039780_HepG2--hepatoblastoma-_FOXP1_MACS_FOXP1_MA0481.3.damo.pwm.bed	5018
1	1946	GATA2	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	GATA2 HUVEC-C (HUVEC, umbilical vein endothelial cells) GATA2	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	GATA2	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048219_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	7114
1	1953	GATA2	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	GATA2 CD34+ cells GATA2	CD34+ cells	NULL	GATA2	DMSO	GEO	GSE60792_gata2_cd34-dmso_MACS_GATA2_MA0036.3.damo.pwm.bed	5479
1	1972	GATA3	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	GATA3 WA09 (embryonic stem cells) GATA3	WA09 (embryonic stem cells)	NULL	GATA3	BMP4 for 3 day	GTRD	EXP040702_WA09--embryonic-stem-cells-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	9231
1	2002	GATA3	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	GATA3 SH-SY5Y (neuroblastoma) GATA3	SH-SY5Y (neuroblastoma)	BTO:0000793	GATA3		GEO	GSE65664_gata3_shsy5y_MACS_GATA3_MA0037.3.damo.pwm.bed	7709
1	2114	HNF1A	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	HNF1A NY15 (pancreatic cancer-derived cells) HNF1A	NY15 (pancreatic cancer-derived cells)	NULL	HNF1A		GTRD	EXP048083_NY15--pancreatic-cancer-derived-cells-_HNF1A_MACS_HNF1A_MA0046.2.damo.pwm.bed	2564
1	2157	HOXA9	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	HOXA9 SEM (childhood B acute lymphoblastic leukemia) HOXA9	SEM (childhood B acute lymphoblastic leukemia)	NULL	HOXA9		GEO	GSE38339_hoxa9_sem_MACS_HOXA9_MA0594.2.damo.pwm.bed	3503
1	2176	HSF1	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	HSF1 K562 (myelogenous leukemia) HSF1	K562 (myelogenous leukemia)	NULL	HSF1	30 min at 42C	GTRD	EXP030798_K562--myelogenous-leukemia-_HSF1_MACS_HSF1_MA0486.2.damo.pwm.bed	700
1	2191	HSF1	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	HSF1 MCF7 (Invasive ductal breast carcinoma) HSF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	HSF1	CHX_10UM	GEO	GSE45852_hsf1_mcf7-chx-10um_MACS_HSF1_MA0486.2.damo.pwm.bed	882
1	2201	IRF1	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	IRF1 HAEC (human aortic endothelial cells) IRF1	HAEC (human aortic endothelial cells)	NULL	IRF1	TNFa, 4h	GTRD	EXP038039_HAEC--human-aortic-endothelial-cells-_IRF1_MACS_IRF1_MA0050.2.damo.pwm.bed	3737
1	2671	MAF	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	MAF keratinocytes MAF	keratinocytes	NULL	MAF	epidermal_PROLIF	GEO	GSE52953_maf_epidermal-keratinocytes-prolif_MACS_MAF_MA0501.1.damo.pwm.bed	2965
1	3043	NR1H4	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	NR1H4 NR1H4	NA	NA	NR1H4	NA	GEO	GSE57227_nr1h4_primaryhepatocyte-dmso_MACS_NR1H4_MA1110.1.damo.pwm.bed	764
1	3044	NR1H4	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	NR1H4 NR1H4	NA	NA	NR1H4	NA	GEO	GSE57227_nr1h4_primaryhepatocyte-gw4064_MACS_NR1H4_MA1110.1.damo.pwm.bed	2031
1	3114	NR3C1	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039724_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	2729
1	3129	NR3C1	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	NR3C1 MCF10A (breast epithelial cells) NR3C1	MCF10A (breast epithelial cells)	BTO:0001939	NR3C1	Treatment: dexamethasone (DEX) 20 min;	GTRD	EXP047627_MCF10A--breast-epithelial-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	2268
1	3162	NR3C1	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	NR3C1 ZR-75-1 (invasive ductal carcinoma) NR3C1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	NR3C1	DEX	GEO	GSE72249_nr3c1_zr751-dex_MACS_NR3C1_MA0113.3.damo.pwm.bed	15313
1	3254	POU5F1	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	POU5F1 HUES64 (embryonic stem cells) POU5F1	HUES64 (embryonic stem cells)	NULL	POU5F1		GTRD	EXP036732_HUES64--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	7209
1	3313	RARA	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	RARA U937 (adult acute monocytic leukemia) RARA	U937 (adult acute monocytic leukemia)	BTO:0001412	RARA	Treatment: 3 mg/mL ATRA for 3 days	GTRD	EXP049794_U937--adult-acute-monocytic-leukemia-_RARA_MACS_RARA_MA0729.1.damo.pwm.bed	2773
1	3319	RARG	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	RARG RWPE1 (prostate epithelial cells) RARG	RWPE1 (prostate epithelial cells)	BTO:0003709	RARG	Treatment: 10 uM DMSO for 2 hr Gender: male Source: non-malignant prostate cell line infected with BAC-RARG-EGFP	GTRD	EXP048635_RWPE1--prostate-epithelial-cells-_RARG_MACS_RARG_MA0859.1.damo.pwm.bed	1626
1	3424	REST	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	REST GM12878 (female B-cells lymphoblastoid cell line) REST	GM12878 (female B-cells lymphoblastoid cell line)	NULL	REST		GTRD	EXP054611_GM12878--female-B-cells-lymphoblastoid-cell-line-_REST_MACS_REST_MA0138.2.damo.pwm.bed	4469
1	3452	RUNX1	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	RUNX1 Jurkat E6.1 (T-cells) RUNX1	Jurkat E6.1 (T-cells)	BTO:0001948	RUNX1	NULL	GTRD	EXP000300_Jurkat-E6.1--T-cells-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	1539
1	3596	SOX2	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	SOX2 HUES64 (embryonic stem cells) SOX2	HUES64 (embryonic stem cells)	NULL	SOX2		GTRD	EXP036751_HUES64--embryonic-stem-cells-_SOX2_MACS_SOX2_MA0143.4.damo.pwm.bed	5728
1	3716	SRF	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	SRF HEL (Erythro Leukemia) SRF	HEL (Erythro Leukemia)	NULL	SRF	Treatment: Treated with 15nM TPA for 24 hours Source: HEL-iMKL1 cells	GTRD	EXP053075_HEL--Erythro-Leukemia-_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	2205
1	3768	TAL1	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	TAL1 RPMI-8402 (T acute lymphoblastic leukemia) TAL1	RPMI-8402 (T acute lymphoblastic leukemia)	BTO:0001880	TAL1	NA	GEO	GSE39179_tal1_rpmi8402_MACS_TAL1_MA0091.1.damo.pwm.bed	3589
1	3803	TCF7	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	TCF7 DLD-1 (colon adenocarcinoma) TCF7	DLD-1 (colon adenocarcinoma)	BTO:0000391	TCF7	1 ug/mL Doxycycline	GTRD	EXP033179_DLD-1--colon-adenocarcinoma-_TCF7_MACS_TCF7_MA0769.2.damo.pwm.bed	1959
1	3909	TFAP2C	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	Treatment: with Estrogen +1,6-Hexanediol;	GTRD	EXP058230_MCF7--Invasive-ductal-breast-carcinoma-_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	1031
1	3910	TFAP2C	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	Treatment: with Estrogen +1,6-Hexanediol;	GTRD	EXP058230_MCF7--Invasive-ductal-breast-carcinoma-_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	970
1	3911	TFAP2C	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	Treatment: with Estrogen +1,6-Hexanediol;	GTRD	EXP058230_MCF7--Invasive-ductal-breast-carcinoma-_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	873
1	3984	TP53	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	TP53 PHA-simulated human T-lynphocytes TP53	PHA-simulated human T-lynphocytes	NULL	TP53	Treatment: 0.1% DMSO for 24 hrs Source: healthy volunteer#116	GTRD	EXP048275_PHA-simulated-human-T-lynphocytes_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	1899
1	4031	TP63	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	TP63 HaCaT (keratinocytes) TP63	HaCaT (keratinocytes)	BTO:0000552	TP63	Ad-LacZ and 3 ng/ml of TGF-beta3 for 1.5 hrs	GTRD	EXP033937_HaCaT--keratinocytes-_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	6048
1	4098	VDR	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	100 nM 1,25(OH)2D3 for 2h	GTRD	EXP037993_THP-1--acute-monocytic-leukemia-_VDR_MACS_VDR_MA0693.2.damo.pwm.bed	3066
1	4157	ZFX	0.165636482708724	1.01481681733708	2	1941	1611	3462	3462	2340	2	202	205	ZFX RPMI-8402 (T acute lymphoblastic leukemia) ZFX	RPMI-8402 (T acute lymphoblastic leukemia)	BTO:0001880	ZFX	NA	GEO	GSE43147_zfx_rpmi8402_MACS_ZFX_MA0146.2.damo.pwm.bed	440
1	1152	ERG	0.165583400897153	0.911969953863901	31	1990	2022	881	2022	1630	34	173	173	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	SH3_DHT	GEO	GSE79128_erg_vcap-sh3-dht_MACS_ERG_MA0474.2.damo.pwm.bed	9849
1	760	CTCF	0.165470530122928	0.899753560184675	17	1991	2082	1846	2082	1970	19	187	188	CTCF vagina CTCF	vagina	BTO:0000243	CTCF		GTRD	EXP040000_vagina_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	21502
1	1084	ELF1	0.165470530122928	0.899753560184675	17	1991	2082	1846	2082	1970	19	187	188	ELF1 K562 (myelogenous leukemia) ELF1	K562 (myelogenous leukemia)	NULL	ELF1		ENCODE	ENCSR975SSR_K562_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	4493
1	1153	ESR1	0.165470530122928	0.899753560184675	17	1991	2082	1846	2082	1970	19	187	188	ESR1 Ishikawa (endometrial adenocarcinoma) ESR1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	ESR1	1 h with 10 nM Estradiol (Myers)	ENCODE	ENCSR000BIY_Ishikawa_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	22549
1	1294	ESR1	0.165470530122928	0.899753560184675	17	1991	2082	1846	2082	1970	19	187	188	ESR1 breast tumor ESR1	breast tumor	NULL	ESR1	Female	GTRD	EXP040663_breast-tumor_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	5992
1	2313	JUN	0.165470530122928	0.899753560184675	17	1991	2082	1846	2082	1970	19	187	188	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039496_A549--lung-carcinoma-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	13233
1	3668	SPI1	0.165470530122928	0.899753560184675	17	1991	2082	1846	2082	1970	19	187	188	SPI1 GM12878 (female B-cells lymphoblastoid cell line) SPI1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	SPI1		GTRD	EXP054623_GM12878--female-B-cells-lymphoblastoid-cell-line-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	47436
1	3964	TP53	0.165470530122928	0.899753560184675	17	1991	2082	1846	2082	1970	19	187	188	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	irradiation 7.5h + Nutlin	GTRD	EXP036830_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	17025
1	2643	KLF5	0.164497540296911	0.920100645593828	50	1998	1978	275	1998	1420	54	154	153	KLF5 HEK293T (embryonic kidney) KLF5	HEK293T (embryonic kidney)	BTO:0002181	KLF5	Treatment: Over-expressing KLF5 WT	GTRD	EXP049095_HEK293T--embryonic-kidney-_KLF5_MACS_KLF5_MA0599.1.damo.pwm.bed	18312
1	562	CTCF	0.163758232876216	0.909302069912715	30	1999	2046	937	2046	1660	33	174	174	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		Array Express	ERP000380_ctcf_mcf7_MACS_CTCF_MA0139.1.damo.pwm.bed	43674
1	621	CTCF	0.163758232876216	0.909302069912715	30	1999	2046	937	2046	1660	33	174	174	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	unstimulated	GTRD	EXP033165_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42556
1	978	CTCF	0.163758232876216	0.909302069912715	30	1999	2046	937	2046	1660	33	174	174	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF		GEO	GSE70482_ctcf_k562_MACS_CTCF_MA0139.1.damo.pwm.bed	44145
1	3144	NR3C1	0.163758232876216	0.909302069912715	30	1999	2046	937	2046	1660	33	174	174	NR3C1 HASM2 (Human airway smooth muscle 2) NR3C1	HASM2 (Human airway smooth muscle 2)	NULL	NR3C1	Treatment: dexamethasone for 4 hr Genotype: Ad-KLF15 transduction	GTRD	EXP049659_HASM2--Human-airway-smooth-muscle-2-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	38863
1	4158	ZFX	0.163758232876216	0.909302069912715	30	1999	2046	937	2046	1660	33	174	174	ZFX DAOY (medulloblastoma) ZFX	DAOY (medulloblastoma)	BTO:0004328	ZFX	NA	GEO	GSE45394_zfx_daoy_MACS_ZFX_MA0146.2.damo.pwm.bed	7312
1	3544	RXRA	0.162320954610444	0.917353142410713	48	2004	2003	317	2004	1440	52	156	155	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP045021_liver_RXRA_MACS_RXRA_MA0115.1.damo.pwm.bed	48566
1	458	CTCF	0.162081332609838	0.893861874824445	16	2005	2113	1909	2113	2010	18	188	189	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	1 h with 0.02% Dimethyl sufloxide (DMSO) (Myers)	ENCODE	ENCSR000BNO_T47D_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	26379
1	1163	ESR1	0.162081332609838	0.893861874824445	16	2005	2113	1909	2113	2010	18	188	189	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SHCRT_E2	Array Express	ERP000380_esr1_mcf7-shcrt-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	34084
1	1577	FOSL2	0.162081332609838	0.893861874824445	16	2005	2113	1909	2113	2010	18	188	189	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP039419_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	16894
1	1728	FOXA1	0.162081332609838	0.893861874824445	16	2005	2113	1909	2113	2010	18	188	189	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	Treatment: treated with 10nM  R1881 for 4 hours	GTRD	EXP049579_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	83834
1	2347	JUN	0.162081332609838	0.893861874824445	16	2005	2113	1909	2113	2010	18	188	189	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 20 minute	GTRD	EXP040320_A549--lung-carcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	17616
1	2767	MXI1	0.162081332609838	0.893861874824445	16	2005	2113	1909	2113	2010	18	188	189	MXI1 GM12878 (female B-cells lymphoblastoid cell line) MXI1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MXI1	NA	ENCODE	ENCSR000DZI_GM12878_MXI1_MACS_MXI1_MA1108.2.damo.pwm.bed	4537
1	531	CTCF	0.16186196666162	0.906467422475808	29	2011	2055	1013	2055	1690	32	175	175	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DVA_fibroblast_of_lung_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37585
1	3199	OTX2	0.16186196666162	0.906467422475808	29	2011	2055	1013	2055	1690	32	175	175	OTX2 D283 Med (medulloblastoma) OTX2	D283 Med (medulloblastoma)	NULL	OTX2		GTRD	EXP038196_D283-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	93215
1	3736	STAT3	0.16186196666162	0.906467422475808	29	2011	2055	1013	2055	1690	32	175	175	STAT3 HCC70 (ductal breast carcinoma) STAT3	HCC70 (ductal breast carcinoma)	NULL	STAT3	ethanol	GTRD	EXP037703_HCC70--ductal-breast-carcinoma-_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	28028
1	205	AR	0.161418696887593	0.88414887421394	7	2014	2162	2812	2812	2330	8	197	199	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	SH1_R1881	GEO	GSE79128_AR_vcap-sh1-r1881_MACS_AR_MA0007.3.damo.pwm.bed	22606
1	878	CTCF	0.161418696887593	0.88414887421394	7	2014	2162	2812	2812	2330	8	197	199	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: 110 mM NaCl for 7.5 min  Source: T47D whole cell	GTRD	EXP053045_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	24747
1	1072	EHF	0.161418696887593	0.88414887421394	7	2014	2162	2812	2812	2330	8	197	199	EHF epidermal keratinocytes EHF	epidermal keratinocytes	NULL	EHF	day3 of differentiation	GTRD	EXP037599_epidermal-keratinocytes_EHF_MACS_EHF_MA0598.3.damo.pwm.bed	1139
1	1236	ESR1	0.161418696887593	0.88414887421394	7	2014	2162	2812	2812	2330	8	197	199	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	siCTCF	GTRD	EXP037655_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	16137
1	1238	ESR1	0.161418696887593	0.88414887421394	7	2014	2162	2812	2812	2330	8	197	199	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	White Medium + E2	GTRD	EXP037775_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	17939
1	1311	ESR1	0.161418696887593	0.88414887421394	7	2014	2162	2812	2812	2330	8	197	199	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	100nm E2 (45 min)	GTRD	EXP040960_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	17136
1	1437	ESR2	0.161418696887593	0.88414887421394	7	2014	2162	2812	2812	2330	8	197	199	ESR2 U2OS (osteosarcoma) ESR2	U2OS (osteosarcoma)	BTO:0001938	ESR2	NULL	GTRD	EXP000204_U2OS--osteosarcoma-_ESR2_MACS_ESR2_MA0258.2.damo.pwm.bed	11673
1	2018	GATA4	0.161418696887593	0.88414887421394	7	2014	2162	2812	2812	2330	8	197	199	GATA4 iPSC-derived cardiomyocytes GATA4	iPSC-derived cardiomyocytes	NULL	GATA4	G296S mutant	GTRD	EXP037720_iPSC-derived-cardiomyocytes_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	10774
1	2212	IRF4	0.161418696887593	0.88414887421394	7	2014	2162	2812	2812	2330	8	197	199	IRF4 IRF4	NA	NA	IRF4	NA	GEO	GSE56857_irf4_ocily10_MACS_IRF4_MA1419.1.damo.pwm.bed	10104
1	3612	SOX2	0.161418696887593	0.88414887421394	7	2014	2162	2812	2812	2330	8	197	199	SOX2 KYSE70 (esophageal squamous carcinoma) SOX2	KYSE70 (esophageal squamous carcinoma)	NULL	SOX2		GEO	GSE46837_sox2_kyse70_MACS_SOX2_MA0143.4.damo.pwm.bed	4820
1	4166	ZNF740	0.161418696887593	0.88414887421394	7	2014	2162	2812	2812	2330	8	197	199	ZNF740 K562 (myelogenous leukemia) ZNF740	K562 (myelogenous leukemia)	NULL	ZNF740	NA	ENCODE	ENCSR737UST_K562_ZNF740_MACS_ZNF740_MA0753.2.damo.pwm.bed	2764
1	420	CREB1	0.160029725255707	0.914377237043058	46	2025	2010	349	2025	1460	50	158	157	CREB1 HepG2 (hepatoblastoma) CREB1	HepG2 (hepatoblastoma)	BTO:0000599	CREB1		ENCODE	ENCSR000BVL_HepG2_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	18377
1	559	CTCF	0.160029725255707	0.914377237043058	46	2025	2010	349	2025	1460	50	158	157	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	E2_SHCTR	Array Express	ERP000209_ctcf_mcf7-e2-shctr_MACS_CTCF_MA0139.1.damo.pwm.bed	77780
1	1840	FOXA2	0.160029725255707	0.914377237043058	46	2025	2010	349	2025	1460	50	158	157	FOXA2 A549 (lung carcinoma) FOXA2	A549 (lung carcinoma)	BTO:0000018	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL	GTRD	EXP049305_A549--lung-carcinoma-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	61874
1	33	AR	0.159889625574802	0.903449870958794	28	2028	2070	1068	2070	1720	31	176	176	AR HEK293 (embryonic kidney) AR	HEK293 (embryonic kidney)	NULL	AR	10 nM R1881	GTRD	EXP032872_HEK293--embryonic-kidney-_AR_MACS_AR_MA0007.3.damo.pwm.bed	76249
1	622	CTCF	0.159889625574802	0.903449870958794	28	2028	2070	1068	2070	1720	31	176	176	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	progestin R5020-stimulated	GTRD	EXP033166_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42207
1	1464	ETS1	0.159889625574802	0.903449870958794	28	2028	2070	1068	2070	1720	31	176	176	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1		GTRD	EXP038279_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	16295
1	2957	MYOD1	0.159889625574802	0.903449870958794	28	2028	2070	1068	2070	1720	31	176	176	MYOD1 RH4 (alveolar rhabdomyosarcoma) MYOD1	RH4 (alveolar rhabdomyosarcoma)	NULL	MYOD1	NA	GTRD	EXP037530_RH4--alveolar-rhabdomyosarcoma-_MYOD1_MACS_MYOD1_MA0499.2.damo.pwm.bed	41734
1	2922	MYC	0.158838053266128	0.912794995932345	45	2032	2021	383	2032	1480	49	159	158	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	Doxy	GEO	GSE44672_myc_u2os-dox_MACS_MYC_MA0147.3.damo.pwm.bed	16264
1	95	AR	0.158447412096389	0.887280541205206	15	2033	2138	1993	2138	2050	17	189	190	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: 10 nM DHT+ 500 nM JQ1 for 6 hrs  TF: full-length AR (AR-FL)	GTRD	EXP049392_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	45010
1	2842	MYC	0.158447412096389	0.887280541205206	15	2033	2138	1993	2138	2050	17	189	190	MYC HUES64 (embryonic stem cells) MYC	HUES64 (embryonic stem cells)	NULL	MYC		GTRD	EXP036775_HUES64--embryonic-stem-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	3210
1	2974	NEUROG2	0.158447412096389	0.887280541205206	15	2033	2138	1993	2138	2050	17	189	190	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	2 DPT	GTRD	EXP037150_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	20259
1	3092	NR3C1	0.158447412096389	0.887280541205206	15	2033	2138	1993	2138	2050	17	189	190	NR3C1 IMR90 (lung fibroblasts) NR3C1	IMR90 (lung fibroblasts)	NULL	NR3C1		Array Express	ERP007093_nr3c1_imr90_MACS_NR3C1_MA0113.3.damo.pwm.bed	28830
1	3986	TP53	0.158447412096389	0.887280541205206	15	2033	2138	1993	2138	2050	17	189	190	TP53 PHA-simulated human T-lynphocytes TP53	PHA-simulated human T-lynphocytes	NULL	TP53	Treatment: 10 uM Nutlin-3 for 24 hrs Source: healthy volunteer #116	GTRD	EXP048277_PHA-simulated-human-T-lynphocytes_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	8297
1	2311	JUN	0.157835721702544	0.900231122365992	27	2038	2080	1135	2080	1750	30	177	177	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039416_A549--lung-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	19658
1	2351	JUN	0.157835721702544	0.900231122365992	27	2038	2080	1135	2080	1750	30	177	177	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 5 minute	GTRD	EXP040322_A549--lung-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	22918
1	540	CTCF	0.157613882226886	0.911144711129668	44	2040	2024	408	2040	1490	48	160	159	CTCF keratinocytes CTCF	keratinocytes	NULL	CTCF		ENCODE	ENCSR000DWX_keratinocyte_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	55204
1	3731	STAT3	0.157613882226886	0.911144711129668	44	2040	2024	408	2040	1490	48	160	159	STAT3 STAT3	NA	NA	STAT3	NA	NA	ENCSR000DPB_MCF_10A_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	47234
1	3924	TFAP2C	0.157613882226886	0.911144711129668	44	2040	2024	408	2040	1490	48	160	159	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C		GEO	GSE36351_tfap2c_mcf7_MACS_TFAP2C_MA0524.2.damo.pwm.bed	73691
1	1469	ETS1	0.155933714714717	0.917164759362956	67	2043	2004	68	2043	1370	72	137	135	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1	VEGF_12H	GEO	GSE41166_ets1_huvec-vegf-12h_MACS_ETS1_MA0098.3.damo.pwm.bed	37974
1	2691	MAX	0.155933714714717	0.917164759362956	67	2043	2004	68	2043	1370	72	137	135	MAX HepG2 (hepatoblastoma) MAX	HepG2 (hepatoblastoma)	BTO:0000599	MAX		ENCODE	ENCSR000BTM_HepG2_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	34215
1	701	CTCF	0.155694185903893	0.896790360135159	26	2045	2108	1204	2108	1790	29	178	178	CTCF testis CTCF	testis	BTO:0001363	CTCF		GTRD	EXP039536_testis_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	28264
1	926	CTCF	0.155694185903893	0.896790360135159	26	2045	2108	1204	2108	1790	29	178	178	CTCF SK-N-SH (neuroblastoma) CTCF	SK-N-SH (neuroblastoma)	BTO:0001620	CTCF		GTRD	EXP058186_SK-N-SH--neuroblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34746
1	1455	ETS1	0.155694185903893	0.896790360135159	26	2045	2108	1204	2108	1790	29	178	178	ETS1 CD4+ CD25+ CD45RA+ T-cells ETS1	CD4+ CD25+ CD45RA+ T-cells	NULL	ETS1		GTRD	EXP032567_CD4--CD25--CD45RA--T-cells_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	10880
1	1724	FOXA1	0.154535671129455	0.879880165724485	14	2048	2192	2073	2192	2100	16	190	191	FOXA1 22RV1 (prostate carcinoma) FOXA1	22RV1 (prostate carcinoma)	BTO:0002999	FOXA1	Treatment: Cells were harvested in log phase growth Genotype: wildtype	GTRD	EXP048994_22RV1--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	20773
1	2503	JUNB	0.154535671129455	0.879880165724485	14	2048	2192	2073	2192	2100	16	190	191	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039540_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	19139
1	1641	FOXA1	0.153731309425736	0.905740640790551	41	2050	2059	476	2059	1530	45	163	162	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1		Array Express	ERP001226_foxa1_lncap_MACS_FOXA1_MA0148.4.damo.pwm.bed	93742
1	3522	RXRA	0.153731309425736	0.905740640790551	41	2050	2059	476	2059	1530	45	163	162	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP040231_liver_RXRA_MACS_RXRA_MA0115.1.damo.pwm.bed	41077
1	541	CTCF	0.153458285705445	0.893103793422101	25	2052	2119	1262	2119	1810	28	179	179	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DWY_fibroblast_of_lung_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	33852
1	1881	GABPA	0.153458285705445	0.893103793422101	25	2052	2119	1262	2119	1810	28	179	179	GABPA HepG2 (hepatoblastoma) GABPA	HepG2 (hepatoblastoma)	BTO:0000599	GABPA		GTRD	EXP040044_HepG2--hepatoblastoma-_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	12456
1	4101	VDR	0.153458285705445	0.893103793422101	25	2052	2119	1262	2119	1810	28	179	179	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	100 nM 1,25(OH)2D3 for 24h	GTRD	EXP037995_THP-1--acute-monocytic-leukemia-_VDR_MACS_VDR_MA0074.1.damo.pwm.bed	22439
1	1018	E2F1	0.152900280783765	0.913531229139592	63	2055	2019	103	2055	1390	68	141	139	E2F1 LNCaP (prostate carcinoma) E2F1	LNCaP (prostate carcinoma)	BTO:0001321	E2F1	Vehicle	GTRD	EXP032868_LNCaP--prostate-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	20592
1	3215	PAX5	0.152900280783765	0.913531229139592	63	2055	2019	103	2055	1390	68	141	139	PAX5 GM12892 (female B-cells lymphoblastoid cell line) PAX5	GM12892 (female B-cells lymphoblastoid cell line)	NULL	PAX5		ENCODE	ENCSR000BJI_GM12892_PAX5_MACS_PAX5_MA0014.3.damo.pwm.bed	20641
1	1161	ESR1	0.152882967158621	0.866104624877452	6	2057	2244	2948	2948	2420	7	198	200	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2_TAM	Array Express	ERP000380_esr1_mcf7-e2-tam_MACS_ESR1_MA0112.3.damo.pwm.bed	10943
1	1253	ESR1	0.152882967158621	0.866104624877452	6	2057	2244	2948	2948	2420	7	198	200	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	640min E2	GTRD	EXP038343_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	7280
1	2202	IRF1	0.152882967158621	0.866104624877452	6	2057	2244	2948	2948	2420	7	198	200	IRF1 CD14 IRF1	CD14	NA	IRF1	LPS	GEO	GSE43036_irf1_cd14-lps_MACS_IRF1_MA0050.2.damo.pwm.bed	8620
1	2651	KLF5	0.152882967158621	0.866104624877452	6	2057	2244	2948	2948	2420	7	198	200	KLF5 YCC3 (gastric adenocarcinoma) KLF5	YCC3 (gastric adenocarcinoma)	NULL	KLF5		GEO	GSE51705_klf5_ycc3_MACS_KLF5_MA0599.1.damo.pwm.bed	1889
1	3158	NR3C1	0.152882967158621	0.866104624877452	6	2057	2244	2948	2948	2420	7	198	200	NR3C1 hMSC NR3C1	hMSC	NA	NR3C1	DMI	GEO	GSE68864_nr3c1_hmsc-dmi_MACS_NR3C1_MA0113.3.damo.pwm.bed	4529
1	3797	TCF4	0.152882967158621	0.866104624877452	6	2057	2244	2948	2948	2420	7	198	200	TCF4 SH-SY5Y (neuroblastoma) TCF4	SH-SY5Y (neuroblastoma)	BTO:0000793	TCF4	Treatment: none	GTRD	EXP049704_SH-SY5Y--neuroblastoma-_TCF4_MACS_TCF4_MA0830.2.damo.pwm.bed	8086
1	4015	TP53	0.152882967158621	0.866104624877452	6	2057	2244	2948	2948	2420	7	198	200	TP53 GM00011 (fetal skin fibroblasts) TP53	GM00011 (fetal skin fibroblasts)	NULL	TP53		GEO	GSE55727_tp53_gm00011_MACS_TP53_MA0106.3.damo.pwm.bed	4818
1	591	CTCF	0.152361551687211	0.903771178651152	40	2064	2067	502	2067	1540	44	164	163	CTCF GM12871 (male B-cells) CTCF	GM12871 (male B-cells)	NULL	CTCF		GTRD	EXP011189_GM12871--male-B-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49665
1	1631	FOXA1	0.152361551687211	0.903771178651152	40	2064	2067	502	2067	1540	44	164	163	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	1 h with 0.02% Dimethyl sufloxide (DMSO) (Myers)	ENCODE	ENCSR000BKY_T47D_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	75371
1	3882	TFAP2C	0.152361551687211	0.903771178651152	40	2064	2067	502	2067	1540	44	164	163	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions;	GTRD	EXP047535_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	30779
1	2793	MYC	0.151279027820397	0.911522494079009	61	2067	2023	127	2067	1410	66	143	141	MYC K562 (myelogenous leukemia) MYC	K562 (myelogenous leukemia)	NULL	MYC		ENCODE	ENCSR000EGJ_K562_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	30342
1	473	CTCF	0.151120528530871	0.889144106206766	24	2068	2130	1324	2130	1840	27	180	180	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF		ENCODE	ENCSR000DLK_H1-hESC_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	43288
1	896	CTCF	0.151120528530871	0.889144106206766	24	2068	2130	1324	2130	1840	27	180	180	CTCF NHLF (lung fibroblasts) CTCF	NHLF (lung fibroblasts)	NULL	CTCF	Treatment: None;	GTRD	EXP054033_NHLF--lung-fibroblasts-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35434
1	1292	ESR1	0.151120528530871	0.889144106206766	24	2068	2130	1324	2130	1840	27	180	180	ESR1 breast tumor ESR1	breast tumor	NULL	ESR1	Responder	GTRD	EXP038798_breast-tumor_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	23683
1	1672	FOXA1	0.151120528530871	0.889144106206766	24	2068	2130	1324	2130	1840	27	180	180	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	DMSO	GTRD	EXP037591_T47D--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	45597
1	1746	FOXA1	0.151120528530871	0.889144106206766	24	2068	2130	1324	2130	1840	27	180	180	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	Treatment: hormone-deprived cells treated with vehicle;	GTRD	EXP058101_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	68019
1	3504	RUNX1	0.151120528530871	0.889144106206766	24	2068	2130	1324	2130	1840	27	180	180	RUNX1 Jurkat (T-cells) RUNX1	Jurkat (T-cells)	BTO:0000661	RUNX1		GEO	GSE76181_runx1_jurkat_MACS_RUNX1_MA0002.2.damo.pwm.bed	26249
1	2796	MYC	0.15095094114196	0.901707956072001	39	2074	2076	547	2076	1570	43	165	164	MYC K562 (myelogenous leukemia) MYC	K562 (myelogenous leukemia)	NULL	MYC		ENCODE	ENCSR000FAG_K562_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	13576
1	2918	MYC	0.15095094114196	0.901707956072001	39	2074	2076	547	2076	1570	43	165	164	MYC NCI-H128 (small cell lung carcinoma) MYC	NCI-H128 (small cell lung carcinoma)	BTO:0003025	MYC		GEO	GSE41105_myc_h128_MACS_MYC_MA0147.3.damo.pwm.bed	29483
1	3585	SNAI2	0.15095094114196	0.901707956072001	39	2074	2076	547	2076	1570	43	165	164	SNAI2 keratinocytes SNAI2	keratinocytes	NULL	SNAI2	SNAI2_diff	GEO	GSE55421_snai2_keratinocytes-snai2-diff_MACS_SNAI2_MA0745.2.damo.pwm.bed	59854
1	846	CTCF	0.150306272899692	0.871496843679192	13	2077	2217	2153	2217	2150	15	191	192	CTCF WA09 (embryonic stem cells) CTCF	WA09 (embryonic stem cells)	NULL	CTCF	Treatment: under normal conditions	GTRD	EXP047906_WA09--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	21064
1	1227	ESR1	0.150306272899692	0.871496843679192	13	2077	2217	2153	2217	2150	15	191	192	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	IL1b+ICI	GTRD	EXP036977_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	13876
1	1506	FLI1	0.150306272899692	0.871496843679192	13	2077	2217	2153	2217	2150	15	191	192	FLI1 NB4 (acute promyelocytic leukemia ) FLI1	NB4 (acute promyelocytic leukemia )	NULL	FLI1		GEO	GSE23730_fli1_nb4_MACS_FLI1_MA0475.2.damo.pwm.bed	15455
1	1639	FOXA1	0.150306272899692	0.871496843679192	13	2077	2217	2153	2217	2150	15	191	192	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	E2_TAM	Array Express	ERP000380_foxa1_t47d-e2-tam_MACS_FOXA1_MA0148.4.damo.pwm.bed	40029
1	2501	JUNB	0.150306272899692	0.871496843679192	13	2077	2217	2153	2217	2150	15	191	192	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039540_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	18283
1	2589	JUND	0.150306272899692	0.871496843679192	13	2077	2217	2153	2217	2150	15	191	192	JUND HCT-116 (colon carcinoma) JUND	HCT-116 (colon carcinoma)	BTO:0001109	JUND		ENCODE	ENCSR000BSA_HCT116_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	20402
1	2634	KLF4	0.150306272899692	0.871496843679192	13	2077	2217	2153	2217	2150	15	191	192	KLF4 WA09 (embryonic stem cells) KLF4	WA09 (embryonic stem cells)	NULL	KLF4	Treatment: under normal conditions	GTRD	EXP047912_WA09--embryonic-stem-cells-_KLF4_MACS_KLF4_MA0039.4.damo.pwm.bed	4322
1	1064	EGR1	0.149497435500287	0.899544314696993	38	2084	2089	576	2089	1580	42	166	165	EGR1 K562 (myelogenous leukemia) EGR1	K562 (myelogenous leukemia)	NULL	EGR1		GTRD	EXP039497_K562--myelogenous-leukemia-_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	19343
1	1777	FOXA1	0.149497435500287	0.899544314696993	38	2084	2089	576	2089	1580	42	166	165	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	SHCTR_R1881	GEO	GSE56086_foxa1_vcap-shctr-r1881_MACS_FOXA1_MA0148.4.damo.pwm.bed	151769
1	457	CTCF	0.148672547071386	0.884879779243782	23	2086	2151	1391	2151	1880	26	181	181	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF		ENCODE	ENCSR000BNH_H1-hESC_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	44002
1	594	CTCF	0.148672547071386	0.884879779243782	23	2086	2151	1391	2151	1880	26	181	181	CTCF HepG2 (hepatoblastoma) CTCF	HepG2 (hepatoblastoma)	BTO:0000599	CTCF		GTRD	EXP030400_HepG2--hepatoblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	50764
1	639	CTCF	0.148672547071386	0.884879779243782	23	2086	2151	1391	2151	1880	26	181	181	CTCF PC9 (lung adenocarcinoma) CTCF	PC9 (lung adenocarcinoma)	NULL	CTCF		GTRD	EXP036849_PC9--lung-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40068
1	1439	ESR2	0.148672547071386	0.884879779243782	23	2086	2151	1391	2151	1880	26	181	181	ESR2 MDA-MB-231ERb(triple negative breast cancer) ESR2	MDA-MB-231ERb(triple negative breast cancer)	NULL	ESR2	Treatment: ethanol vehicle for 3 hr Passages: 20-25	GTRD	EXP048148_MDA-MB-231ERb-triple-negative-breast-cancer-_ESR2_MACS_ESR2_MA0258.2.damo.pwm.bed	6896
1	1668	FOXA1	0.148672547071386	0.884879779243782	23	2086	2151	1391	2151	1880	26	181	181	FOXA1 MCF-7L (invasive ductal carcinoma) FOXA1	MCF-7L (invasive ductal carcinoma)	NULL	FOXA1	tamoxifen	GTRD	EXP037125_MCF-7L--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	45331
1	1760	FOXA1	0.148672547071386	0.884879779243782	23	2086	2151	1391	2151	1880	26	181	181	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	SHCTR_R1881	GEO	GSE37345_foxa1_lncap-shctr-r1881_MACS_FOXA1_MA0148.4.damo.pwm.bed	91386
1	1918	GATA1	0.148672547071386	0.884879779243782	23	2086	2151	1391	2151	1880	26	181	181	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1		GTRD	EXP040807_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	55554
1	2952	MYCN	0.148672547071386	0.884879779243782	23	2086	2151	1391	2151	1880	26	181	181	MYCN Kelly (neuroblastoma) MYCN	Kelly (neuroblastoma)	NULL	MYCN		GEO	GSE80151_mycn_kelly_MACS_MYCN_MA0104.4.damo.pwm.bed	6908
1	3575	SMAD3	0.148672547071386	0.884879779243782	23	2086	2151	1391	2151	1880	26	181	181	SMAD3 HCC1954 (ductal breast carcinoma) SMAD3	HCC1954 (ductal breast carcinoma)	BTO:0005368	SMAD3	Treatment: TGF-beta CellType: Immortalized human mammary epithelial cells	GTRD	EXP047903_HCC1954--ductal-breast-carcinoma-_SMAD3_MACS_SMAD3_MA1622.1.damo.pwm.bed	34315
1	3844	TFAP2A	0.148672547071386	0.884879779243782	23	2086	2151	1391	2151	1880	26	181	181	TFAP2A HeLa S3 (cervical adenocarcinoma) TFAP2A	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	TFAP2A	None	GTRD	EXP010503_HeLa-S3--cervical-adenocarcinoma-_TFAP2A_MACS_TFAP2A_MA0003.4.damo.pwm.bed	20858
1	3872	TFAP2C	0.148672547071386	0.884879779243782	23	2086	2151	1391	2151	1880	26	181	181	TFAP2C HeLa S3 (cervical adenocarcinoma) TFAP2C	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	TFAP2C	None	GTRD	EXP010559_HeLa-S3--cervical-adenocarcinoma-_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	21537
1	2983	NEUROG2	0.147998840937402	0.897272945505202	37	2097	2105	607	2105	1600	41	167	166	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	1 DPT	GTRD	EXP037154_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	33209
1	1791	FOXA1	0.147806569492548	0.907063032230911	57	2098	2052	174	2098	1440	62	147	145	FOXA1 LNCaP-abl (Prostate carcinoma) FOXA1	LNCaP-abl (Prostate carcinoma)	NULL	FOXA1	SHCTR	GEO	GSE63034_foxa1_lncap-abl-shctr_MACS_FOXA1_MA0148.4.damo.pwm.bed	150309
1	2801	MYC	0.147806569492548	0.907063032230911	57	2098	2052	174	2098	1440	62	147	145	MYC HUVEC-C (HUVEC, umbilical vein endothelial cells) MYC	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	MYC	NULL	GTRD	EXP000986_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	25750
1	4086	USF2	0.146887059682752	0.9058460497021	56	2100	2058	192	2100	1450	61	148	146	USF2 R3/R4 erythroid cells USF2	R3/R4 erythroid cells	NULL	USF2		GTRD	EXP035048_R3-R4-erythroid-cells_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	27017
1	1383	ESR1	0.146104962778795	0.880274249245583	22	2101	2189	1459	2189	1920	25	182	182	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GEO	GSE14664_esr1_mcf7-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	45439
1	1571	FOSL2	0.146104962778795	0.880274249245583	22	2101	2189	1459	2189	1920	25	182	182	FOSL2 HepG2 (hepatoblastoma) FOSL2	HepG2 (hepatoblastoma)	BTO:0000599	FOSL2		ENCODE	ENCSR000BHP_HepG2_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	19649
1	3874	TFAP2C	0.146104962778795	0.880274249245583	22	2101	2189	1459	2189	1920	25	182	182	TFAP2C HeLa S3 (cervical adenocarcinoma) TFAP2C	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	TFAP2C	None	GTRD	EXP010559_HeLa-S3--cervical-adenocarcinoma-_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	21482
1	2641	KLF5	0.145945668571747	0.904584310835063	55	2104	2066	211	2104	1460	60	149	147	KLF5 HEK293T (embryonic kidney) KLF5	HEK293T (embryonic kidney)	BTO:0002181	KLF5	Treatment: Over-expressing KLF5 E419Q	GTRD	EXP049093_HEK293T--embryonic-kidney-_KLF5_MACS_KLF5_MA0599.1.damo.pwm.bed	19582
1	880	CTCF	0.145710750479339	0.861919830674806	12	2105	2265	2233	2265	2200	14	192	193	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: 110 mM NaCl for 60 min  Source: T47D whole cell	GTRD	EXP053047_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	25287
1	1787	FOXA1	0.145710750479339	0.861919830674806	12	2105	2265	2233	2265	2200	14	192	193	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1		GEO	GSE59530_foxa1_mcf7_MACS_FOXA1_MA0148.4.damo.pwm.bed	27941
1	1795	FOXA1	0.145710750479339	0.861919830674806	12	2105	2265	2233	2265	2200	14	192	193	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1		GEO	GSE64656_foxa1_lncap_MACS_FOXA1_MA0148.4.damo.pwm.bed	72532
1	2371	JUN	0.145710750479339	0.861919830674806	12	2105	2265	2233	2265	2200	14	192	193	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: 17beta estradiol 10nM for 1hr;	GTRD	EXP047660_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	15447
1	3013	NFIC	0.145710750479339	0.861919830674806	12	2105	2265	2233	2265	2200	14	192	193	NFIC K562 (myelogenous leukemia) NFIC	K562 (myelogenous leukemia)	NULL	NFIC	NA	GTRD	EXP039955_K562--myelogenous-leukemia-_NFIC_MACS_NFIC_MA0119.1.damo.pwm.bed	21273
1	4079	USF2	0.145710750479339	0.861919830674806	12	2105	2265	2233	2265	2200	14	192	193	USF2 GM12878 (female B-cells lymphoblastoid cell line) USF2	GM12878 (female B-cells lymphoblastoid cell line)	NULL	USF2		ENCODE	ENCSR000DZU_GM12878_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	4036
1	4082	USF2	0.145710750479339	0.861919830674806	12	2105	2265	2233	2265	2200	14	192	193	USF2 HepG2 (hepatoblastoma) USF2	HepG2 (hepatoblastoma)	BTO:0000599	USF2		ENCODE	ENCSR000EEF_HepG2_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	7970
1	2907	MYC	0.144856762073312	0.89237403385168	35	2112	2123	691	2123	1640	39	169	168	MYC BL41(Burkitt lymphoma) MYC	BL41(Burkitt lymphoma)	NULL	MYC		GEO	GSE30726_myc_bl41_MACS_MYC_MA0147.3.damo.pwm.bed	13952
1	3485	RUNX1	0.144856762073312	0.89237403385168	35	2112	2123	691	2123	1640	39	169	168	RUNX1 ME-1 (acute myeloid leukemia ) RUNX1	ME-1 (acute myeloid leukemia )	NULL	RUNX1	Treatment: no dox; Genotype: CBFB-MYH11 knockdown construct, RUNX1 wildtype;	GTRD	EXP058216_ME-1--acute-myeloid-leukemia--_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	24172
1	970	CTCF	0.1439943087175	0.901917647191454	53	2114	2075	236	2114	1480	58	151	149	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF	TROP	GEO	GSE52457_ctcf_h1-trop_MACS_CTCF_MA0139.1.damo.pwm.bed	77854
1	4122	YY1	0.143913964359051	0.90911674272241	82	2115	2051	13	2115	1390	88	122	119	YY1 GM12878 (female B-cells lymphoblastoid cell line) YY1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	YY1		ENCODE	ENCSR000BNP_GM12878_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	67878
1	703	CTCF	0.143407222390295	0.875284857812552	21	2116	2206	1535	2206	1950	24	183	183	CTCF Peyer's patch CTCF	Peyer's patch	NULL	CTCF		GTRD	EXP039547_Peyer-s-patch_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34668
1	987	CTCF	0.143407222390295	0.875284857812552	21	2116	2206	1535	2206	1950	24	183	183	CTCF VCaP (prostate carcinoma) CTCF	VCaP (prostate carcinoma)	BTO:0003215	CTCF	ETOH	GEO	GSE84432_ctcf_vcap-etoh_MACS_CTCF_MA0139.1.damo.pwm.bed	36873
1	1651	FOXA1	0.143407222390295	0.875284857812552	21	2116	2206	1535	2206	1950	24	183	183	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	NULL	GTRD	EXP000624_T47D--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	37716
1	2991	NFE2	0.143407222390295	0.875284857812552	21	2116	2206	1535	2206	1950	24	183	183	NFE2 K562 (myelogenous leukemia) NFE2	K562 (myelogenous leukemia)	NULL	NFE2		ENCODE	ENCSR000FCC_K562_NFE2_MACS_NFE2_MA0841.1.damo.pwm.bed	32173
1	528	CTCF	0.143207990945391	0.889727823303516	34	2120	2128	729	2128	1660	38	170	169	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DUS_mammary_epithelial_cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46934
1	1643	FOXA1	0.143207990945391	0.889727823303516	34	2120	2128	729	2128	1660	38	170	169	FOXA1 MDA-MB-453 (breast adenocarcinoma) FOXA1	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	FOXA1		Array Express	ERP001226_foxa1_mdamb453_MACS_FOXA1_MA0148.4.damo.pwm.bed	121163
1	4119	YY1	0.142982772627097	0.900507867066434	52	2122	2079	244	2122	1480	57	152	150	YY1 K562 (myelogenous leukemia) YY1	K562 (myelogenous leukemia)	NULL	YY1		ENCODE	ENCSR000BKU_K562_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	24540
1	76	AR	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	treatment: targeting ARV1/3/4/7 siARVs+R1881	GTRD	EXP048921_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	13558
1	124	AR	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	DHAT_18H	GEO	GSE28950_AR_vcap-dhat-18h_MACS_AR_MA0007.3.damo.pwm.bed	28279
1	147	AR	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	AR DU145 (prostate carcinoma) AR	DU145 (prostate carcinoma)	BTO:0001332	AR	FOXA1_ARQ6540X	GEO	GSE47987_AR_du145-foxa1-arq6540x_MACS_AR_MA0007.3.damo.pwm.bed	19896
1	162	AR	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	AR LHSAR (prostate epithelial cells) AR	LHSAR (prostate epithelial cells)	NULL	AR	HOXB13	GEO	GSE56288_AR_lhsar-hoxb13_MACS_AR_MA0007.3.damo.pwm.bed	19730
1	279	BATF	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	BATF OCI-LY10 (diffuse large B-cell lymphoma) BATF	OCI-LY10 (diffuse large B-cell lymphoma)	NULL	BATF	NA	GEO	GSE56857_batf_ocily10_MACS_BATF_MA0462.2.damo.pwm.bed	6946
1	1034	E2F4	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	E2F4 HeLa S3 (cervical adenocarcinoma) E2F4	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	E2F4		ENCODE	ENCSR000EVL_HeLa-S3_E2F4_MACS_E2F4_MA0470.2.damo.pwm.bed	1370
1	1366	ESR1	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053229_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	7503
1	1773	FOXA1	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	FOXA1 DU145 (prostate carcinoma) FOXA1	DU145 (prostate carcinoma)	BTO:0001332	FOXA1		GEO	GSE47987_foxa1_du145_MACS_FOXA1_MA0148.4.damo.pwm.bed	3432
1	1969	GATA3	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3	E2, DEX	GTRD	EXP037457_MCF7--Invasive-ductal-breast-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	18053
1	2030	GATA6	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	GATA6 HUES64 (embryonic stem cells) GATA6	HUES64 (embryonic stem cells)	NULL	GATA6		GTRD	EXP036793_HUES64--embryonic-stem-cells-_GATA6_MACS_GATA6_MA1104.2.damo.pwm.bed	24536
1	2044	GATA6	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	GATA6 HUG1N GATA6	HUG1N	NA	GATA6		GEO	GSE51936_gata6_hug1n_MACS_GATA6_MA1104.2.damo.pwm.bed	5077
1	2262	JUN	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	JUN Calu-3 (lung adenocarcinoma) JUN	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUN		GTRD	EXP037683_Calu-3--lung-adenocarcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	5442
1	2263	JUN	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	JUN Calu-3 (lung adenocarcinoma) JUN	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUN		GTRD	EXP037683_Calu-3--lung-adenocarcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	5450
1	2267	JUN	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	JUN Calu-3 (lung adenocarcinoma) JUN	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUN		GTRD	EXP037683_Calu-3--lung-adenocarcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	5454
1	2268	JUN	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	JUN Calu-3 (lung adenocarcinoma) JUN	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUN		GTRD	EXP037683_Calu-3--lung-adenocarcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	5458
1	2620	JUND	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	JUND PC3(bone mets prostate adenocarcinoma) JUND	PC3(bone mets prostate adenocarcinoma)	NULL	JUND		GEO	GSE29808_jund_pc3_MACS_JUND_MA0491.2.damo.pwm.bed	5373
1	3146	NR3C1	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	NR3C1 SUP-B15 (Childhood B acute lymphoblastic leukemia) NR3C1	SUP-B15 (Childhood B acute lymphoblastic leukemia)	NULL	NR3C1	Treatment: 1uM dexamethasone in 0.02% ethanol Genotype: traslocation t(9;22)(q34;11) ? BCR-ABL1 e1-a2 fusion	GTRD	EXP052965_SUP-B15--Childhood-B-acute-lymphoblastic-leukemia-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	13374
1	3378	RELA	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	RELA AC16 (normal cardiomyocytes) RELA	AC16 (normal cardiomyocytes)	NULL	RELA	TNFA	GEO	GSE51169_rela_ac16-tnfa_MACS_RELA_MA0107.1.damo.pwm.bed	3000
1	3406	REST	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	REST Ishikawa (endometrial adenocarcinoma) REST	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	REST		ENCODE	ENCSR000BUU_Ishikawa_REST_MACS_REST_MA0138.2.damo.pwm.bed	10003
1	3818	TCF7L2	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	TCF7L2 HUES64 (embryonic stem cells) TCF7L2	HUES64 (embryonic stem cells)	NULL	TCF7L2		GTRD	EXP036767_HUES64--embryonic-stem-cells-_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	6720
1	3840	TEAD4	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	TEAD4 MKN28 (gastric tubular adenocarcinoma) TEAD4	MKN28 (gastric tubular adenocarcinoma)	BTO:0002381	TEAD4		GEO	GSE44416_tead4_mkn28_MACS_TEAD4_MA0809.2.damo.pwm.bed	4867
1	4024	TP53	0.142653900411616	0.842061627664786	5	2123	2347	3053	3053	2510	6	199	201	TP53 IMR90 (lung fibroblasts) TP53	IMR90 (lung fibroblasts)	NULL	TP53	NUT3A	GEO	GSE58740_tp53_imr90-nut3a_MACS_TP53_MA0106.3.damo.pwm.bed	3591
1	800	CTCF	0.141946215115403	0.899043591705589	51	2145	2091	261	2145	1500	56	153	151	CTCF neural progenitors CTCF	neural progenitors	NULL	CTCF		GTRD	EXP040290_neural-progenitors_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	64099
1	3542	RXRA	0.141946215115403	0.899043591705589	51	2145	2091	261	2145	1500	56	153	151	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP045021_liver_RXRA_MACS_RXRA_MA0065.2.damo.pwm.bed	52471
1	466	CTCF	0.141803356961171	0.906680097536446	78	2147	2054	21	2147	1410	84	126	123	CTCF GM12891 (male B- cells lymphoblastoid cell line) CTCF	GM12891 (male B- cells lymphoblastoid cell line)	NULL	CTCF		ENCODE	ENCSR000DKX_GM12891_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	94019
1	1803	FOXA1	0.141503517837936	0.886936313844745	33	2148	2144	778	2148	1690	37	171	170	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1		GEO	GSE72249_foxa1_mcf7_MACS_FOXA1_MA0148.4.damo.pwm.bed	47767
1	1876	GABPA	0.141503517837936	0.886936313844745	33	2148	2144	778	2148	1690	37	171	170	GABPA K562 (myelogenous leukemia) GABPA	K562 (myelogenous leukemia)	NULL	GABPA		ENCODE	ENCSR290MUH_K562_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	15212
1	493	CTCF	0.140883739410908	0.897521930384484	50	2150	2102	275	2150	1510	55	154	152	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DPG_fibroblast_of_upper_leg_skin_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48760
1	3543	RXRA	0.140883739410908	0.897521930384484	50	2150	2102	275	2150	1510	55	154	152	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP045021_liver_RXRA_MACS_RXRA_MA0074.1.damo.pwm.bed	48022
1	4125	YY1	0.140883739410908	0.897521930384484	50	2150	2102	275	2150	1510	55	154	152	YY1 A549 (lung carcinoma) YY1	A549 (lung carcinoma)	BTO:0000018	YY1	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BPM_A549_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	19542
1	290	BHLHE22	0.140689421964449	0.850873522173838	11	2153	2308	2332	2332	2260	13	193	194	BHLHE22 CAL-1 (plasmacytoid dendritic neoplasm) BHLHE22	CAL-1 (plasmacytoid dendritic neoplasm)	NULL	BHLHE22	NA	GEO	GSE43876_bhlhe22_cal1_MACS_BHLHE22_MA0818.1.damo.pwm.bed	16094
1	667	CTCF	0.140689421964449	0.850873522173838	11	2153	2308	2332	2332	2260	13	193	194	CTCF MCF10AT1 (breast premetastatic epithelial cells) CTCF	MCF10AT1 (breast premetastatic epithelial cells)	NULL	CTCF		GTRD	EXP038624_MCF10AT1--breast-premetastatic-epithelial-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34671
1	2174	HSF1	0.140689421964449	0.850873522173838	11	2153	2308	2332	2332	2260	13	193	194	HSF1 GM12878 (female B-cells lymphoblastoid cell line) HSF1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	HSF1		ENCODE	ENCSR009MBP_GM12878_HSF1_MACS_HSF1_MA0486.2.damo.pwm.bed	3656
1	2369	JUN	0.140689421964449	0.850873522173838	11	2153	2308	2332	2332	2260	13	193	194	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: 17beta estradiol 10nM for 1hr;	GTRD	EXP047660_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	14785
1	2370	JUN	0.140689421964449	0.850873522173838	11	2153	2308	2332	2332	2260	13	193	194	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: 17beta estradiol 10nM for 1hr;	GTRD	EXP047660_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	15299
1	2992	NFE2	0.140689421964449	0.850873522173838	11	2153	2308	2332	2332	2260	13	193	194	NFE2 K562 (myelogenous leukemia) NFE2	K562 (myelogenous leukemia)	NULL	NFE2		GTRD	EXP040018_K562--myelogenous-leukemia-_NFE2_MACS_NFE2_MA0501.1.damo.pwm.bed	31106
1	39	AR	0.14056740098993	0.869861526103243	20	2159	2231	1606	2231	2000	23	184	184	AR CWR22 (prostate carcinoma) AR	CWR22 (prostate carcinoma)	BTO:0004594	AR		GTRD	EXP034146_CWR22--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	27642
1	1757	FOXA1	0.14056740098993	0.869861526103243	20	2159	2231	1606	2231	2000	23	184	184	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	ETOH	GEO	GSE28264_foxa1_lncap-etoh_MACS_FOXA1_MA0148.4.damo.pwm.bed	79220
1	1491	FLI1	0.139794397767969	0.895939776063203	49	2161	2111	299	2161	1520	54	155	153	FLI1 A-673 clone Asp114 (Ewing sarcoma) FLI1	A-673 clone Asp114 (Ewing sarcoma)	NULL	FLI1	no doxycycline, serum-induction	GTRD	EXP038248_A-673-clone-Asp114--Ewing-sarcoma-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	64968
1	1277	ESR1	0.139740130874758	0.883987435415453	32	2162	2173	825	2173	1720	36	172	171	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Doxycycline + E2	GTRD	EXP038390_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	39421
1	2587	JUND	0.139740130874758	0.883987435415453	32	2162	2173	825	2173	1720	36	172	171	JUND WA01 (H1, human embryonic stem cells) JUND	WA01 (H1, human embryonic stem cells)	NULL	JUND		ENCODE	ENCSR000BKP_H1-hESC_JUND_MACS_JUND_MA0492.1.damo.pwm.bed	13533
1	3358	RELA	0.139740130874758	0.883987435415453	32	2162	2173	825	2173	1720	36	172	171	RELA HAEC (human aortic endothelial cells) RELA	HAEC (human aortic endothelial cells)	NULL	RELA	control, 4h	GTRD	EXP038048_HAEC--human-aortic-endothelial-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	10520
1	3538	RXRA	0.139740130874758	0.883987435415453	32	2162	2173	825	2173	1720	36	172	171	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA S427F	GTRD	EXP040816_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA0512.2.damo.pwm.bed	11428
1	582	CTCF	0.138677187841691	0.894293785046686	48	2166	2112	317	2166	1530	53	156	154	CTCF lymphoblastoid cells CTCF	lymphoblastoid cells	NULL	CTCF	NULL	GTRD	EXP000781_lymphoblastoid-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	57927
1	1043	E2F6	0.138239016897711	0.90232501345012	72	2167	2074	36	2167	1430	78	132	129	E2F6 K562 (myelogenous leukemia) E2F6	K562 (myelogenous leukemia)	NULL	E2F6		ENCODE	ENCSR000BLI_K562_E2F6_MACS_E2F6_MA0471.2.damo.pwm.bed	36905
1	2963	NEUROD1	0.137914345772713	0.880867737316947	31	2168	2182	881	2182	1740	35	173	172	NEUROD1 D341 Med (medulloblastoma) NEUROD1	D341 Med (medulloblastoma)	NULL	NEUROD1	shGFP	GTRD	EXP038206_D341-Med--medulloblastoma-_NEUROD1_MACS_NEUROD1_MA1109.1.damo.pwm.bed	37855
1	3887	TFAP2C	0.137914345772713	0.880867737316947	31	2168	2182	881	2182	1740	35	173	172	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions;	GTRD	EXP047536_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	23753
1	4126	YY1	0.137914345772713	0.880867737316947	31	2168	2182	881	2182	1740	35	173	172	YY1 SK-N-SH (neuroblastoma) YY1	SK-N-SH (neuroblastoma)	BTO:0001620	YY1		ENCODE	ENCSR000BSM_SK-N-SH_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	16678
1	1073	EHF	0.137571963259255	0.863945067955421	19	2171	2256	1697	2256	2040	22	185	185	EHF bronchial epithelial cells EHF	bronchial epithelial cells	BTO:0002922	EHF		GTRD	EXP037682_bronchial-epithelial-cells_EHF_MACS_EHF_MA0598.3.damo.pwm.bed	12160
1	1642	FOXA1	0.137571963259255	0.863945067955421	19	2171	2256	1697	2256	2040	22	185	185	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1		Array Express	ERP001226_foxa1_mcf7_MACS_FOXA1_MA0148.4.damo.pwm.bed	62934
1	2230	JUN	0.137571963259255	0.863945067955421	19	2171	2256	1697	2256	2040	22	185	185	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN		ENCODE	ENCSR000FAH_K562_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	18577
1	2980	NEUROG2	0.137571963259255	0.863945067955421	19	2171	2256	1697	2256	2040	22	185	185	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	0.5 DPT	GTRD	EXP037153_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	22655
1	3531	RXRA	0.137571963259255	0.863945067955421	19	2171	2256	1697	2256	2040	22	185	185	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA WT	GTRD	EXP040815_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA0512.2.damo.pwm.bed	10380
1	2854	MYC	0.137531048738595	0.89258035429505	47	2176	2122	333	2176	1540	52	157	155	MYC LNCaP (prostate carcinoma) MYC	LNCaP (prostate carcinoma)	BTO:0001321	MYC	R1881	GTRD	EXP037068_LNCaP--prostate-carcinoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	18287
1	3912	TFAP2C	0.136354856708883	0.89079559606142	46	2177	2126	349	2177	1550	51	158	156	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C		GEO	GSE21234_tfap2c_mcf7_MACS_TFAP2C_MA0524.2.damo.pwm.bed	75207
1	40	AR	0.136022375526358	0.877562185164018	30	2178	2196	937	2196	1770	34	174	173	AR CWR22 (prostate carcinoma) AR	CWR22 (prostate carcinoma)	BTO:0004594	AR	DHT	GTRD	EXP034147_CWR22--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	55856
1	797	CTCF	0.136022375526358	0.877562185164018	30	2178	2196	937	2196	1770	34	174	173	CTCF GM23338 CTCF	GM23338	NULL	CTCF		GTRD	EXP040259_GM23338_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	66821
1	836	CTCF	0.136022375526358	0.877562185164018	30	2178	2196	937	2196	1770	34	174	173	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 150min + Flavopiridol 30min	GTRD	EXP047803_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49692
1	1081	ELF1	0.136022375526358	0.877562185164018	30	2178	2196	937	2196	1770	34	174	173	ELF1 SK-N-SH (neuroblastoma) ELF1	SK-N-SH (neuroblastoma)	BTO:0001620	ELF1		ENCODE	ENCSR000BTA_SK-N-SH_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	8683
1	1797	FOXA1	0.136022375526358	0.877562185164018	30	2178	2196	937	2196	1770	34	174	173	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	PHFRPMIFCS	GEO	GSE69043_foxa1_lncap-phfrpmifcs_MACS_FOXA1_MA0148.4.damo.pwm.bed	76958
1	2237	JUN	0.136022375526358	0.877562185164018	30	2178	2196	937	2196	1770	34	174	173	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN	NULL	GTRD	EXP000309_K562--myelogenous-leukemia-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	32543
1	117	AR	0.135167789153022	0.837990419703962	10	2184	2380	2442	2442	2340	12	194	195	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053225_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	37153
1	1551	FOS	0.135167789153022	0.837990419703962	10	2184	2380	2442	2442	2340	12	194	195	FOS THP-1 (acute monocytic leukemia) FOS	THP-1 (acute monocytic leukemia)	BTO:0001370	FOS	Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA)	GTRD	EXP047824_THP-1--acute-monocytic-leukemia-_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	7757
1	1553	FOS	0.135167789153022	0.837990419703962	10	2184	2380	2442	2442	2340	12	194	195	FOS THP-1 (acute monocytic leukemia) FOS	THP-1 (acute monocytic leukemia)	BTO:0001370	FOS	Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA)	GTRD	EXP047824_THP-1--acute-monocytic-leukemia-_FOS_MACS_FOS_MA1141.1.damo.pwm.bed	7802
1	1770	FOXA1	0.135167789153022	0.837990419703962	10	2184	2380	2442	2442	2340	12	194	195	FOXA1 DU145 (prostate carcinoma) FOXA1	DU145 (prostate carcinoma)	BTO:0001332	FOXA1	FOXA1_ARC562S	GEO	GSE47987_foxa1_du145-foxa1-arc562s_MACS_FOXA1_MA0148.4.damo.pwm.bed	62786
1	2102	HIF1A	0.135167789153022	0.837990419703962	10	2184	2380	2442	2442	2340	12	194	195	HIF1A PC3(bone mets prostate adenocarcinoma) HIF1A	PC3(bone mets prostate adenocarcinoma)	NULL	HIF1A	Treatment: hypoxia(0.2% O2), siSMAD3; Genotype: SMAD3 knockout;	GTRD	EXP057827_PC3-bone-mets-prostate-adenocarcinoma-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	5321
1	2167	HOXB13	0.135167789153022	0.837990419703962	10	2184	2380	2442	2442	2340	12	194	195	HOXB13 LNCaP (prostate carcinoma) HOXB13	LNCaP (prostate carcinoma)	BTO:0001321	HOXB13	Treatment: treated with 10nM  vehicle for 4 hours	GTRD	EXP049580_LNCaP--prostate-carcinoma-_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	38217
1	2404	JUN	0.135167789153022	0.837990419703962	10	2184	2380	2442	2442	2340	12	194	195	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 012Passage: P3-6	GTRD	EXP048212_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	11840
1	2405	JUN	0.135167789153022	0.837990419703962	10	2184	2380	2442	2442	2340	12	194	195	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 012Passage: P3-6	GTRD	EXP048212_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	11285
1	2407	JUN	0.135167789153022	0.837990419703962	10	2184	2380	2442	2442	2340	12	194	195	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 012Passage: P3-6	GTRD	EXP048212_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	11204
1	2409	JUN	0.135167789153022	0.837990419703962	10	2184	2380	2442	2442	2340	12	194	195	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 012Passage: P3-6	GTRD	EXP048212_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	11437
1	2410	JUN	0.135167789153022	0.837990419703962	10	2184	2380	2442	2442	2340	12	194	195	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 012Passage: P3-6	GTRD	EXP048212_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	11008
1	2411	JUN	0.135167789153022	0.837990419703962	10	2184	2380	2442	2442	2340	12	194	195	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 012Passage: P3-6	GTRD	EXP048212_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	12135
1	1012	E2F1	0.134145380734261	0.896977962830562	66	2196	2106	78	2196	1460	72	138	135	E2F1 LNCaP (prostate carcinoma) E2F1	LNCaP (prostate carcinoma)	BTO:0001321	E2F1	BICALUTAMIDE	GTRD	EXP032857_LNCaP--prostate-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	18949
1	1046	E2F6	0.134145380734261	0.896977962830562	66	2196	2106	78	2196	1460	72	138	135	E2F6 K562 (myelogenous leukemia) E2F6	K562 (myelogenous leukemia)	NULL	E2F6		ENCODE	ENCSR000EWJ_K562_E2F6_MACS_E2F6_MA0471.2.damo.pwm.bed	30229
1	444	CTCF	0.134060095892207	0.874053920910127	29	2198	2211	1013	2211	1810	33	175	174	CTCF HeLa S3 (cervical adenocarcinoma) CTCF	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	CTCF		ENCODE	ENCSR000AOA_HeLa-S3_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	55060
1	2235	JUN	0.134060095892207	0.874053920910127	29	2198	2211	1013	2211	1810	33	175	174	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN	NULL	GTRD	EXP000309_K562--myelogenous-leukemia-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	32648
1	885	CTCF	0.133907475922437	0.886994948691343	44	2200	2143	408	2200	1580	49	160	158	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: pre treatment with 500 nM triptolide for 2 hrs, 110 mM NaCl for 60 min  + triptolide Source: T47D whole cell	GTRD	EXP053052_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37158
1	165	AR	0.132633680797475	0.884969586930648	43	2201	2147	429	2201	1590	48	161	159	AR prostate AR	prostate	NULL	AR	cancer	GEO	GSE56288_AR_prostate-cancer_MACS_AR_MA0007.3.damo.pwm.bed	77818
1	294	BHLHE40	0.132633680797475	0.884969586930648	43	2201	2147	429	2201	1590	48	161	159	BHLHE40 K562 (myelogenous leukemia) BHLHE40	K562 (myelogenous leukemia)	NULL	BHLHE40	NA	ENCODE	ENCSR000EGV_K562_BHLHE40_MACS_BHLHE40_MA0464.2.damo.pwm.bed	24254
1	518	CTCF	0.132633680797475	0.884969586930648	43	2201	2147	429	2201	1590	48	161	159	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DTI_cardiac_muscle_cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	47405
1	1495	FLI1	0.132633680797475	0.884969586930648	43	2201	2147	429	2201	1590	48	161	159	FLI1 A-673 clone Asp114 (Ewing sarcoma) FLI1	A-673 clone Asp114 (Ewing sarcoma)	NULL	FLI1		GTRD	EXP047963_A-673-clone-Asp114--Ewing-sarcoma-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	59048
1	647	CTCF	0.132023005978694	0.870323977865685	28	2205	2227	1068	2227	1830	32	176	175	CTCF neutrophils CTCF	neutrophils	NULL	CTCF		GTRD	EXP036863_neutrophils_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	16626
1	737	CTCF	0.132023005978694	0.870323977865685	28	2205	2227	1068	2227	1830	32	176	175	CTCF transverse colon CTCF	transverse colon	NULL	CTCF		GTRD	EXP039772_transverse-colon_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27869
1	2703	MAX	0.132023005978694	0.870323977865685	28	2205	2227	1068	2227	1830	32	176	175	MAX GM12878 (female B-cells lymphoblastoid cell line) MAX	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MAX	NULL	GTRD	EXP000438_GM12878--female-B-cells-_MAX_MACS_MAX_MA0059.1.damo.pwm.bed	19681
1	712	CTCF	0.131324608202261	0.882853876095581	42	2208	2177	454	2208	1610	47	162	160	CTCF bipolar neuron CTCF	bipolar neuron	NULL	CTCF	0.5 μg/mL doxycycline hyclate (CHEBI:34730) for 4 day	GTRD	EXP039610_bipolar-neuron_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	62864
1	1063	EGR1	0.131324608202261	0.882853876095581	42	2208	2177	454	2208	1610	47	162	160	EGR1 K562 (myelogenous leukemia) EGR1	K562 (myelogenous leukemia)	NULL	EGR1		GTRD	EXP039443_K562--myelogenous-leukemia-_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	18376
1	1647	FOXA1	0.131324608202261	0.882853876095581	42	2208	2177	454	2208	1610	47	162	160	FOXA1 FOXA1	NA	NA	FOXA1	NA	Array Express	ERP003828_foxa1_zr751_MACS_FOXA1_MA0148.4.damo.pwm.bed	148244
1	438	CTCF	0.13105023057849	0.850336826310838	17	2211	2316	1846	2316	2120	20	187	187	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000ALV_mammary_epithelial_cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35153
1	609	CTCF	0.13105023057849	0.850336826310838	17	2211	2316	1846	2316	2120	20	187	187	CTCF PrEC (prostate cells) CTCF	PrEC (prostate cells)	BTO:0003160	CTCF		GTRD	EXP031555_PrEC--prostate-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37891
1	2860	MYC	0.13105023057849	0.850336826310838	17	2211	2316	1846	2316	2120	20	187	187	MYC BT168 (glioblastoma stem cells) MYC	BT168 (glioblastoma stem cells)	NULL	MYC	Untreated with Dox	GTRD	EXP037765_BT168--glioblastoma-stem-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	4974
1	2970	NEUROG2	0.13105023057849	0.850336826310838	17	2211	2316	1846	2316	2120	20	187	187	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	1 DPT	GTRD	EXP037148_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	26086
1	2971	NEUROG2	0.13105023057849	0.850336826310838	17	2211	2316	1846	2316	2120	20	187	187	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	1 DPT	GTRD	EXP037148_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	25678
1	3006	NFE2L2	0.13105023057849	0.850336826310838	17	2211	2316	1846	2316	2120	20	187	187	NFE2L2 A375 (malignant melanoma) NFE2L2	A375 (malignant melanoma)	BTO:0002806	NFE2L2	DMSO	GEO	GSE57431_NFE2L2_a375-dmso_MACS_NFE2L2_MA0150.2.damo.pwm.bed	6056
1	3572	SMAD3	0.13105023057849	0.850336826310838	17	2211	2316	1846	2316	2120	20	187	187	SMAD3 HCC1954 (ductal breast carcinoma) SMAD3	HCC1954 (ductal breast carcinoma)	BTO:0005368	SMAD3	Treatment: no CellType: Immortalized human mammary epithelial cells	GTRD	EXP047902_HCC1954--ductal-breast-carcinoma-_SMAD3_MACS_SMAD3_MA0513.1.damo.pwm.bed	25358
1	1050	EBF1	0.130276252181261	0.891598009752593	61	2218	2125	127	2218	1490	67	143	140	EBF1 GM12878 (female B-cells lymphoblastoid cell line) EBF1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	EBF1	NA	ENCODE	ENCSR000BGU_GM12878_EBF1_MACS_EBF1_MA0154.4.damo.pwm.bed	63565
1	135	AR	0.130036761664511	0.808419107310708	4	2219	2515	3182	3182	2640	5	200	202	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR		GEO	GSE32892_AR_vcap_MACS_AR_MA0007.3.damo.pwm.bed	11909
1	349	CEBPA	0.130036761664511	0.808419107310708	4	2219	2515	3182	3182	2640	5	200	202	CEBPA Kasumi-1 (acute myeloblastic leukemia) CEBPA	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	CEBPA	SIRUNX1ETO	GEO	GSE60130_cebpa_kasumi1-sirunx1eto_MACS_CEBPA_MA0102.4.damo.pwm.bed	8240
1	1199	ESR1	0.130036761664511	0.808419107310708	4	2219	2515	3182	3182	2640	5	200	202	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	1hr with 100nM E2, crosslinked with 1% formaldehyde	GTRD	EXP034119_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	6035
1	1445	ESRRA	0.130036761664511	0.808419107310708	4	2219	2515	3182	3182	2640	5	200	202	ESRRA A549 (lung carcinoma) ESRRA	A549 (lung carcinoma)	BTO:0000018	ESRRA		ENCODE	ENCSR473SUA_A549_ESRRA_MACS_ESRRA_MA0592.3.damo.pwm.bed	2584
1	1503	FLI1	0.130036761664511	0.808419107310708	4	2219	2515	3182	3182	2640	5	200	202	FLI1 A-673 clone Asp114 (Ewing sarcoma) FLI1	A-673 clone Asp114 (Ewing sarcoma)	NULL	FLI1	Passage: 15-19	GTRD	EXP049962_A-673-clone-Asp114--Ewing-sarcoma-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	6792
1	2155	HOXA9	0.130036761664511	0.808419107310708	4	2219	2515	3182	3182	2640	5	200	202	HOXA9 HEK293-FT (human embryonic kidney, female transformed) HOXA9	HEK293-FT (human embryonic kidney, female transformed)	NULL	HOXA9	NUP98-HOXA9-FLAG expression	GTRD	EXP036954_HEK293-FT--human-embryonic-kidney--female-transformed-_HOXA9_MACS_HOXA9_MA0594.2.damo.pwm.bed	29639
1	2179	HSF1	0.130036761664511	0.808419107310708	4	2219	2515	3182	3182	2640	5	200	202	HSF1 BPE (mammary epithelial cells) HSF1	BPE (mammary epithelial cells)	NULL	HSF1	HEAT	GEO	GSE38901_hsf1_bpe-heat_MACS_HSF1_MA0486.2.damo.pwm.bed	2886
1	2227	JUN	0.130036761664511	0.808419107310708	4	2219	2515	3182	3182	2640	5	200	202	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN	30 m of Interferon alpha (Snyder)	ENCODE	ENCSR000EGH_K562_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	4471
1	2356	JUN	0.130036761664511	0.808419107310708	4	2219	2515	3182	3182	2640	5	200	202	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: ethanol 1hr;	GTRD	EXP047659_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	6390
1	2357	JUN	0.130036761664511	0.808419107310708	4	2219	2515	3182	3182	2640	5	200	202	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: ethanol 1hr;	GTRD	EXP047659_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	5792
1	2359	JUN	0.130036761664511	0.808419107310708	4	2219	2515	3182	3182	2640	5	200	202	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: ethanol 1hr;	GTRD	EXP047659_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	5839
1	2361	JUN	0.130036761664511	0.808419107310708	4	2219	2515	3182	3182	2640	5	200	202	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: ethanol 1hr;	GTRD	EXP047659_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	5627
1	2362	JUN	0.130036761664511	0.808419107310708	4	2219	2515	3182	3182	2640	5	200	202	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: ethanol 1hr;	GTRD	EXP047659_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	5750
1	2621	JUND	0.130036761664511	0.808419107310708	4	2219	2515	3182	3182	2640	5	200	202	JUND JUND	NA	NA	JUND	NA	GEO	GSE59021_jund_du145_MACS_JUND_MA0491.2.damo.pwm.bed	1848
1	3220	PAX5	0.130036761664511	0.808419107310708	4	2219	2515	3182	3182	2640	5	200	202	PAX5 OCI-LY7 (diffuse large B-cell lymphoma) PAX5	OCI-LY7 (diffuse large B-cell lymphoma)	NULL	PAX5		GEO	GSE69558_pax5_ocily7_MACS_PAX5_MA0014.3.damo.pwm.bed	3918
1	3403	REST	0.130036761664511	0.808419107310708	4	2219	2515	3182	3182	2640	5	200	202	REST MCF7 (Invasive ductal breast carcinoma) REST	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	REST		ENCODE	ENCSR000BSP_MCF-7_REST_MACS_REST_MA0138.2.damo.pwm.bed	8608
1	3673	SPI1	0.130036761664511	0.808419107310708	4	2219	2515	3182	3182	2640	5	200	202	SPI1 OCI-LY10 (diffuse large B-cell lymphoma) SPI1	OCI-LY10 (diffuse large B-cell lymphoma)	NULL	SPI1		GEO	GSE56857_spi1_ocily10_MACS_SPI1_MA0080.5.damo.pwm.bed	6570
1	3974	TP53	0.130036761664511	0.808419107310708	4	2219	2515	3182	3182	2640	5	200	202	TP53 SJSA-1(osteosarcoma) TP53	SJSA-1(osteosarcoma)	BTO:0004216	TP53	Nutlin	GTRD	EXP037751_SJSA-1-osteosarcoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	10647
1	296	BHLHE40	0.129978739980973	0.880642000985384	41	2237	2185	476	2237	1630	46	163	161	BHLHE40 GM12878 (female B-cells lymphoblastoid cell line) BHLHE40	GM12878 (female B-cells lymphoblastoid cell line)	NULL	BHLHE40	NA	GTRD	EXP039562_GM12878--female-B-cells-_BHLHE40_MACS_BHLHE40_MA0464.2.damo.pwm.bed	28305
1	969	CTCF	0.129978739980973	0.880642000985384	41	2237	2185	476	2237	1630	46	163	161	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF	NEUR	GEO	GSE52457_ctcf_h1-neur_MACS_CTCF_MA0139.1.damo.pwm.bed	51425
1	1215	ESR1	0.129978739980973	0.880642000985384	41	2237	2185	476	2237	1630	46	163	161	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	10nM Estradiol + 10 nM R5020	GTRD	EXP036364_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	14985
1	4118	YY1	0.129978739980973	0.880642000985384	41	2237	2185	476	2237	1630	46	163	161	YY1 GM12891 (male B- cells lymphoblastoid cell line) YY1	GM12891 (male B- cells lymphoblastoid cell line)	NULL	YY1		ENCODE	ENCSR000BKJ_GM12891_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	21680
1	2672	MAFB	0.129906183116103	0.866350940543936	27	2241	2242	1135	2242	1870	31	177	176	MAFB pancreatic islets MAFB	pancreatic islets	NULL	MAFB	NA	Array Express	ERP004003_mafb_islet_MACS_MAFB_MA0117.2.damo.pwm.bed	48470
1	3470	RUNX1	0.129906183116103	0.866350940543936	27	2241	2242	1135	2242	1870	31	177	176	RUNX1 SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) RUNX1	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	RUNX1		GTRD	EXP037833_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	23207
1	2773	MXI1	0.129447416100702	0.890404655492018	60	2243	2127	137	2243	1500	66	144	141	MXI1 SK-N-SH (neuroblastoma) MXI1	SK-N-SH (neuroblastoma)	BTO:0001620	MXI1	NA	ENCODE	ENCSR000EIA_SK-N-SH_MXI1_MACS_MXI1_MA1108.2.damo.pwm.bed	23453
1	128	AR	0.129051412578636	0.822769345537451	9	2244	2440	2564	2564	2420	11	195	196	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	1F5	GEO	GSE30623_ar_lncap1f5_MACS_AR_MA0007.3.damo.pwm.bed	13151
1	134	AR	0.129051412578636	0.822769345537451	9	2244	2440	2564	2564	2420	11	195	196	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	R1881	GEO	GSE32892_AR_vcap-r1881_MACS_AR_MA0007.3.damo.pwm.bed	44834
1	244	ATF3	0.129051412578636	0.822769345537451	9	2244	2440	2564	2564	2420	11	195	196	ATF3 WA01 (H1, human embryonic stem cells) ATF3	WA01 (H1, human embryonic stem cells)	NULL	ATF3		ENCODE	ENCSR000BKC_H1-hESC_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	4098
1	735	CTCF	0.129051412578636	0.822769345537451	9	2244	2440	2564	2564	2420	11	195	196	CTCF suprapubic skin CTCF	suprapubic skin	NULL	CTCF		GTRD	EXP039759_suprapubic-skin_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	9846
1	1449	ESRRA	0.129051412578636	0.822769345537451	9	2244	2440	2564	2564	2420	11	195	196	ESRRA SK-BR-3 (breast adenocarcinoma) ESRRA	SK-BR-3 (breast adenocarcinoma)	BTO:0002419	ESRRA	EGF	GEO	GSE81651_esrra_skbr3-egf_MACS_ESRRA_MA0592.3.damo.pwm.bed	14345
1	2171	HOXB13	0.129051412578636	0.822769345537451	9	2244	2440	2564	2564	2420	11	195	196	HOXB13 LNCaP95 HOXB13	LNCaP95	NULL	HOXB13	Treatment: 10 nM ETOH for 4 hrs Genotype: shARfl transfection	GTRD	EXP052945_LNCaP95_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	60434
1	2513	JUNB	0.129051412578636	0.822769345537451	9	2244	2440	2564	2564	2420	11	195	196	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039614_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	12390
1	2549	JUNB	0.129051412578636	0.822769345537451	9	2244	2440	2564	2564	2420	11	195	196	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP040036_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	12270
1	2552	JUNB	0.129051412578636	0.822769345537451	9	2244	2440	2564	2564	2420	11	195	196	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP040036_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	12529
1	2564	JUNB	0.129051412578636	0.822769345537451	9	2244	2440	2564	2564	2420	11	195	196	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP040136_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	9304
1	2565	JUNB	0.129051412578636	0.822769345537451	9	2244	2440	2564	2564	2420	11	195	196	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP040136_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	9375
1	2566	JUNB	0.129051412578636	0.822769345537451	9	2244	2440	2564	2564	2420	11	195	196	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP040136_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	9982
1	2568	JUNB	0.129051412578636	0.822769345537451	9	2244	2440	2564	2564	2420	11	195	196	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP040136_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	9632
1	3095	NR3C1	0.129051412578636	0.822769345537451	9	2244	2440	2564	2564	2420	11	195	196	NR3C1 LNCaP (prostate carcinoma) NR3C1	LNCaP (prostate carcinoma)	BTO:0001321	NR3C1	100 nM DHT+Dex	GTRD	EXP030503_LNCaP--prostate-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	29935
1	3404	REST	0.129051412578636	0.822769345537451	9	2244	2440	2564	2564	2420	11	195	196	REST HL-60 (acute myeloid leukemia) REST	HL-60 (acute myeloid leukemia)	BTO:0000738	REST		ENCODE	ENCSR000BTF_HL-60_REST_MACS_REST_MA0138.2.damo.pwm.bed	8116
1	3436	REST	0.129051412578636	0.822769345537451	9	2244	2440	2564	2564	2420	11	195	196	REST K562 (myelogenous leukemia) REST	K562 (myelogenous leukemia)	NULL	REST		GEO	GSE70482_rest_k562_MACS_REST_MA0138.2.damo.pwm.bed	5105
1	3	AR	0.128594459234685	0.878327627456053	40	2260	2194	502	2260	1650	45	164	162	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	FOXA1	Array Express	ERP003503_AR_lncap-foxa1_MACS_AR_MA0007.3.damo.pwm.bed	48491
1	3528	RXRA	0.128594459234685	0.878327627456053	40	2260	2194	502	2260	1650	45	164	162	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP040231_liver_RXRA_MACS_RXRA_MA1148.1.damo.pwm.bed	40969
1	2642	KLF5	0.127730750521429	0.887887014827027	58	2262	2137	154	2262	1520	64	146	143	KLF5 HEK293T (embryonic kidney) KLF5	HEK293T (embryonic kidney)	BTO:0002181	KLF5	Treatment: Over-expressing KLF5 E419Q	GTRD	EXP049094_HEK293T--embryonic-kidney-_KLF5_MACS_KLF5_MA0599.1.damo.pwm.bed	25636
1	1686	FOXA1	0.127704231021229	0.862110536457325	26	2263	2263	1204	2263	1910	30	178	177	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	Veh_90	GTRD	EXP038787_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	50532
1	1105	ELK1	0.127485838476852	0.842458118699542	16	2264	2343	1909	2343	2170	19	188	188	ELK1 HeLa S3 (cervical adenocarcinoma) ELK1	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	ELK1	NULL	GTRD	EXP000576_HeLa-S3--cervical-adenocarcinoma-_ELK1_MACS_ELK1_MA0028.2.damo.pwm.bed	4076
1	2923	MYC	0.127485838476852	0.842458118699542	16	2264	2343	1909	2343	2170	19	188	188	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC		GEO	GSE44672_myc_u2os_MACS_MYC_MA0147.3.damo.pwm.bed	3774
1	3521	RXRA	0.127170042117695	0.875903843498445	39	2266	2203	547	2266	1670	44	165	163	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP040231_liver_RXRA_MACS_RXRA_MA0065.2.damo.pwm.bed	39121
1	3620	SOX2	0.127170042117695	0.875903843498445	39	2266	2203	547	2266	1670	44	165	163	SOX2 hNSC (neural stem cells) SOX2	hNSC (neural stem cells)	NULL	SOX2		GEO	GSE69479_sox2_hnsc_MACS_SOX2_MA0143.4.damo.pwm.bed	62508
1	2941	MYCN	0.126841812610853	0.886558834475441	57	2268	2146	174	2268	1530	63	147	144	MYCN Kelly (neuroblastoma) MYCN	Kelly (neuroblastoma)	NULL	MYCN		GTRD	EXP038398_Kelly--neuroblastoma-_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	25563
1	6	AR	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	Vehicle	GTRD	EXP000408_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	2386
1	89	AR	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: Ethanol for 4 hrs Genotype: Bag-1L knockout and Bag-1L wildtype	GTRD	EXP049281_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	5092
1	144	AR	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	SHCTR	GEO	GSE47120_AR_lncap-shctr_MACS_AR_MA0007.3.damo.pwm.bed	1154
1	224	ARNT	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	ARNT HUVEC-C (HUVEC, umbilical vein endothelial cells) ARNT	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ARNT	Passage: 4-6	GTRD	EXP049262_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ARNT_MACS_ARNT_MA0006.1.damo.pwm.bed	712
1	277	BACH2	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	BACH2 OCI-LY7 (diffuse large B-cell lymphoma) BACH2	OCI-LY7 (diffuse large B-cell lymphoma)	NULL	BACH2		GEO	GSE69558_bach2_ocily7_MACS_BACH2_MA1101.2.damo.pwm.bed	1889
1	285	BCL6	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	BCL6 OCI-LY1 (diffuse large B-cell lymphoma) BCL6	OCI-LY1 (diffuse large B-cell lymphoma)	NULL	BCL6	UV	GTRD	EXP040596_OCI-LY1--diffuse-large-B-cell-lymphoma-_BCL6_MACS_BCL6_MA0463.2.damo.pwm.bed	8139
1	649	CTCF	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	CTCF 226LDM (normal breast luminal cells) CTCF	226LDM (normal breast luminal cells)	NULL	CTCF	hydroxyurea and nocodazole	GTRD	EXP036891_226LDM--normal-breast-luminal-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	68
1	662	CTCF	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	CTCF U2OS (osteosarcoma) CTCF	U2OS (osteosarcoma)	BTO:0001938	CTCF		GTRD	EXP037952_U2OS--osteosarcoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	5642
1	999	CUX1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	CUX1 K562 (myelogenous leukemia) CUX1	K562 (myelogenous leukemia)	NULL	CUX1	NA	GTRD	EXP038272_K562--myelogenous-leukemia-_CUX1_MACS_CUX1_MA0754.1.damo.pwm.bed	1947
1	1098	ELF5	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	ELF5 T47D (invasive ductal carcinoma) ELF5	T47D (invasive ductal carcinoma)	BTO:0001248	ELF5	ELF5_48H	GEO	GSE31216_elf5_t47d-elf5-48h_MACS_ELF5_MA0136.2.damo.pwm.bed	181
1	1137	ERG	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	ERG RWPE1 (prostate epithelial cells) ERG	RWPE1 (prostate epithelial cells)	BTO:0003709	ERG	Treatment: no Genotype: expressing point-mutant(S96E) of ERF	GTRD	EXP049001_RWPE1--prostate-epithelial-cells-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	749
1	1240	ESR1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	White Medium	GTRD	EXP037778_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	3020
1	1328	ESR1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	ESR1 MDA-MB-134 (invasive lobular breast carcinoma) ESR1	MDA-MB-134 (invasive lobular breast carcinoma)	NULL	ESR1	Treatment: DMSO Passage: between 10 and12 CellType: Epithelial ERalpha positive breast cancer cell line	GTRD	EXP048177_MDA-MB-134--invasive-lobular-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	5868
1	1356	ESR1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: Vehicle for 60 mins Genotype: ER+/PR+	GTRD	EXP049938_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	2998
1	1370	ESR1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 10 nM 17-beta-estradiol for 30 mins Genotype: pS118-ER	GTRD	EXP053336_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	2817
1	1380	ESR1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	ESR1 MCF7L-TamR(immortalized breast epithelial, tamoxifen resistant cell line) E	MCF7L-TamR(immortalized breast epithelial, tamoxifen resistant cell line)	NULL	ESR1		GTRD	EXP057867_MCF7L-TamR-immortalized-breast-epithelial--tamoxifen-resistant-cell-line-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	2344
1	1418	ESR1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GEO	GSE60270_esr1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	4935
1	1434	ESR1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1		GEO	GSE72249_esr1_t47d_MACS_ESR1_MA0112.3.damo.pwm.bed	3248
1	1629	FOSL2	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	FOSL2 hFOB 1.19 (fetal osteoblast) FOSL2	hFOB 1.19 (fetal osteoblast)	BTO:0005224	FOSL2	DIFF	GEO	GSE82295_fosl2_hfob-diff_MACS_FOSL2_MA0478.1.damo.pwm.bed	1464
1	1697	FOXA1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	FOXA1 A1A3(breast cancer cells) FOXA1	A1A3(breast cancer cells)	NULL	FOXA1	Treatment: 1hr Dex, PBS 72 hr CellLine: A1A3 from T47D cell line	GTRD	EXP048403_A1A3-breast-cancer-cells-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	6924
1	1762	FOXA1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	FOXA1 HuH7 (hepatocellular carcinoma) FOXA1	HuH7 (hepatocellular carcinoma)	BTO:0001950	FOXA1	ASYNC	GEO	GSE39241_foxa1_huh7-async_MACS_FOXA1_MA0148.4.damo.pwm.bed	4491
1	1822	FOXA2	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	FOXA2 liver FOXA2	liver	BTO:0000759	FOXA2	NULL	GTRD	EXP000903_liver_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	2907
1	1951	GATA2	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	GATA2 TSU-1621-MT (adult acute myeloid leukemia) GATA2	TSU-1621-MT (adult acute myeloid leukemia)	NULL	GATA2		GEO	GSE60477_gata2_tsu1621mt_MACS_GATA2_MA0036.3.damo.pwm.bed	5886
1	2026	GATA4	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	GATA4 KATOIII (signet ring cell gastric adenocarcinoma) GATA4	KATOIII (signet ring cell gastric adenocarcinoma)	NULL	GATA4		GEO	GSE51705_gata4_katoiii_MACS_GATA4_MA0482.2.damo.pwm.bed	792
1	2050	GFI1B	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	GFI1B SET2 (Adult acute megakaryoblastic leukemia, Homo Sapiens) GFI1B	SET2 (Adult acute megakaryoblastic leukemia, Homo Sapiens)	NULL	GFI1B	Treatment: DMSO; Genotype: drug-resistant SET-2 LSD1 (Leu659_Asn660insArg);	GTRD	EXP058351_SET2--Adult-acute-megakaryoblastic-leukemia--Homo-Sapiens-_GFI1B_MACS_GFI1B_MA0483.1.damo.pwm.bed	1253
1	2051	GFI1B	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	GFI1B SET2 (Adult acute megakaryoblastic leukemia, Homo Sapiens) GFI1B	SET2 (Adult acute megakaryoblastic leukemia, Homo Sapiens)	NULL	GFI1B	Treatment: GSK-LSD1 for 48 hrs; Genotype: drug-resistant SET-2 LSD1 (Leu659_Asn660insArg);	GTRD	EXP058353_SET2--Adult-acute-megakaryoblastic-leukemia--Homo-Sapiens-_GFI1B_MACS_GFI1B_MA0483.1.damo.pwm.bed	1493
1	2087	HIF1A	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	HIF1A RCC4 (kidney cancer cell line) HIF1A	RCC4 (kidney cancer cell line)	BTO:0005691	HIF1A	Treatment: degree of hypoxia - normoxia	GTRD	EXP048723_RCC4--kidney-cancer-cell-line-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	592
1	2146	HNF4A	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	HNF4A HCT-116 (colon carcinoma) HNF4A	HCT-116 (colon carcinoma)	BTO:0001109	HNF4A	TCF4_DOX	GEO	GSE62890_hnf4a_hct166-tcf4-dox_MACS_HNF4A_MA0114.4.damo.pwm.bed	1674
1	2147	HNF4A	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	HNF4A HCT-116 (colon carcinoma) HNF4A	HCT-116 (colon carcinoma)	BTO:0001109	HNF4A	TCF4	GEO	GSE62890_hnf4a_hct166-tcf4_MACS_HNF4A_MA0114.4.damo.pwm.bed	1987
1	2184	HSF1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	HSF1 HCT-15 (colon carcinoma) HSF1	HCT-15 (colon carcinoma)	BTO:0002201	HSF1		GEO	GSE38901_hsf1_hct15_MACS_HSF1_MA0486.2.damo.pwm.bed	380
1	2192	HSF1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	HSF1 MCF7 (Invasive ductal breast carcinoma) HSF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	HSF1		GEO	GSE45852_hsf1_mcf7_MACS_HSF1_MA0486.2.damo.pwm.bed	574
1	2193	HSF1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	HSF1 HCT-116 (colon carcinoma) HSF1	HCT-116 (colon carcinoma)	BTO:0001109	HSF1	KOFBXW7	GEO	GSE57398_hsf1_hct166-kofbxw7-heat_MACS_HSF1_MA0486.2.damo.pwm.bed	164
1	2677	MAFK	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	MAFK GM12878 (female B-cells lymphoblastoid cell line) MAFK	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MAFK	NA	ENCODE	ENCSR000DYV_GM12878_MAFK_MACS_MAFK_MA0496.3.damo.pwm.bed	1410
1	2753	MITF	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	MITF melanocytes MITF	melanocytes	NULL	MITF	none	GTRD	EXP033916_melanocytes_MITF_MACS_MITF_MA0620.3.damo.pwm.bed	395
1	2782	MYBL2	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	MYBL2 K562 (myelogenous leukemia) MYBL2	K562 (myelogenous leukemia)	NULL	MYBL2	NA	GTRD	EXP039755_K562--myelogenous-leukemia-_MYBL2_MACS_MYBL2_MA0777.1.damo.pwm.bed	633
1	3055	NR2C2	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	NR2C2 HeLa (cervical adenocarcinoma) NR2C2	HeLa (cervical adenocarcinoma)	BTO:0000567	NR2C2		GEO	GSE46237_nr2c2_hela_MACS_NR2C2_MA0504.1.damo.pwm.bed	558
1	3125	NR3C1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	NR3C1 breast tumor NR3C1	breast tumor	NULL	NR3C1	Male	GTRD	EXP040669_breast-tumor_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	1342
1	3127	NR3C1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	NR3C1 MCF10A (breast epithelial cells) NR3C1	MCF10A (breast epithelial cells)	BTO:0001939	NR3C1	Treatment: untreated;	GTRD	EXP047625_MCF10A--breast-epithelial-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	539
1	3160	NR3C1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	NR3C1 MCF7 (Invasive ductal breast carcinoma) NR3C1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NR3C1	DEX	GEO	GSE72249_nr3c1_mcf7-dex_MACS_NR3C1_MA0113.3.damo.pwm.bed	7546
1	3246	POU5F1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	POU5F1 WA01 (H1, human embryonic stem cells) POU5F1	WA01 (H1, human embryonic stem cells)	NULL	POU5F1		ENCODE	ENCSR000BMU_H1-hESC_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	2676
1	3255	POU5F1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	POU5F1 HUES64 (embryonic stem cells) POU5F1	HUES64 (embryonic stem cells)	NULL	POU5F1		GTRD	EXP036732_HUES64--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	5968
1	3266	POU5F1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	POU5F1 MRC-5 (fetal lung fibroblasts) POU5F1	MRC-5 (fetal lung fibroblasts)	BTO:0001590	POU5F1	Treatment: Oct4, Sox2 and Klf4 addition for 5 days Passage: 8	GTRD	EXP048944_MRC-5--fetal-lung-fibroblasts-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	5094
1	3381	RELA	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	RELA MCF7 (Invasive ductal breast carcinoma) RELA	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RELA		GEO	GSE59530_rela_mcf7_MACS_RELA_MA0107.1.damo.pwm.bed	378
1	3387	RELA	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	RELA LNCaP (prostate carcinoma) RELA	LNCaP (prostate carcinoma)	BTO:0001321	RELA	TNFA	GEO	GSE83860_rela_lncap-tnfa_MACS_RELA_MA0107.1.damo.pwm.bed	2124
1	3451	RUNX1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	RUNX1 K562 (myelogenous leukemia) RUNX1	K562 (myelogenous leukemia)	NULL	RUNX1		ENCODE	ENCSR414TYY_K562_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	1943
1	3558	SIX1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	SIX1 SIX1	NA	NA	SIX1	NA	GEO	GSE75948_six1_fetal-kidney-17w_MACS_SIX1_MA1118.1.damo.pwm.bed	2258
1	3578	SMAD4	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	SMAD4 endoderm SMAD4	endoderm	NA	SMAD4	NA	GEO	GSE29422_smad4_endoderm_MACS_SMAD4_MA1153.1.damo.pwm.bed	4723
1	3587	SOX10	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	SOX10 501Mel (melanoma) SOX10	501Mel (melanoma)	BTO:0002956	SOX10	NA	GEO	GSE61965_sox10_501mel_MACS_SOX10_MA0442.2.damo.pwm.bed	2863
1	3590	SOX17	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	SOX17 HUES64 (embryonic stem cells) SOX17	HUES64 (embryonic stem cells)	NULL	SOX17	NA	GTRD	EXP036747_HUES64--embryonic-stem-cells-_SOX17_MACS_SOX17_MA0078.1.damo.pwm.bed	859
1	3723	STAT1	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	STAT1 K562 (myelogenous leukemia) STAT1	K562 (myelogenous leukemia)	NULL	STAT1	30 m of Interferon alpha (Snyder)	ENCODE	ENCSR000FAV_K562_STAT1_MACS_STAT1_MA0137.3.damo.pwm.bed	273
1	3796	TCF4	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	TCF4 SH-SY5Y (neuroblastoma) TCF4	SH-SY5Y (neuroblastoma)	BTO:0000793	TCF4	Treatment: none	GTRD	EXP049703_SH-SY5Y--neuroblastoma-_TCF4_MACS_TCF4_MA0830.2.damo.pwm.bed	2464
1	3976	TP53	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	Treatment: 4GY for 2hrs;	GTRD	EXP047468_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	2080
1	3979	TP53	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	TP53 PHA-simulated human T-lynphocytes TP53	PHA-simulated human T-lynphocytes	NULL	TP53	Treatment: 10 uM Nutlin-3 for 24 hrs Source: healthy volunteer #45	GTRD	EXP048268_PHA-simulated-human-T-lynphocytes_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	2351
1	4033	TP63	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	TP63 HaCaT (keratinocytes) TP63	HaCaT (keratinocytes)	BTO:0000552	TP63	Ad-dnRAS and 3 ng/ml of TGF-beta3 for 1.5 hrs	GTRD	EXP033939_HaCaT--keratinocytes-_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	3037
1	4061	TP73	0.126710347136664	1.01474380742647	1	2269	1660	3655	3655	2530	1	203	206	TP73 GM12878 (female B-cells lymphoblastoid cell line) TP73	GM12878 (female B-cells lymphoblastoid cell line)	NULL	TP73	NA	GTRD	EXP038553_GM12878--female-B-cells-_TP73_MACS_TP73_MA0861.1.damo.pwm.bed	1828
1	780	CTCF	0.125411220078447	0.857575143433781	25	2324	2282	1262	2324	1960	29	179	178	CTCF pancreas CTCF	pancreas	BTO:0000988	CTCF		GTRD	EXP040107_pancreas_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	33140
1	1788	FOXA1	0.125411220078447	0.857575143433781	25	2324	2282	1262	2324	1960	29	179	178	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	E2	GEO	GSE60270_foxa1_mcf7-e2_MACS_FOXA1_MA0148.4.damo.pwm.bed	64535
1	2234	JUN	0.125411220078447	0.857575143433781	25	2324	2282	1262	2324	1960	29	179	178	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN	NULL	GTRD	EXP000309_K562--myelogenous-leukemia-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	26068
1	1839	FOXA2	0.12419331345212	0.870697094454027	37	2327	2225	607	2327	1720	42	167	165	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL	GTRD	EXP049303_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	104199
1	3639	SP2	0.12419331345212	0.870697094454027	37	2327	2225	607	2327	1720	42	167	165	SP2 HEK293T (embryonic kidney) SP2	HEK293T (embryonic kidney)	BTO:0002181	SP2	NA	Array Express	ERP007114_sp2_hek293t_MACS_SP2_MA0516.2.damo.pwm.bed	8394
1	2975	NEUROG2	0.123688639147959	0.833703777776749	15	2329	2403	1993	2403	2240	18	189	189	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	2 DPT	GTRD	EXP037150_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	19820
1	475	CTCF	0.123020618324819	0.852713191326367	24	2330	2299	1324	2330	1980	28	180	179	CTCF HepG2 (hepatoblastoma) CTCF	HepG2 (hepatoblastoma)	BTO:0000599	CTCF		ENCODE	ENCSR000DLS_HepG2_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	51632
1	1869	GABPA	0.123020618324819	0.852713191326367	24	2330	2299	1324	2330	1980	28	180	179	GABPA HepG2 (hepatoblastoma) GABPA	HepG2 (hepatoblastoma)	BTO:0000599	GABPA		ENCODE	ENCSR000BJK_HepG2_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	7016
1	2438	JUN	0.123020618324819	0.852713191326367	24	2330	2299	1324	2330	1980	28	180	179	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057919_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	27567
1	3846	TFAP2A	0.123020618324819	0.852713191326367	24	2330	2299	1324	2330	1980	28	180	179	TFAP2A HeLa S3 (cervical adenocarcinoma) TFAP2A	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	TFAP2A	None	GTRD	EXP010503_HeLa-S3--cervical-adenocarcinoma-_TFAP2A_MACS_TFAP2A_MA0872.1.damo.pwm.bed	21503
1	3632	SP1	0.122726172403459	0.888772440381101	78	2334	2136	21	2334	1500	85	126	122	SP1 HCT-116 (colon carcinoma) SP1	HCT-116 (colon carcinoma)	BTO:0001109	SP1		GTRD	EXP036144_HCT-116--colon-carcinoma-_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	34539
1	506	CTCF	0.122636933269599	0.867896762072383	36	2335	2237	645	2335	1740	41	168	166	CTCF GM12866 (male B-cells) CTCF	GM12866 (male B-cells)	NULL	CTCF		ENCODE	ENCSR000DRF_GM12866_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45845
1	833	CTCF	0.122636933269599	0.867896762072383	36	2335	2237	645	2335	1740	41	168	166	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 45min	GTRD	EXP047800_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	55571
1	2917	MYC	0.122636933269599	0.867896762072383	36	2335	2237	645	2335	1740	41	168	166	MYC BJ (fibroblasts) MYC	BJ (fibroblasts)	NULL	MYC	INDUCED	GEO	GSE36570_myc_bj-induced_MACS_MYC_MA0147.3.damo.pwm.bed	20603
1	1352	ESR1	0.122218442901065	0.804508574705391	8	2338	2552	2697	2697	2530	10	196	197	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	Passsage: <10	GTRD	EXP049892_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	11209
1	1850	FOXK1	0.122218442901065	0.804508574705391	8	2338	2552	2697	2697	2530	10	196	197	FOXK1 HEK293T (embryonic kidney) FOXK1	HEK293T (embryonic kidney)	BTO:0002181	FOXK1	NA	GEO	GSE51673_foxk1_hek293t_MACS_FOXK1_MA0852.2.damo.pwm.bed	2019
1	2388	JUN	0.122218442901065	0.804508574705391	8	2338	2552	2697	2697	2530	10	196	197	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048210_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	10958
1	2389	JUN	0.122218442901065	0.804508574705391	8	2338	2552	2697	2697	2530	10	196	197	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048210_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	10920
1	2390	JUN	0.122218442901065	0.804508574705391	8	2338	2552	2697	2697	2530	10	196	197	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048210_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	10385
1	2391	JUN	0.122218442901065	0.804508574705391	8	2338	2552	2697	2697	2530	10	196	197	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048210_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	10337
1	2393	JUN	0.122218442901065	0.804508574705391	8	2338	2552	2697	2697	2530	10	196	197	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048210_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	10358
1	2394	JUN	0.122218442901065	0.804508574705391	8	2338	2552	2697	2697	2530	10	196	197	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048210_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	10750
1	2395	JUN	0.122218442901065	0.804508574705391	8	2338	2552	2697	2697	2530	10	196	197	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048210_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	10838
1	2563	JUNB	0.122218442901065	0.804508574705391	8	2338	2552	2697	2697	2530	10	196	197	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP040136_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	9598
1	2665	MAF	0.122218442901065	0.804508574705391	8	2338	2552	2697	2697	2530	10	196	197	MAF Th17-cells MAF	Th17-cells	BTO:0005655	MAF	CellType:pool of expanded Th17 clones; Tissue: primary Th17-IL-10+ lymphocytes; ActivationState: recently activeted;Day:5;	GTRD	EXP047557_Th17-cells_MAF_MACS_MAF_MA0501.1.damo.pwm.bed	7057
1	3007	NFIA	0.122218442901065	0.804508574705391	8	2338	2552	2697	2697	2530	10	196	197	NFIA HepG2 (hepatoblastoma) NFIA	HepG2 (hepatoblastoma)	BTO:0000599	NFIA	NA	GTRD	EXP038543_HepG2--hepatoblastoma-_NFIA_MACS_NFIA_MA0670.1.damo.pwm.bed	9551
1	3217	PAX5	0.122218442901065	0.804508574705391	8	2338	2552	2697	2697	2530	10	196	197	PAX5 Namalwa (Burkitt lymphoma) PAX5	Namalwa (Burkitt lymphoma)	BTO:0003289	PAX5	none	GTRD	EXP031939_Namalwa--Burkitt-lymphoma-_PAX5_MACS_PAX5_MA0014.3.damo.pwm.bed	8179
1	3346	RELA	0.122218442901065	0.804508574705391	8	2338	2552	2697	2697	2530	10	196	197	RELA GM18526 (B – cells Lymphoblastoid Cell Lines) RELA	GM18526 (B – cells Lymphoblastoid Cell Lines)	NULL	RELA	TNF-alpha induced (6h)	GTRD	EXP000770_GM18526--B-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	5127
1	2881	MYC	0.121040142127793	0.87747393125009	51	2352	2202	261	2352	1600	57	153	150	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shSCR;	GTRD	EXP047486_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	15676
1	293	BHLHE40	0.121032256190523	0.864952095510542	35	2353	2255	691	2353	1770	40	169	167	BHLHE40 HepG2 (hepatoblastoma) BHLHE40	HepG2 (hepatoblastoma)	BTO:0000599	BHLHE40	NA	ENCODE	ENCSR000EDT_HepG2_BHLHE40_MACS_BHLHE40_MA0464.2.damo.pwm.bed	18512
1	325	CEBPA	0.120525211443868	0.847488430727771	23	2354	2328	1391	2354	2020	27	181	180	CEBPA SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) CEBPA	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	CEBPA	Treatment: ethanol; Genotype: inducible version of CEBPA (C/EBPalpha-ER);	GTRD	EXP047670_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	13619
1	2122	HNF4A	0.120525211443868	0.847488430727771	23	2354	2328	1391	2354	2020	27	181	180	HNF4A HepG2 (hepatoblastoma) HNF4A	HepG2 (hepatoblastoma)	BTO:0000599	HNF4A		Array Express	ERP000209_hnf4a_hepg2_MACS_HNF4A_MA0114.4.damo.pwm.bed	29845
1	3354	RELA	0.120525211443868	0.847488430727771	23	2354	2328	1391	2354	2020	27	181	180	RELA MCF7 (Invasive ductal breast carcinoma) RELA	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RELA	IL1b for 45m	GTRD	EXP036986_MCF7--Invasive-ductal-breast-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	18846
1	3520	RXRA	0.120525211443868	0.847488430727771	23	2354	2328	1391	2354	2020	27	181	180	RXRA monocyte-derived macrophages RXRA	monocyte-derived macrophages	NULL	RXRA	untreated	GTRD	EXP036837_monocyte-derived-macrophages_RXRA_MACS_RXRA_MA1147.1.damo.pwm.bed	11929
1	3772	TBX21	0.120525211443868	0.847488430727771	23	2354	2328	1391	2354	2020	27	181	180	TBX21 CD4 TBX21	CD4	NA	TBX21	TH1	GEO	GSE62482_tbx21_cd4-th1_MACS_TBX21_MA0690.1.damo.pwm.bed	11790
1	3845	TFAP2A	0.120525211443868	0.847488430727771	23	2354	2328	1391	2354	2020	27	181	180	TFAP2A HeLa S3 (cervical adenocarcinoma) TFAP2A	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	TFAP2A	None	GTRD	EXP010503_HeLa-S3--cervical-adenocarcinoma-_TFAP2A_MACS_TFAP2A_MA0810.1.damo.pwm.bed	20807
1	3173	NRF1	0.119988543818298	0.875748446841821	50	2360	2205	275	2360	1610	56	154	151	NRF1 K562 (myelogenous leukemia) NRF1	K562 (myelogenous leukemia)	NULL	NRF1		ENCODE	ENCSR494TDU_K562_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	13310
1	408	CEBPG	0.119631023600854	0.82391923340306	14	2361	2432	2073	2432	2290	17	190	190	CEBPG K562 (myelogenous leukemia) CEBPG	K562 (myelogenous leukemia)	NULL	CEBPG	NA	ENCODE	ENCSR620VIC_K562_CEBPG_MACS_CEBPG_MA0838.1.damo.pwm.bed	27165
1	414	CREB1	0.119631023600854	0.82391923340306	14	2361	2432	2073	2432	2290	17	190	190	CREB1 A549 (lung carcinoma) CREB1	A549 (lung carcinoma)	BTO:0000018	CREB1	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BRA_A549_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	4109
1	2224	JUN	0.119631023600854	0.82391923340306	14	2361	2432	2073	2432	2290	17	190	190	JUN JUN	NA	NA	JUN	NA	NA	ENCSR000EFA_endothelial_cell_of_umbilical_vein_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	29202
1	2618	JUND	0.119631023600854	0.82391923340306	14	2361	2432	2073	2432	2290	17	190	190	JUND liver JUND	liver	BTO:0000759	JUND		GTRD	EXP040078_liver_JUND_MACS_JUND_MA1142.1.damo.pwm.bed	10132
1	2843	MYC	0.119631023600854	0.82391923340306	14	2361	2432	2073	2432	2290	17	190	190	MYC HUES64 (embryonic stem cells) MYC	HUES64 (embryonic stem cells)	NULL	MYC		GTRD	EXP036775_HUES64--embryonic-stem-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	2931
1	3149	NR3C1	0.119631023600854	0.82391923340306	14	2361	2432	2073	2432	2290	17	190	190	NR3C1 HeLa-B2 NR3C1	HeLa-B2	NA	NR3C1	P65KD_TA_TNFA	GEO	GSE24518_nr3c1_helab2-p65kd-ta-tnfa_MACS_NR3C1_MA0113.3.damo.pwm.bed	14867
1	4080	USF2	0.119631023600854	0.82391923340306	14	2361	2432	2073	2432	2290	17	190	190	USF2 WA01 (H1, human embryonic stem cells) USF2	WA01 (H1, human embryonic stem cells)	NULL	USF2		ENCODE	ENCSR000ECD_H1-hESC_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	6557
1	3201	OTX2	0.119376867378378	0.861852067659222	34	2368	2272	729	2368	1790	39	170	168	OTX2 D341 Med (medulloblastoma) OTX2	D341 Med (medulloblastoma)	NULL	OTX2		GTRD	EXP038199_D341-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	69542
1	3493	RUNX1	0.119376867378378	0.861852067659222	34	2368	2272	729	2368	1790	39	170	168	RUNX1 TSU-1621-MT (adult acute myeloid leukemia) RUNX1	TSU-1621-MT (adult acute myeloid leukemia)	NULL	RUNX1		GEO	GSE60477_runx1_tsu1621mt_MACS_RUNX1_MA0002.2.damo.pwm.bed	53838
1	2705	MAX	0.118910630551915	0.87395412812718	49	2370	2213	299	2370	1630	55	155	152	MAX HeLa (cervical adenocarcinoma) MAX	HeLa (cervical adenocarcinoma)	BTO:0000567	MAX		GTRD	EXP031874_HeLa--cervical-adenocarcinoma-_MAX_MACS_MAX_MA0059.1.damo.pwm.bed	35271
1	2717	MAX	0.118910630551915	0.87395412812718	49	2370	2213	299	2370	1630	55	155	152	MAX P493-6 (B-cell lymphoma) MAX	P493-6 (B-cell lymphoma)	BTO:0003291	MAX		GEO	GSE36354_max_p493_MACS_MAX_MA0058.3.damo.pwm.bed	26087
1	943	CTCF	0.118045775684617	0.882225002272739	70	2372	2180	42	2372	1530	77	134	130	CTCF SUM159PT (Triple negative breast cancer) CTCF	SUM159PT (Triple negative breast cancer)	NULL	CTCF		GEO	GSE46055_ctcf_sum159_MACS_CTCF_MA0139.1.damo.pwm.bed	44148
1	1006	E2F1	0.118045775684617	0.882225002272739	70	2372	2180	42	2372	1530	77	134	130	E2F1 MCF7 (Invasive ductal breast carcinoma) E2F1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	E2F1	NULL	GTRD	EXP000658_MCF7--Invasive-ductal-breast-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	19120
1	441	CTCF	0.117917009731032	0.841859032870746	22	2374	2369	1459	2374	2070	26	182	181	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000ANE_skeletal_muscle_myoblast_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	44860
1	1036	E2F4	0.117917009731032	0.841859032870746	22	2374	2369	1459	2374	2070	26	182	181	E2F4 mesenchymal stem cells-derived adipocytes E2F4	mesenchymal stem cells-derived adipocytes	NULL	E2F4	NULL	GTRD	EXP000564_mesenchymal-stem-cells-derived-adipocytes_E2F4_MACS_E2F4_MA0470.2.damo.pwm.bed	5068
1	1337	ESR1	0.117917009731032	0.841859032870746	22	2374	2369	1459	2374	2070	26	182	181	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	H3B-5942	GTRD	EXP048583_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	11632
1	2596	JUND	0.117917009731032	0.841859032870746	22	2374	2369	1459	2374	2070	26	182	181	JUND HeLa S3 (cervical adenocarcinoma) JUND	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	JUND		ENCODE	ENCSR000EDH_HeLa-S3_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	36650
1	440	CTCF	0.117668174174279	0.858584488538647	33	2378	2278	778	2378	1810	38	171	169	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF		ENCODE	ENCSR000AMF_H1-hESC_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	69374
1	494	CTCF	0.117668174174279	0.858584488538647	33	2378	2278	778	2378	1810	38	171	169	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DPM_fibroblast_of_lung_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40882
1	1361	ESR1	0.117668174174279	0.858584488538647	33	2378	2278	778	2378	1810	38	171	169	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 10 nM E2 for4 hrs Genotype: ER+/PR+	GTRD	EXP049946_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	46823
1	3770	TBX21	0.117668174174279	0.858584488538647	33	2378	2278	778	2378	1810	38	171	169	TBX21 GM12878 (female B-cells lymphoblastoid cell line) TBX21	GM12878 (female B-cells lymphoblastoid cell line)	NULL	TBX21		ENCODE	ENCSR739IHN_GM12878_TBX21_MACS_TBX21_MA0690.1.damo.pwm.bed	44000
1	1679	FOXA1	0.11667222956071	0.8701438823287	47	2382	2230	333	2382	1650	53	157	154	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	siCtl	GTRD	EXP038435_VCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	140998
1	732	CTCF	0.115903389375251	0.855135848170395	32	2383	2289	825	2383	1830	37	172	170	CTCF tibial artery CTCF	tibial artery	NULL	CTCF		GTRD	EXP039723_tibial-artery_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29046
1	1685	FOXA1	0.115903389375251	0.855135848170395	32	2383	2289	825	2383	1830	37	172	170	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1		GTRD	EXP038772_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	65377
1	2985	NEUROG2	0.115903389375251	0.855135848170395	32	2383	2289	825	2383	1830	37	172	170	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	1 DPT	GTRD	EXP037155_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	28138
1	3825	TEAD1	0.115903389375251	0.855135848170395	32	2383	2289	825	2383	1830	37	172	170	TEAD1 MCF-7 C4-12 (invasive breast ductal carcinoma) TEAD1	MCF-7 C4-12 (invasive breast ductal carcinoma)	NULL	TEAD1	Genotype: wildtype	GTRD	EXP047969_MCF-7-C4-12--invasive-breast-ductal-carcinoma-_TEAD1_MACS_TEAD1_MA0090.3.damo.pwm.bed	48184
1	671	CTCF	0.115509801873371	0.868119668384727	46	2387	2234	349	2387	1660	52	158	155	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		GTRD	EXP038774_MCF7--Invasive-ductal-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	62133
1	1479	ETV4	0.115509801873371	0.868119668384727	46	2387	2234	349	2387	1660	52	158	155	ETV4 HepG2 (hepatoblastoma) ETV4	HepG2 (hepatoblastoma)	BTO:0000599	ETV4	NA	ENCODE	ENCSR714YZG_HepG2_ETV4_MACS_ETV4_MA0764.2.damo.pwm.bed	20960
1	2825	MYC	0.115509801873371	0.868119668384727	46	2387	2234	349	2387	1660	52	158	155	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	HA-OmoMYCwt, Doxycycline	GTRD	EXP036030_U2OS--osteosarcoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	15401
1	34	AR	0.115280547960847	0.812911258845785	13	2390	2499	2153	2499	2350	16	191	191	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Bicalutamide	GTRD	EXP033082_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	42973
1	287	BCL6	0.115280547960847	0.812911258845785	13	2390	2499	2153	2499	2350	16	191	191	BCL6 OCI-LY1 (diffuse large B-cell lymphoma) BCL6	OCI-LY1 (diffuse large B-cell lymphoma)	NULL	BCL6	Treatment: BCL6 targeted siRNA	GTRD	EXP052977_OCI-LY1--diffuse-large-B-cell-lymphoma-_BCL6_MACS_BCL6_MA0463.2.damo.pwm.bed	5633
1	1759	FOXA1	0.115280547960847	0.812911258845785	13	2390	2499	2153	2499	2350	16	191	191	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	1F5	GEO	GSE30623_foxa1_lncap1f5_MACS_FOXA1_MA0148.4.damo.pwm.bed	33623
1	2366	JUN	0.115280547960847	0.812911258845785	13	2390	2499	2153	2499	2350	16	191	191	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: 17beta estradiol 10nM for 1hr;	GTRD	EXP047660_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	15443
1	2562	JUNB	0.115280547960847	0.812911258845785	13	2390	2499	2153	2499	2350	16	191	191	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP040135_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	15670
1	3475	RUNX1	0.115280547960847	0.812911258845785	13	2390	2499	2153	2499	2350	16	191	191	RUNX1 ME-1 (acute myeloid leukemia ) RUNX1	ME-1 (acute myeloid leukemia )	NULL	RUNX1	Treatment: Al-10-49 (1uM) for 6 hr; CellType: human inv(16) leukemia cell line;	GTRD	EXP047573_ME-1--acute-myeloid-leukemia--_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	7243
1	4001	TP53	0.115280547960847	0.812911258845785	13	2390	2499	2153	2499	2350	16	191	191	TP53 MCF10A (breast epithelial cells) TP53	MCF10A (breast epithelial cells)	BTO:0001939	TP53	Treatment: 5 uM Nutlin3A for 6 hrs;	GTRD	EXP057964_MCF10A--breast-epithelial-cells-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	16776
1	1794	FOXA1	0.115187139584205	0.835776473428922	21	2397	2395	1535	2397	2110	25	183	182	FOXA1 PDAC FOXA1	PDAC	NA	FOXA1	SHCTR	GEO	GSE64557_foxa1_pdac-shctr_MACS_FOXA1_MA0148.4.damo.pwm.bed	35480
1	3533	RXRA	0.115187139584205	0.835776473428922	21	2397	2395	1535	2397	2110	25	183	182	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA WT	GTRD	EXP040815_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA1147.1.damo.pwm.bed	10854
1	18	AR	0.114508443385949	0.782194364324678	7	2399	2677	2812	2812	2630	9	197	198	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR		GTRD	EXP030504_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	10285
1	1324	ESR1	0.114508443385949	0.782194364324678	7	2399	2677	2812	2812	2630	9	197	198	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 500 nM AZD201 2 hr; Passage: p21;	GTRD	EXP047707_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	13123
1	1438	ESR2	0.114508443385949	0.782194364324678	7	2399	2677	2812	2812	2630	9	197	198	ESR2 U2OS (osteosarcoma) ESR2	U2OS (osteosarcoma)	BTO:0001938	ESR2	E2	GTRD	EXP000205_U2OS--osteosarcoma-_ESR2_MACS_ESR2_MA0258.2.damo.pwm.bed	22433
1	1962	GATA3	0.114508443385949	0.782194364324678	7	2399	2677	2812	2812	2630	9	197	198	GATA3 Th1-cells GATA3	Th1-cells	BTO:0001678	GATA3		GTRD	EXP031083_Th1-cells_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	14516
1	2316	JUN	0.114508443385949	0.782194364324678	7	2399	2677	2812	2812	2630	9	197	198	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039496_A549--lung-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	9870
1	2317	JUN	0.114508443385949	0.782194364324678	7	2399	2677	2812	2812	2630	9	197	198	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039496_A549--lung-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	9886
1	2470	JUN	0.114508443385949	0.782194364324678	7	2399	2677	2812	2812	2630	9	197	198	JUN BT-549 (breast invasive ductal carcinoma) JUN	BT-549 (breast invasive ductal carcinoma)	BTO:0002548	JUN		GEO	GSE46166_jun_bt549_MACS_JUN_MA0489.1.damo.pwm.bed	12167
1	2657	LEF1	0.114508443385949	0.782194364324678	7	2399	2677	2812	2812	2630	9	197	198	LEF1 K562 (myelogenous leukemia) LEF1	K562 (myelogenous leukemia)	NULL	LEF1		GTRD	EXP039909_K562--myelogenous-leukemia-_LEF1_MACS_LEF1_MA0768.1.damo.pwm.bed	6980
1	2928	MYC	0.114508443385949	0.782194364324678	7	2399	2677	2812	2812	2630	9	197	198	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	SHTERT	GEO	GSE60223_myc_p493-shtert_MACS_MYC_MA0147.3.damo.pwm.bed	1280
1	2968	NEUROG2	0.114508443385949	0.782194364324678	7	2399	2677	2812	2812	2630	9	197	198	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	0.5 DPT	GTRD	EXP037147_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	13256
1	2969	NEUROG2	0.114508443385949	0.782194364324678	7	2399	2677	2812	2812	2630	9	197	198	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	0.5 DPT	GTRD	EXP037147_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	12616
1	3071	NR2F2	0.114317172583061	0.866009989022666	45	2410	2251	383	2410	1680	51	159	156	NR2F2 K562 (myelogenous leukemia) NR2F2	K562 (myelogenous leukemia)	NULL	NR2F2		ENCODE	ENCSR000BRS_K562_NR2F2_MACS_NR2F2_MA1111.1.damo.pwm.bed	40180
1	3913	TFAP2C	0.114317172583061	0.866009989022666	45	2410	2251	383	2410	1680	51	159	156	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C		GEO	GSE21234_tfap2c_mcf7_MACS_TFAP2C_MA0814.2.damo.pwm.bed	74777
1	3925	TFAP2C	0.114317172583061	0.866009989022666	45	2410	2251	383	2410	1680	51	159	156	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C		GEO	GSE36351_tfap2c_mcf7_MACS_TFAP2C_MA0814.2.damo.pwm.bed	74626
1	498	CTCF	0.114079512621039	0.851491133251865	31	2413	2304	881	2413	1870	36	173	171	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DPY_fibroblast_of_the_aortic_adventitia_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40530
1	1124	ERG	0.114079512621039	0.851491133251865	31	2413	2304	881	2413	1870	36	173	171	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	mutational form of the peptide (*ERG inhibitory peptidomimetics*)	GTRD	EXP033707_VCaP--prostate-carcinoma-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	17616
1	3886	TFAP2C	0.114079512621039	0.851491133251865	31	2413	2304	881	2413	1870	36	173	171	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions;	GTRD	EXP047536_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	23385
1	46	AR	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	AR BicR (prostate cancer) AR	BicR (prostate cancer)	NULL	AR	DHT 10 nM	GTRD	EXP034604_BicR--prostate-cancer-_AR_MACS_AR_MA0007.3.damo.pwm.bed	8777
1	97	AR	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	AR VCaP and LTAD cells AR	VCaP and LTAD cells	NULL	AR	Treatment: 24h DHT 10 nM	GTRD	EXP049449_VCaP-and-LTAD-cells_AR_MACS_AR_MA0007.3.damo.pwm.bed	12487
1	200	AR	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	AR MDA-MB-453 (breast adenocarcinoma) AR	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	AR	DHT	GEO	GSE74069_AR_mdamb45-dht_MACS_AR_MA0007.3.damo.pwm.bed	15412
1	1234	ESR1	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	DMSO	GTRD	EXP037590_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	5246
1	1426	ESR1	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2PG	GEO	GSE68356_ESR1_mcf7-e2pg_MACS_ESR1_MA0112.3.damo.pwm.bed	14523
1	1481	ETV6	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	ETV6 K562 (myelogenous leukemia) ETV6	K562 (myelogenous leukemia)	NULL	ETV6		ENCODE	ENCSR000FCE_K562_ETV6_MACS_ETV6_MA0645.1.damo.pwm.bed	3687
1	1758	FOXA1	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	1F5_SIFOXA1	GEO	GSE30623_foxa1_lncap1f5-sifoxa1_MACS_FOXA1_MA0148.4.damo.pwm.bed	8900
1	1970	GATA3	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	GATA3 CLB-Ga (neuroblastoma) GATA3	CLB-Ga (neuroblastoma)	NULL	GATA3	none	GTRD	EXP039005_CLB-Ga--neuroblastoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	14910
1	2664	MAF	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	MAF Th17-cells MAF	Th17-cells	BTO:0005655	MAF	CellType:pool of expanded Th17 clones; Tissue: primary Th17-IL-10+ lymphocytes; ActivationState: recently activeted;Day:5;	GTRD	EXP047553_Th17-cells_MAF_MACS_MAF_MA1520.1.damo.pwm.bed	3330
1	2678	MAFK	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	MAFK WA01 (H1, human embryonic stem cells) MAFK	WA01 (H1, human embryonic stem cells)	NULL	MAFK	NA	ENCODE	ENCSR000EBS_H1-hESC_MAFK_MACS_MAFK_MA0496.3.damo.pwm.bed	11108
1	2758	MITF	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	MITF retina MITF	retina	BTO:0001175	MITF	pigment	GEO	GSE60024_mitf_retinal-pigment_MACS_MITF_MA0620.3.damo.pwm.bed	2212
1	3153	NR3C1	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	NR3C1 LNCaP (prostate carcinoma) NR3C1	LNCaP (prostate carcinoma)	BTO:0001321	NR3C1	1F5	GEO	GSE30623_nr3c1_lncap-1f5_MACS_NR3C1_MA0113.3.damo.pwm.bed	8269
1	3299	PRDM1	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	PRDM1 HeLa S3 (cervical adenocarcinoma) PRDM1	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	PRDM1		ENCODE	ENCSR000ECY_HeLa-S3_PRDM1_MACS_PRDM1_MA0508.3.damo.pwm.bed	3577
1	3361	RELA	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	RELA HUVEC-C (HUVEC, umbilical vein endothelial cells) RELA	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	RELA	Treatment: confluent, treated with Scr siRNA Passage: 4	GTRD	EXP049054_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	13554
1	3556	SIX1	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	SIX1 SIX1	NA	NA	SIX1	NA	GEO	GSE73865_six1_hek_MACS_SIX1_MA1118.1.damo.pwm.bed	5251
1	3689	SPI1	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	SPI1 RS4-11 (adult B acute lymphoblastic leukemia) SPI1	RS4-11 (adult B acute lymphoblastic leukemia)	BTO:0004505	SPI1		GEO	GSE71616_spi1_rsa411_MACS_SPI1_MA0080.5.damo.pwm.bed	8068
1	3697	SREBF1	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	SREBF1 HepG2 (hepatoblastoma) SREBF1	HepG2 (hepatoblastoma)	BTO:0000599	SREBF1	DMEM with 0.5% BSA supplemented with 100 nM insulin and 10 uM 22-hydroxycholesterol for 6 h. (Snyder)	ENCODE	ENCSR000EEO_HepG2_SREBF1_MACS_SREBF1_MA0595.1.damo.pwm.bed	885
1	3728	STAT2	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	STAT2 K562 (myelogenous leukemia) STAT2	K562 (myelogenous leukemia)	NULL	STAT2	30 m of Interferon alpha (Snyder)	ENCODE	ENCSR000FAT_K562_STAT2_MACS_STAT2_MA0517.1.damo.pwm.bed	1182
1	3990	TP53	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	TP53 A498 TP53	A498	BTO:0003769	TP53	Treatment: 4GY for 2hrs;	GTRD	EXP051016_A498_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	3142
1	3992	TP53	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	TP53 A549 (lung carcinoma) TP53	A549 (lung carcinoma)	BTO:0000018	TP53	Treatment: 4GY for 2hrs;	GTRD	EXP051021_A549--lung-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	3125
1	4017	TP53	0.113844174145233	0.757973728071386	3	2416	2776	3316	3316	2840	4	201	203	TP53 keratinocytes TP53	keratinocytes	NULL	TP53	ADRIA	GEO	GSE56674_tp53_keratinocyte-adria_MACS_TP53_MA0106.3.damo.pwm.bed	6971
1	416	CREB1	0.113146016354881	0.874755176924601	63	2437	2210	103	2437	1580	70	141	137	CREB1 WA01 (H1, human embryonic stem cells) CREB1	WA01 (H1, human embryonic stem cells)	NULL	CREB1		ENCODE	ENCSR000BSN_H1-hESC_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	28600
1	230	ASCL1	0.112325716586412	0.829184137163841	20	2438	2415	1606	2438	2150	24	184	183	ASCL1 fibroblasts ASCL1	fibroblasts	NULL	ASCL1		GTRD	EXP030567_fibroblasts_ASCL1_MACS_ASCL1_MA1631.1.damo.pwm.bed	40642
1	247	ATF3	0.112325716586412	0.829184137163841	20	2438	2415	1606	2438	2150	24	184	183	ATF3 A549 (lung carcinoma) ATF3	A549 (lung carcinoma)	BTO:0000018	ATF3	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BPS_A549_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	9205
1	1707	FOXA1	0.112325716586412	0.829184137163841	20	2438	2415	1606	2438	2150	24	184	183	FOXA1 MCF7 WS8 cells FOXA1	MCF7 WS8 cells	NULL	FOXA1	Treatment: 45 min 10^-7 4OHT	GTRD	EXP048446_MCF7-WS8-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	36763
1	1708	FOXA1	0.112325716586412	0.829184137163841	20	2438	2415	1606	2438	2150	24	184	183	FOXA1 MCF7 WS8 cells FOXA1	MCF7 WS8 cells	NULL	FOXA1	Treatment: 45 min 10^-7 4OHT	GTRD	EXP048447_MCF7-WS8-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	39083
1	1712	FOXA1	0.112325716586412	0.829184137163841	20	2438	2415	1606	2438	2150	24	184	183	FOXA1 MCF7 WS8 cells FOXA1	MCF7 WS8 cells	NULL	FOXA1	Treatment: 45 min ethanol	GTRD	EXP048451_MCF7-WS8-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	36083
1	3280	POU5F1	0.112325716586412	0.829184137163841	20	2438	2415	1606	2438	2150	24	184	183	POU5F1 hESC-1 (Embryonic stem cells) POU5F1	hESC-1 (Embryonic stem cells)	NULL	POU5F1	NAIVE	GEO	GSE69646_pou5f1_esc-naive_MACS_POU5F1_MA1115.1.damo.pwm.bed	38282
1	3465	RUNX1	0.112325716586412	0.829184137163841	20	2438	2415	1606	2438	2150	24	184	183	RUNX1 Kasumi-1 (acute myeloblastic leukemia) RUNX1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	RUNX1	MEIS2 KD	GTRD	EXP036424_Kasumi-1--acute-myeloblastic-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	15154
1	3896	TFAP2C	0.112325716586412	0.829184137163841	20	2438	2415	1606	2438	2150	24	184	183	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p28; CellType: Prime UCLA1 hESSCs;	GTRD	EXP047539_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	8933
1	22	AR	0.112193309651198	0.84763361239232	30	2446	2324	937	2446	1900	35	174	172	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	DHT for 4h	GTRD	EXP031106_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	40812
1	612	CTCF	0.112193309651198	0.84763361239232	30	2446	2324	937	2446	1900	35	174	172	CTCF HCT-116 (colon carcinoma) CTCF	HCT-116 (colon carcinoma)	BTO:0001109	CTCF	DNMT3BKO	GTRD	EXP032760_HCT-116--colon-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	51001
1	2994	NFE2	0.112193309651198	0.84763361239232	30	2446	2324	937	2446	1900	35	174	172	NFE2 erythroid cells NFE2	erythroid cells	NULL	NFE2	R3R4	GEO	GSE43625_nfe2_erythroid-r3r4_MACS_NFE2_MA0841.1.damo.pwm.bed	16771
1	3730	STAT3	0.112193309651198	0.84763361239232	30	2446	2324	937	2446	1900	35	174	172	STAT3 STAT3	NA	NA	STAT3	NA	NA	ENCSR000DOQ_MCF_10A_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	38533
1	2761	MLX	0.11183680281643	0.86151377089539	43	2450	2274	429	2450	1720	49	161	158	MLX HepG2 (hepatoblastoma) MLX	HepG2 (hepatoblastoma)	BTO:0000599	MLX	NA	GTRD	EXP039860_HepG2--hepatoblastoma-_MLX_MACS_MLX_MA0663.1.damo.pwm.bed	19689
1	3779	TCF12	0.11183680281643	0.86151377089539	43	2450	2274	429	2450	1720	49	161	158	TCF12 WA01 (H1, human embryonic stem cells) TCF12	WA01 (H1, human embryonic stem cells)	NULL	TCF12	NA	ENCODE	ENCSR000BIT_H1-hESC_TCF12_MACS_TCF12_MA0521.1.damo.pwm.bed	32290
1	430	CREM	0.110786696009497	0.870941946569583	60	2452	2224	137	2452	1600	67	144	140	CREM K562 (myelogenous leukemia) CREM	K562 (myelogenous leukemia)	NULL	CREM	NA	ENCODE	ENCSR077DKV_K562_CREM_MACS_CREM_MA0609.2.damo.pwm.bed	38894
1	141	AR	0.110598804951485	0.800435079561418	12	2453	2576	2233	2576	2420	15	192	192	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	DHT	GEO	GSE43720_AR_lncap-dht_MACS_AR_MA0007.3.damo.pwm.bed	27366
1	1483	ETV6	0.110598804951485	0.800435079561418	12	2453	2576	2233	2576	2420	15	192	192	ETV6 GM12878 (female B-cells lymphoblastoid cell line) ETV6	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ETV6		ENCODE	ENCSR626VUC_GM12878_ETV6_MACS_ETV6_MA0645.1.damo.pwm.bed	16719
1	1612	FOSL2	0.110598804951485	0.800435079561418	12	2453	2576	2233	2576	2420	15	192	192	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039862_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	14809
1	1614	FOSL2	0.110598804951485	0.800435079561418	12	2453	2576	2233	2576	2420	15	192	192	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039862_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	14800
1	1636	FOXA1	0.110598804951485	0.800435079561418	12	2453	2576	2233	2576	2420	15	192	192	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	E2_TAM	Array Express	ERP000380_foxa1_mcf7-e2-tam_MACS_FOXA1_MA0148.4.damo.pwm.bed	47075
1	2367	JUN	0.110598804951485	0.800435079561418	12	2453	2576	2233	2576	2420	15	192	192	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: 17beta estradiol 10nM for 1hr;	GTRD	EXP047660_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	15431
1	2368	JUN	0.110598804951485	0.800435079561418	12	2453	2576	2233	2576	2420	15	192	192	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: 17beta estradiol 10nM for 1hr;	GTRD	EXP047660_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	16150
1	3132	NR3C1	0.110598804951485	0.800435079561418	12	2453	2576	2233	2576	2420	15	192	192	NR3C1 MCF10A (breast epithelial cells) NR3C1	MCF10A (breast epithelial cells)	BTO:0001939	NR3C1	Treatment: EGF + DEX 20 min;	GTRD	EXP047630_MCF10A--breast-epithelial-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	20685
1	4115	XBP1	0.110598804951485	0.800435079561418	12	2453	2576	2233	2576	2420	15	192	192	XBP1 HS578T (invasive ductal breast carcinoma) XBP1	HS578T (invasive ductal breast carcinoma)	BTO:0003885	XBP1	HYPO_GLUDEP	GEO	GSE49952_xbp1_hs578t-hypo-gludep_MACS_XBP1_MA0844.1.damo.pwm.bed	2332
1	3388	RELB	0.110546646321658	0.859115927126785	42	2462	2276	454	2462	1730	48	162	159	RELB GM12878 (female B-cells lymphoblastoid cell line) RELB	GM12878 (female B-cells lymphoblastoid cell line)	NULL	RELB	NA	GTRD	EXP054686_GM12878--female-B-cells-lymphoblastoid-cell-line-_RELB_MACS_RELB_MA1117.1.damo.pwm.bed	43442
1	904	CTCF	0.110241289164826	0.8435445834358	29	2463	2339	1013	2463	1940	34	175	173	CTCF HSMM dirived skeletal muscle myotubes CTCF	HSMM dirived skeletal muscle myotubes	NULL	CTCF	Treatment: None;	GTRD	EXP054041_HSMM-dirived-skeletal-muscle-myotubes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	52936
1	1489	FLI1	0.110241289164826	0.8435445834358	29	2463	2339	1013	2463	1940	34	175	173	FLI1 CD34+ hematopoietic stem cells FLI1	CD34+ hematopoietic stem cells	NULL	FLI1		GTRD	EXP031972_CD34--hematopoietic-stem-cells_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	20204
1	2768	MXI1	0.110241289164826	0.8435445834358	29	2463	2339	1013	2463	1940	34	175	173	MXI1 WA01 (H1, human embryonic stem cells) MXI1	WA01 (H1, human embryonic stem cells)	NULL	MXI1	NA	ENCODE	ENCSR000EBR_H1-hESC_MXI1_MACS_MXI1_MA1108.2.damo.pwm.bed	8966
1	984	CTCF	0.109962681657962	0.869577062840749	59	2466	2233	143	2466	1610	66	145	141	CTCF RCC 7860 (Renal cell carcinoma) CTCF	RCC 7860 (Renal cell carcinoma)	BTO:0003781	CTCF	NORMOXIA	GEO	GSE78113_ctcf_786o-normoxia_MACS_CTCF_MA0139.1.damo.pwm.bed	63941
1	160	AR	0.109321696680426	0.822015558422107	19	2467	2457	1697	2467	2210	23	185	184	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	SHPIAS1_R1881	GEO	GSE56086_AR_vcap-shpias1-r1881_MACS_AR_MA0007.3.damo.pwm.bed	83992
1	423	CREB1	0.109321696680426	0.822015558422107	19	2467	2457	1697	2467	2210	23	185	184	CREB1 HepG2 (hepatoblastoma) CREB1	HepG2 (hepatoblastoma)	BTO:0000599	CREB1		GTRD	EXP040314_HepG2--hepatoblastoma-_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	33282
1	1653	FOXA1	0.109321696680426	0.822015558422107	19	2467	2457	1697	2467	2210	23	185	184	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	regular medium	GTRD	EXP000722_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	46078
1	2319	JUN	0.109321696680426	0.822015558422107	19	2467	2457	1697	2467	2210	23	185	184	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039507_A549--lung-carcinoma-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	11764
1	2322	JUN	0.109321696680426	0.822015558422107	19	2467	2457	1697	2467	2210	23	185	184	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN		GTRD	EXP039637_A549--lung-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	9631
1	2436	JUN	0.109321696680426	0.822015558422107	19	2467	2457	1697	2467	2210	23	185	184	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057919_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	21661
1	2442	JUN	0.109321696680426	0.822015558422107	19	2467	2457	1697	2467	2210	23	185	184	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057919_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	22477
1	3014	NFIC	0.109321696680426	0.822015558422107	19	2467	2457	1697	2467	2210	23	185	184	NFIC K562 (myelogenous leukemia) NFIC	K562 (myelogenous leukemia)	NULL	NFIC	NA	GTRD	EXP039955_K562--myelogenous-leukemia-_NFIC_MACS_NFIC_MA0161.2.damo.pwm.bed	24607
1	2880	MYC	0.108255464042649	0.866694449547137	57	2475	2240	174	2475	1630	64	147	143	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shSCR;	GTRD	EXP047485_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	21280
1	3174	NRF1	0.108255464042649	0.866694449547137	57	2475	2240	174	2475	1630	64	147	143	NRF1 K562 (myelogenous leukemia) NRF1	K562 (myelogenous leukemia)	NULL	NRF1		ENCODE	ENCSR837EYC_K562_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	17713
1	1151	ERG	0.108219676983984	0.839203074826025	28	2477	2375	1068	2477	1970	33	176	174	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	SH2_DHT	GEO	GSE79128_erg_vcap-sh2-dht_MACS_ERG_MA0474.2.damo.pwm.bed	9521
1	2233	JUN	0.108219676983984	0.839203074826025	28	2477	2375	1068	2477	1970	33	176	174	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN	NULL	GTRD	EXP000309_K562--myelogenous-leukemia-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	29110
1	694	CTCF	0.107859812473658	0.853988798216896	40	2479	2293	502	2479	1760	46	164	161	CTCF gastroesophageal sphincter CTCF	gastroesophageal sphincter	NULL	CTCF		GTRD	EXP039474_gastroesophageal-sphincter_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	32353
1	849	CTCF	0.107859812473658	0.853988798216896	40	2479	2293	502	2479	1760	46	164	161	CTCF WA09 (embryonic stem cells) CTCF	WA09 (embryonic stem cells)	NULL	CTCF	Treatment: under heat shock conditions	GTRD	EXP047930_WA09--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	71672
1	1819	FOXA2	0.107859812473658	0.853988798216896	40	2479	2293	502	2479	1760	46	164	161	FOXA2 H9 FOXA2	H9	NULL	FOXA2		Array Express	ERP004206_foxa2_esc-h9_MACS_FOXA2_MA0047.3.damo.pwm.bed	130865
1	1085	ELF1	0.107371239348273	0.865172208353403	56	2482	2254	192	2482	1640	63	148	144	ELF1 SNU175 (adenocarcinoma) ELF1	SNU175 (adenocarcinoma)	NULL	ELF1		GTRD	EXP037554_SNU175--adenocarcinoma-_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	22756
1	2628	KLF11	0.107103173570042	0.873406382058567	81	2483	2215	16	2483	1570	89	123	118	KLF11 hMADS-3 (adipose-derived stem cells) KLF11	hMADS-3 (adipose-derived stem cells)	NULL	KLF11	differentiaiton inductors	GTRD	EXP033779_hMADS-3--adipose-derived-stem-cells-_KLF11_MACS_KLF11_MA1512.1.damo.pwm.bed	24475
1	2771	MXI1	0.107103173570042	0.873406382058567	81	2483	2215	16	2483	1570	89	123	118	MXI1 IMR90 (lung fibroblasts) MXI1	IMR90 (lung fibroblasts)	NULL	MXI1	NA	ENCODE	ENCSR000EFE_IMR-90_MXI1_MACS_MXI1_MA1108.2.damo.pwm.bed	31521
1	2779	MYB	0.106460267161827	0.851245010027775	39	2485	2307	547	2485	1780	45	165	162	MYB CD4 MYB	CD4	NA	MYB	TH1	GEO	GSE72266_myb_cd4-th1_MACS_MYB_MA0100.3.damo.pwm.bed	25106
1	1681	FOXA1	0.10616270129362	0.814192181563645	18	2486	2487	1785	2487	2250	22	186	185	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1		GTRD	EXP038763_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	66240
1	2059	GRHL2	0.10616270129362	0.814192181563645	18	2486	2487	1785	2487	2250	22	186	185	GRHL2 MCF7 (Invasive ductal breast carcinoma) GRHL2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GRHL2	control	GTRD	EXP040962_MCF7--Invasive-ductal-breast-carcinoma-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	28418
1	2440	JUN	0.10616270129362	0.814192181563645	18	2486	2487	1785	2487	2250	22	186	185	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057919_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	20286
1	2631	KLF16	0.10616270129362	0.814192181563645	18	2486	2487	1785	2487	2250	22	186	185	KLF16 K562 (myelogenous leukemia) KLF16	K562 (myelogenous leukemia)	NULL	KLF16	NA	GTRD	EXP039636_K562--myelogenous-leukemia-_KLF16_MACS_KLF16_MA0741.1.damo.pwm.bed	16868
1	2908	MYC	0.10616270129362	0.814192181563645	18	2486	2487	1785	2487	2250	22	186	185	MYC Blue1 (sporadic Burkitt lymphoma) MYC	Blue1 (sporadic Burkitt lymphoma)	NULL	MYC		GEO	GSE30726_myc_blue1_MACS_MYC_MA0147.3.damo.pwm.bed	4174
1	2942	MYCN	0.10616270129362	0.814192181563645	18	2486	2487	1785	2487	2250	22	186	185	MYCN NB-1643 (neuroblastoma) MYCN	NB-1643 (neuroblastoma)	BTO:0002833	MYCN		GTRD	EXP038399_NB-1643--neuroblastoma-_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	10728
1	2981	NEUROG2	0.10616270129362	0.814192181563645	18	2486	2487	1785	2487	2250	22	186	185	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	0.5 DPT	GTRD	EXP037153_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	21685
1	3322	RBPJ	0.10616270129362	0.814192181563645	18	2486	2487	1785	2487	2250	22	186	185	RBPJ CUTLL1 (T-cell lymphoblastic lymphoma 1) RBPJ	CUTLL1 (T-cell lymphoblastic lymphoma 1)	NULL	RBPJ	GSI 72 hrs, wash out 4 hrs	GTRD	EXP032408_CUTLL1--T-cell-lymphoblastic-lymphoma-1-_RBPJ_MACS_RBPJ_MA1116.1.damo.pwm.bed	9423
1	3707	SRF	0.10616270129362	0.814192181563645	18	2486	2487	1785	2487	2250	22	186	185	SRF HepG2 (hepatoblastoma) SRF	HepG2 (hepatoblastoma)	BTO:0000599	SRF		ENCODE	ENCSR000BLV_HepG2_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	8159
1	1853	FOXK2	0.106124387189568	0.834585490956352	27	2495	2400	1135	2495	2010	32	177	175	FOXK2 K562 (myelogenous leukemia) FOXK2	K562 (myelogenous leukemia)	NULL	FOXK2	NA	ENCODE	ENCSR508DQA_K562_FOXK2_MACS_FOXK2_MA1103.2.damo.pwm.bed	15539
1	3537	RXRA	0.106124387189568	0.834585490956352	27	2495	2400	1135	2495	2010	32	177	175	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA S427F	GTRD	EXP040816_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA0159.1.damo.pwm.bed	11044
1	28	AR	0.105705160118187	0.754305825759709	6	2497	2810	2948	2948	2750	8	198	199	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Vehicle	GTRD	EXP032861_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	23707
1	107	AR	0.105705160118187	0.754305825759709	6	2497	2810	2948	2948	2750	8	198	199	AR LNCaP95 AR	LNCaP95	NULL	AR	Treatment: 10nM DHT for 4 hrs Genotype: shGFP	GTRD	EXP052949_LNCaP95_AR_MACS_AR_MA0007.3.damo.pwm.bed	20564
1	260	ATF4	0.105705160118187	0.754305825759709	6	2497	2810	2948	2948	2750	8	198	199	ATF4 HAP1 (chronic myelogenous leukemia) ATF4	HAP1 (chronic myelogenous leukemia)	NULL	ATF4	2 mM histidinol, 24 hours	GTRD	EXP035036_HAP1--chronic-myelogenous-leukemia-_ATF4_MACS_ATF4_MA0833.2.damo.pwm.bed	25714
1	2194	HSF1	0.105705160118187	0.754305825759709	6	2497	2810	2948	2948	2750	8	198	199	HSF1 U2OS (osteosarcoma) HSF1	U2OS (osteosarcoma)	BTO:0001938	HSF1	HEAT_20	GEO	GSE60984_hsf1_u2os-heat-20_MACS_HSF1_MA0486.2.damo.pwm.bed	8570
1	3688	SPI1	0.105705160118187	0.754305825759709	6	2497	2810	2948	2948	2750	8	198	199	SPI1 RS4-11 (adult B acute lymphoblastic leukemia) SPI1	RS4-11 (adult B acute lymphoblastic leukemia)	BTO:0004505	SPI1	DEX	GEO	GSE71616_spi1_rsa411-dex_MACS_SPI1_MA0080.5.damo.pwm.bed	15533
1	317	CEBPA	0.105539969594958	0.786175954206523	11	2502	2640	2332	2640	2490	14	193	193	CEBPA SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) CEBPA	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	CEBPA	RUNX1-EVI1 KD after 10 days	GTRD	EXP037839_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	9655
1	1369	ESR1	0.105539969594958	0.786175954206523	11	2502	2640	2332	2640	2490	14	193	193	ESR1 primary endometrium cancer ESR1	primary endometrium cancer	NULL	ESR1	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053241_primary-endometrium-cancer_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	9329
1	1580	FOSL2	0.105539969594958	0.786175954206523	11	2502	2640	2332	2640	2490	14	193	193	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP039502_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	13534
1	1596	FOSL2	0.105539969594958	0.786175954206523	11	2502	2640	2332	2640	2490	14	193	193	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039680_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	13214
1	1597	FOSL2	0.105539969594958	0.786175954206523	11	2502	2640	2332	2640	2490	14	193	193	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039680_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	13454
1	1598	FOSL2	0.105539969594958	0.786175954206523	11	2502	2640	2332	2640	2490	14	193	193	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039680_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	13717
1	1599	FOSL2	0.105539969594958	0.786175954206523	11	2502	2640	2332	2640	2490	14	193	193	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039680_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	13355
1	1729	FOXA1	0.105539969594958	0.786175954206523	11	2502	2640	2332	2640	2490	14	193	193	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	Passsage: <10	GTRD	EXP049900_T47D--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	21773
1	2379	JUN	0.105539969594958	0.786175954206523	11	2502	2640	2332	2640	2490	14	193	193	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: tamoxifen 1μM for 1hr;	GTRD	EXP047661_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	18364
1	3029	NFYA	0.105539969594958	0.786175954206523	11	2502	2640	2332	2640	2490	14	193	193	NFYA K562 (myelogenous leukemia) NFYA	K562 (myelogenous leukemia)	NULL	NFYA	NA	ENCODE	ENCSR000EGR_K562_NFYA_MACS_NFYA_MA0060.3.damo.pwm.bed	4230
1	3170	NRF1	0.105539969594958	0.786175954206523	11	2502	2640	2332	2640	2490	14	193	193	NRF1 HepG2 (hepatoblastoma) NRF1	HepG2 (hepatoblastoma)	BTO:0000599	NRF1		ENCODE	ENCSR000EEH_HepG2_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	1958
1	3379	RELA	0.105539969594958	0.786175954206523	11	2502	2640	2332	2640	2490	14	193	193	RELA HUVEC-C (HUVEC, umbilical vein endothelial cells) RELA	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	RELA	TNF_JQ1	GEO	GSE53998_rela_huvec-tnf-jq1_MACS_RELA_MA0107.1.damo.pwm.bed	14471
1	2101	HIF1A	0.105538819811693	0.861953432917736	54	2514	2264	225	2514	1670	61	150	146	HIF1A PC3(bone mets prostate adenocarcinoma) HIF1A	PC3(bone mets prostate adenocarcinoma)	NULL	HIF1A	Treatment: hypoxia(0.2% O2), siCtrl;	GTRD	EXP057826_PC3-bone-mets-prostate-adenocarcinoma-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	34121
1	988	CTCF	0.103950989867057	0.829665188851473	26	2515	2411	1204	2515	2040	31	178	176	CTCF VCaP (prostate carcinoma) CTCF	VCaP (prostate carcinoma)	BTO:0003215	CTCF	R1881	GEO	GSE84432_ctcf_vcap-r1881_MACS_CTCF_MA0139.1.damo.pwm.bed	40435
1	2315	JUN	0.103950989867057	0.829665188851473	26	2515	2411	1204	2515	2040	31	178	176	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039496_A549--lung-carcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	15895
1	3636	SP1	0.103950989867057	0.829665188851473	26	2515	2411	1204	2515	2040	31	178	176	SP1 A375 (malignant melanoma) SP1	A375 (malignant melanoma)	BTO:0002806	SP1	25 μM A771726	GTRD	EXP036993_A375--malignant-melanoma-_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	5518
1	3794	TCF4	0.103950989867057	0.829665188851473	26	2515	2411	1204	2515	2040	31	178	176	TCF4 CAL-1 (plasmacytoid dendritic neoplasm) TCF4	CAL-1 (plasmacytoid dendritic neoplasm)	NULL	TCF4		GTRD	EXP037180_CAL-1--plasmacytoid-dendritic-neoplasm-_TCF4_MACS_TCF4_MA0830.2.damo.pwm.bed	31575
1	519	CTCF	0.103541087040927	0.845355646457485	37	2519	2335	607	2519	1820	43	167	164	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DTL_choroid_plexus_epithelial_cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54171
1	548	CTCF	0.103541087040927	0.845355646457485	37	2519	2335	607	2519	1820	43	167	164	CTCF IMR90 (lung fibroblasts) CTCF	IMR90 (lung fibroblasts)	NULL	CTCF		ENCODE	ENCSR000EFI_IMR-90_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45921
1	2903	MYC	0.103541087040927	0.845355646457485	37	2519	2335	607	2519	1820	43	167	164	MYC G401 (rhabdoid tumor of the kidney) MYC	G401 (rhabdoid tumor of the kidney)	BTO:0002586	MYC	Passage: ten-thirty; Genotype: EGFP transfection;	GTRD	EXP057894_G401--rhabdoid-tumor-of-the-kidney-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	9215
1	728	CTCF	0.102834811585827	0.805620481218972	17	2522	2545	1846	2545	2300	21	187	186	CTCF upper lobe of left lung CTCF	upper lobe of left lung	NULL	CTCF		GTRD	EXP039700_upper-lobe-of-left-lung_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	26590
1	2701	MAX	0.102834811585827	0.805620481218972	17	2522	2545	1846	2545	2300	21	187	186	MAX K562 (myelogenous leukemia) MAX	K562 (myelogenous leukemia)	NULL	MAX		ENCODE	ENCSR000FAE_K562_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	9399
1	3085	NR2F6	0.102834811585827	0.805620481218972	17	2522	2545	1846	2545	2300	21	187	186	NR2F6 K562 (myelogenous leukemia) NR2F6	K562 (myelogenous leukemia)	NULL	NR2F6	NA	GTRD	EXP040021_K562--myelogenous-leukemia-_NR2F6_MACS_NR2F6_MA1539.1.damo.pwm.bed	22272
1	3574	SMAD3	0.102834811585827	0.805620481218972	17	2522	2545	1846	2545	2300	21	187	186	SMAD3 HCC1954 (ductal breast carcinoma) SMAD3	HCC1954 (ductal breast carcinoma)	BTO:0005368	SMAD3	Treatment: TGF-beta CellType: Immortalized human mammary epithelial cells	GTRD	EXP047903_HCC1954--ductal-breast-carcinoma-_SMAD3_MACS_SMAD3_MA0513.1.damo.pwm.bed	29796
1	166	AR	0.102621239564784	0.856646983713956	51	2526	2286	261	2526	1690	58	153	149	AR prostate AR	prostate	NULL	AR		GEO	GSE56288_AR_prostate-normal_MACS_AR_MA0007.3.damo.pwm.bed	47546
1	2786	MYC	0.102621239564784	0.856646983713956	51	2526	2286	261	2526	1690	58	153	149	MYC MYC	NA	NA	MYC	NA	NA	ENCSR000DLU_endothelial_cell_of_umbilical_vein_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	22424
1	651	CTCF	0.102018026135405	0.842191163816685	36	2528	2345	645	2528	1840	42	168	165	CTCF RH4 (alveolar rhabdomyosarcoma) CTCF	RH4 (alveolar rhabdomyosarcoma)	NULL	CTCF		GTRD	EXP037532_RH4--alveolar-rhabdomyosarcoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	58842
1	1927	GATA1	0.101694675072333	0.824411970151823	25	2529	2431	1262	2529	2070	30	179	177	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1		GEO	GSE70482_gata1_k562_MACS_GATA1_MA0035.4.damo.pwm.bed	96140
1	1024	E2F1	0.100599767124581	0.863226756730502	69	2530	2261	47	2530	1610	77	135	130	E2F1 LNCaP (prostate carcinoma) E2F1	LNCaP (prostate carcinoma)	BTO:0001321	E2F1	Treatment: CDT for 72 hrs Genotype: knockdown with shRB of RB	GTRD	EXP049491_LNCaP--prostate-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	23883
1	3631	SP1	0.100599767124581	0.863226756730502	69	2530	2261	47	2530	1610	77	135	130	SP1 HCT-116 (colon carcinoma) SP1	HCT-116 (colon carcinoma)	BTO:0001109	SP1		GTRD	EXP036143_HCT-116--colon-carcinoma-_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	28664
1	2954	MYCN	0.100555832689757	0.852752562091137	49	2532	2298	299	2532	1710	56	155	151	MYCN SHEP-21N MYCN	SHEP-21N	NA	MYCN	DOX_0H	GEO	GSE80151_mycn_shep21-dox-0h_MACS_MYCN_MA0104.4.damo.pwm.bed	17864
1	3626	SP1	0.100450187242095	0.838866000215071	35	2533	2378	691	2533	1870	41	169	166	SP1 K562 (myelogenous leukemia) SP1	K562 (myelogenous leukemia)	NULL	SP1		ENCODE	ENCSR991ELG_K562_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	7686
1	31	AR	0.100048912713941	0.769722249442714	10	2534	2729	2442	2729	2570	13	194	194	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Vehicle	GTRD	EXP032867_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	28447
1	2372	JUN	0.100048912713941	0.769722249442714	10	2534	2729	2442	2729	2570	13	194	194	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: tamoxifen 1μM for 1hr;	GTRD	EXP047661_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	17766
1	2373	JUN	0.100048912713941	0.769722249442714	10	2534	2729	2442	2729	2570	13	194	194	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: tamoxifen 1μM for 1hr;	GTRD	EXP047661_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	17242
1	2406	JUN	0.100048912713941	0.769722249442714	10	2534	2729	2442	2729	2570	13	194	194	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 012Passage: P3-6	GTRD	EXP048212_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	11284
1	2408	JUN	0.100048912713941	0.769722249442714	10	2534	2729	2442	2729	2570	13	194	194	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 012Passage: P3-6	GTRD	EXP048212_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	11384
1	2500	JUNB	0.100048912713941	0.769722249442714	10	2534	2729	2442	2729	2570	13	194	194	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039540_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	16195
1	2502	JUNB	0.100048912713941	0.769722249442714	10	2534	2729	2442	2729	2570	13	194	194	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039540_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	16019
1	2504	JUNB	0.100048912713941	0.769722249442714	10	2534	2729	2442	2729	2570	13	194	194	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039540_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	16529
1	2505	JUNB	0.100048912713941	0.769722249442714	10	2534	2729	2442	2729	2570	13	194	194	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039540_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	16574
1	2683	MAFK	0.100048912713941	0.769722249442714	10	2534	2729	2442	2729	2570	13	194	194	MAFK K562 (myelogenous leukemia) MAFK	K562 (myelogenous leukemia)	NULL	MAFK	NA	ENCODE	ENCSR000EGX_K562_MAFK_MACS_MAFK_MA0496.3.damo.pwm.bed	21126
1	3494	RUNX1	0.100048912713941	0.769722249442714	10	2534	2729	2442	2729	2570	13	194	194	RUNX1 Kasumi-1 (acute myeloblastic leukemia) RUNX1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	RUNX1		GEO	GSE62847_runx1_kasumi1_MACS_RUNX1_MA0002.2.damo.pwm.bed	10855
1	411	CEBPG	0.0993502126101713	0.818791467947816	24	2545	2471	1324	2545	2110	29	180	178	CEBPG K562 (myelogenous leukemia) CEBPG	K562 (myelogenous leukemia)	NULL	CEBPG	NA	GTRD	EXP039945_K562--myelogenous-leukemia-_CEBPG_MACS_CEBPG_MA0838.1.damo.pwm.bed	46662
1	1110	ELK4	0.0993502126101713	0.818791467947816	24	2545	2471	1324	2545	2110	29	180	178	ELK4 HeLa S3 (cervical adenocarcinoma) ELK4	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	ELK4	NULL	GTRD	EXP000581_HeLa-S3--cervical-adenocarcinoma-_ELK4_MACS_ELK4_MA0076.2.damo.pwm.bed	8307
1	2110	HMBOX1	0.0993502126101713	0.818791467947816	24	2545	2471	1324	2545	2110	29	180	178	HMBOX1 K562 (myelogenous leukemia) HMBOX1	K562 (myelogenous leukemia)	NULL	HMBOX1	NA	ENCODE	ENCSR757IIU_K562_HMBOX1_MACS_HMBOX1_MA0895.1.damo.pwm.bed	35650
1	2238	JUN	0.0993502126101713	0.818791467947816	24	2545	2471	1324	2545	2110	29	180	178	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN	NULL	GTRD	EXP000309_K562--myelogenous-leukemia-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	25910
1	2239	JUN	0.0993502126101713	0.818791467947816	24	2545	2471	1324	2545	2110	29	180	178	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN	NULL	GTRD	EXP000309_K562--myelogenous-leukemia-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	26050
1	2864	MYC	0.0993502126101713	0.818791467947816	24	2545	2471	1324	2545	2110	29	180	178	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	200 nM OHT (endogenous Myc activated) and 0.2 µg/mL Tetracyclin (Myc transgene repressed)	GTRD	EXP038947_P493-6--B-cell-lymphoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	8877
1	2947	MYCN	0.0993502126101713	0.818791467947816	24	2545	2471	1324	2545	2110	29	180	178	MYCN BE2C MYCN	BE2C	NULL	MYCN	Treatment: untreated	GTRD	EXP049482_BE2C_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	17811
1	45	AR	0.0993223263429695	0.796188218195713	16	2552	2595	1909	2595	2350	20	188	187	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	10 nmol/l of mibolerone	GTRD	EXP034504_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	60764
1	771	CTCF	0.0993223263429695	0.796188218195713	16	2552	2595	1909	2595	2350	20	188	187	CTCF ovary CTCF	ovary	BTO:0000975	CTCF		GTRD	EXP040068_ovary_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	16715
1	782	CTCF	0.0993223263429695	0.796188218195713	16	2552	2595	1909	2595	2350	20	188	187	CTCF adrenal gland CTCF	adrenal gland	BTO:0000047	CTCF		GTRD	EXP040128_adrenal-gland_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	24675
1	1068	EGR1	0.0993223263429695	0.796188218195713	16	2552	2595	1909	2595	2350	20	188	187	EGR1 HL-60 (acute myeloid leukemia) EGR1	HL-60 (acute myeloid leukemia)	BTO:0000738	EGR1	Treatment: PMA treated (16h)	GTRD	EXP047938_HL-60--acute-myeloid-leukemia-_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	8082
1	1576	FOSL2	0.0993223263429695	0.796188218195713	16	2552	2595	1909	2595	2350	20	188	187	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP039419_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	18937
1	1578	FOSL2	0.0993223263429695	0.796188218195713	16	2552	2595	1909	2595	2350	20	188	187	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP039419_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	18894
1	1579	FOSL2	0.0993223263429695	0.796188218195713	16	2552	2595	1909	2595	2350	20	188	187	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP039419_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	18904
1	1683	FOXA1	0.0993223263429695	0.796188218195713	16	2552	2595	1909	2595	2350	20	188	187	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1		GTRD	EXP038765_T47D--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	50304
1	1721	FOXA1	0.0993223263429695	0.796188218195713	16	2552	2595	1909	2595	2350	20	188	187	FOXA1 22RV1 (prostate carcinoma) FOXA1	22RV1 (prostate carcinoma)	BTO:0002999	FOXA1	Treatment: R1881	GTRD	EXP048915_22RV1--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	34079
1	1954	GATA2	0.0993223263429695	0.796188218195713	16	2552	2595	1909	2595	2350	20	188	187	GATA2 LNCaP (prostate carcinoma) GATA2	LNCaP (prostate carcinoma)	BTO:0001321	GATA2	CSFCS	GEO	GSE69043_gata2_lncap-csfcs_MACS_GATA2_MA0036.3.damo.pwm.bed	58313
1	2062	GRHL2	0.0993223263429695	0.796188218195713	16	2552	2595	1909	2595	2350	20	188	187	GRHL2 MCF7 (Invasive ductal breast carcinoma) GRHL2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GRHL2	100nm E2 (45 min)	GTRD	EXP040965_MCF7--Invasive-ductal-breast-carcinoma-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	23226
1	2415	JUN	0.0993223263429695	0.796188218195713	16	2552	2595	1909	2595	2350	20	188	187	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: non-transformed	GTRD	EXP048571_MCF10A-ER-Src_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	30872
1	462	CTCF	0.0988355749445491	0.835368215272474	34	2564	2397	729	2564	1900	40	170	167	CTCF D54 (H54, Human glioblastoma) CTCF	D54 (H54, Human glioblastoma)	NULL	CTCF		ENCODE	ENCSR000DKN_H54_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	56715
1	884	CTCF	0.0988355749445491	0.835368215272474	34	2564	2397	729	2564	1900	40	170	167	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: 110 mM NaCl for 60 min  + triptolide Source: T47D whole cell	GTRD	EXP053051_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	22619
1	3210	OTX2	0.0988355749445491	0.835368215272474	34	2564	2397	729	2564	1900	40	170	167	OTX2 D341 Med (medulloblastoma) OTX2	D341 Med (medulloblastoma)	NULL	OTX2	shOTX2.1393	GTRD	EXP038215_D341-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	72796
1	2650	KLF5	0.0979605699028042	0.858703125757281	65	2567	2277	89	2567	1640	73	139	134	KLF5 KATOIII (signet ring cell gastric adenocarcinoma) KLF5	KATOIII (signet ring cell gastric adenocarcinoma)	NULL	KLF5		GEO	GSE51705_klf5_katoiii_MACS_KLF5_MA0599.1.damo.pwm.bed	23900
1	1090	ELF1	0.0972602978164502	0.857466766971333	64	2568	2285	95	2568	1650	72	140	135	ELF1 SK-N-MC (Askin tumor) ELF1	SK-N-MC (Askin tumor)	BTO:0002914	ELF1	SHFLI_96H	GEO	GSE61944_elf1_skmnc-shfli-96h_MACS_ELF1_MA0473.3.damo.pwm.bed	33490
1	790	CTCF	0.0971720651367809	0.831684640884792	33	2569	2408	778	2569	1920	39	171	168	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		GTRD	EXP040241_MCF7--Invasive-ductal-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	63245
1	412	CEBPG	0.0969119072188065	0.81276440216452	23	2570	2506	1391	2570	2160	28	181	179	CEBPG K562 (myelogenous leukemia) CEBPG	K562 (myelogenous leukemia)	NULL	CEBPG	NA	GTRD	EXP039945_K562--myelogenous-leukemia-_CEBPG_MACS_CEBPG_MA1636.1.damo.pwm.bed	43612
1	661	CTCF	0.0969119072188065	0.81276440216452	23	2570	2506	1391	2570	2160	28	181	179	CTCF retinoblastoma xenograft CTCF	retinoblastoma xenograft	NULL	CTCF		GTRD	EXP037803_retinoblastoma-xenograft_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27428
1	2873	MYC	0.0965432100620161	0.856185127037788	63	2572	2288	103	2572	1650	71	141	136	MYC HEK293T (embryonic kidney) MYC	HEK293T (embryonic kidney)	BTO:0002181	MYC	Treatment: withKL-1 or KL-2 inhibitors was administrated only once; Genotype: cells lentiviral infected with control vector;	GTRD	EXP047291_HEK293T--embryonic-kidney-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	20054
1	2824	MYC	0.0961089745175848	0.843965170362976	45	2573	2338	383	2573	1760	52	159	155	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	HA-OmoMYCwt, Doxycycline	GTRD	EXP036030_U2OS--osteosarcoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	15247
1	425	CREB1	0.0956074776027823	0.785759512404141	15	2574	2652	1993	2652	2410	19	189	188	CREB1 MDA-MB-134 (invasive lobular breast carcinoma) CREB1	MDA-MB-134 (invasive lobular breast carcinoma)	NULL	CREB1	Treatment:a cocktail of 10 µM forskolin plus 100 µM 3-isobutyl-1-methylxanthine (FI) for 1hr Passage: between 10 and12 CellType: Epithelial ERalpha positive breast cancer cell line	GTRD	EXP048182_MDA-MB-134--invasive-lobular-breast-carcinoma-_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	9841
1	1421	ESR1	0.0956074776027823	0.785759512404141	15	2574	2652	1993	2652	2410	19	189	188	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GEO	GSE68355_ESR1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	34340
1	1745	FOXA1	0.0956074776027823	0.785759512404141	15	2574	2652	1993	2652	2410	19	189	188	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	Treatment: hormone-deprived cells treated with 10 nM estrogen for 45 mins;	GTRD	EXP058100_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	47742
1	1842	FOXA2	0.0956074776027823	0.785759512404141	15	2574	2652	1993	2652	2410	19	189	188	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL Genotype: FOXA2 mimo released	GTRD	EXP049307_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	79019
1	2936	MYC	0.0956074776027823	0.785759512404141	15	2574	2652	1993	2652	2410	19	189	188	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC		GEO	GSE77356_myc_u2os_MACS_MYC_MA0147.3.damo.pwm.bed	3790
1	35	AR	0.0955091028655932	0.718452410844157	5	2579	2949	3053	3053	2860	7	199	200	AR LNCaP C4-2 (prostate carcinoma) AR	LNCaP C4-2 (prostate carcinoma)	BTO:0005672	AR	10 nmol/l of mibolerone	GTRD	EXP033417_LNCaP-C4-2--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	30795
1	53	AR	0.0955091028655932	0.718452410844157	5	2579	2949	3053	3053	2860	7	199	200	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	treated for 24 hours with 1mM hydroxyurea +3 hour 10nm DHT	GTRD	EXP036469_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	22673
1	71	AR	0.0955091028655932	0.718452410844157	5	2579	2949	3053	3053	2860	7	199	200	AR HEE (human epididymis epithelial cells) AR	HEE (human epididymis epithelial cells)	NULL	AR	Treatment: treatment of 1 nM R1881 (methyltrienolone) for 12 -16 hr	GTRD	EXP048158_HEE--human-epididymis-epithelial-cells-_AR_MACS_AR_MA0007.3.damo.pwm.bed	13487
1	91	AR	0.0955091028655932	0.718452410844157	5	2579	2949	3053	3053	2860	7	199	200	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: 10 nM DHT for 4 hrs Genotype: Bag-1L wildtype	GTRD	EXP049284_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	20596
1	300	CDX2	0.0955091028655932	0.718452410844157	5	2579	2949	3053	3053	2860	7	199	200	CDX2 Wnt+Fgf-specified intestinal culture cells CDX2	Wnt+Fgf-specified intestinal culture cells	NULL	CDX2	Genotype: wildtype;	GTRD	EXP058137_Wnt-Fgf-specified-intestinal-culture-cells_CDX2_MACS_CDX2_MA0465.2.damo.pwm.bed	118721
1	972	CTCF	0.0955091028655932	0.718452410844157	5	2579	2949	3053	3053	2860	7	199	200	CTCF HEK293 (embryonic kidney) CTCF	HEK293 (embryonic kidney)	NULL	CTCF		GEO	GSE68976_ctcf_hek293_MACS_CTCF_MA0139.1.damo.pwm.bed	13531
1	1122	ERG	0.0955091028655932	0.718452410844157	5	2579	2949	3053	3053	2860	7	199	200	ERG metastatic prostate cancer tissue ERG	metastatic prostate cancer tissue	NULL	ERG	NULL	GTRD	EXP000739_metastatic-prostate-cancer-tissue_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	2641
1	2521	JUNB	0.0955091028655932	0.718452410844157	5	2579	2949	3053	3053	2860	7	199	200	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB		GTRD	EXP039779_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	11003
1	3212	OTX2	0.0955091028655932	0.718452410844157	5	2579	2949	3053	3053	2860	7	199	200	OTX2 retina OTX2	retina	BTO:0001175	OTX2	pigment	GEO	GSE60024_otx2_retinal-pigment_MACS_OTX2_MA0712.2.damo.pwm.bed	13696
1	3694	SPIB	0.0955091028655932	0.718452410844157	5	2579	2949	3053	3053	2860	7	199	200	SPIB OCI-LY3 (diffuse large B-cell lymphoma) SPIB	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	SPIB	SHCTR	GEO	GSE56857_spib_ocily3-shctr_MACS_SPIB_MA0081.2.damo.pwm.bed	25043
1	2341	JUN	0.0954573951685215	0.827800719711134	32	2589	2423	825	2589	1950	38	172	169	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN		GTRD	EXP040265_A549--lung-carcinoma-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	17089
1	1816	FOXA2	0.0950572197614283	0.853479029652707	61	2590	2296	127	2590	1670	69	143	138	FOXA2 A549 (lung carcinoma) FOXA2	A549 (lung carcinoma)	BTO:0000018	FOXA2	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BRE_A549_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	69545
1	2849	MYC	0.0950572197614283	0.853479029652707	61	2590	2296	127	2590	1670	69	143	138	MYC HUES64 (embryonic stem cells) MYC	HUES64 (embryonic stem cells)	NULL	MYC		GTRD	EXP036778_HUES64--embryonic-stem-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	18846
1	606	CTCF	0.0949264443349665	0.841532658330436	44	2592	2373	408	2592	1790	51	160	156	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	oestrogen	GTRD	EXP030933_MCF7--Invasive-ductal-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	62227
1	1711	FOXA1	0.0943735487878114	0.806285669400904	22	2593	2538	1459	2593	2200	27	182	180	FOXA1 MCF7 WS8 cells FOXA1	MCF7 WS8 cells	NULL	FOXA1	Treatment: 45 min 10^-8 E2	GTRD	EXP048450_MCF7-WS8-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	45540
1	1919	GATA1	0.0943735487878114	0.806285669400904	22	2593	2538	1459	2593	2200	27	182	180	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1		GTRD	EXP040807_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	55620
1	2337	JUN	0.0943735487878114	0.806285669400904	22	2593	2538	1459	2593	2200	27	182	180	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 15 minute	GTRD	EXP040263_A549--lung-carcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	16827
1	3481	RUNX1	0.0943735487878114	0.806285669400904	22	2593	2538	1459	2593	2200	27	182	180	RUNX1 pre-B-lymphoblast cells with BCP-ALL RUNX1	pre-B-lymphoblast cells with BCP-ALL	NULL	RUNX1	DIsease: human precursor leukemia (BCP-ALL) Tissue: bone marrow	GTRD	EXP048192_pre-B-lymphoblast-cells-with-BCP-ALL_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	16702
1	301	CDX2	0.0940587441892207	0.750525042902531	9	2597	2821	2564	2821	2660	12	195	195	CDX2 naive endoderm CDX2	naive endoderm	NULL	CDX2	Treatment: Doxycycline; Genotype: wildtype; Source: induced CDX2 culture cells;	GTRD	EXP058138_naive-endoderm_CDX2_MACS_CDX2_MA0465.2.damo.pwm.bed	130730
1	1100	ELK1	0.0940587441892207	0.750525042902531	9	2597	2821	2564	2821	2660	12	195	195	ELK1 K562 (myelogenous leukemia) ELK1	K562 (myelogenous leukemia)	NULL	ELK1		ENCODE	ENCSR000EFU_K562_ELK1_MACS_ELK1_MA0028.2.damo.pwm.bed	3082
1	1132	ERG	0.0940587441892207	0.750525042902531	9	2597	2821	2564	2821	2660	12	195	195	ERG HUVEC-C (HUVEC, umbilical vein endothelial cells) ERG	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ERG	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048201_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	4390
1	1242	ESR1	0.0940587441892207	0.750525042902531	9	2597	2821	2564	2821	2660	12	195	195	ESR1 patient-derived pleaural effusion ESR1	patient-derived pleaural effusion	NULL	ESR1	N/A	GTRD	EXP037780_patient-derived-pleaural-effusion_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	16823
1	2332	JUN	0.0940587441892207	0.750525042902531	9	2597	2821	2564	2821	2660	12	195	195	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 10 minute	GTRD	EXP040248_A549--lung-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	16703
1	2662	LHX9	0.0940587441892207	0.750525042902531	9	2597	2821	2564	2821	2660	12	195	195	LHX9 HCT-116 (colon carcinoma) LHX9	HCT-116 (colon carcinoma)	BTO:0001109	LHX9	Genotype: Expressing LHX9-V5 open reading frame Tissue: colon	GTRD	EXP053273_HCT-116--colon-carcinoma-_LHX9_MACS_LHX9_MA0701.2.damo.pwm.bed	10590
1	2763	MNT	0.0940587441892207	0.750525042902531	9	2597	2821	2564	2821	2660	12	195	195	MNT K562 (myelogenous leukemia) MNT	K562 (myelogenous leukemia)	NULL	MNT	NA	GTRD	EXP039471_K562--myelogenous-leukemia-_MNT_MACS_MNT_MA0825.1.damo.pwm.bed	2667
1	3134	NR3C1	0.0940587441892207	0.750525042902531	9	2597	2821	2564	2821	2660	12	195	195	NR3C1 MCF10A (breast epithelial cells) NR3C1	MCF10A (breast epithelial cells)	BTO:0001939	NR3C1	Treatment: EGF + DEX 60 min;	GTRD	EXP047632_MCF10A--breast-epithelial-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	17423
1	3459	RUNX1	0.0940587441892207	0.750525042902531	9	2597	2821	2564	2821	2660	12	195	195	RUNX1 Kasumi-1 (acute myeloblastic leukemia) RUNX1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	RUNX1		GTRD	EXP031176_Kasumi-1--acute-myeloblastic-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	12688
1	3512	RXRA	0.0940587441892207	0.750525042902531	9	2597	2821	2564	2821	2660	12	195	195	RXRA SK-N-SH (neuroblastoma) RXRA	SK-N-SH (neuroblastoma)	BTO:0001620	RXRA		ENCODE	ENCSR000BVG_SK-N-SH_RXRA_MACS_RXRA_MA0512.2.damo.pwm.bed	12879
1	3944	TFEB	0.0940587441892207	0.750525042902531	9	2597	2821	2564	2821	2660	12	195	195	TFEB HUVEC-C (HUVEC, umbilical vein endothelial cells) TFEB	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	TFEB	Strain: endothelial cells from umbilical cords newborn healthy humans	GTRD	EXP053387_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_TFEB_MACS_TFEB_MA0692.1.damo.pwm.bed	7688
1	3860	TFAP2A	0.0937137077839788	0.838994874089214	43	2608	2377	429	2608	1800	50	161	157	TFAP2A WA09 (embryonic stem cells) TFAP2A	WA09 (embryonic stem cells)	NULL	TFAP2A	BMP4 for 3 day	GTRD	EXP040709_WA09--embryonic-stem-cells-_TFAP2A_MACS_TFAP2A_MA0810.1.damo.pwm.bed	32120
1	1556	FOS	0.0936891532254181	0.823700317457267	31	2609	2439	881	2609	1980	37	173	170	FOS MCF10A-ER-Src FOS	MCF10A-ER-Src	NULL	FOS	Genotype: non-transformed	GTRD	EXP048567_MCF10A-ER-Src_FOS_MACS_FOS_MA1134.1.damo.pwm.bed	72511
1	1015	E2F1	0.0934997085908939	0.850569780256734	59	2610	2315	143	2610	1690	67	145	140	E2F1 LNCaP (prostate carcinoma) E2F1	LNCaP (prostate carcinoma)	BTO:0001321	E2F1	Vehicle	GTRD	EXP032862_LNCaP--prostate-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	17348
1	4090	USF2	0.0926931583676997	0.849033743065157	58	2611	2323	154	2611	1700	66	146	141	USF2 IMR90 (lung fibroblasts) USF2	IMR90 (lung fibroblasts)	NULL	USF2		GTRD	EXP039798_IMR90--lung-fibroblasts-_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	32729
1	763	CTCF	0.0924697402621031	0.836345521187527	42	2612	2393	454	2612	1820	49	162	158	CTCF tibial nerve CTCF	tibial nerve	NULL	CTCF		GTRD	EXP040027_tibial-nerve_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	32418
1	3937	TFAP4	0.0924697402621031	0.836345521187527	42	2612	2393	454	2612	1820	49	162	158	TFAP4 COLO-320 (colon adenocarcinoma) TFAP4	COLO-320 (colon adenocarcinoma)	BTO:0002047	TFAP4	NA	GTRD	EXP037553_COLO-320--colon-adenocarcinoma-_TFAP4_MACS_TFAP4_MA1570.1.damo.pwm.bed	57111
1	3484	RUNX1	0.0918675241218422	0.847440371750719	57	2614	2334	174	2614	1710	65	147	142	RUNX1 cord blood CD34 cells RUNX1	cord blood CD34 cells	NULL	RUNX1	Genotype: RUNX1mut transduced;	GTRD	EXP058042_cord-blood-CD34-cells_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	39384
1	1340	ESR1	0.0918647669203652	0.819365503858249	30	2615	2467	937	2615	2010	36	174	171	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Fulvestrant	GTRD	EXP048586_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	14143
1	1518	FOS	0.0918647669203652	0.819365503858249	30	2615	2467	937	2615	2010	36	174	171	FOS FOS	NA	NA	FOS	NA	NA	ENCSR000DOT_MCF_10A_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	62586
1	1554	FOS	0.0918647669203652	0.819365503858249	30	2615	2467	937	2615	2010	36	174	171	FOS MCF10A-ER-Src FOS	MCF10A-ER-Src	NULL	FOS	Genotype: non-transformed	GTRD	EXP048567_MCF10A-ER-Src_FOS_MACS_FOS_MA0099.3.damo.pwm.bed	70464
1	1557	FOS	0.0918647669203652	0.819365503858249	30	2615	2467	937	2615	2010	36	174	171	FOS MCF10A-ER-Src FOS	MCF10A-ER-Src	NULL	FOS	Genotype: non-transformed	GTRD	EXP048567_MCF10A-ER-Src_FOS_MACS_FOS_MA1141.1.damo.pwm.bed	67959
1	96	AR	0.0918183392174213	0.673910423672498	2	2619	3097	3462	3462	3060	3	202	204	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: 10 nM DHT+10 uM MDV3100 TF: full-length AR (AR-FL)	GTRD	EXP049393_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	8134
1	239	ATF2	0.0918183392174213	0.673910423672498	2	2619	3097	3462	3462	3060	3	202	204	ATF2 GM12878 (female B-cells lymphoblastoid cell line) ATF2	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ATF2	NA	GTRD	EXP039489_GM12878--female-B-cells-_ATF2_MACS_ATF2_MA1632.1.damo.pwm.bed	12052
1	1033	E2F4	0.0918183392174213	0.673910423672498	2	2619	3097	3462	3462	3060	3	202	204	E2F4 GM12878 (female B-cells lymphoblastoid cell line) E2F4	GM12878 (female B-cells lymphoblastoid cell line)	NULL	E2F4		ENCODE	ENCSR000DYY_GM12878_E2F4_MACS_E2F4_MA0470.2.damo.pwm.bed	713
1	1365	ESR1	0.0918183392174213	0.673910423672498	2	2619	3097	3462	3462	3060	3	202	204	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: FA (control)	GTRD	EXP053228_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	3431
1	1444	ESRRA	0.0918183392174213	0.673910423672498	2	2619	3097	3462	3462	3060	3	202	204	ESRRA HepG2 (hepatoblastoma) ESRRA	HepG2 (hepatoblastoma)	BTO:0000599	ESRRA	low-glucose DMEM with 0.5% BSA supplemented with 1uM forskolin and 1mM pyruvate for 6h. (Snyder)	ENCODE	ENCSR000EEW_HepG2_ESRRA_MACS_ESRRA_MA0592.3.damo.pwm.bed	897
1	2042	GATA6	0.0918183392174213	0.673910423672498	2	2619	3097	3462	3462	3060	3	202	204	GATA6 KATOIII (signet ring cell gastric adenocarcinoma) GATA6	KATOIII (signet ring cell gastric adenocarcinoma)	NULL	GATA6		GEO	GSE51705_gata6_katoiii_MACS_GATA6_MA1104.2.damo.pwm.bed	1990
1	2047	GFI1B	0.0918183392174213	0.673910423672498	2	2619	3097	3462	3462	3060	3	202	204	GFI1B HEK293 (embryonic kidney) GFI1B	HEK293 (embryonic kidney)	NULL	GFI1B		GTRD	EXP039926_HEK293--embryonic-kidney-_GFI1B_MACS_GFI1B_MA0483.1.damo.pwm.bed	1736
1	2106	HIF1A	0.0918183392174213	0.673910423672498	2	2619	3097	3462	3462	3060	3	202	204	HIF1A macrophages HIF1A	macrophages	NULL	HIF1A	HYPO_IL	GEO	GSE43109_hif1a_macrophage-hypo-il_MACS_HIF1A_MA1106.1.damo.pwm.bed	1143
1	2472	JUN	0.0918183392174213	0.673910423672498	2	2619	3097	3462	3462	3060	3	202	204	JUN BT-549 (breast invasive ductal carcinoma) JUN	BT-549 (breast invasive ductal carcinoma)	BTO:0002548	JUN	TNF	GEO	GSE71976_jun_bt549-tnf_MACS_JUN_MA0488.1.damo.pwm.bed	3461
1	2909	MYC	0.0918183392174213	0.673910423672498	2	2619	3097	3462	3462	3060	3	202	204	MYC CA-46 (Burkitt lymphoma) MYC	CA-46 (Burkitt lymphoma)	BTO:0000789	MYC		GEO	GSE30726_myc_ca46_MACS_MYC_MA0147.3.damo.pwm.bed	643
1	2990	NFE2	0.0918183392174213	0.673910423672498	2	2619	3097	3462	3462	3060	3	202	204	NFE2 K562 (myelogenous leukemia) NFE2	K562 (myelogenous leukemia)	NULL	NFE2		ENCODE	ENCSR000FAF_K562_NFE2_MACS_NFE2_MA0841.1.damo.pwm.bed	4041
1	3265	POU5F1	0.0918183392174213	0.673910423672498	2	2619	3097	3462	3462	3060	3	202	204	POU5F1 MRC-5 (fetal lung fibroblasts) POU5F1	MRC-5 (fetal lung fibroblasts)	BTO:0001590	POU5F1	Treatment: Oct4, Sox2 and Klf4 addition for 5 days Passage: 8	GTRD	EXP048944_MRC-5--fetal-lung-fibroblasts-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	6094
1	3396	REST	0.0918183392174213	0.673910423672498	2	2619	3097	3462	3462	3060	3	202	204	REST PFSK1 (primitive neuroectodermal tumor) REST	PFSK1 (primitive neuroectodermal tumor)	NULL	REST		ENCODE	ENCSR000BJP_PFSK-1_REST_MACS_REST_MA0138.2.damo.pwm.bed	5280
1	3474	RUNX1	0.0918183392174213	0.673910423672498	2	2619	3097	3462	3462	3060	3	202	204	RUNX1 ME-1 (acute myeloid leukemia ) RUNX1	ME-1 (acute myeloid leukemia )	NULL	RUNX1	Treatment: DMSO for 6 hr; CellType: human inv(16) leukemia cell line;	GTRD	EXP047572_ME-1--acute-myeloid-leukemia--_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	2443
1	3490	RUNX1	0.0918183392174213	0.673910423672498	2	2619	3097	3462	3462	3060	3	202	204	RUNX1 Jurkat (T-cells) RUNX1	Jurkat (T-cells)	BTO:0000661	RUNX1		GEO	GSE42575_runx1_jurkat_MACS_RUNX1_MA0002.2.damo.pwm.bed	3694
1	3745	STAT3	0.0918183392174213	0.673910423672498	2	2619	3097	3462	3462	3060	3	202	204	STAT3 SU-DHL-1 (Anaplastic large cell lymphoma) STAT3	SU-DHL-1 (Anaplastic large cell lymphoma)	BTO:0005058	STAT3	Treatment: 300 nM Crizotinib for 3 hrs	GTRD	EXP053282_SU-DHL-1--Anaplastic-large-cell-lymphoma-_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	535
1	4032	TP63	0.0918183392174213	0.673910423672498	2	2619	3097	3462	3462	3060	3	202	204	TP63 HaCaT (keratinocytes) TP63	HaCaT (keratinocytes)	BTO:0000552	TP63	Ad-caRAS and 3 ng/ml of TGF-beta3 for 1.5 hrs	GTRD	EXP033938_HaCaT--keratinocytes-_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	6684
1	4109	VDR	0.0918183392174213	0.673910423672498	2	2619	3097	3462	3462	3060	3	202	204	VDR LX-2 (hepatic stellate cells) VDR	LX-2 (hepatic stellate cells)	BTO:0003516	VDR		GEO	GSE38103_vdr_lx2_MACS_VDR_MA0693.2.damo.pwm.bed	1303
1	4152	YY1	0.0918183392174213	0.673910423672498	2	2619	3097	3462	3462	3060	3	202	204	YY1 HeLa (cervical adenocarcinoma) YY1	HeLa (cervical adenocarcinoma)	BTO:0000567	YY1		GEO	GSE31417_yy1_hela_MACS_YY1_MA0095.2.damo.pwm.bed	772
1	740	CTCF	0.0917283573266692	0.79930322263097	21	2638	2585	1535	2638	2250	26	183	181	CTCF coronary artery CTCF	coronary artery	BTO:0000290	CTCF		GTRD	EXP039802_coronary-artery_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27678
1	2229	JUN	0.0917283573266692	0.79930322263097	21	2638	2585	1535	2638	2250	26	183	181	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN		ENCODE	ENCSR000FAH_K562_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	22725
1	2576	JUNB	0.0917283573266692	0.79930322263097	21	2638	2585	1535	2638	2250	26	183	181	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: non-transformed	GTRD	EXP048569_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	46445
1	3873	TFAP2C	0.0917283573266692	0.79930322263097	21	2638	2585	1535	2638	2250	26	183	181	TFAP2C HeLa S3 (cervical adenocarcinoma) TFAP2C	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	TFAP2C	None	GTRD	EXP010559_HeLa-S3--cervical-adenocarcinoma-_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	21954
1	706	CTCF	0.0916700982511663	0.774168272461542	14	2642	2705	2073	2705	2470	18	190	189	CTCF testis CTCF	testis	BTO:0001363	CTCF		GTRD	EXP039569_testis_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	18071
1	708	CTCF	0.0916700982511663	0.774168272461542	14	2642	2705	2073	2705	2470	18	190	189	CTCF ascending aorta CTCF	ascending aorta	NULL	CTCF		GTRD	EXP039576_ascending-aorta_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	17823
1	1670	FOXA1	0.0916700982511663	0.774168272461542	14	2642	2705	2073	2705	2470	18	190	189	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	No treatment	GTRD	EXP037433_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	42289
1	1904	GATA1	0.0916700982511663	0.774168272461542	14	2642	2705	2073	2705	2470	18	190	189	GATA1 CD36+ erythroid cells GATA1	CD36+ erythroid cells	NULL	GATA1	BRG1 RNAi KD	GTRD	EXP000913_CD36--erythroid-cells_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	16004
1	2412	JUN	0.0916700982511663	0.774168272461542	14	2642	2705	2073	2705	2470	18	190	189	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: non-transformed	GTRD	EXP048571_MCF10A-ER-Src_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	29182
1	2861	MYC	0.0916700982511663	0.774168272461542	14	2642	2705	2073	2705	2470	18	190	189	MYC BT168 (glioblastoma stem cells) MYC	BT168 (glioblastoma stem cells)	NULL	MYC	Untreated with Dox	GTRD	EXP037765_BT168--glioblastoma-stem-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	4356
1	3062	NR2F1	0.0916700982511663	0.774168272461542	14	2642	2705	2073	2705	2470	18	190	189	NR2F1 cranial neural crest cells NR2F1	cranial neural crest cells	NULL	NR2F1	NA	GTRD	EXP035243_cranial-neural-crest-cells_NR2F1_MACS_NR2F1_MA0017.2.damo.pwm.bed	29539
1	164	AR	0.091193464414137	0.833577774568143	41	2649	2404	476	2649	1840	48	163	159	AR PLHSAR AR	PLHSAR	NA	AR	FOXA1_HOXB13	GEO	GSE56288_AR_plhsar-foxa1-hoxb13_MACS_AR_MA0007.3.damo.pwm.bed	165694
1	497	CTCF	0.089981491089372	0.814776296097491	29	2650	2485	1013	2650	2050	35	175	172	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DPV_fibroblast_of_skin_of_abdomen_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39234
1	3066	NR2F1	0.089981491089372	0.814776296097491	29	2650	2485	1013	2650	2050	35	175	172	NR2F1 HepG2 (hepatoblastoma) NR2F1	HepG2 (hepatoblastoma)	BTO:0000599	NR2F1	NA	GTRD	EXP039919_HepG2--hepatoblastoma-_NR2F1_MACS_NR2F1_MA1537.1.damo.pwm.bed	23493
1	2762	MNT	0.0898837471239772	0.830684224434443	40	2652	2409	502	2652	1850	47	164	160	MNT K562 (myelogenous leukemia) MNT	K562 (myelogenous leukemia)	NULL	MNT	NA	GTRD	EXP039391_K562--myelogenous-leukemia-_MNT_MACS_MNT_MA0825.1.damo.pwm.bed	14983
1	2959	MYOD1	0.0898837471239772	0.830684224434443	40	2652	2409	502	2652	1850	47	164	160	MYOD1 rhabdomyosarcoma MYOD1	rhabdomyosarcoma	NULL	MYOD1	NA	GEO	GSE50413_myod1_Rhabdomyosarcoma_MACS_MYOD1_MA0499.2.damo.pwm.bed	57410
1	3849	TFAP2A	0.0890211702599663	0.851665444676268	75	2654	2303	28	2654	1660	84	129	123	TFAP2A H9-derived neural crest cells TFAP2A	H9-derived neural crest cells	NULL	TFAP2A		GTRD	EXP030996_H9-derived-neural-crest-cells_TFAP2A_MACS_TFAP2A_MA0872.1.damo.pwm.bed	55302
1	1474	ETV1	0.0889689225857763	0.791756681896058	20	2655	2618	1606	2655	2290	25	184	182	ETV1 GIST882 (Gastrointestinal stromal tumor) ETV1	GIST882 (Gastrointestinal stromal tumor)	NULL	ETV1	Treatment: cells were harvested in log phase growth	GTRD	EXP048910_GIST882--Gastrointestinal-stromal-tumor-_ETV1_MACS_ETV1_MA0761.2.damo.pwm.bed	6643
1	515	CTCF	0.08853939635061	0.82765681278788	39	2656	2425	547	2656	1880	46	165	161	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DSU_astrocyte_of_the_spinal_cord_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49784
1	3855	TFAP2A	0.08853939635061	0.82765681278788	39	2656	2425	547	2656	1880	46	165	161	TFAP2A cranial neural crest cells TFAP2A	cranial neural crest cells	NULL	TFAP2A		GTRD	EXP035244_cranial-neural-crest-cells_TFAP2A_MACS_TFAP2A_MA0872.1.damo.pwm.bed	47331
1	1058	EGR1	0.0885076471591111	0.850755465013092	74	2658	2314	33	2658	1670	83	130	124	EGR1 K562 (myelogenous leukemia) EGR1	K562 (myelogenous leukemia)	NULL	EGR1		ENCODE	ENCSR000BNE_K562_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	42133
1	2336	JUN	0.0880363948120362	0.809910356925205	28	2659	2512	1068	2659	2080	34	176	173	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 15 minute	GTRD	EXP040263_A549--lung-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	19632
1	3814	TCF7L2	0.0880363948120362	0.809910356925205	28	2659	2512	1068	2659	2080	34	176	173	TCF7L2 PANC1 (pancreatic ductal adenocarcinoma) TCF7L2	PANC1 (pancreatic ductal adenocarcinoma)	NULL	TCF7L2		ENCODE	ENCSR000EXL_Panc1_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	18010
1	51	AR	0.087487619210349	0.727835674019546	8	2661	2913	2697	2913	2760	11	196	196	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	treated for 24 hours with 0.5μM PD-0332991 +3 hour 10nm DHT	GTRD	EXP036466_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	34769
1	108	AR	0.087487619210349	0.727835674019546	8	2661	2913	2697	2913	2760	11	196	196	AR LNCaP95 AR	LNCaP95	NULL	AR	Treatment: 10nM DHT for 4 hrs Genotype: shARv7 transfection	GTRD	EXP052951_LNCaP95_AR_MACS_AR_MA0007.3.damo.pwm.bed	17694
1	2318	JUN	0.087487619210349	0.727835674019546	8	2661	2913	2697	2913	2760	11	196	196	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039496_A549--lung-carcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	10060
1	2331	JUN	0.087487619210349	0.727835674019546	8	2661	2913	2697	2913	2760	11	196	196	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 10 minute	GTRD	EXP040248_A549--lung-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	15925
1	2392	JUN	0.087487619210349	0.727835674019546	8	2661	2913	2697	2913	2760	11	196	196	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048210_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	11327
1	2469	JUN	0.087487619210349	0.727835674019546	8	2661	2913	2697	2913	2760	11	196	196	JUN BT-549 (breast invasive ductal carcinoma) JUN	BT-549 (breast invasive ductal carcinoma)	BTO:0002548	JUN		GEO	GSE46166_jun_bt549_MACS_JUN_MA0488.1.damo.pwm.bed	12667
1	2548	JUNB	0.087487619210349	0.727835674019546	8	2661	2913	2697	2913	2760	11	196	196	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039942_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	13324
1	2567	JUNB	0.087487619210349	0.727835674019546	8	2661	2913	2697	2913	2760	11	196	196	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP040136_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	9751
1	3040	NR1H2	0.087487619210349	0.727835674019546	8	2661	2913	2697	2913	2760	11	196	196	NR1H2 HT29 (colon adenocarcinoma) NR1H2	HT29 (colon adenocarcinoma)	BTO:0000182	NR1H2	GW3965_2H	GEO	GSE77039_nr1h2_ht29-gw3965-2h_MACS_NR1H2_MA0115.1.damo.pwm.bed	9299
1	3621	SOX4	0.087487619210349	0.727835674019546	8	2661	2913	2697	2913	2760	11	196	196	SOX4 HMLE-Twist-ER (breast cancer) SOX4	HMLE-Twist-ER (breast cancer)	NULL	SOX4	Treatment:doxycicline and TGF-beta CellType: Immortalized human mammary epithelial cells	GTRD	EXP047893_HMLE-Twist-ER--breast-cancer-_SOX4_MACS_SOX4_MA0867.2.damo.pwm.bed	6514
1	1263	ESR1	0.0874872373366024	0.761209304842478	13	2671	2766	2153	2766	2530	17	191	190	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Doxycycline + E2	GTRD	EXP038376_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	26670
1	1742	FOXA1	0.0874872373366024	0.761209304842478	13	2671	2766	2153	2766	2530	17	191	190	FOXA1 primary breast cancer FOXA1	primary breast cancer	NULL	FOXA1	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053239_primary-breast-cancer_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	22286
1	2143	HNF4A	0.0874872373366024	0.761209304842478	13	2671	2766	2153	2766	2530	17	191	190	HNF4A GP5d (colon adenocarcinoma) HNF4A	GP5d (colon adenocarcinoma)	NULL	HNF4A		GEO	GSE51234_hnf4a_gp5d_MACS_HNF4A_MA0114.4.damo.pwm.bed	11720
1	3064	NR2F1	0.0874872373366024	0.761209304842478	13	2671	2766	2153	2766	2530	17	191	190	NR2F1 cranial neural crest cells NR2F1	cranial neural crest cells	NULL	NR2F1	NA	GTRD	EXP035243_cranial-neural-crest-cells_NR2F1_MACS_NR2F1_MA1538.1.damo.pwm.bed	28286
1	3224	PBX2	0.0874872373366024	0.761209304842478	13	2671	2766	2153	2766	2530	17	191	190	PBX2 K562 (myelogenous leukemia) PBX2	K562 (myelogenous leukemia)	NULL	PBX2	NA	GTRD	EXP039437_K562--myelogenous-leukemia-_PBX2_MACS_PBX2_MA1113.2.damo.pwm.bed	24496
1	3541	RXRA	0.0874872373366024	0.761209304842478	13	2671	2766	2153	2766	2530	17	191	190	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA S427F	GTRD	EXP040816_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA1148.1.damo.pwm.bed	8106
1	3671	SPI1	0.0874872373366024	0.761209304842478	13	2671	2766	2153	2766	2530	17	191	190	SPI1 macrophages SPI1	macrophages	NULL	SPI1	IL4	GEO	GSE47188_spi1_macrophage-il4_MACS_SPI1_MA0080.5.damo.pwm.bed	3318
1	489	CTCF	0.0871591578122357	0.824486761496615	38	2678	2428	576	2678	1890	45	166	162	CTCF keratinocytes CTCF	keratinocytes	NULL	CTCF		ENCODE	ENCSR000DNC_keratinocyte_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	56512
1	1419	ESR1	0.0871591578122357	0.824486761496615	38	2678	2428	576	2678	1890	45	166	162	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	PROG	GEO	GSE68355_ESR1_mcf7-prog_MACS_ESR1_MA0112.3.damo.pwm.bed	56671
1	2964	NEUROD1	0.0871591578122357	0.824486761496615	38	2678	2428	576	2678	1890	45	166	162	NEUROD1 D341 Med (medulloblastoma) NEUROD1	D341 Med (medulloblastoma)	NULL	NEUROD1	shNEUROD1.1579	GTRD	EXP038208_D341-Med--medulloblastoma-_NEUROD1_MACS_NEUROD1_MA1109.1.damo.pwm.bed	22456
1	229	ASCL1	0.0860871385713138	0.783575597481707	19	2681	2657	1697	2681	2340	24	185	183	ASCL1 fibroblasts ASCL1	fibroblasts	NULL	ASCL1		GTRD	EXP030567_fibroblasts_ASCL1_MACS_ASCL1_MA1100.2.damo.pwm.bed	40741
1	750	CTCF	0.0860871385713138	0.783575597481707	19	2681	2657	1697	2681	2340	24	185	183	CTCF adrenal gland CTCF	adrenal gland	BTO:0000047	CTCF		GTRD	EXP039880_adrenal-gland_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31897
1	1091	ELF1	0.0860871385713138	0.783575597481707	19	2681	2657	1697	2681	2340	24	185	183	ELF1 SK-N-MC (Askin tumor) ELF1	SK-N-MC (Askin tumor)	BTO:0002914	ELF1	SHGFP_96H	GEO	GSE61944_elf1_skmnc-shgfp-96h_MACS_ELF1_MA0473.3.damo.pwm.bed	5912
1	1125	ERG	0.0860871385713138	0.783575597481707	19	2681	2657	1697	2681	2340	24	185	183	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	functional form of the peptide (*ERG inhibitory peptidomimetics*)	GTRD	EXP033708_VCaP--prostate-carcinoma-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	10611
1	1841	FOXA2	0.0860871385713138	0.783575597481707	19	2681	2657	1697	2681	2340	24	185	183	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL Genotype: Mimo FOXA2	GTRD	EXP049306_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	78132
1	2320	JUN	0.0860871385713138	0.783575597481707	19	2681	2657	1697	2681	2340	24	185	183	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039507_A549--lung-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	11925
1	2416	JUN	0.0860871385713138	0.783575597481707	19	2681	2657	1697	2681	2340	24	185	183	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: non-transformed	GTRD	EXP048571_MCF10A-ER-Src_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	33468
1	2427	JUN	0.0860871385713138	0.783575597481707	19	2681	2657	1697	2681	2340	24	185	183	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057912_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	31142
1	2600	JUND	0.0860871385713138	0.783575597481707	19	2681	2657	1697	2681	2340	24	185	183	JUND SK-N-SH (neuroblastoma) JUND	SK-N-SH (neuroblastoma)	BTO:0001620	JUND		ENCODE	ENCSR000EIB_SK-N-SH_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	28134
1	3476	RUNX1	0.0860871385713138	0.783575597481707	19	2681	2657	1697	2681	2340	24	185	183	RUNX1 HEE (human epididymis epithelial cells) RUNX1	HEE (human epididymis epithelial cells)	NULL	RUNX1	Treatment: treatment of 1 nM R1881 (methyltrienolone) for 12 -16 hr	GTRD	EXP048162_HEE--human-epididymis-epithelial-cells-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	11389
1	3864	TFAP2A	0.0860871385713138	0.783575597481707	19	2681	2657	1697	2681	2340	24	185	183	TFAP2A hiPSC TFAP2A	hiPSC	NULL	TFAP2A	Genotype: wildtype Treatment: hiPSC differentiation into hNCC (passage 2)	GTRD	EXP052981_hiPSC_TFAP2A_MACS_TFAP2A_MA0003.4.damo.pwm.bed	38281
1	3866	TFAP2A	0.0860871385713138	0.783575597481707	19	2681	2657	1697	2681	2340	24	185	183	TFAP2A hiPSC TFAP2A	hiPSC	NULL	TFAP2A	Genotype: wildtype Treatment: hiPSC differentiation into hNCC (passage 2)	GTRD	EXP052981_hiPSC_TFAP2A_MACS_TFAP2A_MA0872.1.damo.pwm.bed	38441
1	4016	TP53	0.0860871385713138	0.783575597481707	19	2681	2657	1697	2681	2340	24	185	183	TP53 GM06170 (fetal skin fibroblasts) TP53	GM06170 (fetal skin fibroblasts)	NULL	TP53		GEO	GSE55727_tp53_gm06170_MACS_TP53_MA0106.3.damo.pwm.bed	12436
1	3942	TFDP1	0.0860263477168731	0.80474263786258	27	2694	2551	1135	2694	2130	33	177	174	TFDP1 MM1.S (plasma cell myeloma) TFDP1	MM1.S (plasma cell myeloma)	BTO:0003933	TFDP1	none	GTRD	EXP037392_MM1.S--plasma-cell-myeloma-_TFDP1_MACS_TFDP1_MA1122.1.damo.pwm.bed	6577
1	1870	GABPA	0.0845185357847965	0.832293838347527	49	2695	2405	299	2695	1800	57	155	150	GABPA K562 (myelogenous leukemia) GABPA	K562 (myelogenous leukemia)	NULL	GABPA		ENCODE	ENCSR000BLO_K562_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	21220
1	2882	MYC	0.0845185357847965	0.832293838347527	49	2695	2405	299	2695	1800	57	155	150	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shSCR;	GTRD	EXP047486_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	14978
1	1349	ESR1	0.0842856682260831	0.817679524883997	36	2697	2478	645	2697	1940	43	168	164	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: E2 (estrogen) for 45 min  Genotype: wildtype TET2 Passage: 6-10	GTRD	EXP048693_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	29313
1	1856	FOXO1	0.0842856682260831	0.817679524883997	36	2697	2478	645	2697	1940	43	168	164	FOXO1 hESC-1 (Embryonic stem cells) FOXO1	hESC-1 (Embryonic stem cells)	NULL	FOXO1		GEO	GSE69542_foxo1_hesc_MACS_FOXO1_MA0480.1.damo.pwm.bed	58898
1	3328	REL	0.0842856682260831	0.817679524883997	36	2697	2478	645	2697	1940	43	168	164	REL GM12878 (female B-cells lymphoblastoid cell line) REL	GM12878 (female B-cells lymphoblastoid cell line)	NULL	REL	NA	GTRD	EXP054687_GM12878--female-B-cells-lymphoblastoid-cell-line-_REL_MACS_REL_MA0101.1.damo.pwm.bed	21898
1	3467	RUNX1	0.0842856682260831	0.817679524883997	36	2697	2478	645	2697	1940	43	168	164	RUNX1 THP-1 (acute monocytic leukemia) RUNX1	THP-1 (acute monocytic leukemia)	BTO:0001370	RUNX1		GTRD	EXP037304_THP-1--acute-monocytic-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	24774
1	3791	TCF3	0.0842856682260831	0.817679524883997	36	2697	2478	645	2697	1940	43	168	164	TCF3 Kasumi-1 (acute myeloblastic leukemia) TCF3	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	TCF3		GEO	GSE43834_TCF3_kasumi1_MACS_TCF3_MA0522.3.damo.pwm.bed	39831
1	442	CTCF	0.0839480056912524	0.799244955473311	26	2702	2589	1204	2702	2160	32	178	175	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000ANO_fibroblast_of_lung_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36010
1	1522	FOS	0.0839480056912524	0.799244955473311	26	2702	2589	1204	2702	2160	32	178	175	FOS K562 (myelogenous leukemia) FOS	K562 (myelogenous leukemia)	NULL	FOS	NULL	GTRD	EXP000310_K562--myelogenous-leukemia-_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	22309
1	2324	JUN	0.0839480056912524	0.799244955473311	26	2702	2589	1204	2702	2160	32	178	175	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039981_A549--lung-carcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	14720
1	2874	MYC	0.0838884833242904	0.842095251823505	66	2705	2346	78	2705	1710	75	138	132	MYC HEK293T (embryonic kidney) MYC	HEK293T (embryonic kidney)	BTO:0002181	MYC	Treatment: withKL-1 or KL-2 inhibitors was administrated only once; Genotype: cells lentiviral infected with control vector;	GTRD	EXP047291_HEK293T--embryonic-kidney-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	20762
1	65	AR	0.0834925190220726	0.670648515890999	4	2706	3123	3182	3182	3000	6	200	201	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR		GTRD	EXP038432_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	11892
1	186	AR	0.0834925190220726	0.670648515890999	4	2706	3123	3182	3182	3000	6	200	201	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR		GEO	GSE63202_AR_lncap_MACS_AR_MA0007.3.damo.pwm.bed	9786
1	1295	ESR1	0.0834925190220726	0.670648515890999	4	2706	3123	3182	3182	3000	6	200	201	ESR1 breast tumor ESR1	breast tumor	NULL	ESR1	Male	GTRD	EXP040670_breast-tumor_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	3484
1	1382	ESR1	0.0834925190220726	0.670648515890999	4	2706	3123	3182	3182	3000	6	200	201	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: with Estrogen +1,6-Hexanediol;	GTRD	EXP058226_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12955
1	2166	HOXB13	0.0834925190220726	0.670648515890999	4	2706	3123	3182	3182	3000	6	200	201	HOXB13 LNCaP (prostate carcinoma) HOXB13	LNCaP (prostate carcinoma)	BTO:0001321	HOXB13	Treatment: treated with 10nM  R1881 for 4 hours	GTRD	EXP049560_LNCaP--prostate-carcinoma-_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	20938
1	2200	IRF1	0.0834925190220726	0.670648515890999	4	2706	3123	3182	3182	3000	6	200	201	IRF1 HAEC (human aortic endothelial cells) IRF1	HAEC (human aortic endothelial cells)	NULL	IRF1	IL1b, 4h	GTRD	EXP038038_HAEC--human-aortic-endothelial-cells-_IRF1_MACS_IRF1_MA0050.2.damo.pwm.bed	5797
1	2594	JUND	0.0834925190220726	0.670648515890999	4	2706	3123	3182	3182	3000	6	200	201	JUND GM12878 (female B-cells lymphoblastoid cell line) JUND	GM12878 (female B-cells lymphoblastoid cell line)	NULL	JUND		ENCODE	ENCSR000DYS_GM12878_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	3719
1	3455	RUNX1	0.0834925190220726	0.670648515890999	4	2706	3123	3182	3182	3000	6	200	201	RUNX1 K562 (myelogenous leukemia) RUNX1	K562 (myelogenous leukemia)	NULL	RUNX1		GTRD	EXP000585_K562--myelogenous-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	4757
1	3511	RXRA	0.0834925190220726	0.670648515890999	4	2706	3123	3182	3182	3000	6	200	201	RXRA WA01 (H1, human embryonic stem cells) RXRA	WA01 (H1, human embryonic stem cells)	NULL	RXRA		ENCODE	ENCSR000BJW_H1-hESC_RXRA_MACS_RXRA_MA0512.2.damo.pwm.bed	2723
1	3667	SPI1	0.0834925190220726	0.670648515890999	4	2706	3123	3182	3182	3000	6	200	201	SPI1 GM12878 (female B-cells lymphoblastoid cell line) SPI1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	SPI1		GTRD	EXP054612_GM12878--female-B-cells-lymphoblastoid-cell-line-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	11583
1	3906	TFAP2C	0.0834925190220726	0.670648515890999	4	2706	3123	3182	3182	3000	6	200	201	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	Treatment: with Estrogen;	GTRD	EXP058229_MCF7--Invasive-ductal-breast-carcinoma-_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	5335
1	3907	TFAP2C	0.0834925190220726	0.670648515890999	4	2706	3123	3182	3182	3000	6	200	201	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	Treatment: with Estrogen;	GTRD	EXP058229_MCF7--Invasive-ductal-breast-carcinoma-_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	5293
1	3908	TFAP2C	0.0834925190220726	0.670648515890999	4	2706	3123	3182	3182	3000	6	200	201	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	Treatment: with Estrogen;	GTRD	EXP058229_MCF7--Invasive-ductal-breast-carcinoma-_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	5311
1	4000	TP53	0.0834925190220726	0.670648515890999	4	2706	3123	3182	3182	3000	6	200	201	TP53 MCF10A (breast epithelial cells) TP53	MCF10A (breast epithelial cells)	BTO:0001939	TP53	Treatment: DMSO for 6 hrs;	GTRD	EXP057963_MCF10A--breast-epithelial-cells-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	4006
1	2100	HIF1A	0.0832440786135209	0.840821474761565	65	2720	2374	89	2720	1730	74	139	133	HIF1A PC3(bone mets prostate adenocarcinoma) HIF1A	PC3(bone mets prostate adenocarcinoma)	NULL	HIF1A	Treatment: hypoxia(0.2% O2), siCtrl;	GTRD	EXP057826_PC3-bone-mets-prostate-adenocarcinoma-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	39523
1	1282	ESR1	0.0830741337900632	0.774677259747448	18	2721	2704	1785	2721	2400	23	186	184	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	siNT	GTRD	EXP038770_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	45111
1	44	AR	0.0830327232761663	0.746626086596228	12	2722	2845	2233	2845	2600	16	192	191	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	ethanol	GTRD	EXP034503_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	25754
1	1372	ESR1	0.0830327232761663	0.746626086596228	12	2722	2845	2233	2845	2600	16	192	191	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 10 nM 17-beta-estradiol for 30 mins Genotype: pS118-ER	GTRD	EXP053338_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	23977
1	1613	FOSL2	0.0830327232761663	0.746626086596228	12	2722	2845	2233	2845	2600	16	192	191	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039862_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	15665
1	1615	FOSL2	0.0830327232761663	0.746626086596228	12	2722	2845	2233	2845	2600	16	192	191	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039862_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	15144
1	2376	JUN	0.0830327232761663	0.746626086596228	12	2722	2845	2233	2845	2600	16	192	191	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: tamoxifen 1μM for 1hr;	GTRD	EXP047661_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	19436
1	2680	MAFK	0.0830327232761663	0.746626086596228	12	2722	2845	2233	2845	2600	16	192	191	MAFK HepG2 (hepatoblastoma) MAFK	HepG2 (hepatoblastoma)	BTO:0000599	MAFK	NA	ENCODE	ENCSR000EDZ_HepG2_MAFK_MACS_MAFK_MA0496.3.damo.pwm.bed	55847
1	805	CTCF	0.0827895656599388	0.814020387923718	35	2728	2497	691	2728	1970	42	169	165	CTCF SK-N-AS (neuroblastoma) CTCF	SK-N-AS (neuroblastoma)	BTO:0002827	CTCF		GTRD	EXP040384_SK-N-AS--neuroblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	55545
1	3883	TFAP2C	0.0827895656599388	0.814020387923718	35	2728	2497	691	2728	1970	42	169	165	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions;	GTRD	EXP047535_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	28718
1	2769	MXI1	0.0824548555610787	0.827715115565289	47	2730	2424	333	2730	1830	55	157	152	MXI1 HeLa S3 (cervical adenocarcinoma) MXI1	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	MXI1	NA	ENCODE	ENCSR000ECU_HeLa-S3_MXI1_MACS_MXI1_MA1108.2.damo.pwm.bed	14271
1	1775	FOXA1	0.0819079711549214	0.838130121831731	63	2731	2379	103	2731	1740	72	141	135	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	ETOH	GEO	GSE56086_foxa1_vcap-etoh_MACS_FOXA1_MA0148.4.damo.pwm.bed	199138
1	2314	JUN	0.0817977962028882	0.793385485580858	25	2732	2614	1262	2732	2200	31	179	176	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039496_A549--lung-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	15258
1	3308	RARA	0.0817977962028882	0.793385485580858	25	2732	2614	1262	2732	2200	31	179	176	RARA UPR9 (hematopoietic stem cells) RARA	UPR9 (hematopoietic stem cells)	NULL	RARA	5 hours zinc	GTRD	EXP000748_UPR9--hematopoietic-stem-cells-_RARA_MACS_RARA_MA0159.1.damo.pwm.bed	17224
1	1722	FOXA1	0.0812518648365518	0.810174479486286	34	2734	2511	729	2734	1990	41	170	166	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	Treatment: Cells were harvested in log phase growth Genotype: wildtype	GTRD	EXP048988_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	102672
1	2802	MYC	0.0812157276183561	0.836709032017666	62	2735	2392	118	2735	1750	71	142	136	MYC HUVEC-C (HUVEC, umbilical vein endothelial cells) MYC	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	MYC	NULL	GTRD	EXP000986_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	29309
1	2639	KLF4	0.0802906878046164	0.822751044552057	45	2736	2456	383	2736	1860	53	159	154	KLF4 keratinocytes KLF4	keratinocytes	NULL	KLF4	diff	GEO	GSE57702_klf4_keratinocyte-diff_MACS_KLF4_MA0039.4.damo.pwm.bed	31105
1	996	CUX1	0.080234644793265	0.700605790888154	7	2737	3015	2812	3015	2850	10	197	197	CUX1 MCF7 (Invasive ductal breast carcinoma) CUX1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CUX1	NA	ENCODE	ENCSR017CEO_MCF-7_CUX1_MACS_CUX1_MA0754.1.damo.pwm.bed	10881
1	1023	E2F1	0.080234644793265	0.700605790888154	7	2737	3015	2812	3015	2850	10	197	197	E2F1 K562 (myelogenous leukemia) E2F1	K562 (myelogenous leukemia)	NULL	E2F1		GTRD	EXP040307_K562--myelogenous-leukemia-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	7472
1	1305	ESR1	0.080234644793265	0.700605790888154	7	2737	3015	2812	3015	2850	10	197	197	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	100nm E2 (45 min)	GTRD	EXP040954_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	15558
1	1851	FOXK2	0.080234644793265	0.700605790888154	7	2737	3015	2812	3015	2850	10	197	197	FOXK2 HepG2 (hepatoblastoma) FOXK2	HepG2 (hepatoblastoma)	BTO:0000599	FOXK2	NA	ENCODE	ENCSR171FUX_HepG2_FOXK2_MACS_FOXK2_MA1103.2.damo.pwm.bed	6369
1	2165	HOXB13	0.080234644793265	0.700605790888154	7	2737	3015	2812	3015	2850	10	197	197	HOXB13 LNCaP (prostate carcinoma) HOXB13	LNCaP (prostate carcinoma)	BTO:0001321	HOXB13	Treatment: treated with 10nM  vehicle for 4 hours	GTRD	EXP049559_LNCaP--prostate-carcinoma-_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	24586
1	2670	MAF	0.080234644793265	0.700605790888154	7	2737	3015	2812	3015	2850	10	197	197	MAF Th17-cells MAF	Th17-cells	BTO:0005655	MAF	CellType:pool of expanded Th17 clones; Tissue: primary Th17-IL-10+ lymphocytes; ActivationState: recently activeted;Day:5;	GTRD	EXP047561_Th17-cells_MAF_MACS_MAF_MA1520.1.damo.pwm.bed	6360
1	3151	NR3C1	0.080234644793265	0.700605790888154	7	2737	3015	2812	3015	2850	10	197	197	NR3C1 HeLa-B2 NR3C1	HeLa-B2	NA	NR3C1	TA	GEO	GSE24518_nr3c1_helab2-ta_MACS_NR3C1_MA0113.3.damo.pwm.bed	7135
1	3229	PDX1	0.080234644793265	0.700605790888154	7	2737	3015	2812	3015	2850	10	197	197	PDX1 CyT49-derived endodermal cells PDX1	CyT49-derived endodermal cells	NULL	PDX1	none	GTRD	EXP033205_CyT49-derived-endodermal-cells_PDX1_MACS_PDX1_MA0132.2.damo.pwm.bed	9155
1	3389	RELB	0.080234644793265	0.700605790888154	7	2737	3015	2812	3015	2850	10	197	197	RELB L1236 (Hodgkin lymphoma) RELB	L1236 (Hodgkin lymphoma)	NULL	RELB	NA	GEO	GSE63736_relb_l1236_MACS_RELB_MA1117.1.damo.pwm.bed	10169
1	3463	RUNX1	0.080234644793265	0.700605790888154	7	2737	3015	2812	3015	2850	10	197	197	RUNX1 CD4+ CD25- T-cells RUNX1	CD4+ CD25- T-cells	NULL	RUNX1		GTRD	EXP032572_CD4--CD25--T-cells_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	3418
1	3703	SREBF1	0.080234644793265	0.700605790888154	7	2737	3015	2812	3015	2850	10	197	197	SREBF1 A549 (lung carcinoma) SREBF1	A549 (lung carcinoma)	BTO:0000018	SREBF1		ENCODE	ENCSR897MYK_A549_SREBF1_MACS_SREBF1_MA0829.2.damo.pwm.bed	1677
1	1563	FOSL1	0.0799201990729712	0.76496391126585	17	2748	2749	1846	2749	2450	22	187	185	FOSL1 K562 (myelogenous leukemia) FOSL1	K562 (myelogenous leukemia)	NULL	FOSL1	NA	ENCODE	ENCSR000BMV_K562_FOSL1_MACS_FOSL1_MA0477.2.damo.pwm.bed	14564
1	1957	GATA3	0.0799201990729712	0.76496391126585	17	2748	2749	1846	2749	2450	22	187	185	GATA3 T47D (invasive ductal carcinoma) GATA3	T47D (invasive ductal carcinoma)	BTO:0001248	GATA3	1 h with 0.02% Dimethyl sufloxide (DMSO) (Myers)	ENCODE	ENCSR000BMX_T47D_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	34650
1	2010	GATA4	0.0799201990729712	0.76496391126585	17	2748	2749	1846	2749	2450	22	187	185	GATA4 HUES64 (embryonic stem cells) GATA4	HUES64 (embryonic stem cells)	NULL	GATA4		GTRD	EXP036789_HUES64--embryonic-stem-cells-_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	33448
1	2722	MECOM	0.0799201990729712	0.76496391126585	17	2748	2749	1846	2749	2450	22	187	185	MECOM SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) MECOM	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	MECOM	NA	GTRD	EXP037834_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_MECOM_MACS_MECOM_MA0029.1.damo.pwm.bed	17326
1	2940	MYCN	0.0797571995847196	0.842461502970071	85	2752	2342	9	2752	1700	95	119	112	MYCN NGP (neuroblastoma) MYCN	NGP (neuroblastoma)	NULL	MYCN		GTRD	EXP038397_NGP--neuroblastoma-_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	185849
1	2862	MYC	0.0796709462370529	0.806127935396393	33	2753	2542	778	2753	2020	40	171	167	MYC HCT-116 (colon carcinoma) MYC	HCT-116 (colon carcinoma)	BTO:0001109	MYC	na	GTRD	EXP037785_HCT-116--colon-carcinoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	8931
1	3211	OTX2	0.0796709462370529	0.806127935396393	33	2753	2542	778	2753	2020	40	171	167	OTX2 D283 Med (medulloblastoma) OTX2	D283 Med (medulloblastoma)	NULL	OTX2		GTRD	EXP053393_D283-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	63701
1	3954	TP53	0.0796709462370529	0.806127935396393	33	2753	2542	778	2753	2020	40	171	167	TP53 lymphoblastoid cells TP53	lymphoblastoid cells	NULL	TP53	Doxo	GTRD	EXP030850_lymphoblastoid-cells_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	22844
1	1056	EGR1	0.0795719035667621	0.787128156274942	24	2756	2626	1324	2756	2240	30	180	177	EGR1 WA01 (H1, human embryonic stem cells) EGR1	WA01 (H1, human embryonic stem cells)	NULL	EGR1		ENCODE	ENCSR000BJA_H1-hESC_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	7099
1	1802	FOXA1	0.0795719035667621	0.787128156274942	24	2756	2626	1324	2756	2240	30	180	177	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	E2	GEO	GSE72249_foxa1_mcf7-e2_MACS_FOXA1_MA0148.4.damo.pwm.bed	50531
1	2068	GRHL2	0.0795719035667621	0.787128156274942	24	2756	2626	1324	2756	2240	30	180	177	GRHL2 MCF7 WS8 cells GRHL2	MCF7 WS8 cells	NULL	GRHL2	Treatment: 45 min ethanol	GTRD	EXP048454_MCF7-WS8-cells_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	22503
1	2865	MYC	0.0795719035667621	0.787128156274942	24	2756	2626	1324	2756	2240	30	180	177	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	200 nM OHT (endogenous Myc activated) and 0.2 µg/mL Tetracyclin (Myc transgene repressed)	GTRD	EXP038947_P493-6--B-cell-lymphoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	9709
1	3079	NR2F6	0.0795719035667621	0.787128156274942	24	2756	2626	1324	2756	2240	30	180	177	NR2F6 HepG2 (hepatoblastoma) NR2F6	HepG2 (hepatoblastoma)	BTO:0000599	NR2F6	NA	ENCODE	ENCSR518WPL_HepG2_NR2F6_MACS_NR2F6_MA0677.1.damo.pwm.bed	32566
1	3080	NR2F6	0.0795719035667621	0.787128156274942	24	2756	2626	1324	2756	2240	30	180	177	NR2F6 HepG2 (hepatoblastoma) NR2F6	HepG2 (hepatoblastoma)	BTO:0000599	NR2F6	NA	ENCODE	ENCSR518WPL_HepG2_NR2F6_MACS_NR2F6_MA0728.1.damo.pwm.bed	32566
1	1467	ETS1	0.0791691483526256	0.820111079429598	44	2762	2466	408	2762	1880	52	160	155	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048199_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	24155
1	1077	ELF1	0.0790387510796054	0.832120692060741	59	2763	2407	143	2763	1770	68	145	139	ELF1 K562 (myelogenous leukemia) ELF1	K562 (myelogenous leukemia)	NULL	ELF1		ENCODE	ENCSR000BMD_K562_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	44694
1	1581	FOSL2	0.0782766856537502	0.730093643300704	11	2764	2889	2332	2889	2660	15	193	192	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP039502_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	14283
1	1582	FOSL2	0.0782766856537502	0.730093643300704	11	2764	2889	2332	2889	2660	15	193	192	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP039502_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	14829
1	1583	FOSL2	0.0782766856537502	0.730093643300704	11	2764	2889	2332	2889	2660	15	193	192	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP039502_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	14608
1	1584	FOSL2	0.0782766856537502	0.730093643300704	11	2764	2889	2332	2889	2660	15	193	192	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039554_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	13136
1	1585	FOSL2	0.0782766856537502	0.730093643300704	11	2764	2889	2332	2889	2660	15	193	192	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039554_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	13660
1	1586	FOSL2	0.0782766856537502	0.730093643300704	11	2764	2889	2332	2889	2660	15	193	192	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039554_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	13614
1	1587	FOSL2	0.0782766856537502	0.730093643300704	11	2764	2889	2332	2889	2660	15	193	192	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039554_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	13473
1	1838	FOXA2	0.0782766856537502	0.730093643300704	11	2764	2889	2332	2889	2660	15	193	192	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL Genotype: FOXA2 unind	GTRD	EXP049302_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	18617
1	2338	JUN	0.0782766856537502	0.730093643300704	11	2764	2889	2332	2889	2660	15	193	192	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 15 minute	GTRD	EXP040263_A549--lung-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	13271
1	3841	TEAD4	0.0782766856537502	0.730093643300704	11	2764	2889	2332	2889	2660	15	193	192	TEAD4 SNU216 (gastric tubular adenocarcinoma) TEAD4	SNU216 (gastric tubular adenocarcinoma)	NULL	TEAD4		GEO	GSE44416_tead4_snu216_MACS_TEAD4_MA0809.2.damo.pwm.bed	21813
1	1096	ELF4	0.0780451060807148	0.801865465475227	32	2774	2570	825	2774	2060	39	172	168	ELF4 K562 (myelogenous leukemia) ELF4	K562 (myelogenous leukemia)	NULL	ELF4	NA	GTRD	EXP040067_K562--myelogenous-leukemia-_ELF4_MACS_ELF4_MA0641.1.damo.pwm.bed	9858
1	3885	TFAP2C	0.0780451060807148	0.801865465475227	32	2774	2570	825	2774	2060	39	172	168	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions;	GTRD	EXP047536_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	24035
1	4088	USF2	0.0780451060807148	0.801865465475227	32	2774	2570	825	2774	2060	39	172	168	USF2 GM12878 (female B-cells lymphoblastoid cell line) USF2	GM12878 (female B-cells lymphoblastoid cell line)	NULL	USF2		GTRD	EXP038558_GM12878--female-B-cells-_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	36541
1	2588	JUND	0.0772662546755154	0.780431915262925	23	2777	2688	1391	2777	2290	29	181	178	JUND A549 (lung carcinoma) JUND	A549 (lung carcinoma)	BTO:0000018	JUND	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BRF_A549_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	14874
1	729	CTCF	0.0766147165271125	0.75431916189616	16	2778	2806	1909	2806	2500	21	188	186	CTCF gastrocnemius medialis CTCF	gastrocnemius medialis	NULL	CTCF		GTRD	EXP039704_gastrocnemius-medialis_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	20250
1	1485	ETV6	0.0766147165271125	0.75431916189616	16	2778	2806	1909	2806	2500	21	188	186	ETV6 GM12878 (female B-cells lymphoblastoid cell line) ETV6	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ETV6		GTRD	EXP038555_GM12878--female-B-cells-_ETV6_MACS_ETV6_MA0645.1.damo.pwm.bed	22987
1	3534	RXRA	0.0766147165271125	0.75431916189616	16	2778	2806	1909	2806	2500	21	188	186	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA WT	GTRD	EXP040815_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA1148.1.damo.pwm.bed	9911
1	4070	USF1	0.0766147165271125	0.75431916189616	16	2778	2806	1909	2806	2500	21	188	186	USF1 A549 (lung carcinoma) USF1	A549 (lung carcinoma)	BTO:0000018	USF1	1 h with 100 nM Dexamethasone (Myers)	ENCODE	ENCSR000BHX_A549_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	8112
1	530	CTCF	0.0763725527343226	0.79737016593615	31	2782	2593	881	2782	2090	38	173	169	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DUX_fibroblast_of_pulmonary_artery_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46643
1	2820	MYC	0.0763725527343226	0.79737016593615	31	2782	2593	881	2782	2090	38	173	169	MYC Raji (Burkitt lymphoma) MYC	Raji (Burkitt lymphoma)	BTO:0001154	MYC		GTRD	EXP035848_Raji--Burkitt-lymphoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	7188
1	3848	TFAP2A	0.0752179916356158	0.833889958987074	74	2784	2402	33	2784	1740	84	130	123	TFAP2A H9-derived neural crest cells TFAP2A	H9-derived neural crest cells	NULL	TFAP2A		GTRD	EXP030996_H9-derived-neural-crest-cells_TFAP2A_MACS_TFAP2A_MA0810.1.damo.pwm.bed	55205
1	1637	FOXA1	0.0748765059783155	0.773249840132979	22	2785	2716	1459	2785	2320	28	182	179	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1		Array Express	ERP000380_foxa1_mcf7_MACS_FOXA1_MA0148.4.damo.pwm.bed	47172
1	1848	FOXA3	0.0748765059783155	0.773249840132979	22	2785	2716	1459	2785	2320	28	182	179	FOXA3 HepG2 (hepatoblastoma) FOXA3	HepG2 (hepatoblastoma)	BTO:0000599	FOXA3	NA	GTRD	EXP039891_HepG2--hepatoblastoma-_FOXA3_MACS_FOXA3_MA1683.1.damo.pwm.bed	45846
1	2595	JUND	0.0748765059783155	0.773249840132979	22	2785	2716	1459	2785	2320	28	182	179	JUND WA01 (H1, human embryonic stem cells) JUND	WA01 (H1, human embryonic stem cells)	NULL	JUND		ENCODE	ENCSR000EBZ_H1-hESC_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	15572
1	375	CEBPB	0.0746514033968506	0.792623301340066	30	2788	2617	937	2788	2110	37	174	170	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP039591_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	36641
1	3861	TFAP2A	0.0744017633774999	0.808349301357987	40	2789	2533	502	2789	1940	48	164	159	TFAP2A WA09 (embryonic stem cells) TFAP2A	WA09 (embryonic stem cells)	NULL	TFAP2A	BMP4 for 3 day	GTRD	EXP040709_WA09--embryonic-stem-cells-_TFAP2A_MACS_TFAP2A_MA0872.1.damo.pwm.bed	30609
1	4042	TP63	0.0744017633774999	0.808349301357987	40	2789	2533	502	2789	1940	48	164	159	TP63 keratinocytes TP63	keratinocytes	NULL	TP63		GEO	GSE33571_tp63_keratinocytes_MACS_TP63_MA0525.2.damo.pwm.bed	24961
1	2848	MYC	0.0742041837506084	0.821269470108865	53	2791	2465	236	2791	1830	62	151	145	MYC HUES64 (embryonic stem cells) MYC	HUES64 (embryonic stem cells)	NULL	MYC		GTRD	EXP036778_HUES64--embryonic-stem-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	15960
1	1525	FOS	0.0731850695223	0.71119408253291	10	2792	2984	2442	2984	2740	14	194	193	FOS GM12878 (female B-cells lymphoblastoid cell line) FOS	GM12878 (female B-cells lymphoblastoid cell line)	NULL	FOS	NULL	GTRD	EXP000437_GM12878--female-B-cells-_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	2335
1	3015	NFIC	0.0731850695223	0.71119408253291	10	2792	2984	2442	2984	2740	14	194	193	NFIC K562 (myelogenous leukemia) NFIC	K562 (myelogenous leukemia)	NULL	NFIC	NA	GTRD	EXP039955_K562--myelogenous-leukemia-_NFIC_MACS_NFIC_MA1527.1.damo.pwm.bed	21290
1	3706	SRF	0.0731850695223	0.71119408253291	10	2792	2984	2442	2984	2740	14	194	193	SRF K562 (myelogenous leukemia) SRF	K562 (myelogenous leukemia)	NULL	SRF		ENCODE	ENCSR000BLK_K562_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	4911
1	3775	TBX5	0.0731850695223	0.71119408253291	10	2792	2984	2442	2984	2740	14	194	193	TBX5 iPSC-derived cardiomyocytes TBX5	iPSC-derived cardiomyocytes	NULL	TBX5	G296S mutant	GTRD	EXP037721_iPSC-derived-cardiomyocytes_TBX5_MACS_TBX5_MA0807.1.damo.pwm.bed	14389
1	172	AR	0.0731460960066868	0.742603327600673	15	2796	2864	1993	2864	2550	20	189	187	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	DHT24H	GEO	GSE58428_AR_vcap-dht24h_MACS_AR_MA0007.3.damo.pwm.bed	33157
1	3853	TFAP2A	0.0731353770358376	0.80507095095734	39	2797	2549	547	2797	1960	47	165	160	TFAP2A cranial neural crest cells TFAP2A	cranial neural crest cells	NULL	TFAP2A		GTRD	EXP035244_cranial-neural-crest-cells_TFAP2A_MACS_TFAP2A_MA0003.4.damo.pwm.bed	47663
1	1669	FOXA1	0.072879681236688	0.787604050188521	29	2798	2625	1013	2798	2150	36	175	171	FOXA1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) FOXA1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	FOXA1	tamoxifen	GTRD	EXP037126_MCF7-TamR--invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	68491
1	968	CTCF	0.0724394547500533	0.817072782890049	51	2799	2483	261	2799	1850	60	153	147	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF	MESEN	GEO	GSE52457_ctcf_h1-mesen_MACS_CTCF_MA0139.1.damo.pwm.bed	85879
1	4123	YY1	0.0724394547500533	0.817072782890049	51	2799	2483	261	2799	1850	60	153	147	YY1 HepG2 (hepatoblastoma) YY1	HepG2 (hepatoblastoma)	BTO:0000599	YY1		ENCODE	ENCSR000BNT_HepG2_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	22789
1	1786	FOXA1	0.0723980328805976	0.765528050775799	21	2801	2746	1535	2801	2360	27	183	180	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	TNF	GEO	GSE59530_foxa1_mcf7-tnf_MACS_FOXA1_MA0148.4.damo.pwm.bed	33103
1	2480	JUNB	0.0723980328805976	0.765528050775799	21	2801	2746	1535	2801	2360	27	183	180	JUNB HAEC (human aortic endothelial cells) JUNB	HAEC (human aortic endothelial cells)	NULL	JUNB	control, 4h	GTRD	EXP038040_HAEC--human-aortic-endothelial-cells-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	31087
1	3536	RXRA	0.0723980328805976	0.765528050775799	21	2801	2746	1535	2801	2360	27	183	180	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA S427F	GTRD	EXP040816_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA0115.1.damo.pwm.bed	9751
1	16	AR	0.072174859151466	0.667320688980191	6	2804	3150	2948	3150	2970	9	198	198	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	100 nM DHT	GTRD	EXP030500_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	12326
1	3167	NR5A2	0.072174859151466	0.667320688980191	6	2804	3150	2948	3150	2970	9	198	198	NR5A2 MCF7 (Invasive ductal breast carcinoma) NR5A2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NR5A2	NA	GTRD	EXP032283_MCF7--Invasive-ductal-breast-carcinoma-_NR5A2_MACS_NR5A2_MA0505.1.damo.pwm.bed	13855
1	3693	SPIB	0.072174859151466	0.667320688980191	6	2804	3150	2948	3150	2970	9	198	198	SPIB OCI-LY10 (diffuse large B-cell lymphoma) SPIB	OCI-LY10 (diffuse large B-cell lymphoma)	NULL	SPIB		GEO	GSE56857_spib_ocily10_MACS_SPIB_MA0081.2.damo.pwm.bed	16554
1	881	CTCF	0.0718373574532504	0.801640172439298	38	2807	2573	576	2807	1990	46	166	161	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: no stress  Source: T47D whole cell	GTRD	EXP053048_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31395
1	3369	RELA	0.0718373574532504	0.801640172439298	38	2807	2573	576	2807	1990	46	166	161	RELA A549 (lung carcinoma) RELA	A549 (lung carcinoma)	BTO:0000018	RELA	Treatment: TNFa induction (12 hours);	GTRD	EXP054133_A549--lung-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	38662
1	1070	EGR2	0.071510213327364	0.82605977761968	67	2809	2427	68	2809	1770	77	137	130	EGR2 HEK293 (embryonic kidney) EGR2	HEK293 (embryonic kidney)	NULL	EGR2	NA	GTRD	EXP039511_HEK293--embryonic-kidney-_EGR2_MACS_EGR2_MA0472.2.damo.pwm.bed	60646
1	1020	E2F1	0.0710553132204021	0.782289206878163	28	2810	2675	1068	2810	2180	35	176	172	E2F1 Raji (Burkitt lymphoma) E2F1	Raji (Burkitt lymphoma)	BTO:0001154	E2F1	100 nM of JQ1	GTRD	EXP035851_Raji--Burkitt-lymphoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	6888
1	2346	JUN	0.0710553132204021	0.782289206878163	28	2810	2675	1068	2810	2180	35	176	172	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 20 minute	GTRD	EXP040320_A549--lung-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	22588
1	2704	MAX	0.0705925834072386	0.812539554353422	49	2812	2508	299	2812	1870	58	155	149	MAX HeLa (cervical adenocarcinoma) MAX	HeLa (cervical adenocarcinoma)	BTO:0000567	MAX		GTRD	EXP031874_HeLa--cervical-adenocarcinoma-_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	30007
1	3177	NRF1	0.0705925834072386	0.812539554353422	49	2812	2508	299	2812	1870	58	155	149	NRF1 K562 (myelogenous leukemia) NRF1	K562 (myelogenous leukemia)	NULL	NRF1		GTRD	EXP038536_K562--myelogenous-leukemia-_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	15661
1	905	CTCF	0.0705067316585773	0.798046981641521	37	2814	2592	607	2814	2000	45	167	162	CTCF osteoblasts CTCF	osteoblasts	NULL	CTCF	Treatment: None;	GTRD	EXP054042_osteoblasts_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	56480
1	1388	ESR1	0.0698259233008299	0.757204370662779	20	2815	2800	1606	2815	2410	26	184	181	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SIGATA_E2	GEO	GSE40129_esr1_mcf7-sigata-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	48903
1	2815	MYC	0.0698259233008299	0.757204370662779	20	2815	2800	1606	2815	2410	26	184	181	MYC FB8470 (fibroblasts) MYC	FB8470 (fibroblasts)	NULL	MYC	NULL	GTRD	EXP001024_FB8470--fibroblasts-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	7817
1	1003	DUX4	0.0695017302420215	0.729647296149332	14	2817	2903	2073	2903	2600	19	190	188	DUX4 induced pluripotent stem cells DUX4	induced pluripotent stem cells	NULL	DUX4	18hr dox-induction	GTRD	EXP038408_induced-pluripotent-stem-cells_DUX4_MACS_DUX4_MA0468.1.damo.pwm.bed	129116
1	1333	ESR1	0.0695017302420215	0.729647296149332	14	2817	2903	2073	2903	2600	19	190	188	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	H3B-6545	GTRD	EXP048579_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12463
1	1334	ESR1	0.0695017302420215	0.729647296149332	14	2817	2903	2073	2903	2600	19	190	188	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Saturated H3B-6545	GTRD	EXP048580_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	11302
1	1564	FOSL1	0.0695017302420215	0.729647296149332	14	2817	2903	2073	2903	2600	19	190	188	FOSL1 HCT-116 (colon carcinoma) FOSL1	HCT-116 (colon carcinoma)	BTO:0001109	FOSL1	NA	ENCODE	ENCSR000BTE_HCT116_FOSL1_MACS_FOSL1_MA0477.2.damo.pwm.bed	24568
1	1836	FOXA2	0.0695017302420215	0.729647296149332	14	2817	2903	2073	2903	2600	19	190	188	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL Genotype: CDT1 mimo FOXA2	GTRD	EXP049298_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	61484
1	1905	GATA1	0.0695017302420215	0.729647296149332	14	2817	2903	2073	2903	2600	19	190	188	GATA1 CD36+ erythroid cells GATA1	CD36+ erythroid cells	NULL	GATA1	BRG1 RNAi KD	GTRD	EXP000913_CD36--erythroid-cells_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	17101
1	2681	MAFK	0.0695017302420215	0.729647296149332	14	2817	2903	2073	2903	2600	19	190	188	MAFK HepG2 (hepatoblastoma) MAFK	HepG2 (hepatoblastoma)	BTO:0000599	MAFK	NA	ENCODE	ENCSR000EEB_HepG2_MAFK_MACS_MAFK_MA0496.3.damo.pwm.bed	79576
1	2713	MAX	0.0695017302420215	0.729647296149332	14	2817	2903	2073	2903	2600	19	190	188	MAX COLO-829 (melanoma) MAX	COLO-829 (melanoma)	NULL	MAX	Treatment: none	GTRD	EXP053272_COLO-829--melanoma-_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	8665
1	759	CTCF	0.0691761289543287	0.776652831027054	27	2825	2696	1135	2825	2220	34	177	173	CTCF tibial nerve CTCF	tibial nerve	NULL	CTCF		GTRD	EXP039994_tibial-nerve_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27462
1	785	CTCF	0.0691761289543287	0.776652831027054	27	2825	2696	1135	2825	2220	34	177	173	CTCF esophagus squamous epithelium CTCF	esophagus squamous epithelium	NULL	CTCF		GTRD	EXP040157_esophagus-squamous-epithelium_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30844
1	3002	NFE2L2	0.0691761289543287	0.776652831027054	27	2825	2696	1135	2825	2220	34	177	173	NFE2L2 A549 (lung carcinoma) NFE2L2	A549 (lung carcinoma)	BTO:0000018	NFE2L2	CellType: human lung adenocarcinoma epithelial A549 cells Genotype: wildtype	GTRD	EXP048467_A549--lung-carcinoma-_NFE2L2_MACS_NFE2L2_MA0150.2.damo.pwm.bed	13668
1	3740	STAT3	0.0691761289543287	0.776652831027054	27	2825	2696	1135	2825	2220	34	177	173	STAT3 NCI-H358 (human nnon small cell lung cancer cell line) STAT3	NCI-H358 (human nnon small cell lung cancer cell line)	BTO:0002835	STAT3		GTRD	EXP048895_NCI-H358--human-nnon-small-cell-lung-cancer-cell-line-_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	18073
1	2067	GRHL2	0.0691424888970006	0.794280482012645	36	2829	2610	645	2829	2030	44	168	163	GRHL2 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) GRHL2	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	GRHL2	Treatment: 45 min ethanol	GTRD	EXP048444_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	42494
1	2868	MYC	0.0691424888970006	0.794280482012645	36	2829	2610	645	2829	2030	44	168	163	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	0.2 µg/mL Tetracycline (Myc transgene repressed) for 72h and then released in fresh medium without Tetracycline for 1h	GTRD	EXP038951_P493-6--B-cell-lymphoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	12455
1	79	AR	0.0690239347147551	0.603716428909769	3	2831	3339	3316	3339	3160	5	201	202	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: Cells were harvested in log phase growth Genotype: HNF4G overexpression	GTRD	EXP048987_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	12596
1	88	AR	0.0690239347147551	0.603716428909769	3	2831	3339	3316	3339	3160	5	201	202	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: 10 nM DHT for 4 hrs Genotype: Bag-1L knockout and vector	GTRD	EXP049280_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	13819
1	106	AR	0.0690239347147551	0.603716428909769	3	2831	3339	3316	3339	3160	5	201	202	AR LNCaP95 AR	LNCaP95	NULL	AR	Treatment: 10nM DHT for 4 hrs Genotype: shARv7 transfection	GTRD	EXP052947_LNCaP95_AR_MACS_AR_MA0007.3.damo.pwm.bed	9986
1	270	BACH1	0.0690239347147551	0.603716428909769	3	2831	3339	3316	3339	3160	5	201	202	BACH1 BACH1	NA	NA	BACH1	NA	NA	ENCSR699TNT_HepG2_BACH1_MACS_BACH1_MA0591.1.damo.pwm.bed	6555
1	1158	ESR1	0.0690239347147551	0.603716428909769	3	2831	3339	3316	3339	3160	5	201	202	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	100nM bisphenol A (CHEBI:33216) for 30 minute	ENCODE	ENCSR000BQD_T47D_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12585
1	1237	ESR1	0.0690239347147551	0.603716428909769	3	2831	3339	3316	3339	3160	5	201	202	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	siNT	GTRD	EXP037656_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12363
1	2204	IRF2	0.0690239347147551	0.603716428909769	3	2831	3339	3316	3339	3160	5	201	202	IRF2 CD34+ hematopoietic stem cells-derived proerythroblasts IRF2	CD34+ hematopoietic stem cells-derived proerythroblasts	NULL	IRF2	adult bone marrow	GTRD	EXP031449_CD34--hematopoietic-stem-cells-derived-proerythroblasts_IRF2_MACS_IRF2_MA0051.1.damo.pwm.bed	2491
1	2738	MEF2B	0.0690239347147551	0.603716428909769	3	2831	3339	3316	3339	3160	5	201	202	MEF2B DOHH2 (diffuse large B-cell lymphoma) MEF2B	DOHH2 (diffuse large B-cell lymphoma)	NULL	MEF2B		GEO	GSE69558_mef2b_dohh2_MACS_MEF2B_MA0660.1.damo.pwm.bed	5836
1	2747	MEIS1	0.0690239347147551	0.603716428909769	3	2831	3339	3316	3339	3160	5	201	202	MEIS1 A-673 clone Asp114 (Ewing sarcoma) MEIS1	A-673 clone Asp114 (Ewing sarcoma)	NULL	MEIS1	NA	GTRD	EXP052992_A-673-clone-Asp114--Ewing-sarcoma-_MEIS1_MACS_MEIS1_MA1639.1.damo.pwm.bed	5237
1	2997	NFE2L2	0.0690239347147551	0.603716428909769	3	2831	3339	3316	3339	3160	5	201	202	NFE2L2 A549 (lung carcinoma) NFE2L2	A549 (lung carcinoma)	BTO:0000018	NFE2L2		ENCODE	ENCSR584GHV_A549_NFE2L2_MACS_NFE2L2_MA0150.2.damo.pwm.bed	9049
1	3131	NR3C1	0.0690239347147551	0.603716428909769	3	2831	3339	3316	3339	3160	5	201	202	NR3C1 MCF10A (breast epithelial cells) NR3C1	MCF10A (breast epithelial cells)	BTO:0001939	NR3C1	Treatment: dexamethasone (DEX) 60 min;	GTRD	EXP047629_MCF10A--breast-epithelial-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	4478
1	3157	NR3C1	0.0690239347147551	0.603716428909769	3	2831	3339	3316	3339	3160	5	201	202	NR3C1 NALM-6 (adult B acute lymphoblastic leukemia) NR3C1	NALM-6 (adult B acute lymphoblastic leukemia)	BTO:0003288	NR3C1		GEO	GSE67046_nr3c1_nalm6_MACS_NR3C1_MA0113.3.damo.pwm.bed	9753
1	3303	PRDM1	0.0690239347147551	0.603716428909769	3	2831	3339	3316	3339	3160	5	201	202	PRDM1 HUES64 (embryonic stem cells) PRDM1	HUES64 (embryonic stem cells)	NULL	PRDM1		GTRD	EXP036695_HUES64--embryonic-stem-cells-_PRDM1_MACS_PRDM1_MA0508.3.damo.pwm.bed	1935
1	3477	RUNX1	0.0690239347147551	0.603716428909769	3	2831	3339	3316	3339	3160	5	201	202	RUNX1 NALM-6 (adult B acute lymphoblastic leukemia) RUNX1	NALM-6 (adult B acute lymphoblastic leukemia)	BTO:0003288	RUNX1	Tissue: Peripheral blood	GTRD	EXP048188_NALM-6--adult-B-acute-lymphoblastic-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	2464
1	4062	TP73	0.0690239347147551	0.603716428909769	3	2831	3339	3316	3339	3160	5	201	202	TP73 TP73	NA	NA	TP73	NA	GEO	GSE15780_tp73_saos-rep1_MACS_TP73_MA0861.1.damo.pwm.bed	15365
1	417	CREB1	0.0677435803742722	0.790328758609416	35	2846	2619	691	2846	2050	43	169	164	CREB1 K562 (myelogenous leukemia) CREB1	K562 (myelogenous leukemia)	NULL	CREB1		ENCODE	ENCSR000BSO_K562_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	15694
1	2885	MYC	0.0677435803742722	0.790328758609416	35	2846	2619	691	2846	2050	43	169	164	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 1;	GTRD	EXP047488_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	10358
1	1638	FOXA1	0.0677192259186312	0.689380823862279	9	2848	3060	2564	3060	2820	13	195	194	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	TAMR_E2_TAM	Array Express	ERP000380_foxa1_mcf7tamr-e2-tam_MACS_FOXA1_MA0148.4.damo.pwm.bed	35675
1	3107	NR3C1	0.0677192259186312	0.689380823862279	9	2848	3060	2564	3060	2820	13	195	194	NR3C1 MCF7 (Invasive ductal breast carcinoma) NR3C1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NR3C1	ICI, DEX, pBox mutant	GTRD	EXP037452_MCF7--Invasive-ductal-breast-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	17964
1	3505	RUNX2	0.0677192259186312	0.689380823862279	9	2848	3060	2564	3060	2820	13	195	194	RUNX2 SaOS2 (osteosarcoma) RUNX2	SaOS2 (osteosarcoma)	BTO:0000971	RUNX2		GTRD	EXP037204_SaOS2--osteosarcoma-_RUNX2_MACS_RUNX2_MA0511.2.damo.pwm.bed	10625
1	3583	SNAI2	0.0677192259186312	0.689380823862279	9	2848	3060	2564	3060	2820	13	195	194	SNAI2 keratinocytes SNAI2	keratinocytes	NULL	SNAI2	SHCTR	GEO	GSE55421_snai2_keratinocytes-shctr_MACS_SNAI2_MA0745.2.damo.pwm.bed	6578
1	23	AR	0.0672398609702843	0.770665833002541	26	2852	2724	1204	2852	2260	33	178	174	AR VCS2 (prostate carcinoma) AR	VCS2 (prostate carcinoma)	NULL	AR	DHT for 4h	GTRD	EXP031107_VCS2--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	43041
1	1159	ESR1	0.0672398609702843	0.770665833002541	26	2852	2724	1204	2852	2260	33	178	174	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	Array Express	ERP000209_esr1_mcf7-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	54951
1	1801	FOXA1	0.0672398609702843	0.770665833002541	26	2852	2724	1204	2852	2260	33	178	174	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	DEX	GEO	GSE72249_foxa1_mcf7-dex_MACS_FOXA1_MA0148.4.damo.pwm.bed	49909
1	2240	JUN	0.0672398609702843	0.770665833002541	26	2852	2724	1204	2852	2260	33	178	174	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN	NULL	GTRD	EXP000309_K562--myelogenous-leukemia-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	28343
1	2586	JUND	0.0672398609702843	0.770665833002541	26	2852	2724	1204	2852	2260	33	178	174	JUND WA01 (H1, human embryonic stem cells) JUND	WA01 (H1, human embryonic stem cells)	NULL	JUND		ENCODE	ENCSR000BKP_H1-hESC_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	10405
1	1329	ESR1	0.0671549779442571	0.748206666608194	19	2857	2840	1697	2857	2460	25	185	182	ESR1 MDA-MB-134 (invasive lobular breast carcinoma) ESR1	MDA-MB-134 (invasive lobular breast carcinoma)	NULL	ESR1	Treatment: 100 nM estradiol (E2) for 1hr Passage: between 10 and12 CellType: Epithelial ERalpha positive breast cancer cell line	GTRD	EXP048178_MDA-MB-134--invasive-lobular-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	37017
1	1628	FOSL2	0.0671549779442571	0.748206666608194	19	2857	2840	1697	2857	2460	25	185	182	FOSL2 hESC-1 (Embryonic stem cells) FOSL2	hESC-1 (Embryonic stem cells)	NULL	FOSL2		GEO	GSE69539_fosl2_hesc_MACS_FOSL2_MA0478.1.damo.pwm.bed	32898
1	3894	TFAP2C	0.0671549779442571	0.748206666608194	19	2857	2840	1697	2857	2460	25	185	182	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p28; CellType: Prime UCLA1 hESSCs;	GTRD	EXP047539_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	8863
1	1461	ETS1	0.0666373618897017	0.802321485127416	45	2860	2567	383	2860	1940	54	159	153	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1	VEGF stimulation for 4hours	GTRD	EXP038276_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	25252
1	446	CTCF	0.0663089193629463	0.786178756938489	34	2861	2637	729	2861	2080	42	170	165	CTCF osteoblasts CTCF	osteoblasts	NULL	CTCF		ENCODE	ENCSR000APF_osteoblast_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	52957
1	676	CTCF	0.0663089193629463	0.786178756938489	34	2861	2637	729	2861	2080	42	170	165	CTCF heart left ventricle CTCF	heart left ventricle	NULL	CTCF		GTRD	EXP039370_heart-left-ventricle_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35343
1	2943	MYCN	0.0663089193629463	0.786178756938489	34	2861	2637	729	2861	2080	42	170	165	MYCN IMR-5 (Neuroblastoma) MYCN	IMR-5 (Neuroblastoma)	NULL	MYCN	Treatment: DMSO for 4 hr	GTRD	EXP048884_IMR-5--Neuroblastoma-_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	12027
1	966	CTCF	0.0657046280121415	0.812462569595612	58	2864	2510	154	2864	1840	68	146	139	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF	EMB	GEO	GSE52457_ctcf_h1-emb_MACS_CTCF_MA0139.1.damo.pwm.bed	96285
1	1798	FOXA1	0.065667987744036	0.715244346300701	13	2865	2970	2153	2970	2660	18	191	189	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	R1881	GEO	GSE69043_foxa1_lncap-r1881_MACS_FOXA1_MA0148.4.damo.pwm.bed	50537
1	2061	GRHL2	0.065667987744036	0.715244346300701	13	2865	2970	2153	2970	2660	18	191	189	GRHL2 MCF7 (Invasive ductal breast carcinoma) GRHL2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GRHL2	control	GTRD	EXP040964_MCF7--Invasive-ductal-breast-carcinoma-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	18648
1	3169	NRF1	0.065667987744036	0.715244346300701	13	2865	2970	2153	2970	2660	18	191	189	NRF1 HeLa S3 (cervical adenocarcinoma) NRF1	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	NRF1		ENCODE	ENCSR000EDJ_HeLa-S3_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	2695
1	4068	USF1	0.065667987744036	0.715244346300701	13	2865	2970	2153	2970	2660	18	191	189	USF1 GM12878 (female B-cells lymphoblastoid cell line) USF1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	USF1		ENCODE	ENCSR000BGI_GM12878_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	8568
1	1155	ESR1	0.0652441470342575	0.764295481685935	25	2869	2755	1262	2869	2300	32	179	175	ESR1 Ishikawa (endometrial adenocarcinoma) ESR1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	ESR1	1 h with 100 nM Genistein (Myers)	ENCODE	ENCSR000BKL_Ishikawa_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	25936
1	3895	TFAP2C	0.0643797210641637	0.738450773165298	18	2870	2871	1785	2871	2510	24	186	183	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p28; CellType: Prime UCLA1 hESSCs;	GTRD	EXP047539_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	8438
1	1128	ERG	0.0642418657647656	0.808776794395003	56	2871	2514	192	2871	1860	66	148	141	ERG Kasumi-1 (acute myeloblastic leukemia) ERG	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	ERG		GTRD	EXP037192_Kasumi-1--acute-myeloblastic-leukemia-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	47151
1	1879	GABPA	0.0634259007272067	0.79347980646296	42	2872	2612	454	2872	1980	51	162	156	GABPA CUTLL1 (T-cell lymphoblastic lymphoma 1) GABPA	CUTLL1 (T-cell lymphoblastic lymphoma 1)	NULL	GABPA	vehicle	GTRD	EXP032405_CUTLL1--T-cell-lymphoblastic-lymphoma-1-_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	60147
1	2799	MYC	0.0634259007272067	0.79347980646296	42	2872	2612	454	2872	1980	51	162	156	MYC GM12878 (female B-cells lymphoblastoid cell line) MYC	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MYC	NULL	GTRD	EXP000439_GM12878--female-B-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	21677
1	2809	MYC	0.0633278073804107	0.777225148805757	32	2874	2694	825	2874	2130	40	172	167	MYC HepG2 (hepatoblastoma) MYC	HepG2 (hepatoblastoma)	BTO:0000599	MYC	NULL	GTRD	EXP000993_HepG2--hepatoblastoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	10732
1	3180	NRF1	0.0633278073804107	0.777225148805757	32	2874	2694	825	2874	2130	40	172	167	NRF1 HepG2 (hepatoblastoma) NRF1	HepG2 (hepatoblastoma)	BTO:0000599	NRF1		GTRD	EXP038544_HepG2--hepatoblastoma-_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	8596
1	1572	FOSL2	0.0631865352556263	0.757504816902756	24	2876	2797	1324	2876	2330	31	180	176	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BQO_A549_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	31860
1	206	AR	0.0631538429015599	0.625707488117328	5	2877	3278	3053	3278	3070	8	199	199	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	SH2_DHT	GEO	GSE79128_AR_vcap-sh2-dht_MACS_AR_MA0007.3.damo.pwm.bed	23313
1	208	AR	0.0631538429015599	0.625707488117328	5	2877	3278	3053	3278	3070	8	199	199	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	SH3_DHT	GEO	GSE79128_AR_vcap-sh3-dht_MACS_AR_MA0007.3.damo.pwm.bed	14273
1	222	ARNT	0.0631538429015599	0.625707488117328	5	2877	3278	3053	3278	3070	8	199	199	ARNT GM12878 (female B-cells lymphoblastoid cell line) ARNT	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ARNT		GTRD	EXP040302_GM12878--female-B-cells-_ARNT_MACS_ARNT_MA0259.1.damo.pwm.bed	3445
1	583	CTCF	0.0631538429015599	0.625707488117328	5	2877	3278	3053	3278	3070	8	199	199	CTCF CD34+ hematopoietic stem cells CTCF	CD34+ hematopoietic stem cells	NULL	CTCF		GTRD	EXP000908_CD34--hematopoietic-stem-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	9873
1	933	CTCF	0.0631538429015599	0.625707488117328	5	2877	3278	3053	3278	3070	8	199	199	CTCF hESC-1 (Embryonic stem cells) CTCF	hESC-1 (Embryonic stem cells)	NULL	CTCF		GEO	GSE20650_ctcf_esc_MACS_CTCF_MA0139.1.damo.pwm.bed	17383
1	1753	FOXA1	0.0631538429015599	0.625707488117328	5	2877	3278	3053	3278	3070	8	199	199	FOXA1 22RV1 (prostate carcinoma) FOXA1	22RV1 (prostate carcinoma)	BTO:0002999	FOXA1	Treatment: ethanol (Vehicle) treatment for 24 hrs;	GTRD	EXP058394_22RV1--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	27821
1	2032	GATA6	0.0631538429015599	0.625707488117328	5	2877	3278	3053	3278	3070	8	199	199	GATA6 WA01 (H1, human embryonic stem cells) GATA6	WA01 (H1, human embryonic stem cells)	NULL	GATA6		GTRD	EXP037214_WA01--H1--human-embryonic-stem-cells-_GATA6_MACS_GATA6_MA1104.2.damo.pwm.bed	70384
1	2522	JUNB	0.0631538429015599	0.625707488117328	5	2877	3278	3053	3278	3070	8	199	199	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB		GTRD	EXP039779_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	11162
1	2523	JUNB	0.0631538429015599	0.625707488117328	5	2877	3278	3053	3278	3070	8	199	199	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB		GTRD	EXP039779_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	11340
1	2524	JUNB	0.0631538429015599	0.625707488117328	5	2877	3278	3053	3278	3070	8	199	199	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB		GTRD	EXP039779_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	11498
1	2525	JUNB	0.0631538429015599	0.625707488117328	5	2877	3278	3053	3278	3070	8	199	199	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB		GTRD	EXP039779_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	11065
1	2526	JUNB	0.0631538429015599	0.625707488117328	5	2877	3278	3053	3278	3070	8	199	199	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB		GTRD	EXP039779_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	11341
1	2527	JUNB	0.0631538429015599	0.625707488117328	5	2877	3278	3053	3278	3070	8	199	199	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB		GTRD	EXP039779_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	11538
1	3365	RELA	0.0631538429015599	0.625707488117328	5	2877	3278	3053	3278	3070	8	199	199	RELA Detroit 562 (Pharyngeal squamous cell carcinoma) RELA	Detroit 562 (Pharyngeal squamous cell carcinoma)	BTO:0000834	RELA	treatment: TNFalfa	GTRD	EXP049364_Detroit-562--Pharyngeal-squamous-cell-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	11711
1	3566	SMAD3	0.0631538429015599	0.625707488117328	5	2877	3278	3053	3278	3070	8	199	199	SMAD3 HMLE-Twist-ER (breast cancer) SMAD3	HMLE-Twist-ER (breast cancer)	NULL	SMAD3	Treatment: TGF-beta CellType: Immortalized human mammary epithelial cells	GTRD	EXP047891_HMLE-Twist-ER--breast-cancer-_SMAD3_MACS_SMAD3_MA1622.1.damo.pwm.bed	7624
1	3820	TCF7L2	0.0631538429015599	0.625707488117328	5	2877	3278	3053	3278	3070	8	199	199	TCF7L2 CD34+ cells TCF7L2	CD34+ cells	NULL	TCF7L2	PROG_BIO	GEO	GSE29194_tcf7l2_CD34-prog-bio_MACS_TCF7L2_MA0523.1.damo.pwm.bed	7006
1	516	CTCF	0.0623057639422894	0.790273460201764	41	2893	2621	476	2893	2000	50	163	157	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DTA_brain_microvascular_endothelial_cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	59572
1	3847	TFAP2A	0.0621646696460061	0.814185592553747	71	2894	2496	39	2894	1810	82	133	125	TFAP2A H9-derived neural crest cells TFAP2A	H9-derived neural crest cells	NULL	TFAP2A		GTRD	EXP030996_H9-derived-neural-crest-cells_TFAP2A_MACS_TFAP2A_MA0003.4.damo.pwm.bed	54607
1	2819	MYC	0.0619211079505191	0.802705254367062	53	2895	2566	236	2895	1900	63	151	144	MYC HeLa (cervical adenocarcinoma) MYC	HeLa (cervical adenocarcinoma)	BTO:0000567	MYC		GTRD	EXP031873_HeLa--cervical-adenocarcinoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	30768
1	58	AR	0.0618357688774275	0.663924923513696	8	2896	3157	2697	3157	2920	12	196	195	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	R1881+Doxycycline	GTRD	EXP037067_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	55308
1	100	AR	0.0618357688774275	0.663924923513696	8	2896	3157	2697	3157	2920	12	196	195	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: treated with 10nM  R1881 for 4 hours	GTRD	EXP049574_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	27020
1	113	AR	0.0618357688774275	0.663924923513696	8	2896	3157	2697	3157	2920	12	196	195	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment:  transfected twice with with 5nM of siControl every 24 hours, 100nM of DHT for 2 hrs	GTRD	EXP052982_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	28285
1	1825	FOXA2	0.0618357688774275	0.663924923513696	8	2896	3157	2697	3157	2920	12	196	195	FOXA2 endometrioid adenocarcinoma FOXA2	endometrioid adenocarcinoma	NULL	FOXA2	tumor E	GTRD	EXP036414_endometrioid-adenocarcinoma_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	8621
1	2295	JUN	0.0618357688774275	0.663924923513696	8	2896	3157	2697	3157	2920	12	196	195	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	oxpapc, 4h	GTRD	EXP038044_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	10467
1	2297	JUN	0.0618357688774275	0.663924923513696	8	2896	3157	2697	3157	2920	12	196	195	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	oxpapc, 4h	GTRD	EXP038044_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	10992
1	2507	JUNB	0.0618357688774275	0.663924923513696	8	2896	3157	2697	3157	2920	12	196	195	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039614_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	12233
1	2508	JUNB	0.0618357688774275	0.663924923513696	8	2896	3157	2697	3157	2920	12	196	195	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039614_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	12976
1	2509	JUNB	0.0618357688774275	0.663924923513696	8	2896	3157	2697	3157	2920	12	196	195	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039614_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	12847
1	2510	JUNB	0.0618357688774275	0.663924923513696	8	2896	3157	2697	3157	2920	12	196	195	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039614_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	12655
1	2511	JUNB	0.0618357688774275	0.663924923513696	8	2896	3157	2697	3157	2920	12	196	195	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039614_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	12398
1	2512	JUNB	0.0618357688774275	0.663924923513696	8	2896	3157	2697	3157	2920	12	196	195	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039614_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	12656
1	2993	NFE2	0.0618357688774275	0.663924923513696	8	2896	3157	2697	3157	2920	12	196	195	NFE2 K562 (myelogenous leukemia) NFE2	K562 (myelogenous leukemia)	NULL	NFE2		GTRD	EXP040018_K562--myelogenous-leukemia-_NFE2_MACS_NFE2_MA0841.1.damo.pwm.bed	23710
1	3021	NFKB1	0.0618357688774275	0.663924923513696	8	2896	3157	2697	3157	2920	12	196	195	NFKB1 MCF10A-ER-Src NFKB1	MCF10A-ER-Src	NULL	NFKB1	Genotype: non-transformed	GTRD	EXP048573_MCF10A-ER-Src_NFKB1_MACS_NFKB1_MA0105.4.damo.pwm.bed	8653
1	4084	USF2	0.0618357688774275	0.663924923513696	8	2896	3157	2697	3157	2920	12	196	195	USF2 K562 (myelogenous leukemia) USF2	K562 (myelogenous leukemia)	NULL	USF2		ENCODE	ENCSR359NFW_K562_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	7357
1	738	CTCF	0.061779001725402	0.772388377488756	31	2911	2719	881	2911	2170	39	173	168	CTCF uterus CTCF	uterus	BTO:0001424	CTCF		GTRD	EXP039781_uterus_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	28074
1	1883	GABPA	0.061779001725402	0.772388377488756	31	2911	2719	881	2911	2170	39	173	168	GABPA GM12878 (female B-cells lymphoblastoid cell line) GABPA	GM12878 (female B-cells lymphoblastoid cell line)	NULL	GABPA		GTRD	EXP054610_GM12878--female-B-cells-lymphoblastoid-cell-line-_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	8469
1	2695	MAX	0.061779001725402	0.772388377488756	31	2911	2719	881	2911	2170	39	173	168	MAX A549 (lung carcinoma) MAX	A549 (lung carcinoma)	BTO:0000018	MAX		ENCODE	ENCSR000DYG_A549_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	11896
1	197	AR	0.0616302761320459	0.699139076907021	12	2914	3026	2233	3026	2720	17	192	190	AR AR	NA	NA	AR	NA	GEO	GSE71704_AR_c42-shpsa_MACS_AR_MA0007.3.damo.pwm.bed	14077
1	1257	ESR1	0.0616302761320459	0.699139076907021	12	2914	3026	2233	3026	2720	17	192	190	ESR1 endometrioid adenocarcinoma ESR1	endometrioid adenocarcinoma	NULL	ESR1		GTRD	EXP038352_endometrioid-adenocarcinoma_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	21233
1	1733	FOXA1	0.0616302761320459	0.699139076907021	12	2914	3026	2233	3026	2720	17	192	190	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	siOCT1	GTRD	EXP051010_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	37046
1	2686	MAFK	0.0616302761320459	0.699139076907021	12	2914	3026	2233	3026	2720	17	192	190	MAFK OCI-LY7 (diffuse large B-cell lymphoma) MAFK	OCI-LY7 (diffuse large B-cell lymphoma)	NULL	MAFK	NA	GEO	GSE47784_mafk_ocily7_MACS_MAFK_MA0496.3.damo.pwm.bed	14919
1	3479	RUNX1	0.0616302761320459	0.699139076907021	12	2914	3026	2233	3026	2720	17	192	190	RUNX1 pre-B-lymphoblast cells with BCP-ALL RUNX1	pre-B-lymphoblast cells with BCP-ALL	NULL	RUNX1	DIsease: human precursor leukemia (BCP-ALL) Tissue: bone marrow	GTRD	EXP048190_pre-B-lymphoblast-cells-with-BCP-ALL_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	12128
1	3939	TFAP4	0.0616302761320459	0.699139076907021	12	2914	3026	2233	3026	2720	17	192	190	TFAP4 Kasumi-1 (acute myeloblastic leukemia) TFAP4	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	TFAP4	NA	GEO	GSE45738_tfap4_kasumi1_MACS_TFAP4_MA0691.1.damo.pwm.bed	12054
1	3823	TEAD1	0.0614944272722556	0.727837875132703	17	2920	2912	1846	2920	2560	23	187	184	TEAD1 pancreas TEAD1	pancreas	BTO:0000988	TEAD1	12D	Array Express	ERP008682_tead1_pancreas-12d_MACS_TEAD1_MA0090.3.damo.pwm.bed	19019
1	2343	JUN	0.0611598114646263	0.786924691175329	40	2921	2633	502	2921	2020	49	164	158	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN		GTRD	EXP040265_A549--lung-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	19783
1	3859	TFAP2A	0.0611598114646263	0.786924691175329	40	2921	2633	502	2921	2020	49	164	158	TFAP2A WA09 (embryonic stem cells) TFAP2A	WA09 (embryonic stem cells)	NULL	TFAP2A	BMP4 for 3 day	GTRD	EXP040709_WA09--embryonic-stem-cells-_TFAP2A_MACS_TFAP2A_MA0003.4.damo.pwm.bed	31419
1	1888	GABPA	0.0611126132578234	0.800523739189902	52	2923	2575	244	2923	1910	62	152	145	GABPA VCaP (prostate carcinoma) GABPA	VCaP (prostate carcinoma)	BTO:0003215	GABPA	R1881	GEO	GSE49091_gabpa_vcap-r1881_MACS_GABPA_MA0062.3.damo.pwm.bed	37450
1	727	CTCF	0.0610644930431959	0.750251944258018	23	2924	2833	1391	2924	2380	30	181	177	CTCF transverse colon CTCF	transverse colon	NULL	CTCF		GTRD	EXP039699_transverse-colon_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30696
1	2920	MYC	0.0610644930431959	0.750251944258018	23	2924	2833	1391	2924	2380	30	181	177	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC		GEO	GSE42262_myc_p4936_MACS_MYC_MA0147.3.damo.pwm.bed	5797
1	3573	SMAD3	0.0610644930431959	0.750251944258018	23	2924	2833	1391	2924	2380	30	181	177	SMAD3 HCC1954 (ductal breast carcinoma) SMAD3	HCC1954 (ductal breast carcinoma)	BTO:0005368	SMAD3	Treatment: no CellType: Immortalized human mammary epithelial cells	GTRD	EXP047902_HCC1954--ductal-breast-carcinoma-_SMAD3_MACS_SMAD3_MA1622.1.damo.pwm.bed	31708
1	2226	JUN	0.0599874257983545	0.783424808595551	39	2927	2670	547	2927	2050	48	165	159	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN		ENCODE	ENCSR000EFS_K562_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	28874
1	2831	MYC	0.0599874257983545	0.783424808595551	39	2927	2670	547	2927	2050	48	165	159	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	HA-OmoMYCwt	GTRD	EXP036033_U2OS--osteosarcoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	12707
1	3787	TCF3	0.0596034044225251	0.807878990900395	66	2929	2535	78	2929	1850	77	138	130	TCF3 GM12878 (female B-cells lymphoblastoid cell line) TCF3	GM12878 (female B-cells lymphoblastoid cell line)	NULL	TCF3		ENCODE	ENCSR000BQT_GM12878_TCF3_MACS_TCF3_MA0522.3.damo.pwm.bed	46865
1	3867	TFAP2A	0.0594414429226961	0.795902183580869	50	2930	2607	275	2930	1940	60	154	147	TFAP2A MCF7 (Invasive ductal breast carcinoma) TFAP2A	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2A	E2	GEO	GSE60270_tfap2a_mcf7-e2_MACS_TFAP2A_MA0003.4.damo.pwm.bed	29544
1	3868	TFAP2A	0.0594414429226961	0.795902183580869	50	2930	2607	275	2930	1940	60	154	147	TFAP2A MCF7 (Invasive ductal breast carcinoma) TFAP2A	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2A	E2	GEO	GSE60270_tfap2a_mcf7-e2_MACS_TFAP2A_MA0810.1.damo.pwm.bed	29396
1	1471	ETS1	0.0590517329500044	0.806467673431569	65	2932	2536	89	2932	1850	76	139	131	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1	VEGF_4H	GEO	GSE41166_ets1_huvec-vegf-4h_MACS_ETS1_MA0098.3.damo.pwm.bed	36028
1	2718	MAX	0.0590517329500044	0.806467673431569	65	2932	2536	89	2932	1850	76	139	131	MAX U-87MG MAX	U-87MG	NA	MAX		GEO	GSE36354_max_u87mg_MACS_MAX_MA0058.3.damo.pwm.bed	54709
1	248	ATF3	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	ATF3 HCT-116 (colon carcinoma) ATF3	HCT-116 (colon carcinoma)	BTO:0001109	ATF3		ENCODE	ENCSR000BUG_HCT116_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	2398
1	268	BACH1	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	BACH1 BACH1	NA	NA	BACH1	NA	NA	ENCSR043EHG_A549_BACH1_MACS_BACH1_MA0591.1.damo.pwm.bed	4232
1	281	BATF3	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	BATF3 GM12878 (female B-cells lymphoblastoid cell line) BATF3	GM12878 (female B-cells lymphoblastoid cell line)	NULL	BATF3		GTRD	EXP038551_GM12878--female-B-cells-_BATF3_MACS_BATF3_MA0835.2.damo.pwm.bed	8257
1	284	BCL6	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	BCL6 OCI-LY1 (diffuse large B-cell lymphoma) BCL6	OCI-LY1 (diffuse large B-cell lymphoma)	NULL	BCL6		GTRD	EXP040595_OCI-LY1--diffuse-large-B-cell-lymphoma-_BCL6_MACS_BCL6_MA0463.2.damo.pwm.bed	618
1	428	CREB1	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	CREB1 KG1 (acute myeloid leukemia) CREB1	KG1 (acute myeloid leukemia)	BTO:0000670	CREB1	DMSO	GEO	GSE74928_CREB1_kg1-dmso_MACS_CREB1_MA0018.4.damo.pwm.bed	282
1	998	CUX1	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	CUX1 K562 (myelogenous leukemia) CUX1	K562 (myelogenous leukemia)	NULL	CUX1	NA	GTRD	EXP038271_K562--myelogenous-leukemia-_CUX1_MACS_CUX1_MA0754.1.damo.pwm.bed	1318
1	1000	CUX1	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	CUX1 K562 (myelogenous leukemia) CUX1	K562 (myelogenous leukemia)	NULL	CUX1	NA	GTRD	EXP038273_K562--myelogenous-leukemia-_CUX1_MACS_CUX1_MA0754.1.damo.pwm.bed	1663
1	1179	ESR1	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	hormone starved for 3 days, treated with 1% ethanol for 45 minutes	GTRD	EXP000177_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	437
1	1188	ESR1	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	ESR1 ECC-1 (endometrial adenocarcinoma) ESR1	ECC-1 (endometrial adenocarcinoma)	BTO:0005365	ESR1	E2	GTRD	EXP000888_ECC-1--endometrial-adenocarcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	2084
1	1296	ESR1	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	100 nM ICI for 30 min	GTRD	EXP040889_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	4537
1	1406	ESR1	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2_JQ1	GEO	GSE55921_esr1_mcf7-e2-jq1_MACS_ESR1_MA0112.3.damo.pwm.bed	2603
1	1424	ESR1	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1		GEO	GSE68355_ESR1_t47d_MACS_ESR1_MA0112.3.damo.pwm.bed	3626
1	1717	FOXA1	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	FOXA1 prostate tumor FOXA1	prostate tumor	NULL	FOXA1	Patient: #2	GTRD	EXP048495_prostate-tumor_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	780
1	1861	FOXP1	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	FOXP1 HT (diffuse large B-cell lymphoma) FOXP1	HT (diffuse large B-cell lymphoma)	NULL	FOXP1	NA	GTRD	EXP034308_HT--diffuse-large-B-cell-lymphoma-_FOXP1_MACS_FOXP1_MA0481.3.damo.pwm.bed	2544
1	1910	GATA1	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	bmp	GTRD	EXP000940_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	17526
1	1911	GATA1	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	bmp	GTRD	EXP000940_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	18842
1	1967	GATA3	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3	ICI	GTRD	EXP037455_MCF7--Invasive-ductal-breast-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	7363
1	2083	HIF1A	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	HIF1A HKC8 (kidney proximal tubule cell line) HIF1A	HKC8 (kidney proximal tubule cell line)	NULL	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 16 hours, HIF2a knockout	GTRD	EXP048721_HKC8--kidney-proximal-tubule-cell-line-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	739
1	2084	HIF1A	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	HIF1A HKC8 (kidney proximal tubule cell line) HIF1A	HKC8 (kidney proximal tubule cell line)	NULL	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 16 hours, HIF2a knockout	GTRD	EXP048721_HKC8--kidney-proximal-tubule-cell-line-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	553
1	2188	HSF1	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	HSF1 NCI-H441 (squamous cell lung carcinoma ) HSF1	NCI-H441 (squamous cell lung carcinoma )	BTO:0001910	HSF1		GEO	GSE38901_hsf1_ncih441_MACS_HSF1_MA0486.2.damo.pwm.bed	861
1	2633	KLF4	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	KLF4 U87 (glioblastoma) KLF4	U87 (glioblastoma)	NULL	KLF4		GTRD	EXP038480_U87--glioblastoma-_KLF4_MACS_KLF4_MA0039.4.damo.pwm.bed	314
1	2728	MEF2B	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	MEF2B SU-DHL-10 (diffuse large B-cell lymphoma) MEF2B	SU-DHL-10 (diffuse large B-cell lymphoma)	NULL	MEF2B	Genotype: wiltype MEF2B with Flag and HA	GTRD	EXP048300_SU-DHL-10--diffuse-large-B-cell-lymphoma-_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	3984
1	3099	NR3C1	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	NR3C1 MDA-MB-231 (breast adenocarcinoma) NR3C1	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	NR3C1	dexametasone	GTRD	EXP033449_MDA-MB-231--breast-adenocarcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	1353
1	3156	NR3C1	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	NR3C1 NALM-6 (adult B acute lymphoblastic leukemia) NR3C1	NALM-6 (adult B acute lymphoblastic leukemia)	BTO:0003288	NR3C1	CASP1	GEO	GSE67046_nr3c1_nalm6-casp1_MACS_NR3C1_MA0113.3.damo.pwm.bed	3298
1	3219	PAX5	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	PAX5 DOHH2 (diffuse large B-cell lymphoma) PAX5	DOHH2 (diffuse large B-cell lymphoma)	NULL	PAX5		GEO	GSE69558_pax5_dohh2_MACS_PAX5_MA0014.3.damo.pwm.bed	787
1	3272	POU5F1	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	POU5F1 MRC-5 (fetal lung fibroblasts) POU5F1	MRC-5 (fetal lung fibroblasts)	BTO:0001590	POU5F1	Treatment: Oct4, Sox2-VP16 (strong activator), Klf4 and Myc addition for 5 days Passage: 8	GTRD	EXP048952_MRC-5--fetal-lung-fibroblasts-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	2519
1	3394	REST	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	REST HepG2 (hepatoblastoma) REST	HepG2 (hepatoblastoma)	BTO:0000599	REST		ENCODE	ENCSR000BJL_HepG2_REST_MACS_REST_MA0138.2.damo.pwm.bed	4247
1	3407	REST	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	REST HCT-116 (colon carcinoma) REST	HCT-116 (colon carcinoma)	BTO:0001109	REST		ENCODE	ENCSR000BVI_HCT116_REST_MACS_REST_MA0138.2.damo.pwm.bed	3918
1	3425	REST	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	REST GM12878 (female B-cells lymphoblastoid cell line) REST	GM12878 (female B-cells lymphoblastoid cell line)	NULL	REST		GTRD	EXP054614_GM12878--female-B-cells-lymphoblastoid-cell-line-_REST_MACS_REST_MA0138.2.damo.pwm.bed	3804
1	3444	RFX5	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	RFX5 WA01 (H1, human embryonic stem cells) RFX5	WA01 (H1, human embryonic stem cells)	NULL	RFX5	NA	ENCODE	ENCSR000ECF_H1-hESC_RFX5_MACS_RFX5_MA0510.2.damo.pwm.bed	1046
1	3611	SOX2	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	SOX2 H9 SOX2	H9	NULL	SOX2		GEO	GSE46837_sox2_h9_MACS_SOX2_MA0143.4.damo.pwm.bed	2116
1	3617	SOX2	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	SOX2 hiPSC SOX2	hiPSC	NULL	SOX2	INHI	GEO	GSE67282_sox2_ipsc-inhi_MACS_SOX2_MA0143.4.damo.pwm.bed	2039
1	3692	SPI1	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	SPI1 K562 (myelogenous leukemia) SPI1	K562 (myelogenous leukemia)	NULL	SPI1		GEO	GSE74999_spi1_k562_MACS_SPI1_MA0080.5.damo.pwm.bed	1808
1	3819	TCF7L2	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	TCF7L2 HUES64 (embryonic stem cells) TCF7L2	HUES64 (embryonic stem cells)	NULL	TCF7L2		GTRD	EXP036768_HUES64--embryonic-stem-cells-_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	1729
1	3957	TP53	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	TP53 BJ (fibroblasts) TP53	BJ (fibroblasts)	NULL	TP53	ionizing radiation	GTRD	EXP032954_BJ--fibroblasts-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	1723
1	3960	TP53	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	irradiation 2.5h	GTRD	EXP036826_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	5089
1	4020	TP53	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	TP53 HCT-116 (colon carcinoma) TP53	HCT-116 (colon carcinoma)	BTO:0001109	TP53	5FU	GEO	GSE58506_tp53_hct166-5fu_MACS_TP53_MA0106.3.damo.pwm.bed	2600
1	4026	TP53	0.0589041641848882	0.505737014972263	1	2934	3531	3655	3655	3370	2	203	205	TP53 HCT-116 (colon carcinoma) TP53	HCT-116 (colon carcinoma)	BTO:0001109	TP53	DMSO_KOATF3	GEO	GSE74355_tp53_htc116-dmso-koatf3_MACS_TP53_MA0106.3.damo.pwm.bed	821
1	2483	JUNB	0.0588754213196413	0.742489183970171	22	2972	2865	1459	2972	2430	29	182	178	JUNB HAEC (human aortic endothelial cells) JUNB	HAEC (human aortic endothelial cells)	NULL	JUNB	control, 4h	GTRD	EXP038040_HAEC--human-aortic-endothelial-cells-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	30987
1	3664	SPI1	0.0588754213196413	0.742489183970171	22	2972	2865	1459	2972	2430	29	182	178	SPI1 THP-1 (acute monocytic leukemia) SPI1	THP-1 (acute monocytic leukemia)	BTO:0001370	SPI1	Treatment: 250nM OG86 for 24 hr in RPMI with 10% fetal bovine serum	GTRD	EXP048338_THP-1--acute-monocytic-leukemia-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	70105
1	2830	MYC	0.058787975444821	0.779764376478866	38	2974	2689	576	2974	2080	47	166	160	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	HA-OmoMYCwt	GTRD	EXP036033_U2OS--osteosarcoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	12066
1	2852	MYC	0.058787975444821	0.779764376478866	38	2974	2689	576	2974	2080	47	166	160	MYC GEN2.2 (blastic plasmacytoid dendritic cell neoplasm) MYC	GEN2.2 (blastic plasmacytoid dendritic cell neoplasm)	NULL	MYC		GTRD	EXP036998_GEN2.2--blastic-plasmacytoid-dendritic-cell-neoplasm-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	12400
1	3181	NRF1	0.058787975444821	0.779764376478866	38	2974	2689	576	2974	2080	47	166	160	NRF1 MCF7 (Invasive ductal breast carcinoma) NRF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NRF1		GTRD	EXP038568_MCF7--Invasive-ductal-breast-carcinoma-_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	10163
1	1555	FOS	0.0585587671591217	0.761898503562447	29	2977	2763	1013	2977	2250	37	175	170	FOS MCF10A-ER-Src FOS	MCF10A-ER-Src	NULL	FOS	Genotype: non-transformed	GTRD	EXP048567_MCF10A-ER-Src_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	70735
1	2844	MYC	0.0585587671591217	0.761898503562447	29	2977	2763	1013	2977	2250	37	175	170	MYC HUES64 (embryonic stem cells) MYC	HUES64 (embryonic stem cells)	NULL	MYC		GTRD	EXP036776_HUES64--embryonic-stem-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	8593
1	1065	EGR1	0.0584931726309131	0.716251175593059	16	2979	2963	1909	2979	2620	22	188	185	EGR1 liver EGR1	liver	BTO:0000759	EGR1		GTRD	EXP044797_liver_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	6236
1	2419	JUN	0.0584931726309131	0.716251175593059	16	2979	2963	1909	2979	2620	22	188	185	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: non-transformed	GTRD	EXP048571_MCF10A-ER-Src_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	33354
1	2435	JUN	0.0584931726309131	0.716251175593059	16	2979	2963	1909	2979	2620	22	188	185	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057919_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	22464
1	2914	MYC	0.0584931726309131	0.716251175593059	16	2979	2963	1909	2979	2620	22	188	185	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	CMYC_24H	GEO	GSE36354_myc_p493-cmyc-24h_MACS_MYC_MA0147.3.damo.pwm.bed	4913
1	971	CTCF	0.0584866001786776	0.805002540434132	64	2983	2550	95	2983	1880	75	140	132	CTCF erythroid cells CTCF	erythroid cells	NULL	CTCF		GEO	GSE67783_ctcf_erythroid_MACS_CTCF_MA0139.1.damo.pwm.bed	50599
1	415	CREB1	0.0575608163008701	0.775933132770628	37	2984	2701	607	2984	2100	46	167	161	CREB1 A549 (lung carcinoma) CREB1	A549 (lung carcinoma)	BTO:0000018	CREB1	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BRC_A549_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	15904
1	3633	SP1	0.0575608163008701	0.775933132770628	37	2984	2701	607	2984	2100	46	167	161	SP1 HUES64 (embryonic stem cells) SP1	HUES64 (embryonic stem cells)	NULL	SP1		GTRD	EXP036754_HUES64--embryonic-stem-cells-_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	8672
1	3854	TFAP2A	0.0575608163008701	0.775933132770628	37	2984	2701	607	2984	2100	46	167	161	TFAP2A cranial neural crest cells TFAP2A	cranial neural crest cells	NULL	TFAP2A		GTRD	EXP035244_cranial-neural-crest-cells_TFAP2A_MACS_TFAP2A_MA0810.1.damo.pwm.bed	45710
1	110	AR	0.0573732317731724	0.681012180093754	11	2987	3080	2332	3080	2800	16	193	191	AR LNCaP95 AR	LNCaP95	NULL	AR	Treatment: 10nM DHT for 4 hrs Genotype: shARv7 transfection	GTRD	EXP052953_LNCaP95_AR_MACS_AR_MA0007.3.damo.pwm.bed	39193
1	1528	FOS	0.0573732317731724	0.681012180093754	11	2987	3080	2332	3080	2800	16	193	191	FOS K562 (myelogenous leukemia) FOS	K562 (myelogenous leukemia)	NULL	FOS	24 hours following induction with TPA	GTRD	EXP000589_K562--myelogenous-leukemia-_FOS_MACS_FOS_MA1134.1.damo.pwm.bed	13405
1	1529	FOS	0.0573732317731724	0.681012180093754	11	2987	3080	2332	3080	2800	16	193	191	FOS K562 (myelogenous leukemia) FOS	K562 (myelogenous leukemia)	NULL	FOS	24 hours following induction with TPA	GTRD	EXP000589_K562--myelogenous-leukemia-_FOS_MACS_FOS_MA1141.1.damo.pwm.bed	13741
1	2119	HNF1B	0.0573732317731724	0.681012180093754	11	2987	3080	2332	3080	2800	16	193	191	HNF1B PDAC HNF1B	PDAC	NA	HNF1B	NA	GEO	GSE64557_hnf1b_pdac_MACS_HNF1B_MA0153.2.damo.pwm.bed	24747
1	2457	JUN	0.0573732317731724	0.681012180093754	11	2987	3080	2332	3080	2800	16	193	191	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: control (scrambled shRNA);	GTRD	EXP058211_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	7705
1	1011	E2F1	0.0573153541139097	0.80190338344618	62	2992	2568	118	2992	1890	73	142	134	E2F1 LNCaP (prostate carcinoma) E2F1	LNCaP (prostate carcinoma)	BTO:0001321	E2F1	Vehicle	GTRD	EXP032856_LNCaP--prostate-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	21655
1	3649	SPI1	0.0573153541139097	0.80190338344618	62	2992	2568	118	2992	1890	73	142	134	SPI1 LCL (lymphoblastoid cell line) SPI1	LCL (lymphoblastoid cell line)	NULL	SPI1		Array Express	ERP004110_spi1_lcl_MACS_SPI1_MA0080.5.damo.pwm.bed	151294
1	687	CTCF	0.0568848120970598	0.756200399534396	28	2994	2802	1068	2994	2290	36	176	171	CTCF esophagus squamous epithelium CTCF	esophagus squamous epithelium	NULL	CTCF		GTRD	EXP039454_esophagus-squamous-epithelium_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39064
1	1029	E2F1	0.0567944198165811	0.788259538104021	47	2995	2622	333	2995	1980	57	157	150	E2F1 HMEC-1 E2F1	HMEC-1	NA	E2F1		GEO	GSE62425_e2f1_hmec_MACS_E2F1_MA0024.3.damo.pwm.bed	11947
1	2721	MAX	0.0567944198165811	0.788259538104021	47	2995	2622	333	2995	1980	57	157	150	MAX P493-6 (B-cell lymphoma) MAX	P493-6 (B-cell lymphoma)	BTO:0003291	MAX		GEO	GSE42262_max_p4936_MACS_MAX_MA0058.3.damo.pwm.bed	17698
1	3175	NRF1	0.0567944198165811	0.788259538104021	47	2995	2622	333	2995	1980	57	157	150	NRF1 HepG2 (hepatoblastoma) NRF1	HepG2 (hepatoblastoma)	BTO:0000599	NRF1		ENCODE	ENCSR853ADA_HepG2_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	13206
1	1764	FOXA1	0.056616675905131	0.734162037174164	21	2998	2881	1535	2998	2470	28	183	179	FOXA1 NCI-H3122 (lung adenocarcinoma) FOXA1	NCI-H3122 (lung adenocarcinoma)	NULL	FOXA1		GEO	GSE39998_foxa1_ncih3122_MACS_FOXA1_MA0148.4.damo.pwm.bed	43698
1	78	AR	0.0554871205508559	0.633832082959021	7	2999	3254	2812	3254	3020	11	197	196	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: Cells were harvested in log phase growth Genotype: wildtype	GTRD	EXP048986_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	24009
1	1331	ESR1	0.0554871205508559	0.633832082959021	7	2999	3254	2812	3254	3020	11	197	196	ESR1 Ishikawa (endometrial adenocarcinoma) ESR1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	ESR1	Treatment: 100 nM Dexamethasone and 10 nM Estradiol for 1 hour	GTRD	EXP048231_Ishikawa--endometrial-adenocarcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	14110
1	1335	ESR1	0.0554871205508559	0.633832082959021	7	2999	3254	2812	3254	3020	11	197	196	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	800	GTRD	EXP048581_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	10805
1	1482	ETV6	0.0554871205508559	0.633832082959021	7	2999	3254	2812	3254	3020	11	197	196	ETV6 K562 (myelogenous leukemia) ETV6	K562 (myelogenous leukemia)	NULL	ETV6		ENCODE	ENCSR124BJR_K562_ETV6_MACS_ETV6_MA0645.1.damo.pwm.bed	4225
1	2103	HIF1A	0.0554871205508559	0.633832082959021	7	2999	3254	2812	3254	3020	11	197	196	HIF1A PC3(bone mets prostate adenocarcinoma) HIF1A	PC3(bone mets prostate adenocarcinoma)	NULL	HIF1A	Treatment: hypoxia(0.2% O2), siSMAD3; Genotype: SMAD3 knockout;	GTRD	EXP057827_PC3-bone-mets-prostate-adenocarcinoma-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	4799
1	2168	HOXB13	0.0554871205508559	0.633832082959021	7	2999	3254	2812	3254	3020	11	197	196	HOXB13 LNCaP (prostate carcinoma) HOXB13	LNCaP (prostate carcinoma)	BTO:0001321	HOXB13	Treatment: treated with 10nM  R1881 for 4 hours	GTRD	EXP049581_LNCaP--prostate-carcinoma-_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	38138
1	2296	JUN	0.0554871205508559	0.633832082959021	7	2999	3254	2812	3254	3020	11	197	196	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	oxpapc, 4h	GTRD	EXP038044_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	8721
1	2348	JUN	0.0554871205508559	0.633832082959021	7	2999	3254	2812	3254	3020	11	197	196	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 20 minute	GTRD	EXP040320_A549--lung-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	15260
1	2382	JUN	0.0554871205508559	0.633832082959021	7	2999	3254	2812	3254	3020	11	197	196	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048209_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	7141
1	2542	JUNB	0.0554871205508559	0.633832082959021	7	2999	3254	2812	3254	3020	11	197	196	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039942_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	12494
1	3100	NR3C1	0.0554871205508559	0.633832082959021	7	2999	3254	2812	3254	3020	11	197	196	NR3C1 acute myeloblastic leukemia NR3C1	acute myeloblastic leukemia	NULL	NR3C1	dexametasone	GTRD	EXP033653_acute-myeloblastic-leukemia_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	11121
1	3385	RELA	0.0554871205508559	0.633832082959021	7	2999	3254	2812	3254	3020	11	197	196	RELA LNCaP (prostate carcinoma) RELA	LNCaP (prostate carcinoma)	BTO:0001321	RELA	DHT_TNFA	GEO	GSE83860_rela_lncap-dht-tnfa_MACS_RELA_MA0107.1.damo.pwm.bed	10656
1	3724	STAT1	0.0554871205508559	0.633832082959021	7	2999	3254	2812	3254	3020	11	197	196	STAT1 HeLa S3 (cervical adenocarcinoma) STAT1	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	STAT1	IFN gamma	GTRD	EXP000489_HeLa-S3--cervical-adenocarcinoma-_STAT1_MACS_STAT1_MA0137.3.damo.pwm.bed	10049
1	2520	JUNB	0.0553699222803173	0.703551611091289	15	3012	3009	1993	3012	2670	21	189	186	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039744_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	23476
1	2673	MAFF	0.0553699222803173	0.703551611091289	15	3012	3009	1993	3012	2670	21	189	186	MAFF HepG2 (hepatoblastoma) MAFF	HepG2 (hepatoblastoma)	BTO:0000599	MAFF	NA	ENCODE	ENCSR000EEC_HepG2_MAFF_MACS_MAFF_MA0495.3.damo.pwm.bed	70406
1	3458	RUNX1	0.0553699222803173	0.703551611091289	15	3012	3009	1993	3012	2670	21	189	186	RUNX1 Kasumi-1 (acute myeloblastic leukemia) RUNX1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	RUNX1		GTRD	EXP031175_Kasumi-1--acute-myeloblastic-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	16552
1	1264	ESR1	0.0551665874193571	0.750165887930824	27	3015	2836	1135	3015	2330	35	177	172	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Doxycycline + E2	GTRD	EXP038377_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	42633
1	1844	FOXA2	0.0550207437116017	0.767712469469369	35	3016	2742	691	3016	2150	44	169	163	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Treatment: addition of 200 uM mimosine over night Genotype: Clonal FOXA2 doxycycline inducible cells	GTRD	EXP049379_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	79400
1	2774	MYB	0.054932309817175	0.782633715432015	45	3017	2672	383	3017	2020	55	159	152	MYB PF-382 (childhood T acute lymphoblastic leukemia) MYB	PF-382 (childhood T acute lymphoblastic leukemia)	NULL	MYB		GTRD	EXP038331_PF-382--childhood-T-acute-lymphoblastic-leukemia-_MYB_MACS_MYB_MA0100.3.damo.pwm.bed	40659
1	3179	NRF1	0.054932309817175	0.782633715432015	45	3017	2672	383	3017	2020	55	159	152	NRF1 K562 (myelogenous leukemia) NRF1	K562 (myelogenous leukemia)	NULL	NRF1		GTRD	EXP038538_K562--myelogenous-leukemia-_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	14312
1	3185	NRF1	0.0548044926344761	0.794970781141959	58	3019	2609	154	3019	1930	69	146	138	NRF1 HCC1954 (ductal breast carcinoma) NRF1	HCC1954 (ductal breast carcinoma)	BTO:0005368	NRF1		GEO	GSE67867_nrf1_hcc1954_MACS_NRF1_MA0506.1.damo.pwm.bed	14946
1	234	ASCL1	0.0542855986670964	0.72520792233055	20	3020	2929	1606	3020	2520	27	184	180	ASCL1 SCLC ASCL1	SCLC	NA	ASCL1	ASCLP	GEO	GSE61197_ascl1_sclc-asclp_MACS_ASCL1_MA1100.2.damo.pwm.bed	30997
1	2063	GRHL2	0.0542855986670964	0.72520792233055	20	3020	2929	1606	3020	2520	27	184	180	GRHL2 MCF7 (Invasive ductal breast carcinoma) GRHL2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GRHL2	100nm E2 (45 min)	GTRD	EXP040966_MCF7--Invasive-ductal-breast-carcinoma-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	29051
1	2570	JUNB	0.0542855986670964	0.72520792233055	20	3020	2929	1606	3020	2520	27	184	180	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: non-transformed	GTRD	EXP048569_MCF10A-ER-Src_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	46448
1	2571	JUNB	0.0542855986670964	0.72520792233055	20	3020	2929	1606	3020	2520	27	184	180	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: non-transformed	GTRD	EXP048569_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	47280
1	2572	JUNB	0.0542855986670964	0.72520792233055	20	3020	2929	1606	3020	2520	27	184	180	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: non-transformed	GTRD	EXP048569_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	47147
1	2573	JUNB	0.0542855986670964	0.72520792233055	20	3020	2929	1606	3020	2520	27	184	180	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: non-transformed	GTRD	EXP048569_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	46653
1	2574	JUNB	0.0542855986670964	0.72520792233055	20	3020	2929	1606	3020	2520	27	184	180	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: non-transformed	GTRD	EXP048569_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	47314
1	2575	JUNB	0.0542855986670964	0.72520792233055	20	3020	2929	1606	3020	2520	27	184	180	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: non-transformed	GTRD	EXP048569_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	46653
1	2913	MYC	0.0542855986670964	0.72520792233055	20	3020	2929	1606	3020	2520	27	184	180	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	CMYC_1H	GEO	GSE36354_myc_p493-cmyc-1h_MACS_MYC_MA0147.3.damo.pwm.bed	5889
1	3023	NFKB1	0.0542855986670964	0.72520792233055	20	3020	2929	1606	3020	2520	27	184	180	NFKB1 GM12878 (female B-cells lymphoblastoid cell line) NFKB1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	NFKB1		GTRD	EXP054688_GM12878--female-B-cells-lymphoblastoid-cell-line-_NFKB1_MACS_NFKB1_MA0105.4.damo.pwm.bed	16606
1	3822	TCF7L2	0.0542855986670964	0.72520792233055	20	3020	2929	1606	3020	2520	27	184	180	TCF7L2 LNCaP (prostate carcinoma) TCF7L2	LNCaP (prostate carcinoma)	BTO:0001321	TCF7L2		GEO	GSE51621_tcf7l2_lncap_MACS_TCF7L2_MA0523.1.damo.pwm.bed	17348
1	4089	USF2	0.0542855986670964	0.72520792233055	20	3020	2929	1606	3020	2520	27	184	180	USF2 SK-N-SH (neuroblastoma) USF2	SK-N-SH (neuroblastoma)	BTO:0001620	USF2		GTRD	EXP039372_SK-N-SH--neuroblastoma-_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	6564
1	1008	E2F1	0.0541407195397087	0.793070866733919	57	3032	2616	174	3032	1940	68	147	139	E2F1 MCF7 (Invasive ductal breast carcinoma) E2F1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	E2F1	NULL	GTRD	EXP000660_MCF7--Invasive-ductal-breast-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	18978
1	1472	ETS1	0.0539709809812519	0.77964466193399	44	3033	2692	408	3033	2040	54	160	153	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1		GEO	GSE41166_ets1_huvec_MACS_ETS1_MA0098.3.damo.pwm.bed	18043
1	560	CTCF	0.0537064982497924	0.763297505773909	34	3034	2758	729	3034	2170	43	170	164	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	E2	Array Express	ERP000380_ctcf_mcf7-e2_MACS_CTCF_MA0139.1.damo.pwm.bed	48262
1	2869	MYC	0.0537064982497924	0.763297505773909	34	3034	2758	729	3034	2170	43	170	164	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	0.2 µg/mL Tetracycline (Myc transgene repressed) for 72h and then released in fresh medium without Tetracycline for 1h	GTRD	EXP038951_P493-6--B-cell-lymphoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	12165
1	1060	EGR1	0.0534028042657703	0.743765456514102	26	3036	2853	1204	3036	2360	34	178	173	EGR1 HCT-116 (colon carcinoma) EGR1	HCT-116 (colon carcinoma)	BTO:0001109	EGR1		ENCODE	ENCSR000BRZ_HCT116_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	9603
1	2956	MYF5	0.0534028042657703	0.743765456514102	26	3036	2853	1204	3036	2360	34	178	173	MYF5 RH18 (alveolar rhabdomyosarcoma) MYF5	RH18 (alveolar rhabdomyosarcoma)	BTO:0005380	MYF5	NA	GTRD	EXP037595_RH18--alveolar-rhabdomyosarcoma-_MYF5_MACS_MYF5_MA1641.1.damo.pwm.bed	19988
1	3011	NFIC	0.0534028042657703	0.743765456514102	26	3036	2853	1204	3036	2360	34	178	173	NFIC SK-N-SH (neuroblastoma) NFIC	SK-N-SH (neuroblastoma)	BTO:0001620	NFIC	NA	ENCODE	ENCSR000BSV_SK-N-SH_NFIC_MACS_NFIC_MA0161.2.damo.pwm.bed	38430
1	3200	OTX2	0.0534028042657703	0.743765456514102	26	3036	2853	1204	3036	2360	34	178	173	OTX2 D283 Med (medulloblastoma) OTX2	D283 Med (medulloblastoma)	NULL	OTX2		GTRD	EXP038197_D283-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	98089
1	3399	REST	0.0534028042657703	0.743765456514102	26	3036	2853	1204	3036	2360	34	178	173	REST HepG2 (hepatoblastoma) REST	HepG2 (hepatoblastoma)	BTO:0000599	REST		ENCODE	ENCSR000BOT_HepG2_REST_MACS_REST_MA0138.2.damo.pwm.bed	14873
1	2798	MYC	0.0529889930870856	0.776529649285427	43	3041	2700	429	3041	2060	53	161	154	MYC K562 (myelogenous leukemia) MYC	K562 (myelogenous leukemia)	NULL	MYC	NULL	GTRD	EXP000311_K562--myelogenous-leukemia-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	20159
1	27	AR	0.052984635363826	0.57219275698234	4	3042	3435	3182	3435	3220	7	200	200	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	BICALUTAMIDE	GTRD	EXP032859_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	12995
1	87	AR	0.052984635363826	0.57219275698234	4	3042	3435	3182	3435	3220	7	200	200	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: 10 nM DHT for 4 hrs Genotype: Bag-1L knockout	GTRD	EXP049278_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	12962
1	116	AR	0.052984635363826	0.57219275698234	4	3042	3435	3182	3435	3220	7	200	200	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: FA (control)	GTRD	EXP053224_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	15895
1	269	BACH1	0.052984635363826	0.57219275698234	4	3042	3435	3182	3435	3220	7	200	200	BACH1 BACH1	NA	NA	BACH1	NA	NA	ENCSR585CVE_GM12878_BACH1_MACS_BACH1_MA0591.1.damo.pwm.bed	1701
1	3017	NFIC	0.052984635363826	0.57219275698234	4	3042	3435	3182	3435	3220	7	200	200	NFIC HepG2 (hepatoblastoma) NFIC	HepG2 (hepatoblastoma)	BTO:0000599	NFIC	NA	GTRD	EXP040843_HepG2--hepatoblastoma-_NFIC_MACS_NFIC_MA0161.2.damo.pwm.bed	5681
1	3824	TEAD1	0.052984635363826	0.57219275698234	4	3042	3435	3182	3435	3220	7	200	200	TEAD1 SF268 (astrocytoma ) TEAD1	SF268 (astrocytoma )	BTO:0003772	TEAD1		GTRD	EXP034063_SF268--astrocytoma--_TEAD1_MACS_TEAD1_MA0090.3.damo.pwm.bed	23693
1	3832	TEAD4	0.052984635363826	0.57219275698234	4	3042	3435	3182	3435	3220	7	200	200	TEAD4 HepG2 (hepatoblastoma) TEAD4	HepG2 (hepatoblastoma)	BTO:0000599	TEAD4		ENCODE	ENCSR000BRP_HepG2_TEAD4_MACS_TEAD4_MA0809.2.damo.pwm.bed	8413
1	4099	VDR	0.052984635363826	0.57219275698234	4	3042	3435	3182	3435	3220	7	200	200	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	EtOH for 24h	GTRD	EXP037994_THP-1--acute-monocytic-leukemia-_VDR_MACS_VDR_MA0074.1.damo.pwm.bed	5318
1	939	CTCF	0.0528811321874364	0.660459116604784	10	3050	3175	2442	3175	2890	15	194	192	CTCF VA13 (transformed lung fibroblasts) CTCF	VA13 (transformed lung fibroblasts)	NULL	CTCF		GEO	GSE41048_ctcf_wi38va13_MACS_CTCF_MA0139.1.damo.pwm.bed	19330
1	2556	JUNB	0.0528811321874364	0.660459116604784	10	3050	3175	2442	3175	2890	15	194	192	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP040135_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	14860
1	2559	JUNB	0.0528811321874364	0.660459116604784	10	3050	3175	2442	3175	2890	15	194	192	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP040135_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	15648
1	2560	JUNB	0.0528811321874364	0.660459116604784	10	3050	3175	2442	3175	2890	15	194	192	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP040135_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	14979
1	2561	JUNB	0.0528811321874364	0.660459116604784	10	3050	3175	2442	3175	2890	15	194	192	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP040135_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	15645
1	2619	JUND	0.0528811321874364	0.660459116604784	10	3050	3175	2442	3175	2890	15	194	192	JUND liver JUND	liver	BTO:0000759	JUND		GTRD	EXP040078_liver_JUND_MACS_JUND_MA1144.1.damo.pwm.bed	8423
1	3449	RFX5	0.0528811321874364	0.660459116604784	10	3050	3175	2442	3175	2890	15	194	192	RFX5 A549 (lung carcinoma) RFX5	A549 (lung carcinoma)	BTO:0000018	RFX5	NA	ENCODE	ENCSR064LJN_A549_RFX5_MACS_RFX5_MA0510.2.damo.pwm.bed	3360
1	3644	SPDEF	0.0528811321874364	0.660459116604784	10	3050	3175	2442	3175	2890	15	194	192	SPDEF A549 (lung carcinoma) SPDEF	A549 (lung carcinoma)	BTO:0000018	SPDEF	NA	GTRD	EXP037793_A549--lung-carcinoma-_SPDEF_MACS_SPDEF_MA0686.1.damo.pwm.bed	6933
1	3806	TCF7	0.0528811321874364	0.660459116604784	10	3050	3175	2442	3175	2890	15	194	192	TCF7 HepG2 (hepatoblastoma) TCF7	HepG2 (hepatoblastoma)	BTO:0000599	TCF7		GTRD	EXP039875_HepG2--hepatoblastoma-_TCF7_MACS_TCF7_MA0769.2.damo.pwm.bed	16021
1	2646	KLF5	0.0523618867365132	0.758660387835446	33	3059	2775	778	3059	2200	42	171	165	KLF5 HCC95 (squamous cell lung carcinoma) KLF5	HCC95 (squamous cell lung carcinoma)	NULL	KLF5	Treatment: Over-expressing KLF5 D418N	GTRD	EXP049098_HCC95--squamous-cell-lung-carcinoma-_KLF5_MACS_KLF5_MA0599.1.damo.pwm.bed	12160
1	21	AR	0.0521186729666096	0.689572280090558	14	3060	3053	2073	3060	2730	20	190	187	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	100 nM DHT	GTRD	EXP030507_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	59512
1	1779	FOXA1	0.0521186729666096	0.689572280090558	14	3060	3053	2073	3060	2730	20	190	187	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1		GEO	GSE56288_foxa1_lncap_MACS_FOXA1_MA0148.4.damo.pwm.bed	22516
1	1941	GATA2	0.0521186729666096	0.689572280090558	14	3060	3053	2073	3060	2730	20	190	187	GATA2 SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) GATA2	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	GATA2	RUNX1-EVI1 KD	GTRD	EXP037841_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	17930
1	2418	JUN	0.0521186729666096	0.689572280090558	14	3060	3053	2073	3060	2730	20	190	187	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: non-transformed	GTRD	EXP048571_MCF10A-ER-Src_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	30390
1	3063	NR2F1	0.0521186729666096	0.689572280090558	14	3060	3053	2073	3060	2730	20	190	187	NR2F1 cranial neural crest cells NR2F1	cranial neural crest cells	NULL	NR2F1	NA	GTRD	EXP035243_cranial-neural-crest-cells_NR2F1_MACS_NR2F1_MA1537.1.damo.pwm.bed	29739
1	3708	SRF	0.0521186729666096	0.689572280090558	14	3060	3053	2073	3060	2730	20	190	187	SRF GM12878 (female B-cells lymphoblastoid cell line) SRF	GM12878 (female B-cells lymphoblastoid cell line)	NULL	SRF		ENCODE	ENCSR000BMI_GM12878_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	9834
1	3748	STAT4	0.0521186729666096	0.689572280090558	14	3060	3053	2073	3060	2730	20	190	187	STAT4 T-cells STAT4	T-cells	NULL	STAT4	IL-12	GTRD	EXP000395_T-cells_STAT4_MACS_STAT4_MA0518.1.damo.pwm.bed	9254
1	2856	MYC	0.0520599993712164	0.786926878629218	54	3067	2632	225	3067	1970	65	150	142	MYC LNCaP (prostate carcinoma) MYC	LNCaP (prostate carcinoma)	BTO:0001321	MYC	R1881+Doxycycline	GTRD	EXP037069_LNCaP--prostate-carcinoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	26022
1	2891	MYC	0.0519859844608756	0.773281655844149	42	3068	2714	454	3068	2080	52	162	155	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 4;	GTRD	EXP047491_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	13685
1	2962	NEUROD1	0.0519859844608756	0.773281655844149	42	3068	2714	454	3068	2080	52	162	155	NEUROD1 D341 Med (medulloblastoma) NEUROD1	D341 Med (medulloblastoma)	NULL	NEUROD1		GTRD	EXP038201_D341-Med--medulloblastoma-_NEUROD1_MACS_NEUROD1_MA1109.1.damo.pwm.bed	49182
1	2476	JUNB	0.0518795619822809	0.71555461978996	19	3070	2967	1697	3070	2580	26	185	181	JUNB K562 (myelogenous leukemia) JUNB	K562 (myelogenous leukemia)	NULL	JUNB		ENCODE	ENCSR000DJY_K562_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	20337
1	2816	MYC	0.0518795619822809	0.71555461978996	19	3070	2967	1697	3070	2580	26	185	181	MYC FB8470 (fibroblasts) MYC	FB8470 (fibroblasts)	NULL	MYC	NULL	GTRD	EXP001024_FB8470--fibroblasts-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	7173
1	4065	TWIST1	0.0518795619822809	0.71555461978996	19	3070	2967	1697	3070	2580	26	185	181	TWIST1 SHEP-21N TWIST1	SHEP-21N	NA	TWIST1	DOX_0H	GEO	GSE80151_twist1_shep21-dox-0h_MACS_TWIST1_MA1123.2.damo.pwm.bed	17782
1	596	CTCF	0.0515921856034115	0.736966009485132	25	3073	2873	1262	3073	2400	33	179	174	CTCF skeletal muscles and myoblasts CTCF	skeletal muscles and myoblasts	NULL	CTCF		GTRD	EXP030402_skeletal-muscles-and-myoblasts_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49942
1	618	CTCF	0.0515921856034115	0.736966009485132	25	3073	2873	1262	3073	2400	33	179	174	CTCF PC3(bone mets prostate adenocarcinoma) CTCF	PC3(bone mets prostate adenocarcinoma)	NULL	CTCF		GTRD	EXP033039_PC3-bone-mets-prostate-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46343
1	3540	RXRA	0.0515921856034115	0.736966009485132	25	3073	2873	1262	3073	2400	33	179	174	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA S427F	GTRD	EXP040816_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA1147.1.damo.pwm.bed	10992
1	98	AR	0.0511462821859886	0.50328896907938	2	3076	3571	3462	3571	3370	4	202	203	AR VCaP and LTAD cells AR	VCaP and LTAD cells	NULL	AR	Treatment: 24h DHT 1 nM	GTRD	EXP049450_VCaP-and-LTAD-cells_AR_MACS_AR_MA0007.3.damo.pwm.bed	12177
1	274	BACH2	0.0511462821859886	0.50328896907938	2	3076	3571	3462	3571	3370	4	202	203	BACH2 B-cells BACH2	B-cells	NULL	BACH2	siBACH2	GTRD	EXP040450_B-cells_BACH2_MACS_BACH2_MA1470.1.damo.pwm.bed	2802
1	280	BATF	0.0511462821859886	0.50328896907938	2	3076	3571	3462	3571	3370	4	202	203	BATF OCI-LY3 (diffuse large B-cell lymphoma) BATF	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	BATF	NA	GEO	GSE56857_batf_ocily3_MACS_BATF_MA0462.2.damo.pwm.bed	2476
1	941	CTCF	0.0511462821859886	0.50328896907938	2	3076	3571	3462	3571	3370	4	202	203	CTCF monocyte CTCF	monocyte	NA	CTCF	BLOOD	GEO	GSE43098_ctcf_monocytes-blood_MACS_CTCF_MA0139.1.damo.pwm.bed	8073
1	1202	ESR1	0.0511462821859886	0.50328896907938	2	3076	3571	3462	3571	3370	4	202	203	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	cells transfected with siCTL, and 1hr with 100nM E2, double crosslinked	GTRD	EXP034122_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	9993
1	2031	GATA6	0.0511462821859886	0.50328896907938	2	3076	3571	3462	3571	3370	4	202	203	GATA6 HUES64 (embryonic stem cells) GATA6	HUES64 (embryonic stem cells)	NULL	GATA6		GTRD	EXP036794_HUES64--embryonic-stem-cells-_GATA6_MACS_GATA6_MA1104.2.damo.pwm.bed	14580
1	2173	HSF1	0.0511462821859886	0.50328896907938	2	3076	3571	3462	3571	3370	4	202	203	HSF1 HepG2 (hepatoblastoma) HSF1	HepG2 (hepatoblastoma)	BTO:0000599	HSF1	low-glucose DMEM with 0.5% BSA supplemented with 1uM forskolin and 1mM pyruvate for 6h. (Snyder)	ENCODE	ENCSR000EET_HepG2_HSF1_MACS_HSF1_MA0486.2.damo.pwm.bed	1185
1	2183	HSF1	0.0511462821859886	0.50328896907938	2	3076	3571	3462	3571	3370	4	202	203	HSF1 colon HSF1	colon	NA	HSF1	tumor	GEO	GSE38901_hsf1_colon-tumor_MACS_HSF1_MA0486.2.damo.pwm.bed	796
1	2592	JUND	0.0511462821859886	0.50328896907938	2	3076	3571	3462	3571	3370	4	202	203	JUND T47D (invasive ductal carcinoma) JUND	T47D (invasive ductal carcinoma)	BTO:0001248	JUND		ENCODE	ENCSR000BVO_T47D_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	6114
1	2602	JUND	0.0511462821859886	0.50328896907938	2	3076	3571	3462	3571	3370	4	202	203	JUND GM12878 (female B-cells lymphoblastoid cell line) JUND	GM12878 (female B-cells lymphoblastoid cell line)	NULL	JUND	NULL	GTRD	EXP000436_GM12878--female-B-cells-_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	10418
1	2604	JUND	0.0511462821859886	0.50328896907938	2	3076	3571	3462	3571	3370	4	202	203	JUND GM12878 (female B-cells lymphoblastoid cell line) JUND	GM12878 (female B-cells lymphoblastoid cell line)	NULL	JUND	NULL	GTRD	EXP000436_GM12878--female-B-cells-_JUND_MACS_JUND_MA1142.1.damo.pwm.bed	10087
1	2605	JUND	0.0511462821859886	0.50328896907938	2	3076	3571	3462	3571	3370	4	202	203	JUND GM12878 (female B-cells lymphoblastoid cell line) JUND	GM12878 (female B-cells lymphoblastoid cell line)	NULL	JUND	NULL	GTRD	EXP000436_GM12878--female-B-cells-_JUND_MACS_JUND_MA1144.1.damo.pwm.bed	10101
1	2685	MAFK	0.0511462821859886	0.50328896907938	2	3076	3571	3462	3571	3370	4	202	203	MAFK MCF7 (Invasive ductal breast carcinoma) MAFK	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	MAFK	NA	ENCODE	ENCSR555PBN_MCF-7_MAFK_MACS_MAFK_MA0496.3.damo.pwm.bed	8728
1	3304	PRDM1	0.0511462821859886	0.50328896907938	2	3076	3571	3462	3571	3370	4	202	203	PRDM1 HUES64 (embryonic stem cells) PRDM1	HUES64 (embryonic stem cells)	NULL	PRDM1	HUES64 dEN	GTRD	EXP036696_HUES64--embryonic-stem-cells-_PRDM1_MACS_PRDM1_MA0508.3.damo.pwm.bed	2886
1	3306	PRDM1	0.0511462821859886	0.50328896907938	2	3076	3571	3462	3571	3370	4	202	203	PRDM1 U266 (plasma cell myeloma) PRDM1	U266 (plasma cell myeloma)	BTO:0001594	PRDM1		GTRD	EXP040447_U266--plasma-cell-myeloma-_PRDM1_MACS_PRDM1_MA0508.3.damo.pwm.bed	2632
1	3349	RELA	0.0511462821859886	0.50328896907938	2	3076	3571	3462	3571	3370	4	202	203	RELA BEAS-2B (bronchial epithelium) RELA	BEAS-2B (bronchial epithelium)	NULL	RELA	TNF	GTRD	EXP036256_BEAS-2B--bronchial-epithelium-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	4845
1	3411	REST	0.0511462821859886	0.50328896907938	2	3076	3571	3462	3571	3370	4	202	203	REST K562 (myelogenous leukemia) REST	K562 (myelogenous leukemia)	NULL	REST		GTRD	EXP031113_K562--myelogenous-leukemia-_REST_MACS_REST_MA0138.2.damo.pwm.bed	5954
1	3804	TCF7	0.0511462821859886	0.50328896907938	2	3076	3571	3462	3571	3370	4	202	203	TCF7 DLD-1 (colon adenocarcinoma) TCF7	DLD-1 (colon adenocarcinoma)	BTO:0000391	TCF7	1 ug/mL Doxycycline	GTRD	EXP033180_DLD-1--colon-adenocarcinoma-_TCF7_MACS_TCF7_MA0769.2.damo.pwm.bed	1881
1	3815	TCF7L2	0.0511462821859886	0.50328896907938	2	3076	3571	3462	3571	3370	4	202	203	TCF7L2 K562 (myelogenous leukemia) TCF7L2	K562 (myelogenous leukemia)	NULL	TCF7L2	bio	GTRD	EXP000958_K562--myelogenous-leukemia-_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	9730
1	3833	TEAD4	0.0509862418842235	0.753785064939756	32	3095	2815	825	3095	2240	41	172	166	TEAD4 WA01 (H1, human embryonic stem cells) TEAD4	WA01 (H1, human embryonic stem cells)	NULL	TEAD4		ENCODE	ENCSR000BRY_H1-hESC_TEAD4_MACS_TEAD4_MA0809.2.damo.pwm.bed	43215
1	1010	E2F1	0.0505964693948654	0.782428584196204	52	3096	2674	244	3096	2000	63	152	144	E2F1 OCI-LY1 (diffuse large B-cell lymphoma) E2F1	OCI-LY1 (diffuse large B-cell lymphoma)	NULL	E2F1	DMSO	GTRD	EXP032102_OCI-LY1--diffuse-large-B-cell-lymphoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	13012
1	500	CTCF	0.0499154509722321	0.766355798729557	40	3097	2744	502	3097	2110	50	164	157	CTCF BJ (fibroblasts) CTCF	BJ (fibroblasts)	NULL	CTCF		ENCODE	ENCSR000DQI_BJ_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45209
1	1061	EGR1	0.0499154509722321	0.766355798729557	40	3097	2744	502	3097	2110	50	164	157	EGR1 Ishikawa (endometrial adenocarcinoma) EGR1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	EGR1		ENCODE	ENCSR000BSQ_Ishikawa_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	12135
1	278	BATF	0.0497334847145695	0.729730307296124	24	3099	2900	1324	3099	2440	32	180	175	BATF GM12878 (female B-cells lymphoblastoid cell line) BATF	GM12878 (female B-cells lymphoblastoid cell line)	NULL	BATF	NA	ENCODE	ENCSR000BGT_GM12878_BATF_MACS_BATF_MA0462.2.damo.pwm.bed	51722
1	2070	GRHL2	0.0497334847145695	0.729730307296124	24	3099	2900	1324	3099	2440	32	180	175	GRHL2 MCF7 WS8 cells GRHL2	MCF7 WS8 cells	NULL	GRHL2	Treatment: 45 min ethanol	GTRD	EXP048456_MCF7-WS8-cells_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	25795
1	3519	RXRA	0.0497334847145695	0.729730307296124	24	3099	2900	1324	3099	2440	32	180	175	RXRA monocyte-derived macrophages RXRA	monocyte-derived macrophages	NULL	RXRA	untreated	GTRD	EXP036837_monocyte-derived-macrophages_RXRA_MACS_RXRA_MA1146.1.damo.pwm.bed	13103
1	2637	KLF4	0.0493960313789603	0.705118342717177	18	3102	2999	1785	3102	2630	25	186	182	KLF4 MCF7 (Invasive ductal breast carcinoma) KLF4	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	KLF4		GEO	GSE41561_klf4_mcf7_MACS_KLF4_MA0039.4.damo.pwm.bed	6369
1	2953	MYCN	0.0493960313789603	0.705118342717177	18	3102	2999	1785	3102	2630	25	186	182	MYCN NGP (neuroblastoma) MYCN	NGP (neuroblastoma)	NULL	MYCN		GEO	GSE80151_mycn_ngp_MACS_MYCN_MA0104.4.damo.pwm.bed	7579
1	2800	MYC	0.0488472008158568	0.762660877029031	39	3104	2761	547	3104	2140	49	165	158	MYC GM12878 (female B-cells lymphoblastoid cell line) MYC	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MYC	NULL	GTRD	EXP000439_GM12878--female-B-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	19483
1	3683	SPI1	0.0488472008158568	0.762660877029031	39	3104	2761	547	3104	2140	49	165	158	SPI1 DOHH2 (diffuse large B-cell lymphoma) SPI1	DOHH2 (diffuse large B-cell lymphoma)	NULL	SPI1		GEO	GSE69558_spi1_dohh2_MACS_SPI1_MA0080.5.damo.pwm.bed	73276
1	213	AR	0.0487336782391138	0.674111110089202	13	3106	3094	2153	3106	2780	19	191	188	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	R1881_4H	GEO	GSE84432_AR_vcap-r1881-4h_MACS_AR_MA0007.3.damo.pwm.bed	55427
1	875	CTCF	0.0487336782391138	0.674111110089202	13	3106	3094	2153	3106	2780	19	191	188	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: 110 mM NaCl for 7.5 min  Source: T47D whole cell	GTRD	EXP053042_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	28717
1	2755	MITF	0.0487336782391138	0.674111110089202	13	3106	3094	2153	3106	2780	19	191	188	MITF K562 (myelogenous leukemia) MITF	K562 (myelogenous leukemia)	NULL	MITF		GTRD	EXP040317_K562--myelogenous-leukemia-_MITF_MACS_MITF_MA0620.3.damo.pwm.bed	28681
1	17	AR	0.0486236818439303	0.597709784750682	6	3109	3366	2948	3366	3140	10	198	197	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	100 nM DHT+Dex	GTRD	EXP030501_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	22150
1	54	AR	0.0486236818439303	0.597709784750682	6	3109	3366	2948	3366	3140	10	198	197	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	2μg/mL aphidicolin for 15 hours, followed by washout and treatment with 50ng/mL nocodozole for 9 hours +3 hour 10nm DHT	GTRD	EXP036470_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	32748
1	2021	GATA4	0.0486236818439303	0.597709784750682	6	3109	3366	2948	3366	3140	10	198	197	GATA4 A549 (lung carcinoma) GATA4	A549 (lung carcinoma)	BTO:0000018	GATA4		GTRD	EXP048969_A549--lung-carcinoma-_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	8725
1	2115	HNF1A	0.0486236818439303	0.597709784750682	6	3109	3366	2948	3366	3140	10	198	197	HNF1A HEE (human epididymis epithelial cells) HNF1A	HEE (human epididymis epithelial cells)	NULL	HNF1A	Treatment: untreated	GTRD	EXP048856_HEE--human-epididymis-epithelial-cells-_HNF1A_MACS_HNF1A_MA0046.2.damo.pwm.bed	15643
1	2679	MAFK	0.0486236818439303	0.597709784750682	6	3109	3366	2948	3366	3140	10	198	197	MAFK HeLa S3 (cervical adenocarcinoma) MAFK	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	MAFK	NA	ENCODE	ENCSR000ECK_HeLa-S3_MAFK_MACS_MAFK_MA0496.3.damo.pwm.bed	13597
1	3487	RUNX1	0.0486236818439303	0.597709784750682	6	3109	3366	2948	3366	3140	10	198	197	RUNX1 Jurkat (T-cells) RUNX1	Jurkat (T-cells)	BTO:0000661	RUNX1		GEO	GSE29180_runx1_jurkat_MACS_RUNX1_MA0002.2.damo.pwm.bed	6978
1	3702	SREBF1	0.0486236818439303	0.597709784750682	6	3109	3366	2948	3366	3140	10	198	197	SREBF1 A549 (lung carcinoma) SREBF1	A549 (lung carcinoma)	BTO:0000018	SREBF1		ENCODE	ENCSR897MYK_A549_SREBF1_MACS_SREBF1_MA0595.1.damo.pwm.bed	1620
1	3778	TBX5	0.0486236818439303	0.597709784750682	6	3109	3366	2948	3366	3140	10	198	197	TBX5 iPSC-derived cardiomyocytes TBX5	iPSC-derived cardiomyocytes	NULL	TBX5	day 30	GTRD	EXP053380_iPSC-derived-cardiomyocytes_TBX5_MACS_TBX5_MA0807.1.damo.pwm.bed	13824
1	3927	TFAP2C	0.0482354916809117	0.786849430002045	63	3117	2635	103	3117	1950	75	141	132	TFAP2C MDA-MB-453 (breast adenocarcinoma) TFAP2C	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	TFAP2C		GEO	GSE36351_tfap2c_mdamb453_MACS_TFAP2C_MA0814.2.damo.pwm.bed	59788
1	1540	FOS	0.0481392351337439	0.743247340369182	30	3118	2858	937	3118	2300	39	174	168	FOS IMR90 (lung fibroblasts) FOS	IMR90 (lung fibroblasts)	NULL	FOS		GTRD	EXP039888_IMR90--lung-fibroblasts-_FOS_MACS_FOS_MA1134.1.damo.pwm.bed	41266
1	1561	FOS	0.0481392351337439	0.743247340369182	30	3118	2858	937	3118	2300	39	174	168	FOS MCF10A-ER-Src FOS	MCF10A-ER-Src	NULL	FOS	Genotype: transformed	GTRD	EXP048568_MCF10A-ER-Src_FOS_MACS_FOS_MA1141.1.damo.pwm.bed	90835
1	1687	FOXA1	0.0481392351337439	0.743247340369182	30	3118	2858	937	3118	2300	39	174	168	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	Cocktail_90	GTRD	EXP038788_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	71083
1	1872	GABPA	0.0481392351337439	0.743247340369182	30	3118	2858	937	3118	2300	39	174	168	GABPA SK-N-SH (neuroblastoma) GABPA	SK-N-SH (neuroblastoma)	BTO:0001620	GABPA		ENCODE	ENCSR000BTG_SK-N-SH_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	9376
1	2944	MYCN	0.0481392351337439	0.743247340369182	30	3118	2858	937	3118	2300	39	174	168	MYCN IMR-5 (Neuroblastoma) MYCN	IMR-5 (Neuroblastoma)	NULL	MYCN	Treatment: 1uM CD532 for 4 hr	GTRD	EXP048885_IMR-5--Neuroblastoma-_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	11652
1	121	AR	0.0481386998633115	0.63695963997465	9	3123	3246	2564	3246	2980	14	195	193	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: 10 nm DHT;	GTRD	EXP054343_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	26289
1	3276	POU5F1	0.0481386998633115	0.63695963997465	9	3123	3246	2564	3246	2980	14	195	193	POU5F1 HUES8 (Embryonic stem cell, blastocyst stage) POU5F1	HUES8 (Embryonic stem cell, blastocyst stage)	NULL	POU5F1	Genotype: SOX17-GFP knockout;	GTRD	EXP057925_HUES8--Embryonic-stem-cell--blastocyst-stage-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	24234
1	3624	SP1	0.0481386998633115	0.63695963997465	9	3123	3246	2564	3246	2980	14	195	193	SP1 K562 (myelogenous leukemia) SP1	K562 (myelogenous leukemia)	NULL	SP1		ENCODE	ENCSR000BKO_K562_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	1982
1	4092	USF2	0.0481386998633115	0.63695963997465	9	3123	3246	2564	3246	2980	14	195	193	USF2 K562 (myelogenous leukemia) USF2	K562 (myelogenous leukemia)	NULL	USF2	Treatment: no	GTRD	EXP048313_K562--myelogenous-leukemia-_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	3168
1	789	CTCF	0.047825509279118	0.722016297950995	23	3127	2942	1391	3127	2490	31	181	176	CTCF HCT-116 (colon carcinoma) CTCF	HCT-116 (colon carcinoma)	BTO:0001109	CTCF		GTRD	EXP040228_HCT-116--colon-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48187
1	3083	NR2F6	0.047825509279118	0.722016297950995	23	3127	2942	1391	3127	2490	31	181	176	NR2F6 K562 (myelogenous leukemia) NR2F6	K562 (myelogenous leukemia)	NULL	NR2F6	NA	GTRD	EXP040021_K562--myelogenous-leukemia-_NR2F6_MACS_NR2F6_MA0677.1.damo.pwm.bed	27787
1	4102	VDR	0.047825509279118	0.722016297950995	23	3127	2942	1391	3127	2490	31	181	176	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	100 nM 1,25(OH)2D3 for 24h	GTRD	EXP037995_THP-1--acute-monocytic-leukemia-_VDR_MACS_VDR_MA0693.2.damo.pwm.bed	23902
1	427	CREB1	0.0477564837862757	0.758798725952923	38	3130	2773	576	3130	2160	48	166	159	CREB1 LNCaP (prostate carcinoma) CREB1	LNCaP (prostate carcinoma)	BTO:0001321	CREB1		GEO	GSE63034_creb1_lncap_MACS_CREB1_MA0018.4.damo.pwm.bed	15407
1	1293	ESR1	0.0477564837862757	0.758798725952923	38	3130	2773	576	3130	2160	48	166	159	ESR1 MCF10A (breast epithelial cells) ESR1	MCF10A (breast epithelial cells)	BTO:0001939	ESR1	Cells were lentivirally transduced with MYC-ERVD and stable pools were treated with 100nM 4-OHT for 24h.	GTRD	EXP038958_MCF10A--breast-epithelial-cells-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	16931
1	2857	MYC	0.0474790702670245	0.772330541842223	48	3132	2722	317	3132	2060	59	156	148	MYC LNCaP (prostate carcinoma) MYC	LNCaP (prostate carcinoma)	BTO:0001321	MYC	R1881+Doxycycline	GTRD	EXP037069_LNCaP--prostate-carcinoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	21742
1	3468	RUNX1	0.0474790702670245	0.772330541842223	48	3132	2722	317	3132	2060	59	156	148	RUNX1 NB4 (acute promyelocytic leukemia ) RUNX1	NB4 (acute promyelocytic leukemia )	NULL	RUNX1		GTRD	EXP037460_NB4--acute-promyelocytic-leukemia--_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	35427
1	3940	TFAP4	0.0468326530809083	0.693801325282888	17	3134	3046	1846	3134	2680	24	187	183	TFAP4 DLD-1 (colon adenocarcinoma) TFAP4	DLD-1 (colon adenocarcinoma)	BTO:0000391	TFAP4	NA	GEO	GSE46935_tfap4_dld1_MACS_TFAP4_MA0691.1.damo.pwm.bed	22843
1	1087	ELF1	0.0466429497353749	0.754758909373966	37	3135	2804	607	3135	2180	47	167	160	ELF1 GM12878 (female B-cells lymphoblastoid cell line) ELF1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ELF1		GTRD	EXP039944_GM12878--female-B-cells-_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	13845
1	2292	JUN	0.0466429497353749	0.754758909373966	37	3135	2804	607	3135	2180	47	167	160	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	IL1b, 4h	GTRD	EXP038043_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	47424
1	1062	EGR1	0.045867152635256	0.713776314451211	22	3137	2979	1459	3137	2520	30	182	177	EGR1 MCF7 (Invasive ductal breast carcinoma) EGR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	EGR1		ENCODE	ENCSR000BUX_MCF-7_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	9340
1	2270	JUN	0.045867152635256	0.713776314451211	22	3137	2979	1459	3137	2520	30	182	177	JUN RCC 7860 (Renal cell carcinoma) JUN	RCC 7860 (Renal cell carcinoma)	BTO:0003781	JUN		GTRD	EXP037742_786-O--renal-carcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	23767
1	2335	JUN	0.045867152635256	0.713776314451211	22	3137	2979	1459	3137	2520	30	182	177	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 15 minute	GTRD	EXP040263_A549--lung-carcinoma-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	18203
1	1440	ESR2	0.0455062591795739	0.750530077331647	36	3140	2818	645	3140	2200	46	168	161	ESR2 MDA-MB-231ERb(triple negative breast cancer) ESR2	MDA-MB-231ERb(triple negative breast cancer)	NULL	ESR2	Treatment: 1 nM estradiol for 3 hr Passage: 20-25	GTRD	EXP048149_MDA-MB-231ERb-triple-negative-breast-cancer-_ESR2_MACS_ESR2_MA0258.2.damo.pwm.bed	24135
1	2236	JUN	0.0455062591795739	0.750530077331647	36	3140	2818	645	3140	2200	46	168	161	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN	NULL	GTRD	EXP000309_K562--myelogenous-leukemia-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	39729
1	3178	NRF1	0.0455062591795739	0.750530077331647	36	3140	2818	645	3140	2200	46	168	161	NRF1 K562 (myelogenous leukemia) NRF1	K562 (myelogenous leukemia)	NULL	NRF1		GTRD	EXP038537_K562--myelogenous-leukemia-_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	9337
1	2875	MYC	0.0454168323499951	0.777977957496287	58	3143	2693	154	3143	2000	70	146	137	MYC HEK293T (embryonic kidney) MYC	HEK293T (embryonic kidney)	BTO:0002181	MYC	Treatment: withKL-1 or KL-2 inhibitors was administrated only once; Genotype: cells lentiviral infected shRNA targeting MYC;	GTRD	EXP047292_HEK293T--embryonic-kidney-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	18209
1	253	ATF3	0.0452097987251855	0.656921077538564	12	3144	3188	2233	3188	2860	18	192	189	ATF3 dermal fibroblasts ATF3	dermal fibroblasts	BTO:0004419	ATF3	overexpressed ATF3	GTRD	EXP037426_dermal-fibroblasts_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	17378
1	769	CTCF	0.0452097987251855	0.656921077538564	12	3144	3188	2233	3188	2860	18	192	189	CTCF HEK293 (embryonic kidney) CTCF	HEK293 (embryonic kidney)	NULL	CTCF		GTRD	EXP040061_HEK293--embryonic-kidney-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	9080
1	1338	ESR1	0.0452097987251855	0.656921077538564	12	3144	3188	2233	3188	2860	18	192	189	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Saturated H3B-5942	GTRD	EXP048584_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	11647
1	2060	GRHL2	0.0452097987251855	0.656921077538564	12	3144	3188	2233	3188	2860	18	192	189	GRHL2 MCF7 (Invasive ductal breast carcinoma) GRHL2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GRHL2	control	GTRD	EXP040963_MCF7--Invasive-ductal-breast-carcinoma-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	18542
1	2915	MYC	0.0452097987251855	0.656921077538564	12	3144	3188	2233	3188	2860	18	192	189	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC		GEO	GSE36354_myc_p493_MACS_MYC_MA0147.3.damo.pwm.bed	3212
1	3098	NR3C1	0.0452097987251855	0.656921077538564	12	3144	3188	2233	3188	2860	18	192	189	NR3C1 embryonic kidney NR3C1	embryonic kidney	NULL	NR3C1	dexamethasone, stably expressing SUMOylation-defective GR	GTRD	EXP032211_embryonic-kidney_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	31363
1	4078	USF1	0.0452097987251855	0.656921077538564	12	3144	3188	2233	3188	2860	18	192	189	USF1 HCT-116 (colon carcinoma) USF1	HCT-116 (colon carcinoma)	BTO:0001109	USF1		ENCODE	ENCSR000BVK_HCT116_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	10172
1	2352	JUN	0.0451604628647067	0.731519756507446	28	3151	2883	1068	3151	2370	37	176	170	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 5 minute	GTRD	EXP040322_A549--lung-carcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	23699
1	2702	MAX	0.0451604628647067	0.731519756507446	28	3151	2883	1068	3151	2370	37	176	170	MAX GM12878 (female B-cells lymphoblastoid cell line) MAX	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MAX	NULL	GTRD	EXP000438_GM12878--female-B-cells-_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	20743
1	1009	E2F1	0.0449682214343565	0.763648011107331	45	3153	2756	383	3153	2100	56	159	151	E2F1 MCF7 (Invasive ductal breast carcinoma) E2F1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	E2F1	NULL	GTRD	EXP000663_MCF7--Invasive-ductal-breast-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	15415
1	2916	MYC	0.0449682214343565	0.763648011107331	45	3153	2756	383	3153	2100	56	159	151	MYC U-87MG MYC	U-87MG	NA	MYC		GEO	GSE36354_myc_u87mg_MACS_MYC_MA0147.3.damo.pwm.bed	14134
1	1071	EGR3	0.0448829264276304	0.786673069263468	75	3155	2636	28	3155	1940	88	129	119	EGR3 HEK293 (embryonic kidney) EGR3	HEK293 (embryonic kidney)	NULL	EGR3	NA	GTRD	EXP035892_HEK293--embryonic-kidney-_EGR3_MACS_EGR3_MA0732.1.damo.pwm.bed	95395
1	1854	FOXO1	0.0441998411453828	0.77394015140083	56	3156	2712	192	3156	2020	68	148	139	FOXO1 pre- leukemia stem cells (CD34+ human cord blood cells) FOXO1	pre- leukemia stem cells (CD34+ human cord blood cells)	NULL	FOXO1	Treatment: untreated	GTRD	EXP048924_pre--leukemia-stem-cells--CD34--human-cord-blood-cells-_FOXO1_MACS_FOXO1_MA0480.1.damo.pwm.bed	31644
1	876	CTCF	0.0441873757935988	0.681488781039675	16	3157	3078	1909	3157	2710	23	188	184	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: 110 mM NaCl for 60 min  Source: T47D whole cell	GTRD	EXP053043_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29020
1	3052	NR2C2	0.0441873757935988	0.681488781039675	16	3157	3078	1909	3157	2710	23	188	184	NR2C2 K562 (myelogenous leukemia) NR2C2	K562 (myelogenous leukemia)	NULL	NR2C2		ENCODE	ENCSR750LYM_K562_NR2C2_MACS_NR2C2_MA0504.1.damo.pwm.bed	9018
1	1565	FOSL1	0.0438574342747345	0.704956106046683	21	3159	3001	1535	3159	2560	29	183	178	FOSL1 K562 (myelogenous leukemia) FOSL1	K562 (myelogenous leukemia)	NULL	FOSL1	NA	ENCODE	ENCSR239ZLZ_K562_FOSL1_MACS_FOSL1_MA0477.2.damo.pwm.bed	31556
1	2482	JUNB	0.0438574342747345	0.704956106046683	21	3159	3001	1535	3159	2560	29	183	178	JUNB HAEC (human aortic endothelial cells) JUNB	HAEC (human aortic endothelial cells)	NULL	JUNB	control, 4h	GTRD	EXP038040_HAEC--human-aortic-endothelial-cells-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	31549
1	2484	JUNB	0.0438574342747345	0.704956106046683	21	3159	3001	1535	3159	2560	29	183	178	JUNB HAEC (human aortic endothelial cells) JUNB	HAEC (human aortic endothelial cells)	NULL	JUNB	control, 4h	GTRD	EXP038040_HAEC--human-aortic-endothelial-cells-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	31460
1	2764	MNT	0.0438574342747345	0.704956106046683	21	3159	3001	1535	3159	2560	29	183	178	MNT K562 (myelogenous leukemia) MNT	K562 (myelogenous leukemia)	NULL	MNT	NA	GTRD	EXP039709_K562--myelogenous-leukemia-_MNT_MACS_MNT_MA0825.1.damo.pwm.bed	7549
1	3171	NRF1	0.0438574342747345	0.704956106046683	21	3159	3001	1535	3159	2560	29	183	178	NRF1 K562 (myelogenous leukemia) NRF1	K562 (myelogenous leukemia)	NULL	NRF1		ENCODE	ENCSR000EHH_K562_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	4672
1	3172	NRF1	0.0438574342747345	0.704956106046683	21	3159	3001	1535	3159	2560	29	183	178	NRF1 MCF7 (Invasive ductal breast carcinoma) NRF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NRF1		ENCODE	ENCSR135ANT_MCF-7_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	4422
1	3461	RUNX1	0.0432091104870289	0.757247985404052	43	3165	2798	429	3165	2130	54	161	153	RUNX1 CUTLL1 (T-cell lymphoblastic lymphoma 1) RUNX1	CUTLL1 (T-cell lymphoblastic lymphoma 1)	NULL	RUNX1	vehicle	GTRD	EXP032406_CUTLL1--T-cell-lymphoblastic-lymphoma-1-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	37352
1	3936	TFAP4	0.0432091104870289	0.757247985404052	43	3165	2798	429	3165	2130	54	161	153	TFAP4 COLO-320 (colon adenocarcinoma) TFAP4	COLO-320 (colon adenocarcinoma)	BTO:0002047	TFAP4	NA	GTRD	EXP037553_COLO-320--colon-adenocarcinoma-_TFAP4_MACS_TFAP4_MA0691.1.damo.pwm.bed	56917
1	690	CTCF	0.0431621293187743	0.741454775510219	34	3167	2867	729	3167	2250	44	170	163	CTCF tibial nerve CTCF	tibial nerve	NULL	CTCF		GTRD	EXP039463_tibial-nerve_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31765
1	1492	FLI1	0.0431621293187743	0.741454775510219	34	3167	2867	729	3167	2250	44	170	163	FLI1 A-673 clone Asp114 (Ewing sarcoma) FLI1	A-673 clone Asp114 (Ewing sarcoma)	NULL	FLI1		GTRD	EXP047960_A-673-clone-Asp114--Ewing-sarcoma-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	48940
1	2629	KLF12	0.0431621293187743	0.741454775510219	34	3167	2867	729	3167	2250	44	170	163	KLF12 HEK293 (embryonic kidney) KLF12	HEK293 (embryonic kidney)	NULL	KLF12	NA	GTRD	EXP035943_HEK293--embryonic-kidney-_KLF12_MACS_KLF12_MA0742.1.damo.pwm.bed	8890
1	1222	ESR1	0.0431325975404296	0.609833233709782	8	3170	3326	2697	3326	3060	13	196	194	ESR1 endometrioid adenocarcinoma ESR1	endometrioid adenocarcinoma	NULL	ESR1	tumor C	GTRD	EXP036410_endometrioid-adenocarcinoma_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	8146
1	2674	MAFF	0.0431325975404296	0.609833233709782	8	3170	3326	2697	3326	3060	13	196	194	MAFF K562 (myelogenous leukemia) MAFF	K562 (myelogenous leukemia)	NULL	MAFF	NA	ENCODE	ENCSR000EGI_K562_MAFF_MACS_MAFF_MA0495.3.damo.pwm.bed	24504
1	3496	RUNX1	0.0429304388806522	0.769589033621969	54	3172	2740	225	3172	2050	66	150	141	RUNX1 CD34+ cells RUNX1	CD34+ cells	NULL	RUNX1		GEO	GSE64862_runx1_cd34_MACS_RUNX1_MA0002.2.damo.pwm.bed	27202
1	1191	ESR1	0.0420455137841896	0.718400013264875	26	3173	2959	1204	3173	2450	35	178	172	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	oestrogen	GTRD	EXP030928_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	58978
1	1625	FOSL2	0.0420455137841896	0.718400013264875	26	3173	2959	1204	3173	2450	35	178	172	FOSL2 LPS141 (Dedifferentiated liposarcoma) FOSL2	LPS141 (Dedifferentiated liposarcoma)	NULL	FOSL2		GTRD	EXP057976_LPS141--Dedifferentiated-liposarcoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	52720
1	431	CREM	0.0419541052892238	0.736580052424576	33	3175	2876	778	3175	2280	43	171	164	CREM GM12878 (female B-cells lymphoblastoid cell line) CREM	GM12878 (female B-cells lymphoblastoid cell line)	NULL	CREM	NA	ENCODE	ENCSR839XZU_GM12878_CREM_MACS_CREM_MA0609.2.damo.pwm.bed	27018
1	883	CTCF	0.0419541052892238	0.736580052424576	33	3175	2876	778	3175	2280	43	171	164	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: 110 mM NaCl for 60 min  Source: T47D whole cell	GTRD	EXP053050_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	22871
1	2810	MYC	0.0419541052892238	0.736580052424576	33	3175	2876	778	3175	2280	43	171	164	MYC HepG2 (hepatoblastoma) MYC	HepG2 (hepatoblastoma)	BTO:0000599	MYC	NULL	GTRD	EXP000993_HepG2--hepatoblastoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	11330
1	2904	MYC	0.0419541052892238	0.736580052424576	33	3175	2876	778	3175	2280	43	171	164	MYC G401 (rhabdoid tumor of the kidney) MYC	G401 (rhabdoid tumor of the kidney)	BTO:0002586	MYC	Passage: ten-thirty; Genotype: EGFP transfection;	GTRD	EXP057894_G401--rhabdoid-tumor-of-the-kidney-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	8713
1	1661	FOXA1	0.0417955522530919	0.69549366170103	20	3179	3036	1606	3179	2610	28	184	179	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	shCtrl	GTRD	EXP035557_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	67734
1	1958	GATA3	0.0417955522530919	0.69549366170103	20	3179	3036	1606	3179	2610	28	184	179	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3		ENCODE	ENCSR000BST_MCF-7_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	64723
1	2071	GRHL2	0.0417955522530919	0.69549366170103	20	3179	3036	1606	3179	2610	28	184	179	GRHL2 HBE GRHL2	HBE	NA	GRHL2		GEO	GSE46194_grhl2_hbe_MACS_GRHL2_MA1105.2.damo.pwm.bed	40252
1	1013	E2F1	0.0416077956866798	0.764898010760789	52	3182	2753	244	3182	2060	64	152	143	E2F1 LNCaP (prostate carcinoma) E2F1	LNCaP (prostate carcinoma)	BTO:0001321	E2F1	Vehicle	GTRD	EXP032858_LNCaP--prostate-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	15138
1	3641	SP2	0.0416077956866798	0.764898010760789	52	3182	2753	244	3182	2060	64	152	143	SP2 HEK293 (embryonic kidney) SP2	HEK293 (embryonic kidney)	NULL	SP2	NA	GTRD	EXP039876_HEK293--embryonic-kidney-_SP2_MACS_SP2_MA0516.2.damo.pwm.bed	14615
1	1394	ESR1	0.0415430429967939	0.637696971423155	11	3184	3229	2332	3229	2920	17	193	190	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GEO	GSE45822_esr1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	30934
1	1527	FOS	0.0415430429967939	0.637696971423155	11	3184	3229	2332	3229	2920	17	193	190	FOS K562 (myelogenous leukemia) FOS	K562 (myelogenous leukemia)	NULL	FOS	24 hours following induction with TPA	GTRD	EXP000589_K562--myelogenous-leukemia-_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	14073
1	1592	FOSL2	0.0415430429967939	0.637696971423155	11	3184	3229	2332	3229	2920	17	193	190	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039658_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	12868
1	1593	FOSL2	0.0415430429967939	0.637696971423155	11	3184	3229	2332	3229	2920	17	193	190	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039658_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	12858
1	1594	FOSL2	0.0415430429967939	0.637696971423155	11	3184	3229	2332	3229	2920	17	193	190	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039658_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	13418
1	1595	FOSL2	0.0415430429967939	0.637696971423155	11	3184	3229	2332	3229	2920	17	193	190	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039658_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	13481
1	2453	JUN	0.0415430429967939	0.637696971423155	11	3184	3229	2332	3229	2920	17	193	190	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: control (scrambled shRNA);	GTRD	EXP058211_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	8109
1	2460	JUN	0.0415430429967939	0.637696971423155	11	3184	3229	2332	3229	2920	17	193	190	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: control (scrambled shRNA);	GTRD	EXP058211_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	8231
1	2901	MYC	0.0415430429967939	0.637696971423155	11	3184	3229	2332	3229	2920	17	193	190	MYC G401 (rhabdoid tumor of the kidney) MYC	G401 (rhabdoid tumor of the kidney)	BTO:0002586	MYC	Passage: ten-thirty; Genotype: EGFP transfection;	GTRD	EXP057893_G401--rhabdoid-tumor-of-the-kidney-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	2647
1	238	ASCL1	0.0414586198014926	0.668045030842376	15	3193	3142	1993	3193	2780	22	189	185	ASCL1 NCI-H889 (small cell lung carcinoma) ASCL1	NCI-H889 (small cell lung carcinoma)	BTO:0005667	ASCL1		GEO	GSE69394_ascl1_h889_MACS_ASCL1_MA1100.2.damo.pwm.bed	32075
1	3090	NR3C1	0.0414586198014926	0.668045030842376	15	3193	3142	1993	3193	2780	22	189	185	NR3C1 IMR90 (lung fibroblasts) NR3C1	IMR90 (lung fibroblasts)	NULL	NR3C1	GLUCC	Array Express	ERP007081_nr3c1_imr90-glucc_MACS_NR3C1_MA0113.3.damo.pwm.bed	28403
1	3327	RBPJ	0.0414586198014926	0.668045030842376	15	3193	3142	1993	3193	2780	22	189	185	RBPJ CUTLL1 (T-cell lymphoblastic lymphoma 1) RBPJ	CUTLL1 (T-cell lymphoblastic lymphoma 1)	NULL	RBPJ		GEO	GSE29600_rbpj_cutll_MACS_RBPJ_MA1116.1.damo.pwm.bed	5497
1	3726	STAT1	0.0414586198014926	0.668045030842376	15	3193	3142	1993	3193	2780	22	189	185	STAT1 HeLa S3 (cervical adenocarcinoma) STAT1	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	STAT1	IFNgamma	GTRD	EXP000505_HeLa-S3--cervical-adenocarcinoma-_STAT1_MACS_STAT1_MA0137.3.damo.pwm.bed	15253
1	4077	USF1	0.0414586198014926	0.668045030842376	15	3193	3142	1993	3193	2780	22	189	185	USF1 SK-N-SH (neuroblastoma) USF1	SK-N-SH (neuroblastoma)	BTO:0001620	USF1		ENCODE	ENCSR000BTZ_SK-N-SH_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	10024
1	26	AR	0.0414571860347202	0.500816543313362	3	3198	3591	3316	3591	3370	6	201	201	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	BICALUTAMIDE	GTRD	EXP032855_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	7677
1	59	AR	0.0414571860347202	0.500816543313362	3	3198	3591	3316	3591	3370	6	201	201	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR		GTRD	EXP037262_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	13621
1	92	AR	0.0414571860347202	0.500816543313362	3	3198	3591	3316	3591	3370	6	201	201	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: 10 nM DHT for 4 hrs Genotype: Bag-1L knockout	GTRD	EXP049286_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	15036
1	158	AR	0.0414571860347202	0.500816543313362	3	3198	3591	3316	3591	3370	6	201	201	AR AR	NA	NA	AR	NA	GEO	GSE55062_AR_vcap-dht-mdv3100_MACS_AR_MA0007.3.damo.pwm.bed	15178
1	2195	HSF1	0.0414571860347202	0.500816543313362	3	3198	3591	3316	3591	3370	6	201	201	HSF1 U2OS (osteosarcoma) HSF1	U2OS (osteosarcoma)	BTO:0001938	HSF1	HEAT	GEO	GSE60984_hsf1_u2os-heat_MACS_HSF1_MA0486.2.damo.pwm.bed	7517
1	2632	KLF4	0.0414571860347202	0.500816543313362	3	3198	3591	3316	3591	3370	6	201	201	KLF4 MCF7 (Invasive ductal breast carcinoma) KLF4	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	KLF4		ENCODE	ENCSR265WJC_MCF-7_KLF4_MACS_KLF4_MA0039.4.damo.pwm.bed	1950
1	2655	KLF9	0.0414571860347202	0.500816543313362	3	3198	3591	3316	3591	3370	6	201	201	KLF9 GBM1A KLF9	GBM1A	NA	KLF9	NA	GEO	GSE62211_klf9_gbm1b_MACS_KLF9_MA1107.2.damo.pwm.bed	876
1	3018	NFIC	0.0414571860347202	0.500816543313362	3	3198	3591	3316	3591	3370	6	201	201	NFIC HepG2 (hepatoblastoma) NFIC	HepG2 (hepatoblastoma)	BTO:0000599	NFIC	NA	GTRD	EXP040843_HepG2--hepatoblastoma-_NFIC_MACS_NFIC_MA1527.1.damo.pwm.bed	6415
1	3827	TEAD1	0.0414571860347202	0.500816543313362	3	3198	3591	3316	3591	3370	6	201	201	TEAD1 CC-LP-1 (intrahepatic cholangiocarcinoma) TEAD1	CC-LP-1 (intrahepatic cholangiocarcinoma)	NULL	TEAD1		GEO	GSE62272_tead1_cclp1_MACS_TEAD1_MA0090.3.damo.pwm.bed	3431
1	3472	RUNX1	0.0413801262611401	0.750295417829476	41	3207	2832	476	3207	2170	52	163	155	RUNX1 SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) RUNX1	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	RUNX1	RUNX1-EVI1 KD after 10 days	GTRD	EXP037837_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	32033
1	168	AR	0.0411997619149501	0.553545682331584	5	3208	3459	3053	3459	3240	9	199	198	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	DHT24H	GEO	GSE58428_AR_lncap-dht24h_MACS_AR_MA0007.3.damo.pwm.bed	13725
1	196	AR	0.0411997619149501	0.553545682331584	5	3208	3459	3053	3459	3240	9	199	198	AR DUCaP (prostate carcinoma) AR	DUCaP (prostate carcinoma)	NULL	AR	ANDROGEN	GEO	GSE70679_AR_ducap-androgen_MACS_AR_MA0007.3.damo.pwm.bed	21213
1	424	CREB1	0.0411997619149501	0.553545682331584	5	3208	3459	3053	3459	3240	9	199	198	CREB1 MDA-MB-134 (invasive lobular breast carcinoma) CREB1	MDA-MB-134 (invasive lobular breast carcinoma)	NULL	CREB1	Treatment:100 nM estradiol (E2) for 1hr Passage: between 10 and12 CellType: Epithelial ERalpha positive breast cancer cell line	GTRD	EXP048181_MDA-MB-134--invasive-lobular-breast-carcinoma-_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	1474
1	1115	EOMES	0.0411997619149501	0.553545682331584	5	3208	3459	3053	3459	3240	9	199	198	EOMES hESC-1 (Embryonic stem cells) EOMES	hESC-1 (Embryonic stem cells)	NULL	EOMES	NA	GEO	GSE26097_eomes_esc_MACS_EOMES_MA0800.1.damo.pwm.bed	31879
1	2148	HNF4A	0.0411997619149501	0.553545682331584	5	3208	3459	3053	3459	3240	9	199	198	HNF4A HCT-116 (colon carcinoma) HNF4A	HCT-116 (colon carcinoma)	BTO:0001109	HNF4A		GEO	GSE62890_hnf4a_hct166_MACS_HNF4A_MA0114.4.damo.pwm.bed	5293
1	2887	MYC	0.0404390193684116	0.746592308280747	40	3213	2851	502	3213	2190	51	164	156	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 1;	GTRD	EXP047489_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	11427
1	3058	NR2F1	0.0404358780695135	0.711241816487613	25	3214	2983	1262	3214	2490	34	179	173	NR2F1 K562 (myelogenous leukemia) NR2F1	K562 (myelogenous leukemia)	NULL	NR2F1	NA	ENCODE	ENCSR970NKQ_K562_NR2F1_MACS_NR2F1_MA0017.2.damo.pwm.bed	33816
1	1536	FOS	0.0396809510242475	0.685317771842839	19	3215	3072	1697	3215	2660	27	185	180	FOS HUVEC-C (HUVEC, umbilical vein endothelial cells) FOS	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FOS	NULL	GTRD	EXP000672_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FOS_MACS_FOS_MA1134.1.damo.pwm.bed	40074
1	1537	FOS	0.0396809510242475	0.685317771842839	19	3215	3072	1697	3215	2660	27	185	180	FOS HUVEC-C (HUVEC, umbilical vein endothelial cells) FOS	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FOS	NULL	GTRD	EXP000672_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FOS_MACS_FOS_MA1141.1.damo.pwm.bed	40332
1	2785	MYC	0.0396809510242475	0.685317771842839	19	3215	3072	1697	3215	2660	27	185	180	MYC HepG2 (hepatoblastoma) MYC	HepG2 (hepatoblastoma)	BTO:0000599	MYC		ENCODE	ENCSR000DLR_HepG2_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	6851
1	2892	MYC	0.0394799756995335	0.742726245875184	39	3218	2863	547	3218	2210	50	165	157	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 4;	GTRD	EXP047491_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	13387
1	533	CTCF	0.0394649105422416	0.726075441751947	31	3219	2924	881	3219	2340	41	173	166	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DVI_retinal_pigment_epithelial_cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46121
1	3679	SPI1	0.0394649105422416	0.726075441751947	31	3219	2924	881	3219	2340	41	173	166	SPI1 Kasumi-1 (acute myeloblastic leukemia) SPI1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	SPI1	SIRUNX1ETO	GEO	GSE60130_spi1_kasumi1-sirunx1eto_MACS_SPI1_MA0080.5.damo.pwm.bed	47350
1	3367	RELA	0.038791081703017	0.703636650737019	24	3221	3007	1324	3221	2520	33	180	174	RELA Detroit 562 (Pharyngeal squamous cell carcinoma) RELA	Detroit 562 (Pharyngeal squamous cell carcinoma)	BTO:0000834	RELA	Treatment: Poly I:C	GTRD	EXP049366_Detroit-562--Pharyngeal-squamous-cell-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	21099
1	3539	RXRA	0.038791081703017	0.703636650737019	24	3221	3007	1324	3221	2520	33	180	174	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA S427F	GTRD	EXP040816_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA1146.1.damo.pwm.bed	11466
1	2075	HAND2	0.0386455117938117	0.653308523126499	14	3223	3198	2073	3223	2830	21	190	186	HAND2 CLB-Ga (neuroblastoma) HAND2	CLB-Ga (neuroblastoma)	NULL	HAND2	none	GTRD	EXP039006_CLB-Ga--neuroblastoma-_HAND2_MACS_HAND2_MA1638.1.damo.pwm.bed	33850
1	2334	JUN	0.0386455117938117	0.653308523126499	14	3223	3198	2073	3223	2830	21	190	186	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 15 minute	GTRD	EXP040263_A549--lung-carcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	13892
1	2349	JUN	0.0386455117938117	0.653308523126499	14	3223	3198	2073	3223	2830	21	190	186	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 5 minute	GTRD	EXP040322_A549--lung-carcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	18128
1	2413	JUN	0.0386455117938117	0.653308523126499	14	3223	3198	2073	3223	2830	21	190	186	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: non-transformed	GTRD	EXP048571_MCF10A-ER-Src_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	28879
1	2417	JUN	0.0386455117938117	0.653308523126499	14	3223	3198	2073	3223	2830	21	190	186	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: non-transformed	GTRD	EXP048571_MCF10A-ER-Src_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	30780
1	2645	KLF5	0.0386455117938117	0.653308523126499	14	3223	3198	2073	3223	2830	21	190	186	KLF5 HCC95 (squamous cell lung carcinoma) KLF5	HCC95 (squamous cell lung carcinoma)	NULL	KLF5	Treatment: Over-expressing KLF5 E419Q	GTRD	EXP049097_HCC95--squamous-cell-lung-carcinoma-_KLF5_MACS_KLF5_MA0599.1.damo.pwm.bed	5979
1	3130	NR3C1	0.0386455117938117	0.653308523126499	14	3223	3198	2073	3223	2830	21	190	186	NR3C1 MCF10A (breast epithelial cells) NR3C1	MCF10A (breast epithelial cells)	BTO:0001939	NR3C1	Treatment: dexamethasone (DEX) 60 min;	GTRD	EXP047628_MCF10A--breast-epithelial-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	24312
1	1131	ERG	0.0380631340741107	0.751474906801791	47	3230	2817	333	3230	2130	59	157	148	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG		GTRD	EXP038637_VCaP--prostate-carcinoma-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	24449
1	1204	ESR1	0.037854160519746	0.578172227725018	7	3231	3411	2812	3411	3150	12	197	195	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2+PG	GTRD	EXP034903_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	7125
1	2298	JUN	0.037854160519746	0.578172227725018	7	3231	3411	2812	3411	3150	12	197	195	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	oxpapc, 4h	GTRD	EXP038044_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	7998
1	2384	JUN	0.037854160519746	0.578172227725018	7	3231	3411	2812	3411	3150	12	197	195	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048209_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	7175
1	2543	JUNB	0.037854160519746	0.578172227725018	7	3231	3411	2812	3411	3150	12	197	195	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039942_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	12505
1	2544	JUNB	0.037854160519746	0.578172227725018	7	3231	3411	2812	3411	3150	12	197	195	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039942_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	13125
1	2545	JUNB	0.037854160519746	0.578172227725018	7	3231	3411	2812	3411	3150	12	197	195	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039942_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	13157
1	2546	JUNB	0.037854160519746	0.578172227725018	7	3231	3411	2812	3411	3150	12	197	195	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039942_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	12561
1	2547	JUNB	0.037854160519746	0.578172227725018	7	3231	3411	2812	3411	3150	12	197	195	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039942_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	13173
1	4010	TP53	0.037854160519746	0.578172227725018	7	3231	3411	2812	3411	3150	12	197	195	TP53 hESC-1 (Embryonic stem cells) TP53	hESC-1 (Embryonic stem cells)	NULL	TP53	DAMAGED	GEO	GSE39912_tp53_esc-damaged_MACS_TP53_MA0106.3.damo.pwm.bed	10320
1	1069	EGR2	0.0378329621062708	0.77335871796262	77	3240	2713	24	3240	1990	91	127	116	EGR2 HEK293 (embryonic kidney) EGR2	HEK293 (embryonic kidney)	NULL	EGR2	NA	GTRD	EXP035947_HEK293--embryonic-kidney-_EGR2_MACS_EGR2_MA0472.2.damo.pwm.bed	69670
1	1526	FOS	0.0377314015284703	0.616057185863615	10	3241	3319	2442	3319	3000	16	194	191	FOS K562 (myelogenous leukemia) FOS	K562 (myelogenous leukemia)	NULL	FOS	24 hours following induction with TPA	GTRD	EXP000589_K562--myelogenous-leukemia-_FOS_MACS_FOS_MA0099.3.damo.pwm.bed	13551
1	1785	FOXA1	0.0377314015284703	0.616057185863615	10	3241	3319	2442	3319	3000	16	194	191	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	E2	GEO	GSE59530_foxa1_mcf7-e2_MACS_FOXA1_MA0148.4.damo.pwm.bed	29698
1	2312	JUN	0.0377314015284703	0.616057185863615	10	3241	3319	2442	3319	3000	16	194	191	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039496_A549--lung-carcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	10989
1	2558	JUNB	0.0377314015284703	0.616057185863615	10	3241	3319	2442	3319	3000	16	194	191	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP040135_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	14999
1	3610	SOX2	0.0377314015284703	0.616057185863615	10	3241	3319	2442	3319	3000	16	194	191	SOX2 BJ (fibroblasts) SOX2	BJ (fibroblasts)	NULL	SOX2	INDUCED	GEO	GSE36570_sox2_bj-induced_MACS_SOX2_MA0143.4.damo.pwm.bed	76252
1	1030	E2F1	0.0375134093136565	0.674346257860084	18	3246	3091	1785	3246	2710	26	186	181	E2F1 LNCaP-abl (Prostate carcinoma) E2F1	LNCaP-abl (Prostate carcinoma)	NULL	E2F1		GEO	GSE67809_e2f1_lncap-abl_MACS_E2F1_MA0024.3.damo.pwm.bed	5388
1	1134	ERG	0.0375134093136565	0.674346257860084	18	3246	3091	1785	3246	2710	26	186	181	ERG HUVEC-C (HUVEC, umbilical vein endothelial cells) ERG	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ERG	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048203_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	13500
1	1781	FOXA1	0.0375134093136565	0.674346257860084	18	3246	3091	1785	3246	2710	26	186	181	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	ETOH24H	GEO	GSE58428_foxa1_lncap-etoh24h_MACS_FOXA1_MA0148.4.damo.pwm.bed	65389
1	1017	E2F1	0.0373864474207971	0.761463017121211	58	3249	2765	154	3249	2060	71	146	136	E2F1 LNCaP (prostate carcinoma) E2F1	LNCaP (prostate carcinoma)	BTO:0001321	E2F1	BICALUTAMIDE	GTRD	EXP032865_LNCaP--prostate-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	18280
1	1016	E2F1	0.0373126982118207	0.748462194732254	46	3250	2837	349	3250	2150	58	158	149	E2F1 LNCaP (prostate carcinoma) E2F1	LNCaP (prostate carcinoma)	BTO:0001321	E2F1	BICALUTAMIDE	GTRD	EXP032863_LNCaP--prostate-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	15214
1	1093	ELF3	0.0373126982118207	0.748462194732254	46	3250	2837	349	3250	2150	58	158	149	ELF3 PDAC ELF3	PDAC	NA	ELF3	KOKLF5	GEO	GSE64557_elf3_pdac-koklf5_MACS_ELF3_MA0640.2.damo.pwm.bed	45750
1	2625	KLF1	0.0373126982118207	0.748462194732254	46	3250	2837	349	3250	2150	58	158	149	KLF1 HEK293 (embryonic kidney) KLF1	HEK293 (embryonic kidney)	NULL	KLF1	NA	GTRD	EXP035894_HEK293--embryonic-kidney-_KLF1_MACS_KLF1_MA0493.1.damo.pwm.bed	21494
1	2845	MYC	0.0368770704252619	0.714436447530163	29	3253	2974	1013	3253	2410	39	175	168	MYC HUES64 (embryonic stem cells) MYC	HUES64 (embryonic stem cells)	NULL	MYC		GTRD	EXP036776_HUES64--embryonic-stem-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	9277
1	2889	MYC	0.0368770704252619	0.714436447530163	29	3253	2974	1013	3253	2410	39	175	168	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 4;	GTRD	EXP047490_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	9268
1	576	CTCF	0.0365894311450366	0.769124692282113	73	3255	2741	35	3255	2010	87	131	120	CTCF normal epidermal keratinocytes CTCF	normal epidermal keratinocytes	NULL	CTCF	NULL	GTRD	EXP000600_normal-epidermal-keratinocytes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	89606
1	1476	ETV1	0.0364941033049373	0.73004908580215	36	3256	2899	645	3256	2270	47	168	160	ETV1 COLO800 (human melanoma cells) ETV1	COLO800 (human melanoma cells)	NULL	ETV1	Treatment: cells were harvested in log phase growth	GTRD	EXP048912_COLO800--human-melanoma-cells-_ETV1_MACS_ETV1_MA0761.2.damo.pwm.bed	24050
1	1487	FLI1	0.0359106012825234	0.766715313950813	71	3257	2743	39	3257	2010	85	133	122	FLI1 HUVEC-C (HUVEC, umbilical vein endothelial cells) FLI1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FLI1	NULL	GTRD	EXP000132_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	63010
1	1845	FOXA2	0.0357482115667004	0.637085358302797	13	3258	3242	2153	3258	2880	20	191	187	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Genotype: clonal FOXA2 doxycycline inducible cells, OXA2 GATA4 Coexpressing	GTRD	EXP049380_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	74487
1	2459	JUN	0.0357482115667004	0.637085358302797	13	3258	3242	2153	3258	2880	20	191	187	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: control (scrambled shRNA);	GTRD	EXP058211_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	11223
1	2902	MYC	0.0357482115667004	0.637085358302797	13	3258	3242	2153	3258	2880	20	191	187	MYC G401 (rhabdoid tumor of the kidney) MYC	G401 (rhabdoid tumor of the kidney)	BTO:0002586	MYC	Passage: ten-thirty; Genotype: EGFP transfection;	GTRD	EXP057893_G401--rhabdoid-tumor-of-the-kidney-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	3272
1	3810	TCF7L2	0.0357482115667004	0.637085358302797	13	3258	3242	2153	3258	2880	20	191	187	TCF7L2 HeLa S3 (cervical adenocarcinoma) TCF7L2	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	TCF7L2		ENCODE	ENCSR000EVE_HeLa-S3_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	11884
1	266	BACH1	0.0355459733770666	0.708136169095098	28	3262	2995	1068	3262	2440	38	176	169	BACH1 WA01 (H1, human embryonic stem cells) BACH1	WA01 (H1, human embryonic stem cells)	NULL	BACH1	NA	ENCODE	ENCSR000EBQ_H1-hESC_BACH1_MACS_BACH1_MA0591.1.damo.pwm.bed	14931
1	1624	FOSL2	0.0355459733770666	0.708136169095098	28	3262	2995	1068	3262	2440	38	176	169	FOSL2 LPS141 (Dedifferentiated liposarcoma) FOSL2	LPS141 (Dedifferentiated liposarcoma)	NULL	FOSL2		GTRD	EXP057976_LPS141--Dedifferentiated-liposarcoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	56002
1	2804	MYC	0.0354623190542743	0.72542551742421	35	3264	2927	691	3264	2290	46	169	161	MYC normal epidermal keratinocytes MYC	normal epidermal keratinocytes	NULL	MYC	NULL	GTRD	EXP000989_normal-epidermal-keratinocytes_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	13748
1	2479	JUNB	0.0353957265041987	0.686913183013592	22	3265	3068	1459	3265	2600	31	182	176	JUNB HAEC (human aortic endothelial cells) JUNB	HAEC (human aortic endothelial cells)	NULL	JUNB	control, 4h	GTRD	EXP038040_HAEC--human-aortic-endothelial-cells-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	31160
1	2481	JUNB	0.0353957265041987	0.686913183013592	22	3265	3068	1459	3265	2600	31	182	176	JUNB HAEC (human aortic endothelial cells) JUNB	HAEC (human aortic endothelial cells)	NULL	JUNB	control, 4h	GTRD	EXP038040_HAEC--human-aortic-endothelial-cells-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	31510
1	3084	NR2F6	0.0353957265041987	0.686913183013592	22	3265	3068	1459	3265	2600	31	182	176	NR2F6 K562 (myelogenous leukemia) NR2F6	K562 (myelogenous leukemia)	NULL	NR2F6	NA	GTRD	EXP040021_K562--myelogenous-leukemia-_NR2F6_MACS_NR2F6_MA0728.1.damo.pwm.bed	26732
1	1743	FOXA1	0.0352931541224611	0.6624837761902	17	3268	3173	1846	3268	2760	25	187	182	FOXA1 primary prostate cancer FOXA1	primary prostate cancer	NULL	FOXA1	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053243_primary-prostate-cancer_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	24283
1	1843	FOXA2	0.0352931541224611	0.6624837761902	17	3268	3173	1846	3268	2760	25	187	182	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Treatment: addition of 200 uM mimosine over night Genotype: Clonal FOXA2 doxycycline inducible cells	GTRD	EXP049378_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	77665
1	1007	E2F1	0.0351601934162867	0.752767894017548	54	3270	2816	225	3270	2100	67	150	140	E2F1 MCF7 (Invasive ductal breast carcinoma) E2F1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	E2F1	NULL	GTRD	EXP000659_MCF7--Invasive-ductal-breast-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	19822
1	3926	TFAP2C	0.0348208068147171	0.762707920282192	68	3271	2760	56	3271	2030	82	136	125	TFAP2C MDA-MB-453 (breast adenocarcinoma) TFAP2C	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	TFAP2C		GEO	GSE36351_tfap2c_mdamb453_MACS_TFAP2C_MA0524.2.damo.pwm.bed	65102
1	2099	HIF1A	0.0344122462675515	0.720581365335355	34	3272	2945	729	3272	2320	45	170	162	HIF1A PC3(bone mets prostate adenocarcinoma) HIF1A	PC3(bone mets prostate adenocarcinoma)	NULL	HIF1A	Treatment: siCtrl;	GTRD	EXP057821_PC3-bone-mets-prostate-adenocarcinoma-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	51217
1	2210	IRF4	0.0344122462675515	0.720581365335355	34	3272	2945	729	3272	2320	45	170	162	IRF4 GM12878 (female B-cells lymphoblastoid cell line) IRF4	GM12878 (female B-cells lymphoblastoid cell line)	NULL	IRF4		ENCODE	ENCSR000BGY_GM12878_IRF4_MACS_IRF4_MA1419.1.damo.pwm.bed	32606
1	2886	MYC	0.0344122462675515	0.720581365335355	34	3272	2945	729	3272	2320	45	170	162	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 1;	GTRD	EXP047488_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	11025
1	3277	POU5F1	0.034190157520054	0.701481024767682	27	3275	3012	1135	3275	2470	37	177	170	POU5F1 HUES8 (Embryonic stem cell, blastocyst stage) POU5F1	HUES8 (Embryonic stem cell, blastocyst stage)	NULL	POU5F1	Genotype: SOX17-GFP knockout;	GTRD	EXP057927_HUES8--Embryonic-stem-cell--blastocyst-stage-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	49407
1	1886	GABPA	0.0339791441877286	0.747905966095259	52	3276	2843	244	3276	2120	65	152	142	GABPA Jurkat (T-cells) GABPA	Jurkat (T-cells)	BTO:0000661	GABPA		GEO	GSE49091_gabpa_jurkat_MACS_GABPA_MA0062.3.damo.pwm.bed	61896
1	1570	FOSL1	0.033776136320592	0.591518217551735	9	3277	3387	2564	3387	3080	15	195	192	FOSL1 BT-549 (breast invasive ductal carcinoma) FOSL1	BT-549 (breast invasive ductal carcinoma)	BTO:0002548	FOSL1	NA	GEO	GSE46166_fosl1_bt549_MACS_FOSL1_MA0477.2.damo.pwm.bed	16372
1	2557	JUNB	0.033776136320592	0.591518217551735	9	3277	3387	2564	3387	3080	15	195	192	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP040135_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	15433
1	2783	MYC	0.033645536555082	0.677694389597617	21	3279	3087	1535	3279	2630	30	183	177	MYC GM12878 (female B-cells lymphoblastoid cell line) MYC	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MYC		ENCODE	ENCSR000DKU_GM12878_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	6148
1	3757	STAT5B	0.033645536555082	0.677694389597617	21	3279	3087	1535	3279	2630	30	183	177	STAT5B CD8 STAT5B	CD8	NA	STAT5B	H9	GEO	GSE64713_stat5b_cd8-h9_MACS_STAT5B_MA0519.1.damo.pwm.bed	15254
1	3508	RUNX3	0.0333715553924653	0.745333652210135	51	3281	2852	261	3281	2130	64	153	143	RUNX3 GM12878 (female B-cells lymphoblastoid cell line) RUNX3	GM12878 (female B-cells lymphoblastoid cell line)	NULL	RUNX3	NA	ENCODE	ENCSR000BRI_GM12878_RUNX3_MACS_RUNX3_MA0684.2.damo.pwm.bed	82726
1	132	AR	0.0331883193588347	0.498319371030307	4	3282	3601	3182	3601	3360	8	200	199	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	R1881_1C26	GEO	GSE32892_AR_vcap-r1881-1c26_MACS_AR_MA0007.3.damo.pwm.bed	15595
1	179	AR	0.0331883193588347	0.498319371030307	4	3282	3601	3182	3601	3360	8	200	199	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	R1881_HOTAIR	GEO	GSE61268_AR_lncap-r1881-hotair_MACS_AR_MA0007.3.damo.pwm.bed	9734
1	209	AR	0.0331883193588347	0.498319371030307	4	3282	3601	3182	3601	3360	8	200	199	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	DHT_TNFA	GEO	GSE83860_AR_lncap-dht-tnfa_MACS_AR_MA0007.3.damo.pwm.bed	20267
1	2113	HNF1A	0.0331883193588347	0.498319371030307	4	3282	3601	3182	3601	3360	8	200	199	HNF1A HepG2 (hepatoblastoma) HNF1A	HepG2 (hepatoblastoma)	BTO:0000599	HNF1A		GTRD	EXP039789_HepG2--hepatoblastoma-_HNF1A_MACS_HNF1A_MA0046.2.damo.pwm.bed	8142
1	2116	HNF1A	0.0331883193588347	0.498319371030307	4	3282	3601	3182	3601	3360	8	200	199	HNF1A HEE (human epididymis epithelial cells) HNF1A	HEE (human epididymis epithelial cells)	NULL	HNF1A	Treatment: untreated	GTRD	EXP048857_HEE--human-epididymis-epithelial-cells-_HNF1A_MACS_HNF1A_MA0046.2.damo.pwm.bed	11809
1	2924	MYC	0.0331883193588347	0.498319371030307	4	3282	3601	3182	3601	3360	8	200	199	MYC LS174T (colon adenocarcinoma) MYC	LS174T (colon adenocarcinoma)	BTO:0001553	MYC	BI8622	GEO	GSE59223_myc_ls174t-bi8622_MACS_MYC_MA0147.3.damo.pwm.bed	2913
1	3376	RELA	0.0331883193588347	0.498319371030307	4	3282	3601	3182	3601	3360	8	200	199	RELA IMR90 (lung fibroblasts) RELA	IMR90 (lung fibroblasts)	NULL	RELA	TNF	GEO	GSE43070_rela_imr90-tnf_MACS_RELA_MA0107.1.damo.pwm.bed	9008
1	3502	RUNX1	0.0331883193588347	0.498319371030307	4	3282	3601	3182	3601	3360	8	200	199	RUNX1 CD34+ cells RUNX1	CD34+ cells	NULL	RUNX1	FETAL	GEO	GSE70660_runx1_cd34-fetal_MACS_RUNX1_MA0002.2.damo.pwm.bed	5025
1	3843	TEAD4	0.0331883193588347	0.498319371030307	4	3282	3601	3182	3601	3360	8	200	199	TEAD4 HuCCT1 (intrahepatic cholangiocarcinoma) TEAD4	HuCCT1 (intrahepatic cholangiocarcinoma)	BTO:0003911	TEAD4		GEO	GSE68296_tead4_hucct1_MACS_TEAD4_MA0809.2.damo.pwm.bed	7660
1	776	CTCF	0.0330210089389746	0.649619072762565	16	3291	3210	1909	3291	2800	24	188	183	CTCF upper lobe of left lung CTCF	upper lobe of left lung	NULL	CTCF		GTRD	EXP040087_upper-lobe-of-left-lung_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	20517
1	3041	NR1H2	0.0330210089389746	0.649619072762565	16	3291	3210	1909	3291	2800	24	188	183	NR1H2 HT29 (colon adenocarcinoma) NR1H2	HT29 (colon adenocarcinoma)	BTO:0000182	NR1H2	GW3965_48H	GEO	GSE77039_nr1h2_ht29-gw3965-48h_MACS_NR1H2_MA0115.1.damo.pwm.bed	17654
1	3561	SIX2	0.0330210089389746	0.649619072762565	16	3291	3210	1909	3291	2800	24	188	183	SIX2 kidney SIX2	kidney	BTO:0000671	SIX2	fetal_17w	GEO	GSE75948_six2_fetal-kidney-17w_MACS_SIX2_MA1119.1.damo.pwm.bed	43926
1	3660	SPI1	0.0330210089389746	0.649619072762565	16	3291	3210	1909	3291	2800	24	188	183	SPI1 THP-1 (acute monocytic leukemia) SPI1	THP-1 (acute monocytic leukemia)	BTO:0001370	SPI1	Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA)	GTRD	EXP047818_THP-1--acute-monocytic-leukemia-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	61570
1	1395	ESR1	0.0328130307010765	0.754878626431049	63	3295	2803	103	3295	2070	77	141	130	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GEO	GSE48930_esr1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	61547
1	1627	FOSL2	0.032809806430942	0.694441668537375	26	3296	3040	1204	3296	2510	36	178	171	FOSL2 LPS141 (Dedifferentiated liposarcoma) FOSL2	LPS141 (Dedifferentiated liposarcoma)	NULL	FOSL2		GTRD	EXP057976_LPS141--Dedifferentiated-liposarcoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	52654
1	1959	GATA3	0.032809806430942	0.694441668537375	26	3296	3040	1204	3296	2510	36	178	171	GATA3 SK-N-SH (neuroblastoma) GATA3	SK-N-SH (neuroblastoma)	BTO:0001620	GATA3		ENCODE	ENCSR000BTH_SK-N-SH_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	95522
1	305	CDX2	0.0327683679997607	0.619140765255312	12	3298	3306	2233	3306	2950	19	192	188	CDX2 LS180 (colon cancer) CDX2	LS180 (colon cancer)	NULL	CDX2		GEO	GSE31939_cdx2_ls180_MACS_CDX2_MA0465.2.damo.pwm.bed	27299
1	2456	JUN	0.0327683679997607	0.619140765255312	12	3298	3306	2233	3306	2950	19	192	188	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: control (scrambled shRNA);	GTRD	EXP058211_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	10803
1	3339	RELA	0.0327683679997607	0.619140765255312	12	3298	3306	2233	3306	2950	19	192	188	RELA GM19193 (female B-cells Lymphoblastoid Cell Lines) RELA	GM19193 (female B-cells Lymphoblastoid Cell Lines)	NULL	RELA	TNF-alpha induced (6h)	GTRD	EXP000756_GM19193--female-B-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	10237
1	3829	TEAD1	0.0327683679997607	0.619140765255312	12	3298	3306	2233	3306	2950	19	192	188	TEAD1 HuCCT1 (intrahepatic cholangiocarcinoma) TEAD1	HuCCT1 (intrahepatic cholangiocarcinoma)	BTO:0003911	TEAD1		GEO	GSE68296_tead1_hucct1_MACS_TEAD1_MA0090.3.damo.pwm.bed	28061
1	181	AR	0.0323043837701752	0.540738355244735	6	3302	3483	2948	3483	3240	11	198	196	AR prostate AR	prostate	NULL	AR	DHT	GEO	GSE61838_AR_prostate-dht_MACS_AR_MA0007.3.damo.pwm.bed	15464
1	204	AR	0.0323043837701752	0.540738355244735	6	3302	3483	2948	3483	3240	11	198	196	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	SH1_DHT	GEO	GSE79128_AR_vcap-sh1-dht_MACS_AR_MA0007.3.damo.pwm.bed	26210
1	2139	HNF4A	0.0323043837701752	0.540738355244735	6	3302	3483	2948	3483	3240	11	198	196	HNF4A hiPSC HNF4A	hiPSC	NULL	HNF4A	Developmental stage: day 8;	GTRD	EXP057766_hiPSC_HNF4A_MACS_HNF4A_MA1494.1.damo.pwm.bed	7382
1	2751	MGA	0.0323043837701752	0.540738355244735	6	3302	3483	2948	3483	3240	11	198	196	MGA K562 (myelogenous leukemia) MGA	K562 (myelogenous leukemia)	NULL	MGA	NA	GTRD	EXP040079_K562--myelogenous-leukemia-_MGA_MACS_MGA_MA0801.1.damo.pwm.bed	5244
1	3560	SIX2	0.0323043837701752	0.540738355244735	6	3302	3483	2948	3483	3240	11	198	196	SIX2 kidney SIX2	kidney	BTO:0000671	SIX2	fetal_16w	GEO	GSE75948_six2_fetal-kidney-16w_MACS_SIX2_MA1119.1.damo.pwm.bed	22009
1	82	AR	0.0322574331890449	0.710170813066219	32	3307	2990	825	3307	2370	43	172	164	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: control	GTRD	EXP049186_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	28053
1	1727	FOXA1	0.0322574331890449	0.710170813066219	32	3307	2990	825	3307	2370	43	172	164	FOXA1 RT4 (Bladder carcinoma cells) FOXA1	RT4 (Bladder carcinoma cells)	NULL	FOXA1	Treatment: not applicable Stage:adult  Tissue: transitional cell papilloma	GTRD	EXP049024_RT4--Bladder-carcinoma-cells-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	59707
1	1275	ESR1	0.031861031709497	0.667825659705942	20	3309	3147	1606	3309	2690	29	184	178	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP038388_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	24996
1	1535	FOS	0.031861031709497	0.667825659705942	20	3309	3147	1606	3309	2690	29	184	178	FOS HUVEC-C (HUVEC, umbilical vein endothelial cells) FOS	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FOS	NULL	GTRD	EXP000672_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	42988
1	1943	GATA2	0.031861031709497	0.667825659705942	20	3309	3147	1606	3309	2690	29	184	178	GATA2 endometrial stromal cells GATA2	endometrial stromal cells	NULL	GATA2		GTRD	EXP040835_endometrial-stromal-cells_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	52185
1	2877	MYC	0.0314804416039371	0.737000091163654	48	3312	2872	317	3312	2170	61	156	146	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shSCR;	GTRD	EXP047484_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	18052
1	1515	FOS	0.0314052381159844	0.6869853924056	25	3313	3067	1262	3313	2550	35	179	172	FOS FOS	NA	NA	FOS	NA	NA	ENCSR000DON_MCF_10A_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	64757
1	3629	SP1	0.0310340242504063	0.747445519193851	59	3314	2844	143	3314	2100	73	145	134	SP1 HCT-116 (colon carcinoma) SP1	HCT-116 (colon carcinoma)	BTO:0001109	SP1		GTRD	EXP036140_HCT-116--colon-carcinoma-_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	36295
1	4127	YY1	0.0308273146606803	0.734000753673642	47	3315	2882	333	3315	2180	60	157	147	YY1 Ishikawa (endometrial adenocarcinoma) YY1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	YY1		ENCODE	ENCSR000BSY_Ishikawa_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	25215
1	2033	GATA6	0.0306985869012351	0.635621520263818	15	3316	3251	1993	3316	2850	23	189	184	GATA6 definitive endoderm from HUES8 GATA6	definitive endoderm from HUES8	NULL	GATA6	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057913_definitive-endoderm-from-HUES8_GATA6_MACS_GATA6_MA1104.2.damo.pwm.bed	39891
1	2355	JUN	0.0306985869012351	0.635621520263818	15	3316	3251	1993	3316	2850	23	189	184	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 5 minute	GTRD	EXP040322_A549--lung-carcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	18172
1	426	CREB1	0.0301628508639383	0.730881868144462	46	3318	2886	349	3318	2180	59	158	148	CREB1 LNCaP-abl (Prostate carcinoma) CREB1	LNCaP-abl (Prostate carcinoma)	NULL	CREB1		GEO	GSE63034_creb1_lncap-abl_MACS_CREB1_MA0018.4.damo.pwm.bed	19479
1	2995	NFE2L2	0.0301628508639383	0.730881868144462	46	3318	2886	349	3318	2180	59	158	148	NFE2L2 NFE2L2	NA	NA	NFE2L2	NA	NA	ENCSR485GKE_K562_NFE2L2_MACS_NFE2L2_MA0150.2.damo.pwm.bed	37495
1	3024	NFKB1	0.0301628508639383	0.730881868144462	46	3318	2886	349	3318	2180	59	158	148	NFKB1 L1236 (Hodgkin lymphoma) NFKB1	L1236 (Hodgkin lymphoma)	NULL	NFKB1		GEO	GSE63736_nfkb1_l1236_MACS_NFKB1_MA0105.4.damo.pwm.bed	39102
1	3865	TFAP2A	0.0300431714024651	0.657237532894004	19	3321	3187	1697	3321	2740	28	185	179	TFAP2A hiPSC TFAP2A	hiPSC	NULL	TFAP2A	Genotype: wildtype Treatment: hiPSC differentiation into hNCC (passage 2)	GTRD	EXP052981_hiPSC_TFAP2A_MACS_TFAP2A_MA0810.1.damo.pwm.bed	40654
1	1541	FOS	0.0300306317716736	0.698681603807017	30	3322	3032	937	3322	2430	41	174	166	FOS IMR90 (lung fibroblasts) FOS	IMR90 (lung fibroblasts)	NULL	FOS		GTRD	EXP039888_IMR90--lung-fibroblasts-_FOS_MACS_FOS_MA1141.1.damo.pwm.bed	41241
1	2340	JUN	0.0300306317716736	0.698681603807017	30	3322	3032	937	3322	2430	41	174	166	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN		GTRD	EXP040265_A549--lung-carcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	16698
1	288	BCL6	0.0297097581681643	0.599187732075023	11	3324	3361	2332	3361	3010	18	193	189	BCL6 BCL6	NA	NA	BCL6	NA	GEO	GSE59538_bcl6_icn12_MACS_BCL6_MA0463.2.damo.pwm.bed	14838
1	2321	JUN	0.0297097581681643	0.599187732075023	11	3324	3361	2332	3361	3010	18	193	189	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039507_A549--lung-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	9347
1	2714	MAX	0.0297097581681643	0.599187732075023	11	3324	3361	2332	3361	3010	18	193	189	MAX COLO-829 (melanoma) MAX	COLO-829 (melanoma)	NULL	MAX	Treatment: none	GTRD	EXP053272_COLO-829--melanoma-_MAX_MACS_MAX_MA0059.1.damo.pwm.bed	7194
1	3392	REST	0.0297097581681643	0.599187732075023	11	3324	3361	2332	3361	3010	18	193	189	REST WA01 (H1, human embryonic stem cells) REST	WA01 (H1, human embryonic stem cells)	NULL	REST		ENCODE	ENCSR000BHM_H1-hESC_REST_MACS_REST_MA0138.2.damo.pwm.bed	18201
1	3456	RUNX1	0.0297097581681643	0.599187732075023	11	3324	3361	2332	3361	3010	18	193	189	RUNX1 K562 (myelogenous leukemia) RUNX1	K562 (myelogenous leukemia)	NULL	RUNX1	24 hours following induction with TPA	GTRD	EXP000587_K562--myelogenous-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	14938
1	1393	ESR1	0.0296837877439228	0.563458212276878	8	3329	3452	2697	3452	3160	14	196	193	ESR1 VCaP (prostate carcinoma) ESR1	VCaP (prostate carcinoma)	BTO:0003215	ESR1	E2_ERA	GEO	GSE43985_esr1_vcap-e2-era_MACS_ESR1_MA0112.3.damo.pwm.bed	12562
1	3097	NR3C1	0.0296837877439228	0.563458212276878	8	3329	3452	2697	3452	3160	14	196	193	NR3C1 embryonic kidney NR3C1	embryonic kidney	NULL	NR3C1	dexamethasone, stably expressing wt GR	GTRD	EXP032210_embryonic-kidney_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	20349
1	3622	SOX6	0.0296837877439228	0.563458212276878	8	3329	3452	2697	3452	3160	14	196	193	SOX6 K562 (myelogenous leukemia) SOX6	K562 (myelogenous leukemia)	NULL	SOX6	NA	ENCODE	ENCSR788RSW_K562_SOX6_MACS_SOX6_MA0515.1.damo.pwm.bed	23105
1	2876	MYC	0.0295990228344227	0.741090964006837	56	3332	2870	192	3332	2130	70	148	137	MYC HEK293T (embryonic kidney) MYC	HEK293T (embryonic kidney)	BTO:0002181	MYC	Treatment: withKL-1 or KL-2 inhibitors was administrated only once; Genotype: cells lentiviral infected shRNA targeting MYC;	GTRD	EXP047292_HEK293T--embryonic-kidney-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	17186
1	41	AR	0.0290351380780164	0.710420148501524	36	3333	2989	645	3333	2320	48	168	159	AR CWR22 (prostate carcinoma) AR	CWR22 (prostate carcinoma)	BTO:0004594	AR	DHT+Bicalutamide	GTRD	EXP034148_CWR22--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	40211
1	2716	MAX	0.0288908418844	0.69248259570723	29	3334	3049	1013	3334	2470	40	175	167	MAX P493-6 (B-cell lymphoma) MAX	P493-6 (B-cell lymphoma)	BTO:0003291	MAX	CMYC_24H	GEO	GSE36354_max_p493-cmyc-24h_MACS_MAX_MA0058.3.damo.pwm.bed	12033
1	2890	MYC	0.0288908418844	0.69248259570723	29	3334	3049	1013	3334	2470	40	175	167	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 4;	GTRD	EXP047490_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	9458
1	2797	MYC	0.0288001061254597	0.724261658027179	44	3336	2941	408	3336	2230	57	160	150	MYC K562 (myelogenous leukemia) MYC	K562 (myelogenous leukemia)	NULL	MYC	NULL	GTRD	EXP000311_K562--myelogenous-leukemia-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	21314
1	2818	MYC	0.0285945851998792	0.736440666379736	54	3337	2880	225	3337	2150	68	150	139	MYC HeLa (cervical adenocarcinoma) MYC	HeLa (cervical adenocarcinoma)	BTO:0000567	MYC		GTRD	EXP031873_HeLa--cervical-adenocarcinoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	31631
1	1574	FOSL2	0.0285255654028928	0.670671380339183	23	3338	3121	1391	3338	2620	33	181	174	FOSL2 SK-N-SH (neuroblastoma) FOSL2	SK-N-SH (neuroblastoma)	BTO:0001620	FOSL2		ENCODE	ENCSR000BVB_SK-N-SH_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	42468
1	3471	RUNX1	0.0285255654028928	0.670671380339183	23	3338	3121	1391	3338	2620	33	181	174	RUNX1 SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) RUNX1	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	RUNX1		GTRD	EXP037836_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	22588
1	267	BACH1	0.0284541865300507	0.335769077978151	1	3340	3753	3655	3753	3580	3	203	204	BACH1 K562 (myelogenous leukemia) BACH1	K562 (myelogenous leukemia)	NULL	BACH1	NA	ENCODE	ENCSR000EGD_K562_BACH1_MACS_BACH1_MA0591.1.damo.pwm.bed	2796
1	1298	ESR1	0.0284541865300507	0.335769077978151	1	3340	3753	3655	3753	3580	3	203	204	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	vehicle for 3h	GTRD	EXP040893_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	4250
1	1386	ESR1	0.0284541865300507	0.335769077978151	1	3340	3753	3655	3753	3580	3	203	204	ESR1 H3396 (breast carcinoma) ESR1	H3396 (breast carcinoma)	NULL	ESR1	ETOH	GEO	GSE32349_esr1_h3396-etoh_MACS_ESR1_MA0112.3.damo.pwm.bed	883
1	2088	HIF1A	0.0284541865300507	0.335769077978151	1	3340	3753	3655	3753	3580	3	203	204	HIF1A RCC4 (kidney cancer cell line) HIF1A	RCC4 (kidney cancer cell line)	BTO:0005691	HIF1A	Treatment: degree of hypoxia - normoxia	GTRD	EXP048723_RCC4--kidney-cancer-cell-line-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	745
1	2097	HIF1A	0.0284541865300507	0.335769077978151	1	3340	3753	3655	3753	3580	3	203	204	HIF1A HKC8 (kidney proximal tubule cell line) HIF1A	HKC8 (kidney proximal tubule cell line)	NULL	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 16 hours	GTRD	EXP048753_HKC8--kidney-proximal-tubule-cell-line-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	1377
1	2111	HMBOX1	0.0284541865300507	0.335769077978151	1	3340	3753	3655	3753	3580	3	203	204	HMBOX1 HeLa (cervical adenocarcinoma) HMBOX1	HeLa (cervical adenocarcinoma)	BTO:0000567	HMBOX1	NA	GEO	GSE46237_hmbox1_hela_MACS_HMBOX1_MA0895.1.damo.pwm.bed	1801
1	2198	IRF1	0.0284541865300507	0.335769077978151	1	3340	3753	3655	3753	3580	3	203	204	IRF1 K562 (myelogenous leukemia) IRF1	K562 (myelogenous leukemia)	NULL	IRF1	Interferon alpha treatment - 6 hours (Snyder)	ENCODE	ENCSR000EGL_K562_IRF1_MACS_IRF1_MA0050.2.damo.pwm.bed	2136
1	3148	NR3C1	0.0284541865300507	0.335769077978151	1	3340	3753	3655	3753	3580	3	203	204	NR3C1 macrophages NR3C1	macrophages	NULL	NR3C1	Treatment: treated with 1 micromolar (1uM) TA for 4 hours; Source: Adult Human Peripheral Blood; Donor:Buffycoat 11;	GTRD	EXP057902_macrophages_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	1977
1	3390	REST	0.0284541865300507	0.335769077978151	1	3340	3753	3655	3753	3580	3	203	204	REST K562 (myelogenous leukemia) REST	K562 (myelogenous leukemia)	NULL	REST		ENCODE	ENCSR000ATM_K562_REST_MACS_REST_MA0138.2.damo.pwm.bed	5172
1	3410	REST	0.0284541865300507	0.335769077978151	1	3340	3753	3655	3753	3580	3	203	204	REST U87 (glioblastoma) REST	U87 (glioblastoma)	NULL	REST	None	GTRD	EXP010585_U87--glioblastoma-_REST_MACS_REST_MA0138.2.damo.pwm.bed	4481
1	3423	REST	0.0284541865300507	0.335769077978151	1	3340	3753	3655	3753	3580	3	203	204	REST K562 (myelogenous leukemia) REST	K562 (myelogenous leukemia)	NULL	REST	Treatment: None;	GTRD	EXP054063_K562--myelogenous-leukemia-_REST_MACS_REST_MA0138.2.damo.pwm.bed	5093
1	3478	RUNX1	0.0284541865300507	0.335769077978151	1	3340	3753	3655	3753	3580	3	203	204	RUNX1 NALM-6 (adult B acute lymphoblastic leukemia) RUNX1	NALM-6 (adult B acute lymphoblastic leukemia)	BTO:0003288	RUNX1	Tissue: Peripheral blood	GTRD	EXP048189_NALM-6--adult-B-acute-lymphoblastic-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	3423
1	3839	TEAD4	0.0284541865300507	0.335769077978151	1	3340	3753	3655	3753	3580	3	203	204	TEAD4 WA01 (H1, human embryonic stem cells) TEAD4	WA01 (H1, human embryonic stem cells)	NULL	TEAD4	Treatment: None Genotype: wildtype hESC	GTRD	EXP049867_WA01--H1--human-embryonic-stem-cells-_TEAD4_MACS_TEAD4_MA0809.2.damo.pwm.bed	4856
1	3965	TP53	0.0284541865300507	0.335769077978151	1	3340	3753	3655	3753	3580	3	203	204	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	400 ng/mL neocarzinostatin for 3 h	GTRD	EXP036872_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	2402
1	3970	TP53	0.0284541865300507	0.335769077978151	1	3340	3753	3655	3753	3580	3	203	204	TP53 HCT-116 (colon carcinoma) TP53	HCT-116 (colon carcinoma)	BTO:0001109	TP53	Nutlin	GTRD	EXP037747_HCT-116--colon-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	8401
1	3993	TP53	0.0284541865300507	0.335769077978151	1	3340	3753	3655	3753	3580	3	203	204	TP53 HCT-116 (colon carcinoma) TP53	HCT-116 (colon carcinoma)	BTO:0001109	TP53	Treatment: 4GY for 2hrs;	GTRD	EXP051022_HCT-116--colon-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	1307
1	4030	TP63	0.0284541865300507	0.335769077978151	1	3340	3753	3655	3753	3580	3	203	204	TP63 HaCaT (keratinocytes) TP63	HaCaT (keratinocytes)	BTO:0000552	TP63	Ad-LacZ	GTRD	EXP033936_HaCaT--keratinocytes-_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	5594
1	4036	TP63	0.0284541865300507	0.335769077978151	1	3340	3753	3655	3753	3580	3	203	204	TP63 surface ectoderm cells TP63	surface ectoderm cells	NULL	TP63	Treatment: Doxycycline for 2 days  Geenotype: TetO:Tp63+/-	GTRD	EXP053349_surface-ectoderm-cells_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	8660
1	4093	VDR	0.0284541865300507	0.335769077978151	1	3340	3753	3655	3753	3580	3	203	204	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	1α,25(OH)2D3	GTRD	EXP000242_THP-1--acute-monocytic-leukemia-_VDR_MACS_VDR_MA0074.1.damo.pwm.bed	1652
1	122	AR	0.0283995987236912	0.400818576750854	2	3359	3714	3462	3714	3510	5	202	202	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Genotype: Renilla knockout; Treatment: shRenilla;	GTRD	EXP058316_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	7970
1	187	AR	0.0283995987236912	0.400818576750854	2	3359	3714	3462	3714	3510	5	202	202	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR		GEO	GSE64656_AR_lncap_MACS_AR_MA0007.3.damo.pwm.bed	10587
1	235	ASCL1	0.0283995987236912	0.400818576750854	2	3359	3714	3462	3714	3510	5	202	202	ASCL1 NCI-H128 (small cell lung carcinoma) ASCL1	NCI-H128 (small cell lung carcinoma)	BTO:0003025	ASCL1		GEO	GSE69394_ascl1_h128_MACS_ASCL1_MA1100.2.damo.pwm.bed	6074
1	257	ATF3	0.0283995987236912	0.400818576750854	2	3359	3714	3462	3714	3510	5	202	202	ATF3 HCT-116 (colon carcinoma) ATF3	HCT-116 (colon carcinoma)	BTO:0001109	ATF3	DMSO_KOATF3	GEO	GSE74355_atf3_htc116-dmso-koatf3_MACS_ATF3_MA0605.2.damo.pwm.bed	643
1	298	CDX2	0.0283995987236912	0.400818576750854	2	3359	3714	3462	3714	3510	5	202	202	CDX2 HUES64 (embryonic stem cells) CDX2	HUES64 (embryonic stem cells)	NULL	CDX2		GTRD	EXP036697_HUES64--embryonic-stem-cells-_CDX2_MACS_CDX2_MA0465.2.damo.pwm.bed	5046
1	1059	EGR1	0.0283995987236912	0.400818576750854	2	3359	3714	3462	3714	3510	5	202	202	EGR1 GM12878 (female B-cells lymphoblastoid cell line) EGR1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	EGR1		ENCODE	ENCSR000BRG_GM12878_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	1686
1	1104	ELK1	0.0283995987236912	0.400818576750854	2	3359	3714	3462	3714	3510	5	202	202	ELK1 WA01 (H1, human embryonic stem cells) ELK1	WA01 (H1, human embryonic stem cells)	NULL	ELK1		Array Express	ERP002417_elk1_esc-h1_MACS_ELK1_MA0028.2.damo.pwm.bed	677
1	1425	ESR1	0.0283995987236912	0.400818576750854	2	3359	3714	3462	3714	3510	5	202	202	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GEO	GSE68356_ESR1_mcf7-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	11742
1	2207	IRF3	0.0283995987236912	0.400818576750854	2	3359	3714	3462	3714	3510	5	202	202	IRF3 HepG2 (hepatoblastoma) IRF3	HepG2 (hepatoblastoma)	BTO:0000599	IRF3	NA	ENCODE	ENCSR000EEJ_HepG2_IRF3_MACS_IRF3_MA1418.1.damo.pwm.bed	419
1	3009	NFIB	0.0283995987236912	0.400818576750854	2	3359	3714	3462	3714	3510	5	202	202	NFIB MCF7 (Invasive ductal breast carcinoma) NFIB	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NFIB	NA	GTRD	EXP039948_MCF7--Invasive-ductal-breast-carcinoma-_NFIB_MACS_NFIB_MA1643.1.damo.pwm.bed	12566
1	3077	NR2F2	0.0283995987236912	0.400818576750854	2	3359	3714	3462	3714	3510	5	202	202	NR2F2 VA13 (transformed lung fibroblasts) NR2F2	VA13 (transformed lung fibroblasts)	NULL	NR2F2		GEO	GSE46237_nr2f2_wi38va13_MACS_NR2F2_MA1111.1.damo.pwm.bed	3581
1	3135	NR3C1	0.0283995987236912	0.400818576750854	2	3359	3714	3462	3714	3510	5	202	202	NR3C1 MCF10A (breast epithelial cells) NR3C1	MCF10A (breast epithelial cells)	BTO:0001939	NR3C1	Treatment: EGF + DEX 60 min;	GTRD	EXP047633_MCF10A--breast-epithelial-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	4295
1	3813	TCF7L2	0.0283995987236912	0.400818576750854	2	3359	3714	3462	3714	3510	5	202	202	TCF7L2 MCF7 (Invasive ductal breast carcinoma) TCF7L2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TCF7L2		ENCODE	ENCSR000EWT_MCF-7_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	7575
1	4009	TP53	0.0283995987236912	0.400818576750854	2	3359	3714	3462	3714	3510	5	202	202	TP53 IMR90 (lung fibroblasts) TP53	IMR90 (lung fibroblasts)	NULL	TP53		GEO	GSE31558_tp53_imr90_MACS_TP53_MA0106.3.damo.pwm.bed	620
1	2329	JUN	0.0281933732898613	0.645850243158513	18	3373	3216	1785	3373	2790	27	186	180	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 10 minute	GTRD	EXP040248_A549--lung-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	22511
1	3168	NRF1	0.0281933732898613	0.645850243158513	18	3373	3216	1785	3373	2790	27	186	180	NRF1 WA01 (H1, human embryonic stem cells) NRF1	WA01 (H1, human embryonic stem cells)	NULL	NRF1		ENCODE	ENCSR000ECC_H1-hESC_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	4041
1	496	CTCF	0.0281308481110327	0.705629568983174	35	3375	2998	691	3375	2350	47	169	160	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DPS_fibroblast_of_gingiva_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45205
1	2888	MYC	0.0273927642215072	0.717087453582392	42	3376	2961	454	3376	2260	55	162	152	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 1;	GTRD	EXP047489_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	12500
1	2289	JUN	0.0272131772728463	0.700614091555081	34	3377	3014	729	3377	2370	46	170	161	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	IL1b, 4h	GTRD	EXP038043_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	44588
1	2690	MAX	0.0270168853258032	0.728776275502878	51	3378	2911	261	3378	2180	65	153	142	MAX A549 (lung carcinoma) MAX	A549 (lung carcinoma)	BTO:0000018	MAX		ENCODE	ENCSR000BTJ_A549_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	23200
1	2870	MYC	0.0266726296583967	0.713274205224108	41	3379	2982	476	3379	2280	54	163	153	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	0.2 µg/mL Tetracycline (Myc transgene repressed) for 72h and then released in fresh medium without Tetracycline for 24h	GTRD	EXP038952_P493-6--B-cell-lymphoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	21637
1	1413	ESR1	0.0265791876155978	0.576871616771768	10	3380	3420	2442	3420	3080	17	194	190	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GEO	GSE60270_esr1_mcf7-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	26490
1	2350	JUN	0.0265791876155978	0.576871616771768	10	3380	3420	2442	3420	3080	17	194	190	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 5 minute	GTRD	EXP040322_A549--lung-carcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	17349
1	3762	T	0.0265791876155978	0.576871616771768	10	3380	3420	2442	3420	3080	17	194	190	T H9 T	H9	NULL	T	MESODERM	GEO	GSE60606_t_hes-mesoderm_MACS_T_MA0009.2.damo.pwm.bed	18454
1	1517	FOS	0.0265605031443034	0.679057500503069	27	3383	3085	1135	3383	2530	38	177	169	FOS FOS	NA	NA	FOS	NA	NA	ENCSR000DOP_MCF_10A_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	78030
1	2806	MYC	0.0265605031443034	0.679057500503069	27	3383	3085	1135	3383	2530	38	177	169	MYC GM12878 (female B-cells lymphoblastoid cell line) MYC	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MYC	NULL	GTRD	EXP000990_GM12878--female-B-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	7953
1	52	AR	0.0265031191481295	0.495797078158659	5	3385	3613	3053	3613	3350	10	199	197	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	treated for 24 hours with 2μg/mL aphidicolin +3 hour 10nm DHT	GTRD	EXP036468_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	29688
1	2380	JUN	0.0265031191481295	0.495797078158659	5	3385	3613	3053	3613	3350	10	199	197	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048209_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	6534
1	2381	JUN	0.0265031191481295	0.495797078158659	5	3385	3613	3053	3613	3350	10	199	197	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048209_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	6611
1	2383	JUN	0.0265031191481295	0.495797078158659	5	3385	3613	3053	3613	3350	10	199	197	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048209_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	6375
1	2385	JUN	0.0265031191481295	0.495797078158659	5	3385	3613	3053	3613	3350	10	199	197	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048209_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	6447
1	2386	JUN	0.0265031191481295	0.495797078158659	5	3385	3613	3053	3613	3350	10	199	197	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048209_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	6340
1	2387	JUN	0.0265031191481295	0.495797078158659	5	3385	3613	3053	3613	3350	10	199	197	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048209_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	6727
1	3325	RBPJ	0.0265031191481295	0.495797078158659	5	3385	3613	3053	3613	3350	10	199	197	RBPJ LAL-B (All-B patient-derived cell line) RBPJ	LAL-B (All-B patient-derived cell line)	NULL	RBPJ	Treatment: none;	GTRD	EXP055428_LAL-B--All-B-patient-derived-cell-line-_RBPJ_MACS_RBPJ_MA1116.1.damo.pwm.bed	3904
1	3550	RXRA	0.0265031191481295	0.495797078158659	5	3385	3613	3053	3613	3350	10	199	197	RXRA MCF7 (Invasive ductal breast carcinoma) RXRA	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RXRA	Treatment: none;	GTRD	EXP054366_MCF7--Invasive-ductal-breast-carcinoma-_RXRA_MACS_RXRA_MA0065.2.damo.pwm.bed	35077
1	3613	SOX2	0.0265031191481295	0.495797078158659	5	3385	3613	3053	3613	3350	10	199	197	SOX2 TT (hereditary thyroid gland medullary carcinoma) SOX2	TT (hereditary thyroid gland medullary carcinoma)	BTO:0003074	SOX2		GEO	GSE46837_sox2_tt_MACS_SOX2_MA0143.4.damo.pwm.bed	7333
1	3817	TCF7L2	0.0265031191481295	0.495797078158659	5	3385	3613	3053	3613	3350	10	199	197	TCF7L2 HUES64 (embryonic stem cells) TCF7L2	HUES64 (embryonic stem cells)	NULL	TCF7L2		GTRD	EXP036766_HUES64--embryonic-stem-cells-_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	11846
1	2855	MYC	0.0264722321243001	0.726022134770061	50	3396	2926	275	3396	2200	64	154	143	MYC LNCaP (prostate carcinoma) MYC	LNCaP (prostate carcinoma)	BTO:0001321	MYC	R1881	GTRD	EXP037068_LNCaP--prostate-carcinoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	20682
1	1146	ERG	0.026282400766362	0.695359010180578	33	3397	3039	778	3397	2400	45	171	162	ERG Jurkat (T-cells) ERG	Jurkat (T-cells)	BTO:0000661	ERG		GEO	GSE49091_erg_jurkat_MACS_ERG_MA0474.2.damo.pwm.bed	37494
1	2339	JUN	0.0259149061444132	0.603580780197213	13	3398	3354	2153	3398	2970	21	191	186	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 15 minute	GTRD	EXP040263_A549--lung-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	14014
1	2455	JUN	0.0259149061444132	0.603580780197213	13	3398	3354	2153	3398	2970	21	191	186	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: control (scrambled shRNA);	GTRD	EXP058211_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	10762
1	2515	JUNB	0.0259149061444132	0.603580780197213	13	3398	3354	2153	3398	2970	21	191	186	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039744_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	23241
1	3769	TAL1	0.0259149061444132	0.603580780197213	13	3398	3354	2153	3398	2970	21	191	186	TAL1 MOLT3 (adult T acute lymphoblastic leukemia) TAL1	MOLT3 (adult T acute lymphoblastic leukemia)	NULL	TAL1	NA	GEO	GSE59657_tal1_molt3_MACS_TAL1_MA0091.1.damo.pwm.bed	26905
1	1534	FOS	0.0255575671525365	0.652188872816125	21	3402	3205	1535	3402	2710	31	183	176	FOS HUVEC-C (HUVEC, umbilical vein endothelial cells) FOS	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FOS	NULL	GTRD	EXP000672_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FOS_MACS_FOS_MA0099.3.damo.pwm.bed	45945
1	2808	MYC	0.0255575671525365	0.652188872816125	21	3402	3205	1535	3402	2710	31	183	176	MYC HeLa S3 (cervical adenocarcinoma) MYC	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	MYC	NULL	GTRD	EXP000991_HeLa-S3--cervical-adenocarcinoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	7115
1	4067	TWIST1	0.0255575671525365	0.652188872816125	21	3402	3205	1535	3402	2710	31	183	176	TWIST1 SHEP-21N TWIST1	SHEP-21N	NA	TWIST1		GEO	GSE80151_twist1_shep21_MACS_TWIST1_MA1123.2.damo.pwm.bed	19284
1	2293	JUN	0.0254693253070161	0.531063647890932	7	3405	3498	2812	3498	3240	13	197	194	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	oxpapc, 4h	GTRD	EXP038044_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	8998
1	2294	JUN	0.0254693253070161	0.531063647890932	7	3405	3498	2812	3498	3240	13	197	194	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	oxpapc, 4h	GTRD	EXP038044_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	8935
1	2299	JUN	0.0254693253070161	0.531063647890932	7	3405	3498	2812	3498	3240	13	197	194	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	oxpapc, 4h	GTRD	EXP038044_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	8665
1	1558	FOS	0.0253711159574168	0.671776407547915	26	3408	3118	1204	3408	2580	37	178	170	FOS MCF10A-ER-Src FOS	MCF10A-ER-Src	NULL	FOS	Genotype: transformed	GTRD	EXP048568_MCF10A-ER-Src_FOS_MACS_FOS_MA0099.3.damo.pwm.bed	86734
1	2805	MYC	0.0253711159574168	0.671776407547915	26	3408	3118	1204	3408	2580	37	178	170	MYC GM12878 (female B-cells lymphoblastoid cell line) MYC	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MYC	NULL	GTRD	EXP000990_GM12878--female-B-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	7610
1	1031	E2F1	0.0253552020669215	0.72018824642469	48	3410	2948	317	3410	2220	62	156	145	E2F1 mesenchymal E2F1	mesenchymal	NA	E2F1		GEO	GSE77260_e2f1_mesenchymal_MACS_E2F1_MA0024.3.damo.pwm.bed	12859
1	49	AR	0.0246171762370006	0.427276814571444	3	3411	3694	3316	3694	3470	7	201	200	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	siControl	GTRD	EXP036106_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	11234
1	1001	DUX4	0.0246171762370006	0.427276814571444	3	3411	3694	3316	3694	3470	7	201	200	DUX4 myoblasts DUX4	myoblasts	NULL	DUX4	myoblasts transduced with lentivirus carrying DUX4	GTRD	EXP000278_myoblasts_DUX4_MACS_DUX4_MA0468.1.damo.pwm.bed	36449
1	1875	GABPA	0.0246171762370006	0.427276814571444	3	3411	3694	3316	3694	3470	7	201	200	GABPA MCF7 (Invasive ductal breast carcinoma) GABPA	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GABPA		ENCODE	ENCSR038RXU_MCF-7_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	1288
1	2725	MEF2A	0.0246171762370006	0.427276814571444	3	3411	3694	3316	3694	3470	7	201	200	MEF2A SK-N-SH (neuroblastoma) MEF2A	SK-N-SH (neuroblastoma)	BTO:0001620	MEF2A	NA	ENCODE	ENCSR000BVC_SK-N-SH_MEF2A_MACS_MEF2A_MA0052.4.damo.pwm.bed	9469
1	3128	NR3C1	0.0246171762370006	0.427276814571444	3	3411	3694	3316	3694	3470	7	201	200	NR3C1 MCF10A (breast epithelial cells) NR3C1	MCF10A (breast epithelial cells)	BTO:0001939	NR3C1	Treatment: dexamethasone (DEX) 20 min;	GTRD	EXP047626_MCF10A--breast-epithelial-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	9131
1	3371	RELA	0.0246171762370006	0.427276814571444	3	3411	3694	3316	3694	3470	7	201	200	RELA HeLa-B2 RELA	HeLa-B2	NA	RELA	GRKD_TA_TNFA	GEO	GSE24518_rela_helab2-grkd-ta-tnfa_MACS_RELA_MA0107.1.damo.pwm.bed	3979
1	3978	TP53	0.0246171762370006	0.427276814571444	3	3411	3694	3316	3694	3470	7	201	200	TP53 PHA-simulated human T-lynphocytes TP53	PHA-simulated human T-lynphocytes	NULL	TP53	Treatment: 0.3 ug/ml Doxorubicin for 24 hrs Source: healthy volunteer #45	GTRD	EXP048267_PHA-simulated-human-T-lynphocytes_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	4710
1	3209	OTX2	0.0244482236266533	0.700827495004404	38	3418	3013	576	3418	2340	51	166	156	OTX2 D341 Med (medulloblastoma) OTX2	D341 Med (medulloblastoma)	NULL	OTX2	shGFP	GTRD	EXP038214_D341-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	92034
1	304	CDX2	0.0244066387842413	0.620295202204694	16	3419	3301	1909	3419	2880	25	188	182	CDX2 LS180 (colon cancer) CDX2	LS180 (colon cancer)	NULL	CDX2	125	GEO	GSE31939_cdx2_ls180-125_MACS_CDX2_MA0465.2.damo.pwm.bed	28703
1	432	CREM	0.0244066387842413	0.620295202204694	16	3419	3301	1909	3419	2880	25	188	182	CREM HepG2 (hepatoblastoma) CREM	HepG2 (hepatoblastoma)	BTO:0000599	CREM	NA	GTRD	EXP040023_HepG2--hepatoblastoma-_CREM_MACS_CREM_MA0609.2.damo.pwm.bed	10738
1	1714	FOXA1	0.0244066387842413	0.620295202204694	16	3419	3301	1909	3419	2880	25	188	182	FOXA1 MCF7 WS8 cells FOXA1	MCF7 WS8 cells	NULL	FOXA1	Treatment: 45 min ethanol	GTRD	EXP048453_MCF7-WS8-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	30531
1	1783	FOXA1	0.0244066387842413	0.620295202204694	16	3419	3301	1909	3419	2880	25	188	182	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	ETOH24H	GEO	GSE58428_foxa1_vcap-etoh24h_MACS_FOXA1_MA0148.4.damo.pwm.bed	39756
1	2955	MYCN	0.0243939186976821	0.727615158563978	57	3423	2923	174	3423	2170	72	147	135	MYCN SHEP-21N MYCN	SHEP-21N	NA	MYCN		GEO	GSE80151_mycn_shep21_MACS_MYCN_MA0104.4.damo.pwm.bed	24321
1	675	CTCF	0.0243829494057977	0.68406433067177	31	3424	3075	881	3424	2460	43	173	164	CTCF esophagus muscularis mucosa CTCF	esophagus muscularis mucosa	NULL	CTCF		GTRD	EXP039334_esophagus-muscularis-mucosa_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	28424
1	1884	GABPA	0.0242018228223937	0.71388659104058	46	3425	2976	349	3425	2250	60	158	147	GABPA GM12878 (female B-cells lymphoblastoid cell line) GABPA	GM12878 (female B-cells lymphoblastoid cell line)	NULL	GABPA		GTRD	EXP054616_GM12878--female-B-cells-lymphoblastoid-cell-line-_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	34360
1	2813	MYC	0.0242018228223937	0.71388659104058	46	3425	2976	349	3425	2250	60	158	147	MYC MCF7 (Invasive ductal breast carcinoma) MYC	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	MYC	NULL	GTRD	EXP001022_MCF7--Invasive-ductal-breast-carcinoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	23343
1	3653	SPI1	0.0242018228223937	0.71388659104058	46	3425	2976	349	3425	2250	60	158	147	SPI1 monocyte-derived macrophages SPI1	monocyte-derived macrophages	NULL	SPI1	none	GTRD	EXP038591_monocyte-derived-macrophages_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	84203
1	2276	JUN	0.024043658820547	0.641999442733876	20	3428	3224	1606	3428	2750	30	184	177	JUN RCC 7860 (Renal cell carcinoma) JUN	RCC 7860 (Renal cell carcinoma)	BTO:0003781	JUN		GTRD	EXP037742_786-O--renal-carcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	23771
1	2485	JUNB	0.024043658820547	0.641999442733876	20	3428	3224	1606	3428	2750	30	184	177	JUNB HAEC (human aortic endothelial cells) JUNB	HAEC (human aortic endothelial cells)	NULL	JUNB	control, 4h	GTRD	EXP038040_HAEC--human-aortic-endothelial-cells-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	30781
1	2696	MAX	0.0239665955529764	0.725359183158213	56	3430	2928	192	3430	2180	71	148	136	MAX HeLa S3 (cervical adenocarcinoma) MAX	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	MAX		ENCODE	ENCSR000ECN_HeLa-S3_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	22447
1	2287	JUN	0.023686116239797	0.696310464780237	37	3431	3034	607	3431	2360	50	167	157	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	IL1b, 4h	GTRD	EXP038043_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	47423
1	2867	MYC	0.023686116239797	0.696310464780237	37	3431	3034	607	3431	2360	50	167	157	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	none (Myc transgene expressed)	GTRD	EXP038948_P493-6--B-cell-lymphoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	25581
1	2853	MYC	0.0236117891130212	0.710546421490183	45	3433	2988	383	3433	2270	59	159	148	MYC GEN2.2 (blastic plasmacytoid dendritic cell neoplasm) MYC	GEN2.2 (blastic plasmacytoid dendritic cell neoplasm)	NULL	MYC		GTRD	EXP036998_GEN2.2--blastic-plasmacytoid-dendritic-cell-neoplasm-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	16602
1	1053	EBF1	0.0234635115615742	0.58513304534279	12	3434	3391	2233	3434	3020	20	192	187	EBF1 LCL (lymphoblastoid cell line) EBF1	LCL (lymphoblastoid cell line)	NULL	EBF1	NA	GEO	GSE75503_ebf1_lcl_MACS_EBF1_MA0154.4.damo.pwm.bed	15846
1	2441	JUN	0.0234635115615742	0.58513304534279	12	3434	3391	2233	3434	3020	20	192	187	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057919_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	17628
1	2514	JUNB	0.0234635115615742	0.58513304534279	12	3434	3391	2233	3434	3020	20	192	187	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039744_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	21064
1	2516	JUNB	0.0234635115615742	0.58513304534279	12	3434	3391	2233	3434	3020	20	192	187	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039744_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	20398
1	2517	JUNB	0.0234635115615742	0.58513304534279	12	3434	3391	2233	3434	3020	20	192	187	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039744_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	21050
1	2518	JUNB	0.0234635115615742	0.58513304534279	12	3434	3391	2233	3434	3020	20	192	187	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039744_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	20808
1	2519	JUNB	0.0234635115615742	0.58513304534279	12	3434	3391	2233	3434	3020	20	192	187	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039744_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	21060
1	3395	REST	0.0234635115615742	0.58513304534279	12	3434	3391	2233	3434	3020	20	192	187	REST PANC1 (pancreatic ductal adenocarcinoma) REST	PANC1 (pancreatic ductal adenocarcinoma)	NULL	REST		ENCODE	ENCSR000BJO_Panc1_REST_MACS_REST_MA0138.2.damo.pwm.bed	16643
1	3659	SPI1	0.0234635115615742	0.58513304534279	12	3434	3391	2233	3434	3020	20	192	187	SPI1 THP-1 (acute monocytic leukemia) SPI1	THP-1 (acute monocytic leukemia)	BTO:0001370	SPI1	Treatment: untreated, eGFP(EP mRNA)	GTRD	EXP047817_THP-1--acute-monocytic-leukemia-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	55900
1	286	BCL6	0.0233877652146634	0.551748974856435	9	3443	3466	2564	3466	3160	16	195	191	BCL6 OCI-LY1 (diffuse large B-cell lymphoma) BCL6	OCI-LY1 (diffuse large B-cell lymphoma)	NULL	BCL6	Treatment: untreated (control siRNA)	GTRD	EXP052976_OCI-LY1--diffuse-large-B-cell-lymphoma-_BCL6_MACS_BCL6_MA0463.2.damo.pwm.bed	10792
1	429	CREB1	0.0233877652146634	0.551748974856435	9	3443	3466	2564	3466	3160	16	195	191	CREB1 KG1 (acute myeloid leukemia) CREB1	KG1 (acute myeloid leukemia)	BTO:0000670	CREB1	XX65023	GEO	GSE74928_CREB1_kg1-xx65023_MACS_CREB1_MA0018.4.damo.pwm.bed	3319
1	2961	MYOG	0.0233877652146634	0.551748974856435	9	3443	3466	2564	3466	3160	16	195	191	MYOG RH4 (alveolar rhabdomyosarcoma) MYOG	RH4 (alveolar rhabdomyosarcoma)	NULL	MYOG	NA	GTRD	EXP037531_RH4--alveolar-rhabdomyosarcoma-_MYOG_MACS_MYOG_MA0500.2.damo.pwm.bed	16244
1	3421	REST	0.0233877652146634	0.551748974856435	9	3443	3466	2564	3466	3160	16	195	191	REST A549 (lung carcinoma) REST	A549 (lung carcinoma)	BTO:0000018	REST		GTRD	EXP040092_A549--lung-carcinoma-_REST_MACS_REST_MA0138.2.damo.pwm.bed	6828
1	1351	ESR1	0.0229612220350568	0.731200407057667	67	3447	2885	68	3447	2130	83	137	124	ESR1 MDA-MB-231 (breast adenocarcinoma) ESR1	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	ESR1	Treatment: E2, 100 nM, 0 min Genotype: ER-alfa L540Q	GTRD	EXP049533_MDA-MB-231--breast-adenocarcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	58920
1	1494	FLI1	0.0229141305025383	0.69159112558994	36	3448	3051	645	3448	2380	49	168	158	FLI1 A-673 clone Asp114 (Ewing sarcoma) FLI1	A-673 clone Asp114 (Ewing sarcoma)	NULL	FLI1		GTRD	EXP047962_A-673-clone-Asp114--Ewing-sarcoma-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	34804
1	3518	RXRA	0.0229141305025383	0.69159112558994	36	3448	3051	645	3448	2380	49	168	158	RXRA UPR9 (hematopoietic stem cells) RXRA	UPR9 (hematopoietic stem cells)	NULL	RXRA	5 hours zinc	GTRD	EXP000750_UPR9--hematopoietic-stem-cells-_RXRA_MACS_RXRA_MA0115.1.damo.pwm.bed	25729
1	2330	JUN	0.022512258533101	0.631090977824671	19	3450	3268	1697	3450	2800	29	185	178	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 10 minute	GTRD	EXP040248_A549--lung-carcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	21389
1	2938	MYCN	0.0224760040402454	0.605896011556761	15	3451	3332	1993	3451	2930	24	189	183	MYCN Tet21N (neuroblastoma) MYCN	Tet21N (neuroblastoma)	BTO:0004654	MYCN	None	GTRD	EXP036325_Tet21N--neuroblastoma-_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	4261
1	3337	RELA	0.0224760040402454	0.605896011556761	15	3451	3332	1993	3451	2930	24	189	183	RELA GM19099 (female B-cells Lymphoblastoid Cell Lines) RELA	GM19099 (female B-cells Lymphoblastoid Cell Lines)	NULL	RELA	human recombinant TNF-alpha from eBioscience [product# 14-8329-62] (Snyder)	ENCODE	ENCSR000EBI_GM19099_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	12021
1	1559	FOS	0.0224360986757438	0.671598010519705	29	3453	3120	1013	3453	2530	41	175	166	FOS MCF10A-ER-Src FOS	MCF10A-ER-Src	NULL	FOS	Genotype: transformed	GTRD	EXP048568_MCF10A-ER-Src_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	95991
1	2622	JUND	0.0221325967497941	0.686657148828534	35	3454	3071	691	3454	2410	48	169	159	JUND JUND	NA	NA	JUND	NA	GEO	GSE61369_jund_artery-smooth-muscle_MACS_JUND_MA0491.2.damo.pwm.bed	118029
1	2280	JUN	0.0214464193667624	0.664871279980805	28	3455	3155	1068	3455	2560	40	176	167	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	TNFa, 4h	GTRD	EXP038042_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	42268
1	2065	GRHL2	0.0213418966638935	0.681495148120907	34	3456	3077	729	3456	2420	47	170	160	GRHL2 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) GRHL2	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	GRHL2	Treatment: 45 min ethanol	GTRD	EXP048442_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	41775
1	1074	EHF	0.0212386549724525	0.70989378261829	50	3457	2993	275	3457	2240	65	154	142	EHF RWPE1 (prostate epithelial cells) EHF	RWPE1 (prostate epithelial cells)	BTO:0003709	EHF	Infection: retrovirus expressing FLAG-EHF Treatment: nearly confluent 150 mm dishes were treated with 1% formaldehyde, and harvested in Farnham lysis buffer and a crude nuclear pellet collected after centrifugation	GTRD	EXP048485_RWPE1--prostate-epithelial-cells-_EHF_MACS_EHF_MA0598.3.damo.pwm.bed	33866
1	3025	NFKB2	0.0212386549724525	0.70989378261829	50	3457	2993	275	3457	2240	65	154	142	NFKB2 GM12878 (female B-cells lymphoblastoid cell line) NFKB2	GM12878 (female B-cells lymphoblastoid cell line)	NULL	NFKB2	NA	GTRD	EXP054689_GM12878--female-B-cells-lymphoblastoid-cell-line-_NFKB2_MACS_NFKB2_MA0778.1.damo.pwm.bed	43722
1	1846	FOXA2	0.0211611467090742	0.493249283009473	6	3459	3624	2948	3624	3340	12	198	195	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Genotype: Clonal FOXA2 doxycycline inducible cells, CDT1	GTRD	EXP049381_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	19641
1	1860	FOXP1	0.0211611467090742	0.493249283009473	6	3459	3624	2948	3624	3340	12	198	195	FOXP1 HBL1 (diffuse large B-cell lymphoma) FOXP1	HBL1 (diffuse large B-cell lymphoma)	NULL	FOXP1	NA	GTRD	EXP034307_HBL1--diffuse-large-B-cell-lymphoma-_FOXP1_MACS_FOXP1_MA0481.3.damo.pwm.bed	1301
1	2011	GATA4	0.0211611467090742	0.493249283009473	6	3459	3624	2948	3624	3340	12	198	195	GATA4 HUES64 (embryonic stem cells) GATA4	HUES64 (embryonic stem cells)	NULL	GATA4		GTRD	EXP036790_HUES64--embryonic-stem-cells-_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	32341
1	3491	RUNX1	0.0211611467090742	0.493249283009473	6	3459	3624	2948	3624	3340	12	198	195	RUNX1 Kasumi-1 (acute myeloblastic leukemia) RUNX1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	RUNX1		GEO	GSE45738_runx1_kasumi1_MACS_RUNX1_MA0002.2.damo.pwm.bed	12209
1	3763	TAL1	0.0211611467090742	0.493249283009473	6	3459	3624	2948	3624	3340	12	198	195	TAL1 K562 (myelogenous leukemia) TAL1	K562 (myelogenous leukemia)	NULL	TAL1	NA	ENCODE	ENCSR000EHB_K562_TAL1_MACS_TAL1_MA0140.2.damo.pwm.bed	29369
1	236	ASCL1	0.0209825758305708	0.564726285598614	11	3464	3449	2332	3464	3080	19	193	188	ASCL1 NCI-H2107 (small cell lung carcinoma) ASCL1	NCI-H2107 (small cell lung carcinoma)	NULL	ASCL1		GEO	GSE69394_ascl1_h2107_MACS_ASCL1_MA1100.2.damo.pwm.bed	22389
1	2454	JUN	0.0209825758305708	0.564726285598614	11	3464	3449	2332	3464	3080	19	193	188	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: control (scrambled shRNA);	GTRD	EXP058211_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	9680
1	3091	NR3C1	0.0209825758305708	0.564726285598614	11	3464	3449	2332	3464	3080	19	193	188	NR3C1 U2OS (osteosarcoma) NR3C1	U2OS (osteosarcoma)	BTO:0001938	NR3C1	GLUCC	Array Express	ERP007081_nr3c1_u2os-glucc_MACS_NR3C1_MA0113.3.damo.pwm.bed	44490
1	3559	SIX2	0.0209657916455974	0.619386629481527	18	3467	3305	1785	3467	2850	28	186	179	SIX2 HEK SIX2	HEK	NA	SIX2		GEO	GSE73865_six2_hek_MACS_SIX2_MA1119.1.damo.pwm.bed	48175
1	2803	MYC	0.0205424694936146	0.676090564483606	33	3468	3089	778	3468	2440	46	171	161	MYC normal epidermal keratinocytes MYC	normal epidermal keratinocytes	NULL	MYC	NULL	GTRD	EXP000989_normal-epidermal-keratinocytes_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	13771
1	318	CEBPA	0.020526433318982	0.590227821025597	14	3469	3389	2073	3469	2980	23	190	184	CEBPA SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) CEBPA	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	CEBPA	RUNX1-EVI1 KD after 10 days	GTRD	EXP037839_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	14374
1	3026	NFKB2	0.020526433318982	0.590227821025597	14	3469	3389	2073	3469	2980	23	190	184	NFKB2 L1236 (Hodgkin lymphoma) NFKB2	L1236 (Hodgkin lymphoma)	NULL	NFKB2	NA	GEO	GSE63736_nfkb2_l1236_MACS_NFKB2_MA0778.1.damo.pwm.bed	20202
1	14	AR	0.0205063609178948	0.440836987674943	4	3471	3679	3182	3679	3440	9	200	198	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	R1881	GTRD	EXP000733_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	12309
1	210	AR	0.0205063609178948	0.440836987674943	4	3471	3679	3182	3679	3440	9	200	198	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	DHT	GEO	GSE83860_AR_lncap-dht_MACS_AR_MA0007.3.damo.pwm.bed	25368
1	656	CTCF	0.0205063609178948	0.440836987674943	4	3471	3679	3182	3679	3440	9	200	198	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	100 nM 17-beta-estradiol for 45 min	GTRD	EXP037647_MCF7--Invasive-ductal-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	12741
1	3010	NFIB	0.0205063609178948	0.440836987674943	4	3471	3679	3182	3679	3440	9	200	198	NFIB MCF7 (Invasive ductal breast carcinoma) NFIB	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NFIB	NA	GTRD	EXP039996_MCF7--Invasive-ductal-breast-carcinoma-_NFIB_MACS_NFIB_MA1643.1.damo.pwm.bed	14598
1	3835	TEAD4	0.0205063609178948	0.440836987674943	4	3471	3679	3182	3679	3440	9	200	198	TEAD4 A549 (lung carcinoma) TEAD4	A549 (lung carcinoma)	BTO:0000018	TEAD4		ENCODE	ENCSR000BUD_A549_TEAD4_MACS_TEAD4_MA0809.2.damo.pwm.bed	7802
1	2583	JUNB	0.0204732175367894	0.638063965634149	22	3476	3228	1459	3476	2720	33	182	174	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: transformed	GTRD	EXP048570_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	62781
1	1560	FOS	0.0204469370882972	0.657782127656116	27	3477	3184	1135	3477	2600	39	177	168	FOS MCF10A-ER-Src FOS	MCF10A-ER-Src	NULL	FOS	Genotype: transformed	GTRD	EXP048568_MCF10A-ER-Src_FOS_MACS_FOS_MA1134.1.damo.pwm.bed	88249
1	1626	FOSL2	0.0204469370882972	0.657782127656116	27	3477	3184	1135	3477	2600	39	177	168	FOSL2 LPS141 (Dedifferentiated liposarcoma) FOSL2	LPS141 (Dedifferentiated liposarcoma)	NULL	FOSL2		GTRD	EXP057976_LPS141--Dedifferentiated-liposarcoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	55989
1	2599	JUND	0.0204469370882972	0.657782127656116	27	3477	3184	1135	3477	2600	39	177	168	JUND K562 (myelogenous leukemia) JUND	K562 (myelogenous leukemia)	NULL	JUND		ENCODE	ENCSR000EGN_K562_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	32242
1	42	AR	0.0201527173260722	0.523257896981799	8	3480	3512	2697	3512	3230	15	196	192	AR CWR22 (prostate carcinoma) AR	CWR22 (prostate carcinoma)	BTO:0004594	AR	DHT+MDV3100	GTRD	EXP034149_CWR22--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	22525
1	73	AR	0.0201527173260722	0.523257896981799	8	3480	3512	2697	3512	3230	15	196	192	AR LNCaP-abl (Prostate carcinoma) AR	LNCaP-abl (Prostate carcinoma)	NULL	AR	Treatment: vehicle (DMSO) of 5 uM for 4-5 days Passages: 61-64 Phenotype: AR-positive, EZH2 inhibitor -sensitive	GTRD	EXP048900_LNCaP-abl--Prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	18604
1	3473	RUNX1	0.0201527173260722	0.523257896981799	8	3480	3512	2697	3512	3230	15	196	192	RUNX1 HL-60 (acute myeloid leukemia) RUNX1	HL-60 (acute myeloid leukemia)	BTO:0000738	RUNX1		GTRD	EXP040800_HL-60--acute-myeloid-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	12472
1	2636	KLF4	0.0198953507906574	0.687428937781005	39	3483	3065	547	3483	2360	53	165	154	KLF4 BJ (fibroblasts) KLF4	BJ (fibroblasts)	NULL	KLF4	INDUCED	GEO	GSE36570_klf4_bj-induced_MACS_KLF4_MA0039.4.damo.pwm.bed	45085
1	2025	GATA4	0.0197348189999317	0.670427536152032	32	3484	3137	825	3484	2480	45	172	162	GATA4 AGS (gastric adenocarcinoma) GATA4	AGS (gastric adenocarcinoma)	BTO:0001007	GATA4		GEO	GSE51705_gata4_ags_MACS_GATA4_MA0482.2.damo.pwm.bed	59640
1	2303	JUN	0.0197348189999317	0.670427536152032	32	3484	3137	825	3484	2480	45	172	162	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	control, 4h	GTRD	EXP038046_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	52776
1	1726	FOXA1	0.0194385927806927	0.650302217327435	26	3486	3209	1204	3486	2630	38	178	169	FOXA1 RT4 (Bladder carcinoma cells) FOXA1	RT4 (Bladder carcinoma cells)	NULL	FOXA1	Treatment: not applicable Stage:adult  Tissue: transitional cell papilloma	GTRD	EXP049023_RT4--Bladder-carcinoma-cells-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	43590
1	2790	MYC	0.0192652580801034	0.710063618162386	56	3487	2992	192	3487	2220	72	148	135	MYC MYC	NA	NA	MYC	NA	NA	ENCSR000DOS_MCF_10A_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	33013
1	2471	JUN	0.0189195212105082	0.664488750631097	31	3488	3156	881	3488	2510	44	173	163	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN		GEO	GSE66081_jun_mdamb231_MACS_JUN_MA0489.1.damo.pwm.bed	56305
1	1044	E2F6	0.0188885851737527	0.707669104819501	55	3489	2997	211	3489	2230	71	149	136	E2F6 WA01 (H1, human embryonic stem cells) E2F6	WA01 (H1, human embryonic stem cells)	NULL	E2F6		ENCODE	ENCSR000BSI_H1-hESC_E2F6_MACS_E2F6_MA0471.2.damo.pwm.bed	38756
1	418	CREB1	0.0187625381407411	0.694024002954418	45	3490	3044	383	3490	2310	60	159	147	CREB1 GM12878 (female B-cells lymphoblastoid cell line) CREB1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	CREB1		ENCODE	ENCSR000BUF_GM12878_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	31548
1	2933	MYC	0.0187625381407411	0.694024002954418	45	3490	3044	383	3490	2310	60	159	147	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	Doxy	GEO	GSE77356_myc_u2os-dox_MACS_MYC_MA0147.3.damo.pwm.bed	20189
1	212	AR	0.0185640257146349	0.573117638584579	13	3492	3434	2153	3492	3030	22	191	185	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	R1881_30M	GEO	GSE84432_AR_vcap-r1881-30m_MACS_AR_MA0007.3.damo.pwm.bed	53687
1	2053	GLIS1	0.0185503690078318	0.716705636630285	67	3493	2962	68	3493	2170	84	137	123	GLIS1 HEK293 (embryonic kidney) GLIS1	HEK293 (embryonic kidney)	NULL	GLIS1	NA	GTRD	EXP035916_HEK293--embryonic-kidney-_GLIS1_MACS_GLIS1_MA0735.1.damo.pwm.bed	65165
1	2458	JUN	0.0184834505338185	0.542033798203026	10	3494	3482	2442	3494	3140	18	194	189	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: control (scrambled shRNA);	GTRD	EXP058211_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	8644
1	2007	GATA3	0.0184224826634925	0.642400139706941	25	3495	3221	1262	3495	2660	37	179	170	GATA3 Jurkat (T-cells) GATA3	Jurkat (T-cells)	BTO:0000661	GATA3		GEO	GSE76181_gata3_jurkat_MACS_GATA3_MA0037.3.damo.pwm.bed	39697
1	2445	JUN	0.0184224826634925	0.642400139706941	25	3495	3221	1262	3495	2660	37	179	170	JUN MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line) JUN	MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line)	NULL	JUN		GTRD	EXP058065_MDA-MB-231p27CK-DD--breast-cancer-cells--phosphimimetic-p27-cell-line-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	27177
1	2807	MYC	0.0179596918839637	0.617836918343576	20	3497	3314	1606	3497	2810	31	184	176	MYC HeLa S3 (cervical adenocarcinoma) MYC	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	MYC	NULL	GTRD	EXP000991_HeLa-S3--cervical-adenocarcinoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	6830
1	3571	SMAD3	0.0179596918839637	0.617836918343576	20	3497	3314	1606	3497	2810	31	184	176	SMAD3 MDA-MB-231 (breast adenocarcinoma) SMAD3	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	SMAD3	Treatment: TGF-beta CellType: Immortalized human mammary epithelial cells	GTRD	EXP047901_MDA-MB-231--breast-adenocarcinoma-_SMAD3_MACS_SMAD3_MA1622.1.damo.pwm.bed	47849
1	2829	MYC	0.0179348978258633	0.673514048934673	36	3499	3116	645	3499	2420	50	168	157	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	empty vector, Doxycycline	GTRD	EXP036032_U2OS--osteosarcoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	16285
1	2251	JUN	0.0178404043756938	0.593223671651602	16	3500	3384	1909	3500	2930	26	188	181	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	dexametasone	GTRD	EXP033443_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	17843
1	1470	ETS1	0.0172685249772986	0.668457866304896	35	3501	3140	691	3501	2440	49	169	158	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1	VEGF_1H	GEO	GSE41166_ets1_huvec-vegf-1h_MACS_ETS1_MA0098.3.damo.pwm.bed	15427
1	3650	SPI1	0.0172685249772986	0.668457866304896	35	3501	3140	691	3501	2440	49	169	158	SPI1 monocyte-derived macrophages SPI1	monocyte-derived macrophages	NULL	SPI1	untreated	GTRD	EXP036835_monocyte-derived-macrophages_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	46419
1	1032	E2F4	0.0169118253210925	0.694253317094704	50	3503	3042	275	3503	2270	66	154	141	E2F4 E2F4	NA	NA	E2F4	NA	NA	ENCSR000DOR_MCF_10A_E2F4_MACS_E2F4_MA0470.2.damo.pwm.bed	15920
1	2935	MYC	0.0169118253210925	0.694253317094704	50	3503	3042	275	3503	2270	66	154	141	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	SHRCTR	GEO	GSE77356_myc_u2os-shrctr_MACS_MYC_MA0147.3.damo.pwm.bed	20724
1	275	BACH2	0.0168999780111136	0.490675596081058	7	3505	3630	2812	3630	3320	14	197	193	BACH2 OCI-LY7 (diffuse large B-cell lymphoma) BACH2	OCI-LY7 (diffuse large B-cell lymphoma)	NULL	BACH2		GEO	GSE44420_bach2_ocily7_MACS_BACH2_MA1101.2.damo.pwm.bed	7273
1	352	CEBPB	0.0168999780111136	0.490675596081058	7	3505	3630	2812	3630	3320	14	197	193	CEBPB HCT-116 (colon carcinoma) CEBPB	HCT-116 (colon carcinoma)	BTO:0001109	CEBPB		ENCODE	ENCSR000BSD_HCT116_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	15464
1	2091	HIF1A	0.0168999780111136	0.490675596081058	7	3505	3630	2812	3630	3320	14	197	193	HIF1A HepG2 (hepatoblastoma) HIF1A	HepG2 (hepatoblastoma)	BTO:0000599	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 16 hours	GTRD	EXP048737_HepG2--hepatoblastoma-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	3131
1	2486	JUNB	0.0168999780111136	0.490675596081058	7	3505	3630	2812	3630	3320	14	197	193	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039331_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	12820
1	2490	JUNB	0.0168999780111136	0.490675596081058	7	3505	3630	2812	3630	3320	14	197	193	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039331_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	12835
1	2492	JUNB	0.0168999780111136	0.490675596081058	7	3505	3630	2812	3630	3320	14	197	193	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039331_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	13231
1	1067	EGR1	0.0168090943908272	0.448529708168595	5	3511	3675	3053	3675	3410	11	199	196	EGR1 HL-60 (acute myeloid leukemia) EGR1	HL-60 (acute myeloid leukemia)	BTO:0000738	EGR1	Treatment: untreated	GTRD	EXP047937_HL-60--acute-myeloid-leukemia-_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	3238
1	2013	GATA4	0.0168090943908272	0.448529708168595	5	3511	3675	3053	3675	3410	11	199	196	GATA4 HUES64 (embryonic stem cells) GATA4	HUES64 (embryonic stem cells)	NULL	GATA4	shGATA4	GTRD	EXP036792_HUES64--embryonic-stem-cells-_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	24476
1	2206	IRF3	0.0168090943908272	0.448529708168595	5	3511	3675	3053	3675	3410	11	199	196	IRF3 HeLa S3 (cervical adenocarcinoma) IRF3	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	IRF3	NA	ENCODE	ENCSR000EDF_HeLa-S3_IRF3_MACS_IRF3_MA1418.1.damo.pwm.bed	1187
1	3335	RELA	0.0168090943908272	0.448529708168595	5	3511	3675	3053	3675	3410	11	199	196	RELA GM18526 (B – cells Lymphoblastoid Cell Lines) RELA	GM18526 (B – cells Lymphoblastoid Cell Lines)	NULL	RELA	human recombinant TNF-alpha from eBioscience [product# 14-8329-62] (Snyder)	ENCODE	ENCSR000EBA_GM18526_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	3221
1	2269	JUN	0.0166937927222273	0.606684900861629	19	3515	3330	1697	3515	2850	30	185	177	JUN RCC 7860 (Renal cell carcinoma) JUN	RCC 7860 (Renal cell carcinoma)	BTO:0003781	JUN		GTRD	EXP037742_786-O--renal-carcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	23530
1	2590	JUND	0.0166937927222273	0.606684900861629	19	3515	3330	1697	3515	2850	30	185	177	JUND SK-N-SH (neuroblastoma) JUND	SK-N-SH (neuroblastoma)	BTO:0001620	JUND		ENCODE	ENCSR000BSK_SK-N-SH_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	35878
1	2290	JUN	0.0164347770965082	0.64481925096547	28	3517	3218	1068	3517	2600	41	176	166	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	IL1b, 4h	GTRD	EXP038043_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	41082
1	3214	PAX5	0.0164347770965082	0.64481925096547	28	3517	3218	1068	3517	2600	41	176	166	PAX5 GM12891 (male B- cells lymphoblastoid cell line) PAX5	GM12891 (male B- cells lymphoblastoid cell line)	NULL	PAX5		ENCODE	ENCSR000BJH_GM12891_PAX5_MACS_PAX5_MA0014.3.damo.pwm.bed	12929
1	2452	JUN	0.0163722583299175	0.62518584424078	23	3519	3294	1391	3519	2730	35	181	172	JUN MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line) JUN	MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line)	NULL	JUN		GTRD	EXP058065_MDA-MB-231p27CK-DD--breast-cancer-cells--phosphimimetic-p27-cell-line-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	25269
1	3826	TEAD1	0.0163722583299175	0.62518584424078	23	3519	3294	1391	3519	2730	35	181	172	TEAD1 T47D (invasive ductal carcinoma) TEAD1	T47D (invasive ductal carcinoma)	BTO:0001248	TEAD1		GTRD	EXP047976_T47D--invasive-ductal-carcinoma-_TEAD1_MACS_TEAD1_MA0090.3.damo.pwm.bed	46299
1	2248	JUN	0.0162697523967076	0.578545032332503	15	3521	3406	1993	3521	2970	25	189	182	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	dexametasone	GTRD	EXP033443_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	17712
1	2249	JUN	0.0162697523967076	0.578545032332503	15	3521	3406	1993	3521	2970	25	189	182	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	dexametasone	GTRD	EXP033443_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	17016
1	2252	JUN	0.0162697523967076	0.578545032332503	15	3521	3406	1993	3521	2970	25	189	182	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	dexametasone	GTRD	EXP033443_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	17146
1	2253	JUN	0.0162697523967076	0.578545032332503	15	3521	3406	1993	3521	2970	25	189	182	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	dexametasone	GTRD	EXP033443_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	17033
1	2254	JUN	0.0162697523967076	0.578545032332503	15	3521	3406	1993	3521	2970	25	189	182	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	dexametasone	GTRD	EXP033443_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	17637
1	2878	MYC	0.0160801595755832	0.688138012138561	48	3526	3064	317	3526	2300	64	156	143	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shSCR;	GTRD	EXP047484_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	19170
1	112	AR	0.0159816163565162	0.516651864167787	9	3527	3521	2564	3527	3200	17	195	190	AR LNCaP95 AR	LNCaP95	NULL	AR	Treatment: 10nM DHT for 4 hrs Genotype: shARv7 transfection	GTRD	EXP052955_LNCaP95_AR_MACS_AR_MA0007.3.damo.pwm.bed	36965
1	273	BACH2	0.0156608655518253	0.332485315584929	2	3528	3772	3462	3772	3590	6	202	201	BACH2 B-cells BACH2	B-cells	NULL	BACH2	siBACH2	GTRD	EXP040450_B-cells_BACH2_MACS_BACH2_MA1101.2.damo.pwm.bed	3391
1	1401	ESR1	0.0156608655518253	0.332485315584929	2	3528	3772	3462	3772	3590	6	202	201	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2_10M	GEO	GSE54855_esr1_mcf7-e2-10m_MACS_ESR1_MA0112.3.damo.pwm.bed	4345
1	2105	HIF1A	0.0156608655518253	0.332485315584929	2	3528	3772	3462	3772	3590	6	202	201	HIF1A HUVEC-C (HUVEC, umbilical vein endothelial cells) HIF1A	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	HIF1A	HYPOX	GEO	GSE39089_hif1a_huvec-hypox_MACS_HIF1A_MA1106.1.damo.pwm.bed	1890
1	2156	HOXA9	0.0156608655518253	0.332485315584929	2	3528	3772	3462	3772	3590	6	202	201	HOXA9 HEK293-FT (human embryonic kidney, female transformed) HOXA9	HEK293-FT (human embryonic kidney, female transformed)	NULL	HOXA9	HOXA9-FLAG expression	GTRD	EXP036955_HEK293-FT--human-embryonic-kidney--female-transformed-_HOXA9_MACS_HOXA9_MA0594.2.damo.pwm.bed	19912
1	3447	RFX5	0.0156608655518253	0.332485315584929	2	3528	3772	3462	3772	3590	6	202	201	RFX5 K562 (myelogenous leukemia) RFX5	K562 (myelogenous leukemia)	NULL	RFX5	NA	ENCODE	ENCSR000EGO_K562_RFX5_MACS_RFX5_MA0510.2.damo.pwm.bed	1256
1	3754	STAT5A	0.0156608655518253	0.332485315584929	2	3528	3772	3462	3772	3590	6	202	201	STAT5A CD4+ CD25+ CD45RA+ T-cells STAT5A	CD4+ CD25+ CD45RA+ T-cells	NULL	STAT5A		GTRD	EXP032562_CD4--CD25--CD45RA--T-cells_STAT5A_MACS_STAT5A_MA1624.1.damo.pwm.bed	1707
1	3764	TAL1	0.0156608655518253	0.332485315584929	2	3528	3772	3462	3772	3590	6	202	201	TAL1 K562 (myelogenous leukemia) TAL1	K562 (myelogenous leukemia)	NULL	TAL1	NA	ENCODE	ENCSR106FRG_K562_TAL1_MACS_TAL1_MA0140.2.damo.pwm.bed	20262
1	1473	ETV1	0.0155964201332202	0.637568859066696	27	3535	3238	1135	3535	2640	40	177	167	ETV1 GIST-T1 (Gastrointestinal stromal tumor) ETV1	GIST-T1 (Gastrointestinal stromal tumor)	NULL	ETV1	Treatment: cells were harvested in log phase growth	GTRD	EXP048909_GIST-T1--Gastrointestinal-stromal-tumor-_ETV1_MACS_ETV1_MA0761.2.damo.pwm.bed	18363
1	2203	IRF2	0.0155964201332202	0.637568859066696	27	3535	3238	1135	3535	2640	40	177	167	IRF2 K562 (myelogenous leukemia) IRF2	K562 (myelogenous leukemia)	NULL	IRF2		ENCODE	ENCSR376WCJ_K562_IRF2_MACS_IRF2_MA0051.1.damo.pwm.bed	12603
1	2282	JUN	0.0155964201332202	0.637568859066696	27	3535	3238	1135	3535	2640	40	177	167	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	TNFa, 4h	GTRD	EXP038042_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	40228
1	2288	JUN	0.0155964201332202	0.637568859066696	27	3535	3238	1135	3535	2640	40	177	167	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	IL1b, 4h	GTRD	EXP038043_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	40931
1	3643	SP4	0.0150491607825242	0.692746577340062	55	3539	3048	211	3539	2270	72	149	135	SP4 HEK293 (embryonic kidney) SP4	HEK293 (embryonic kidney)	NULL	SP4	NA	GTRD	EXP035954_HEK293--embryonic-kidney-_SP4_MACS_SP4_MA0685.1.damo.pwm.bed	19153
1	1195	ESR1	0.0150312893057011	0.665820298813025	38	3540	3154	576	3540	2420	53	166	154	ESR1 MCF10A (breast epithelial cells) ESR1	MCF10A (breast epithelial cells)	BTO:0001939	ESR1		GTRD	EXP033710_MCF10A--breast-epithelial-cells-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	23066
1	2291	JUN	0.0147547197474762	0.629927547894784	26	3541	3270	1204	3541	2670	39	178	168	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	IL1b, 4h	GTRD	EXP038043_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	39052
1	2272	JUN	0.0147008754841127	0.562624319382735	14	3542	3455	2073	3542	3020	24	190	183	JUN RCC 7860 (Renal cell carcinoma) JUN	RCC 7860 (Renal cell carcinoma)	BTO:0003781	JUN		GTRD	EXP037742_786-O--renal-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	17663
1	3334	RELA	0.0144395516366357	0.372094283731736	3	3543	3747	3316	3747	3540	8	201	199	RELA GM18505 (female B-cells Lymphoblastoid Cell Lines) RELA	GM18505 (female B-cells Lymphoblastoid Cell Lines)	NULL	RELA	human recombinant TNF-alpha from eBioscience [product# 14-8329-62] (Snyder)	ENCODE	ENCSR000EAW_GM18505_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	4422
1	1054	EBF1	0.0143090315142145	0.605808318631151	21	3544	3334	1535	3544	2800	33	183	174	EBF1 MUTUL EBF1	MUTUL	NA	EBF1	NA	GEO	GSE75503_ebf1_mutul_MACS_EBF1_MA0154.4.damo.pwm.bed	47046
1	2579	JUNB	0.0143090315142145	0.605808318631151	21	3544	3334	1535	3544	2800	33	183	174	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: transformed	GTRD	EXP048570_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	63920
1	2581	JUNB	0.0143090315142145	0.605808318631151	21	3544	3334	1535	3544	2800	33	183	174	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: transformed	GTRD	EXP048570_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	63850
1	3656	SPI1	0.0141582946703542	0.581934092093698	17	3547	3403	1846	3547	2930	28	187	179	SPI1 MDM(monocyte derived macrophages) SPI1	MDM(monocyte derived macrophages)	NULL	SPI1	Treatment: H5N1 IAV infected 6hr	GTRD	EXP047757_MDM-monocyte-derived-macrophages-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	79054
1	50	AR	0.0139591595002873	0.250752982824555	1	3548	3799	3655	3799	3670	4	203	203	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	siOCT1	GTRD	EXP036107_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	4993
1	271	BACH1	0.0139591595002873	0.250752982824555	1	3548	3799	3655	3799	3670	4	203	203	BACH1 K562 (myelogenous leukemia) BACH1	K562 (myelogenous leukemia)	NULL	BACH1	NA	ENCODE	ENCSR740NPG_K562_BACH1_MACS_BACH1_MA0591.1.damo.pwm.bed	6121
1	1354	ESR1	0.0139591595002873	0.250752982824555	1	3548	3799	3655	3799	3670	4	203	203	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	Passsage: <10 Genotype: wt/R330fs mutant with CRISPR	GTRD	EXP049894_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	5860
1	1436	ESR1	0.0139591595002873	0.250752982824555	1	3548	3799	3655	3799	3670	4	203	203	ESR1 ZR-75-1 (invasive ductal carcinoma) ESR1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	ESR1		GEO	GSE72249_esr1_zr751_MACS_ESR1_MA0112.3.damo.pwm.bed	13406
1	1562	FOS	0.0139591595002873	0.250752982824555	1	3548	3799	3655	3799	3670	4	203	203	FOS MV-4-11 (Childhood acute monocytic leukemia) FOS	MV-4-11 (Childhood acute monocytic leukemia)	BTO:0004479	FOS		GEO	GSE64862_fos_mv411_MACS_FOS_MA0476.1.damo.pwm.bed	4941
1	2040	GATA6	0.0139591595002873	0.250752982824555	1	3548	3799	3655	3799	3670	4	203	203	GATA6 Caco-2 (colon adenocarcinoma) GATA6	Caco-2 (colon adenocarcinoma)	BTO:0000195	GATA6	PROLIF	GEO	GSE23436_gata6_caco2-prolif_MACS_GATA6_MA1104.2.damo.pwm.bed	13040
1	2098	HIF1A	0.0139591595002873	0.250752982824555	1	3548	3799	3655	3799	3670	4	203	203	HIF1A HKC8 (kidney proximal tubule cell line) HIF1A	HKC8 (kidney proximal tubule cell line)	NULL	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 16 hours	GTRD	EXP048753_HKC8--kidney-proximal-tubule-cell-line-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	1289
1	2603	JUND	0.0139591595002873	0.250752982824555	1	3548	3799	3655	3799	3670	4	203	203	JUND GM12878 (female B-cells lymphoblastoid cell line) JUND	GM12878 (female B-cells lymphoblastoid cell line)	NULL	JUND	NULL	GTRD	EXP000436_GM12878--female-B-cells-_JUND_MACS_JUND_MA1141.1.damo.pwm.bed	8264
1	3302	PRDM1	0.0139591595002873	0.250752982824555	1	3548	3799	3655	3799	3670	4	203	203	PRDM1 HUES64 (embryonic stem cells) PRDM1	HUES64 (embryonic stem cells)	NULL	PRDM1		GTRD	EXP036694_HUES64--embryonic-stem-cells-_PRDM1_MACS_PRDM1_MA0508.3.damo.pwm.bed	2576
1	3600	SOX2	0.0139591595002873	0.250752982824555	1	3548	3799	3655	3799	3670	4	203	203	SOX2 HUES64 (embryonic stem cells) SOX2	HUES64 (embryonic stem cells)	NULL	SOX2		GTRD	EXP036809_HUES64--embryonic-stem-cells-_SOX2_MACS_SOX2_MA0143.4.damo.pwm.bed	8124
1	3720	STAT1	0.0139591595002873	0.250752982824555	1	3548	3799	3655	3799	3670	4	203	203	STAT1 K562 (myelogenous leukemia) STAT1	K562 (myelogenous leukemia)	NULL	STAT1	Interferon gamma treatment - 6 hours (Snyder)	ENCODE	ENCSR000EHJ_K562_STAT1_MACS_STAT1_MA0137.3.damo.pwm.bed	1727
1	3752	STAT5A	0.0139591595002873	0.250752982824555	1	3548	3799	3655	3799	3670	4	203	203	STAT5A CD4+ CD25+ CD45RA+ T-cells STAT5A	CD4+ CD25+ CD45RA+ T-cells	NULL	STAT5A		GTRD	EXP032561_CD4--CD25--CD45RA--T-cells_STAT5A_MACS_STAT5A_MA1624.1.damo.pwm.bed	977
1	142	AR	0.013910905607774	0.621864752152099	25	3560	3297	1262	3560	2710	38	179	169	AR AR	NA	NA	AR	NA	GEO	GSE43785_AR_lncap_MACS_AR_MA0007.3.damo.pwm.bed	88696
1	3682	SPI1	0.0137197344709808	0.693766306598661	62	3561	3047	118	3561	2240	80	142	127	SPI1 macrophages SPI1	macrophages	NULL	SPI1	TPP	GEO	GSE66594_spi1_macrophages-tpp_MACS_SPI1_MA0080.5.damo.pwm.bed	116426
1	1041	E2F4	0.013667885695938	0.453051378901903	6	3562	3671	2948	3671	3390	13	198	194	E2F4 MCF7 (Invasive ductal breast carcinoma) E2F4	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	E2F4	TAM	GEO	GSE41561_e2f4_mcf7-tam_MACS_E2F4_MA0470.2.damo.pwm.bed	3273
1	1051	EBF1	0.013667885695938	0.453051378901903	6	3562	3671	2948	3671	3390	13	198	194	EBF1 GM12878 (female B-cells lymphoblastoid cell line) EBF1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	EBF1	NA	ENCODE	ENCSR000DZQ_GM12878_EBF1_MACS_EBF1_MA0154.4.damo.pwm.bed	17163
1	3637	SP2	0.0134979848718768	0.488075619857827	8	3564	3636	2697	3636	3300	16	196	191	SP2 K562 (myelogenous leukemia) SP2	K562 (myelogenous leukemia)	NULL	SP2	NA	ENCODE	ENCSR000BNL_K562_SP2_MACS_SP2_MA0516.2.damo.pwm.bed	3420
1	3941	TFDP1	0.0134979848718768	0.488075619857827	8	3564	3636	2697	3636	3300	16	196	191	TFDP1 K562 (myelogenous leukemia) TFDP1	K562 (myelogenous leukemia)	NULL	TFDP1		ENCODE	ENCSR017GBO_K562_TFDP1_MACS_TFDP1_MA1122.1.damo.pwm.bed	2868
1	2960	MYOD1	0.0134642660712056	0.666697330084689	42	3566	3153	454	3566	2390	58	162	149	MYOD1 myoblasts MYOD1	myoblasts	NULL	MYOD1	NA	GEO	GSE50413_myod1_myoblast_MACS_MYOD1_MA0499.2.damo.pwm.bed	44346
1	2450	JUN	0.0132776461479093	0.59518225207104	20	3567	3375	1606	3567	2850	32	184	175	JUN MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line) JUN	MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line)	NULL	JUN		GTRD	EXP058065_MDA-MB-231p27CK-DD--breast-cancer-cells--phosphimimetic-p27-cell-line-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	24483
1	2580	JUNB	0.0132776461479093	0.59518225207104	20	3567	3375	1606	3567	2850	32	184	175	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: transformed	GTRD	EXP048570_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	62952
1	3647	SPI1	0.0132776461479093	0.59518225207104	20	3567	3375	1606	3567	2850	32	184	175	SPI1 GM12891 (male B- cells lymphoblastoid cell line) SPI1	GM12891 (male B- cells lymphoblastoid cell line)	NULL	SPI1		ENCODE	ENCSR000BIJ_GM12891_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	50900
1	3665	SPI1	0.0132776461479093	0.59518225207104	20	3567	3375	1606	3567	2850	32	184	175	SPI1 THP-1 (acute monocytic leukemia) SPI1	THP-1 (acute monocytic leukemia)	BTO:0001370	SPI1	Treatment: 100nM VDR ligand 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) for 24 hrs Cell type: human monocytic cell line	GTRD	EXP049120_THP-1--acute-monocytic-leukemia-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	96744
1	3756	STAT5B	0.0132776461479093	0.59518225207104	20	3567	3375	1606	3567	2850	32	184	175	STAT5B T-cells STAT5B	T-cells	NULL	STAT5B	IL-2	GTRD	EXP000399_T-cells_STAT5B_MACS_STAT5B_MA1625.1.damo.pwm.bed	17412
1	1538	FOS	0.013171988432616	0.632738446657755	29	3572	3267	1013	3572	2620	43	175	164	FOS IMR90 (lung fibroblasts) FOS	IMR90 (lung fibroblasts)	NULL	FOS		GTRD	EXP039888_IMR90--lung-fibroblasts-_FOS_MACS_FOS_MA0099.3.damo.pwm.bed	42719
1	1086	ELF1	0.0130132598769912	0.662605869941346	41	3573	3172	476	3573	2410	57	163	150	ELF1 COLO-320 (colon adenocarcinoma) ELF1	COLO-320 (colon adenocarcinoma)	BTO:0002047	ELF1		GTRD	EXP037555_COLO-320--colon-adenocarcinoma-_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	15775
1	3658	SPI1	0.0128961516100182	0.56815445194729	16	3574	3445	1909	3574	2980	27	188	180	SPI1 MDM(monocyte derived macrophages) SPI1	MDM(monocyte derived macrophages)	NULL	SPI1	Treatment: IFNb treated 6hr	GTRD	EXP047759_MDM-monocyte-derived-macrophages-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	67635
1	3737	STAT3	0.0128961516100182	0.56815445194729	16	3574	3445	1909	3574	2980	27	188	180	STAT3 MDA-MB-468 (breast adenocarcinoma) STAT3	MDA-MB-468 (breast adenocarcinoma)	BTO:0001570	STAT3	ethanol	GTRD	EXP037704_MDA-MB-468--breast-adenocarcinoma-_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	14315
1	1684	FOXA1	0.0126894033017348	0.510857897305428	10	3576	3526	2442	3576	3180	19	194	188	FOXA1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) FOXA1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	FOXA1		GTRD	EXP038766_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	39508
1	3343	RELA	0.0126894033017348	0.510857897305428	10	3576	3526	2442	3576	3180	19	194	188	RELA GM12892 (female B-cells lymphoblastoid cell line) RELA	GM12892 (female B-cells lymphoblastoid cell line)	NULL	RELA	TNF-alpha induced (6h)	GTRD	EXP000764_GM12892--female-B-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	11424
1	3662	SPI1	0.0126894033017348	0.510857897305428	10	3576	3526	2442	3576	3180	19	194	188	SPI1 THP-1 (acute monocytic leukemia) SPI1	THP-1 (acute monocytic leukemia)	BTO:0001370	SPI1	Treatment: Pam3csk4 treated 4hr, IAV NS1(EP mRNA)	GTRD	EXP047820_THP-1--acute-monocytic-leukemia-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	49055
1	2630	KLF15	0.0126581259411806	0.672851223251461	48	3579	3117	317	3579	2340	65	156	142	KLF15 HEK293 (embryonic kidney) KLF15	HEK293 (embryonic kidney)	NULL	KLF15	NA	GTRD	EXP035969_HEK293--embryonic-kidney-_KLF15_MACS_KLF15_MA1513.1.damo.pwm.bed	18181
1	2535	JUNB	0.0124974102618851	0.394834426262255	4	3580	3728	3182	3728	3500	10	200	197	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP039868_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	9948
1	2536	JUNB	0.0124974102618851	0.394834426262255	4	3580	3728	3182	3728	3500	10	200	197	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP039868_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	9974
1	2537	JUNB	0.0124974102618851	0.394834426262255	4	3580	3728	3182	3728	3500	10	200	197	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP039868_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	9812
1	2538	JUNB	0.0124974102618851	0.394834426262255	4	3580	3728	3182	3728	3500	10	200	197	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP039868_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	10228
1	2539	JUNB	0.0124974102618851	0.394834426262255	4	3580	3728	3182	3728	3500	10	200	197	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP039868_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	9928
1	2540	JUNB	0.0124974102618851	0.394834426262255	4	3580	3728	3182	3728	3500	10	200	197	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP039868_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	10285
1	2541	JUNB	0.0124974102618851	0.394834426262255	4	3580	3728	3182	3728	3500	10	200	197	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP039868_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	10285
1	2905	MYC	0.0124974102618851	0.394834426262255	4	3580	3728	3182	3728	3500	10	200	197	MYC G401 (rhabdoid tumor of the kidney) MYC	G401 (rhabdoid tumor of the kidney)	BTO:0002586	MYC	Passage: ten-thirty; Genotype: SNF5 transfection;	GTRD	EXP057897_G401--rhabdoid-tumor-of-the-kidney-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	1617
1	2906	MYC	0.0124974102618851	0.394834426262255	4	3580	3728	3182	3728	3500	10	200	197	MYC G401 (rhabdoid tumor of the kidney) MYC	G401 (rhabdoid tumor of the kidney)	BTO:0002586	MYC	Passage: ten-thirty; Genotype: SNF5 transfection;	GTRD	EXP057897_G401--rhabdoid-tumor-of-the-kidney-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	1490
1	3336	RELA	0.0124974102618851	0.394834426262255	4	3580	3728	3182	3728	3500	10	200	197	RELA GM18951 (B-cells Lymphoblastoid Cell Lines) RELA	GM18951 (B-cells Lymphoblastoid Cell Lines)	NULL	RELA	human recombinant TNF-alpha from eBioscience [product# 14-8329-62] (Snyder)	ENCODE	ENCSR000EBD_GM18951_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	4798
1	3733	STAT3	0.0124974102618851	0.394834426262255	4	3580	3728	3182	3728	3500	10	200	197	STAT3 Th17-cells STAT3	Th17-cells	BTO:0005655	STAT3		GTRD	EXP036973_Th17-cells_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	831
1	3687	SPI1	0.0124794784176254	0.625720564540351	28	3591	3277	1068	3591	2650	42	176	165	SPI1 CD34+ cells SPI1	CD34+ cells	NULL	SPI1	FETAL	GEO	GSE70660_spi1_cd34-fetal_MACS_SPI1_MA0080.5.damo.pwm.bed	60680
1	3663	SPI1	0.0122497556762559	0.583851020752638	19	3592	3401	1697	3592	2900	31	185	176	SPI1 THP-1 (acute monocytic leukemia) SPI1	THP-1 (acute monocytic leukemia)	BTO:0001370	SPI1	Treatment: DMSO for 24 hr in RPMI with 10% fetal bovine serum	GTRD	EXP048337_THP-1--acute-monocytic-leukemia-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	85137
1	3642	SP3	0.0122300942973962	0.639958399538405	33	3593	3226	778	3593	2530	48	171	159	SP3 HEK293 (embryonic kidney) SP3	HEK293 (embryonic kidney)	NULL	SP3	NA	GTRD	EXP039318_HEK293--embryonic-kidney-_SP3_MACS_SP3_MA0746.2.damo.pwm.bed	10472
1	2326	JUN	0.0122226587035493	0.60433540859071	23	3594	3337	1391	3594	2770	36	181	171	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039981_A549--lung-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	14272
1	2828	MYC	0.0121011502101262	0.653910058075027	39	3595	3197	547	3595	2450	55	165	152	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	empty vector, Doxycycline	GTRD	EXP036032_U2OS--osteosarcoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	17641
1	2423	JUN	0.0117865718308711	0.618340042526496	27	3596	3313	1135	3596	2680	41	177	166	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: transformed	GTRD	EXP048572_MCF10A-ER-Src_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	63694
1	3640	SP2	0.0116566802763567	0.687089245145764	66	3597	3066	78	3597	2250	85	138	122	SP2 HEK293 (embryonic kidney) SP2	HEK293 (embryonic kidney)	NULL	SP2	NA	GTRD	EXP035889_HEK293--embryonic-kidney-_SP2_MACS_SP2_MA0516.2.damo.pwm.bed	22049
1	2789	MYC	0.011643822424247	0.55329485770887	15	3598	3464	1993	3598	3020	26	189	181	MYC MYC	NA	NA	MYC	NA	NA	ENCSR000DOM_MCF_10A_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	12059
1	3684	SPI1	0.011643822424247	0.55329485770887	15	3598	3464	1993	3598	3020	26	189	181	SPI1 OCI-LY7 (diffuse large B-cell lymphoma) SPI1	OCI-LY7 (diffuse large B-cell lymphoma)	NULL	SPI1		GEO	GSE69558_spi1_ocily7_MACS_SPI1_MA0080.5.damo.pwm.bed	31725
1	2866	MYC	0.0116407968458497	0.649287510638417	38	3600	3214	576	3600	2460	54	166	153	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	none (Myc transgene expressed)	GTRD	EXP038948_P493-6--B-cell-lymphoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	24929
1	1776	FOXA1	0.0116224625905328	0.675659317291103	54	3601	3090	225	3601	2310	72	150	135	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	R1881	GEO	GSE56086_foxa1_vcap-r1881_MACS_FOXA1_MA0148.4.damo.pwm.bed	206835
1	419	CREB1	0.0115969360411846	0.526379431127478	12	3602	3509	2233	3602	3110	22	192	185	CREB1 Ishikawa (endometrial adenocarcinoma) CREB1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	CREB1		ENCODE	ENCSR000BUR_Ishikawa_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	4302
1	1516	FOS	0.0113815438387176	0.594789231381311	22	3603	3380	1459	3603	2810	35	182	172	FOS FOS	NA	NA	FOS	NA	NA	ENCSR000DOO_MCF_10A_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	67229
1	2578	JUNB	0.0113815438387176	0.594789231381311	22	3603	3380	1459	3603	2810	35	182	172	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: transformed	GTRD	EXP048570_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	69302
1	3183	NRF1	0.0113815438387176	0.594789231381311	22	3603	3380	1459	3603	2810	35	182	172	NRF1 Namalwa (Burkitt lymphoma) NRF1	Namalwa (Burkitt lymphoma)	BTO:0003289	NRF1		GEO	GSE53133_nrf1_namalwa_MACS_NRF1_MA0506.1.damo.pwm.bed	5411
1	1569	FOSL1	0.0112283263695535	0.571744343884992	18	3606	3443	1785	3606	2940	30	186	177	FOSL1 MDA231-LM2-4175 (breast adenocarcinoma) FOSL1	MDA231-LM2-4175 (breast adenocarcinoma)	NULL	FOSL1	NA	GTRD	EXP038404_MDA231-LM2-4175--breast-adenocarcinoma-_FOSL1_MACS_FOSL1_MA1142.1.damo.pwm.bed	28048
1	2285	JUN	0.0111781296673028	0.644468576517944	37	3607	3220	607	3607	2480	53	167	154	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	IL1b, 4h	GTRD	EXP038043_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	48638
1	2858	MYC	0.0110935807371714	0.627886888078599	31	3608	3273	881	3608	2590	46	173	161	MYC HT1080 (fibrosarcoma) MYC	HT1080 (fibrosarcoma)	NULL	MYC		GTRD	EXP037759_HT1080--fibrosarcoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	10458
1	2692	MAX	0.0110700285175634	0.681762602521971	63	3609	3076	103	3609	2260	82	141	125	MAX Ishikawa (endometrial adenocarcinoma) MAX	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	MAX		ENCODE	ENCSR000BTY_Ishikawa_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	28424
1	7	AR	0.0110605825992792	0.455659943542566	7	3610	3663	2812	3663	3360	15	197	192	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	AR stimulated	GTRD	EXP000409_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	43913
1	2487	JUNB	0.0110605825992792	0.455659943542566	7	3610	3663	2812	3663	3360	15	197	192	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039331_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	12608
1	2488	JUNB	0.0110605825992792	0.455659943542566	7	3610	3663	2812	3663	3360	15	197	192	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039331_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	12666
1	2489	JUNB	0.0110605825992792	0.455659943542566	7	3610	3663	2812	3663	3360	15	197	192	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039331_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	12489
1	2491	JUNB	0.0110605825992792	0.455659943542566	7	3610	3663	2812	3663	3360	15	197	192	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039331_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	12490
1	3333	RELA	0.0110605825992792	0.455659943542566	7	3610	3663	2812	3663	3360	15	197	192	RELA GM15510 (B-cells) RELA	GM15510 (B-cells)	NULL	RELA	human recombinant TNF-alpha from eBioscience [product# 14-8329-62] (Snyder)	ENCODE	ENCSR000EAQ_GM15510_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	4853
1	3366	RELA	0.0110605825992792	0.455659943542566	7	3610	3663	2812	3663	3360	15	197	192	RELA Detroit 562 (Pharyngeal squamous cell carcinoma) RELA	Detroit 562 (Pharyngeal squamous cell carcinoma)	BTO:0000834	RELA	Treatment: Pam2CSK4	GTRD	EXP049365_Detroit-562--Pharyngeal-squamous-cell-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	11561
1	2900	MYC	0.0108307231249463	0.655034622609696	43	3617	3196	429	3617	2410	60	161	147	MYC Tet21N (neuroblastoma) MYC	Tet21N (neuroblastoma)	BTO:0004654	MYC	Treatment: 1ug/mL doxycycline for 7 days prior to harvest Genotype: wildtype MYC Passage: 10 -15  Cell type: neuroblastoma cell line	GTRD	EXP053294_Tet21N--neuroblastoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	14186
1	2300	JUN	0.0107782541236956	0.48544894860321	9	3618	3638	2564	3638	3270	18	195	189	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	oxpapc, 4h	GTRD	EXP038044_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	12303
1	2752	MITF	0.0107782541236956	0.48544894860321	9	3618	3638	2564	3638	3270	18	195	189	MITF K562 (myelogenous leukemia) MITF	K562 (myelogenous leukemia)	NULL	MITF		ENCODE	ENCSR000FCB_K562_MITF_MACS_MITF_MA0620.3.damo.pwm.bed	6281
1	2894	MYC	0.0107136049958965	0.639442314857998	36	3620	3227	645	3620	2500	52	168	155	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 4;	GTRD	EXP047492_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	11596
1	1276	ESR1	0.0105245492956255	0.621416804017277	30	3621	3298	937	3621	2620	45	174	162	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Doxycycline	GTRD	EXP038389_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	44589
1	1539	FOS	0.0105245492956255	0.621416804017277	30	3621	3298	937	3621	2620	45	174	162	FOS IMR90 (lung fibroblasts) FOS	IMR90 (lung fibroblasts)	NULL	FOS		GTRD	EXP039888_IMR90--lung-fibroblasts-_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	43724
1	3384	RELA	0.0105245492956255	0.621416804017277	30	3621	3298	937	3621	2620	45	174	162	RELA SGBS (Simpson Golabi Behmel syndrome type 1 adipocytes) RELA	SGBS (Simpson Golabi Behmel syndrome type 1 adipocytes)	NULL	RELA	TNF	GEO	GSE64233_rela_sgbs-tnf_MACS_RELA_MA0107.1.damo.pwm.bed	41020
1	3581	SNAI2	0.0105124133298797	0.409135059771839	5	3624	3712	3053	3712	3460	12	199	195	SNAI2 keratinocytes SNAI2	keratinocytes	NULL	SNAI2	LacZ_DIFF	GEO	GSE55421_snai2_keratinocytes-lacz-diff_MACS_SNAI2_MA0745.2.damo.pwm.bed	4114
1	3758	STAT5B	0.0105124133298797	0.409135059771839	5	3624	3712	3053	3712	3460	12	199	195	STAT5B CD8 STAT5B	CD8	NA	STAT5B	H9RET	GEO	GSE64713_stat5b_cd8-h9ret_MACS_STAT5B_MA0519.1.damo.pwm.bed	5569
1	2250	JUN	0.0104068456534036	0.537225849163874	14	3626	3492	2073	3626	3060	25	190	182	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	dexametasone	GTRD	EXP033443_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	17206
1	2261	JUN	0.0104068456534036	0.537225849163874	14	3626	3492	2073	3626	3060	25	190	182	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	compaund A	GTRD	EXP033444_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	18619
1	3480	RUNX1	0.0104068456534036	0.537225849163874	14	3626	3492	2073	3626	3060	25	190	182	RUNX1 pre-B-lymphoblast cells with BCP-ALL RUNX1	pre-B-lymphoblast cells with BCP-ALL	NULL	RUNX1	DIsease: human precursor leukemia (BCP-ALL) Tissue: bone marrow	GTRD	EXP048191_pre-B-lymphoblast-cells-with-BCP-ALL_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	13339
1	4107	VDR	0.0104068456534036	0.537225849163874	14	3626	3492	2073	3626	3060	25	190	182	VDR LX-2 (hepatic stellate cells) VDR	LX-2 (hepatic stellate cells)	BTO:0003516	VDR	CALCIPOTRIOL_TGFB1	GEO	GSE38103_vdr_lx2-calcipotriol-tgfb1_MACS_VDR_MA0693.2.damo.pwm.bed	16554
1	2283	JUN	0.0104041669774366	0.602380805003998	25	3630	3359	1262	3630	2750	39	179	168	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	TNFa, 4h	GTRD	EXP038042_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	39717
1	2286	JUN	0.0104041669774366	0.602380805003998	25	3630	3359	1262	3630	2750	39	179	168	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	IL1b, 4h	GTRD	EXP038043_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	38984
1	2893	MYC	0.010247716133473	0.634196916346789	35	3632	3253	691	3632	2530	51	169	156	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 4;	GTRD	EXP047492_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	10984
1	3672	SPI1	0.0100799539485151	0.505635845870713	11	3633	3569	2332	3633	3180	21	193	186	SPI1 H929 (plasma cell myeloma) SPI1	H929 (plasma cell myeloma)	BTO:0002416	SPI1		GEO	GSE56857_spi1_ncih929_MACS_SPI1_MA0080.5.damo.pwm.bed	23485
1	2791	MYC	0.00995607843223188	0.614631315147718	29	3634	3324	1013	3634	2660	44	175	163	MYC A549 (lung carcinoma) MYC	A549 (lung carcinoma)	BTO:0000018	MYC		ENCODE	ENCSR000DYC_A549_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	8965
1	3351	RELA	0.00979098175254626	0.669037728560919	57	3635	3139	174	3635	2320	76	147	131	RELA monocyte-derived macrophages RELA	monocyte-derived macrophages	NULL	RELA	TNF (10ng/ml) for 24 hours	GTRD	EXP036832_monocyte-derived-macrophages_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	52327
1	2577	JUNB	0.00971520827351594	0.573898493955356	20	3636	3426	1606	3636	2890	33	184	174	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: transformed	GTRD	EXP048570_MCF10A-ER-Src_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	61309
1	2582	JUNB	0.00971520827351594	0.573898493955356	20	3636	3426	1606	3636	2890	33	184	174	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: transformed	GTRD	EXP048570_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	63227
1	3735	STAT3	0.00938906796568726	0.607508764326188	28	3638	3328	1068	3638	2680	43	176	164	STAT3 MDA-MB-231 (breast adenocarcinoma) STAT3	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	STAT3	ethanol	GTRD	EXP037701_MDA-MB-231--breast-adenocarcinoma-_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	18234
1	3218	PAX5	0.00921887702559852	0.544873218592105	16	3639	3479	1909	3639	3010	28	188	179	PAX5 L428 (Hodgkin lymphoma) PAX5	L428 (Hodgkin lymphoma)	BTO:0000406	PAX5	Mifepristone	GTRD	EXP031940_L428--Hodgkin-lymphoma-_PAX5_MACS_PAX5_MA0014.3.damo.pwm.bed	13274
1	2274	JUN	0.00919167968196287	0.519796344620074	13	3640	3516	2153	3640	3100	24	191	183	JUN RCC 7860 (Renal cell carcinoma) JUN	RCC 7860 (Renal cell carcinoma)	BTO:0003781	JUN		GTRD	EXP037742_786-O--renal-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	18328
1	3008	NFIA	0.00919167968196287	0.519796344620074	13	3640	3516	2153	3640	3100	24	191	183	NFIA K562 (myelogenous leukemia) NFIA	K562 (myelogenous leukemia)	NULL	NFIA	NA	GTRD	EXP038549_K562--myelogenous-leukemia-_NFIA_MACS_NFIA_MA0670.1.damo.pwm.bed	25291
1	3386	RELA	0.00892076698949334	0.457021122248421	8	3642	3657	2697	3657	3330	17	196	190	RELA LNCaP (prostate carcinoma) RELA	LNCaP (prostate carcinoma)	BTO:0001321	RELA	SIFOXA1_TNFA	GEO	GSE83860_rela_lncap-sifoxa1-tnfa_MACS_RELA_MA0107.1.damo.pwm.bed	16220
1	3654	SPI1	0.00892076698949334	0.457021122248421	8	3642	3657	2697	3657	3330	17	196	190	SPI1 monocyte-derived macrophages SPI1	monocyte-derived macrophages	NULL	SPI1	LPS	GTRD	EXP040651_monocyte-derived-macrophages_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	29563
1	2832	MYC	0.00884740963739115	0.617012884195868	32	3644	3317	825	3644	2600	48	172	159	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	HA-OmoMYCwt, Doxycycline	GTRD	EXP036034_U2OS--osteosarcoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	15288
1	2859	MYC	0.00884740963739115	0.617012884195868	32	3644	3317	825	3644	2600	48	172	159	MYC HT1080 (fibrosarcoma) MYC	HT1080 (fibrosarcoma)	NULL	MYC		GTRD	EXP037759_HT1080--fibrosarcoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	11008
1	202	AR	0.00870667264664692	0.418593892503387	6	3646	3707	2948	3707	3430	14	198	193	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	DHT	GEO	GSE79128_AR_vcap-dht_MACS_AR_MA0007.3.damo.pwm.bed	19055
1	3638	SP2	0.00870667264664692	0.418593892503387	6	3646	3707	2948	3707	3430	14	198	193	SP2 WA01 (H1, human embryonic stem cells) SP2	WA01 (H1, human embryonic stem cells)	NULL	SP2	NA	ENCODE	ENCSR000BQG_H1-hESC_SP2_MACS_SP2_MA0516.2.damo.pwm.bed	1623
1	1484	ETV6	0.0086014573920749	0.482787932904973	10	3648	3640	2442	3648	3240	20	194	187	ETV6 GM12878 (female B-cells lymphoblastoid cell line) ETV6	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ETV6		GTRD	EXP038554_GM12878--female-B-cells-_ETV6_MACS_ETV6_MA0645.1.damo.pwm.bed	15761
1	2243	JUN	0.0086014573920749	0.482787932904973	10	3648	3640	2442	3648	3240	20	194	187	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN		GTRD	EXP033442_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	16172
1	2	AR	0.00856342362897366	0.283636055452806	2	3650	3788	3462	3788	3630	7	202	200	AR MDA-MB-453 (breast adenocarcinoma) AR	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	AR		Array Express	ERP001226_AR_mdamb453_MACS_AR_MA0007.3.damo.pwm.bed	18097
1	214	ARNT	0.00856342362897366	0.283636055452806	2	3650	3788	3462	3788	3630	7	202	200	ARNT renal tubular cells ARNT	renal tubular cells	NULL	ARNT	1 mM dimethyloxalylglycine	GTRD	EXP036852_renal-tubular-cells_ARNT_MACS_ARNT_MA0004.1.damo.pwm.bed	1903
1	215	ARNT	0.00856342362897366	0.283636055452806	2	3650	3788	3462	3788	3630	7	202	200	ARNT renal tubular cells ARNT	renal tubular cells	NULL	ARNT	1 mM dimethyloxalylglycine	GTRD	EXP036852_renal-tubular-cells_ARNT_MACS_ARNT_MA0006.1.damo.pwm.bed	1976
1	216	ARNT	0.00856342362897366	0.283636055452806	2	3650	3788	3462	3788	3630	7	202	200	ARNT renal tubular cells ARNT	renal tubular cells	NULL	ARNT	1 mM dimethyloxalylglycine	GTRD	EXP036852_renal-tubular-cells_ARNT_MACS_ARNT_MA0259.1.damo.pwm.bed	1573
1	3016	NFIC	0.00856342362897366	0.283636055452806	2	3650	3788	3462	3788	3630	7	202	200	NFIC HepG2 (hepatoblastoma) NFIC	HepG2 (hepatoblastoma)	BTO:0000599	NFIC	NA	GTRD	EXP040843_HepG2--hepatoblastoma-_NFIC_MACS_NFIC_MA0119.1.damo.pwm.bed	6619
1	3155	NR3C1	0.00856342362897366	0.283636055452806	2	3650	3788	3462	3788	3630	7	202	200	NR3C1 U2OS (osteosarcoma) NR3C1	U2OS (osteosarcoma)	BTO:0001938	NR3C1	SHNS	GEO	GSE65847_nr3c1_u2os-shns_MACS_NR3C1_MA0113.3.damo.pwm.bed	15065
1	3464	RUNX1	0.00856342362897366	0.283636055452806	2	3650	3788	3462	3788	3630	7	202	200	RUNX1 Kasumi-1 (acute myeloblastic leukemia) RUNX1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	RUNX1		GTRD	EXP036423_Kasumi-1--acute-myeloblastic-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	3576
1	3554	SCRT1	0.00856342362897366	0.283636055452806	2	3650	3788	3462	3788	3630	7	202	200	SCRT1 HEK293 (embryonic kidney) SCRT1	HEK293 (embryonic kidney)	NULL	SCRT1	NA	GTRD	EXP039621_HEK293--embryonic-kidney-_SCRT1_MACS_SCRT1_MA0743.2.damo.pwm.bed	3961
1	3685	SPI1	0.00855760116203523	0.628465870529491	37	3658	3272	607	3658	2510	54	167	153	SPI1 K562 (myelogenous leukemia) SPI1	K562 (myelogenous leukemia)	NULL	SPI1		GEO	GSE70482_spi1_k562_MACS_SPI1_MA0080.5.damo.pwm.bed	57064
1	1446	ESRRA	0.00836561431244944	0.329169770642433	3	3659	3779	3316	3779	3580	9	201	198	ESRRA MCF7 (Invasive ductal breast carcinoma) ESRRA	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESRRA		ENCODE	ENCSR954WVZ_MCF-7_ESRRA_MACS_ESRRA_MA0592.3.damo.pwm.bed	5316
1	2008	GATA4	0.00836561431244944	0.329169770642433	3	3659	3779	3316	3779	3580	9	201	198	GATA4 HUES64 (embryonic stem cells) GATA4	HUES64 (embryonic stem cells)	NULL	GATA4		GTRD	EXP036707_HUES64--embryonic-stem-cells-_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	5149
1	3414	REST	0.00836561431244944	0.329169770642433	3	3659	3779	3316	3779	3580	9	201	198	REST WA01 (H1, human embryonic stem cells) REST	WA01 (H1, human embryonic stem cells)	NULL	REST		GTRD	EXP036861_WA01--H1--human-embryonic-stem-cells-_REST_MACS_REST_MA0138.2.damo.pwm.bed	3650
1	2327	JUN	0.00835965754658538	0.574952211460695	22	3662	3424	1459	3662	2850	36	182	171	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039981_A549--lung-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	14051
1	2353	JUN	0.00835965754658538	0.574952211460695	22	3662	3424	1459	3662	2850	36	182	171	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 5 minute	GTRD	EXP040322_A549--lung-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	23068
1	2344	JUN	0.0082634352590478	0.592155228556019	26	3664	3385	1204	3664	2750	41	178	166	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN		GTRD	EXP040265_A549--lung-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	16087
1	1566	FOSL1	0.00823910077246242	0.529912296409867	15	3665	3503	1993	3665	3050	27	189	180	FOSL1 MDA231-LM2-4175 (breast adenocarcinoma) FOSL1	MDA231-LM2-4175 (breast adenocarcinoma)	NULL	FOSL1	NA	GTRD	EXP038404_MDA231-LM2-4175--breast-adenocarcinoma-_FOSL1_MACS_FOSL1_MA0477.2.damo.pwm.bed	25121
1	1567	FOSL1	0.00823910077246242	0.529912296409867	15	3665	3503	1993	3665	3050	27	189	180	FOSL1 MDA231-LM2-4175 (breast adenocarcinoma) FOSL1	MDA231-LM2-4175 (breast adenocarcinoma)	NULL	FOSL1	NA	GTRD	EXP038404_MDA231-LM2-4175--breast-adenocarcinoma-_FOSL1_MACS_FOSL1_MA1128.1.damo.pwm.bed	25995
1	1568	FOSL1	0.00823910077246242	0.529912296409867	15	3665	3503	1993	3665	3050	27	189	180	FOSL1 MDA231-LM2-4175 (breast adenocarcinoma) FOSL1	MDA231-LM2-4175 (breast adenocarcinoma)	NULL	FOSL1	NA	GTRD	EXP038404_MDA231-LM2-4175--breast-adenocarcinoma-_FOSL1_MACS_FOSL1_MA1137.1.damo.pwm.bed	25963
1	2271	JUN	0.00823910077246242	0.529912296409867	15	3665	3503	1993	3665	3050	27	189	180	JUN RCC 7860 (Renal cell carcinoma) JUN	RCC 7860 (Renal cell carcinoma)	BTO:0003781	JUN		GTRD	EXP037742_786-O--renal-carcinoma-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	19299
1	3486	RUNX1	0.00823910077246242	0.529912296409867	15	3665	3503	1993	3665	3050	27	189	180	RUNX1 ME-1 (acute myeloid leukemia ) RUNX1	ME-1 (acute myeloid leukemia )	NULL	RUNX1	Treatment: 600 ng/ml doxycycline; Genotype: CBFB-MYH11 knockdown construct, RUNX1 knockdown;	GTRD	EXP058217_ME-1--acute-myeloid-leukemia--_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	18869
1	2304	JUN	0.00817520467324879	0.623369129832036	36	3670	3296	645	3670	2540	53	168	154	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	control, 4h	GTRD	EXP038046_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	58529
1	3759	STAT5B	0.00808610980737729	0.550225027094251	18	3671	3470	1785	3671	2980	31	186	176	STAT5B STAT5B	NA	NA	STAT5B	NA	GEO	GSE64713_stat5b_cd8-il2_MACS_STAT5B_MA0519.1.damo.pwm.bed	17240
1	3466	RUNX1	0.00805403237442224	0.63589866561488	42	3672	3250	454	3672	2460	60	162	147	RUNX1 MV-4-11 (Childhood acute monocytic leukemia) RUNX1	MV-4-11 (Childhood acute monocytic leukemia)	BTO:0004479	RUNX1		GTRD	EXP037302_MV4-11--childhood-acute-monocytic-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	35842
1	256	ATF3	0.00791801308075755	0.60419688430554	30	3673	3338	937	3673	2650	46	174	161	ATF3 HCT-116 (colon carcinoma) ATF3	HCT-116 (colon carcinoma)	BTO:0001109	ATF3	CAMP	GEO	GSE74355_atf3_htc116-camp_MACS_ATF3_MA0605.2.damo.pwm.bed	51889
1	2814	MYC	0.00790623204264141	0.646905635308147	49	3674	3215	299	3674	2400	68	155	139	MYC MCF7 (Invasive ductal breast carcinoma) MYC	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	MYC	NULL	GTRD	EXP001022_MCF7--Invasive-ductal-breast-carcinoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	25704
1	2788	MYC	0.00764559578313506	0.655342485836877	57	3675	3195	174	3675	2350	77	147	130	MYC MCF7 (Invasive ductal breast carcinoma) MYC	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	MYC		ENCODE	ENCSR000DMQ_MCF-7_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	29267
1	2153	HNF4G	0.00751436922556613	0.357196635611011	4	3676	3748	3182	3748	3540	11	200	196	HNF4G 22RV1 (prostate carcinoma) HNF4G	22RV1 (prostate carcinoma)	BTO:0002999	HNF4G	Treatment: Cells were harvested in log phase growth Genotype: wildtype	GTRD	EXP048996_22RV1--prostate-carcinoma-_HNF4G_MACS_HNF4G_MA0484.2.damo.pwm.bed	15937
1	2666	MAF	0.00751436922556613	0.357196635611011	4	3676	3748	3182	3748	3540	11	200	196	MAF Th17-cells MAF	Th17-cells	BTO:0005655	MAF	CellType:pool of expanded Th17 clones; Tissue: primary Th17-IL-10+ lymphocytes; ActivationState: recently activeted;Day:5;	GTRD	EXP047557_Th17-cells_MAF_MACS_MAF_MA1520.1.damo.pwm.bed	6100
1	2277	JUN	0.00745672371436748	0.597327638063335	29	3678	3374	1013	3678	2690	45	175	162	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	TNFa, 4h	GTRD	EXP038042_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	44456
1	2899	MYC	0.00743154458514938	0.627301228440479	40	3679	3274	502	3679	2480	58	164	149	MYC Tet21N (neuroblastoma) MYC	Tet21N (neuroblastoma)	BTO:0004654	MYC	Treatment: 1ug/mL doxycycline for 7 days prior to harvest Genotype: wildtype MYC Passage: 10 -15  Cell type: neuroblastoma cell line	GTRD	EXP053294_Tet21N--neuroblastoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	13255
1	3184	NRF1	0.00743154458514938	0.627301228440479	40	3679	3274	502	3679	2480	58	164	149	NRF1 T47D (invasive ductal carcinoma) NRF1	T47D (invasive ductal carcinoma)	BTO:0001248	NRF1	HAEGIN2	GEO	GSE59935_nrf1_t47d-haegin2_MACS_NRF1_MA0506.1.damo.pwm.bed	10336
1	3382	RELA	0.00728237574131033	0.513778239658029	14	3681	3523	2073	3681	3090	26	190	181	RELA CD4 RELA	CD4	NA	RELA	TH1_DMSO	GEO	GSE62482_rela_cd4-th1-dmso_MACS_RELA_MA0107.1.damo.pwm.bed	10067
1	1037	E2F4	0.0071755952220688	0.457520131970231	9	3682	3651	2564	3682	3300	19	195	188	E2F4 MCF7 (Invasive ductal breast carcinoma) E2F4	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	E2F4	Treatment:  treated with 100nm Tamoxifen for 48hrs;	GTRD	EXP054360_MCF7--Invasive-ductal-breast-carcinoma-_E2F4_MACS_E2F4_MA0470.2.damo.pwm.bed	4173
1	2354	JUN	0.0071755952220688	0.457520131970231	9	3682	3651	2564	3682	3300	19	195	188	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 5 minute	GTRD	EXP040322_A549--lung-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	17248
1	2478	JUNB	0.0071755952220688	0.457520131970231	9	3682	3651	2564	3682	3300	19	195	188	JUNB GM12878 (female B-cells lymphoblastoid cell line) JUNB	GM12878 (female B-cells lymphoblastoid cell line)	NULL	JUNB		ENCODE	ENCSR897MMC_GM12878_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	34237
1	3330	RELA	0.0071755952220688	0.457520131970231	9	3682	3651	2564	3682	3300	19	195	188	RELA GM12878 (female B-cells lymphoblastoid cell line) RELA	GM12878 (female B-cells lymphoblastoid cell line)	NULL	RELA	human recombinant TNF-alpha from eBioscience [product# 14-8329-62] (Snyder)	ENCODE	ENCSR000EAG_GM12878_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	13302
1	1852	FOXK2	0.00715656220884093	0.575136646794657	24	3686	3423	1324	3686	2810	39	180	168	FOXK2 K562 (myelogenous leukemia) FOXK2	K562 (myelogenous leukemia)	NULL	FOXK2	NA	ENCODE	ENCSR302AWT_K562_FOXK2_MACS_FOXK2_MA1103.2.damo.pwm.bed	17495
1	2085	HIF1A	0.00714185616013387	0.425021155738502	7	3687	3702	2812	3702	3400	16	197	191	HIF1A RCC4 (kidney cancer cell line) HIF1A	RCC4 (kidney cancer cell line)	BTO:0005691	HIF1A	Treatment: degree of hypoxia - normoxia	GTRD	EXP048722_RCC4--kidney-cancer-cell-line-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	3020
1	2086	HIF1A	0.00714185616013387	0.425021155738502	7	3687	3702	2812	3702	3400	16	197	191	HIF1A RCC4 (kidney cancer cell line) HIF1A	RCC4 (kidney cancer cell line)	BTO:0005691	HIF1A	Treatment: degree of hypoxia - normoxia	GTRD	EXP048722_RCC4--kidney-cancer-cell-line-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	2809
1	2919	MYC	0.00714185616013387	0.425021155738502	7	3687	3702	2812	3702	3400	16	197	191	MYC MM1.S (plasma cell myeloma) MYC	MM1.S (plasma cell myeloma)	BTO:0003933	MYC	JQ1	GEO	GSE42161_myc_mm1s-jq1_MACS_MYC_MA0147.3.damo.pwm.bed	2305
1	3340	RELA	0.00714185616013387	0.425021155738502	7	3687	3702	2812	3702	3400	16	197	191	RELA GM18505 (female B-cells Lymphoblastoid Cell Lines) RELA	GM18505 (female B-cells Lymphoblastoid Cell Lines)	NULL	RELA	TNF-alpha induced (6h)	GTRD	EXP000758_GM18505--female-B-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	7045
1	3364	RELA	0.00714185616013387	0.425021155738502	7	3687	3702	2812	3702	3400	16	197	191	RELA Detroit 562 (Pharyngeal squamous cell carcinoma) RELA	Detroit 562 (Pharyngeal squamous cell carcinoma)	BTO:0000834	RELA	Treatment: LPS	GTRD	EXP049363_Detroit-562--Pharyngeal-squamous-cell-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	13527
1	2446	JUN	0.00703548516291153	0.553864800581851	20	3692	3458	1606	3692	2920	34	184	173	JUN MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line) JUN	MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line)	NULL	JUN		GTRD	EXP058065_MDA-MB-231p27CK-DD--breast-cancer-cells--phosphimimetic-p27-cell-line-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	25434
1	3359	RELA	0.00703102837334721	0.606712137783166	33	3693	3329	778	3693	2600	50	171	157	RELA HAEC (human aortic endothelial cells) RELA	HAEC (human aortic endothelial cells)	NULL	RELA	IL1b, 4h	GTRD	EXP038049_HAEC--human-aortic-endothelial-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	24123
1	302	CDX2	0.00688911963910164	0.199676483512704	1	3694	3820	3655	3820	3720	5	203	202	CDX2 Caco-2 (colon adenocarcinoma) CDX2	Caco-2 (colon adenocarcinoma)	BTO:0000195	CDX2	PROLIF	GEO	GSE23436_cdx2_caco2-prolif_MACS_CDX2_MA0465.2.damo.pwm.bed	2743
1	1231	ESR1	0.00688911963910164	0.199676483512704	1	3694	3820	3655	3820	3720	5	203	202	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	ICI	GTRD	EXP037443_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	4251
1	1718	FOXA1	0.00688911963910164	0.199676483512704	1	3694	3820	3655	3820	3720	5	203	202	FOXA1 prostate tumor FOXA1	prostate tumor	NULL	FOXA1	Patient: #3	GTRD	EXP048496_prostate-tumor_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	1990
1	3350	RELA	0.00688911963910164	0.199676483512704	1	3694	3820	3655	3820	3720	5	203	202	RELA BEAS-2B (bronchial epithelium) RELA	BEAS-2B (bronchial epithelium)	NULL	RELA	dexamethasone + TNF	GTRD	EXP036259_BEAS-2B--bronchial-epithelium-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	5097
1	3551	RXRA	0.00688911963910164	0.199676483512704	1	3694	3820	3655	3820	3720	5	203	202	RXRA MCF7 (Invasive ductal breast carcinoma) RXRA	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RXRA	Treatment: none;	GTRD	EXP054366_MCF7--Invasive-ductal-breast-carcinoma-_RXRA_MACS_RXRA_MA0115.1.damo.pwm.bed	35916
1	3677	SPI1	0.00688911963910164	0.199676483512704	1	3694	3820	3655	3820	3720	5	203	202	SPI1 dendrite SPI1	dendrite	NA	SPI1		GEO	GSE58864_spi1_dendrite_MACS_SPI1_MA0080.5.damo.pwm.bed	13571
1	2241	JUN	0.00685793040441256	0.480106484612093	11	3700	3642	2332	3700	3220	22	193	185	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN		GTRD	EXP033442_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	17019
1	2247	JUN	0.00685793040441256	0.480106484612093	11	3700	3642	2332	3700	3220	22	193	185	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN		GTRD	EXP033442_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	16922
1	3341	RELA	0.00685793040441256	0.480106484612093	11	3700	3642	2332	3700	3220	22	193	185	RELA GM19099 (female B-cells Lymphoblastoid Cell Lines) RELA	GM19099 (female B-cells Lymphoblastoid Cell Lines)	NULL	RELA	TNF-alpha induced (6h)	GTRD	EXP000760_GM19099--female-B-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	13582
1	3347	RELA	0.00685793040441256	0.480106484612093	11	3700	3642	2332	3700	3220	22	193	185	RELA GM12878 (female B-cells lymphoblastoid cell line) RELA	GM12878 (female B-cells lymphoblastoid cell line)	NULL	RELA	TNF-alpha induced (6h)	GTRD	EXP000772_GM12878--female-B-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	11260
1	1505	FLI1	0.00668704903225815	0.642155896421775	52	3704	3223	244	3704	2390	72	152	135	FLI1 HUVEC-C (HUVEC, umbilical vein endothelial cells) FLI1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FLI1		GTRD	EXP053003_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	44580
1	3360	RELA	0.0066587503232144	0.629294747729731	44	3705	3271	408	3705	2460	63	160	144	RELA HAEC (human aortic endothelial cells) RELA	HAEC (human aortic endothelial cells)	NULL	RELA	TNFa, 4h	GTRD	EXP038050_HAEC--human-aortic-endothelial-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	46162
1	3022	NFKB1	0.00654513265793143	0.582561272651575	27	3706	3402	1135	3706	2750	43	177	164	NFKB1 MCF10A-ER-Src NFKB1	MCF10A-ER-Src	NULL	NFKB1	Genotype: transformed	GTRD	EXP048574_MCF10A-ER-Src_NFKB1_MACS_NFKB1_MA0105.4.damo.pwm.bed	38428
1	156	AR	0.00651753860086864	0.52319519494055	16	3707	3515	1909	3707	3040	29	188	178	AR PC3(bone mets prostate adenocarcinoma) AR	PC3(bone mets prostate adenocarcinoma)	NULL	AR	R1881	GEO	GSE54110_AR_pc3-r1881_MACS_AR_MA0007.3.damo.pwm.bed	60594
1	3372	RELA	0.00648528012063468	0.375793794801802	5	3708	3744	3053	3744	3500	13	199	194	RELA HeLa-B2 RELA	HeLa-B2	NA	RELA	TA_TNFA	GEO	GSE24518_rela_helab2-ta-tnfa_MACS_RELA_MA0107.1.damo.pwm.bed	8311
1	3842	TEAD4	0.00648528012063468	0.375793794801802	5	3708	3744	3053	3744	3500	13	199	194	TEAD4 MDA-MB-231 (breast adenocarcinoma) TEAD4	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	TEAD4		GEO	GSE66081_tead4_mdamb231_MACS_TEAD4_MA0809.2.damo.pwm.bed	11914
1	2756	MITF	0.00639105011503553	0.542328683715459	19	3710	3480	1697	3710	2960	33	185	174	MITF melanocytes MITF	melanocytes	NULL	MITF	BRAFV600E	GEO	GSE50681_mitf_melanocyte-brafv600e_MACS_MITF_MA0620.3.damo.pwm.bed	14307
1	3182	NRF1	0.00639105011503553	0.542328683715459	19	3710	3480	1697	3710	2960	33	185	174	NRF1 MCF7 (Invasive ductal breast carcinoma) NRF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NRF1		GTRD	EXP038569_MCF7--Invasive-ductal-breast-carcinoma-_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	5113
1	2275	JUN	0.00635428079716286	0.496330388024658	13	3712	3611	2153	3712	3160	25	191	182	JUN RCC 7860 (Renal cell carcinoma) JUN	RCC 7860 (Renal cell carcinoma)	BTO:0003781	JUN		GTRD	EXP037742_786-O--renal-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	18228
1	2302	JUN	0.00627626242238041	0.594330295134105	31	3713	3383	881	3713	2660	48	173	159	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	control, 4h	GTRD	EXP038046_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	54595
1	3331	RELA	0.00581908674555592	0.429418498191712	8	3714	3692	2697	3714	3370	18	196	189	RELA GM12891 (male B- cells lymphoblastoid cell line) RELA	GM12891 (male B- cells lymphoblastoid cell line)	NULL	RELA	human recombinant TNF-alpha from eBioscience [product# 14-8329-62] (Snyder)	ENCODE	ENCSR000EAI_GM12891_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	14885
1	3837	TEAD4	0.00581908674555592	0.429418498191712	8	3714	3692	2697	3714	3370	18	196	189	TEAD4 SK-N-SH (neuroblastoma) TEAD4	SK-N-SH (neuroblastoma)	BTO:0001620	TEAD4		ENCODE	ENCSR000BUQ_SK-N-SH_TEAD4_MACS_TEAD4_MA0809.2.damo.pwm.bed	21714
1	225	ARNT	0.00580991298082964	0.650700844230513	68	3716	3208	56	3716	2330	90	136	117	ARNT T47D (invasive ductal carcinoma) ARNT	T47D (invasive ductal carcinoma)	BTO:0001248	ARNT	HAEGIN2	GEO	GSE59935_arnt_t47d-haegin2_MACS_ARNT_MA0004.1.damo.pwm.bed	85556
1	2443	JUN	0.00576464357518954	0.508197452243361	15	3717	3530	1993	3717	3080	28	189	179	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN		GTRD	EXP058063_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	13158
1	252	ATF3	0.00576148258477266	0.530048634041295	18	3718	3501	1785	3718	3000	32	186	175	ATF3 glioblastoma cells ATF3	glioblastoma cells	NULL	ATF3	Dox + Arvanil + BMP7	GTRD	EXP031157_glioblastoma-cells_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	35850
1	2448	JUN	0.00576148258477266	0.530048634041295	18	3718	3501	1785	3718	3000	32	186	175	JUN MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line) JUN	MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line)	NULL	JUN		GTRD	EXP058065_MDA-MB-231p27CK-DD--breast-cancer-cells--phosphimimetic-p27-cell-line-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	24896
1	2246	JUN	0.00575792082269594	0.457395265963735	10	3720	3655	2442	3720	3270	21	194	186	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN		GTRD	EXP033442_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	16365
1	3696	SPIB	0.00575792082269594	0.457395265963735	10	3720	3655	2442	3720	3270	21	194	186	SPIB OCI-LY3 (diffuse large B-cell lymphoma) SPIB	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	SPIB		GEO	GSE56857_spib_ocily3_MACS_SPIB_MA0081.2.damo.pwm.bed	23781
1	3652	SPI1	0.00568412215119624	0.626263386763311	47	3722	3276	333	3722	2440	67	157	140	SPI1 monocyte-derived macrophages SPI1	monocyte-derived macrophages	NULL	SPI1	IFN-gamma	GTRD	EXP038590_monocyte-derived-macrophages_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	102674
1	2424	JUN	0.00555480592555498	0.545885959607695	21	3723	3476	1535	3723	2910	36	183	171	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: transformed	GTRD	EXP048572_MCF10A-ER-Src_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	59515
1	272	BACH2	0.00547214659269786	0.388725451411639	6	3724	3740	2948	3740	3470	15	198	192	BACH2 B-cells BACH2	B-cells	NULL	BACH2		GTRD	EXP040449_B-cells_BACH2_MACS_BACH2_MA1101.2.damo.pwm.bed	13854
1	2092	HIF1A	0.00547214659269786	0.388725451411639	6	3724	3740	2948	3740	3470	15	198	192	HIF1A HepG2 (hepatoblastoma) HIF1A	HepG2 (hepatoblastoma)	BTO:0000599	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 16 hours	GTRD	EXP048737_HepG2--hepatoblastoma-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	3126
1	2208	IRF3	0.00547214659269786	0.388725451411639	6	3724	3740	2948	3740	3470	15	198	192	IRF3 GM12878 (female B-cells lymphoblastoid cell line) IRF3	GM12878 (female B-cells lymphoblastoid cell line)	NULL	IRF3	NA	ENCODE	ENCSR408JQO_GM12878_IRF3_MACS_IRF3_MA1418.1.damo.pwm.bed	1957
1	2244	JUN	0.00546105228999426	0.477397082920078	12	3727	3646	2233	3727	3200	24	192	183	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN		GTRD	EXP033442_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	17341
1	2257	JUN	0.00546105228999426	0.477397082920078	12	3727	3646	2233	3727	3200	24	192	183	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	compaund A	GTRD	EXP033444_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	17363
1	2260	JUN	0.00546105228999426	0.477397082920078	12	3727	3646	2233	3727	3200	24	192	183	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	compaund A	GTRD	EXP033444_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	17368
1	1462	ETS1	0.00527571910745798	0.619024797380581	45	3730	3310	383	3730	2470	65	159	142	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1	VEGF stimulation for 12hours	GTRD	EXP038277_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	30365
1	1468	ETS1	0.00527571910745798	0.619024797380581	45	3730	3310	383	3730	2470	65	159	142	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1	Treatment: agent VEGF, timepoint 12 Passage: P3-6	GTRD	EXP048200_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	30436
1	2278	JUN	0.00516882541989146	0.573509531838624	28	3732	3428	1068	3732	2740	45	176	162	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	TNFa, 4h	GTRD	EXP038042_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	43381
1	2301	JUN	0.00516882541989146	0.573509531838624	28	3732	3428	1068	3732	2740	45	176	162	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	control, 4h	GTRD	EXP038046_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	51822
1	2305	JUN	0.00516882541989146	0.573509531838624	28	3732	3428	1068	3732	2740	45	176	162	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	control, 4h	GTRD	EXP038046_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	50714
1	2306	JUN	0.00516882541989146	0.573509531838624	28	3732	3428	1068	3732	2740	45	176	162	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	control, 4h	GTRD	EXP038046_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	50028
1	2307	JUN	0.00516882541989146	0.573509531838624	28	3732	3428	1068	3732	2740	45	176	162	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	control, 4h	GTRD	EXP038046_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	51796
1	3795	TCF4	0.00516882541989146	0.573509531838624	28	3732	3428	1068	3732	2740	45	176	162	TCF4 GEN2.2 (blastic plasmacytoid dendritic cell neoplasm) TCF4	GEN2.2 (blastic plasmacytoid dendritic cell neoplasm)	NULL	TCF4		GTRD	EXP037181_GEN2.2--blastic-plasmacytoid-dendritic-cell-neoplasm-_TCF4_MACS_TCF4_MA0830.2.damo.pwm.bed	42642
1	1225	ESR1	0.00514935418813776	0.516952921801525	17	3738	3520	1846	3738	3030	31	187	176	ESR1 U2OS (osteosarcoma) ESR1	U2OS (osteosarcoma)	BTO:0001938	ESR1	E2	GTRD	EXP036907_U2OS--osteosarcoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	61856
1	2325	JUN	0.00504271329007892	0.534974133581078	20	3739	3496	1606	3739	2950	35	184	172	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039981_A549--lung-carcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	14062
1	2422	JUN	0.00504271329007892	0.534974133581078	20	3739	3496	1606	3739	2950	35	184	172	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: transformed	GTRD	EXP048572_MCF10A-ER-Src_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	58612
1	3202	OTX2	0.00495755993096433	0.584958367991601	32	3741	3400	825	3741	2660	50	172	157	OTX2 D341 Med (medulloblastoma) OTX2	D341 Med (medulloblastoma)	NULL	OTX2		GTRD	EXP038200_D341-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	86791
1	2426	JUN	0.00479320413767472	0.548189944488905	23	3742	3473	1391	3742	2870	39	181	168	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: transformed	GTRD	EXP048572_MCF10A-ER-Src_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	65195
1	2682	MAFK	0.00479320413767472	0.548189944488905	23	3742	3473	1391	3742	2870	39	181	168	MAFK IMR90 (lung fibroblasts) MAFK	IMR90 (lung fibroblasts)	NULL	MAFK	NA	ENCODE	ENCSR000EFH_IMR-90_MAFK_MACS_MAFK_MA0496.3.damo.pwm.bed	77567
1	3326	RBPJ	0.0047170380414155	0.432386668148597	9	3744	3687	2564	3744	3330	20	195	187	RBPJ NHEK RBPJ	NHEK	NA	RBPJ		GEO	GSE29498_rbpj_NHEK_MACS_RBPJ_MA1116.1.damo.pwm.bed	19869
1	3368	RELA	0.0047170380414155	0.432386668148597	9	3744	3687	2564	3744	3330	20	195	187	RELA Detroit 562 (Pharyngeal squamous cell carcinoma) RELA	Detroit 562 (Pharyngeal squamous cell carcinoma)	BTO:0000834	RELA	Treatment: M tri-DAP	GTRD	EXP049367_Detroit-562--Pharyngeal-squamous-cell-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	14111
1	3535	RXRA	0.0047170380414155	0.432386668148597	9	3744	3687	2564	3744	3330	20	195	187	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA S427F	GTRD	EXP040816_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA0065.2.damo.pwm.bed	7123
1	3661	SPI1	0.0047170380414155	0.432386668148597	9	3744	3687	2564	3744	3330	20	195	187	SPI1 THP-1 (acute monocytic leukemia) SPI1	THP-1 (acute monocytic leukemia)	BTO:0001370	SPI1	Treatment: untreated, IAV NS1(EP mRNA)	GTRD	EXP047819_THP-1--acute-monocytic-leukemia-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	51023
1	2833	MYC	0.00465744467233428	0.578577548677451	31	3748	3404	881	3748	2680	49	173	158	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	HA-OmoMYCwt, Doxycycline	GTRD	EXP036034_U2OS--osteosarcoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	16078
1	3651	SPI1	0.00465744467233428	0.578577548677451	31	3748	3404	881	3748	2680	49	173	158	SPI1 monocyte-derived macrophages SPI1	monocyte-derived macrophages	NULL	SPI1	IL-4	GTRD	EXP036836_monocyte-derived-macrophages_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	38881
1	1865	FOXP1	0.00464102481486525	0.247045770428111	2	3750	3811	3462	3811	3670	8	202	199	FOXP1 LNCaP (prostate carcinoma) FOXP1	LNCaP (prostate carcinoma)	BTO:0001321	FOXP1	NA	GEO	GSE62492_foxp1_lncap-dht_MACS_FOXP1_MA0481.3.damo.pwm.bed	6538
1	3027	NFYA	0.00464102481486525	0.247045770428111	2	3750	3811	3462	3811	3670	8	202	199	NFYA GM12878 (female B-cells lymphoblastoid cell line) NFYA	GM12878 (female B-cells lymphoblastoid cell line)	NULL	NFYA	NA	ENCODE	ENCSR000DNN_GM12878_NFYA_MACS_NFYA_MA0060.3.damo.pwm.bed	753
1	3338	RELA	0.00464102481486525	0.247045770428111	2	3750	3811	3462	3811	3670	8	202	199	RELA GM19193 (female B-cells Lymphoblastoid Cell Lines) RELA	GM19193 (female B-cells Lymphoblastoid Cell Lines)	NULL	RELA	human recombinant TNF-alpha from eBioscience [product# 14-8329-62] (Snyder)	ENCODE	ENCSR000EBM_GM19193_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	3507
1	3753	STAT5A	0.00464102481486525	0.247045770428111	2	3750	3811	3462	3811	3670	8	202	199	STAT5A CD4+ CD25+ CD45RA+ T-cells STAT5A	CD4+ CD25+ CD45RA+ T-cells	NULL	STAT5A		GTRD	EXP032562_CD4--CD25--CD45RA--T-cells_STAT5A_MACS_STAT5A_MA0519.1.damo.pwm.bed	1864
1	2242	JUN	0.004609600296719	0.456801774363834	11	3754	3659	2332	3754	3250	23	193	184	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN		GTRD	EXP033442_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	16936
1	2273	JUN	0.00455743609820235	0.502950303076998	16	3755	3590	1909	3755	3080	30	188	177	JUN RCC 7860 (Renal cell carcinoma) JUN	RCC 7860 (Renal cell carcinoma)	BTO:0003781	JUN		GTRD	EXP037742_786-O--renal-carcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	19985
1	2447	JUN	0.00454445484465605	0.523396623620484	19	3756	3511	1697	3756	2990	34	185	173	JUN MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line) JUN	MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line)	NULL	JUN		GTRD	EXP058065_MDA-MB-231p27CK-DD--breast-cancer-cells--phosphimimetic-p27-cell-line-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	25987
1	1519	FOS	0.00437653577622052	0.538405545247389	22	3757	3491	1459	3757	2900	38	182	169	FOS FOS	NA	NA	FOS	NA	NA	ENCSR000EVU_endothelial_cell_of_umbilical_vein_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	49094
1	2258	JUN	0.00434209171389041	0.474659288191703	13	3758	3649	2153	3758	3190	26	191	181	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	compaund A	GTRD	EXP033444_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	17963
1	2444	JUN	0.00434209171389041	0.474659288191703	13	3758	3649	2153	3758	3190	26	191	181	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN		GTRD	EXP058063_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	13780
1	3678	SPI1	0.00410892667986164	0.54948726075576	25	3760	3472	1262	3760	2830	42	179	165	SPI1 Kasumi-1 (acute myeloblastic leukemia) SPI1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	SPI1	SICTR	GEO	GSE60130_spi1_kasumi1-sictr_MACS_SPI1_MA0080.5.damo.pwm.bed	52779
1	2281	JUN	0.00406909358279077	0.564925700470523	29	3761	3448	1013	3761	2740	47	175	160	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	TNFa, 4h	GTRD	EXP038042_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	45422
1	3666	SPI1	0.00406195431047696	0.511093209333742	18	3762	3525	1785	3762	3020	33	186	174	SPI1 THP-1 (acute monocytic leukemia) SPI1	THP-1 (acute monocytic leukemia)	BTO:0001370	SPI1	Treatment: EtOH (vehicle) for 24hrs Cell type: human monocytic cell line	GTRD	EXP049121_THP-1--acute-monocytic-leukemia-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	88128
1	2041	GATA6	0.00394858269793231	0.347208333903508	5	3763	3752	3053	3763	3520	14	199	193	GATA6 AGS (gastric adenocarcinoma) GATA6	AGS (gastric adenocarcinoma)	BTO:0001007	GATA6		GEO	GSE51705_gata6_ags_MACS_GATA6_MA1104.2.damo.pwm.bed	24307
1	2827	MYC	0.00378206989434749	0.557616794599064	28	3764	3457	1068	3764	2760	46	176	161	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	empty vector	GTRD	EXP036031_U2OS--osteosarcoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	12073
1	2945	MYCN	0.00377011067636445	0.540648766145051	24	3765	3488	1324	3765	2860	41	180	166	MYCN HIV-1 latently-infected central memory T cells cultured from uninfected pri	HIV-1 latently-infected central memory T cells cultured from uninfected primary T cells	NULL	MYCN	mTreatment: mycn-low lvl induced by 16 hr doxycycline	GTRD	EXP048926_HIV-1-latently-infected-central-memory-T-cells-cultured-from-uninfected-primary-T-cells_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	13502
1	3577	SMAD3	0.00377011067636445	0.540648766145051	24	3765	3488	1324	3765	2860	41	180	166	SMAD3 PC3(bone mets prostate adenocarcinoma) SMAD3	PC3(bone mets prostate adenocarcinoma)	NULL	SMAD3	Treatment: hypoxia (0.2% O2);	GTRD	EXP057828_PC3-bone-mets-prostate-adenocarcinoma-_SMAD3_MACS_SMAD3_MA1622.1.damo.pwm.bed	45736
1	3780	TCF12	0.00377011067636445	0.540648766145051	24	3765	3488	1324	3765	2860	41	180	166	TCF12 SK-N-SH (neuroblastoma) TCF12	SK-N-SH (neuroblastoma)	BTO:0001620	TCF12	NA	ENCODE	ENCSR000BSL_SK-N-SH_TCF12_MACS_TCF12_MA0521.1.damo.pwm.bed	47703
1	2255	JUN	0.00368167051126772	0.455845079916229	12	3768	3660	2233	3768	3220	25	192	182	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	compaund A	GTRD	EXP033444_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	17925
1	2817	MYC	0.00368167051126772	0.455845079916229	12	3768	3660	2233	3768	3220	25	192	182	MYC D54 (H54, Human glioblastoma) MYC	D54 (H54, Human glioblastoma)	NULL	MYC	NULL	GTRD	EXP001028_D54--glioblastoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	6358
1	3362	RELA	0.00368167051126772	0.455845079916229	12	3768	3660	2233	3768	3220	25	192	182	RELA HUVEC-C (HUVEC, umbilical vein endothelial cells) RELA	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	RELA	Treatment: confluent, treated with Scr siRNA and stimulated with IL-1beta Passage: 4	GTRD	EXP049055_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	44703
1	1026	E2F1	0.00363098183701989	0.63009385638687	71	3771	3269	39	3771	2360	95	133	112	E2F1 U87 (glioblastoma) E2F1	U87 (glioblastoma)	NULL	E2F1	Treatment: Mock	GTRD	EXP049850_U87--glioblastoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	32575
1	2451	JUN	0.00359724269704044	0.497986189732272	17	3772	3610	1846	3772	3080	32	187	175	JUN MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line) JUN	MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line)	NULL	JUN		GTRD	EXP058065_MDA-MB-231p27CK-DD--breast-cancer-cells--phosphimimetic-p27-cell-line-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	23182
1	2421	JUN	0.00357761263971833	0.517131341929846	20	3773	3518	1606	3773	2970	36	184	171	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: transformed	GTRD	EXP048572_MCF10A-ER-Src_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	58828
1	2449	JUN	0.00357761263971833	0.517131341929846	20	3773	3518	1606	3773	2970	36	184	171	JUN MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line) JUN	MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line)	NULL	JUN		GTRD	EXP058065_MDA-MB-231p27CK-DD--breast-cancer-cells--phosphimimetic-p27-cell-line-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	26542
1	2826	MYC	0.00350066610029345	0.549957823369392	27	3775	3471	1135	3775	2790	45	177	162	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	empty vector	GTRD	EXP036031_U2OS--osteosarcoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	11766
1	2754	MITF	0.00340538591206668	0.165612161635803	1	3776	3826	3655	3826	3750	6	203	201	MITF melanocytes MITF	melanocytes	NULL	MITF	none	GTRD	EXP033917_melanocytes_MITF_MACS_MITF_MA0620.3.damo.pwm.bed	1785
1	3222	PBX1	0.00340538591206668	0.165612161635803	1	3776	3826	3655	3826	3750	6	203	201	PBX1 MCF7 (Invasive ductal breast carcinoma) PBX1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	PBX1	NA	GTRD	EXP031466_MCF7--Invasive-ductal-breast-carcinoma-_PBX1_MACS_PBX1_MA0070.1.damo.pwm.bed	776
1	3307	PRDM4	0.00340538591206668	0.165612161635803	1	3776	3826	3655	3826	3750	6	203	201	PRDM4 HEK293 (embryonic kidney) PRDM4	HEK293 (embryonic kidney)	NULL	PRDM4	NA	GTRD	EXP039415_HEK293--embryonic-kidney-_PRDM4_MACS_PRDM4_MA1647.1.damo.pwm.bed	2958
1	3483	RUNX1	0.00340538591206668	0.165612161635803	1	3776	3826	3655	3826	3750	6	203	201	RUNX1 LPS141 (Dedifferentiated liposarcoma) RUNX1	LPS141 (Dedifferentiated liposarcoma)	NULL	RUNX1		GTRD	EXP057977_LPS141--Dedifferentiated-liposarcoma-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	3506
1	3499	RUNX1	0.00340538591206668	0.165612161635803	1	3776	3826	3655	3826	3750	6	203	201	RUNX1 U937 (adult acute monocytic leukemia) RUNX1	U937 (adult acute monocytic leukemia)	BTO:0001412	RUNX1		GEO	GSE65427_runx1_u937_MACS_RUNX1_MA0002.2.damo.pwm.bed	5566
1	3801	TCF7	0.00340538591206668	0.165612161635803	1	3776	3826	3655	3826	3750	6	203	201	TCF7 GM12878 (female B-cells lymphoblastoid cell line) TCF7	GM12878 (female B-cells lymphoblastoid cell line)	NULL	TCF7		ENCODE	ENCSR501DKS_GM12878_TCF7_MACS_TCF7_MA0769.2.damo.pwm.bed	7268
1	3811	TCF7L2	0.00340538591206668	0.165612161635803	1	3776	3826	3655	3826	3750	6	203	201	TCF7L2 HeLa S3 (cervical adenocarcinoma) TCF7L2	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	TCF7L2		ENCODE	ENCSR000EVF_HeLa-S3_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	2205
1	2420	JUN	0.00319814097684156	0.505533829394443	19	3783	3570	1697	3783	3020	35	185	172	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: transformed	GTRD	EXP048572_MCF10A-ER-Src_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	58529
1	2694	MAX	0.00308718265418662	0.617034202077981	63	3784	3316	103	3784	2400	87	141	120	MAX SK-N-SH (neuroblastoma) MAX	SK-N-SH (neuroblastoma)	BTO:0001620	MAX		ENCODE	ENCSR000BVD_SK-N-SH_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	33922
1	3363	RELA	0.0030628639589526	0.409643519083278	9	3785	3711	2564	3785	3350	21	195	186	RELA HUVEC-C (HUVEC, umbilical vein endothelial cells) RELA	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	RELA	Treatment: confluent, treated with Notch1 siRNA and stimulated with IL-1beta Passsage: 4	GTRD	EXP049056_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	60447
1	2256	JUN	0.00306183027948309	0.435436367697979	11	3786	3685	2332	3786	3270	24	193	183	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	compaund A	GTRD	EXP033444_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	17514
1	2259	JUN	0.00306183027948309	0.435436367697979	11	3786	3685	2332	3786	3270	24	193	183	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	compaund A	GTRD	EXP033444_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	17103
1	3648	SPI1	0.00305887923163598	0.567459421446112	34	3788	3447	729	3788	2650	54	170	153	SPI1 HL-60 (acute myeloid leukemia) SPI1	HL-60 (acute myeloid leukemia)	BTO:0000738	SPI1		ENCODE	ENCSR000BUW_HL-60_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	86544
1	3186	NRF1	0.00296151959783003	0.602866344863256	52	3789	3358	244	3789	2460	75	152	132	NRF1 HMEC-1 NRF1	HMEC-1	NA	NRF1		GEO	GSE67867_nrf1_hmec_MACS_NRF1_MA0506.1.damo.pwm.bed	16502
1	3755	STAT5B	0.00293346779708983	0.454599230149219	13	3790	3670	2153	3790	3200	27	191	180	STAT5B T-cells STAT5B	T-cells	NULL	STAT5B	IL-2	GTRD	EXP000399_T-cells_STAT5B_MACS_STAT5B_MA0519.1.damo.pwm.bed	13166
1	3345	RELA	0.00286404021547289	0.373943825688218	7	3791	3746	2812	3791	3450	18	197	189	RELA GM18951 (B-cells Lymphoblastoid Cell Lines) RELA	GM18951 (B-cells Lymphoblastoid Cell Lines)	NULL	RELA	TNF-alpha induced (6h)	GTRD	EXP000768_GM18951--B-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	7727
1	1139	ERG	0.00286088374231432	0.610872801979492	60	3792	3325	137	3792	2420	84	144	123	ERG SKNO-1 (acute myeloid leukemia) ERG	SKNO-1 (acute myeloid leukemia)	NULL	ERG		GEO	GSE23730_erg_skno1_MACS_ERG_MA0474.2.damo.pwm.bed	53323
1	3453	RUNX1	0.00269788311976243	0.569963986460809	37	3793	3444	607	3793	2610	58	167	149	RUNX1 megakaryocytes RUNX1	megakaryocytes	NULL	RUNX1	NULL	GTRD	EXP000353_megakaryocytes_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	32030
1	2425	JUN	0.0025125955917475	0.500240671872839	20	3794	3600	1606	3794	3000	37	184	170	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: transformed	GTRD	EXP048572_MCF10A-ER-Src_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	59771
1	3681	SPI1	0.00249746410451229	0.618477926162285	85	3795	3312	9	3795	2370	111	119	96	SPI1 macrophages SPI1	macrophages	NULL	SPI1	IL4	GEO	GSE66594_spi1_macrophages-il4_MACS_SPI1_MA0080.5.damo.pwm.bed	169689
1	3145	NR3C1	0.0024932739531265	0.21853141530252	2	3796	3816	3462	3816	3690	9	202	198	NR3C1 THP-1 (acute monocytic leukemia) NR3C1	THP-1 (acute monocytic leukemia)	BTO:0001370	NR3C1	Treatment: Dex, 100 nM, 1hour Tissue: peripheral blood-derived Sex: male	GTRD	EXP049918_THP-1--acute-monocytic-leukemia-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	12654
1	3329	RELA	0.0024932739531265	0.21853141530252	2	3796	3816	3462	3816	3690	9	202	198	RELA GM10847 (female B-cells Lymphoblastoid Cell Lines) RELA	GM10847 (female B-cells Lymphoblastoid Cell Lines)	NULL	RELA	human recombinant TNF-alpha from eBioscience [product# 14-8329-62] (Snyder)	ENCODE	ENCSR000DYM_GM10847_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	5056
1	3576	SMAD3	0.0024932739531265	0.21853141530252	2	3796	3816	3462	3816	3690	9	202	198	SMAD3 MDA-MB-231 (breast adenocarcinoma) SMAD3	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	SMAD3	Treatment: 2 ng/mLTGF beta, 1 hr	GTRD	EXP049373_MDA-MB-231--breast-adenocarcinoma-_SMAD3_MACS_SMAD3_MA1622.1.damo.pwm.bed	4440
1	2245	JUN	0.00248786505653602	0.413225050483174	10	3799	3710	2442	3799	3320	23	194	184	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN		GTRD	EXP033442_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	16330
1	2079	HIF1A	0.0023740668929229	0.32242936908291	5	3800	3783	3053	3800	3550	15	199	192	HIF1A renal tubular cells HIF1A	renal tubular cells	NULL	HIF1A	1 mM dimethyloxalylglycine	GTRD	EXP036851_renal-tubular-cells_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	4043
1	2946	MYCN	0.0023132011237279	0.526653718687736	26	3801	3508	1204	3801	2840	45	178	162	MYCN MYCN3 (neuroblastoma cell line with inducible MYCN expression) MYCN	MYCN3 (neuroblastoma cell line with inducible MYCN expression)	NULL	MYCN	Treatment: mycn-high lvl induced by 16 hr doxycycline	GTRD	EXP048927_MYCN3--neuroblastoma-cell-line-with-inducible-MYCN-expression-_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	11698
1	1025	E2F1	0.00210130330071562	0.561644796552722	38	3802	3456	576	3802	2610	60	166	147	E2F1 LNCaP (prostate carcinoma) E2F1	LNCaP (prostate carcinoma)	BTO:0001321	E2F1	Treatment: CDT for 72 hrs Genotype: knockdown with shCON of CON	GTRD	EXP049492_LNCaP--prostate-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	11731
1	3498	RUNX1	0.00201035706927224	0.415777770140878	11	3803	3709	2332	3803	3280	25	193	182	RUNX1 Kasumi-1 (acute myeloblastic leukemia) RUNX1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	RUNX1		GEO	GSE65427_runx1_kasumi1_MACS_RUNX1_MA0002.2.damo.pwm.bed	13541
1	1138	ERG	0.00196983811877974	0.59186662590398	57	3804	3386	174	3804	2450	82	147	125	ERG HUVEC-C (HUVEC, umbilical vein endothelial cells) ERG	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ERG		GTRD	EXP053004_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	70420
1	3655	SPI1	0.00184817186118937	0.451440088951035	15	3805	3673	1993	3805	3160	31	189	176	SPI1 MDM(monocyte derived macrophages) SPI1	MDM(monocyte derived macrophages)	NULL	SPI1	Treatment: mock infected 6hr	GTRD	EXP047756_MDM-monocyte-derived-macrophages-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	66089
1	3657	SPI1	0.00184817186118937	0.451440088951035	15	3805	3673	1993	3805	3160	31	189	176	SPI1 MDM(monocyte derived macrophages) SPI1	MDM(monocyte derived macrophages)	NULL	SPI1	Treatment: H5N1-dNS1 IAV infected 6hr	GTRD	EXP047758_MDM-monocyte-derived-macrophages-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	73591
1	3691	SPI1	0.00178038746357776	0.352431647258291	7	3807	3751	2812	3807	3460	19	197	188	SPI1 K562 (myelogenous leukemia) SPI1	K562 (myelogenous leukemia)	NULL	SPI1	SAHA	GEO	GSE74999_spi1_k562-saha_MACS_SPI1_MA0080.5.damo.pwm.bed	9337
1	3783	TCF12	0.0016824972469499	0.141273224480299	1	3808	3833	3655	3833	3770	7	203	200	TCF12 K562 (myelogenous leukemia) TCF12	K562 (myelogenous leukemia)	NULL	TCF12	NA	GTRD	EXP039447_K562--myelogenous-leukemia-_TCF12_MACS_TCF12_MA0521.1.damo.pwm.bed	19025
1	2939	MYCN	0.0016068589173899	0.393896759662684	10	3809	3739	2442	3809	3330	24	194	183	MYCN Tet21N (neuroblastoma) MYCN	Tet21N (neuroblastoma)	BTO:0004654	MYCN	0.2 ug/mL DOX for 2HR	GTRD	EXP036327_Tet21N--neuroblastoma-_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	2594
1	2080	HIF1A	0.00151463798537306	0.276481761434758	4	3810	3796	3182	3810	3600	14	200	193	HIF1A renal tubular cells HIF1A	renal tubular cells	NULL	HIF1A	1 mM dimethyloxalylglycine	GTRD	EXP036851_renal-tubular-cells_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	3311
1	3344	RELA	0.00125944593525188	0.319005012232865	6	3811	3784	2948	3811	3510	18	198	189	RELA GM10847 (female B-cells Lymphoblastoid Cell Lines) RELA	GM10847 (female B-cells Lymphoblastoid Cell Lines)	NULL	RELA	TNF-alpha induced (6h)	GTRD	EXP000766_GM10847--female-B-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	7285
1	3356	RELA	0.00125752404177547	0.545768889414624	40	3812	3477	502	3812	2600	64	164	143	RELA RCC 7860 (Renal cell carcinoma) RELA	RCC 7860 (Renal cell carcinoma)	BTO:0003781	RELA		GTRD	EXP037741_786-O--renal-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	33859
1	3500	RUNX1	0.000840502201119622	0.223463576421616	3	3813	3815	3316	3815	3650	13	201	194	RUNX1 Jurkat (T-cells) RUNX1	Jurkat (T-cells)	BTO:0000661	RUNX1		GEO	GSE68976_runx1_jurkat_MACS_RUNX1_MA0002.2.damo.pwm.bed	17007
1	3645	SPI1	0.000831169817782037	0.514619873837293	34	3814	3522	729	3814	2690	58	170	149	SPI1 GM12878 (female B-cells lymphoblastoid cell line) SPI1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	SPI1		ENCODE	ENCSR000BGQ_GM12878_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	71614
1	3332	RELA	0.000829996665753245	0.12301465189591	1	3815	3834	3655	3834	3770	8	203	199	RELA GM12892 (female B-cells lymphoblastoid cell line) RELA	GM12892 (female B-cells lymphoblastoid cell line)	NULL	RELA	human recombinant TNF-alpha from eBioscience [product# 14-8329-62] (Snyder)	ENCODE	ENCSR000EAN_GM12892_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	2766
1	3686	SPI1	0.000778264627751275	0.545709480398397	49	3816	3478	299	3816	2530	76	155	131	SPI1 CD34+ cells SPI1	CD34+ cells	NULL	SPI1	ADULT	GEO	GSE70660_spi1_cd34-adult_MACS_SPI1_MA0080.5.damo.pwm.bed	154599
1	2284	JUN	0.000766588760408297	0.508679920305484	33	3817	3529	778	3817	2710	57	171	150	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	TNFa, 4h	GTRD	EXP038042_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	49633
1	2688	MAX	0.000688086895327245	0.513709351717324	36	3818	3524	645	3818	2660	61	168	146	MAX HCT-116 (colon carcinoma) MAX	HCT-116 (colon carcinoma)	BTO:0001109	MAX		ENCODE	ENCSR000BSH_HCT116_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	18443
1	3342	RELA	0.000664597567796546	0.315545829159524	7	3819	3785	2812	3819	3470	21	197	186	RELA GM15510 (B-cells) RELA	GM15510 (B-cells)	NULL	RELA	TNF-alpha induced (6h)	GTRD	EXP000762_GM15510--B-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	5592
1	3507	RUNX2	0.000664597567796546	0.315545829159524	7	3819	3785	2812	3819	3470	21	197	186	RUNX2 LNCaP C4-2B (prostate carcinoma) RUNX2	LNCaP C4-2B (prostate carcinoma)	BTO:0004959	RUNX2		GEO	GSE33889_runx2_c42b_MACS_RUNX2_MA0511.2.damo.pwm.bed	36921
1	2279	JUN	0.000644107316748272	0.496058453000402	31	3821	3612	881	3821	2770	55	173	152	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	TNFa, 4h	GTRD	EXP038042_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	48726
1	3690	SPI1	0.000606522988689017	0.431254050621474	18	3822	3691	1785	3822	3100	38	186	169	SPI1 K562 (myelogenous leukemia) SPI1	K562 (myelogenous leukemia)	NULL	SPI1	NABUT	GEO	GSE74999_spi1_k562-nabut_MACS_SPI1_MA0080.5.damo.pwm.bed	35099
1	3348	RELA	0.000547953680606035	0.387283680281533	13	3823	3743	2153	3823	3240	31	191	176	RELA GM12891 (male B- cells lymphoblastoid cell line) RELA	GM12891 (male B- cells lymphoblastoid cell line)	NULL	RELA	TNF-alpha induced (6h)	GTRD	EXP000774_GM12891--male-B-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	19931
1	3750	STAT5A	0.000481459480624952	0.264584964703026	5	3824	3797	3053	3824	3560	18	199	189	STAT5A T-cells STAT5A	T-cells	NULL	STAT5A	IL-2	GTRD	EXP000397_T-cells_STAT5A_MACS_STAT5A_MA1624.1.damo.pwm.bed	5122
1	3373	RELA	0.000461339333427597	0.206456185231202	3	3825	3819	3316	3825	3650	14	201	193	RELA HeLa-B2 RELA	HeLa-B2	NA	RELA	TNFA	GEO	GSE24518_rela_helab2-tnfa_MACS_RELA_MA0107.1.damo.pwm.bed	8991
1	3680	SPI1	0.000433733964677748	0.547695321200324	69	3826	3475	47	3826	2450	100	135	107	SPI1 macrophages SPI1	macrophages	NULL	SPI1	IFNG	GEO	GSE66594_spi1_macrophages-ifng_MACS_SPI1_MA0080.5.damo.pwm.bed	147525
1	3646	SPI1	0.00043097723606163	0.438531935818975	21	3827	3684	1535	3827	3020	43	183	164	SPI1 K562 (myelogenous leukemia) SPI1	K562 (myelogenous leukemia)	NULL	SPI1		ENCODE	ENCSR000BGW_K562_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	56378
1	3495	RUNX1	0.000401307507929376	0.523654706894589	49	3828	3510	299	3828	2550	78	155	129	RUNX1 BONE RUNX1	BONE	NA	RUNX1	MARROW	GEO	GSE64862_runx1_bone-marrow_MACS_RUNX1_MA0002.2.damo.pwm.bed	74256
1	3828	TEAD1	0.000348302478907424	0.312051284182907	8	3829	3787	2697	3829	3440	24	196	183	TEAD1 MSTO TEAD1	MSTO	NA	TEAD1		GEO	GSE68170_tead1_msto_MACS_TEAD1_MA0090.3.damo.pwm.bed	17117
1	3834	TEAD4	0.000287919336296761	0.425981732081999	21	3830	3701	1535	3830	3020	44	183	163	TEAD4 Ishikawa (endometrial adenocarcinoma) TEAD4	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	TEAD4		ENCODE	ENCSR000BSW_Ishikawa_TEAD4_MACS_TEAD4_MA0809.2.damo.pwm.bed	27888
1	3569	SMAD3	0.000274192682169731	0.355695801209542	12	3831	3750	2233	3831	3270	31	192	176	SMAD3 MDA-MB-231 (breast adenocarcinoma) SMAD3	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	SMAD3	Treatment: no CellType: Immortalized human mammary epithelial cells	GTRD	EXP047900_MDA-MB-231--breast-adenocarcinoma-_SMAD3_MACS_SMAD3_MA0513.1.damo.pwm.bed	39240
1	3628	SP1	0.000196190214973256	0.491110433564669	43	3832	3629	429	3832	2630	73	161	134	SP1 HEK293 (embryonic kidney) SP1	HEK293 (embryonic kidney)	NULL	SP1		GTRD	EXP035873_HEK293--embryonic-kidney-_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	19122
1	3749	STAT5A	0.000151907749624792	0.255590055650422	6	3833	3798	2948	3833	3530	22	198	185	STAT5A T-cells STAT5A	T-cells	NULL	STAT5A	IL-2	GTRD	EXP000397_T-cells_STAT5A_MACS_STAT5A_MA0519.1.damo.pwm.bed	5920
1	3570	SMAD3	0.00012859139971047	0.324427678816688	11	3834	3782	2332	3834	3320	31	193	176	SMAD3 MDA-MB-231 (breast adenocarcinoma) SMAD3	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	SMAD3	Treatment: no CellType: Immortalized human mammary epithelial cells	GTRD	EXP047900_MDA-MB-231--breast-adenocarcinoma-_SMAD3_MACS_SMAD3_MA1622.1.damo.pwm.bed	38463
1	10	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	1nm R	GTRD	EXP000729_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	596
1	55	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR R1-D567 (prostate cancer) AR	R1-D567 (prostate cancer)	NULL	AR	radiation	GTRD	EXP036886_R1-D567--prostate-cancer-_AR_MACS_AR_MA0007.3.damo.pwm.bed	28
1	56	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR R1-D567 (prostate cancer) AR	R1-D567 (prostate cancer)	NULL	AR		GTRD	EXP036887_R1-D567--prostate-cancer-_AR_MACS_AR_MA0007.3.damo.pwm.bed	228
1	62	AR	0	0	0	3835	3835	3835	3835	3840	2	204	205	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	dihydrotestosterone  (DHT)	GTRD	EXP038190_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	3202
1	63	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Control	GTRD	EXP038191_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	175
1	72	AR	0	0	0	3835	3835	3835	3835	3840	2	204	205	AR HEE (human epididymis epithelial cells) AR	HEE (human epididymis epithelial cells)	NULL	AR	Treatment: treatment of 1 nM R1881 (methyltrienolone) for 12 -16 hr	GTRD	EXP048160_HEE--human-epididymis-epithelial-cells-_AR_MACS_AR_MA0007.3.damo.pwm.bed	3598
1	74	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR LNCaP-abl (Prostate carcinoma) AR	LNCaP-abl (Prostate carcinoma)	NULL	AR	Treatment: GSK126 of 5 uM for 4-5 days Passages: 61-64 Phenotype: AR-positive, EZH2 inhibitor -sensitive	GTRD	EXP048902_LNCaP-abl--Prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	450
1	77	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: targeting AR exon 7 siARFL+ ethanol	GTRD	EXP048922_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	1070
1	81	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: DHT 100nM 4 hours	GTRD	EXP049020_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	1473
1	102	AR	0	0	0	3835	3835	3835	3835	3840	1	204	206	AR R1-AD1 (prostate cancer) AR	R1-AD1 (prostate cancer)	NULL	AR	Treatment: 50 uM VPC14449 + 1 nM ethanol for 4 hrs	GTRD	EXP049664_R1-AD1--prostate-cancer-_AR_MACS_AR_MA0007.3.damo.pwm.bed	254
1	103	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR R1-D567 (prostate cancer) AR	R1-D567 (prostate cancer)	NULL	AR	Treatment: 0.1% DMSO for 4 hrs	GTRD	EXP049665_R1-D567--prostate-cancer-_AR_MACS_AR_MA0007.3.damo.pwm.bed	12
1	104	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR R1-D567 (prostate cancer) AR	R1-D567 (prostate cancer)	NULL	AR	Treatment: 50 uM VPC14449 for 4 hrs	GTRD	EXP049666_R1-D567--prostate-cancer-_AR_MACS_AR_MA0007.3.damo.pwm.bed	94
1	105	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR LNCaP95 AR	LNCaP95	NULL	AR	Treatment: 10 nM ETOH for 4 hrs Genotype: shARfl transfection	GTRD	EXP052946_LNCaP95_AR_MACS_AR_MA0007.3.damo.pwm.bed	48
1	118	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR primary prostate cancer AR	primary prostate cancer	NULL	AR	Treatment: FA (control)	GTRD	EXP053232_primary-prostate-cancer_AR_MACS_AR_MA0007.3.damo.pwm.bed	21
1	123	AR	0	0	0	3835	3835	3835	3835	3840	2	204	205	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Genotype: GREB1 knockout; Treatment: shGREB1;	GTRD	EXP058317_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	2695
1	129	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	KDP53	GEO	GSE31294_AR_lncap-kdp53_MACS_AR_MA0007.3.damo.pwm.bed	34
1	136	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	SHCTR_R1881_HD	GEO	GSE37345_AR_lncap-shctr-r1881-hd_MACS_AR_MA0007.3.damo.pwm.bed	7
1	138	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	DHT	GEO	GSE40050_AR_22rv1-dht_MACS_AR_MA0007.3.damo.pwm.bed	160
1	145	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR DU145 (prostate carcinoma) AR	DU145 (prostate carcinoma)	BTO:0001332	AR	ARG56W	GEO	GSE47987_AR_du145-arg56w_MACS_AR_MA0007.3.damo.pwm.bed	31
1	148	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR DU145 (prostate carcinoma) AR	DU145 (prostate carcinoma)	BTO:0001332	AR	FOXA1_HIGH	GEO	GSE47987_AR_du145-foxa1-high_MACS_AR_MA0007.3.damo.pwm.bed	330
1	151	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR AR	NA	NA	AR	NA	GEO	GSE48308_AR_lncap-dht1nm_MACS_AR_MA0007.3.damo.pwm.bed	8
1	152	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR AR	NA	NA	AR	NA	GEO	GSE48308_AR_lncaparmo-ar-dht100nm_MACS_AR_MA0007.3.damo.pwm.bed	31
1	153	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR AR	NA	NA	AR	NA	GEO	GSE48308_AR_lncaparmo-ar-dht1nm_MACS_AR_MA0007.3.damo.pwm.bed	61
1	167	AR	0	0	0	3835	3835	3835	3835	3840	1	204	206	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	DHT24H_SHFOXA1	GEO	GSE58428_AR_lncap-dht24h-shfoxa1_MACS_AR_MA0007.3.damo.pwm.bed	726
1	173	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	ETOH24H	GEO	GSE58428_AR_vcap-etoh24h_MACS_AR_MA0007.3.damo.pwm.bed	550
1	174	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR AR	NA	NA	AR	NA	GEO	GSE58478_AR_22rv1-arfl-arvs_MACS_AR_MA0007.3.damo.pwm.bed	1954
1	175	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR AR	NA	NA	AR	NA	GEO	GSE58478_AR_22rv1-arvs_MACS_AR_MA0007.3.damo.pwm.bed	1883
1	195	AR	0	0	0	3835	3835	3835	3835	3840	0	204	207	AR MDA-MB-453 (breast adenocarcinoma) AR	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	AR	R1881	GEO	GSE70161_AR_mdamb453-r1881_MACS_AR_MA0007.3.damo.pwm.bed	283
1	201	AR	0	0	0	3835	3835	3835	3835	3840	2	204	205	AR MDA-MB-453 (breast adenocarcinoma) AR	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	AR	MPA	GEO	GSE74069_AR_mdamb45-mpa_MACS_AR_MA0007.3.damo.pwm.bed	6213
1	223	ARNT	0	0	0	3835	3835	3835	3835	3840	1	204	206	ARNT HUVEC-C (HUVEC, umbilical vein endothelial cells) ARNT	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ARNT	Passage: 4-6	GTRD	EXP049262_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ARNT_MACS_ARNT_MA0004.1.damo.pwm.bed	700
1	227	ARNTL	0	0	0	3835	3835	3835	3835	3840	2	204	205	ARNTL U2OS (osteosarcoma) ARNTL	U2OS (osteosarcoma)	BTO:0001938	ARNTL	NA	GTRD	EXP035003_U2OS--osteosarcoma-_ARNTL_MACS_ARNTL_MA0603.1.damo.pwm.bed	531
1	228	ARNTL	0	0	0	3835	3835	3835	3835	3840	1	204	206	ARNTL ARNTL	NA	NA	ARNTL	NA	GEO	GSE74439_arntl_u2os-dmso_MACS_ARNTL_MA0603.1.damo.pwm.bed	12
1	231	ASCL1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ASCL1 G523NS (glioblastoma) ASCL1	G523NS (glioblastoma)	NULL	ASCL1		GTRD	EXP037901_G523NS--glioblastoma-_ASCL1_MACS_ASCL1_MA1100.2.damo.pwm.bed	1692
1	232	ASCL1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ASCL1 G523NS (glioblastoma) ASCL1	G523NS (glioblastoma)	NULL	ASCL1		GTRD	EXP037901_G523NS--glioblastoma-_ASCL1_MACS_ASCL1_MA1631.1.damo.pwm.bed	1409
1	282	BATF3	0	0	0	3835	3835	3835	3835	3840	3	204	204	BATF3 ST-1 (Adult T acute lymphoblastic leukemia) BATF3	ST-1 (Adult T acute lymphoblastic leukemia)	NULL	BATF3	Treatment: BirA enzyme were transduced with N-terminally tagged BATF3 (pRCMV/TO-flag-BIOTIN-BATF3-puro)	GTRD	EXP049467_ST-1--Adult-T-acute-lymphoblastic-leukemia-_BATF3_MACS_BATF3_MA0835.2.damo.pwm.bed	5818
1	303	CDX2	0	0	0	3835	3835	3835	3835	3840	2	204	205	CDX2 COLO-320 (colon adenocarcinoma) CDX2	COLO-320 (colon adenocarcinoma)	BTO:0002047	CDX2		GEO	GSE30026_cdx2_colo320_MACS_CDX2_MA0465.2.damo.pwm.bed	16302
1	413	CLOCK	0	0	0	3835	3835	3835	3835	3840	2	204	205	CLOCK CLOCK	NA	NA	CLOCK	NA	GEO	GSE74439_clock_u2os-6an_MACS_CLOCK_MA0819.1.damo.pwm.bed	166
1	627	CTCF	0	0	0	3835	3835	3835	3835	3840	0	204	207	CTCF SK-OV-3 (ovarian serous cystadenocarcinoma) CTCF	SK-OV-3 (ovarian serous cystadenocarcinoma)	NULL	CTCF		GTRD	EXP036562_SK-OV-3--ovarian-serous-cystadenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	136
1	648	CTCF	0	0	0	3835	3835	3835	3835	3840	0	204	207	CTCF 226LDM (normal breast luminal cells) CTCF	226LDM (normal breast luminal cells)	NULL	CTCF	untreated	GTRD	EXP036890_226LDM--normal-breast-luminal-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	1417
1	688	CTCF	0	0	0	3835	3835	3835	3835	3840	1	204	206	CTCF subcutaneous adipose tissue CTCF	subcutaneous adipose tissue	BTO:0004042	CTCF		GTRD	EXP039456_subcutaneous-adipose-tissue_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	118
1	725	CTCF	0	0	0	3835	3835	3835	3835	3840	0	204	207	CTCF omental fat pad CTCF	omental fat pad	NULL	CTCF		GTRD	EXP039695_omental-fat-pad_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	21
1	731	CTCF	0	0	0	3835	3835	3835	3835	3840	0	204	207	CTCF lower leg skin CTCF	lower leg skin	NULL	CTCF		GTRD	EXP039707_lower-leg-skin_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	8
1	892	CTCF	0	0	0	3835	3835	3835	3835	3840	0	204	207	CTCF EndoC-BH1 (human pancreatic beta cell line) CTCF	EndoC-BH1 (human pancreatic beta cell line)	NULL	CTCF	Source: Pancreas	GTRD	EXP053296_EndoC-BH1--human-pancreatic-beta-cell-line-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	3
1	992	CTCFL	0	0	0	3835	3835	3835	3835	3840	0	204	207	CTCFL NHDF CTCFL	NHDF	NA	CTCFL	NA	GEO	GSE70764_ctcfl_nhdf_MACS_CTCFL_MA1102.2.damo.pwm.bed	2
1	997	CUX1	0	0	0	3835	3835	3835	3835	3840	0	204	207	CUX1 K562 (myelogenous leukemia) CUX1	K562 (myelogenous leukemia)	NULL	CUX1	NA	ENCODE	ENCSR178NTX_K562_CUX1_MACS_CUX1_MA0754.1.damo.pwm.bed	446
1	1028	E2F1	0	0	0	3835	3835	3835	3835	3840	3	204	204	E2F1 U2OS (osteosarcoma) E2F1	U2OS (osteosarcoma)	BTO:0001938	E2F1		GTRD	EXP055169_U2OS--osteosarcoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	343
1	1035	E2F4	0	0	0	3835	3835	3835	3835	3840	0	204	207	E2F4 MCF7 (Invasive ductal breast carcinoma) E2F4	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	E2F4		ENCODE	ENCSR505NMN_MCF-7_E2F4_MACS_E2F4_MA0470.2.damo.pwm.bed	204
1	1038	E2F4	0	0	0	3835	3835	3835	3835	3840	2	204	205	E2F4 MCF7 (Invasive ductal breast carcinoma) E2F4	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	E2F4	Treatment: treated with 100nm ICI 182780 for 48hrs;	GTRD	EXP054361_MCF7--Invasive-ductal-breast-carcinoma-_E2F4_MACS_E2F4_MA0470.2.damo.pwm.bed	853
1	1039	E2F4	0	0	0	3835	3835	3835	3835	3840	1	204	206	E2F4 lymphoblastoid cells E2F4	lymphoblastoid cells	NULL	E2F4		GEO	GSE21488_e2f4_lymphoblastoid_MACS_E2F4_MA0470.2.damo.pwm.bed	244
1	1040	E2F4	0	0	0	3835	3835	3835	3835	3840	2	204	205	E2F4 MCF7 (Invasive ductal breast carcinoma) E2F4	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	E2F4	ICI	GEO	GSE41561_e2f4_mcf7-ici_MACS_E2F4_MA0470.2.damo.pwm.bed	644
1	1042	E2F4	0	0	0	3835	3835	3835	3835	3840	2	204	205	E2F4 retina E2F4	retina	BTO:0001175	E2F4	pigment	GEO	GSE60024_e2f4_retinal-pigment_MACS_E2F4_MA0470.2.damo.pwm.bed	523
1	1089	ELF1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ELF1 ELF1	NA	NA	ELF1	NA	GEO	GSE59021_elf1_du145_MACS_ELF1_MA0473.3.damo.pwm.bed	126
1	1107	ELK4	0	0	0	3835	3835	3835	3835	3840	0	204	207	ELK4 HEK293 (embryonic kidney) ELK4	HEK293 (embryonic kidney)	NULL	ELK4		ENCODE	ENCSR000EVB_HEK293_ELK4_MACS_ELK4_MA0076.2.damo.pwm.bed	134
1	1111	ELK4	0	0	0	3835	3835	3835	3835	3840	0	204	207	ELK4 ELK4	NA	NA	ELK4	NA	GEO	GSE59021_elk4_du145_MACS_ELK4_MA0076.2.damo.pwm.bed	63
1	1127	ERG	0	0	0	3835	3835	3835	3835	3840	0	204	207	ERG RWPE1 (prostate epithelial cells) ERG	RWPE1 (prostate epithelial cells)	BTO:0003709	ERG		GTRD	EXP037057_RWPE1--prostate-epithelial-cells-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	300
1	1166	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		Array Express	ERP000380_esr1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	991
1	1169	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	E2_TAM	Array Express	ERP000380_esr1_t47d-e2-tam_MACS_ESR1_MA0112.3.damo.pwm.bed	655
1	1174	ESR1	0	0	0	3835	3835	3835	3835	3840	1	204	206	ESR1 breast ESR1	breast	NA	ESR1	glyc	Array Express	ERP002305_esr1_breast-glyc_MACS_ESR1_MA0112.3.damo.pwm.bed	45
1	1176	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	MRNAHIST	Array Express	ERP002305_esr1_mcf7-mrnahist_MACS_ESR1_MA0112.3.damo.pwm.bed	988
1	1181	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP000232_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	1167
1	1183	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	ETOH (ethanol)	GTRD	EXP000881_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	657
1	1185	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	ETOH (ethanol)	GTRD	EXP000883_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	346
1	1187	ESR1	0	0	0	3835	3835	3835	3835	3840	1	204	206	ESR1 Ishikawa (endometrial adenocarcinoma) ESR1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	ESR1	E2	GTRD	EXP000886_Ishikawa--endometrial-adenocarcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	1063
1	1198	ESR1	0	0	0	3835	3835	3835	3835	3840	1	204	206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	1hr with ethanol, crosslinked with 1% formaldehyde	GTRD	EXP034118_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	1252
1	1201	ESR1	0	0	0	3835	3835	3835	3835	3840	1	204	206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	cells transfected with siNCAPD3 and H2 together, and 1hr with 100nM E2, double crosslinked	GTRD	EXP034121_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	4364
1	1211	ESR1	0	0	0	3835	3835	3835	3835	3840	1	204	206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Vehicle treatment	GTRD	EXP036167_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	3556
1	1217	ESR1	0	0	0	3835	3835	3835	3835	3840	1	204	206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	DMSO	GTRD	EXP036387_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	308
1	1218	ESR1	0	0	0	3835	3835	3835	3835	3840	1	204	206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP036388_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	1231
1	1219	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	DMSO	GTRD	EXP036389_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	15
1	1220	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP036390_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	247
1	1256	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 endometrioid adenocarcinoma ESR1	endometrioid adenocarcinoma	NULL	ESR1	Tamoxifen-associated	GTRD	EXP038349_endometrioid-adenocarcinoma_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	3067
1	1285	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1		GTRD	EXP038777_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	1693
1	1301	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	control	GTRD	EXP040950_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	376
1	1304	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	control	GTRD	EXP040953_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	186
1	1307	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	control	GTRD	EXP040956_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	231
1	1310	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	control	GTRD	EXP040959_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	704
1	1342	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	Treatment: Hormone-deprived media using RPMI1640 without phenol red and 10% charcoal-stripped FBS) for 5-7 days	GTRD	EXP048597_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	852
1	1345	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: DMSO for 45 min  Genotype: wildtype TET2 Passage: 6-10	GTRD	EXP048685_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	1138
1	1362	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 10 nM R5020 for45 mins Genotype: ER+/PR+	GTRD	EXP049947_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	611
1	1368	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 primary endometrium cancer ESR1	primary endometrium cancer	NULL	ESR1	Treatment: FA (control)	GTRD	EXP053240_primary-endometrium-cancer_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	171
1	1371	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: vehicle (0.01% EtOH) for 30 mins Genotype: pS118-ER	GTRD	EXP053337_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	34
1	1384	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	TLED	GEO	GSE27300_esr1_mcf7-tled_MACS_ESR1_MA0112.3.damo.pwm.bed	1564
1	1389	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 ZR-75-1 (invasive ductal carcinoma) ESR1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	ESR1	SICTR_E2	GEO	GSE40129_esr1_zr751-sictr-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	548
1	1390	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 ZR-75-1 (invasive ductal carcinoma) ESR1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	ESR1	SIGATA_E2	GEO	GSE40129_esr1_zr751-sigata-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	1095
1	1396	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 MDA-MB-134 (invasive lobular breast carcinoma) ESR1	MDA-MB-134 (invasive lobular breast carcinoma)	NULL	ESR1	ETOH	GEO	GSE51022_esr1_mdamb134vi-etoh_MACS_ESR1_MA0112.3.damo.pwm.bed	367
1	1397	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SHESR1	GEO	GSE53531_esr1_mcf7-shesr1_MACS_ESR1_MA0112.3.damo.pwm.bed	16
1	1398	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	LETR_ANDRO	GEO	GSE54592_esr1_letr-andro_MACS_ESR1_MA0112.3.damo.pwm.bed	28
1	1399	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	LETR	GEO	GSE54592_esr1_letr_MACS_ESR1_MA0112.3.damo.pwm.bed	225
1	1402	ESR1	0	0	0	3835	3835	3835	3835	3840	1	204	206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2_120M	GEO	GSE54855_esr1_mcf7-e2-120m_MACS_ESR1_MA0112.3.damo.pwm.bed	1537
1	1403	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2_2M	GEO	GSE54855_esr1_mcf7-e2-2m_MACS_ESR1_MA0112.3.damo.pwm.bed	779
1	1404	ESR1	0	0	0	3835	3835	3835	3835	3840	4	204	203	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2_40M	GEO	GSE54855_esr1_mcf7-e2-40m_MACS_ESR1_MA0112.3.damo.pwm.bed	4274
1	1405	ESR1	0	0	0	3835	3835	3835	3835	3840	1	204	206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2_5M	GEO	GSE54855_esr1_mcf7-e2-5m_MACS_ESR1_MA0112.3.damo.pwm.bed	1208
1	1415	ESR1	0	0	0	3835	3835	3835	3835	3840	1	204	206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SHCTR	GEO	GSE60270_esr1_mcf7-shctr_MACS_ESR1_MA0112.3.damo.pwm.bed	1730
1	1416	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SHFOXA1_E2	GEO	GSE60270_esr1_mcf7-shfoxa1-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	1039
1	1427	ESR1	0	0	0	3835	3835	3835	3835	3840	2	204	205	ESR1 ESR1	NA	NA	ESR1	NA	GEO	GSE68356_ESR1_mcf7-pg_MACS_ESR1_MA0112.3.damo.pwm.bed	2532
1	1428	ESR1	0	0	0	3835	3835	3835	3835	3840	2	204	205	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	E2	GEO	GSE68356_ESR1_t47d-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	1087
1	1429	ESR1	0	0	0	3835	3835	3835	3835	3840	0	204	207	ESR1 ESR1	NA	NA	ESR1	NA	GEO	GSE68356_ESR1_t47d-e2pg_MACS_ESR1_MA0112.3.damo.pwm.bed	514
1	1432	ESR1	0	0	0	3835	3835	3835	3835	3840	1	204	206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GEO	GSE72249_esr1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	2755
1	1486	ETV6	0	0	0	3835	3835	3835	3835	3840	0	204	207	ETV6 Reh (ATCC CRL-8286) ETV6	Reh (ATCC CRL-8286)	BTO:0001163	ETV6	Positive IP/test condition	GTRD	EXP040493_Reh--ATCC-CRL-8286-_ETV6_MACS_ETV6_MA0645.1.damo.pwm.bed	737
1	1509	FLI1	0	0	0	3835	3835	3835	3835	3840	0	204	207	FLI1 SK-N-MC (Askin tumor) FLI1	SK-N-MC (Askin tumor)	BTO:0002914	FLI1	SHFLI_48H	GEO	GSE61944_fli1_skmnc-shfli-48h_MACS_FLI1_MA0475.2.damo.pwm.bed	523
1	1510	FLI1	0	0	0	3835	3835	3835	3835	3840	0	204	207	FLI1 SK-N-MC (Askin tumor) FLI1	SK-N-MC (Askin tumor)	BTO:0002914	FLI1	SHFLI_96H	GEO	GSE61944_fli1_skmnc-shfli-96h_MACS_FLI1_MA0475.2.damo.pwm.bed	126
1	1677	FOXA1	0	0	0	3835	3835	3835	3835	3840	1	204	206	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	ShMEN1	GTRD	EXP038334_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	3931
1	1688	FOXA1	0	0	0	3835	3835	3835	3835	3840	0	204	207	FOXA1 K562 (myelogenous leukemia) FOXA1	K562 (myelogenous leukemia)	NULL	FOXA1		GTRD	EXP039676_K562--myelogenous-leukemia-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	123
1	1690	FOXA1	0	0	0	3835	3835	3835	3835	3840	2	204	205	FOXA1 HepG2 (hepatoblastoma) FOXA1	HepG2 (hepatoblastoma)	BTO:0000599	FOXA1		GTRD	EXP039801_HepG2--hepatoblastoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	4595
1	1692	FOXA1	0	0	0	3835	3835	3835	3835	3840	0	204	207	FOXA1 HEK293T (embryonic kidney) FOXA1	HEK293T (embryonic kidney)	BTO:0002181	FOXA1		GTRD	EXP039910_HEK293T--embryonic-kidney-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	278
1	1716	FOXA1	0	0	0	3835	3835	3835	3835	3840	1	204	206	FOXA1 prostate tumor FOXA1	prostate tumor	NULL	FOXA1	Patient: #1	GTRD	EXP048494_prostate-tumor_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	273
1	1719	FOXA1	0	0	0	3835	3835	3835	3835	3840	1	204	206	FOXA1 prostate tumor FOXA1	prostate tumor	NULL	FOXA1	Patient: #4	GTRD	EXP048497_prostate-tumor_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	553
1	1763	FOXA1	0	0	0	3835	3835	3835	3835	3840	0	204	207	FOXA1 HuH7 (hepatocellular carcinoma) FOXA1	HuH7 (hepatocellular carcinoma)	BTO:0001950	FOXA1	MITO	GEO	GSE39241_foxa1_huh7-mito_MACS_FOXA1_MA0148.4.damo.pwm.bed	13
1	1796	FOXA1	0	0	0	3835	3835	3835	3835	3840	0	204	207	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	ETOH	GEO	GSE69043_foxa1_lncap-etoh_MACS_FOXA1_MA0148.4.damo.pwm.bed	802
1	1799	FOXA1	0	0	0	3835	3835	3835	3835	3840	0	204	207	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	SHGATA2_ETOH	GEO	GSE69043_foxa1_lncap-shgata2-etoh_MACS_FOXA1_MA0148.4.damo.pwm.bed	41
1	1824	FOXA2	0	0	0	3835	3835	3835	3835	3840	0	204	207	FOXA2 endometrioid adenocarcinoma FOXA2	endometrioid adenocarcinoma	NULL	FOXA2	tumor C	GTRD	EXP036411_endometrioid-adenocarcinoma_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	455
1	1857	FOXP1	0	0	0	3835	3835	3835	3835	3840	0	204	207	FOXP1 SU-DHL-4 (diffuse large B-cell lymphoma) FOXP1	SU-DHL-4 (diffuse large B-cell lymphoma)	NULL	FOXP1	NA	Array Express	ERP010999_foxp1_sudhl4_MACS_FOXP1_MA0481.3.damo.pwm.bed	225
1	1862	FOXP1	0	0	0	3835	3835	3835	3835	3840	0	204	207	FOXP1 OCI-LY19 (diffuse large B-cell lymphoma) FOXP1	OCI-LY19 (diffuse large B-cell lymphoma)	NULL	FOXP1	NA	GTRD	EXP034311_OCI-LY19--diffuse-large-B-cell-lymphoma-_FOXP1_MACS_FOXP1_MA0481.3.damo.pwm.bed	889
1	1866	FOXP1	0	0	0	3835	3835	3835	3835	3840	0	204	207	FOXP1 neural-progenitor FOXP1	neural-progenitor	NA	FOXP1	NA	GEO	GSE62718_foxp1_neural-progenitor_MACS_FOXP1_MA0481.3.damo.pwm.bed	1155
1	1900	GATA1	0	0	0	3835	3835	3835	3835	3840	0	204	207	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	24 hours following induction with TPA	GTRD	EXP000588_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	3085
1	1901	GATA1	0	0	0	3835	3835	3835	3835	3840	0	204	207	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	24 hours following induction with TPA	GTRD	EXP000588_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	3006
1	1937	GATA2	0	0	0	3835	3835	3835	3835	3840	0	204	207	GATA2 K562 (myelogenous leukemia) GATA2	K562 (myelogenous leukemia)	NULL	GATA2	bmp	GTRD	EXP000942_K562--myelogenous-leukemia-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	10516
1	1939	GATA2	0	0	0	3835	3835	3835	3835	3840	0	204	207	GATA2 Kasumi-3 (adult acute myeloid leukemia with minimal differentiation) GATA2	Kasumi-3 (adult acute myeloid leukemia with minimal differentiation)	NULL	GATA2		GTRD	EXP036547_Kasumi-3--adult-acute-myeloid-leukemia-with-minimal-differentiation-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	14
1	1942	GATA2	0	0	0	3835	3835	3835	3835	3840	2	204	205	GATA2 WA09 (embryonic stem cells) GATA2	WA09 (embryonic stem cells)	NULL	GATA2	BMP4 for 3 day	GTRD	EXP040707_WA09--embryonic-stem-cells-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	5104
1	1973	GATA3	0	0	0	3835	3835	3835	3835	3840	0	204	207	GATA3 WA09 (embryonic stem cells) GATA3	WA09 (embryonic stem cells)	NULL	GATA3	BMP4 for 3 day	GTRD	EXP040703_WA09--embryonic-stem-cells-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	2418
1	1974	GATA3	0	0	0	3835	3835	3835	3835	3840	0	204	207	GATA3 WA09 (embryonic stem cells) GATA3	WA09 (embryonic stem cells)	NULL	GATA3	BMP4 for 3 day	GTRD	EXP040704_WA09--embryonic-stem-cells-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	488
1	1976	GATA3	0	0	0	3835	3835	3835	3835	3840	0	204	207	GATA3 A1A3(breast cancer cells) GATA3	A1A3(breast cancer cells)	NULL	GATA3	Treatment: 1hr EtOH, Doxycycline 72 hr CellLine: A1A3 from T47D cell line Genotype: Brg1 knockdown	GTRD	EXP048406_A1A3-breast-cancer-cells-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	6284
1	1992	GATA3	0	0	0	3835	3835	3835	3835	3840	0	204	207	GATA3 RPMI-8402 (T acute lymphoblastic leukemia) GATA3	RPMI-8402 (T acute lymphoblastic leukemia)	BTO:0001880	GATA3		GEO	GSE39179_gata3_rpmi8402_MACS_GATA3_MA0037.3.damo.pwm.bed	233
1	1994	GATA3	0	0	0	3835	3835	3835	3835	3840	0	204	207	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3		GEO	GSE40129_gata3_mcf7_MACS_GATA3_MA0037.3.damo.pwm.bed	3180
1	2005	GATA3	0	0	0	3835	3835	3835	3835	3840	0	204	207	GATA3 CD4 GATA3	CD4	NA	GATA3	TH1	GEO	GSE72266_gata3_cd4-th1_MACS_GATA3_MA0037.3.damo.pwm.bed	80
1	2028	GATA6	0	0	0	3835	3835	3835	3835	3840	0	204	207	GATA6 H9 GATA6	H9	NULL	GATA6		Array Express	ERP004206_gata6_esc-h9_MACS_GATA6_MA1104.2.damo.pwm.bed	1609
1	2039	GATA6	0	0	0	3835	3835	3835	3835	3840	0	204	207	GATA6 Caco-2 (colon adenocarcinoma) GATA6	Caco-2 (colon adenocarcinoma)	BTO:0000195	GATA6	DIFF	GEO	GSE23436_gata6_caco2-diff_MACS_GATA6_MA1104.2.damo.pwm.bed	309
1	2049	GFI1B	0	0	0	3835	3835	3835	3835	3840	2	204	205	GFI1B SET2 (Adult acute megakaryoblastic leukemia, Homo Sapiens) GFI1B	SET2 (Adult acute megakaryoblastic leukemia, Homo Sapiens)	NULL	GFI1B	Treatment: GSK-LSD1 for 48 hrs; Genotype: wildtype;	GTRD	EXP058349_SET2--Adult-acute-megakaryoblastic-leukemia--Homo-Sapiens-_GFI1B_MACS_GFI1B_MA0483.1.damo.pwm.bed	1691
1	2078	HIC1	0	0	0	3835	3835	3835	3835	3840	0	204	207	HIC1 HEK293 (embryonic kidney) HIC1	HEK293 (embryonic kidney)	NULL	HIC1	NA	GTRD	EXP039956_HEK293--embryonic-kidney-_HIC1_MACS_HIC1_MA0739.1.damo.pwm.bed	956
1	2081	HIF1A	0	0	0	3835	3835	3835	3835	3840	6	204	201	HIF1A HKC8 (kidney proximal tubule cell line) HIF1A	HKC8 (kidney proximal tubule cell line)	NULL	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 16 hours, HIF2a knockout	GTRD	EXP048717_HKC8--kidney-proximal-tubule-cell-line-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	949
1	2082	HIF1A	0	0	0	3835	3835	3835	3835	3840	5	204	202	HIF1A HKC8 (kidney proximal tubule cell line) HIF1A	HKC8 (kidney proximal tubule cell line)	NULL	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 16 hours, HIF2a knockout	GTRD	EXP048717_HKC8--kidney-proximal-tubule-cell-line-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	849
1	2089	HIF1A	0	0	0	3835	3835	3835	3835	3840	2	204	205	HIF1A HepG2 (hepatoblastoma) HIF1A	HepG2 (hepatoblastoma)	BTO:0000599	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 16 hours	GTRD	EXP048736_HepG2--hepatoblastoma-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	678
1	2090	HIF1A	0	0	0	3835	3835	3835	3835	3840	1	204	206	HIF1A HepG2 (hepatoblastoma) HIF1A	HepG2 (hepatoblastoma)	BTO:0000599	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 16 hours	GTRD	EXP048736_HepG2--hepatoblastoma-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	597
1	2093	HIF1A	0	0	0	3835	3835	3835	3835	3840	0	204	207	HIF1A HKC8 (kidney proximal tubule cell line) HIF1A	HKC8 (kidney proximal tubule cell line)	NULL	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 6 hours	GTRD	EXP048740_HKC8--kidney-proximal-tubule-cell-line-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	41
1	2094	HIF1A	0	0	0	3835	3835	3835	3835	3840	0	204	207	HIF1A HKC8 (kidney proximal tubule cell line) HIF1A	HKC8 (kidney proximal tubule cell line)	NULL	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 6 hours	GTRD	EXP048740_HKC8--kidney-proximal-tubule-cell-line-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	57
1	2096	HIF1A	0	0	0	3835	3835	3835	3835	3840	0	204	207	HIF1A HKC8 (kidney proximal tubule cell line) HIF1A	HKC8 (kidney proximal tubule cell line)	NULL	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 48 hours	GTRD	EXP048746_HKC8--kidney-proximal-tubule-cell-line-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	158
1	2107	HINFP	0	0	0	3835	3835	3835	3835	3840	0	204	207	HINFP hTERT-RPE1 HINFP	hTERT-RPE1	BTO:0004790	HINFP	NA	GTRD	EXP055168_hTERT-RPE1_HINFP_MACS_HINFP_MA0131.2.damo.pwm.bed	27
1	2108	HINFP	0	0	0	3835	3835	3835	3835	3840	0	204	207	HINFP U2OS (osteosarcoma) HINFP	U2OS (osteosarcoma)	BTO:0001938	HINFP	NA	GTRD	EXP055172_U2OS--osteosarcoma-_HINFP_MACS_HINFP_MA0131.2.damo.pwm.bed	71
1	2112	HNF1A	0	0	0	3835	3835	3835	3835	3840	0	204	207	HNF1A Caco-2 (colon adenocarcinoma) HNF1A	Caco-2 (colon adenocarcinoma)	BTO:0000195	HNF1A		GTRD	EXP034791_Caco-2--colon-adenocarcinoma-_HNF1A_MACS_HNF1A_MA0046.2.damo.pwm.bed	1796
1	2117	HNF1B	0	0	0	3835	3835	3835	3835	3840	2	204	205	HNF1B H9 HNF1B	H9	NULL	HNF1B	NA	Array Express	ERP004206_hnf1b_esc-h9_MACS_HNF1B_MA0153.2.damo.pwm.bed	2448
1	2118	HNF1B	0	0	0	3835	3835	3835	3835	3840	0	204	207	HNF1B HUES64 (embryonic stem cells) HNF1B	HUES64 (embryonic stem cells)	NULL	HNF1B	NA	GTRD	EXP036713_HUES64--embryonic-stem-cells-_HNF1B_MACS_HNF1B_MA0153.2.damo.pwm.bed	659
1	2151	HNF4G	0	0	0	3835	3835	3835	3835	3840	0	204	207	HNF4G LNCaP (prostate carcinoma) HNF4G	LNCaP (prostate carcinoma)	BTO:0001321	HNF4G	Treatment: Cells were harvested in log phase growth Genotype: wildtype	GTRD	EXP048990_LNCaP--prostate-carcinoma-_HNF4G_MACS_HNF4G_MA0484.2.damo.pwm.bed	8
1	2162	HOXB13	0	0	0	3835	3835	3835	3835	3840	0	204	207	HOXB13 prostate tumor HOXB13	prostate tumor	NULL	HOXB13	Patient: #1	GTRD	EXP048490_prostate-tumor_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	509
1	2163	HOXB13	0	0	0	3835	3835	3835	3835	3840	1	204	206	HOXB13 prostate tumor HOXB13	prostate tumor	NULL	HOXB13	Patient: #2	GTRD	EXP048491_prostate-tumor_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	722
1	2164	HOXB13	0	0	0	3835	3835	3835	3835	3840	0	204	207	HOXB13 prostate tumor HOXB13	prostate tumor	NULL	HOXB13	Patient: #3	GTRD	EXP048492_prostate-tumor_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	223
1	2177	HSF1	0	0	0	3835	3835	3835	3835	3840	0	204	207	HSF1 WA09 (embryonic stem cells) HSF1	WA09 (embryonic stem cells)	NULL	HSF1	Treatment: under normal conditions	GTRD	EXP047922_WA09--embryonic-stem-cells-_HSF1_MACS_HSF1_MA0486.2.damo.pwm.bed	16
1	2196	HSF2	0	0	0	3835	3835	3835	3835	3840	1	204	206	HSF2 K562 (myelogenous leukemia) HSF2	K562 (myelogenous leukemia)	NULL	HSF2	30 min at 42C	GTRD	EXP030799_K562--myelogenous-leukemia-_HSF2_MACS_HSF2_MA0770.1.damo.pwm.bed	211
1	2199	IRF1	0	0	0	3835	3835	3835	3835	3840	0	204	207	IRF1 K562 (myelogenous leukemia) IRF1	K562 (myelogenous leukemia)	NULL	IRF1	30 m of Interferon alpha (Snyder)	ENCODE	ENCSR000EGU_K562_IRF1_MACS_IRF1_MA0050.2.damo.pwm.bed	470
1	2213	IRF4	0	0	0	3835	3835	3835	3835	3840	1	204	206	IRF4 OCI-LY3 (diffuse large B-cell lymphoma) IRF4	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	IRF4	SHCTR	GEO	GSE56857_irf4_ocily3-shctr_MACS_IRF4_MA1419.1.damo.pwm.bed	5190
1	2214	IRF4	0	0	0	3835	3835	3835	3835	3840	0	204	207	IRF4 OCI-LY3 (diffuse large B-cell lymphoma) IRF4	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	IRF4	SHSPIB	GEO	GSE56857_irf4_ocily3-shspib_MACS_IRF4_MA1419.1.damo.pwm.bed	487
1	2218	JUN	0	0	0	3835	3835	3835	3835	3840	3	204	204	JUN WA01 (H1, human embryonic stem cells) JUN	WA01 (H1, human embryonic stem cells)	NULL	JUN		ENCODE	ENCSR000ECA_H1-hESC_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	1510
1	2219	JUN	0	0	0	3835	3835	3835	3835	3840	3	204	204	JUN WA01 (H1, human embryonic stem cells) JUN	WA01 (H1, human embryonic stem cells)	NULL	JUN		ENCODE	ENCSR000ECA_H1-hESC_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	1427
1	2584	JUNB	0	0	0	3835	3835	3835	3835	3840	1	204	206	JUNB keratinocytes JUNB	keratinocytes	NULL	JUNB	neonatal	GEO	GSE63080_junb_neonatal-keratincoytes_MACS_JUNB_MA0490.2.damo.pwm.bed	74
1	2601	JUND	0	0	0	3835	3835	3835	3835	3840	2	204	205	JUND GM12878 (female B-cells lymphoblastoid cell line) JUND	GM12878 (female B-cells lymphoblastoid cell line)	NULL	JUND		ENCODE	ENCSR000EYV_GM12878_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	3410
1	2656	LEF1	0	0	0	3835	3835	3835	3835	3840	0	204	207	LEF1 HUES64 (embryonic stem cells) LEF1	HUES64 (embryonic stem cells)	NULL	LEF1		GTRD	EXP036720_HUES64--embryonic-stem-cells-_LEF1_MACS_LEF1_MA0768.1.damo.pwm.bed	1224
1	2658	LEF1	0	0	0	3835	3835	3835	3835	3840	0	204	207	LEF1 K562 (myelogenous leukemia) LEF1	K562 (myelogenous leukemia)	NULL	LEF1		GTRD	EXP039982_K562--myelogenous-leukemia-_LEF1_MACS_LEF1_MA0768.1.damo.pwm.bed	393
1	2659	LEF1	0	0	0	3835	3835	3835	3835	3840	0	204	207	LEF1 hESC-1 (Embryonic stem cells) LEF1	hESC-1 (Embryonic stem cells)	NULL	LEF1	WNT3A	GEO	GSE64758_lef1_esc-wnt3a_MACS_LEF1_MA0768.1.damo.pwm.bed	691
1	2660	LEF1	0	0	0	3835	3835	3835	3835	3840	0	204	207	LEF1 hESC-1 (Embryonic stem cells) LEF1	hESC-1 (Embryonic stem cells)	NULL	LEF1		GEO	GSE64758_lef1_esc_MACS_LEF1_MA0768.1.damo.pwm.bed	82
1	2667	MAF	0	0	0	3835	3835	3835	3835	3840	0	204	207	MAF Th17-cells MAF	Th17-cells	BTO:0005655	MAF	CellType:pool of expanded Th17 clones; Tissue: primary Th17-IL-10+ lymphocytes; ActivationState: resting;Day:0;	GTRD	EXP047560_Th17-cells_MAF_MACS_MAF_MA0501.1.damo.pwm.bed	1047
1	2730	MEF2B	0	0	0	3835	3835	3835	3835	3840	1	204	206	MEF2B SU-DHL-10 (diffuse large B-cell lymphoma) MEF2B	SU-DHL-10 (diffuse large B-cell lymphoma)	NULL	MEF2B	Genotype: MEF2B- D83V mutant with flag and HA	GTRD	EXP048302_SU-DHL-10--diffuse-large-B-cell-lymphoma-_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	1153
1	2733	MEF2B	0	0	0	3835	3835	3835	3835	3840	0	204	207	MEF2B HEK293-A MEF2B	HEK293-A	NULL	MEF2B	Genotype: K4E-MEF2B-V5;	GTRD	EXP055129_HEK293-A_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	69
1	2734	MEF2B	0	0	0	3835	3835	3835	3835	3840	0	204	207	MEF2B HEK293-A MEF2B	HEK293-A	NULL	MEF2B	Genotype: K4E-MEF2B-V5;	GTRD	EXP055130_HEK293-A_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	17
1	2736	MEF2B	0	0	0	3835	3835	3835	3835	3840	1	204	206	MEF2B HEK293-A MEF2B	HEK293-A	NULL	MEF2B	Genotype: D83V-MEF2B-V5;	GTRD	EXP055132_HEK293-A_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	473
1	2737	MEF2B	0	0	0	3835	3835	3835	3835	3840	2	204	205	MEF2B MEF2B	NA	NA	MEF2B	NA	GEO	GSE69558_mef2b_db_MACS_MEF2B_MA0660.1.damo.pwm.bed	1595
1	2739	MEF2B	0	0	0	3835	3835	3835	3835	3840	1	204	206	MEF2B KARPAS-422 (diffuse large B-cell lymphoma) MEF2B	KARPAS-422 (diffuse large B-cell lymphoma)	BTO:0004981	MEF2B		GEO	GSE69558_mef2b_karpas422_MACS_MEF2B_MA0660.1.damo.pwm.bed	2156
1	2740	MEF2B	0	0	0	3835	3835	3835	3835	3840	0	204	207	MEF2B OCI-LY7 (diffuse large B-cell lymphoma) MEF2B	OCI-LY7 (diffuse large B-cell lymphoma)	NULL	MEF2B		GEO	GSE69558_mef2b_ocily7_MACS_MEF2B_MA0660.1.damo.pwm.bed	349
1	2741	MEF2B	0	0	0	3835	3835	3835	3835	3840	1	204	206	MEF2B MEF2B	NA	NA	MEF2B	NA	GEO	GSE69558_mef2b_sudhl4_MACS_MEF2B_MA0660.1.damo.pwm.bed	2798
1	2743	MEF2C	0	0	0	3835	3835	3835	3835	3840	0	204	207	MEF2C HUVEC-C (HUVEC, umbilical vein endothelial cells) MEF2C	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	MEF2C	STATIN	GEO	GSE32644_mef2c_huvec-statin_MACS_MEF2C_MA0497.1.damo.pwm.bed	55
1	2744	MEF2C	0	0	0	3835	3835	3835	3835	3840	0	204	207	MEF2C HUVEC-C (HUVEC, umbilical vein endothelial cells) MEF2C	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	MEF2C		GEO	GSE32644_mef2c_huvec_MACS_MEF2C_MA0497.1.damo.pwm.bed	66
1	2748	MEIS1	0	0	0	3835	3835	3835	3835	3840	0	204	207	MEIS1 HSPC MEIS1	HSPC	NA	MEIS1	NA	GEO	GSE26014_meis1_hspc_MACS_MEIS1_MA0498.2.damo.pwm.bed	132
1	2760	MITF	0	0	0	3835	3835	3835	3835	3840	0	204	207	MITF 501Mel (melanoma) MITF	501Mel (melanoma)	BTO:0002956	MITF		GEO	GSE64137_mitf_501mel_MACS_MITF_MA0620.3.damo.pwm.bed	5
1	2777	MYB	0	0	0	3835	3835	3835	3835	3840	0	204	207	MYB MV-4-11 (Childhood acute monocytic leukemia) MYB	MV-4-11 (Childhood acute monocytic leukemia)	BTO:0004479	MYB	Treatment: none	GTRD	EXP049401_MV4-11--childhood-acute-monocytic-leukemia-_MYB_MACS_MYB_MA0100.3.damo.pwm.bed	214
1	2838	MYC	0	0	0	3835	3835	3835	3835	3840	1	204	206	MYC HEK293 (embryonic kidney) MYC	HEK293 (embryonic kidney)	NULL	MYC	WT-MYC expression	GTRD	EXP036690_HEK293--embryonic-kidney-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	219
1	2839	MYC	0	0	0	3835	3835	3835	3835	3840	0	204	207	MYC HEK293 (embryonic kidney) MYC	HEK293 (embryonic kidney)	NULL	MYC	WT-MYC expression	GTRD	EXP036690_HEK293--embryonic-kidney-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	182
1	2840	MYC	0	0	0	3835	3835	3835	3835	3840	0	204	207	MYC HEK293 (embryonic kidney) MYC	HEK293 (embryonic kidney)	NULL	MYC	WBM-MYC expressing	GTRD	EXP036691_HEK293--embryonic-kidney-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	71
1	2841	MYC	0	0	0	3835	3835	3835	3835	3840	0	204	207	MYC HEK293 (embryonic kidney) MYC	HEK293 (embryonic kidney)	NULL	MYC	WBM-MYC expressing	GTRD	EXP036691_HEK293--embryonic-kidney-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	97
1	2895	MYC	0	0	0	3835	3835	3835	3835	3840	5	204	202	MYC MRC-5 (fetal lung fibroblasts) MYC	MRC-5 (fetal lung fibroblasts)	BTO:0001590	MYC	Treatment: Oct4, Sox2, Klf4 and Myc addition for 5 days Passage: 8	GTRD	EXP048963_MRC-5--fetal-lung-fibroblasts-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	812
1	2896	MYC	0	0	0	3835	3835	3835	3835	3840	5	204	202	MYC MRC-5 (fetal lung fibroblasts) MYC	MRC-5 (fetal lung fibroblasts)	BTO:0001590	MYC	Treatment: Oct4, Sox2, Klf4 and Myc addition for 5 days Passage: 8	GTRD	EXP048963_MRC-5--fetal-lung-fibroblasts-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	951
1	2950	MYCN	0	0	0	3835	3835	3835	3835	3840	0	204	207	MYCN BE2C MYCN	BE2C	NULL	MYCN		GEO	GSE72640_mycn_be2c_MACS_MYCN_MA0104.4.damo.pwm.bed	144
1	2965	NEUROD1	0	0	0	3835	3835	3835	3835	3840	1	204	206	NEUROD1 NCI-H524 (small cell lung carcinoma) NEUROD1	NCI-H524 (small cell lung carcinoma)	BTO:0004825	NEUROD1		GEO	GSE69394_neurod1_h524_MACS_NEUROD1_MA1109.1.damo.pwm.bed	2260
1	2998	NFE2L2	0	0	0	3835	3835	3835	3835	3840	0	204	207	NFE2L2 lymphoblastoid cells NFE2L2	lymphoblastoid cells	NULL	NFE2L2	10 uM D,L-sulforaphane for 5 hours	GTRD	EXP031474_lymphoblastoid-cells_NFE2L2_MACS_NFE2L2_MA0150.2.damo.pwm.bed	196
1	2999	NFE2L2	0	0	0	3835	3835	3835	3835	3840	4	204	203	NFE2L2 HAEC (human aortic endothelial cells) NFE2L2	HAEC (human aortic endothelial cells)	NULL	NFE2L2	oxpapc, 4h	GTRD	EXP038047_HAEC--human-aortic-endothelial-cells-_NFE2L2_MACS_NFE2L2_MA0150.2.damo.pwm.bed	2664
1	3003	NFE2L2	0	0	0	3835	3835	3835	3835	3840	0	204	207	NFE2L2 BEAS-2B (bronchial epithelium) NFE2L2	BEAS-2B (bronchial epithelium)	NULL	NFE2L2	Treatment: D,L-sulforaphane (SFN) for 5 hr	GTRD	EXP048850_BEAS-2B--bronchial-epithelium-_NFE2L2_MACS_NFE2L2_MA0150.2.damo.pwm.bed	195
1	3004	NFE2L2	0	0	0	3835	3835	3835	3835	3840	1	204	206	NFE2L2 BEAS-2B (bronchial epithelium) NFE2L2	BEAS-2B (bronchial epithelium)	NULL	NFE2L2	Treatment: 0.1% (v/v) DMSO as vehicle for 5 hr	GTRD	EXP048851_BEAS-2B--bronchial-epithelium-_NFE2L2_MACS_NFE2L2_MA0150.2.damo.pwm.bed	310
1	3039	NKX3-1	0	0	0	3835	3835	3835	3835	3840	0	204	207	NKX3-1 LNCaP (prostate carcinoma) NKX3-1	LNCaP (prostate carcinoma)	BTO:0001321	NKX3-1	ETOH	GEO	GSE28264_nkx3-1_lncap-etoh_MACS_NKX3-1_MA0124.2.damo.pwm.bed	1728
1	3048	NR2C2	0	0	0	3835	3835	3835	3835	3840	0	204	207	NR2C2 GM12878 (female B-cells lymphoblastoid cell line) NR2C2	GM12878 (female B-cells lymphoblastoid cell line)	NULL	NR2C2		ENCODE	ENCSR000EUL_GM12878_NR2C2_MACS_NR2C2_MA0504.1.damo.pwm.bed	153
1	3049	NR2C2	0	0	0	3835	3835	3835	3835	3840	1	204	206	NR2C2 HeLa S3 (cervical adenocarcinoma) NR2C2	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	NR2C2		ENCODE	ENCSR000EVN_HeLa-S3_NR2C2_MACS_NR2C2_MA0504.1.damo.pwm.bed	963
1	3051	NR2C2	0	0	0	3835	3835	3835	3835	3840	1	204	206	NR2C2 K562 (myelogenous leukemia) NR2C2	K562 (myelogenous leukemia)	NULL	NR2C2		ENCODE	ENCSR000EWH_K562_NR2C2_MACS_NR2C2_MA0504.1.damo.pwm.bed	309
1	3057	NR2C2	0	0	0	3835	3835	3835	3835	3840	0	204	207	NR2C2 erythroid cells NR2C2	erythroid cells	NULL	NR2C2	D8	GEO	GSE54759_NR2C2_erythroid-d8_MACS_NR2C2_MA0504.1.damo.pwm.bed	117
1	3101	NR3C1	0	0	0	3835	3835	3835	3835	3840	0	204	207	NR3C1 monocyte-derived macrophages NR3C1	monocyte-derived macrophages	NULL	NR3C1		GTRD	EXP034069_monocyte-derived-macrophages_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	188
1	3108	NR3C1	0	0	0	3835	3835	3835	3835	3840	0	204	207	NR3C1 HepG2 (hepatoblastoma) NR3C1	HepG2 (hepatoblastoma)	BTO:0000599	NR3C1		GTRD	EXP037679_HepG2--hepatoblastoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	523
1	3116	NR3C1	0	0	0	3835	3835	3835	3835	3840	0	204	207	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039836_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	845
1	3123	NR3C1	0	0	0	3835	3835	3835	3835	3840	0	204	207	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1		GTRD	EXP040297_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	16
1	3159	NR3C1	0	0	0	3835	3835	3835	3835	3840	0	204	207	NR3C1 RS4-11 (adult B acute lymphoblastic leukemia) NR3C1	RS4-11 (adult B acute lymphoblastic leukemia)	BTO:0004505	NR3C1	DEX	GEO	GSE71616_nr3c1_rsa411-dex_MACS_NR3C1_MA0113.3.damo.pwm.bed	879
1	3161	NR3C1	0	0	0	3835	3835	3835	3835	3840	0	204	207	NR3C1 T47D (invasive ductal carcinoma) NR3C1	T47D (invasive ductal carcinoma)	BTO:0001248	NR3C1	DEX	GEO	GSE72249_nr3c1_t47d-dex_MACS_NR3C1_MA0113.3.damo.pwm.bed	265
1	3164	NR5A1	0	0	0	3835	3835	3835	3835	3840	0	204	207	NR5A1 H295R (adrenal cortex carcinoma) NR5A1	H295R (adrenal cortex carcinoma)	BTO:0002588	NR5A1		GTRD	EXP031924_H295R--adrenal-cortex-carcinoma-_NR5A1_MACS_NR5A1_MA1540.1.damo.pwm.bed	30
1	3165	NR5A1	0	0	0	3835	3835	3835	3835	3840	0	204	207	NR5A1 H295R (adrenal cortex carcinoma) NR5A1	H295R (adrenal cortex carcinoma)	BTO:0002588	NR5A1	overexpressed SF-1	GTRD	EXP031925_H295R--adrenal-cortex-carcinoma-_NR5A1_MACS_NR5A1_MA1540.1.damo.pwm.bed	170
1	3166	NR5A1	0	0	0	3835	3835	3835	3835	3840	1	204	206	NR5A1 H295R (adrenal cortex carcinoma) NR5A1	H295R (adrenal cortex carcinoma)	BTO:0002588	NR5A1		GTRD	EXP031926_H295R--adrenal-cortex-carcinoma-_NR5A1_MACS_NR5A1_MA1540.1.damo.pwm.bed	47
1	3187	OCT4	0	0	0	3835	3835	3835	3835	3840	0	204	207	OCT4 OCT4	NA	NA	OCT4	NA	GEO	GSE17917_oct4_esc_MACS_OCT4_MA0142.1.damo.pwm.bed	10
1	3188	OCT4	0	0	0	3835	3835	3835	3835	3840	0	204	207	OCT4 OCT4	NA	NA	OCT4	NA	GEO	GSE20650_oct4_esc_MACS_OCT4_MA0142.1.damo.pwm.bed	125
1	3228	PDX1	0	0	0	3835	3835	3835	3835	3840	1	204	206	PDX1 H9 PDX1	H9	NULL	PDX1		Array Express	ERP004206_pdx1_esc-h9_MACS_PDX1_MA0132.2.damo.pwm.bed	2003
1	3242	POU2F1	0	0	0	3835	3835	3835	3835	3840	0	204	207	POU2F1 HCT-116 (colon carcinoma) POU2F1	HCT-116 (colon carcinoma)	BTO:0001109	POU2F1		GTRD	EXP058390_HCT-116--colon-carcinoma-_POU2F1_MACS_POU2F1_MA0785.1.damo.pwm.bed	20
1	3247	POU5F1	0	0	0	3835	3835	3835	3835	3840	3	204	204	POU5F1 POU5F1	NA	NA	POU5F1	NA	NA	ENCSR264RJX_induced_pluripotent_stem_cell_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	7664
1	3248	POU5F1	0	0	0	3835	3835	3835	3835	3840	1	204	206	POU5F1 WA09 (embryonic stem cells) POU5F1	WA09 (embryonic stem cells)	NULL	POU5F1	NULL	GTRD	EXP000209_WA09--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	2929
1	3249	POU5F1	0	0	0	3835	3835	3835	3835	3840	2	204	205	POU5F1 WA09 (embryonic stem cells) POU5F1	WA09 (embryonic stem cells)	NULL	POU5F1	NULL	GTRD	EXP000209_WA09--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	3311
1	3256	POU5F1	0	0	0	3835	3835	3835	3835	3840	0	204	207	POU5F1 WA09 (embryonic stem cells) POU5F1	WA09 (embryonic stem cells)	NULL	POU5F1		GTRD	EXP038693_WA09--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	1057
1	3257	POU5F1	0	0	0	3835	3835	3835	3835	3840	0	204	207	POU5F1 WA09 (embryonic stem cells) POU5F1	WA09 (embryonic stem cells)	NULL	POU5F1		GTRD	EXP038693_WA09--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	956
1	3258	POU5F1	0	0	0	3835	3835	3835	3835	3840	0	204	207	POU5F1 WA09 (embryonic stem cells) POU5F1	WA09 (embryonic stem cells)	NULL	POU5F1		GTRD	EXP038694_WA09--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	3271
1	3259	POU5F1	0	0	0	3835	3835	3835	3835	3840	1	204	206	POU5F1 WA09 (embryonic stem cells) POU5F1	WA09 (embryonic stem cells)	NULL	POU5F1		GTRD	EXP038694_WA09--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	3363
1	3267	POU5F1	0	0	0	3835	3835	3835	3835	3840	0	204	207	POU5F1 MRC-5 (fetal lung fibroblasts) POU5F1	MRC-5 (fetal lung fibroblasts)	BTO:0001590	POU5F1	Treatment: Oct4, Sox2-VP16 (strong activator) and Klf4 addition for 5 days Passage: 8	GTRD	EXP048945_MRC-5--fetal-lung-fibroblasts-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	1724
1	3268	POU5F1	0	0	0	3835	3835	3835	3835	3840	0	204	207	POU5F1 MRC-5 (fetal lung fibroblasts) POU5F1	MRC-5 (fetal lung fibroblasts)	BTO:0001590	POU5F1	Treatment: Oct4, Sox2-VP16 (strong activator) and Klf4 addition for 5 days Passage: 8	GTRD	EXP048945_MRC-5--fetal-lung-fibroblasts-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	1712
1	3271	POU5F1	0	0	0	3835	3835	3835	3835	3840	2	204	205	POU5F1 MRC-5 (fetal lung fibroblasts) POU5F1	MRC-5 (fetal lung fibroblasts)	BTO:0001590	POU5F1	Treatment: Oct4, Sox2-VP16 (strong activator), Klf4 and Myc addition for 5 days Passage: 8	GTRD	EXP048952_MRC-5--fetal-lung-fibroblasts-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	2979
1	3274	POU5F1	0	0	0	3835	3835	3835	3835	3840	2	204	205	POU5F1 iPSC (induced pluripotent stem cells) POU5F1	iPSC (induced pluripotent stem cells)	NULL	POU5F1	Treatment: iPS protocol 3s2 Passage: 20	GTRD	EXP048953_iPSC--induced-pluripotent-stem-cells-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	6443
1	3278	POU5F1	0	0	0	3835	3835	3835	3835	3840	1	204	206	POU5F1 NCCIT (testicular embryonic carcinoma) POU5F1	NCCIT (testicular embryonic carcinoma)	BTO:0004180	POU5F1		GEO	GSE36134_pou5f1_nccit_MACS_POU5F1_MA1115.1.damo.pwm.bed	3849
1	3282	PPARG	0	0	0	3835	3835	3835	3835	3840	0	204	207	PPARG macrophages PPARG	macrophages	NULL	PPARG		Array Express	ERP008801_pparg_macrophage_MACS_PPARG_MA0066.1.damo.pwm.bed	253
1	3318	RARG	0	0	0	3835	3835	3835	3835	3840	0	204	207	RARG RWPE1 (prostate epithelial cells) RARG	RWPE1 (prostate epithelial cells)	BTO:0003709	RARG	Treatment: 10 uM CD437 for 2 hr Gender: male Source: non-malignant prostate cell line infected with BAC-RARG-EGFP	GTRD	EXP048632_RWPE1--prostate-epithelial-cells-_RARG_MACS_RARG_MA0860.1.damo.pwm.bed	1140
1	3323	RBPJ	0	0	0	3835	3835	3835	3835	3840	1	204	206	RBPJ REC-1 (Mantle cell lymphoma) RBPJ	REC-1 (Mantle cell lymphoma)	BTO:0003558	RBPJ	Treatment: untreated	GTRD	EXP049777_REC-1--Mantle-cell-lymphoma-_RBPJ_MACS_RBPJ_MA1116.1.damo.pwm.bed	1135
1	3324	RBPJ	0	0	0	3835	3835	3835	3835	3840	0	204	207	RBPJ SP-49 (Mantle cell lymphoma) RBPJ	SP-49 (Mantle cell lymphoma)	NULL	RBPJ	Treatment: untreated	GTRD	EXP049779_SP-49--Mantle-cell-lymphoma-_RBPJ_MACS_RBPJ_MA1116.1.damo.pwm.bed	377
1	3377	RELA	0	0	0	3835	3835	3835	3835	3840	2	204	205	RELA IMR90 (lung fibroblasts) RELA	IMR90 (lung fibroblasts)	NULL	RELA		GEO	GSE43070_rela_imr90_MACS_RELA_MA0107.1.damo.pwm.bed	497
1	3383	RELA	0	0	0	3835	3835	3835	3835	3840	2	204	205	RELA L1236 (Hodgkin lymphoma) RELA	L1236 (Hodgkin lymphoma)	NULL	RELA		GEO	GSE63736_rela_l1236_MACS_RELA_MA0107.1.damo.pwm.bed	405
1	3405	REST	0	0	0	3835	3835	3835	3835	3840	2	204	205	REST PANC1 (pancreatic ductal adenocarcinoma) REST	PANC1 (pancreatic ductal adenocarcinoma)	NULL	REST		ENCODE	ENCSR000BUP_Panc1_REST_MACS_REST_MA0138.2.damo.pwm.bed	4192
1	3408	REST	0	0	0	3835	3835	3835	3835	3840	0	204	207	REST hepatocytes REST	hepatocytes	NULL	REST		Array Express	ERP000395_rest_hepatocytes_MACS_REST_MA0138.2.damo.pwm.bed	860
1	3409	REST	0	0	0	3835	3835	3835	3835	3840	3	204	204	REST U87 (glioblastoma) REST	U87 (glioblastoma)	NULL	REST	None	GTRD	EXP010296_U87--glioblastoma-_REST_MACS_REST_MA0138.2.damo.pwm.bed	3445
1	3419	REST	0	0	0	3835	3835	3835	3835	3840	3	204	204	REST WA01 (H1, human embryonic stem cells) REST	WA01 (H1, human embryonic stem cells)	NULL	REST		GTRD	EXP039423_WA01--H1--human-embryonic-stem-cells-_REST_MACS_REST_MA0138.2.damo.pwm.bed	2516
1	3431	REST	0	0	0	3835	3835	3835	3835	3840	0	204	207	REST H295R (adrenal cortex carcinoma) REST	H295R (adrenal cortex carcinoma)	BTO:0002588	REST	SF1	GEO	GSE49014_rest_ncih295r-sf1_MACS_REST_MA0138.2.damo.pwm.bed	1687
1	3432	REST	0	0	0	3835	3835	3835	3835	3840	0	204	207	REST H295R (adrenal cortex carcinoma) REST	H295R (adrenal cortex carcinoma)	BTO:0002588	REST		GEO	GSE49014_rest_ncih295r_MACS_REST_MA0138.2.damo.pwm.bed	1637
1	3434	REST	0	0	0	3835	3835	3835	3835	3840	1	204	206	REST GP5d (colon adenocarcinoma) REST	GP5d (colon adenocarcinoma)	NULL	REST	SIRAD21	GEO	GSE51234_rest_gp5d-sirad21_MACS_REST_MA0138.2.damo.pwm.bed	1827
1	3435	REST	0	0	0	3835	3835	3835	3835	3840	0	204	207	REST GP5d (colon adenocarcinoma) REST	GP5d (colon adenocarcinoma)	NULL	REST		GEO	GSE51234_rest_gp5d_MACS_REST_MA0138.2.damo.pwm.bed	1725
1	3442	RFX2	0	0	0	3835	3835	3835	3835	3840	0	204	207	RFX2 GP5d (colon adenocarcinoma) RFX2	GP5d (colon adenocarcinoma)	NULL	RFX2	NA	GEO	GSE51234_rfx2_gp5d_MACS_RFX2_MA0600.2.damo.pwm.bed	246
1	3457	RUNX1	0	0	0	3835	3835	3835	3835	3840	0	204	207	RUNX1 Kasumi-1 (acute myeloblastic leukemia) RUNX1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	RUNX1		GTRD	EXP030418_Kasumi-1--acute-myeloblastic-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	687
1	3469	RUNX1	0	0	0	3835	3835	3835	3835	3840	1	204	206	RUNX1 peripheral blood mononuclear cells RUNX1	peripheral blood mononuclear cells	BTO:0001025	RUNX1		GTRD	EXP037690_peripheral-blood-mononuclear-cells_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	307
1	3482	RUNX1	0	0	0	3835	3835	3835	3835	3840	1	204	206	RUNX1 TF-1 (erythroleukemia) RUNX1	TF-1 (erythroleukemia)	BTO:0004760	RUNX1	Genotype: TF-1-RAD21 Q592*; Treatment: DOX for 6 days;	GTRD	EXP055352_TF-1--erythroleukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	1827
1	3497	RUNX1	0	0	0	3835	3835	3835	3835	3840	1	204	206	RUNX1 RUNX1	NA	NA	RUNX1	NA	GEO	GSE65313_runx1_mcf7_MACS_RUNX1_MA0002.2.damo.pwm.bed	894
1	3503	RUNX1	0	0	0	3835	3835	3835	3835	3840	0	204	207	RUNX1 MCF7 (Invasive ductal breast carcinoma) RUNX1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RUNX1		GEO	GSE75070_runx1_mcf7_MACS_RUNX1_MA0002.2.damo.pwm.bed	21
1	3513	RXRA	0	0	0	3835	3835	3835	3835	3840	0	204	207	RXRA NB4 (acute promyelocytic leukemia ) RXRA	NB4 (acute promyelocytic leukemia )	NULL	RXRA		GTRD	EXP000741_NB4--acute-promyelocytic-leukemia--_RXRA_MACS_RXRA_MA0074.1.damo.pwm.bed	108
1	3514	RXRA	0	0	0	3835	3835	3835	3835	3840	1	204	206	RXRA NB4 (acute promyelocytic leukemia ) RXRA	NB4 (acute promyelocytic leukemia )	NULL	RXRA		GTRD	EXP000741_NB4--acute-promyelocytic-leukemia--_RXRA_MACS_RXRA_MA0159.1.damo.pwm.bed	122
1	3515	RXRA	0	0	0	3835	3835	3835	3835	3840	1	204	206	RXRA NB4 (acute promyelocytic leukemia ) RXRA	NB4 (acute promyelocytic leukemia )	NULL	RXRA		GTRD	EXP000741_NB4--acute-promyelocytic-leukemia--_RXRA_MACS_RXRA_MA0494.1.damo.pwm.bed	153
1	3516	RXRA	0	0	0	3835	3835	3835	3835	3840	0	204	207	RXRA NB4 (acute promyelocytic leukemia ) RXRA	NB4 (acute promyelocytic leukemia )	NULL	RXRA		GTRD	EXP000741_NB4--acute-promyelocytic-leukemia--_RXRA_MACS_RXRA_MA1146.1.damo.pwm.bed	88
1	3517	RXRA	0	0	0	3835	3835	3835	3835	3840	0	204	207	RXRA NB4 (acute promyelocytic leukemia ) RXRA	NB4 (acute promyelocytic leukemia )	NULL	RXRA		GTRD	EXP000741_NB4--acute-promyelocytic-leukemia--_RXRA_MACS_RXRA_MA1147.1.damo.pwm.bed	142
1	3557	SIX1	0	0	0	3835	3835	3835	3835	3840	0	204	207	SIX1 SIX1	NA	NA	SIX1	NA	GEO	GSE75948_six1_fetal-kidney-16w_MACS_SIX1_MA1118.1.damo.pwm.bed	1211
1	3584	SNAI2	0	0	0	3835	3835	3835	3835	3840	1	204	206	SNAI2 keratinocytes SNAI2	keratinocytes	NULL	SNAI2	SHSNAI2	GEO	GSE55421_snai2_keratinocytes-shsnai2_MACS_SNAI2_MA0745.2.damo.pwm.bed	441
1	3597	SOX2	0	0	0	3835	3835	3835	3835	3840	0	204	207	SOX2 HUES64 (embryonic stem cells) SOX2	HUES64 (embryonic stem cells)	NULL	SOX2		GTRD	EXP036753_HUES64--embryonic-stem-cells-_SOX2_MACS_SOX2_MA0142.1.damo.pwm.bed	5679
1	3598	SOX2	0	0	0	3835	3835	3835	3835	3840	2	204	205	SOX2 HUES64 (embryonic stem cells) SOX2	HUES64 (embryonic stem cells)	NULL	SOX2		GTRD	EXP036753_HUES64--embryonic-stem-cells-_SOX2_MACS_SOX2_MA0143.4.damo.pwm.bed	5152
1	3599	SOX2	0	0	0	3835	3835	3835	3835	3840	2	204	205	SOX2 HUES64 (embryonic stem cells) SOX2	HUES64 (embryonic stem cells)	NULL	SOX2		GTRD	EXP036809_HUES64--embryonic-stem-cells-_SOX2_MACS_SOX2_MA0142.1.damo.pwm.bed	8414
1	3601	SOX2	0	0	0	3835	3835	3835	3835	3840	0	204	207	SOX2 MRC-5 (fetal lung fibroblasts) SOX2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	SOX2	Treatment: Oct4, Sox2 and Klf4 addition for 5 days Passage: 8	GTRD	EXP048946_MRC-5--fetal-lung-fibroblasts-_SOX2_MACS_SOX2_MA0142.1.damo.pwm.bed	2800
1	3602	SOX2	0	0	0	3835	3835	3835	3835	3840	0	204	207	SOX2 MRC-5 (fetal lung fibroblasts) SOX2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	SOX2	Treatment: Oct4, Sox2-VP16 (strong activator) and Klf4 addition for 5 days Passage: 8	GTRD	EXP048947_MRC-5--fetal-lung-fibroblasts-_SOX2_MACS_SOX2_MA0142.1.damo.pwm.bed	1263
1	3603	SOX2	0	0	0	3835	3835	3835	3835	3840	2	204	205	SOX2 MRC-5 (fetal lung fibroblasts) SOX2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	SOX2	Treatment: Oct4, Sox2, Klf4 and Myc addition for 5 days Passage: 8	GTRD	EXP048955_MRC-5--fetal-lung-fibroblasts-_SOX2_MACS_SOX2_MA0142.1.damo.pwm.bed	5225
1	3604	SOX2	0	0	0	3835	3835	3835	3835	3840	2	204	205	SOX2 MRC-5 (fetal lung fibroblasts) SOX2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	SOX2	Treatment: Oct4, Sox2, Klf4 and Myc addition for 5 days Passage: 8	GTRD	EXP048955_MRC-5--fetal-lung-fibroblasts-_SOX2_MACS_SOX2_MA0143.4.damo.pwm.bed	5471
1	3605	SOX2	0	0	0	3835	3835	3835	3835	3840	1	204	206	SOX2 MRC-5 (fetal lung fibroblasts) SOX2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	SOX2	Treatment: Oct4, Sox2-VP16 (strong activator), Klf4 and Myc addition for 5 days Passage: 8	GTRD	EXP048956_MRC-5--fetal-lung-fibroblasts-_SOX2_MACS_SOX2_MA0142.1.damo.pwm.bed	1018
1	3606	SOX2	0	0	0	3835	3835	3835	3835	3840	0	204	207	SOX2 MRC-5 (fetal lung fibroblasts) SOX2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	SOX2	Treatment: Oct4, Sox2-VP16 (strong activator), Klf4 and Myc addition for 5 days Passage: 8	GTRD	EXP048956_MRC-5--fetal-lung-fibroblasts-_SOX2_MACS_SOX2_MA0143.4.damo.pwm.bed	675
1	3607	SOX2	0	0	0	3835	3835	3835	3835	3840	0	204	207	SOX2 iPS (derived pancreatic precursor cells) SOX2	iPS (derived pancreatic precursor cells)	NULL	SOX2	Treatment: iPS protocol 3s2 Passage: 20	GTRD	EXP048957_iPS--derived-pancreatic-precursor-cells-_SOX2_MACS_SOX2_MA0142.1.damo.pwm.bed	2441
1	3608	SOX2	0	0	0	3835	3835	3835	3835	3840	0	204	207	SOX2 iPS (derived pancreatic precursor cells) SOX2	iPS (derived pancreatic precursor cells)	NULL	SOX2	Treatment: iPS protocol 3s2 Passage: 20	GTRD	EXP048957_iPS--derived-pancreatic-precursor-cells-_SOX2_MACS_SOX2_MA0143.4.damo.pwm.bed	2088
1	3619	SOX2	0	0	0	3835	3835	3835	3835	3840	0	204	207	SOX2 hESC-1 (Embryonic stem cells) SOX2	hESC-1 (Embryonic stem cells)	NULL	SOX2		GEO	GSE69479_sox2_esc_MACS_SOX2_MA0143.4.damo.pwm.bed	1707
1	3623	SOX9	0	0	0	3835	3835	3835	3835	3840	0	204	207	SOX9 hES-PRE SOX9	hES-PRE	NULL	SOX9	CellType: ES-derived RPE cells	GTRD	EXP048488_hES-PRE_SOX9_MACS_SOX9_MA0077.1.damo.pwm.bed	19
1	3674	SPI1	0	0	0	3835	3835	3835	3835	3840	1	204	206	SPI1 OCI-LY3 (diffuse large B-cell lymphoma) SPI1	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	SPI1	SHCTR	GEO	GSE56857_spi1_ocily3-shctr_MACS_SPI1_MA0080.5.damo.pwm.bed	2094
1	3675	SPI1	0	0	0	3835	3835	3835	3835	3840	0	204	207	SPI1 OCI-LY3 (diffuse large B-cell lymphoma) SPI1	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	SPI1	SHSPIB	GEO	GSE56857_spi1_ocily3-shspib_MACS_SPI1_MA0080.5.damo.pwm.bed	436
1	3676	SPI1	0	0	0	3835	3835	3835	3835	3840	3	204	204	SPI1 OCI-LY3 (diffuse large B-cell lymphoma) SPI1	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	SPI1		GEO	GSE56857_spi1_ocily3_MACS_SPI1_MA0080.5.damo.pwm.bed	2560
1	3695	SPIB	0	0	0	3835	3835	3835	3835	3840	0	204	207	SPIB OCI-LY3 (diffuse large B-cell lymphoma) SPIB	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	SPIB	SHSPIB	GEO	GSE56857_spib_ocily3-shspib_MACS_SPIB_MA0081.2.damo.pwm.bed	1930
1	3699	SREBF1	0	0	0	3835	3835	3835	3835	3840	0	204	207	SREBF1 HepG2 (hepatoblastoma) SREBF1	HepG2 (hepatoblastoma)	BTO:0000599	SREBF1	For sterol deprivation, cells were cultured with pravastatin (2 uM, Sigma) in DMEM with 0.5% BSA for 16 h. (Snyder)	ENCODE	ENCSR000EZP_HepG2_SREBF1_MACS_SREBF1_MA0829.2.damo.pwm.bed	79
1	3721	STAT1	0	0	0	3835	3835	3835	3835	3840	3	204	204	STAT1 K562 (myelogenous leukemia) STAT1	K562 (myelogenous leukemia)	NULL	STAT1	Interferon gamma treatment - 30 minutes (Snyder)	ENCODE	ENCSR000EHK_K562_STAT1_MACS_STAT1_MA0137.3.damo.pwm.bed	1039
1	3722	STAT1	0	0	0	3835	3835	3835	3835	3840	0	204	207	STAT1 K562 (myelogenous leukemia) STAT1	K562 (myelogenous leukemia)	NULL	STAT1	Interferon alpha treatment - 6 hours (Snyder)	ENCODE	ENCSR000FAU_K562_STAT1_MACS_STAT1_MA0137.3.damo.pwm.bed	484
1	3729	STAT2	0	0	0	3835	3835	3835	3835	3840	2	204	205	STAT2 K562 (myelogenous leukemia) STAT2	K562 (myelogenous leukemia)	NULL	STAT2	Interferon alpha treatment - 6 hours (Snyder)	ENCODE	ENCSR000FBC_K562_STAT2_MACS_STAT2_MA0517.1.damo.pwm.bed	1214
1	3747	STAT3	0	0	0	3835	3835	3835	3835	3840	1	204	206	STAT3 U2932 (diffuse large B-cell lymphoma) STAT3	U2932 (diffuse large B-cell lymphoma)	NULL	STAT3		GEO	GSE50723_stat3_u2932_MACS_STAT3_MA0144.2.damo.pwm.bed	397
1	3751	STAT5A	0	0	0	3835	3835	3835	3835	3840	4	204	203	STAT5A CD4+ CD25+ CD45RA+ T-cells STAT5A	CD4+ CD25+ CD45RA+ T-cells	NULL	STAT5A		GTRD	EXP032561_CD4--CD25--CD45RA--T-cells_STAT5A_MACS_STAT5A_MA0519.1.damo.pwm.bed	1015
1	3766	TAL1	0	0	0	3835	3835	3835	3835	3840	1	204	206	TAL1 Jurkat (T-cells) TAL1	Jurkat (T-cells)	BTO:0000661	TAL1	NA	GEO	GSE29180_tal1_jurkat_MACS_TAL1_MA0091.1.damo.pwm.bed	2557
1	3784	TCF12	0	0	0	3835	3835	3835	3835	3840	0	204	207	TCF12 Jurkat (T-cells) TCF12	Jurkat (T-cells)	BTO:0000661	TCF12	NA	GEO	GSE29180_tcf12_jurkat_MACS_TCF12_MA0521.1.damo.pwm.bed	1286
1	3785	TCF12	0	0	0	3835	3835	3835	3835	3840	1	204	206	TCF12 CCRF-CEM (T acute lymphoblastic leukemia) TCF12	CCRF-CEM (T acute lymphoblastic leukemia)	BTO:0000736	TCF12	NA	GEO	GSE33850_tcf12_ccrfcem_MACS_TCF12_MA0521.1.damo.pwm.bed	389
1	3790	TCF3	0	0	0	3835	3835	3835	3835	3840	0	204	207	TCF3 RPMI-8402 (T acute lymphoblastic leukemia) TCF3	RPMI-8402 (T acute lymphoblastic leukemia)	BTO:0001880	TCF3		GEO	GSE39179_tcf3_rpmi8402_MACS_TCF3_MA0522.3.damo.pwm.bed	799
1	3805	TCF7	0	0	0	3835	3835	3835	3835	3840	0	204	207	TCF7 DLD-1 (colon adenocarcinoma) TCF7	DLD-1 (colon adenocarcinoma)	BTO:0000391	TCF7	1 ug/mL Doxycycline	GTRD	EXP033183_DLD-1--colon-adenocarcinoma-_TCF7_MACS_TCF7_MA0769.2.damo.pwm.bed	15
1	3812	TCF7L2	0	0	0	3835	3835	3835	3835	3840	1	204	206	TCF7L2 HepG2 (hepatoblastoma) TCF7L2	HepG2 (hepatoblastoma)	BTO:0000599	TCF7L2		ENCODE	ENCSR000EVQ_HepG2_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	1381
1	3830	TEAD1	0	0	0	3835	3835	3835	3835	3840	0	204	207	TEAD1 hFOB 1.19 (fetal osteoblast) TEAD1	hFOB 1.19 (fetal osteoblast)	BTO:0005224	TEAD1	DIFF	GEO	GSE82295_tead1_hfob-diff_MACS_TEAD1_MA0090.3.damo.pwm.bed	439
1	3856	TFAP2A	0	0	0	3835	3835	3835	3835	3840	0	204	207	TFAP2A WA09 (embryonic stem cells) TFAP2A	WA09 (embryonic stem cells)	NULL	TFAP2A	BMP4 for 3 day	GTRD	EXP040708_WA09--embryonic-stem-cells-_TFAP2A_MACS_TFAP2A_MA0003.4.damo.pwm.bed	353
1	3857	TFAP2A	0	0	0	3835	3835	3835	3835	3840	0	204	207	TFAP2A WA09 (embryonic stem cells) TFAP2A	WA09 (embryonic stem cells)	NULL	TFAP2A	BMP4 for 3 day	GTRD	EXP040708_WA09--embryonic-stem-cells-_TFAP2A_MACS_TFAP2A_MA0810.1.damo.pwm.bed	387
1	3858	TFAP2A	0	0	0	3835	3835	3835	3835	3840	0	204	207	TFAP2A WA09 (embryonic stem cells) TFAP2A	WA09 (embryonic stem cells)	NULL	TFAP2A	BMP4 for 3 day	GTRD	EXP040708_WA09--embryonic-stem-cells-_TFAP2A_MACS_TFAP2A_MA0872.1.damo.pwm.bed	495
1	3862	TFAP2A	0	0	0	3835	3835	3835	3835	3840	0	204	207	TFAP2A WA09 (embryonic stem cells) TFAP2A	WA09 (embryonic stem cells)	NULL	TFAP2A	BMP4 for 3 day	GTRD	EXP040710_WA09--embryonic-stem-cells-_TFAP2A_MACS_TFAP2A_MA0810.1.damo.pwm.bed	48
1	3863	TFAP2A	0	0	0	3835	3835	3835	3835	3840	0	204	207	TFAP2A WA09 (embryonic stem cells) TFAP2A	WA09 (embryonic stem cells)	NULL	TFAP2A	BMP4 for 3 day	GTRD	EXP040710_WA09--embryonic-stem-cells-_TFAP2A_MACS_TFAP2A_MA0872.1.damo.pwm.bed	124
1	3875	TFAP2C	0	0	0	3835	3835	3835	3835	3840	0	204	207	TFAP2C WA09 (embryonic stem cells) TFAP2C	WA09 (embryonic stem cells)	NULL	TFAP2C	BMP4 for 3 day	GTRD	EXP040711_WA09--embryonic-stem-cells-_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	6
1	3951	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	UV_16H	Array Express	ERP004176_tp53_u2os-uv-16h_MACS_TP53_MA0106.3.damo.pwm.bed	1275
1	3952	TP53	0	0	0	3835	3835	3835	3835	3840	4	204	203	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	UV_8H	Array Express	ERP004176_tp53_u2os-uv-8h_MACS_TP53_MA0106.3.damo.pwm.bed	1505
1	3953	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 BC3 TP53	BC3	NA	TP53	NUT	Array Express	ERP014035_tp53_bc3-nut_MACS_TP53_MA0106.3.damo.pwm.bed	462
1	3955	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 lymphoblastoid cells TP53	lymphoblastoid cells	NULL	TP53	ionizing radiation	GTRD	EXP030855_lymphoblastoid-cells_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	509
1	3956	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 BJ (fibroblasts) TP53	BJ (fibroblasts)	NULL	TP53	none	GTRD	EXP032953_BJ--fibroblasts-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	480
1	3958	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	irradiation 0h	GTRD	EXP036824_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	566
1	3959	TP53	0	0	0	3835	3835	3835	3835	3840	4	204	203	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	irradiation 1h	GTRD	EXP036825_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	4156
1	3961	TP53	0	0	0	3835	3835	3835	3835	3840	4	204	203	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	irradiation 4h	GTRD	EXP036827_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	3393
1	3962	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	irradiation 5h	GTRD	EXP036828_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	1991
1	3963	TP53	0	0	0	3835	3835	3835	3835	3840	1	204	206	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	irradiation 7.5h	GTRD	EXP036829_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	3579
1	3966	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	untreated	GTRD	EXP036873_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	165
1	3967	TP53	0	0	0	3835	3835	3835	3835	3840	3	204	204	TP53 MCF-7 C4-12 (invasive breast ductal carcinoma) TP53	MCF-7 C4-12 (invasive breast ductal carcinoma)	NULL	TP53	400 ng/mL neocarzinostatin for 3 h	GTRD	EXP036874_MCF-7-C4-12--invasive-breast-ductal-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	2695
1	3968	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	untreated	GTRD	EXP036875_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	136
1	3969	TP53	0	0	0	3835	3835	3835	3835	3840	1	204	206	TP53 HCT-116 (colon carcinoma) TP53	HCT-116 (colon carcinoma)	BTO:0001109	TP53	DMSO	GTRD	EXP037746_HCT-116--colon-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	1588
1	3971	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	DMSO	GTRD	EXP037748_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	417
1	3973	TP53	0	0	0	3835	3835	3835	3835	3840	2	204	205	TP53 SJSA-1(osteosarcoma) TP53	SJSA-1(osteosarcoma)	BTO:0004216	TP53	DMSO	GTRD	EXP037750_SJSA-1-osteosarcoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	2229
1	3975	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	Treatment: 4GY for 2hrs;	GTRD	EXP047456_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	383
1	3977	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	Treatment: Decitabine;	GTRD	EXP047474_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	922
1	3982	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 PHA-simulated human T-lynphocytes TP53	PHA-simulated human T-lynphocytes	NULL	TP53	Treatment: 0.3 ug/ml Doxorubicin for 24 hrs Source: healthy volunteer #104	GTRD	EXP048273_PHA-simulated-human-T-lynphocytes_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	212
1	3985	TP53	0	0	0	3835	3835	3835	3835	3840	2	204	205	TP53 PHA-simulated human T-lynphocytes TP53	PHA-simulated human T-lynphocytes	NULL	TP53	Treatment: 0.3 ug/ml Doxorubicin for 24 hrs Source: healthy volunteer #116	GTRD	EXP048276_PHA-simulated-human-T-lynphocytes_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	3168
1	3988	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 LOXIMVI TP53	LOXIMVI	NULL	TP53	Treatment: 4GY for 2hrs;	GTRD	EXP051014_LOXIMVI_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	1322
1	3994	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 UACC62 TP53	UACC62	BTO:0004152	TP53	Treatment: 4GY for 2hrs;	GTRD	EXP051023_UACC62_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	333
1	3995	TP53	0	0	0	3835	3835	3835	3835	3840	1	204	206	TP53 UACC257 TP53	UACC257	BTO:0004233	TP53	Treatment: 4GY for 2hrs;	GTRD	EXP051025_UACC257_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	1484
1	3996	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 IMR90 (lung fibroblasts) TP53	IMR90 (lung fibroblasts)	NULL	TP53	Treatment: DMSO for 6hrs; Passage: 30-35;	GTRD	EXP054819_IMR90--lung-fibroblasts-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	385
1	3998	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 foreskin fibroblast TP53	foreskin fibroblast	NULL	TP53	Treatment: DMSO for 6 hrs;	GTRD	EXP057959_foreskin-fibroblast_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	710
1	3999	TP53	0	0	0	3835	3835	3835	3835	3840	3	204	204	TP53 foreskin fibroblast TP53	foreskin fibroblast	NULL	TP53	Treatment: 5 uM Nutlin3A for 6 hrs;	GTRD	EXP057960_foreskin-fibroblast_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	2943
1	4003	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	ETO	GEO	GSE21939_tp53_ps15-u2os-eto_MACS_TP53_MA0106.3.damo.pwm.bed	480
1	4004	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	ACTD	GEO	GSE21939_tp53_u2os-actd-ps15_MACS_TP53_MA0106.3.damo.pwm.bed	411
1	4005	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	ACTD	GEO	GSE21939_tp53_u2os-actd_MACS_TP53_MA0106.3.damo.pwm.bed	381
1	4006	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	ETO	GEO	GSE21939_tp53_u2os-eto-ps15_MACS_TP53_MA0106.3.damo.pwm.bed	435
1	4007	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	ETO	GEO	GSE21939_tp53_u2os-eto-ps46_MACS_TP53_MA0106.3.damo.pwm.bed	57
1	4008	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	ETO	GEO	GSE21939_tp53_u2os-eto_MACS_TP53_MA0106.3.damo.pwm.bed	840
1	4011	TP53	0	0	0	3835	3835	3835	3835	3840	4	204	203	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	DMSO	GEO	GSE46641_tp53_u2os-dmso_MACS_TP53_MA0106.3.damo.pwm.bed	2016
1	4012	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	DXR	GEO	GSE46641_tp53_u2os-dxr_MACS_TP53_MA0106.3.damo.pwm.bed	1938
1	4014	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	NUT	GEO	GSE47041_tp53_mcf7-nut_MACS_TP53_MA0106.3.damo.pwm.bed	23
1	4019	TP53	0	0	0	3835	3835	3835	3835	3840	4	204	203	TP53 keratinocytes TP53	keratinocytes	NULL	TP53		GEO	GSE56674_tp53_keratinocyte_MACS_TP53_MA0106.3.damo.pwm.bed	4054
1	4021	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 HCT-116 (colon carcinoma) TP53	HCT-116 (colon carcinoma)	BTO:0001109	TP53		GEO	GSE58506_tp53_hct166_MACS_TP53_MA0106.3.damo.pwm.bed	424
1	4022	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 HCT-116 (colon carcinoma) TP53	HCT-116 (colon carcinoma)	BTO:0001109	TP53		GEO	GSE58714_tp53_hct166_MACS_TP53_MA0106.3.damo.pwm.bed	30
1	4023	TP53	0	0	0	3835	3835	3835	3835	3840	0	204	207	TP53 IMR90 (lung fibroblasts) TP53	IMR90 (lung fibroblasts)	NULL	TP53	DMSO	GEO	GSE58740_tp53_imr90-dmso_MACS_TP53_MA0106.3.damo.pwm.bed	115
1	4025	TP53	0	0	0	3835	3835	3835	3835	3840	1	204	206	TP53 TP53	NA	NA	TP53	NA	GEO	GSE59176_tp53_mdamb175vii_MACS_TP53_MA0106.3.damo.pwm.bed	186
1	4035	TP63	0	0	0	3835	3835	3835	3835	3840	1	204	206	TP63 keratinocytes TP63	keratinocytes	NULL	TP63	Genotype: shRNA shSC Cells were harvested by scraping from plates and washed twice in 1× PBS before storage at -80°C.	GTRD	EXP048286_keratinocytes_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	895
1	4047	TP63	0	0	0	3835	3835	3835	3835	3840	1	204	206	TP63 keratinocytes TP63	keratinocytes	NULL	TP63	ADRIA	GEO	GSE56674_tp63_keratinocyte-adria_MACS_TP63_MA0525.2.damo.pwm.bed	4088
1	4056	TP63	0	0	0	3835	3835	3835	3835	3840	2	204	205	TP63 HaCaT (keratinocytes) TP63	HaCaT (keratinocytes)	BTO:0000552	TP63	LacZ	GEO	GSE60814_tp63_hacat-lacz-not_MACS_TP63_MA0525.2.damo.pwm.bed	2691
1	4058	TP63	0	0	0	3835	3835	3835	3835	3840	1	204	206	TP63 TP63	NA	NA	TP63	NA	GEO	GSE64298_tp63_dk_MACS_TP63_MA0525.2.damo.pwm.bed	1822
1	4094	VDR	0	0	0	3835	3835	3835	3835	3840	0	204	207	VDR primary foreskin fibroblasts VDR	primary foreskin fibroblasts	BTO:0000452	VDR	vitamin D treated	GTRD	EXP037202_primary-foreskin-fibroblasts_VDR_MACS_VDR_MA0074.1.damo.pwm.bed	208
1	4095	VDR	0	0	0	3835	3835	3835	3835	3840	0	204	207	VDR primary foreskin fibroblasts VDR	primary foreskin fibroblasts	BTO:0000452	VDR	vitamin D treated	GTRD	EXP037202_primary-foreskin-fibroblasts_VDR_MACS_VDR_MA0693.2.damo.pwm.bed	128
1	4096	VDR	0	0	0	3835	3835	3835	3835	3840	4	204	203	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	EtOH for 2h	GTRD	EXP037992_THP-1--acute-monocytic-leukemia-_VDR_MACS_VDR_MA0074.1.damo.pwm.bed	2091
1	4103	VDR	0	0	0	3835	3835	3835	3835	3840	0	204	207	VDR RWPE1 (prostate epithelial cells) VDR	RWPE1 (prostate epithelial cells)	BTO:0003709	VDR	Treatment: vehicle;	GTRD	EXP058194_RWPE1--prostate-epithelial-cells-_VDR_MACS_VDR_MA0074.1.damo.pwm.bed	6
1	4104	VDR	0	0	0	3835	3835	3835	3835	3840	0	204	207	VDR RWPE1 (prostate epithelial cells) VDR	RWPE1 (prostate epithelial cells)	BTO:0003709	VDR	Treatment: vitamin D;	GTRD	EXP058196_RWPE1--prostate-epithelial-cells-_VDR_MACS_VDR_MA0074.1.damo.pwm.bed	89
1	4105	VDR	0	0	0	3835	3835	3835	3835	3840	0	204	207	VDR RWPE1 (prostate epithelial cells) VDR	RWPE1 (prostate epithelial cells)	BTO:0003709	VDR	Treatment: vitamin D;	GTRD	EXP058196_RWPE1--prostate-epithelial-cells-_VDR_MACS_VDR_MA0693.2.damo.pwm.bed	62
1	4108	VDR	0	0	0	3835	3835	3835	3835	3840	4	204	203	VDR LX-2 (hepatic stellate cells) VDR	LX-2 (hepatic stellate cells)	BTO:0003516	VDR	CALCIPOTRIOL	GEO	GSE38103_vdr_lx2-calcipotriol_MACS_VDR_MA0693.2.damo.pwm.bed	1526
1	4110	VDR	0	0	0	3835	3835	3835	3835	3840	0	204	207	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	1H_125D	GEO	GSE51181_VDR_thp1-1h-125d_MACS_VDR_MA0693.2.damo.pwm.bed	35
1	4111	VDR	0	0	0	3835	3835	3835	3835	3840	0	204	207	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	2H_125D	GEO	GSE51181_VDR_thp1-2h-125d_MACS_VDR_MA0693.2.damo.pwm.bed	88
1	4112	VDR	0	0	0	3835	3835	3835	3835	3840	1	204	206	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	CAL	GEO	GSE53041_vdr_thp1-cal_MACS_VDR_MA0693.2.damo.pwm.bed	590
1	4116	XBP1	0	0	0	3835	3835	3835	3835	3840	0	204	207	XBP1 T47D (invasive ductal carcinoma) XBP1	T47D (invasive ductal carcinoma)	BTO:0001248	XBP1	HYPO_GLUDEP	GEO	GSE49952_xbp1_t47d-hypo-gludep_MACS_XBP1_MA0844.1.damo.pwm.bed	22
